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1 Introduction 
  
2 Hyaluronic acid 
1.1 Hyaluronic acid 
1.1.1 Structure and physicochemical properties 
In 1934, John Palmer and Karl Meyer were the first to isolate a novel polysaccharide from 
the vitreous humor of bovine eyes. They named this biopolymer hyaluronic acid, from 
hyaloid (vitreous) and the constituent uronic acid.1 However, the chemical structure of 
hyaluronic acid was determined by Meyer and coworkers not before the 1950s.2 Today, 
hyaluronic acid (HA) is classified as a non-sulfated member of the glycosaminoglycan 
family. Hyaluronic acid is a high molecular weight linear polysaccharide containing 
alternating D-glucuronic acid (GlcUA) and N-acetyl-D-glucosamine (GlcNAc) residues 
linked by -1,4 and -1,3 glycosidic bonds (Figure 1.1).3 
 
Figure 1.1 Chemical structure of hyaluronic acid. 
 
The polysaccharide consists of 2000 – 25000 disaccharide units, corresponding to a 
contour length of 2 – 25 μm.4 Its molecular mass in human normal synovial fluid has been 
estimated to be 6 – 7 x 106 and in rheumatoid fluid 3 – 5 x 106 Dalton.5, 6 HA is able to 
incorporate a large volume of water into its solvent domain, which is more than 1000 times 
greater than the volume of the original material.7 At physiological pH, the carboxylic 
groups of the glucuronic acid residues (pKa 3-4) are dissociated.
8 To maintain charge 
neutrality, exchangeable cation counterions associate to the polyanion. In biochemical 
literature, the term hyaluronate was commonly used to designate the polyanion character. 
Nowadays, in order to emphasize its polysaccharide nature and in agreement with the 
recommendations on polysaccharide nomenclature, the macromolecule is most frequently 
referred to as hyaluronan, regardless of the degree of dissociation.9 
The three-dimensional organization of hyaluronan is a matter of continuous investigations. 
An extended 2-fold helical structure of hyaluronan in solution has been proposed on the 
basis of NMR measurements in dimethylsulfoxide and X-ray fiber diffraction at low pH.10-13 
Newer techniques, using molecular dynamics simulations and high-field NMR experiments 
with 15N-enriched oligosaccharides, propose a fairly more complex secondary structure 
including a 4-fold helix model of hyaluronan.14 In general, the backbone of a hyaluronan 
molecule is stiffened by a combination of the chemical structure of the disaccharide, 
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internal hydrogen bonds, and interactions with the solvent.15 Consequently, in solutions a 
hyaluronan molecule forms a voluminous expanded random coil structure, but this 
structure reflects a very rapid inter-converting set of conformational states.8, 16 
Hyaluronan is essentially present in all tissues and body fluids of vertebrates as well as in 
some bacteria.17 It is a major constituent of the extracellular matrix in most tissues. The 
concentration of hyaluronan is particularly high in rooster comb, in the synovial fluid, in the 
umbilical cord, in the vitreous humor of the eye and in the skin and other connective 
tissues. The lowest concentration is found in blood serum.17, 18 Intracellular locations of 
hyaluronan have also been documented in the cytoplasm, the nucleus and the nucleolus, 
but the intracellular function of the biopolymer is not yet understood.19, 20 
 
1.1.2 Hyaluronan metabolism and physiological functions 
Hyaluronan is synthesized at the inner surface of the plasma membrane as an unbound 
linear polymer, which is different from other glycosaminoglycans (GAGs) that are 
synthesized by resident Golgi enzymes and covalently attached to core proteins.3, 4, 21 The 
biosynthesis of HA is regulated by hyaluronan synthases HAS1, HAS2 and HAS3 
isoenzymes.22, 23 During synthesis, HA is extruded through the plasma membrane into the 
pericellular space.23 Postsynthetic modification, e.g. sulfatation or epimerization, do not 
occur. In humans, HA metabolism is a very fast process compared to the turnover of other 
polysaccharides.17 One third of the HA in a human body is converted every day. 24 
The relatively simple chemical composition of hyaluronan lacks the structural complexity 
of the other GAGs. However, HA is involved in complex processes including cell 
migration, differentiation or wound healing. HA fragments of different size interact with cell 
surface receptors and binding proteins such as CD44 and RHAMM, which are involved in 
signal transduction processes.25-27 Abnormalities in hyaluronan metabolism have been 
implicated in many diseases, such as inflammation, cardiovascular diseases and growth 
and metastasis of tumor cells.28 
 
1.2 Hyaluronidases 
1.2.1 Prevalence and classification of hyaluronidases 
Hyaluronidases represent a class of enzymes that predominantly degrade hyaluronan. 
The corresponding enzymes are widely distributed in nature, being found in mammals, 
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invertebrate animals (crustaceans, leeches, and insects), pathogenic fungi (Candida), 
bacteria e.g. Streptomyces and bacteriophages.29 Today, the term “hyaluronidase”, which 
was coined by Karl Meyer in 1940, might be regarded as imprecise, as these enzymes 
also degrade chondroitin and chondroitin sulfates, albeit at a slower rate. Hence, absolute 
specificity of bacterial and mammalian hyaluronidases for hyaluronan is not given.30 
According to their catalytic mechanism, hyaluronidases are classified into three distinct 
families.31, 32  
The first group of hyaluronidases includes endo--N-acetyl-D-hexosaminidases 
(EC 3.2.1.35, type I hyaluronidases). Type I hyaluronidases are enzymes that cleave the 
-1,4 glycosidic bond of the high-molecular weight substrate with tetrasaccharides as 
main products. Such enzymes are present in mammalian spermatozoa, lysosomes, 
venoms of hymenoptera and snakes. For the prototypic enzyme of this group, the bovine 
testicular enzyme (BTH), it has been shown that it also catalyzes transglycosylation 
reactions, so that di-, hexa-, and octasaccharides are also formed during hydrolysis of 
hyaluronan.29, 33, 34 The second group includes endo--glucuronidases (EC 3.2.1.36, type 
II hyaluronidases). Type II hyaluronidases degrade the -1,3 glycosidic bond of 
hyaluronan. Since these enzymes utilize a hydrolysis mechanism, their mode of action 
resembles that of eukaryotic or vertebrate enzymes (type I) more closely than that of the 
bacterial enzymes (type III). Such enzymes have been isolated from leech and may also 
be present in hookworms.35 The third group includes bacterial hyaluronidases (EC 4.2.2.1, 
type III hyaluronidases). Different from the two other groups of hyaluronidases, type III 
hyaluronidases do not simply catalyze hydrolysis. They degrade hyaluronan via a -
elimination process to yield 4,5-unsaturated oligosaccharides of various lengths, often as 
small as disaccharides. With respect to the catalytic reaction, these enzymes were also 
named hyaluronate lyases. 
 
1.2.2 Hyaluronidases from eukaryotes 
The human genome contains six known DNA sequences encoding hyaluronidase-like 
proteins. They include Hyal-1, Hyal-2, Hyal-3, Hyal-4 and PH-20 (SPAM 1). 
A pseudogene, HYALP1, is not translated.36 According to current research, the 
enzymatically active enzymes Hyal-1 and Hyal-2 are regarded as the most important 
hyaluronidases for the degeneration of hyaluronan in somatic tissues, where they act in a 
complementary manner on the degradation of HA.37-39 The human sperm adhesion 
molecule 1 (SPAM 1) or PH-20 is a membrane bound testicular hyaluronidase with a key 
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role during the fertilization process. The enzyme is bound via a GPI-anchor on the sperm 
surface and is necessary to penetrate the hyaluronan-rich follicle cell layer.40-42 
The bovine enzyme BTH, which is extracted from bull testis, has been used as a 
spreading factor in several medical fields for many years.43 For example, BTH was used 
to study effects on coronary blood flow after myocardial infections.44, 45 
The identity between all sequences of human hyaluronidases varies from 33.1 % (Hyal-3 
and Hyal-4) to 41.2 % (Hyal-4 and PH-20).46, 47 To date, three-dimensional information for 
type I and II hyaluronidases is only available from the crystal structures of the bee venom 
hyaluronidase, a major allergen present in bee venom (PDB-codes: 1FCQ, 1FCU, 1FCV) 
and the mammalian Hyal-1 enzyme (PDB-code: 2PE4). 48, 49 
 
1.2.3 Hyaluronidases from prokaryotes 
Hyaluronidase has been found as a surface protein in a number of gram-positive and 
gram-negative bacteria. Human infections caused by gram-positive microorganisms are 
increasingly difficult to treat, predominantly due to emerging resistant strains, not only 
against penicillin and penicillin-like antibiotics but even against novel antibiotics such as 
vancomycin.50-52 Such bacteria are involved in various diseases such as gas gangrene, 
meningitis, synovitis, hyperplasia, nephritis, mycoplasmosis, periodontal disease, 
mastritis, pneumonia, septicemia, syphilis and toxic shock syndrome.52-57 In this context, 
hyaluronate lyases are suggested to play a major role in pathogenesis and disease 
progression of gram-positive bacteria such as Streptococcus, Staphylococcus, 
Peptostreptococcus, Propionibacterium, Streptomyces and Clostridium species.58-62 The 
hyaluronidase protein potentially acts as a virulence factor; the depolymerization of HA 
in vivo breaks down the physiological barrier of the host connective tissue and exposes 
the host cells to various bacterial toxins. Therefore, the enzymatic degradation of tissue-
hyaluronan would reflect an important step for bacterial invasion and spreading. However, 
due to the lack of experimental data, the specific role of hyaluronidase, e.g. in 
streptococcal pathogenesis, is controversially discussed as the degradation of HA in 
tissue may also be driven by nutritional purposes.32, 54, 63-68 In contrast, hyaluronate lyases 
produced by gram-negative bacteria, are less likely to play a role in pathogenesis.69-71 
In particular, hyaluronate lyases from pathogenic strains of Streptococci, e.g. from 
S. pneumoniae and S. agalactiae, reflect a versatile target for the development of novel 
therapies to investigate and putatively to treat bacterial disease.72 Streptococcus 
pneumoniae is a human pathogen that colonizes the upper respiratory tract and causes 
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life-threatening diseases such as pneumonia, bacteremia, and meningitis throughout the 
world.73-76 The currently licensed pneumococcal vaccine is only moderately effective, and 
it is not prescribed for children younger than 2 years due to poor antibody responses.52 In 
addition, during the last decades, antimicrobial resistance has increased both in the 
USA77-86 and worldwide.87-91 Another member of the Streptococcus genus, S. agalactiae, 
can cause serious disease, especially in neonates.92-94 This reinforces the need for 
improved vaccines and/or the development of small molecules as effective drugs to 
combat pneumococcal infections. 
Moreover, among the bacterial hyaluronidases, the enzymes from Streptococcus 
pneumoniae (SpnHyl) and Streptococcus agalactiae (SagHyal) are best characterized. 
Remarkably, these lyases were found to share substantial sequence identity with regard 
to the active site and thus are likely to use a similar catalytic mechanism.95 Three-
dimensional structural information (X-ray diffraction analysis) for both enzymes is 
available of the native enzyme and of complex structures with hyaluronan substrates 
(cf. Table 1.1). 
Table 1.1 Crystal structures of bacterial hyaluronidases. 
Bacterium PDB 
code 
Ligand Comment Resolution 
(Å) 
Citation 
S. pneumoniae 1EGU none  1.56 ref
95
 
 1LOH HA hexasaccharide  2.00 ref
96
 
 1LXK HA tetrasaccharide  1.53 
 1C82 HA disaccharide  1.70 ref
97
 
 2BRV none complex from 70% sat. 
malonate 
3.30 ref
98
 
 2BRW none complex from 30% 
PEGME 
2.80 
 1OJM unsulfated chondroitin 
disaccharide 
 1.78 ref
30
 
 1OJN 6-sulfated chondroitin 
disaccharide 
Y408F mutant 1.60 
 1OJO 4-sulfated chondroitin 
disaccharide 
Y408F mutant 1.75 
 1OJP 6-sulfated chondroitin 
disaccharide 
 1.90 
 1N7N none W292A mutant 1.55 ref
99
 
 1N7O none F343V mutant 1.50 
 1N7P none W292A/F343V double 
mutant 
1.55 
 1N7Q HA hexasaccharide W291A/W292A double 
mutant 
2.30 
 1N7R HA hexasaccharide W291A/W292A/F343V 
mutant complex 
2.20 
S. agalactiae 1F1S none  2.10 
ref
100
 
 1I8Q HA hexasaccharide  2.20 
 1LXM HA hexasaccharide  2.20 ref
101
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Bacterial hyaluronate lyases are generally composed of four distinct domains, a substrate-
binding module, a spacer domain, a major catalytic domain (-domain), followed by a C-
terminal domain (-domain) that regulates HA access to the cleft.102 The N-terminal 
substrate-binding module and the C-terminal domain are connected to the rest of the 
protein by peptide linkers.98 The stable and fully catalytically active enzyme structure of 
S. pneumoniae hyaluronate lyase (PDB code 1LXM) is a globular protein, which contains 
two distinct structural domains; the -helical domain and the -sheet domain on the C-
terminal region. The full-length four-domain pneumococcal enzyme, recombinantly 
expressed in Escherichia coli, is unstable and undergoes degradation by a (auto)-
proteolytic process.103, 104 The hyaluronate lyases from S. pneumoniae and S. agalactiae 
(strains 3502, 4755) share a sequence homology of approximately 68 %. As illustrated in 
Figure 1.2, in contrast to the pneumococcal lyase, the catalytically active enzyme from 
SagHyal (PDB code 1LOH) is a protein with three domains (spacer domain, -domain, -
domain). 
 
 
Figure 1.2 Modular structure of bacterial hyaluronidases and sequences of 1LXM (from S. agalactiae) and 
1LOH (from S. pneumoniae). 
 
Structural differences between SpnHyl and SagHyl are not primarily due to low sequence 
homology, but rather correspond to specific domain motions, as those enzymes represent 
highly flexible structures.98 As a fact, the architecture, as well as the geometry of the 
active site of hyaluronate lyases is highly conserved (cf. Figure 1.3). 
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Figure 1.3 Superposition of crystal 
structures of SpnHyl (red, PDB 
code 1LOH) and SagHyal (green, 
PDB code 1LXM). 
 
Based on X-ray crystallography followed by structural, biochemical and molecular biology 
studies, a mechanism of catalysis for the bacterial enzyme and its mode of action during 
degradation of hyaluronan substrates has been proposed.98 Accordingly, the helical 
domain contains a large, deep and elongated cleft, which is responsible for substrate 
binding and degradation (Figure 1.4).52, 95, 97  
 
 
 
 
 
Figure 1.4 Three-dimensional view of the crystal structure of SagHyal (PDB code 1LXM) with HA 
hexasaccharide bound to the catalytic cleft (-domain). A zoomed section of the substrate binding cleft is 
shown on the right, displaying HA on the active site. 
 
Most of the amino acid residues along the cleft are either charged (positive patch, 
negative patch) or aromatic. In the narrowest part of the cleft, three catalytic residues, 
Asn429, His479, and Tyr488 (SagHyl numbering101) are located, which degrade the substrate 
 Introduction 9 
through a proton acceptance and donation (PAD) mechanism.95, 105 The aromatic patch, 
located beneath the catalytic site, is regarded to assist the cleavage of hyaluronan by a 
precise positioning of disaccharide units of the polymeric substrate. Following a 
progressive process of degradation, the enzyme moves continuously forward to the 
nonreducing end of the hyaluronan chain with disaccharides being the smallest 
degeneration product. The PAD mechanism involves five steps: (1) enzyme binding to 
hyaluronan; (2) catalytic cleavage of the glycosidic bond; (3) hydrogen exchange with the 
microenvironment; (4) dissacharide product release; (5) translocation of the substrate and 
the processive mode of action of the enzyme.52, 106 The role of the -sheet domains is 
probably only supportive in maintaining the structure of the catalytic cleft as well as 
modulating access to the cleft.106 The catalytic mechanism of cleavage of the ß-1,4 
glycosidic bond of hyaluronan is illustrated in more detail in Figure 1.5. 
 
 
Figure 1.5 Mechanism of hyaluronan degradation by hyaluronate lyase from S. agalactiae (SagHyal3502); 
schematic presentation of hyaluronic acid with HA1, HA2 and HA3 as disaccharide units and the position of 
the sidechains of Tyr
488
, His
479
 and Asn
429
 relative to the substrate (modified from Li and Jedrzejas).
52
 
 
1.2.4 Hyaluronidase inhibitors 
In general, the role of hyaluronan and hyaluronan degrading enzymes, the 
hyaluronidases, is far from being understood. To overcome this misery, potent and 
selective inhibitors might give the ability to characterize and understand the (patho-) 
physiological role of hyaluronidases. Furthermore, from a therapeutic perspective, 
inhibitors might be useful in developing anti-bacterial54, anti-venom/toxin107, anti-tumor108, 
antiallergic agents109 or even as contraceptives.110 Documented hyaluronidase inhibitors 
are of various chemical forms. In most cases, these inhibitors were discovered incidentally 
or by random screening.62 Few inhibitors of streptococcal hyaluronidases were detected in 
complex with the target enzyme (c.f. Table 1.2). However, until today, only very little 
attention has been paid on the rational development of synthetic molecules as 
hyaluronidase inhibitors. 
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Table 1.2 Crystal structures of bacterial hyaluronidases in complex with small molecule inhibitors. 
Bacterium PDB 
code 
Ligand Resolution 
(Å) 
Citation 
S. pneumoniae 2BRP Sulfamic acid 1-decyl-2-(-sulfamoyloxyphenyl)-1H-
indole-6-yl ester 
2.00 ref
111
 
 1W3Y (2E, 4R, 5S)-2,3,4,5-Tetrahydroxy-6-
(palmitoyloxy)hex-2-enoic acid 
1.65 ref
112
 
 1F9G Ascorbic acid 2.00 ref
72
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Enzymes cleaving hyaluronic acid (hyaluronan), the hyaluronidases, are widespread in 
nature. They are not only present in the animal kingdom, but are also considered as 
virulence factors of microorganism, including several pathogenic strains of Streptococci. 
Weak hyaluronidase inhibitors have been identified among natural products and synthetic 
molecules. However, with respect to drug discovery or a rational design of inhibitors, 
hyaluronidases still represent a class of neglected enzymes. Inhibitors of bacterial 
hyaluronate lyases could serve as pharmacological tools or even could be used as new 
adjuvants in the chemotherapy of drug-resistant bacteria. 
In previous studies, hyaluronidase inhibitors among vitamin C derivatives, indoles and 
benzoxazoles were identified in our workgroup. The most potent derivatives showed IC50 
values in the lower micromolar range for bacterial hyaluronidases. Characteristics of the 
most active inhibitors are acidic functional groups and a high degree of lipophilicity, 
resulting in very high plasma protein binding. Hence, such agents represent 
pharmacological tools for in vitro studies rather than for in vivo investigations. 
Focusing on a streptococcal hyaluronidase (SagHyal4755), the aim of this thesis was the 
discovery of novel lead compounds and the elucidation of the structure-activity 
relationships of inhibitors of the bacterial enzyme. From the beginning, only small 
molecules predicted to possess drug-like properties, were accepted as target molecules. 
From the methodological point of view, the project comprises two different approaches: 
(1) In a collaborative project (Origenis GmbH, Martinsried, Germany), a combination of 
innovative computer-assisted methods, of drug design and synthesis technologies should 
be applied to identify novel structural motifs. Initially, a compound library of inhibitors of 
the target enzyme had to be established for the generation of suitable templates in a 
ligand-based drug design approach. By implementation of the methodological repertory of 
the collaboration partner, the structure-activity relationships should be analyzed in silico. 
Accordingly, a selection of predicted inhibitors should be synthesized in parallel by 
multicomponent synthesis, analyzed and tested for biological activity in medium-
throughput and verified as new inhibitors. Successive hit to lead development was 
intended, in order to obtain drug-like inhibitors of the target enzyme. 
(2) As previously shown for SagHyal4755, the introduction of alkyl groups in position 1 of 
hydroxylated 2-phenylindoles (scaffold: 2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol) led to 
the discovery of inhibitors with activities in the lower micromolar range. To further 
elaborate the structure-activity relationships of 2-phenylindoles, a series of substances 
should be optimized in terms of inhibitory activity and selectivity for the target enzyme 
SagHyal4755. In this context, less lipophilic compounds were aimed at to improve drug-like 
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properties. Furthermore, depending on the N-substituent, compounds derived from the 2-
(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol scaffold are known for antiestrogenic activity at 
low nanomolar concentrations. Hence, minimization of this off-target effect had to be 
considered in case of 2-phenylindole-type hyaluronidase inhibitors. To cope with this 
problem, structural modifications on the indole scaffold and bioisosteric replacements 
should be elaborated. 
 
  
 
 
  
3 Methods for the determination of 
hyaluronidase activity 
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3.1 Introduction 
Along with the discovery of hyaluronan and hyaluronan degrading enzymes a variety of 
methods have been developed to determine the enzymatic activity of hyaluronidases. An 
overview of the previously developed and applied test systems was given by Hynes and 
Ferretti in 1994.1 Meanwhile, primarily spectrophotometric,2-7 fluorogenic,8, 9 
enzymoimmunological,10-12 radio-chemical13, 14 and physicochemical15-17 methods have 
been described. In addition, quantitative hyaluronidase assays are also performed by 
chromatography,18-20 capillary zone electrophoresis,21 zymography22 and in agarose plate 
assays.23 Although a lot of methods and assay formats are known today, only very few are 
embedded in routine analyses, e.g., for the identification of hyaluronidase inhibitors. The 
reasons are most commonly low sensitivity or laborious and technically complex workup 
procedures. The most widely used quantitative hyaluronidase assays are colorimetric 
such as the Morgan-Elson assay developed by Reissig et al.2, the “stains-all” assay which 
was developed and investigated by Benchetrit3 and Homer6 or assays based on the 
change in viscosity24 and turbidity.25 In this thesis, a colorimetric and a turbidimetric assay 
are routinely exploited to determine the inhibitory effect of the synthesized compounds. 
Inhibitory activity was elucidated for hyaluronidase inhibitors on bacterial hyaluronate 
lyases from Streptococcus agalactiae strain 4755 (SagHyal4755) and Streptococcus 
pneumoniae (SpnHyl) and the bovine testicular enzyme BTH (formerly commercially 
available, e.g., under the trade name Neopermease®). The principles of both routinely 
applied methods, namely the Morgan-Elson assay and the turbidimetric assay, are briefly 
explained in the following sections. 
 
3.2 Morgan-Elson assay 
The Morgan-Elson assay has been classified as a chemical assay by Hynes and Ferretti.1 
In the incubation mixture enzymatic degradation of the substrate hyaluronan (HA) results 
in HA-fragments of different size and molecular weight. The reducing ends of hyaluronic 
acid fragments bear a characteristic 2-(acetylamino)-2-deoxy-D-glucose (N-acetyl-D-
glucosamine; GlcNAc) moiety. N-acetyl-D-glucosamine residues give colored products 
when treated with an acidic solution of 4-(dimethylamino)benzaldehyde (Ehrlich´s reagent; 
DMAB). Determination of hyaluronidase enzymatic activity is based on the formation of a 
red colored product that can be photometrical detected at a wavelength of 586 nm. 
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The reaction was investigated in more detail and described by Muckenschnabel et al. 
(Figure 3.1).7 At 100 °C under alkaline conditions, the furanose form of N-acetyl-D-
glucosamine residues is converted to the chromogens I (-configuration) and II (-
configuration) after elimination of ROH.26, 27 Subsequent treatment with a mixture of 
concentrated hydrochloric acid and glacial acetic acid results in elimination of water 
yielding chromogen III. In the final step of the Morgan-Elson reaction chromogen III reacts 
with 4-(dimethylamino)benzaldehyde (Ehrlich´s reagent) generating mesomeric forms of 
N3-protonated 3-acetylimino-2-(4-dimethylaminophenyl)methylidene-5-(1,2-dihydroxy-
ethyl)furane (red colored product). 
 
 
Figure 3.1 Mechanism of the Morgan-Elson reaction resulting in red colored products. Adopted from 
Muckenschnabel et al.
7
 
 
The Morgan-Elson assay is a useful, broadly applicable method for the determination of 
hyaluronidase activity in the presence of inhibitors. However, the examination of putative 
inhibitors in the Morgan-Elson assay hides some chemical restrictions. Side-reactions of 
the acidic 4-(dimethylamino)benzaldehyde-solution with inhibitors in the incubation 
mixture might occur and falsify the photometric readout at = 586 nm. For example, we 
previously identified potent inhibitors of SagHyal4755 among indoles and phenylindoles. 
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There has been evidence for such heterocycles to form colored products when treated 
with acidic 4-(dimethylamino)benzaldehyde under assay conditions.28 Moreover, related 
reactions of indole derivatives with 4-(dimethylamino)benzaldehyde were reported in the 
literature. Pindur and coworkers studied the reaction of 3-methyl-1H-indole (1) with 4-
(dimethylamino)benzaldehyde (Figure 3.2).In this case, according to the mechanism 
proposed by van Urk, the elimination of water under acidic conditions yields a colored 
product (cyanine, 2). Subsequent oxidation leads to the formation of a cationic 
bisindolylphenylmethane (3).29, 30  
 
 
 
 
 
 
 
Figure 3.2 Proton catalyzed reaction of 3-
methyl-1H-indole (1) with DMAB (Ehrlich’s 
reagent) according to Pindur. A pH 
dependent equilibrium of bisindolyl-
arylmethane leads to the formation of 
cyanine (2). Oxidation of the latter compound 
yields a trinuclear cyanine (3), representing 
the dominating coloring components.
29, 30
 
 
Extensive investigations of 1,2,3-trimethyl-1H-indole (4) by Pindur and coworkers revealed 
an electrophilic aromatic substitution of 4-(dimethylamino)benzaldehyde (DMAB) in 
position 5 or 6 of the indole scaffold resulting in more intensly colored molecular species 
(cf. 5, 6; Figure 3.3).31 
 
 
Figure 3.3 Proton catalyzed reaction of 1,2,3-trimethyl-1H-indole (4) with DMAB (Ehrlich’s reagent) according 
to Pindur. The formation of colored bisindolylarylmethanes (5,5’- and 6,6’-regioisomeres, 5) and subsequent 
oxidation (cf. 6) was observed.
31
 
Moreover, for indomethacin, a non-steroidal anti-inflammatory drug, also known as an 
inhibitor of SagHyal4755, an analytical procedure is based on the van Urk-reaction and 
providing colored products in the same manner.32 
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Due to these considerations, the Morgan-Elson colorimetric assay was not applied as a 
routine assay for the determination of inhibitory activity on bacterial and mammalian 
hyaluronidases, since false-negative results could not be excluded for novel chemical 
entities. 
Another severe limitation of the Morgan-Elson assay results from the rather harsh workup 
procedures (cf. heating to 100 °C, addition of a solution of concentated hydrochloric acid 
and glacial acetic acid). As we considered these conditions incompatible with an 
automated assay for high-throughput procedures, a transfer of this approach to 96-well or 
384-well MTP assay formats was not attempted. 
 
3.3 Turbidimetric assay 
The turbidimetric assay represents a physicochemical assay according to the 
classification given by Hynes and Ferretti.1 Enzymatic degradation of hyaluronan (HA) 
results in HA-fragments of different size and molecular weight. Non-degraded, high-
molecular hyaluronan (mw > 8 kDa) form insoluble complexes when treated with a 
solution of alkaline cetrimonium bromide (cetyltrimethylammonium bromide, CTAB) 
according to the method initially described by Di Ferrante. In contrast, oligosaccharides 
and smaller hyaluronan fragments (mw < 6 –8 kDa) are not precipitated under these 
conditions. Determination of hyaluronidase activity is based on the loss of transmitted light 
intensity at wavelengths between 580 and 600 nm due to the scattering effect of 
suspended particles. Therefore, hyaluronidase activity is directly proportional to the 
intensity of transmitted light. This fast and highly reproducible assay can be easily 
performed using cuvettes and microtiter plates and represents the standard method for 
the determination of inhibitory activities of the synthesized compounds in this thesis. 
The sensitivities of the aforementioned assays were determined by Hofinger: the limits of 
quantitation were 2 U/mL (Morgan-Elson assay) and 5 U/mL (turbidimetric assay), 
respectively.33 In addition to the previously established 96-well microtiter plate (MTP) 
assay, a modified 96-well MTP assay and a novel 384-well MTP assay format were 
established with respect to (automated) screenings of large compound libraries of 
potential hyaluronidase inhibitors. 
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3.4 Adaptation of turbidimetric assay formats 
3.4.1 General requirements 
3.4.2 Selection of organic solvent 
The effects of commonly used organic solvents (DMF, DMSO, EtOH, MeCN, MeOH) on 
the activity of BTH and SagHyal4755 were previously investigated in our workgroup.
28, 34 
DMSO up to a final assay concentration of 4 % (v/v) was identified as the most suitable 
solvent, with regard to negligible effects on enzymatic activity as well as sufficient 
solubility of inhibitors. Therefore, DMSO was used as the standard solvent for the 
preparation of stock solutions of (purified) inhibitors for pharmacological investigations. 
 
3.4.3 Adjusting the pH value for the study of various 
hyaluronidases 
Hoechstetter and Hofinger studied the pH dependent activity profiles of BTH and 
SagHyal4755.
33, 35 They found highest activity for the bacterial hyaluronate lyase at pH 5.0, 
but it is not possible to select a pH where all investigated enzymes show sufficient high 
activity. A pH value of 6 was reported by Jedrzejas as the optimum pH of SpnHyl.36 To 
obtain comparable results concerning the IC50 values of the investigated inhibitors which 
also depend on pH, BTH and SpnHyl were tested at pH 5.0 where these enzymes show 
considerably high activity in the turbidimetric assay. Thus, the received IC50 values are 
comparable to previously gained data from our workgroup (cf. investigations by Binder, 
Braun, Salmen and Spickenreither).28, 34, 37, 38  
The turbidimetric assay was used in four different standardized formats to identify 
inhibitors of hyaluronidases. The measurements were performed in cuvettes, in 96-well 
flat-bottomed transparent microtiter plates using either manual (“manual 96-well MTP”) or 
automated dispensing (“auto 96-well MTP”) and in 384-well flat-bottomed transparent 
microtiter plates with automatical dispensing (“384-well MTP”). 
Enzymatic activity of BTH, SagHyal4755 and SpnHyl was investigated in all assay formats. 
The Morgan-Elson assay was performed in cuvettes without exception. 
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3.4.4 Plate layout 
Modification of the existing 96-well assay format became necessary as the liquid handling 
system was restricted to provide a minimum volume of 10 µL. Hence, the composition and 
dilution of assay ingredients had to be modified in order to meet these requirements. The 
final concentrations of the assay components remained unchanged to ensure comparable 
results. A representative plate-layout of the auto 96-well is displayed in Figure 3.4. 
 
Figure 3.4 Plate layout for automated dispensing into 96-well microtiter plate. Maximum (“H”) and minimum 
(“L”) samples are placed in column 1, references samples in columns 11 (“A”, concentrations 1-8) and column 
12 (“B”, concentrations 1-8), respectively; 72 screening compounds (“#1”-“#72”) are placed in columns 2 to 10. 
 
In principle, the 96-well format was designed to hold a total of 72 screening compounds at 
a final assay concentration of 200 µM. Each compound was added at a single 
concentration. Maximum and minimum signals (column 1) and reference samples 
(columns 11, 12) were embedded on each plate. To receive additional data for each 
compound from single-concentration measurements, the experiments were performed in 
duplicate. Therefore, a second microtiter plate was prepared in the same way and 
investigated under identical conditions. A representative plate-layout of the auto 384-well 
is displayed in Figure 3.5. 
 
 
 
 
Figure 3.5 Plate layout for 384-well microtiter plate. The MTP accommodates maximum and minimum 
samples in columns 1, 2 and reference compounds in columns 23, 24. 80 screening compounds are placed in 
4 concentrations (z-pattern alignment) from columns 2 to 22. The segment on the right illustrates an 
enlargement of the 384-well MTP (rows A-D, columns 3-6) to display the dilution pattern of 4 random 
compounds (compounds #1 to #4). 
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For the automated 384-well MTP assay format, a total of 80 screening compounds were 
located on each plate. The layout was designed to allow dispensing of every compound in 
four concentrations: 0.2 µM, 2 µM, 20 µM and 200 µM (final assay concentration). 
Replicates were not accomplished for the 384-well assays. 
 
3.5 Experimental procedures 
3.5.1 Materials and methods 
Hyaluronic acid from Streptococcus zooepidemicus was purchased from Aqua Biochem 
GmbH (Dessau, Germany). Stabilized hyaluronate lyase, i.e. 200,000 units (according to 
the supplier, 0.572 mg from S. agalactiae strain 4755 plus 2.2 mg of BSA and 37 mg of 
Tris-HCl per vial) of lyophilized hyaluronate lyase, was kindly provided by id-Pharma 
(Jena, Germany). Lyophilized hyaluronidase from bovine testis (Neopermease®) 
(200,000 units, according to the supplier; 4 mg plus 25 mg of gelatin per vial) was a gift 
from Sanabo (Vienna, Austria). BSA was purchased from Serva (Heidelberg, Germany). 
Ascorbic acid 6-palmitate (Vcpal), diclofenac and 4-(dimethylamino)benzaldehyde 
(DMAB) were purchased from Sigma-Aldrich (Munich, Germany). If not indicated 
otherwise all chemicals were of analytical or HPLC grade and obtained from Merck 
(Darmstadt, Germany). Water was purified by a Milli-Q system (Millipore, Eschborn, 
Germany). 
 
3.5.2 Morgan-Elson assay 
3.5.2.1 Reagents and solutions 
The following reagents and solutions were prepared immediately before usage. 
McIlvaine’s buffer39 was prepared from solution 1 (0.2 M Na2HPO4, 0.1 M NaCl) and 
solution 2 (0.1 M citric acid, 0.1 M NaCl) by mixing appropriate portions to adjust the 
required pH value (pH = 5.0). The alkaline borate solution was prepared from a borate 
solution (solution A: 17.3 g H3BO4 and 7.8 g KOH in 100 mL water) and a potassium 
carbonate solution (solution B: 8.0 g K2CO3 in 10 mL water) by combining 10 volumes of 
solution A and 1 volume of solution B. For the solution of Ehrlich’s reagent, 1 volume of 
concentrated solution (20.0 g 4-(dimethylamino)benzaldehyde dissolved in 25 mL of 
concentrated hydrochloric acid and 75 mL of glacial acetic acid; storage conditions: 4 °C, 
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light protection) was diluted with 4 volumes of glacial acid. Stock solutions containing 
5 mg/mL hyaluronic acid in water and 0.2 mg/mL BSA in water were prepared and stored 
at 4 °C. 
 
3.5.2.2 Incubation of test compounds 
For the incubation mixture, test compounds dissolved in 18 µL DMSO (final DMSO 
concentration: 3.9 % (v/v)) were incubated at 37 °C in the assay mixture containing 
200 μL buffer, 50 μL of BSA solution (0.2 mg/mL in water), 50 μL of HA solution (5 mg/mL 
in water), 82 μL of H2O and 50 μL of enzyme solution. The enzymatic reaction was 
stopped after 60 minutes by addition of 110 μL of alkaline borate solution and subsequent 
heating for 4.5 minutes at 100 °C on a heating block. After cooling on ice for at least 2 
minutes, 1250 μL of reagent solution (Ehrlich’s reagent) was added and the mixture was 
incubated at 37 °C for 20 minutes. The samples were transferred into acryl cuvettes and 
the absorbance of the colored product was measured photometrically at a wavelength of 
586 nm using a Cary 100 UV-Vis spectrometer (Varian, Darmstadt, Germany). As 
reference for 100 % enzymatic activity the formation of the red colored product of a 
sample without inhibitor (replaced by 18 μL of DMSO) was quantified. In absence of both, 
enzyme and inhibitor (replaced by 50 μL of BSA solution and 18 μL of DMSO, 
respectively), a reference for 0 % enzymatic activity was determined. 
 
3.5.2.3 Calculation of enzyme inhibition and IC50 values 
The highest concentration of the test compounds was adjusted to 1 mM. Regularly, a 
dilution series covering a concentration range from 0.5 µM to 1 mM was used for the 
determination of IC50 values. The effect of the test compounds on the enzymatic activity 
was calculated according to Equation 3.1: 
       
              
         
      
Equation 3.1 
A:  calculated enzymatic activity in % 
µsample:  mean extinction of the incubation mixture containing inhibitor (containing enzyme) 
µblank:  mean extinction of the incubation mixture containing inhibitor (without enzyme) 
µmax:  mean extinction of the incubation mixture without inhibitor (containing enzyme) 
µmin:  mean extinction of the incubation mixture without inhibitor (without enzyme) 
 
The enzymatic activities were plotted against the logarithm of the inhibitor concentration 
and IC50 ± SEM values were calculated by curve fitting of the experimental data with 
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Sigma Plot 11.0 (SPSS Inc., Chicago, USA) and are the means of at least two 
independent experiments performed in duplicate. 
 
3.5.2.4 Determination of hyaluronidase activity 
Enzymatic activity was quantified according to the definition of the International Union of 
Biochemistry, i.e. 1 unit (U). Hyaluronidase catalyzes the liberation of 1 mmol N-acetyl-D-
glucosamine (GlcNAc) at the reducing ends of sugars per minute under specified 
conditions. For this purpose, references of known N-acetyl-D-glucosamine (GlcNAc) 
concentration were used. By plotting the absorbance resulting from the formation of the 
red colored product measured at  = 586 nm against a dilution series of GlcNAc a linear 
calibration graph is given. The GlcNAc concentrations typically covered a range from 
0.1 mM to 2 mM, incubation time was set to 30 minutes. The incubation mixture 
containing 200 μL buffer, 50 μL BSA solution (0.2 mg/mL in water), 50 μL of the 
respective GlcNAc dilution (replacing HA), 82 μL H2O and 50 μL BSA (replacing the 
enzyme solution) was treated as previously described. Additionally a blank probe, with 
50 µL HA solution (instead of GlcNAc) was added. For the quantification of hyaluronidase 
activity 50 mL of the respective enzyme solution was incubated with 50 µL HA (5 mg/mL 
in water). Enzymatic activity was calculated according to Equation 3.2: 
    
             
   
 
Equation 3.2 
U:   enzymatic activity (U) 
GlcNAc:  N-acetyl-D-glucosamine at the reducing ends of sugars 
 
According to this definition, a hyaluronidase activity of 0.1 mU (0.1 nmol GlcNAc/min) is 
equivalent to approximately 1 international unit (IU), 1 (relative) turbidity reducing unit 
((r)TRU), 1 national formulatory unit (NFU), 1.5 Benger units and 3.3 viscosity units, 
respectively.7 
 
3.5.3 Turbidimetric assay 
3.5.3.1 Reagents and solutions 
The following dilutions were prepared immediately before usage: McIlvaine’s buffer39 was 
used throughout the measurements as incubation buffer, unless otherwise indicated. For 
BTH, SagHyal4755 and SpnHyl a pH value of 5.0 was applied. The stop reagent was 
prepared from a solution of 2.5 % of cetrimonium bromide (cetyltrimethylammonium 
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bromide, CTAB) in 0.5 N NaOH (w/v). Stock solutions containing 2 mg/mL hyaluronan in 
water and 0.2 mg/mL BSA in water were prepared and stored at 4 °C. Table 3.1 
summarizes the enzymatic activities, pH values and periods of incubation employed in the 
different assay formats. 
Table 3.1 Variants of the the turbidimetric assay, depending on the format. 
Assay 
format 
Enzyme Enzyme 
solution 
prepared 
(mU/mL) 
Enzyme solution 
added to incubation 
mixture (total volume) 
(µL) 
Final enzymatic 
activity in the 
incubation mixture 
(mU) 
pH Incubation 
time 
(min) 
cuvette BTH 9.0 30 µL (270 µL) 0.27 5.0 30 
cuvette SagHyal4755 3.3 30 µL (270 µL) 0.1 5.0 30 
96-well
a
 BTH 27.0 10 µL (73 µL) 0.27 5.0 30 
96-well
a
 SagHyal4755 10.0 10 µL (73 µL) 0.1 5.0 30 
96-well
b
 SagHyal4755 10.0 10 µL (75 µL) 0.1 5.0 30 
384-well
c
 SagHyal4755 10.0 10 µL (40 µL) 0.1 5.0 30 
96-well
a
 SpnHyl 10.0 10 µL (75 µL) 0.1 5.0 30 
a
 turbidimetric assay performed in manually handled 96-well MTP format; 
b
 turbidimetric assay performed in 
96-well MTP format with automated dispension; 
c
 automated dispension. 
 
3.5.3.2 Incubation of hyaluronidase inhibitors 
The measurement of enzymatic activity in the presence of inhibitors was performed in 
cuvettes, in 96-well flat-transparent microtiter plates with manual (“manual 96-well MTP”), 
or automated dispensing (“auto 96-well MTP”), and in 384-well flat transparent microtiter 
plates (“384-well MTP”) using an automated dispensing system. The composition of the 
assay ingredients in the incubation mixture of the differing assay formats are shown in 
Table 3.2. 
Table 3.2 Composition of incubation mixtures for cuvette, manual 96-well, auto 96-well and 384-well format 
employed in the turbidimetric assay. 
Assay 
format 
Buffer 
(pH = 5.0) 
H2O BSA 
 
HA 
 
Inhibitor 
solution 
Enzyme 
solution 
Incubation 
volume 
cuvette 120 µL 50 µL 30 µL 30 µL 10 µL
c
 30 µL 270 µL 
96-wella 31 µL 12.8 µL 8.1 µL 8.1 µL 3 µL
c
 10 µL 73 µL 
96-wellb 31 µL 7.8 µL 8.1 µL 8.1 µL 10 µL
d
 10 µL 75 µL 
384-well 16 µL --- --- 4 µL 10 µL
e
 10 µL 40 µL 
a
 manually handeled assay format; 
b
 automated dispensing assay format; 
c
 inhibitor dissolved in 100 % 
DMSO; 
d
 inhibitor dissolved in a solution of 30 % DMSO in H2O (v/v); 
e
 inhibitor dissolved in a solution of 16 % 
DMSO in H2O (v/v). 
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3.5.3.2.1 Cuvette assay 
The indicated amounts of buffer, H2O, BSA solution and HA solution were provided to 
Eppendorf reaction vessels (cf. Table 3.2). Subsequently, 10 µL of inhibitor solution 
(inhibitor dissolved in 100 % DMSO) was added. After addition of the enzyme solution the 
mixture was immediately incubated at 37 °C for 30 minutes (cf. Table 3.1). The enzymatic 
reaction was stopped by addition of 700 µL alkaline CTAB solution (2.5 % CTAB in 0.5 N 
NaOH (w/v)). Then, the mixture was incubated at room temperature for additional 
20 minutes to allow sufficient development of turbidity. Subsequently, the incubation 
mixture was transferred to cuvettes. The turbidity, quantified as optical density (OD), was 
measured at a wavelength of 580 nm using a Cary 100 UV-Vis spectrometer (Varian, 
Darmstadt, Germany) or at a wavelength of 578 nm using a Dr. Lange LP700 
spectrophotometer (Dr. Bruno Lange GmbH, Berlin, Germany). For the investigation of 
potential inhibitors, samples without inhibitor (minimal signal response) and without both 
inhibitor and enzyme (maximal signal response) were measured as references under 
assay conditions. 
 
3.5.3.2.2 Manually handled 96-well microtiter plate assay 
The indicated amounts of buffer, H2O, BSA solution and HA solution were provided to a 
96-well microtiter plate (cf. Table 3.2). Afterwards, 3 µL of inhibitor solution (inhibitor 
dissolved in 100 % DMSO) were added. Enzyme solution was added and the assay was 
immediately incubated at 37 °C for 30 minutes (cf. Table 3.1). The enzymatic reaction was 
stopped by addition of 200 µL alkaline CTAB solution (2.5 % CTAB in 0.5 N NaOH (w/v)). 
Subsequently, the plates were incubated for 20 minutes at room temperature to allow 
sufficient development of turbidity. The turbidity, quantified as optical density (OD), was 
measured at  =580 nm (absorbance mode) using a Tecan Genios Pro microtiter plate 
reader (Tecan Deutschland GmbH, Crailsheim, Germany) with XFluor Genios Pro 
software (version 4.55). The plates were shaken in the reader for 10 seconds; the OD was 
measured after 2 seconds of settling time by 10 flashes at the center of each well. For the 
investigation of potential inhibitors, samples without inhibitor (minimal signal response) 
and without both inhibitor and enzyme (maximal signal response) were measured as 
references under assay conditions. 
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3.5.3.2.3 96-well Microtiter plate format using an automated dispensing system 
The indicated amounts of buffer, H2O, BSA solution and HA solution were provided with a 
liquid handling system (Tecan TeMo automated liquid handling system, Tecan 
Deutschland GmbH, Crailsheim, Germany; Multidrop liquid dispenser, Mtx Lab systems 
Inc., USA) to 96-well microtiter plates (cf. Table 3.2). Afterwards, 10 µL of inhibitor solution 
(inhibitor dissolved in 30 % DMSO in H2O (v/v)) were added. The enzyme solution was 
dispensed and the assay was immediately incubated at 37 °C for 30 minutes (cf. Table 
3.1). The enzymatic reaction was stopped by addition of 200 µL CTAB solution (2.5 % 
CTAB in 0.5 N NaOH (w/v)). Subsequently the plates were incubated for 20 minutes at 
room temperature. The turbidity, quantified as optical density (OD), was measured at  = 
590 nm (absorbance mode) using a Tecan Ultra microtiter plate reader (Tecan 
Deutschland GmbH, Crailsheim, Germany) with Magellan Data Analysis Software (version 
5). The plates were shaken in the reader for 10 seconds; the OD was measured after 2 
seconds of settling time by 10 flashes at the center of each well. For the investigation of 
potential inhibitors, samples without inhibitor (minimal signal response) and without both 
inhibitor and enzyme (maximal signal response) were measured as references under 
assay conditions. 
 
3.5.3.2.4 384-well Microtiter plate assay using an automated dispensing system 
The indicated amounts of buffer, H2O, BSA solution and HA solution were provided with a 
liquid handling system (Tecan TeMo automated liquid handling system, Tecan 
Deutschland GmbH, Crailsheim, Germany; Multidrop liquid dispenser, Mtx Lab systems 
Inc., USA) to 384-well microtiter plates (Table 3.2). Accordingly, 10 µL of inhibitor solution 
(dissolved in 16 % DMSO in H2O (v/v)) was dispensed. Enzyme solution was added and 
the assay was immediately incubated at 37 °C for 30 minutes. The enzymatic reaction 
was stopped by addition of 200 µL CTAB solution (2.5 % CTAB in 0.5 N NaOH (w/v)). 
Subsequently, the plates were incubated for 20 minutes at room temperature to allow 
sufficient development of turbidity. The turbidity, quantified as optical density (OD), was 
measured at  = 590 nm (absorbance mode) using a Tecan Ultra microtiter plate reader 
(Tecan Deutschland GmbH, Crailsheim, Germany) with Magellan Data Analysis Software 
(version 5). The plates were shaken in the reader for 10 seconds; the OD was measured 
after 2 seconds of settling time by 3 flashes at the center of each well. For the 
investigation of potential inhibitors, samples without inhibitor (minimal signal response) 
and without both inhibitor and enzyme (maximal signal response) were measured as 
references under assay conditions. 
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3.5.3.3 Calculation of enzyme inhibition and IC50 values 
The effect of test compounds on the enzymatic activity was calculated via Equation 3.3: 
       
            
         
     
Equation 3.3 
 
A:  calculated enzymatic activity in % 
µmax:  mean extinction of the incubation mixture without inhibitor (without enzyme) 
µsample: mean extinction of the incubation mixture containing inhibitor (containing enzyme) 
µmin:  mean extinction of the incubation mixture without inhibitor (containing enzyme) 
 
The highest final concentration of the test compounds in the particular assay format was 
adjusted to 1 mM. A dilution series covering a concentration range from 0.5 µM to 1 mM 
was used regularly for the determination of IC50 values using cuvettes and manual 96-well 
assay format. The activities were plotted against the logarithm of the inhibitor 
concentration and IC50 ± SEM values were calculated by curve fitting of the experimental 
data with Sigma Plot 11.0 (SPSS Inc., Chicago, USA) and are the means of at least two 
independent experiments performed in duplicate. 
For measurements performed in the “auto 96-well assay” single concentrations (e.g. 
200 µM) of the test compounds were incubated. The compounds were measured as 
replicates located on two identical 96-well plates. For the auto 384-well assay a dilution 
series of 4 concentrations, covering 0.2 µM, 2.0 µM, 20 µM and 200 µM, was commonly 
used. In both cases blank measurements (without enzyme and HA) were performed per 
MTP. From data obtained from measurements at single concentrations the enzyme 
inhibition was calculated according to Equation 3.4. 
           {
              
           
    } 
Equation 3.4 
 
B:  calculated enzyme inhibition in % 
µ*max:  corrected mean extinction of the incubation mixture without inhibitor (without enzyme) 
µ*sample: corrected mean extinction of the incubation mixture containing inhibitor (containing enzyme) 
µ*min:  corrected mean extinction of the incubation mixture without inhibitor (containing enzyme) 
note:  µ* values were achieved via subtraction of appropriate blank measurements 
 
If possible, the IC50 values were determined by a 4-parameter logistic fit of percentage 
activity versus log concentration in the 384-well format. 
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3.5.3.4 Checking of compound solubility 
Since poor solubility of the tested compounds could lead to false positive results in the 
turbidimetric assay, prior to the investigation of hyaluronidase inhibition the solubility was 
determined, taking the concentration range from 0.5 µM to 1 mM into consideration. To 
verify the solubility of the test compounds, a sample containing 920 µL citrate phosphate 
buffer (pH = 5.0), 120 µL BSA solution (0.2 mg/mL) and 40 µL of a solution of the 
respective test compound (compound dissolved in 100 % DMSO) was measured at a 
wavelength of 580 nm using a Cary 100 UV-Vis spectrometer (Varian, Darmstadt, 
Germany). A cuvette filled with 920 µL of buffer, 120 µL of BSA solution and 40 µL DMSO 
served as reference. Precipitation of the compounds at the investigated concentrations 
(≤ 1 mM) with alkaline CTAB solution (2.5 % CTAB in 0.5 N NaOH (w/v)) was not 
observed and can be excluded. 
 
3.5.3.5 Blank measurements 
Turbidity of screening compounds was quantified at a wavelength of 590 nm using a 
Tecan microplate reader. However, substances obtained from multicomponent synthesis 
frequently appear as colored products (cf. Figure 3.6). Those compounds were also able 
to absorb light at a wavelength of  = 590 nm in the screening for hyaluronidase inhibition. 
 
 
 
 
 
 
Figure 3.6 96-well deep well plate containing 
molecules synthesized via one-pot multicomponent 
synthesis. 
 
Examples of colored compounds in 96-well and a 384-well microtiter plates are given in 
Figure 3.6. Here, the sample compounds were already diluted to the final assay 
concentration. 
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Figure 3.7 Screening plates 
containing colored compounds. 
 
The investigation at a wavelength of 590 nm in the absence of further assay ingredients 
revealed strong extinction for individual colored substances. Hence, such substances 
were able to pretend turbidity which could be interpreted as enzyme inhibition. To avoid 
false-positive results, blank measurements (“blank plates”), i.e. incubation mixtures devoid 
of hyaluronan and enzyme solution (replaced by H2O and BSA solution, respectively), 
became obligatory for routine operations. 
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4 Assessment and validation of screening hits 
using a medium throughput assay format with 
automated dispensing 
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4.1 Introduction 
The ability to identify true active compounds depends on the high quality of assays and 
proper analysis of data. The Z’ factor, presented by Zhang et al. in 1999, provides an easy 
and useful summary of assay quality and has been a widely accepted standard.1 
In this thesis, for the first time, it became possible to test several hundred compounds in 
parallel and to characterize them with regard to inhibition of SagHyal4755. These primary 
screens are less elaborated than conventional assays.2-5 Compounds are only tested in 
duplicate used at a single concentration (200 µM). When a positive result or “hit” is 
discovered in this primary screen, a more accurate and precise secondary screening 
should be performed to allow quantification and the calculation of IC50 values. 
Aiming at a fail-safe discovery of hit compounds, a reliable discrimination between 
molecules with significant biological effects and inactive compounds among a library of 
substances became necessary. As outlined in Table 4.1, special attention was paid to key 
parameters for the validation of assay performance and sensitivity in an automated assay 
format. 
Table 4.1 Criteria to determine assay performance or sensitivity.
6
 
Parameter Equation Comment 
Coefficient of variation 
    
 
√ 
 
     
A measure of the precision 
relative to the mean value, 
calculated for the maximum and 
minimum signals. An acceptable 
limit is < 20 % 
Signal window 
   
                      
    
 
The significant signal between 
max and min controls, acceptable 
value > 2 fold 
Z’ factor 
     
            
|         |
 
Representation of the SW using a 
score where a value of > 0.5 
indicates an acceptable assay. Z’ 
is measured in the absence of 
library compounds 
: standard deviation of the assay signal; n: wells per test compound; µ: mean of the assay signal; max, 
maximum signal; min, minimum signal. 
 
Parameters and methods of high throughput assay validation were adopted from the 
“guidance for assay development and HTS manual”, an open access manual which was 
elaborated by coworkers of the Eli Lilly company.7 Prior to a screening campaign of 
compounds (pre-screening), assay validation involved two aspects. The first aspect 
referred to assay ingredients. Here, it is necessary to provide equal composition of the 
ingredients across all formats (cuvette, 96-well MTP, 384-well MTP) of the turbidimetric 
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assay.7 In addition, the percentage of the components in the incubation mixture had to be 
kept constant. The second aspect of the pre-screening assay validation referred to the 
responses to biologically active compounds. In particular, the span from minimum to 
maximum assay response was monitored over time.7 
 
4.2 Validation of the automated hyaluronidase assay 
For medium-throughput screening, the automated 96-well microtiter plate assay was 
used. Prior to the screening its accuracy and sensitivity had to be determined. To validate 
the reliability of the automated assay parameters such as signal window (SW) and Z’ 
factor, were evaluated (cf. Table 4.1). 
 
4.2.1 Pre-screen assay validation 
4.2.1.1 Assay ingredients 
In view of uniformity, suppliers of chemicals and materials were not changed. Reagents 
were stored in aliquots suitable for consumption on a single day. Leftover reagents were 
not saved or used for following assays. Solutions of reference compounds were prepared 
and diluted shortly before use.7 The percentual composition of the ingredients in the 
different formats of the assay is summarized in Table 4.2. There was only a marginal 
variation in the concentration of buffer components, BSA and HA. The final DMSO 
concentration varied from 3.7 % to 4.1 % (v/v). 
Table 4.2 Percentual composition of assay ingredients in the different formats of the turbidimetric assay. 
 
Assay format Buffer 
(pH 5.0) 
H2O BSA 
(0.2 mg/mL) 
HA 
(2 mg/mL) 
DMSO Enzyme solution
a
 
 
cuvette 44.5 % 18.5 % 11.1 % 11.1 % 3.7 % 11.1 %  
manual 96-well 42.5 % 17.5 % 11.1 % 11.1 % 4.1 % 13.7 %  
auto 96-well 41.4 % 19.7 % 10.8 % 10.8 % 4.0 % 13.3 %  
auto 384-well 40.0 % 21.0 % --- 10.0 % 4.0 % 25.0 %  
 
a 
enzyme solution was diluted with 0.2 mg/mL BSA. 
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4.2.1.2 Signal uniformity and signal separation 
To investigate the variability of standard assay signals, a “plate uniformity assessment” 
study was run for the automated 96-well microtiter plate turbidimetric assay, i.e. the 
uniformity and separation of signals of reference samples was analyzed. For this purpose, 
three different types of signals (maximum, minimum and mid-point signals (diclofenac, 
Vcpal) ) were recorded on three consecutive days.7 Maximum (“max”) assay response 
was obtained for incubation mixtures without inhibitor and without enzyme. Minimum 
(“min”) assay response was recorded for incubation mixtures without inhibitor. Mid-point 
(“mid”) signals referred to incubation mixtures containing enzyme in combination with a 
standard inhibitor (Vcpal) at a final assay concentration of 20 µM. The arrangement of 
standards and samples is shown in Figure 4.1. 
A 
 
B 
 
C 
 
Figure 4.1 Arrangement of standards and samples on 96-well assay plates (A, B, C); “H” = maximum, “M” = 
mid-point, “L” = minimum signal. 
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Plate uniformity, i.e. SW value, was computed from the separation of maximum, mid-point 
and minimum signals. Every plate contained incubation mixtures for the determination of 
maximum, mid-point and minimum signals. On three consecutive days, the procedure was 
repeated to obtain raw data for subsequent plate uniformity study. 
A scatter plot was used to illustrate signal variation between maximum, mid-point and 
minimum signals. The inhibition of hyaluronidase was detected as extinction measured at 
a wavelength of 590 nm. In Figure 4.2, the corresponding signal variation plots for days 1 
to 3 are illustrated. 
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Figure 4.2 Signal variation graph for all plates (A: day 1; B: day 2 and C: day 3). Signal responses for 
maximum, mid-point and minimal signals were plotted versus extinction at 590 nm. Max, mid and min signals 
were sorted “plate wise”, e.g. max signals derived from plate 1 (wells 1-32), plate 2 (wells 33-64) and plate 3 
(wells 65-96) were plotted as ensemble in graph A. 
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By graphical evaluation, the plots displayed an appropriate differentiation between 
maximum and minimum signals. Moreover, maximum signals showed a high degree of 
reproducibility. Despite of several outliers of the minimum signal, the baseline did not 
indicate drift patterns. The mid-point signals, as shown in Figure 4.2, were less uniform. 
From the collected raw data, the coefficient of variation (% CV) for each type of signal 
(maximum, mid-point, minimum) on each plate was computed as follows (Equation 4.1).6, 8 
 
    
 
√ 
 
     
 
Equation 4.1 
% CV:  (percentual) coefficient of variation 
:  standard deviation of the assay signal (max, mid, min signal) 
n: wells per sample (max, mid, min signal) 
µ:  mean of the assay signal (max, mid, min signal) 
 
The results are summarized in Table 4.3. 
Table 4.3 Coefficients of variation in percent (% CV). 
 
Run % CVmax % CVmin % CVmid 
day 1, plate 1 0.2 3.3 3.2 
day 1, plate 2 0.3 4.9 3.7 
day 1, plate 3 0.3 2.6 3.9 
day 2, plate 1 0.2 3.7 3.5 
day 2, plate 2 0.3 3.9 4.2 
day 2, plate 3 0.3 5.1 4.3 
day 3, plate 1 0.3 4.8 2.4 
day 3, plate 2 0.2 4.7 2.8 
day 3, plate 3 0.3 4.3 2.1 
 
According to Eastwood et al. (2007), an acceptable limit for the coefficient of variation 
(% CV) calculated for maximum and minimum signals is less than or equal to 20 %.7 As 
shown in Table 4.3, this was fulfilled for maximum (% CVmax), mid-point (% CVmid) and 
minimum (% CVmin) values. 
Signal window (SW) and Z’ factor were calculated according to Equation 4.2 and Equation 
4.3, respectively.6-8 
    
                      
    
 Equation 4.2 
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 Equation 4.3 
SW:  signal window 
Z’: Z’ factor 
µmax:  mean of the maximum reference signal 
µmin:  mean of the minimum reference signal 
max:  standard deviation of the maximum reference signal 
min:  standard deviation of the maximum reference signal 
 
Signal window (SW) and Z’ data were computed for each microtiter plate every day. The 
results are displayed in Table 4.4. 
Table 4.4 Signal windows (SW) and Z’ factors of days 1 to 3 from plates 1 to 3. 
 
Run SW Z’ 
day 1, plate 1 85.3 0.9 
day 1, plate 2 36.5 0.8 
day 1, plate 3 45.3 0.9 
day 2, plate 1 56.5 0.8 
day 2, plate 2 52.6 0.8 
day 2, plate 3 37.4 0.8 
day 3, plate 1 37.3 0.8 
day 3, plate 2 50.6 0.8 
day 3, plate 3 46.9 0.8 
 
 
The published acceptance criteria for SW and Z’ are summarized in Table 4.5. 
Table 4.5 Acceptance criteria for signal window (SW) and Z’ factor (Z’); adopted from Iversen et al.
8
 
SW Z’ 
recommended: SW > 2 excellent:         Z’ > 0.5 
acceptable:        SW > 1 do-able:           0 < Z’ < 0.5 
unacceptable:    SW < 1 yes/no assay:  Z’ = 0 
 unacceptable:  Z’ < 0 
 
The 96-well microtiter plate hyaluronidase assay with automated dispensing fulfilled all 
required assay performance criteria. Consequently, this assay was used for medium-
throughput screening. 
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4.2.2 On-screen assay validation 
By analogy to the pre-screen validation, sample giving maximum mid-point and minimum 
signals were positioned on every plate as shown in section 3.4.4. Vcpal and diclofenac 
served as reference compounds. Both inhibitors were measured at 8 concentrations. 
Vcpal, one of the most potent hyaluronidase inhibitors, served as primary control. The 
dilution series covered a range from to 0.8 µM to 800 µM (final concentrations). 
Diclofenac, as secondary control, shows over 20 fold less potent inhibition than the 
primary control. The dilution series covered a range from 8 µM to 800 µM (final 
concentrations). 
To determine the robustness of each screening campaign, the IC50 values of Vcpal and 
diclofenac were analyzed for each 96-well screening plate. In addition to the primary and 
secondary control, the correlating Z’ factor was calculated.9 An example is shown in 
Figure 4.3. 
 
Figure 4.3 Robust screening performance evidenced by Z‘ factor (white squares) and stable IC50 values for 
Vcpal (▼) and Diclofenac (▲) used as primary and secondary control in each screening plate. 
 
Here, the screening performance of screening plates ori.hya.47-54 is exemplified. For 
each experiment on a particular plate (“measurement”), IC50 values of the primary 
reference Vcpal (▼), secondary reference Diclofenac (▲) as well as Z’ factor (□) are 
documented. This was performed for every screening plate throughout the testing 
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procedures. Acceptance criteria were Z’ factor > 0.5 (cf. Table 4.5) and no significant drift 
effect concerning IC50 values of the reference compounds across plates. On-screening 
assay validation of screening plates is documented in section B.8 (appendix II). 
 
4.3 Hit validation 
To classify positive screening results as hits, a weight function was applied. 
4.3.1 Hit assessment 
The standard error of the mean of an individual screening compound (SEMi) was 
calculated as follows (Equation 4.4). 
      
  
√ 
 Equation 4.4 
SEMi: standard error of the mean of the extinction measured for an individual screening compound (i) 
i standard deviation of the extinction measured for an individual screening compound (i) 
n: number of samples (sample size) 
 
A weight function of an individual screening compound (wi) was calculated from the SEMi 
according to Equation 4.5. Weighted effect of an individual screening compound (wi*) was 
computed according to Equation 4.6. 
    
 
       
 Equation 4.5 
   
         Equation 4.6 
wi: weight function of an individual screening compound (i) 
SEMi: standard error of the mean of an individual screening compound (i) 
wi*: weighted effect of an individual screening compound (i) 
Ei: extinction in the presence of an individual screening compound (i) 
µEi: mean extinction in the presence of an individual screening compound (i) 
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4.3.2 Representation of screening data 
To illustrate screening data, two different plots, denoted as “effect plot” and “weighted 
effect plot” were used. In the “effect plot”, each compound of the screening plate is plotted 
versus the corresponding mean percentual enzymatic activity derived from duplicate 
measurements. An example is given in Figure 4.4, representing screening data of plate 
ori.hya.scr.3. 
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Figure 4.4 Effect plot of screening plate ori.hya.scr.3. 
 
In Figure 4.4, the mean value for the references of maximal enzymatic activity is indicated 
as a black solid line. Upper and lower limits (threefold standard deviation of maximum 
reference) are indicated as dashed lines. The 50 % effect is indicated as a dashed red 
line. The compounds are listed according to their well number first by column (i.e. A-H) 
then by row (i.e. 1-12) in the graph. Each screening compound was investigated in a 
single-concentration (200 µM). Among 80 compounds, one substance reduced enzymatic 
activity by more than 50 %. 
 
50 Hit validation  
An additional “effect plot” is shown in Figure 4.5. 
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Figure 4.5 Effect plot of screening plate ori.hya.44. 
 
As an example, the screening results for plate ori.hya.44 (88 compounds) are given. 
Different from the previous example, all substances were tested irrespective of 
identification of the target mass. Accordingly, compounds without affirmed target mass are 
labeled as “○“. Test compounds with target mass are marked as “●“. In summary, 16 
substances, including four compounds which were not confirmed by mass spectrometry, 
reduced enzymatic activity to below 50 %. 
To assess the relevance of inhibition data, for each “effect plot” the corresponding 
“weighted effect plot” was additionally computed. In detail, the calculated weighted effect 
wi
* (cf. Equation 4.6) was plotted versus mean percentual enzymatic activity. To accept a 
screening compound as “hit”, the weighted effect wi
* was recommended to be ≥ 1 and the 
enzymatic activity < 50 %. Confirmed hits (“●“) within these limits (“hit window”) were 
subjected to preparative synthesis in order to certify the proposed hyaluronidase 
inhibition. 
The corresponding “weighted effect plot” of plate ori.hya.scr.3 (cf. Figure 4.4) is given in 
Figure 4.6.  
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Figure 4.6 Weighted effect plot of screening plate ori.hya.scr.3. 
 
As illustrated, only a single substance fulfills both recommended criteria: enzymatic 
activity < 50 % (dashed red line) and weighted effect wi
* ≥ 1 (dashed blue line). 
Subsequently, this compound was termed as hit. 
The “weighted effect plot” of plate ori.hya.44 (cf. Figure 4.5) is displayed in Figure 4.7. 
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Figure 4.7 Weighted effect plot of screening plate ori.hya.44. 
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As shown in Figure 4.7, 16 substances reduced enzymatic activity to less than 50 %. 
Different from the effect plot, the weighted effect plot revealed only 10 compounds with 
confirmed molecular mass in the hit window (enzymatic activity < 50 %; weighted effect 
wi
* ≥ 1). Accordingly, these compounds were termed as hits. 
The “effect plots” and “weighted effect plots” for all screening plates are documented in 
section B.9 (appendix II). 
The hit criteria for the screening campaign are summarized in Table 4.6.  
Table 4.6 Acceptance criteria for determination of screening hits. 
Parameter Requirement 
Z’ factor > 0.5 
primary reference  
(Vcpal) 
no drift or edge effects visible for the 
IC50 value 
secondary reference 
(diclofenac) 
no drift or edge effects visible for the 
IC50 value 
inhibitory effect > 50 % 
weighted effect wi
*
 ≥ 1 
 
All identified hit compounds were re-tested as purified compounds for the determination of 
IC50 values. Synthesis and pharmacological characterization of the corresponding 
compounds will be discussed in chapter 5. 
 
4.4 Summary 
According to high-throughput (HTS) techniques, a screening method was devised for 
liquid handling systems, allowing automated dispensing of all assay ingredients. 
Validation according to standard parameters of quality control according to procedures 
established in the pharmaceutical industry proved that the new microplate assay is robust 
and efficient for the screening of large libraries of potential hyaluronidase inhibitors. 
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5.1 Introduction 
Since the first description of hyaluronan in the early 1930s1 and hyaluronan degrading 
enzymes, the hyaluronidases, in the 1940s2, academic research on this topic represents a 
controversial and challenging field. The hyaluronidases have been a group of less 
extensively studied glycosidases.3 Hence, there is little knowledge about the physiological 
role of isoforms of hyaluronidases and their involvement with a variety of diseases. Potent 
and selective hyaluronidase inhibitors are not available so far. However, such compounds 
are required as molecular tools to perform pharmacological studies aiming at more 
detailed insights into the complex functions of hyaluronidases in hyaluronan metabolism. 
Moreover, hyaluronidase inhibitors are of potential therapeutic value. As an example, 
inhibitors of bacterial lyases might be useful as adjuvants to enhance the chemotherapy of 
drug-resistant bacteria. However, in terms of drug research including rational design of 
inhibitors, hyaluronidases have been a class of neglected enzymes. At present, small 
drug-like molecules with sufficient inhibitory potency are not available, although (weak) 
hyaluronidase inhibitors of bacterial enzymes have been discovered among natural 
products and synthetic molecules.3-7 
Over the past decade, research in our laboratories has led to the discovery and validation 
of potent inhibitors of hyaluronidases with a preference for the bacterial enzymes. The 
identification and development of these substances was mainly driven by conventional 
medicinal chemistry approaches. Inhibitors were designed as substrate analogs or 
synthesized according to an iterative optimization process, in several cases starting from 
incidentally discovered inhibitors. For example, lipophilic derivatives of L-ascorbic acid 
(vitamin C) were developed, which are among the most potent inhibitors of the bacterial 
hyaluronidase SagHyal4755 known today.
8-11 Moreover, potent hyaluronidase inhibitors 
were identified among a variety of heterocycles such as benzimidazoles, benzoxazoles, 
indoles, phenylindoles, gluconolactones and some miscellaneous substances.12-20 In 
general, the potency of hyaluronidase inhibitors correlates with lipophilicity, e.g. conferred 
by fatty acid-like moieties, and the presence of negatively charged groups. The drug-like 
properties of highly lipophilic compounds are often strongly affected, for example due to 
low bioavailability or very high plasma protein binding. In fact, the previously identified 
inhibitors are almost completely bound to plasma proteins, which precludes their 
application in studies using protein-rich biological material, e.g. serum, and in in vivo 
investigations. 
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In this context, the rational design of drug-like low molecular weight hyaluronidase 
inhibitors is a difficult challenge. To cope with this problem, a target-based approach for 
the design, synthesis and pharmacological characterization of novel lead inhibitors of a 
streptococcal hyaluronidase (SagHyal4755) is described in this chapter. 
Crystal structures of bacterial hyaluronidases incorporating substrate fragments as well as 
structures in complex with inhibitors were previously published by our workgroup.18, 21-29 
Furthermore, suitable protein structures of the target enzyme were available from the 
protein data bank. A collaborative project with Origenis GmbH, a specialized biotech 
company for computer-assisted drug-design in combination with multicomponent reaction 
synthesis of compound libraries, was launched to expand the range of methods. Modus 
operandi of the venture was in accordance to a ligand-based drug design cycle for the 
identification of lead inhibitors (cf. Figure 5.1).  
 
Figure 5.1 Scheme of the pursued ligand-based drug design cycle for the identification of novel lead inhibitors 
of bacterial hyaluronidase SagHyal4755. 
 
This concept was inspired by standard operation procedures from pharmaceutical 
industry, but was customized for the own purpose and adjusted with regard to the applied 
methodology. The combination of innovative computer-assisted methods for drug design 
and modern synthesis technologies was used to identify novel structural motifs. Initially, a 
compound library comprising 347 selected inhibitors of the target enzyme was analyzed 
(cf. section B.1.1., appendix II). The corresponding structure-activity relationships (SAR) 
were elucidated with the aid of the repertoire of methods of the collaboration partner and 
models of the enzyme in complex with potential inhibitors were generated in silico. For this 
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purpose, only small molecules, predicted to possess drug-like properties and to be 
accessible by multi-component synthesis were taken into consideration. 
A variety of substances was selected for parallel synthesis and biological tests. As 
outlined in Figure 5.1, following an iterative process, the suggested compounds were 
synthesized via parallel synthesis, analyzed and investigated for hyaluronidase inhibition 
in the medium throughput range. In accordance with the chemical parameters, molecular 
structures were synthesized in one-pot reactions miniaturized down to 96 deep-well 
plates. Moreover, automated synthesis was used to synthesize vast compound libraries. 
Virtual screening and docking experiments suggested compounds having a 1H-pyrrol-
2(5H)-one- or a 4-amino-1H-imidazole-2(5H)-(thi)one scaffold as potential hyaluronidase 
inhibitors (Figure 5.2). 
 
Figure 5.2 General structures of the predicted 1,5-dihydropyrrol-2-one-, 4-amino-1H-imidazole-2(5H)-one- and 
4-amino-1H-imidazole-2(5H)-thione-type hyaluronidase inhibitors. 
 
These results prompted us to synthesize two generations of compounds predicted to have 
hyaluronidase inhibitory activity. Several hundred substances were prepared by parallel 
synthesis, analyzed by means of HPLC-MS and investigated for inhibition of the target 
hyaluronate lyase SagHyal4755. 
 
 
 
 
 
 
 
4-Amino-1H-imidazole-2(5H)-thiones as inhibitors of bacterial hyaluronidase: a computer-assisted 
and multicomponent synthesis approach 59 
5.2 Synthesis and characterization of first generation 
inhibitors 
5.2.1 Parallel synthesis of 1H-pyrrol-2(5H)-ones 
The 1H-pyrrol-2(5H)-ones (3-pyrrolin-2-ones, 1,5-dihydro-2H-pyrrol-2-ones) described in 
this section were synthesized by one-pot multicomponent reactions. Several methods 
have been reported for the preparation of 1H-pyrrol-2(5H)-ones in literature.30-38 A 
convenient parallel synthesis was carried out as a “Doebner-type” approach as three 
component condensation (Figure 5.3). 
 
Figure 5.3 Multicomponent synthesis of substituted 3-hydroxylated 1H-pyrrol-2(5H)-ones (4). Substitutions 
patterns of starting materials 1, 2 and 3 cf. section B.3 (appendix II). Reagents and conditions: anhydrous 
EtOH, 20 h, rt. 
 
The reaction of amines 1, aldehydes 2 and suitable pyruvic acid esters (methyl and ethyl 
pyruvates) 3 was utilized for the construction of a series of substituted 3-hydroxy-1H-
pyrrol-2(5H)-ones of general structure 4. In detail, after the generation of the 
corresponding imine species, pyruvic acid esters were added. The mixture was allowed to 
react for 20 hours at ambient temperature to give the target molecules.39-44 
For parallel synthesis, starting materials in anhydrous ethanol were transferred to 96-deep 
well plates with an automated liquid handling system (Figure 5.4). 
  
Figure 5.4 Images of technical equipment used for parallel synthesis (Tecan Genesis RSP 200/8 parallel 
synthesizer). 
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A compound library consisting of 880 substances was obtained from a combinatorial 
reaction matrix of 11 amines, 16 aldehydes and 5 pyruvic acid esters. The compounds 
were left on 10 deep well plates (ori.hya.10-19). After HPLC mass spectral analysis (ESI-
TOF), the solvent was evaporated and the crude substances were dispensed in 
dimethylsulfoxide, adjusting to a concentration of 20 mM. Deep-well plates were sealed 
and stored at -20 °C. Starting materials (amines 1, aldehydes 2, pyruvic ester 3) and mass 
spectral analysis of target molecules 4 on plates ori.hya.10-19 are documented in section 
B.3 (appendix II). 
 
5.2.2 Parallel synthesis of 4-amino-1H-imidazole-2(5H)-ones and  
-thiones 
The reaction of amines 1, aldehydes 2 and isocyanides 5 in the presence of potassium 
cyanate (6) lead to 4-amino-1H-imidazole-2(5H)-ones (7) via incorporation of the cyanate 
counterion (Figure 5.5).45 
 
Figure 5.5 Multicomponent synthesis of substituted 4-amino-1H-imidazole-2(5H)-ones (7); substitutions 
patterns of starting materials 1, 2 and 5 cf. section B.4 (appendix II). Reagents and conditions: anhydrous 
MeOH, pyridinium chloride, 48 h, < 20 °C. 
 
The reactions were carried out as one-pot syntheses under mild conditions. The potential 
of this four-component condensation reaction, which is also referred to as Ugi four-
component condensation (Ugi 4CC), was elucidated for the preparation of a combinatorial 
library of 4-amino-1H-imidazole-2(5H)-ones.46-49  
The mechanism of this condensation reaction involves at first the formation of iminium 
ions, which are formed from carbonyl compounds and amines in solutions of suitable 
acidity.50 Iminium ions in combination with cyanate anions are ideal reaction partners for 
the acid-sensitive isocyanides, which react by electrophilic -additions. The participation 
of cyanate and thiocyanate results in an intramolecular acylation. The nitrogen atom of the 
-aminoalkyl group in the -adduct is acylated by means of a cyclic mechanism, provided 
that a N-H bond is available. This leads to the formation of five-membered, non-aromatic 
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heterocycles, the 4-amino-1H-imidazole-2(5H)-ones and, by analogy, to 4-amino-1H-
imidazole-2(5H)-thiones.50 
A selection of alkyl- and aryl-substituted amines, aldehydes and isocyanides was 
arranged from commercially purchased chemicals. Miniaturized parallel synthesis was 
performed on a liquid handling system (solvent: anhydrous methanol) and was started by 
the addition of amine and aldehyde. After 30 min, the reaction mixtures on the 96-deep-
well plates were cooled to 0 °C. Accordingly excess of pyridinium chloride, potassium 
cyanate and equimolar amounts of isocyanide were added. Product formation was 
observed after 48 hours when stored at temperatures below < 20 °C. 
Similarly, 4-amino-1H-imidazole-2(5H)-thiones 9 were synthesized by analogy with the 
protocol for the preparation of 7, except that potassium cyanate was replaced by 
potassium thiocyanate 8 (Figure 5.6). 45, 46, 51, 52 
 
Figure 5.6 Multicomponent synthesis of substituted 4-amino-1H-imidazole-2(5H)-thiones (9); substitutions 
patterns of starting materials 1, 2 and 5 cf. section B.4 (appendix II). Reagents and conditions: KSCN, 
anhydrous MeOH, pyridinium chloride, 48 h, < 20 °C. 
 
A screening library of 1408 substances was synthesized from combinatorial variation of 11 
amines, 16 aldehydes, 4 isocyanides, potassium cyanate and thiocyanate, respectively. 
The compounds were loaded on to 16 deep-well plates (ori.hya.20-35). After ESI-TOF 
mass spectrometry, the plates were processed as described before. Starting materials 
(amines 1, aldehydes 2, isocyanides 5) and mass spectral analysis of target molecules 7, 
9 on plates ori.hya.20-35 are documented in section B.4 (appendix II). 
 
One-pot synthesis from both campaigns yielded a total of 2288 compounds. The 
uneconomic and time-consuming purification of all these substances was not performed. 
Instead, the crude compounds were analyzed by HPLC-MS (ESI-TOF) and categorized. 
For biological investigations only those wells were selected in which, according to mass 
spectometric analysis, the respective target compound represented the major ingredient. 
A collection of 549 compounds with certified mass spectra and obtained in sufficient 
quantities was subjected to screening. These substances were picked automatically and 
put on 7 deep-well screening plates (ori.hya.scr.1-7, for detais see section B.5 
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(appendix II)). The remaining 1739 compounds were not investigated for hyaluronidase 
inhibitory activity. 
 
5.3 Pharmacological results and discussion of first 
generation inhibitors 
5.3.1 General conditions and screening mode 
Determination of inhibitory activity was assessed using the automated 96-well microtiter 
plate turbidimetric assay. Enzymatic activities of test compounds were computed for an 
assumed final assay concentration of 200 µM. Duplicates were performed on separate 
plates. SagHyal4755 was dispensed with a final enzymatic activity of 0.1 mU. Test 
compounds, buffer ingredients and enzyme solution as well as stopping reagent (CTAB) 
were dispensed with automated liquid handling systems (Tecan TeMo, Tecan 
Deutschland GmbH, Crailsheim, Germany; Multidrop liquid dispenser, Mtx Lab systems 
Inc., USA). Incubation time of screening plates was set to 30 min. A total of 209 
substituted 1H-pyrrol-2(5H)-ones and 340 alkylated and arylated 4-amino-1H-imidazole-
2(5H)-ones and –thiones were tested for hyaluronidase inhibition. Effect of screening 
compounds on enzymatic activity of SagHyal4755 is illustrated by “effect plots” and 
“weighted effect plots”. 
 
5.3.2 Inhibitory activities of screening compounds on 
SagHyal4755 
Among the 549 investigated substances, 3 compounds (5.1, 5.2 and 5.3) were identified 
as screening hits. Relative to the total volume of test compounds this represents a hit rate 
of 0.5 % (0.1 % for 2288 substances). A detailed on-screen assay validation and 
representation of screening data is given in appendix II (sections B.8.2, B.9.3). Chemical 
structures of the identified hits are shown in Figure 5.7. 
 
Figure 5.7 Structures of identified hits (5.1-5.3) from the first screening campaign. 
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At this stage, the criteria to denote a compound as hit (inhibitory effect > 50 %, weighted 
effect ≥ 1 (cf. section 4.3.2)) were loosened to some extent (inhibitory effect 20 % - 50 %, 
weighted effect ≥ 1). Accordingly, 8 additional substances (5.4-5.11, Figure 5.8) with 
certified mass were pharmacologically characterized. These molecules were investigated 
to gain new ideas for novel inhibitors. 
 
Figure 5.8 Structures of additional compounds of the first screening campaign displaying inhibitory activity 
between 20 % and 50 % (5.4-5.11). 
 
The inhibitory activities of compounds 5.1-5.11 are summarized in Table 5.1. 
Table 5.1 Inhibitory activity of compounds 5.1-5.11 on SagHyal4755 and BTH. 
Compound SagHyal4755 
% inhibition
a
 
BTH 
% inhibition 
Comment 
5.1 73 ± 6 inactive hit 
5.2 53 ± 7 inactive hit 
5.3 52 ± 0 inactive hit 
5.4 24 ± 3 inactive missed hit criteria 
5.5 28 ± 3 inactive missed hit criteria 
5.6 38 ± 10 inactive missed hit criteria 
5.7 21 ± 2 inactive missed hit criteria 
5.8 13 ± 7 inactive missed hit criteria 
5.9 26 ± 5 inactive missed hit criteria 
5.10 32 ± 11 inactive missed hit criteria 
5.11 26 ± 3 inactive missed hit criteria 
a
 mean values ± SEM (N = 2, experiments performed in duplicate), maximal concentrations of the test 
compounds were set to an assumed final assay concentration of 200 µM; percent inhibition determined at pH 
5.0 in the automated 96-well turbidimetric assay. 
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Compounds 5.2 and 5.3 were structurally modified by synthesis of the corresponding 
thioxo- (5.12) and oxo- (5.13) analogs (Figure 5.9). Additionally, the pentan-2-ylamino 
moiety in the eastern part of 5.2 was replaced by a sec-butylamino moiety in the oxo- 
(5.14) and thioxo- (5.15) derivative. 
 
Figure 5.9 Structures of newly designed and synthesized 4-amino-1H-imidazole-2(5H)-ones (5.13, 5.14) and  
–thiones (5.12, 5.15). 
 
5.3.3 Inhibitory activities of purified compounds on SagHyal4755 
To determine inhibitory activities of purified substances, screening hits 5.1-5.3 and 5.6, 
5.10 were synthesized in conventional manner. In addition, 5.12-5.15 were synthesized by 
one-pot reactions. In the case of 5.1 and 5.6 the preparation of the target compounds 
failed. Unfortunately, with 5.1 the most active inhibitor of the screening campaign was lost 
at this stage. The inhibitory activities of the remaining purified substances (RP-HPLC) are 
shown in Table 5.2. 
Table 5.2 Inhibitory activity of compounds 5.2, 5.3, 5.10, 5.12-5.15 on SagHyal4755 and BTH. 
Compound SagHyal4755 
IC50 (µM)
a
 
BTH 
IC50 (µM) 
5.2 inactive inactive 
5.3 150 ± 20 inactive 
5.10 inactive inactive 
5.12 > 1500 inactive 
5.13 980 ± 50 inactive 
5.14 1100 ± 55 inactive 
5.15 200 ± 25 inactive 
a
 mean values ± SEM (N = 2, experiments performed in duplicate; IC50 values determined at pH 5.0 in the 96-
well turbidimetric assay. 
 
As shown in Table 5.2, IC50 values of 150 µM and 980 µM were determined for 5.3 and 
5.13, respectively. Compound 5.3 (4-(4-chlorobenzylamino)-5-(3,5-dihydroxyphenyl)-1-(3-
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hydroxyphenyl)-1H-imidazole-2(5H)-thione) represented the most potent confirmed hit. 
Compared to 5.13, the replacement of sulfur by oxygen led to 6.5-fold decrease in 
potency. Pure substance 5.10 revealed a total loss of inhibitory activity, although the 
screening of the raw product suggested moderate inhibition. Concentration dependent 
activity of SagHyal4755 in the presence of 5.3, 5.10 and 5.13 is illustrated in Figure 5.10. 
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Figure 5.10 Concentration dependent activity of SagHyal4755 in the presence of 5.3, 5.10 and 5.13. 
 
For compounds 5.2 (4-amino-1H-imidazole-2(5H)-one) and 5.12 (4-amino-1H-imidazole-
2(5H)-thione) the aromatic substituent at the 4-amino group was replaced by a pentan-2-yl 
moiety. Both derivatives showed a (total) loss of inhibitory activity. However, for analogs 
bearing a sec-butyl residue, IC50 values of 1100 µM (5.14) and 200 µM (5.15) were 
calculated. Concentration dependent activity of SagHyal4755 in the presence of 5.2, 5.12 
and 5.14, 5.15 is shown in Figure 5.11. 
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Figure 5.11 Concentration dependent activity of SagHyal4755 in the presence of 5.2, 5.12 and 5.14, 5.15. 
 
Taken together, regardless of the observed dramatic discrepancies between inhibitory 
activities of raw and purified compounds, the biological activity at the streptococcal lyase 
SagHyal4755 was confirmed for 4-amino-1H-imidazole-2(5H)-thione 5.3. By trend, 
substituted 4-amino-1H-imidazole-2(5H)-thiones (cf. 5.2, 5.3, 5.14) showed a stronger 
inhibition on SagHyal4755 than the structurally related 4-amino-1H-imidazole-2(5H)-ones 
(cf. 5.12, 5.13, 5.15). Therefore, 4-amino-1H-imidazole-2(5H)-thiones bearing aromatic 
moieties were regarded as a promising starting point for further development of 
hyaluronate lyase inhibitors. Hence, a daughter generation of 4-amino-1H-imidazole-
2(5H)-thiones with suitable substitution pattern was prepared by parallel synthesis and 
subjected to evaluation for hyaluronidase inhibition.  The procedures and results will be 
presented in the following section. 
 
5.3.4 Inhibitory activities of purified compounds on BTH 
There are major structural differences between streptococcal lyase SagHyal4755 and the 
bovine testicular hyaluronidase BTH. To ensure that potential activities at mammalian 
hyaluronidases are not overlooked, all substances were also tested for inhibitory activity 
on BTH as a typical hyaluronan hydrolase. However, there was no inhibition of this 
enzyme detected in the investigated concentration range (cf. Table 5.2). 
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5.4 Synthesis and characterization of second 
generation inhibitors 
5.4.1 Parallel synthesis of 4-amino-1H-imidazole-2(5H)-thiones 
The compounds in this section offer a 4-(benzylamino)-1,5-diphenyl-1H-imidazole-2(5H)-
thione core structure with varying substituents. For screening, only aromatic starting 
materials were selected. A combinatorial library of 352 substances was synthesized from 
8 amines (1{1}-{8}), 11 aldehydes (2{1}-{11}) and 4 isocyanides (5{1}-{4}) (Figure 5.12). 
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Figure 5.12 Structures of starting materials (amines 1{1}-{9}, aldehydes 2{1}-{21}, isocyanides 5{1}-{5} and 
ketones 10{1}-{25}) for the multicomponent synthesis of 4-amino-1H-imidazole-2(5H)-thiones. 
 
By analogy with the synthesis outlined in Figure 5.6, equimolar amounts of aromatic 
amines, aldehydes and isocyanides were mixed in anhydrous methanol containing 
pyridinium chloride. As a representative example, the synthesis of 1-(3,5-dichloro-4-
hydroxyphenyl)-4-(4-(trifluoromethyl)benzylamino)-5-(2,4,5-trihydroxyphenyl)-1H-
imidazole-2(5H)-thione (5.22) is shown in Figure 5.13. 
 
Figure 5.13 Synthesis of 1-(3,5-dichloro-4-hydroxyphenyl)-4-(4-(trifluoromethyl)benzylamino)-5-(2,4,5-
trihydroxyphenyl)-1H-imidazole-2(5H)-thione (5.22). Reagents and conditions: KSCN, anhydrous MeOH, 
pyridinium chloride, 48 h, < 20 °C. 
 
All starting materials were commercially available. The MCR-derived compounds 
(352 substances, location: ori.hya.44-47) were analyzed by ESI-TOF mass spectrometry. 
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Details are documented in section B.6 (appendix II). Unexpectedly, these derivatives 
turned out to be unstable, as the target compounds, detected by molecular peaks [M + 
H]+, disappeared during storage of the samples. This was observed for all molecules on 
all plates of this screening campaign. However, the time span until complete 
disappearance of the [M + H]+ varied and took up to 14 days for individual molecules. 
Data analysis (mass spectrometric analysis by LC-MS and ESI-TOF) proposed an 
increase by m/z +16 generating {[M + H]+ +16} target mass signals. Most likely, the 
observed rise in molecular weight, corresponding to the atomic mass of oxygen, was 
caused by an oxidation process. This unexpected finding prompted us to elucidate the 
chemical properties of such molecules and, eventually, to design more stable compounds 
for the determination of hyaluronidase inhibitory activity. 
For chemical studies, the 4-(benzylamino)-1,5-diphenyl-1H-imidazole-2(5H)-thione core 
structure 9 remained unchanged. A repertory of suitable aromatic amines, aldehydes and 
isocyanides was picked for the preparation of additional molecules on the preparative 
scale. Besides, suitable ketones (cf. Figure 5.12), enabling the synthesis of compounds 
with similar substitution patterns or new scaffolds, were provided to prepare 5-methylated 
4-amino-1H-imidazole-2(5H)-thiones. The results are described in the following sections. 
 
5.4.2 Synthesis of 4-amino-5-hydroxy-1H-imidazole-2(5H)-
thiones 
Aromatic amines 1{1}, 1{4}-{7}, hydroxylated aldehydes 2{1}, 2{6}, 2{8}, 2{9} and 
isocyanides 5{1}-{4} were used for the formation of target molecules 5.16-5.25 (Figure 
5.14). 
 
Figure 5.14 Multicomponent synthesis of substituted 4-amino-5-hydroxy-1H-imidazole-2(5H)-thiones (11). 
Reagents and conditions: KSCN, anhydrous MeOH, pyridinium chloride, 48 h, < 20 °C. 
 
The crude products were isolated as yellowish viscous oils and tediously purified using 
RP-HPLC. As observed before, the mass spectrum of the desired products (general 
scaffold 9, Figure 5.14) indicated the formation of compounds corresponding to a 
molecular mass of {[M + H]+ + 16} (general scaffold 11, Figure 5.14). A total conversion to 
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the “m/z +16 adducts” was usually observed between 96 and 192 hours after completion 
of the experiment. For a period of 7 days, m/z +16 adducts were found to represent the 
predominant molecular species of the investigated compounds. When the storage period 
was extended, besides the {[M + H]+ + 16} ion, MS analysis revealed additional molecular 
species, suggesting fragmentation and decomposition. Therefore, substances 5.16-5.25 
were synthesized, stored in solution for 8 days, then purified by RP-HPLC and subjected 
to pharmacological investigations. 
Table 5.3 Substitution pattern for 4-amino-1H-imidazole-2(5H)-thiones 5.16-5.25. 
 
 
Chemset Compound R
1
 R
2
 R
3
 
11{1,6,1} 5.16 
 
 
 
11{4,1,1} 5.17 
 
  
11{4,1,2} 5.18 
 
  
11{4,8,4} 5.19 
 
 
 
11{4,9,1} 5.20 
 
 
 
11{4,9,2} 5.21 
 
 
 
11{5,9,1} 5.22 
  
 
11{5,9,3} 5.23 
  
 
11{6,6,1} 5.24 
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11{7,6,1} 5.25 
 
 
 
Aiming at higher chemical stability of the oxidized species, new structures and substitution 
patterns of the aldehydes (2{12}-{21}) became necessary. For this purpose, hydroxyl-
moieties were strictly excluded. Amine (1{5}) and isocyanide component (5{5}) remained 
unchanged in this approach (Figure 5.15). 
Figure 5.15 General synthesis (multicomponent synthesis) of 4-amino-5-hydroxy-1H-imidazole-2(5H)-thione 
derivatives (11). Reagents and conditions: KSCN, anhydrous MeOH, pyridinium chloride, 48 h, < 20 °C. 
 
Following this strategy, molecules 5.26-5.35 were synthesized (Table 5.4). 
Table 5.4 Substitution pattern for 4-amino-1H-imidazole-2(5H)-thiones 5.26-5.35. 
 
 
Chemset Compound R
2
 
11{5,12,1} 5.26 
 
11{5,13,1} 5.27 
 
11{5,14,1} 5.28 
 
11{5,15,1} 5.29 
 
11{5,16,1} 5.30 
 
11{5,17,1} 5.31 
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11{5,18,1} 5.32 
 
11{5,19,1} 5.33 
 
11{5,20,1} 5.34 
 
11{5,21,1} 5.35 
 
 
Again, due to a fast oxidation process, almost complete conversion of the crude products 
to {[M + H]+ + 16} species within the first 48 hours was observed. For all compounds of 
this series the [M + H]+ molecular peak was no longer detectable after 14 days. Besides 
that, no major molecular fragments or decomposition could be observed. Purification by 
preparative RP-HPLC yielded exclusively the {[M + H]+ + 16} derivatives. As a conclusion, 
substances derived from aldehydes 2{12}-{21} (Figure 5.12) were generally unstable 
toward oxidation in the reaction medium and yielded 5-hydroxylated derivatives. In 
contrast to compounds 5.16-5.25 further decomposition processes were not observed. 
Substances 5.26-35 were obtained as stable 4-amino-5-hydroxy-1H-imidazole-2(5H)-
thiones. 
 
5.4.3 Synthesis of 4-amino-5-methyl-1H-imidazole-2(5H)-thiones 
In order to avoid oxidation on the C-H acidic position 5 of the 4-amino-1H-imidazole-
2(5H)-thiones scaffold, additional modifications for synthesis were investigated. For this 
purpose aldehydes were replaced by suitable aromatic ketones (methylketones) as 
building blocks. To retain the chemical properties of the target compounds, comparable 
aromatic substitution pattern were selected (cf. Figure 5.12). The synthetic protocol was 
slightly modified by extending the reaction time for amine and ketone to at least 
90 minutes to allow sufficient formation of the intermediate ketimine (Figure 5.16). 
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Figure 5.16 Multicomponent synthesis of substituted 1-(3,5-dichloro-4-hydroxyphenyl)-5-methyl-4-(4-
(trifluoromethyl)benzylamino)-1H-imidazole-2(5H)-thiones (12). Reagents and conditions: KSCN, anhydrous 
MeOH, pyridinium chloride, 48 h, < 20 °C.  
Ketones bearing hydroxyl groups as presented in Table 5.5, displayed only marginal 
yields (5.36) or no formation of target molecules (5.37-5.39). 
Table 5.5 Substitution pattern for 1-(3,5-dichloro-4-hydroxyphenyl)-5-methyl-4-(4-(trifluoromethyl)-
benzylamino)-1H-imidazole-2(5H)-thione derivatives 5.36-5.39. 
 
 
Chemset Compound R
2
 
12{5,2,1} 5.36 
 
12{5,7,1} 5.37 
 
12{5,8,1} 5.38 
 
12{5,9,1} 5.39 
 
 
In the case of target molecule 5.37, MS and NMR data suggested the formation of the 
formimidamide derivative instead of the expected product. The same derivative 
associated with no formation of the target substance was observed for 5.38 and 5.39. 
With a proposal by Cereda53, a potential reaction scheme is shown in Figure 5.17. 
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Figure 5.17 Proposed formation of (E)-N'-(3,5-dichloro-4-hydroxyphenyl)-N-(4-(trifluoromethyl)benzyl) 
formimidamide (general scaffold 13, compound 5.37a-5.39a). 
 
Possibly, the intermediate ketamine was formed only to a minor extend from 4-amino-2,6-
dichlorophenol 1{5} in combination with the ketones 10{7}, 10{8} and 10{9}. Subsequently, 
the unbound amine species could react with the added isocyanide, resulting in the 
formation of the formimidamide substance 13. The corresponding compounds were 
termed as 5.37a-5.39a in the experimental section. 
The presence of hydroxyl substituents proved to be detrimental to the synthesis of 5-
methylated 4-amino-1H-imidazole-2(5H)-thiones. Whereas mono-hydroxylated ketones 
(cf. 5.36) eventually led to target molecules in poor yields, an adequate formation of the 
desired products from ketones bearing two or more hydroxylated residues (cf. 5.37-5.39) 
was not observed. 
In the light of experience, a new approach was initiated, taking into account aromatic 
ketones devoid of hydroxyl groups (Figure 5.18). 
 
Figure 5.18 Multicomponent synthesis of 4-amino-5-methyl-1H-imidazole-2(5H)-thiones derivatives 12. 
Reagents and conditions: KSCN, anhydrous MeOH, pyridinium chloride, 48 h, < 20 °C. 
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The pertinent products bearing a methyl group in position C-5 were accessible in good 
yields. Moreover, methylated compounds of the general scaffold 12 did not show oxygen 
sensitivity. This is in accordance with the literature in so far as C-5 autoxidation of 5,5-
disubstituted 4-imino thiohydantoines has not been documented.54-60 
Based on this protocol, substances 5.40-5.70 were obtained as stable 4-amino-5-methyl-
1H-imidazole-2(5H)-thiones after RP-HPLC purification (Table 5.6). 
Table 5.6 Substitution pattern for 4-amino-5-methyl-1H-imidazole-2(5H)-thiones derivatives 5.40-5.70. 
 
 
Chemset Compound R
1
 R
2
 R
3
 
12{1,3,1} 5.40 
   
12{1,3,4} 5.41 
   
12{2,3,5} 5.42 
 
  
12{4,3,3} 5.43 
   
12{5,1,1} 5.44 
 
  
12{5,2,1} 5.45 
 
 
 
12{5,3,1} 5.46 
 
  
12{5,3,2} 5.47 
 
  
12{5,3,5} 5.48 
 
  
12{5,4,1} 5.49 
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12{5,5,1} 5.50 
  
 
12{5,10,1} 5.51 
  
 
12{5,11,1} 5.52 
  
 
12{5,12,1} 5.53 
  
 
12{5,13,1} 5.54 
  
 
12{5,14,1} 5.55 
  
 
12{5,15,1} 5.56 
 
  
12{5,16,1} 5.57 
 
  
12{5,17,1} 5.58 
 
  
12{5,18,1} 5.59 
  
 
12{5,19,1} 5.60 
  
 
12{5,20,1} 5.61 
  
 
12{5,21,1} 5.62 
 
 
 
12{5,22,1} 5.63 
 
  
12{5,23,1} 5.64 
 
  
12{5,24,1} 5.65 
 
  
12{5,25,1} 5.66 
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12{7,3,3} 5.67 
 
  
12{7,3,4} 5.68 
 
  
12{8,3,1} 5.69 
   
12{8,3,2} 5.70 
   
 
As mentioned above (cf. Table 5.5), multicomponent synthesis of 5.38 failed. In an 
experiment, 5.45 was treated with BBr3 to form the corresponding trihydroxylated 
derivative 5.38 by ether cleavage. However, this approach failed, most likely due to harsh 
workup procedures (Figure 5.19). 
 
Figure 5.19 The synthesis of 5.38 via deprotection of 5.45 with BBr3 failed. 
 
Using the ketones shown in Figure 5.20 as building blocks did not result in the required 
products under the specified conditions. Besides, multicomponent synthesis with 2,2,2-
trifluoro-1-phenylethanone and 1-(3,4-dichlorophenyl)-2,2,2-trifluoroethanone was not 
successful (Figure 5.21). 
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Figure 5.20 Several ketones (see boxed substituents) proved to be inappropriate as building blocks in 
multicomponent synthesis. 
 
Figure 5.21 2,2,2-trifluoro-1-phenylethanone and 1-(3,4-dichlorophenyl)-2,2,2-trifluoroethanone proved to be 
inappropriate as building blocks in multicomponent synthesis. 
 
5.4.4 Synthesis of 4-amino-1H-imidazole-2(5H)-ones 
A set of 10 4-amino-1H-imidazole-2(5H)-ones, oxo analogs of 4-amino-5-hydroxy-1H-
imidazole-2(5H)-thiones and 4-amino-5-methyl-1H-imidazole-2(5H)-thiones, was 
synthesized by analogy with the protocol presented in sections 5.4.2 and 5.4.3 (potassium 
thiocyanate replaced by potassium cyanate) and investigated for inhibition of the 
streptococcal lyase SagHyal4755. The design of these compounds was inspired by the 
(moderate to poor) activity of 4-amino-1H-imidazole-2(5H)-ones, which were among the 
first generation of inhibitors (see 5.3.2). The structures are summarized in Table 5.7. 
Table 5.7 Substitution pattern of 4-amino-5-hydroxy-1H-imidazole-2(5H)-ones derivatives 5.71-5.74 and 4-
amino-5-methyl-1H-imidazole-2(5H)-ones derivatives 5.75-5.80. 
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Chemset Compound Thio-analogue R
2
 
14{5,9,1} 5.71 5.22 
 
14{5,12,1} 5.72 5.26 
 
14{5,13,1} 5.73 5.27 
 
14{5,18,1} 5.74 5.32 
 
15{5,2,1} 5.75 5.45 
 
15{5,3,1} 5.76 5.46 
 
15{5,4,1} 5.77 5.49 
 
15{5,5,1} 5.78 5.50 
 
15{5,20,1} 5.79 5.61 
 
15{5,25,1} 5.80 5.66 
 
 
As expected, autoxidation was observed for compounds 5.71-5.74, presumably following 
the same mechanism as the corresponding 4-amino-5-hydroxy-1H-imidazole-2(5H)-
thiones. In the literature the conversion of 4-imino-1,5-dimethyl-3-(4-
nitrophenyl)imidazolidin-2-one to the 5-hydroxy derivative is described to occur in 
solution.61 However, when comparing the oxo- with the corresponding thioxo-compounds, 
the insertion of oxygen in position C-5 was slower in case of substances 5.71-5.74. 
Nevertheless, autoxidation resulted in a full conversion to derivatives with a molecular 
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mass of {[M + H]+ +16}. Purification via HPLC and measurements of inhibitory activity 
were not performed, mass spectral analysis of crude products 5.71-5.74 are documented 
in section B.10 (appendix II). The attempt to apply an analogous protocol to the synthesis 
of 5.75-5.80 failed. 
Interestingly, Ugi pointed out that 4-imino-2-thiohydantoins are formed in high yields only 
from ketones and not from aldehydes, whereas 4-iminohydantoins are easily accessible 
from aldehydes but not very well from ketones.62, 63 Taking into account the experience 
with compounds 5.16-5.80, Ugi’s conclusion might be specified as follows. 2-imino-4-thio-
hydantoins are formed in high yield from both aromatic ketones and aldehydes. However, 
products formed from aldehydes are prone to oxidation. Further decomposition is fostered 
depending on the substitution pattern of the aromatic aldehyde (e.g. (poly-)hydroxylated 
aromatic substituents). Stable products are accessible from aryl ketones unless they are 
hydroxylated. 4-Iminohydantoins are accessible from aromatic aldehydes, and 
autoxidation occurrs by analogy with the decomposition of the corresponding 
thiohydantoines. In accordance to Ugi’s observations, aromatic ketones gave low yields 
under the specified conditions. 
 
5.4.5 Oxidation of 4-amino-1H-imidazole-2(5H)-thiones 
Compound 5.22 (cf. Table 5.3) was selected to monitor the autoxidation process over a 
period of 192 hours. In a qualitative experiment, samples containing 5.22 were analyzed 
by HPLC-MS in 24 hour intervals. Conditions of synthesis and storage such as 
temperature, exposure to light and composition of the solvent were systematically varied. 
A detailed description of the parameters is given in Table 5.8. 
Table 5.8 Experimental settings for samples containing molecule 5.22.  
Measurement  
No. Description 
1 completion of synthesis 
2 + 24 h 
3 + 48 h 
4 + 72 h 
5 + 96 h 
6 + 120 h 
7 + 144 h 
8 + 168 h 
9 + 192 h 
 
Experiment 
No. Description 
1 daylight; ambient temperature; addition of sodium sulfate  
2 light (24 h); ambient temperature 
3 UV-light (254 nm); ambient temperature; addition of sodium 
sulfate 
4 daylight; ambient temperature 
5 light (24 h); ambient temperature; addition of sodium sulfate 
6 UV-light ( = 254 nm); ambient temperature 
7 light protection; ambient temperature; addition of sodium sulfate 
8 light protection; +7 °C 
9 light protection; -20 °C; addition of sodium sulfate 
10 light protection; ambient temperature 
11 light protection; +7 °C; addition of sodium sulfate 
12 light protection; -20 °C 
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The molecular peaks of “compound 1” (5.22, [M + H]+, m/z = 557) and “compound 2” 
(5.22, {[M + H]+ + 16}, m/z = 573) were detected as ion counts from mass spectral 
analysis. To observe the process of oxidation for the ensemble of 12 experiments, ionic 
counts were plotted versus measurements. The results are displayed in Figure 5.22. 
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Figure 5.22 Time dependent insertion of 
oxygen into 5.22 (qualitative experiment). 
 
As a result, temperature (-20 °C, +7 °C, +25 °C), light (= 250 nm, daylight) or condensed 
water in organic solvents did not retard oxidation and the formation of the {[M + H]+ + 16} 
derivative of 5.22 (“compound 2”). Besides, further decomposition of the “{[M + H]+ + 16} 
substance” became obvious from the mass spectrum 340 hours after completion of the 
synthesis. 
The air-sensitivity of 5.22 was examined in more detail by means of a quantitative 
experiment, monitored by HPLC-MS analysis. Mass spectra were recorded from 0 to 336 
hours after the completion of the synthesis. The investigations were performed with the 
crude products which were stored in glass vessels in solution (solvent: anhydrous 
methanol). Substance 5.62 was used as internal standard to analyze the time dependent 
conversion of [M + H]+ (m/z = 557) to the oxidized 5.22 corresponding to a mass of  m/z = 
573 {[M + H]+ + 16}. On column, the investigated compounds showed a sufficient 
separation of molecular peaks (cf. Figure 5.23). Detailed HPLC traces and molecular 
peaks under the specified conditions are given in section B.11 (appendix II). 
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Figure 5.23 Structures, formulas and molecular masses of “compound 1” (5.22, [M + H]
+
), “compound 2” (5.22, 
{[M + H]
+
 +16}) and 5.62. 
 
To quantify the results, the peak area recorded for mass signal [M + H]+ (m/z = 599) of 
5.62 served as reference. The mean peak area derived from triplicate measurements of 
the internal standard was set to 100 %. Mean peak areas (triplicates) of “compound 1” the 
[M + H]+  species of 5.22 was correlated to the reference and expressed as percentual 
value. The same procedure was applied to the {[M + H]+ + 16} species (“compound 2” ) of 
5.22. The time dependent process is plotted in Figure 5.24. 
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Figure 5.24 Time dependent insertion 
of oxygen to 5.22 (quantitative 
experiment) 
 
Evaluation of data clearly showed a depression of the [M + H]+ (m/z = 557) molecular 
peak of “compound 1” over 7 days. Within this time span, the m/z percentage value 
dropped from 100 % to 0 %. The opposite effect was observed for {[M + H]+ + 16} 
(“compound 2”, m/z = 573), representing the predominant molecular species between 
184 and 336 hours after completion of the experiment. As a consequence, 
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pharmacological tests of purified compounds 5.16-5.25 were performed 8 days after 
synthesis. As mentioned above, additional molecular fragmentation was observed after 
340 hours. Hence, due to lack of chemical stability, these compounds were inappropriate 
for the determination of IC50 values, as side products, which might falsify the 
pharmacological data, could not be excluded. 
Only very few information from the literature is available that might help to explain the 
observed insertion of oxygen. In fact, there was no preceding article on the molecules of 
interest, the 4-amino-1H-imidazole-2(5H)-thiones. However, Morel and coworkers, who 
performed a detailed study on the three-component cyclocondensation of 4-amino-2-
(methylthio)imidazolidinium salts, observed autoxidation among several imidazole 
derivatives, which are structurally related to the compounds presented in this thesis. In 
particular, they found that 1-methyl-2-(methylthio)-5-phenyl-3-isopropyl-4-(isopropylamino) 
imidazolium chlorides (16) can be degraded to thioxoimidazolidines (17) via methyl 
chloride elimination (Figure 5.25). This was accompanied by an autoxidation in the 
presence of atmospheric oxygen (18, 19).
58 Structure 19 was confirmed by mass and 
NMR spectral data. Besides, the structure was suggested due to the presence of a strong 
O-H stretching band in the infrared spectra of the isolated molecules. The authors 
reported that there were no details available regarding the oxidation process. In the same 
paper they postulate the intermediate hydroperoxide structure (18), which was reported in 
literature for related cyclic and acyclic systems.64-66 Interestingly, Morel and coworkers 
were able to confirm the structural assignment of a 5-hydroxy derivative (20) by X-ray 
diffraction analysis. 
 
Figure 5.25 Autoxidation of 1-methyl-2-(methylthio)-5-phenyl-3-isopropyl-4-(isopropylamino)imidazolium 
chloride (12) and confirmed molecular structure of derivative 20 (according to Morel
58
). 
 
In 2002, Törnqvist et al. elucidated the formation and degradation of some 
phenylthiohydantoins. In their study, the authors refer to an autoxidation process observed 
for 3-phenyl-1-methylthiohydantoin (21) under basic conditions (Figure 5.26).67 They 
recommend the addition of oxygen to the carbanion moiety  to the carbonyl group.68 
According to the suggested mechanism, the hydrogen peroxide anion is eliminated to 
form a resonance-stabilized immonium ion that finally accepts a nucleophile (cf. 22-
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24a/b).67 In addition, they employed 18O2 for the oxidation of 23 and received molecules of 
structure 24b, incorporating [18O] in 50 % yield. 
 
Figure 5.26 Autoxidation of 3-phenyl-1-methylthiohydantoin (21) (according to Törnqvist
67
). 
 
Very recently, Angelova et al. described the chemoselective autoxidation of structural 
closely related 4-imino-1,5-dimethyl-3-(4-nitrophenyl)imidazolidin-2-one (25) to the 5-
hydroxy derivative 28 (Figure 5.27).61 In their paper, they present a mechanism for the 
conversion to the hydroxyl product. Here, they discuss a mechanism of enamine 
autoxidation involving single electron transfer from the tautomeric enamine to molecular 
oxygen (26). Concerning the hydroperoxide moiety they propose the formation of the 
hydroxyl product from a homolytic cleavage of the peroxide species (cf. 27).61 
 
Figure 5.27 Autoxidation of 4-imino-1,5-dimethyl-3-(4-nitrophenyl)imidazolidin-2-one (25) (according to 
Angelova
61
). 
 
Some hints to X-ray structural analysis of 4-amino-1H-imidazole-2(5H)-ones were found in 
molecules that were investigated by Fehlhammer and coworkers in two papers.69, 70 
Initially aiming at organo-metallic four-component condensations and the investigation of 
crystal packing modes of imidazole derivatives, some compounds were synthesized by 
multicomponent reaction synthesis. The authors obtained crystal structures of two 
oxidized entities (4-(cyclohexylamino)-5-hydroxy-1,5-diphenyl-1H-imidazol-2(5H)-one 29, 
4-(tert-butylamino)-5-hydroxy-1,5-diphenyl-1H-imidazol-2(5H)-one 30). As indicated, both 
of them showed a hydroxyl group in position C-5 (Figure 5.28). However, Fehlhammer 
and coworkers suspected oxidation during the synthesis to give the observed molecules, 
but did not further evaluate or analyze this phenomenon. 
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Figure 5.28 Structures of crystallized 4-amino-1H-imidazole-2(5H)-ones 29 and 30 (adopted from Andre
70
). 
 
As stated above, according to the literature, there is only little knowledge about the 
autoxidation and insertion of oxygen. The cited studies might explain the occurrence of 
{[M + H]+ + 16} molecular structures due to the presence of atmospheric oxygen. Besides, 
it remained unclear, how fast the process of oxidation takes place and whether the 
insertion of oxygen conditions might be prevented under certain conditions. 
As a consequence, the process of oxidation observed for compounds 5.26-5.35, was 
studied in detail by means of [18O] labeling and HPLC-MS analysis. In particular, the focus 
was set to the recommended insertion of oxygen in position C-5 to yield 4-amino-1H-
imidazole-2(5H)-thiones. Three experiments were performed in parallel to elucidate the 
behavior of the products when exposed to an atmosphere of argon, air and 18O2, 
respectively. For the first case, under an atmosphere of argon, the generation of non-
hydroxylated molecules was expected. For the latter two cases, exposure to air or a 
concentrated atmosphere of 18O2, respectively, the incorporation of oxygen to position C-5 
was expected. For the formation of the corresponding target molecules 5.81-5.83, 4-
amino-2,6-dichlorophenol (1{5}) was treated with 4-formylbenzoic acid (2{14}). 
Subsequently, (isocyanomethyl)benzene (5{5}) was added, combined with pyridinium 
chloride in anhydrous methanol (Figure 5.29). 
 
Figure 5.29 Multicomponent synthesis of 4-(4-(benzylamino)-1-(3,5-dichloro-4-hydroxyphenyl)-2-thioxo-2,5-
dihydro-1H-imidazol-5-yl)benzoic acid derivatives 5.81-5.83. Reagents and conditions: (i) argon atmosphere, 
KSCN, anhydrous MeOH, pyridinium chloride, 48 h, < 20 °C, (ii) KSCN, anhydrous MeOH, pyridinium chloride, 
48 h, < 20 °C, (iii) 
18
O2-atmosphere, KSCN, anhydrous MeOH, pyridinium chloride, 48 h, < 20 °C. 
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Compounds 5.81-5.83 were synthesized at the same time under identical general 
conditions. After 2 hours and 72 hours after completion of the experiment, the crude 
reaction mixtures were analyzed by HPLC-MS. A detailed description, including the 
generation of 18O2, and data of MS analysis is given in the experimental section. 
In summary, under an atmosphere of argon, LC-MS control of the crude reaction mixture 
revealed [M + H]+ (m/z = 485) as the predominant molecular peak. The corresponding 
experiment under atmospheric oxygen showed primarily the {[M + H]+ +16} (m/z = 501) 
species. Moreover, when 18O2 was employed for the oxidation, 
18O was incorporated to C-
5 and, as shown by LC-MS, formed the {[M + H]+ +18} (m/z = 503) molecule (Figure 5.30). 
 
   
Figure 5.30 Molecular structures of 4-(4-(benzylamino)-1-(3,5-dichloro-4-hydroxyphenyl)-2-thioxo-2,5-dihydro-
1H-imidazol-5-yl)benzoic acid derivatives 5.81-5.83. 
 
As a consequence, the data indicate autoxidation of 4-amino-1H-imidazole-2(5H)-thiones 
via the insertion of molecular oxygen from air. This process appears to be irreversible and 
is affected immediately by contact with air. Under inert gas conditions (argon), this 
process can be prevented, but the first contact with oxygen-containing atmosphere leads 
to the formation of oxidized compounds. 
 
5.4.6 X-ray structure of 4-amino-5-methyl-1H-imidazole-2(5H)-
thiones 
To confirm the structures of the synthesized 4-amino-5-methyl-1H-imidazole-2(5H)-
thiones, examples of compounds were crystallized for investigations by X-ray diffraction 
analysis. Whereas crystallization of 5.28 from methanol did not yield suitable crystals, 
compound 5.45 gave crystals, which were appropriate for X-ray analysis. The X-ray 
structure of 5.45 is shown in Figure 5.31. 
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Figure 5.31 X-ray crystal structure of rac-1-(3,5-dichloro-4-hydroxyphenyl)-5-methyl-4-[4-(trifluoromethyl)-
benzylamino]-5-(2,4,5-trimethoxyphenyl)-1H-imidazole-2(5H)-thione 5.45. 
 
The substance formed a single crystalline phase in which both enantiomers (R and S) 
were present in an ordered 1:1 ratio in the elementary cell. To describe the three-
dimensional structure in more detail, an ORTEP-style plot and labeling scheme of (5S)-
5.45 is shown in Figure 5.32 and the experimental details (crystal data and structure 
refinement) including atomic coordinates, bond lengths and angles, anisotropic 
displacement parameters, hydrogen coordinates, torsion angles and hydrogen bonds are 
given in section A.3.1 (appendix I). 
 
Figure 5.32 Molecular structure (ORTEP-style) of (5S)-5.45 including atomic numbering scheme. 
 
The molecular structure of (5S)-5.45 shows a five-membered, non-aromatic heterocycle 
with S(1), N(1) and C(8) lying in plane. The phenyl rings are inclined to the imidazole-thione 
ring at various angles. The torsion angles C(10)-N(3)-C(22)-C(23) and N(3)-C(11)-C(13)-C(14) were 
at 71.9 ° and 55.3 °, respectively. The third torsion angle of (5S)-5.45, namely C(8)-N(1)-
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C(9)-N(2) is 9.9 °. Methoxy substituents were in plane with the phenyl ring fused to C(11). 
The amine hydrogen atom H(1N) is trans with respect to N(2). The corresponding cis 
conformation was not achieved, most likely due to steric hindrance of the bulky residues 
on N(1) and the neighboring 2,4,5-trimethoxyphenyl residue. It should be noted, that 
hydrogen was not found at the N(2) atom, in spite of reliable localization of the hydrogen 
atoms, even at the periphery of the molecule. According to the X-ray structural 
investigations, there is no hint to additional tautomeric forms of 5.45. To substantiate 
these findings with respect to possible tautomeric isomers, NMR (1H, 13C) were 
performed. 
As shown in Figure 5.33, two isomers were conceivable for 5.45 by a proton shift along 
the N(2)=C(9)-N(1)H(1N) bond, resulting in the formation of tautomeric “imine” (structure a) 
and “amine” (structure b) structures. The latter “amine” form shares a resonance structure 
(structure c). 
 
Figure 5.33 Tautomers and resonance structures of 4-amino-5-methyl-1H-imidazole-2(5H)-thiones; compound 
5.45 as an example. 
 
Medvedeva et al. reported that structurally related thioiminohydantoins prefer the amine 
form (see Figure 5.33, structure b) in the case of benzyl-substituents for R3. In the same 
paper, they cite a shift of the tautomeric equilibrium in favor of the imine form when there 
is a decrease in the basicity of the exocyclic nitrogen atom.56 The NMR spectra of some 4-
amino-5-methyl-1H-imidazole-2(5H)-thiones are provided in Table 5.9. 
Table 5.9 
1
H-NMR chemical shifts (600 MHz, DMSO-d6, 298 K) of selected 4-amino-5-methyl-1H-imidazole-
2(5H)-thiones. 
Compound  (ppm)
a
:  
NHCH2-p-C6H4-CF3 
 (ppm)
a
:  
NHCH2-p-C6H4-CF3 
 (ppm)
a
:  
Cquat, CS
 (ppm)
a
:  
Cquat, C-4
5.44 9.22 (t, J = 6.0 Hz, 
1H) 
4.74 – 4.61 (m, 2H) 195.52 180.70 
5.45 8.88 (t, J = 5.9 Hz, 
1H) 
4.71 (dd, J = 15.5, 6.3 Hz, 1H), 
4.57 (dd, J = 15.5, 6.3 Hz, 1H 
195.03 181.57 
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5.51 8.97 (t, J = 6.0 Hz, 
1H) 
4.75 (dd, J = 15.4, 6.5 Hz, 1H), 
4.54 (dd, J = 15.4, 5.5 Hz, 1H) 
195.34 181.40 
5.54 9.05 (t, J = 5.7 Hz, 
1H) 
4.74 (dd, J = 15.3, 6.1 Hz, 1H), 
4.62 (dd, J = 15.3, 5.7 Hz, 1H) 
195.35 181.66 
5.55 9.22 (t, J = 6.1 Hz, 
1H) 
4.77 (dd, J = 15.2, 6.4 Hz, 1H), 
4.61 (dd, J = 15.2, 5.7 Hz, 1H) 
195.23 180.29 
5.56 9.24 (t, J = 5.9 Hz, 
1H) 
4.68 (d, J = 5.8 Hz, 2H) 195.51 180.49 
5.57 9.23 (t, J = 6.0 Hz, 
1H) 
4.67 (d, J = 5.9 Hz, 2H) 195.66 180.34 
5.58 9.22 (t, J = 5.7 Hz, 
1H) 
4.67 (d, J = 5.4 Hz, 2H, 195.69 180.29 
5.59 9.27 (t, J = 5.9 Hz, 
1H) 
4.75 – 4.61 (m, 2H) 195.85 180.10 
5.60 9.32 (t, J = 5.9 Hz, 
1H) 
4.73 – 4.62 (m, 2H) 196.03 179.84 
5.61 9.19 (t, J = 6.0 Hz, 
1H) 
4.71 – 4.61 (m, 2H) 195.57 180.71 
5.64 9.20 (t, J = 6.0 Hz, 
1H) 
4.67 (qd, J = 15.5, 6.0 Hz, 2H) 195.79 180.63 
5.65 9.26 (t, J = 5.9 Hz, 
1H) 
4.71 – 4.62 (m, 2H) 195.57 180.40 
a
 relative to TMS 
The vicinal 3JH-C-N-H coupling of the CH2 group with the neigbouring NH (NHCH2-p-C6H4-
CF3) became visible (Figure 5.34). The values of the 
3J coupling constant covered a range 
from 5.4 to 6.5 Hz, the geminal 2JH-C-H coupling from 15.2 to 15.5 Hz. For the investigated 
substances 5.45, 5.51, 5.54 and 5.55 the signals the CH2 protons were separated, 
resulting in dubletts of dubletts (cf. Table 5.9). 
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NHCH2-p-C6H4-CF3:  
compounds 5.45, 5.51, 5.54, 5.55  
NHCH2-p-C6H4-CF3:  
compound 5.64 
NHCH2-p-C6H4-CF3:  
compounds 5.44, 5.56-5.61, 5.65 
   
Figure 5.34 Coupling of the CH2 protons (NHCH2-p-C6H4-CF3) with the neigbouring NH of selected 4-amino-5-
methyl-1H-imidazole-2(5H)-thiones. 
 
As a result, the 1H-NMR spectra confirm that these compounds prefer the “amine” 
tautomeric form in deuterated DMSO at ambient temperature (298 K). The suggested 
structure is also in agreement with the 13C-NMR data. It is important to mention, that a 
double set of signals, e.g. for the C=S group in the range of 175 – 180 ppm, suggesting 
the “imine” structure were not observed under these conditions. Likewise, only one signal 
was visible for the quaternary carbon atom C(9) at approximately 180 ppm. 
It should be stressed that the synthesized 4-amino-5-methyl-1H-imidazole-2(5H)-thiones 
as well as the analogous amino-5-hydroxy-1H-imidazole-2(5H)-ones were synthesized 
and characterized as racemates. It may be speculated about a discrimination of the 
stereoisomers by hyaluronidases. Enantioseparations have not been performed so far, as 
the inhibitory activities of the racemic mixtures were still moderate. 
In summary, it is concluded from X-ray analysis and NMR data that the synthesized cyclic 
amidines exist as tautomers with exocyclic NH group, namely as 4-amino-1H-imidazole-
2(5H)-thiones. 
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5.5 Pharmacological results and discussion of second 
generation inhibitors 
5.5.1 General conditions and screening mode 
Cf. section 5.3.1 
The IC50 values of the compounds were calculated based on 8-point concentration-
response curves (experiment performed in duplicate). 
 
5.5.2 Inhibitory activities of screening compounds on 
SagHyal4755 
Among the tested 352 generated 4-amino-1H-imidazole-2(5H)-thiones, 25 compounds 
were identified as screening hits representing a hit rate of 7.1 %. These hits were located 
on plate ori.hya.44 (11 hits), ori.hya.45 (7 hits), ori.hya.46 (4 hits) and ori.hya.47 (3 
hits). A detailed on-screen assay validation and representation of screening data is given 
in appendix II (sections B.8.3, B.9.4). HPLC-MS analysis revealed the oxidized molecular 
species {[M + H]+ +16} as the predominant structures. The percentual enzyme inhibition 
determined for the 4-amino-1H-imidazole-2(5H)-thione screening hits are summarized in 
Table 5.10. 
Table 5.10 Inhibition of SagHyal4755 by the screening hits from plates ori.hya.44-47. 
Compound Location 
(plate_well) 
SagHyal4755 
 % inhibition
a
 
 ori.hya.44_A2 58 ± 2 
 ori.hya.44_E2 53 ± 6 
5.16 ori.hya.44_A7 64 ± 4 
5.17 ori.hya.44_D2 62 ± 3 
 ori.hya.44_D3 51 ± 5 
 ori.hya.44_D5 62 ± 3 
 ori.hya.44_D6 59 ± 3 
 ori.hya.44_D7 61 ± 3 
 ori.hya.44_A9 58 ± 3 
 ori.hya.44_D9 60 ± 3 
 ori.hya.44_D12 50 ± 4 
5.18 ori.hya.45_D2 62 ± 2 
 ori.hya.45_D5 58 ± 2 
 ori.hya.45_D6 50 ± 2 
 ori.hya.45_D7 57 ± 3 
 ori.hya.45_D9 53 ± 4 
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5.21 ori.hya.45_D10 68 ± 4 
 ori.hya.45_E10 53 ± 5 
 ori.hya.46_D2 53 ± 1 
 ori.hya.46_D3 57 ± 2 
 ori.hya.46_D7 53 ± 2 
 ori.hya.46_D9 61 ± 1 
 ori.hya.47_D5 58 ± 1 
 ori.hya.47_D7 62 ± 2 
 ori.hya.47_E7 51 ± 5 
a
 mean values ± SEM (N = 2, experiments performed in duplicate), maximal concentrations of the test 
compounds were set to an assumed final assay concentration of 200 µM; percent inhibition determined at pH 
5.0 in the automated 96-well turbidimetric assay. 
 
5.5.3 Inhibitory activities of purified compounds on SagHyal4755 
5.5.3.1 4-Amino-5-hydroxy-1H-imidazole-2(5H)-thiones 
Among the 25 identified hits, substances 5.16-5.18, 5.21 (highlighted in Table 5.10) were 
selected, equaling the most potent compounds of this study. Together with the 
distinguished compounds 5.19, 5.20 and 5.22-5.25 a small library of 10 purified 4-amino-
1H-imidazole-2(5H)-thiones was subjected for preparative synthesis and retested on 
SagHyal4755. The IC50 values determined for the 4-amino-5-hydroxy-1H-imidazole-2(5H)-
thione derivatives 5.16-5.25 are summarized in Table 5.11. 
Table 5.11 Inhibitory activity
a
 and calculated logD5.0 values
b
 of purified 4-amino-5-hydroxy-1H-imidazole-
2(5H)-thione derivatives 5.26-5.35. 
Compound SagHyal4755 
IC50 (µM)
a
 
BTH 
IC50 (µM)
a
 
logD5.0
b
 
5.16 850 ± 35 inactive 3.2 
5.17 230 ± 15 inactive 3.5 
5.18 335 ± 35 inactive 4.3 
5.19 270 ± 25 inactive 3.1 
5.20 310 ± 20 inactive 2.5 
5.21 380 ± 10 inactive 3.4 
5.22 80 ± 4.3 inactive 3.7 
5.23 250 ± 20 inactive 3.4 
5.24 230 ± 15 inactive 3.7 
5.25 1200 ± 55 inactive 2.9 
a
 mean values ± SEM (N = 2, experiments performed in duplicate); IC50 values determined at pH 5.0 in the 96-
well turbidimetric assay; 
b 
calculated with ACD-Labs (Advanced Chemistry Development Inc., Toronto, 
Canada) product version 12.00. 
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The investigation of the purified compounds 5.17, 5.18 and 5.21 confirmed the inhibition of 
the target enzyme SagHyal4755 with IC50 values of 230 µM (5.17), 335 µM (5.18) and 380 
µM (5.21), respectively. An exception was 5.16, showing a considerable decrease in 
inhibitory activity (Figure 5.35). 
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Figure 5.35 Concentration dependent inhibition of SagHyal4755 by 5.16-5.18 and 5.21. 
 
Substances 5.19 (IC50 = 270 µM), 5.20 (IC50 = 310 µM), 5.23 (IC50 = 250 µM) and 5.24 
(IC50 = 230 µM) showed moderate inhibition, compound 5.25 (1200 µM) was inactive. With 
an IC50 value of 80 µM, 5.22 represents a 3-fold more potent inhibitor compared to the 
next best substance of this library (Figure 5.36). 
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Figure 5.36 Concentration dependent inhibition of SagHyal4755 in the presence of 5.19-5.20 and 5.22-25. 
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Hence, 5.22 represented the most potent inhibitor among the 4-amino-1H-imidazole-
2(5H)-thione series at this stage of the screening campaign. In view of the (calculated) 
logD5.0 values, all inhibitors are expected to possess drug-like properties. However, 
chemical instability must be taken into account: the oxidized compounds with a mass of 
{[M + H]+ + 16} were stable molecules over a period of 14 days; thus, supposed that the 
hydroxy compounds represent the predominant molecular species, the measured 
inhibition of enzymatic activity can most probably be attributed to the product of 
autoxidation, although, other active molecules cannot be ruled out, e. g.  [M + H]+ or [M + 
H]+ mixed with {[M + H]+ + 16}. Additional molecular fragments might also contribute to the 
inhibitory activities of the investigated mixtures. In conclusion, the discussed compounds 
were inappropriate for a further hit to lead development. 
The IC50 values determined for the 4-amino-5-hydroxy-1H-imidazole-2(5H)-thione 
derivatives 5.26-5.35 are summarized in Table 5.12. 
 
Table 5.12 Inhibition of hyaluronidase activities
a
 and calculated logD5.0 values
b
 of 4-amino-5-hydroxy-1H-
imidazole-2(5H)-thione derivatives 5.26-5.35. 
Compound SagHyal4755 
IC50 (µM)
a
 
BTH 
IC50 (µM)
a
 
logD5.0
b
 
5.26 70.4 ± 3.5 inactive 5.3 
5.27 146 ± 1.5 inactive 5.2 
5.28 7.9 ± 0.9 inactive 4.1 
5.29 31.5 ± 1.3 60 % (c = 200 µM) 5.7 
5.30 49.0 ± 2.4 inactive 6.1 
5.31 180 ± 7.7 inactive 4.2 
5.32 57.6 ± 1.5 inactive 4.9 
5.33 133 ± 0.5 inactive 4.4 
5.34 117 ± 5.4 inactive 4.9 
5.35 55.7 ± 3.1 inactive 2.2 
a
 mean values ± SEM (N = 2, experiments performed in duplicate), maximal concentrations of the test 
compounds were set to an assumed final assay concentration of 200 µM; IC50 values determined at pH 5.0 in 
the automated 96-well turbidimetric assay; 
b 
calculated with ACD-Labs (Advanced Chemistry Development 
Inc., Toronto, Canada) product version 12.00. 
 
Substances 5.26 and 5.27 were designed as stable, C-5 hydroxylated analogs of 5.22. 
For 5.26 and 5.27 IC50 values of 70 µM and 146 µM, respectively, were calculated. As 
ring-hydroxylated products were unstable, a bioisosteric approach was applied. In a first 
attempt, the commercially available heterocyclic aldehydes, 1H-indole-carbaldehydes 
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(cf. 5.29, 5.30), 1H-benzo[d]imidazole-5-carbaldehyde (cf. 5.31) and 1H-indazole-5-
carbaldehyde (cf. 5.32) were used as building blocks. The resulting products 5.29 (IC50 = 
32 µM), 5.30 (IC50 = 49 µM) and 5.32 (IC50 = 58 µM) proved to be superior to the 
corresponding phenyl-substituted parent compounds. A 3-fold decrease in potency was 
investigated for 5.31. In a second series, the phenyl group in the southern part of the 
“minimal inhibitor substrate” 5.26 was expanded in para-position by the addition of five- 
and six-membered ring heterocycles. Thereby substituents bearing imidazole (5.33), 
methylthiazole (5.34) and methylpiperazine moieties (5.35) were prepared to investigate 
the contribution of basic moieties to enzyme inhibition. Inhibitory activities at micromolar 
concentrations were retained (5.33: 133 µM, 5.34: 117 µM). Interestingly, the investigation 
of the most basic compound 5.35 revealed an IC50 value of 56 µM. Considering the logD5.0 
value of 2.2, the molecule might offer beneficial properties to overcome the problem of 
extremely high plasma protein binding. 
The desired chemical properties were furnished in 5.28. Strikingly, with 5.28 the most 
potent inhibitor among 4-amino-1H-imidazole-2(5H)-thiones was found, revealing an IC50 
value of 8 µM. Moreover the compound presumably incorporates drug-like properties with 
a calculated logD5.0 of 4.1. The concentration dependent inhibition of SagHyal4755 in 
presence of 5.28-5.30, 5.35 is depicted in Figure 5.37. 
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Figure 5.37 Concentration dependent inhibition of SagHyal4755 in the presence of 5.28-5.30 and 5.35. 
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5.5.3.2 4-Amino-5-methyl-1H-imidazole-2(5H)-thione derivatives 
The IC50-values determined for the 4-amino-5-methyl-1H-imidazole-2(5H)-thione 
derivatives 5.40-5.70 are summarized in Table 5.13. 
Table 5.13 Inhibitory activities
a
 and calculated logD5.0 values
b
 of 4-amino-5-methyl-1H-imidazole-2(5H)-thione 
derivatives 5.40-5.70. 
Compound SagHyal4755 
IC50 (µM)
a
 
BTH 
IC50 (µM)
a
 
logD5.0
b
 
5.40 inactive inactive 3.9 
5.41 350 ± 13.5 inactive 3.7 
5.42 240 ± 14.8 inactive 2.4 
5.43 810 ± 12.0 inactive 3.7 
5.44 90.0 ± 4.7 inactive 6.4 
5.45 50.4 ± 3.2 inactive 6.3 
5.46 80.2 ± 2.8 inactive 5.3 
5.47 47.9 ± 1.9 inactive 6.1 
5.48 162 ± 3.0 inactive 4.4 
5.49 125 ± 4.9 inactive 6.8 
5.50 97.7 ± 2.1 inactive 6.0 
5.51 90.3 ± 5.3 inactive 6.7 
5.52 160 ± 7.2 inactive 6.5 
5.53 154 ± 5.9 inactive 6.0 
5.54 145 ± 7.8 inactive 5.9 
5.55 130 ± 2.9 inactive 5.6 
5.56 115 ± 1.5 inactive 6.7 
5.57 120 ± 1.6 inactive 7.2 
5.58 130 ± 3.0 inactive 7.4 
5.59 95.1 ± 5.0 inactive 7.3 
5.60 85.1 ± 4.4 inactive 6.2 
5.61 70.2 ± 1.0 inactive 5.5 
5.62 > 500 inactive 8.3 
5.63 150 ± 8.8 inactive 5.8 
5.64 100 ± 5.6 inactive 7.6 
5.65 30 % (c = 120 µM) inactive 6.8 
5.66 59.0 ± 1.0 inactive 6.1 
5.67 140 ± 5.6 inactive 3.4 
5.68 136 ± 2.5 inactive 3.4 
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5.69 240 ± 10.8 50 % (c = 200 µM) 4.5 
5.70 160 ± 7.8 inactive 5.4 
a
 mean values ± SEM (N = 2, experiments performed in duplicate); IC50 values determined at pH 5.0 in the 
auto 96-well turbidimetric assay; 
b 
calculated with ACD-Labs (Advanced Chemistry Development Inc., Toronto, 
Canada) product version 12.00. 
 
Compounds 5.44, 5.45 and 5.49-66 were designed as 5-methyl derivatives of 5.22. 
Substance 5.44 (IC50 = 90 µM), bearing a phenyl moiety without additional substituents, 
represents the prototypical molecule within this series. The introduction of methoxy 
residues yielding mono- (5.51, 5.52), di- (5.53) and tri-methoxy derivatives (5.54, 5.55), in 
general, revealed no major benefit regarding inhibitory activity. An exception was found 
with 5.45, showing an IC50 value of 50 µM. Additional para-substituted moieties were 
introduced in compounds 5.46 and 5.56-5.62. Halogen substituents in 1-(3,5-dichloro-4-
hydroxyphenyl)- 5-methyl-4-(4-(trifluoromethyl)benzylamino)-1H-imidazole-2(5H)-thiones 
did not significantly influence the inhibitory activity, despite increased lipophilicity of 
molecules 5.56 to 5.58. By contrast, when lipophilicity was reduced stepwise by para-CF3 
(5.59), para-NO2 (5.60) and para-B(OH)2 moieties (5.61), inhibition was slightly improved. 
Surprisingly, the 5-methyl analogue 5.46 of the potent inhibitor 5-hydroxy substance 5.28, 
bearing a carboxylic group, showed a 10-fold lower inhibitory potency, although acidic 
groups were identified as activity-enhancing structural features in previous work. At first 
sight C-5 hydroxylation seemed to be superior to C-5 methylation. However, investigation 
of C-5 methylated compounds 5.49 (C-5 hydroxy analogue: 5.29), 5.50 (C-5 hydroxy 
analogue: 5.32) and 5.66 revealed only marginal differences in activity between the 5-
methyl- and the 5-hydroxy-derivatives. Additional chain branching as in compounds 5.63 
and 5.65 resulted in moderate to low enzyme inhibition. Substances 5.62 and 5.64 were 
designed to increase the lipophilicity by the incorporation of a bulky biphenylyl or naphthyl 
moiety. As a result, the biphenylyl substituted compound 5.62, the analogue with highest 
(calculated) logD5.0 value (8.3) within this series, showed only weak inhibition of 
SagHyal4755. For naphthyl analogue 5.64 (logD5.0 = 7.6) an IC50 value of 100 µM was 
calculated. 
To substantiate the inhibitory activities and to elaborate structure-activity relationships of 
4-imino-5-methyl-1H-imidazole-2(5H)-thiones, analogs of compound 5.46, bearing a 
negatively charged benzoic acid moiety in position 5, were tested on SagHyal4755. In order 
to find the right balance between lipophilicity (by experience a prerequisite for inhibitory 
activity) and drug-like properties, a matrix of virtually designed molecules was set up. An 
ensemble of 40 compounds (Figure 5.38) was generated by combination of 8 amines (x-
axis) and 5 isocyanides (y-axis) (cf. Figure 5.39). The corresponding logD5.0 values 
98 Pharmacological results and discussion of second generation inhibitors  
(displayed on z-axis) were calculated for each molecule by the aid of ACDLabs software 
version 12.00 (Advanced Chemistry Development Inc., Toronto, Canada). From these 
data a 3-D mesh plot was drawn (Figure 5.39). The selected amine and isocyanide 
residues span a range from logD5.0 2.3 to 6.1. 
 
Figure 5.38 Amine residues (A-H) and isocyanide residues (I-V) selected as building blocks to virtually 
synthesize and to predict the properties of a small library of 4-(5-methyl-2-thioxo-2,5-dihydro-1H-imidazol-5-
yl)benzoic acid derivatives. 
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Figure 5.39 3-D mesh plot displaying calculated logD5.0 values for a molecular matrix consisting of 8 amines 
and 5 isocyanides virtually used as building blocks as shown in Figure 5.38. 
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Out of 40 possible combinations, based on the predicted properties (Figure 5.39), a set of 
10 representative molecules (5.40-5.43, 5.46-5.48 and 5.67-5.70) was synthesized and 
tested for inhibition of SagHyal4755. As expected, lipophilic inhibitors were most potent. In 
case of 5.47 (combination A-V) the (calculated) logD5.0 of 6.1 corresponds to an IC50 value 
of 48 µM. When 4-amino-2,6-dichlorophenol was replaced by aniline as a building block 
(cf. 5.70, combination H-V), the decrease in lipophilicity (logD5.0 value = 5.4) was 
accompanied with a reduction of inhibitory potency to 160 µM. Substances of significantly 
lower logD5.0 values, such as 5.40 (combination F-I, logD5.0 = 3.9) and 5.43 (combination 
E-II, logD5.0 = 3.7) turned out to be inactive or very weak inhibitors, respectively. However, 
moderate inhibitory activity was regained when the CF3 group in 5.40 was replaced by a 
chlorine substituent (5.41, combination F-IV), despite a rather low logD5.0 of 3.7. 
Interestingly, for 5.42, synthesized from a combination of building blocks D-III, the 
calculated logD5.0 was as low as 2.4 but the IC50 value amounted to 240 µM. Compared to 
the prototypical inhibitor 5.46 (combination A-I, logD5.0 = 5.3), there was not increase in 
potency found for the remaining compounds 5.48 and 5.67-5.69, which cover a logD5.0 
range from 3.4 to 4.5. Hence, no major trends in terms of structure-activity relationships 
(SAR) could be identified among the investigated molecules. The concentration 
dependent effects of 5.40, 5.46 and 5.69 on the enzymatic activity of SagHyal4755 are 
depicted in Figure 5.40. 
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Figure 5.40 Concentration dependent effects of 5.43, 5.49 and 5.72 on the activity of SagHyal4755 . 
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Hyaluronidase inhibitory activity was observed for benzoic acid derivatives covering a 
calculated logD5.0 range from 2.4 to 6.1. With respect to 5-hydroxylated 4-amino-1H-
imidazole-2(5H)-thiones, active compounds covered logD5.0 values from 2.2 - 6.1 (Table 
5.12). Replacement of 5-methyl by a 5-hydroxy group lowers the calculated logD5.0 value 
by approximately 1.2. Modifications in 5-position might be key to adequate drug-like 
properties. Additionally, one might speculate about the contribution of fluorinated 
substituents replacing the 2,6-dichlorophenyl residue in the western part of the 4-amino-
1H-imidazole-2(5H)-thione scaffold. 
 
5.5.4 Inhibitory activities of purified compounds on BTH 
The substances were routinely tested on BTH as a representative example of mammalian 
hyaluronidases. Only compounds 5.29 (60 % inhibition at a final concentration of 200 µM) 
and 5.69 (50 % inhibition at a final concentration of 200 µM) displayed some inhibitory 
activity. IC50 values were not calculated due to the occurrence of colored compounds at 
higher concentrations, indicating the presence of decomposition products and/or 
impurities. 
 
5.5.5 Inhibitory activities of selected compounds on SpnHyl 
All compounds discussed in this chapter were designed as inhibitors of the hyaluronate 
lyase from S. agalactiae (SagHyal4755). To study biological activity on the related 
hyaluronidase from S. pneumonia (SpnHyl), an ensemble of 5 potent inhibitors was 
selected and tested by Dr. J. Hamberger from our workgroup. Under identical assay 
conditions including the same pH value, these substances were inactive on SpnHyl (Table 
5.14). A preference for negatively charged groups (cf. 5.28, 5.46), basic residues (cf. 5.35, 
5.66) or space filling substituents (cf. 5.45) was not detectable. Thus, the investigated 4-
amino-1H-imidazole-2(5H)-thiones are selective for the enzyme SagHyal4755, which was 
used as the biological target in this work. 
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Table 5.14 Inhibitory activity
a
 and calculated logD5.0 values
b
 of 4-imino-1H-imidazole-2(5H)-thione derivatives 
5.28, 5.35, 5.48-5.49 and 5.69. 
Compound SagHyal4755 
IC50 (µM)
a
 
SpnHyl 
IC50 (µM)
a
 
5.28 7.9 ± 0.9 inactive 
5.35 55.7 ± 3.1 inactive 
5.45 50.4 ± 3.2 inactive 
5.46 80.2 ± 2.8 inactive 
5.66 59.0 ± 1.0 inactive 
a
 mean values ± SEM (N = 2, experiments performed in duplicate); IC50 values determined at pH 5.0 in the 
automated 96-well turbidimetric assay. 
 
5.6 Outlook 
Chemically stabilized 4-amino-1H-imidazole-2(5H)-thiones display inhibitory activity on the 
target enzyme SagHyal4755. The evaluation of structurally closely related compounds 
corroborated the biological data for this class of hyaluronate lyase inhibitors. It should be 
stressed that the 4-amino-1H-imidazole-2(5H)-thiones were suggested by virtual 
chemistry, following a ligand-based drug-design approach. These substances are new 
chemical entities and represent a new class of (selective) inhibitors on the target enzyme. 
Common structural features previously investigated for inhibitors of streptococcal 
hyaluronidase included hydrophilic groups combined with hydrophobic alkyl chains. These 
substances were proven to address the active site of hyaluronidases. Examples of potent 
inhibitors were crystallized in complex with S. pneumonia hyaluronidase (SpnHyl) and the 
binding mode was determined by X-ray crystallography. Structural analysis disclosed the 
molecular interactions of these compounds with amino acids at the catalytic site of 
SpnHyl.8, 18 The most potent inhibitors were characterized as molecules combining a 
hydrophilic anchor group which binds in the center of the active site, and rather lipophilic 
moieties that eventually mimic sugar residues of the substrate hyaluronan. Strikingly, 
derivatives of ascorbic acid and indolylalkanoic acid were also identified as potent 
inhibitors of mammalian enzymes.10, 11 Hence, the structural feature, that is hydrophilic 
anchor plus hydrophobic carbon chain, led to almost equipotent inhibition of both bacterial 
and mammalian hyaluronidases. A major drawback of these inhibitors is their very high 
plasma protein binding. In addition, some compounds  showed surfactant-like properties 
in vitro.11 
102 Outlook  
To illustrate a possible correlation between lipophilicity and enzyme inhibition among 
ascorbic acid derivatives and indolylalkanoic acids, the calculated logD5.0 was plotted 
versus the IC50 value. The results are displayed in Figure 5.41. 
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Figure 5.41 IC50 values (µM) plottet versus calculated logD5.0 values of ascorbic acid derivatives (A) and 
indolylalkanoic acid derivatives (B) (data from Spickenreither
11
). 
 
Surprisingly, in case of ascorbic acid derivatives, the most active compounds covered a 
wide range of logD5.0 values, from approximately 0.8 to 6.0. According to Lipinski’s rule of 
five, at first sight, this might allow for the identification of drug-like inhibitors. On the other 
side, it is hard to define a pharmacophore for these structures, as there seems to be no 
specific preference for hydrophilic or hydrophobic moieties. A similar behavior was 
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observed for indolalkylic acid derivatives. Again, a specific correlation between lipophilicity 
and inhibitory activity was difficult to analyze. 
With regard to the structural requirements of 4-amino-1H-imidazole-2(5H)-thione-type 
hyaluronidase inhibitors, the five-membered “thiohydantoin” heterocycle might be 
regarded as a “center” or “hinge-region” to arrange lipophilic aromatic substituents at a 
short distance. These molecules share lipophilic residues which were fused directly to the 
aryl moieties. Another aspect is found in the anti-planar conformation, as the chemical 
scaffold allows a certain rotation and flexibility of substituents relative to the heterocyclic 
core. Possibly, additional insights into the stereochemical requirements can be gained 
from the investigation of pure enantiomers. 
To illustrate a possible correlation between lipophilicity and enzyme inhibition among 4-
amino-1H-imidazole-2(5H)-thiones, the calculated logD5.0 was plotted versus the IC50 
values (Figure 5.42).  
IC
50
 (µM)
0 100 200 300 400 500
lo
g
D
5
.0
-2
0
2
4
6
8
10
12
 
 
Figure 5.42 IC50 values (µM) plottet versus calculated logD5.0 values of 4-amino-1H-imidazole-2(5H)-thiones. 
 
By trend, there seems to be a correlation between lipophilicity and inhibition, suggesting 
potent 4-amino-1H-imidazole-2(5H)-thione hyaluronate lyase inhibitors to possess logD5.0 
in the range from approximately 3.0 to 8.0. However, only one compound (5.28) showed 
one-digit micromolar inhibitory activity. These considerations should not be 
overemphasized, as various substituent patterns and different chemical classes are 
compared. At least, the results suggest different binding modes in the active site for 4-
amino-1H-imidazole-2(5H)-thione on the one hand and ascorbic acid and indole 
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derivatives, sharing lipophilic alkyl chains, on the other hand. Certainly, this concept must 
be restricted to the interaction with SagHyal4755, as inhibition of the prototypical 
mammalian enzyme, BTH, was not observed. 
To substantiate the electronic properties of these “topology-driven” hyaluronidase 
inhibitors, the surface polarities of inhibitors 5.28 (IC50 = 8 µM) and 5.46 (IC50 = 80 µM) 
were computed by a COMSOsim-based model.71 Thermodynamic methods based on 
conductor-like screening models for realistic solvation (COSMO-RS) originated from the 
use of solvation thermodynamics and computational quantum mechanics. These methods 
rely on sigma profiles specific to each molecule. A sigma profile is a molecular-specific 
probability distribution of the surface polarization charge density (), which enables the 
application of solvation-thermodynamic models, e.g. to predict vapor-liquid equilibria.72 To 
display surface polarity of (5R)-5.28, the COSMOsim surface model, color coded by  is 
given in Figure 5.43. 
  
    
Figure 5.43 Surface polarity of (5R)-5.28
a
. The regions of strongly negative molecular polarity are displayed in 
red. The strongly positive molecular regions carrying negative  are colored blue, while the neutral parts of the 
molecules with  close to zero appear green (the negative molecular regions carry a positive polarization 
charge density, , because  is just compensating the molecular electrostatic field and therefore has the 
opposite sign).
71
 
 
a
 The planar scaffold of (5R)-5.28 is fused to a plane level. The scaffold is shown from three spatial directions 
(xy-, xz, yz-projection). 
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The COSMOsim surface model of (5S)-5.28 is given in Figure 5.44. 
  
    
Figure 5.44 Surface polarity of (5S)-5.28
a
. The regions of strongly negative molecular polarity are displayed in 
red. The strongly positive molecular regions carrying negative  are colored blue, while the neutral parts of the 
molecules with  close to zero appear green; 
a 
see Figure 5.43. 
 
As shown, the molecular surface of both enantiomers remained almost identical. The 
electronic surface at the center of the molecule is mainly imposed by the position of the 
hydroxyl group in position 5. Hence, the R- and S-stereoisomers can be described literally 
as mirror images. The COSMOsim surface model of (5R)-5.46 is given in Figure 5.45. 
  
    
Figure 5.45 Surface polarity of (5R)-5.46
a
. The regions of strongly negative molecular polarity are displayed in 
red. The strongly positive molecular regions carrying negative  are colored blue, while the neutral parts of the 
molecules with  close to zero appear green; 
a 
see Figure 5.43. 
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The molecular surface, calculated for (5R)-5.46 (Figure 5.45), indicates an aggregation of 
the 4-benzoic acid substituent and the 4-(trifluoromethyl)benzylamino residue. This results 
in a condensed, rather bulky lipophilic moiety. The situation is different for the computed 
surface of (5R)-5.28 (Figure 5.43), where the aryl residues build up three separate and 
distinct zones. An aggregation or overlapping is not observed. When comparing the 
hydroxylated compound 5.28 and the corresponding methylated compound 5.46, this 
might give an explanation for the 10-fold higher inbitory potency of the 4-amino-5-hydroxy-
1H-imidazole-2(5H)-thione 5.28. 
To highlight promising structural modifications of hyaluronidase inhibitors with respect to 
future work, a sample for a computed protein-ligand interaction is given in Figure 5.46. 
 
Figure 5.46 Crystal structure of SagHyal (PDB code 1LXM) with docked 4-amino-1H-imidazole-2(5H)-thiones. 
 
The screenshot displays the hyaluronan binding site of the target enzyme SagHyal4755 
(pdb code 1lxm)26 in complex with 4-amino-1H-imidazole-2(5H)-thione-type inhibitors. 
Note that enantiomeres of 5-hydroxylated or 5-methylated substances were not 
considered. Interestingly, the docking experiment proposes a highly conserved structural 
conformity for the computed molecules. Besides, the substances share a unitary 
orientation at the active site. 
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To identify common structural features, the molecular shape of the compounds was 
superimposed. A condensed topology, incorporating intermolecular similarity patterns, is 
given in Figure 5.47. 
 
Figure 5.47 Superimposed electronic surface of 4-amino-1H-imidazole-2(5H)-thiones at the hyaluronan 
binding site of SagHyal (pdb code 1LXM). 
 
Based on the molecular topology, modifications of the 4-amino-1H-imidazole-2(5H)-
thiones core structure can be suggested for position 1 and 5. For example, alkyl 
substituents in position 1, e.g. space-filling cycloalkyl residues, might provide additional 
protein-inhibitor interactions. In this context, the alkylated substances 5.12 and 5.15 (see 
5.3.3), might be regarded as prototypic structures. Moreover, aryl-substituents containing 
fused or connected (hetero)aromatic rings attached to position 5 might be valuable 
activity-enhancing residues. 
To conclude, protein-inhibitor interactions of 4-amino-1H-imidazole-2(5H)-thiones are 
most likely driven by the topology of the inhibitors. Furthermore, these structures harbor a 
high degree of freedom for additional modifications. 
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5.7 Summary 
In collaboration with Origenis GmbH a rational approach to identify novel lead inhibitors of 
the streptococcal lyase SagHyal4755 was persued. In silico generated molecules were 
synthesized on demand via parallel synthesis, analyzed and tested for biological activity 
using medium-throughput techniques. Right from the start, the project was focused on the 
prediction of small molecules with drug-like properties and accessible by one-pot 
multicomponent synthesis. 
In a first screening campaign three substances (“hits”) out of 2288 compounds were 
identified to possess moderate in vitro inhibitory activity in the micromolar range on the 
target enzyme. Re-testing of these screening hits as purified compounds, followed by 
rational modifications of similar molecules resulted in substances with retained biological 
activity in the micromolar range. The 4-amino-1H-imidazole-2(5H)-thione scaffold was 
selected as a promising novel structural motif to synthesize additional hyaluronidase 
inhibitors. 
A second screening approach, consisting of 352 4-amino-1H-imidazole-2(5H)-thione 
derivatives revealed a total of 25 hits. Preparative synthesis and purification of selected 
substances confirmed moderate to good inhibition in the micromolar range. However, 
chemical stability of some derivatives was unsatisfactory, due to autoxidation and 
decomposition. To cope with this problem, the process of autoxidation was studied in 
detail by means of [18O] labeling and HPLC-MS analysis. 
With compounds 5.26-5.35, stabilized C-5 hydroxylated molecules were obtained. All 
compounds were characterized as inhibitors following a dose-dependent manner on the 
target enzyme SagHyal4755. Substance 5.28 (IC50 = 8 µM) was identified as one of the 
most potent inhibitor known so far. 
Besides, modification of starting materials (aldehydes replaced by ketones) generated 
stable C-5 methylated compounds which were not prone to oxidation (substances 5.40-
5.70). Also, the molecular topology was highly conserved for these substances. The three-
dimensional structure of corresponding molecules was determined by means of 2D-NMR, 
HRMS and X-ray diffraction analysis. A hit to lead development, under the guideline to 
meet the requirements in terms of drug-like properties, was pursued via rational variation 
of substituents on the core scaffold. 
In summary, the applied innovative methods and modus operandi of the current approach 
were suitable to obtain novel lead inhibitors of the bacterial hyaluronidase SagHyal4755. 
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5.8 Experimental section 
5.8.1 General conditions 
Chemicals and solvents were purchased from ACB Blocks Ltd (Moscow, Russia), Acros 
Organics (Geel, Belgium), Alfa Aesar GmbH & Co. KG (Karlsruhe, Germany), Bachem AG 
(Bubendorf, Switzerland), Biosynth AG (Staad, Switzerland), Chembridge Corporation 
(San Diego, USA), ChemPacific Corporation (Baltimore, USA), Fluka AG (Buchs, 
Switzerland), Frontier Scientific Inc. (Logan, USA), Maybridge (Trevillett, UK), Merck 
KGaA (Darmstadt, Germany), Priaton GmbH (Munich, Germany), Sigma-Aldrich Chemie 
GmbH (Munich, Germany) and Zerenex Molecular Ltd (Greater Manchester, UK) and 
used without further purification. Deuterated solvents for NMR spectroscopy were from 
Deutero GmbH (Kastellaun, Germany). All solvents were of analytical grade or distilled 
prior to use. If moisture-free conditions were required, reactions were performed in dried 
glassware under inert atmosphere (argon or nitrogen); DMF (H2O < 0.01 %) was 
purchased from Sigma-Aldrich Chemie GmbH (Munich, Germany). Millipore water was 
used throughout for the preparation of buffers and HPLC eluents. 
Nuclear Magnetic Resonance spectra were recorded with Avance 300 (1H: 300 MHz, 
13C: 75.5 MHz), Avance 400 (1H: 400 MHz, 13C: 100.6 MHz) and Avance III 600 Kryo 
spectrometer (1H: 600 MHz, 13C: 150.9 MHz) from Bruker BioSpin GmbH (Rheinstetten, 
Germany). Coupling constants (J) are reported in Hz throughout. Multiplicities are 
specified with the following abbreviations: s (singlet), d (doublet), t (triplet), q (quartet), m 
(multiplet), s br (for broad singulet), as well as combinations thereof. The multiplicity of 
carbon atoms (13C-NMR) were determined by DEPT 90 and DEPT 135 (distortionless 
enhancement by polarization transfer): “+” primary and tertiary carbon atom (positive 
DEPT 135 signal), “-“ secondary carbon atom (negative DEPT 135 signal), “quat” 
quaternary carbon atom. For substances measured with the Avance 600 Kryo NMR 
spectrometer, 2D-NMR techniques (HSQC, HMBC, COSY) were used to assign 1H and 
13C chemical shifts. 
Flash chromatography was performed in glass columns on silica gel (Merck silica gel 60, 
particle size 0.040 – 0.063 mm). Automated flash chromatography was performed on a 
Varian IntelliFlash 310 using pre-packed Varian Superflash columns (Varian, Darmstadt, 
Germany). Reactions were routinely monitored by thin layer chromatography (TLC) on 
Merck silica gel 60 F254 aluminum sheets and spots were visualized with UV light at 254 
nm, and/or iodine vapor or ammonium molybdate/cerium(IV) sulphate solution. Microwave 
assisted reactions were performed on an Initiator 2.0 synthesizer (Biotage, Uppsala, 
Sweden). Lyophilisation was done on a Christ alpha 2-4 LD equipped with a vacuubrand 
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RZ 6 rotary vane vacuum pump. Melting points (mp) were measured on a BÜCHI 530 
electrically heated copper block apparatus (Büchi AG, Flawil, Switzerland) using open 
capillaries and are uncorrected. Compounds were dried under reduced pressure (0.1 - 1 
Torr) at room temperature. 
Analytical RP-HPLC was performed on a system consisting of the following components 
(Thermo Separation Products, Switzerland): pump model was P4000 pump, adjusted to a 
SN400 controller and an AS3000 autosampler. For UV/VIS-detection served a Spectra 
Focus detector (Table 5.15). 
Table 5.15 Analytical RP-HPLC system components and parameters. 
stationary 
phase 
column Eurospher-100 C18, 4.0 x 250 mm, 5 µm (Knauer, Berlin, 
Germany) 
temperature 30 °C 
mobile  
phase 
solvent A: acetonitrile (gradient grade) + 0.025 % TFA (v/v) 
B: water (millipore) + 0.025 % TFA (v/v) 
flow 0.7 mL/min 
gradient 00 to 30 min (A/B): 10/90 to 90/10 (v/v) 
detector wavelength  210 nm 
 
HPLC-MS analysis was conducted on an Agilent Technologies 1100 Series (autosampler, 
pump, controller, UV detector) with a Hewlett-Packard 1100 Series detector (ESI-MSD) 
spectrometer (Table 5.16). 
Table 5.16 Analytical HPLC-MS system components and parameters. 
stationary 
phase 
column SunFire
TM
 C18, 2.1 x 50 mm, 2.5 µm (Waters, Dublin, Ireland) 
temperature 40 °C 
mobile  
phase 
solvent A: acetonitrile (gradient grade) 
B: water (LiChrosolv
®
) 
C (modifier): acetonitrile (gradient grade) + 2 % formic acid (for 
analysis) (v/v) 
flow 0.6 mL/min 
gradient 00 to 05 min (A/B): 5/95 to 95/0 (v/v) 
detector wavelength  220 nm, 250 nm 
MS system Hewlett-Packard Series 1100 MSD (Hewlett-Packard, USA) 
 
HPLC-MS analysis of compounds 5.36-5.38 was performed with a system including the 
following components: RP-HPLC and mass spectrometry analysis (MS) was conducted on 
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an Agilent Technologies 1290 Series (autosampler, pump, controller, UV detector) with an 
Agilent Technologies 6540 Series UHD Accurate-Mass (Q-TOF/LC MS) detector. For 
optimal signal detection, 2 different methods depending on the column-type were used: 
method 1 (Zorbax column, Table 5.17), method 2 (Accucore column, Table 5.18). 
Table 5.17 Analytical HPLC-MS system components and parameters (method 1, Zorbax column). 
stationary 
phase 
column 
 
Zorbax Eclipse Plus C18 Rapid Solution HD, 2.1 x 50 mm, 1.8 µm 
(Agilent Technologies, Santa Clara, USA) 
temperature 40 °C 
mobile  
phase 
solvent A: acetonitrile (gradient grade) + 0.1 % formic acid (v/v) 
B: water (LiChrosolv
®
) + 0.1 % formic acid (v/v) 
flow 0.6 mL/min 
gradient 00 to 04 min (A/B): 5/95 to 90/10 (v/v) 
detector wavelength  220 nm 
MS system Agilent Technologies 6540 Series UHD Accurate-Mass (Agilent 
Technologies, Santa Clara, USA) 
 
Table 5.18 Analytical HPLC-MS system components and parameters (method 2, Accucore column). 
stationary 
phase 
column 
 
Accucore aQ, 2.1 x 50 mm, 2.6 µm (Thermo Scientific, Santa 
Clara, USA) 
temperature 40 °C 
mobile  
phase 
solvent A: acetonitrile (gradient grade) + 0.1 % formic acid (v/v) 
B: water (LiChrosolv
®
) + 0.1 % formic acid (v/v) 
flow 0.4 mL/min 
gradient 00 to 04 min (A/B): 0/100 to 90/10 (v/v) 
detector wavelength  220 nm 
MS system Agilent Technologies 6540 Series UHD Accurate-Mass (Agilent 
Technologies, Santa Clara, USA) 
 
Prior to preparative RP-HPLC, a standardized samples preparation was performed: crude 
products were precipitated (solvent indicated) and dried (rotary evaporator). 
Subsequently, the residues were dissolved in 1600 µL acetonitrile, 100 µL acetic acid and 
800 µL H2O (millipore). After filtration through Nylon‐filters (13 mm, 0.45 μm, Roth GmbH, 
Karlsruhe, Germany) the samples were subjected to preparative RP-HPLC. After RP-
HPLC purification, the solvent of the combined product fractions was evaporated (rotary 
evaporator). The residues were dissolved in 1600 µL tert-BuOH with 800 µL H2O 
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(millipore) and subjected to lyophilisation (Alpha 2-4, Christ GmbH, Osterode, Germany). 
Purity of compounds tested for hyaluronidase inhibition was ≥ 95 %. 
Preparative RP-HPLC was conducted on a system consisting of the following 
components: pump models were a Varian PrepStar Model SD-1 (main pump, operating 
solvents A, B), Dionex Ultimate 3000 pump (modifier pump, operating solvent C) and a 
Dionex P580 pump (analytical pump). The system was equipped with a Dionex Ultimate 
3000 Variable Wavelength Detector. For mass detection an assembly of a Rheodyne 
SplitRatio 4000 MRA-switcher, Dionex UVD 340U and Dionex Model Surveyer MSQ mass 
spectrometer system was used. Samples were collected on a Gilson 215 Liquid Handler 
(injector module and sample collector). The Interface was a Dionex UCI-100 (Universal 
Chromatography Interface). Chromeleon Client Software (Version 6.80, Dionex Corp.) and 
Surveyor MSQ Tune (MSQ Standard 2.0 SP1, Thermo Electron Corp.) were embedded 
(Table 5.19). 
Table 5.19 Preparative RP-HPLC system components and parameters. 
stationary 
phase 
column 
 
XBridge
TM
 Prep C18 5 µm OBD
TM
, 19 x 50 mm, 5 µm (Waters, 
Dublin, Ireland) 
temperature room temperature 
mobile  
phase 
solvent A: acetonitrile (gradient grade) 
B: water (LiChrosolv
®
) 
C (modifier): 1:1 acetonitrile (gradient grade), water (millipore) + 
10 % acetic acid (for analysis) (v/v/v) 
flow 40 mL/min (A,B), 2.4 mL/min (C; permanent modifier flow) 
gradient method 1: 00 to 04 min (A/B): 5/95 to 95/5 (v/v) 
method 2: 00 to 05 min (A/B): 5/95 to 80/20 (v/v) 
detector wavelength  220 nm 
MS system Dionex, Model Surveyer MSQ Mass Spectrometer System 
(Dionex, Sunnyvale, USA) 
 
Alternatively, preparative RP-HPLC was performed on a system consisting of the following 
components: pump model was K-1800 (Knauer GmbH, Germany). For UV-detection 
served a K-2000 (Knauer GmbH, Germany) (cf. Table 5.20). 
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Table 5.20 Preparative RP-HPLC system components and parameters. 
stationary 
phase 
column 
 
Nucleodur VP 250/21 100-5 C18ec, 21 x 250 mm, 5 µm 
(Macherey-Nagel, Düren, Germany) 
temperature room temperature 
mobile  
phase 
solvent A: acetonitrile (HPLC grade) 
B: water (millipore) + 0.1 % TFA + 5 % acetonitrile (v/v/v) 
flow 20.0 mL/min 
gradient 00 to 30 min (A/B): 20/80 to 90/10 (v/v) 
detector wavelength  220 nm 
 
Mass spectrometry analysis (MS) was conducted on an Agilent Technologies 1290 Series 
(autosampler, pump, controller, UV detector) with an Agilent Technologies 6540 Series 
UHD Accurate-Mass (Q-TOF/LC MS) detector. Mass spectra (MS) were additionally 
recorded on a Finnigan MAT 95 (EI-MS 70 ev, HR-MS), Finnigan SSQ 710A (CI-MS 
(NH3)) and on a Finnigan ThermoQuest TSQ 7000 (ES-MS) spectrometer. 
 
5.8.2 Chemistry 
5.8.2.1 Parallel synthesis 
5.8.2.1.1 General conditions 
Reaction conditions were adjusted to the microliter scale on 96 deep well plates (total 
volume: 1200 µL) and to the needs of an automated synthesis. Using a Tecan Genesis 
RSP 200/8 parallel synthesizer (Tecan Deutschland GmbH, Crailsheim, Germany) 80 or 
88 reactions were performed simultaneously. After completion of the experiment, each 
compound was assessed on a PerSeptive BioSystems MarinerTM ESI-TOF mass 
spectrometer. The success of the individual syntheses was analyzed and indicated 
automatically by an absolute threshold on signal intensity. The absolute threshold 
specified a threshold value relative to the total intensity per scan. For compounds 
displaying a target mass with an absolute threshold < 30 and < 100, the formation of 
products was regarded as failed or insufficient, respectively (category “red” and “yellow”). 
With an absolute threshold ≥ 100, the formation of products was regarded as successful 
(category “green”). The observed molecular ions for successfully synthesized compounds 
are listed in sections B.3 – B.6 (appendix II). After HPLC-MS analysis, the solvent was 
evaporated with a Genevac HT-4X centrifugal vacuum evaporator (Genevac Inc., 
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Gardiner, USA). Finally, 500 µL of DMSO were added to each well to adjust to a final 
concentration of 0.02 M (assumption: formation of product 100 %). All compounds were 
immediately tested for inhibition of the activity of bacterial hyaluronidase SagHyal4755. 
Final assay concentration of the respective inhibitors was adjusted to 200 µM (assuming 
100 % conversion to product). After the testing procedures the well plates were sealed 
and stored at -20 °C. 
 
5.8.2.1.2 Preparation of 1H-pyrrol-2(5H)-ones (ori.hya.10-19) 
For the parallel synthesis of 1H-pyrrol-2(5H)-ones, solutions of the pertinent amines (0.2 
M, 50 µL, 1 eq) in anhydrous EtOH were dispensed on 96 deep well plates. Aldehydes 
(0.2 M, 50 µL, 1 eq) in anhydrous EtOH were added, and the plates were stacked for 30 
min at ambient temperature. Subsequently, isocyanides (0.2 M, 50 µL, 1 eq) in anhydrous 
EtOH were added. The well plates were sealed and stacked for 24 h at ambient 
temperature. After completion of the experiment, the compounds were analyzed (HPLC-
MS), and the solvent was evaporated. Subsequently, the residues were dissolved in 
DMSO and the samples were stored as described previously. 
 
5.8.2.1.3 Preparation of 4-amino-1H-imidazole-2(5H)-ones (ori.hya.20-27) 
For the parallel synthesis of 4-amino-1H-imidazole-2(5H)-ones, amines (0.2 M, 50 µL, 1 
eq) in MeOH (dry) were dispensed on 96 deep well plates. Aldehydes (0.2 M, 50 µL, 1 eq) 
in MeOH (dry) were added, and the plates were stacked for 30 min at ambient 
temperature. Subsequently a mixture of KOCN (0.8 M, 4 eq) and pyridine hydrochloride 
(0.8 M, 4 eq) in 50 µL MeOH (dry) and isocyanides (0.2 M, 50 µL, 1 eq) in MeOH (dry) 
were added. The well plates were sealed and stacked for 48 h at temperature below 20 
°C. After completion of the experiment, the compounds were analyzed (HPLC-MS), and 
the solvent was evaporated. Subsequently, the residues were dissolved in DMSO and the 
samples were stored as described previously. 
 
5.8.2.1.4 Preparation of 4-amino-1H-imidazole-2(5H)-thiones (ori.hya.28-35) 
For the parallel synthesis of 4-amino-1H-imidazole-2(5H)-thiones, amines (0.2 M, 50 µL, 1 
eq) in MeOH (dry) were dispensed on 96 deep well plates. Aldehydes (0.2 M, 50 µL, 1 eq) 
in MeOH (dry) were added, and the plates were stacked for 30 min at ambient 
temperature. Subsequently a mixture of KSCN (0.8 M, 4 eq) and pyridine hydrochloride 
(0.8 M, 4 eq) in 50 µL MeOH (dry) and isocyanides (0.2 M, 50 µL, 1 eq) in MeOH (dry) 
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were added. The well plates were sealed and stacked for 48 h at temperature below 20 
°C. After completion of the experiment, the compounds were analyzed (HPLC-MS), and 
the solvent was evaporated. Subsequently, the residues were dissolved in DMSO and the 
samples were stored as described previously. 
 
5.8.2.2 Preparation of the compounds 5.2, 5.3, 5.6, 5.10, 5.12-5.15 
5-(3,5-Dihydroxyphenyl)-1-(3-hydroxyphenyl)-4-(pentan-2-ylamino)-1H-imidazol-
2(5H)-one (5.2)52 
The title compound was prepared from 3,5-dihydroxybenzaldehyde (0.3 mmol, 41 mg) 
and 3-aminophenol (0.3 mmol, 33 mg) in anhydrous MeOH (1 mL per mmol). The solution 
was stirred for 1 h at room temperature and was subsequently cooled to 0 °C. After 
addition of KOCN (4 eq), pyridinium chloride (4 eq) and 2-isocyanopentane (0.3 mmol, 29 
mg) the mixture was stirred at room temperature overnight. Removal of the solvent gave 
the crude substance, which was purified by RP-HPLC (Table 5.19, method 2). Yield 
(preparative HPLC): 17.9 mg (16.2 %, pale yellow solid). MS (CI-MS) m/z (rel. int. in %) = 
370.2 ([M + H]+, 100). C20H23N3O4 (Mr = 369.41 g/mol). 
 
4-(4-Chlorobenzylamino)-5-(3,5-dihydroxyphenyl)-1-(3-hydroxyphenyl)-1H-
imidazole-2(5H)-thione (5.3)52 
The title compound was prepared from 3,5-dihydroxybenzaldehyde (0.3 mmol, 41 mg) 
and 3-aminophenol (0.3 mmol, 33 mg) in anhydrous MeOH (1 mL per mmol). The solution 
was stirred for 1 h at room temperature and was subsequently cooled to 0 °C. After 
addition of KSCN (4 eq), pyridinium chloride (4 eq) and 1-chloro-4-
(isocyanomethyl)benzene (0.3 mmol, 45 mg) the mixture was stirred at room temperature 
overnight. Removal of the solvent gave the crude substance, which was purified by RP-
HPLC (Table 5.19, method 2). Yield (preparative HPLC): 6.2 mg (4.7 %, yellow solid). MS 
(CI-MS) m/z (rel. int. in %) = 440.1 ([M + H]+, 100). C22H18ClN3O3S (Mr = 439.91 g/mol). 
 
1-(Cyclohexylmethyl)-5-(3,5-dihydroxyphenyl)-3-hydroxy-1H-pyrrol-2(5H)-one (5.6)40 
To a mixture of cyclohexylmethanamine (0.6 mmol, 68 mg) and 3,5-
dihydroxybenzaldehyde (0.6 mmol, 83 mg) in 5 mL anhydrous EtOH was added a solution 
of methyl 2-oxopropanoate (0.6 mmol, 61 mg) in 2.5 mL anhydrous EtOH. The reaction 
mixture was allowed to stand for 20 h at ambient temperature. The precipitated crude 
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product was filtered off, dried in vacuo and purified by RP-HPLC (Table 5.19, method 2). 
Yield (preparative HPLC): 1.5 mg (1.6 %, colorless solid). MS (CI-MS) m/z (rel. int. in %) = 
304.1 ([M + H]+, 100). C17H21NO4 (Mr = 303.35 g/mol). 
 
2-(3,5-Dihydroxyphenyl)-1-(2,3-dihydroxypropyl)-4-hydroxy-5-oxo-2,5-dihydro-1H-
pyrrole-3-carbonitrile (5.10)40 
To a mixture of 3-aminopropane-1,2-diol (0.6 mmol, 46 mg) and 3,5-
dihydroxybenzaldehyde (0.6 mmol, 83 mg) in 5 mL anhydrous EtOH was added a solution 
of ethyl 3-cyano-2-oxopropanoate (0.6 mmol, 85 mg) in 2.5 mL anhydrous EtOH. The 
reaction mixture was allowed to stand for 20 h at ambient temperature. The precipitated 
crude product was filtered off, dried in vacuo and purified by RP-HPLC (Table 5.19, 
method 2). Yield (preparative HPLC): 2.0 mg (1.1 %, colorless solid). MS (CI-MS) m/z (rel. 
int. in %) = 307.1 ([M + H]+, 100). C14H14N2O6 (Mr = 306.27 g/mol). 
 
5-(3,5-Dihydroxyphenyl)-1-(3-hydroxyphenyl)-4-(pentan-2-ylamino)-1H-imidazole-
2(5H)-thione (5.12)52 
The title compound was prepared from 3,5-dihydroxybenzaldehyde (0.3 mmol, 41 mg) 
and 3-aminophenol (0.3 mmol, 33 mg) in anhydrous MeOH (1 mL per mmol). The solution 
was stirred for 1 h at room temperature and was subsequently cooled to 0 °C. After the 
addition of KSCN (4 eq), pyridinium chloride (4 eq) and 2-isocyanopentane (0.3 mmol, 29 
mg), the mixture was stirred at room temperature overnight. Removal of the solvent gave 
the crude substance, which was purified by RP-HPLC (Table 5.19, method 2). Yield 
(preparative HPLC): 6.9 mg (5.7 %, gray solid). MS (CI-MS) m/z (rel. int. in %) = 386.1 ([M 
+ H]+, 100). C20H23N3O3S (Mr = 385.48 g/mol). 
 
4-(4-Chlorobenzylamino)-5-(3,5-dihydroxyphenyl)-1-(3-hydroxyphenyl)-1H-imidazol-
2(5H)-one (5.13)52 
The title compound was prepared from 3,5-dihydroxybenzaldehyde (0.3 mmol, 41 mg) 
and 3-aminophenol (0.3 mmol, 33 mg) in anhydrous MeOH (1 mL per mmol). The solution 
was stirred for 1 h at room temperature and was subsequently cooled to 0 °C. After the 
addition of KOCN (4 eq), pyridinium chloride (4 eq) and 1-chloro-4-
(isocyanomethyl)benzene (0.3 mmol, 45 mg) the mixture was stirred at room temperature 
overnight. Removal of the solvent gave the crude substance, which was purified by RP-
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HPLC (Table 5.19, method 2). Yield (preparative HPLC): 46.4 mg (36.6 %, orange solid). 
MS (CI-MS) m/z (rel. int. in %) = 424.1 ([M + H]+, 100). C22H18ClN3O4 (Mr = 423.85 g/mol). 
 
4-(sec-Butylamino)-5-(3,5-dihydroxyphenyl)-1-(3-hydroxyphenyl)-1H-imidazol-2(5H)-
one (5.14)52 
The title compound was prepared from 3,5-dihydroxybenzaldehyde (0.3 mmol, 41 mg) 
and 3-aminophenol (0.3 mmol, 33 mg) in anhydrous MeOH (1 mL per mmol). The solution 
was stirred for 1 h at room temperature and was subsequently cooled to 0 °C. After the 
addition of KOCN (4 eq), pyridinium chloride (4 eq) and 2-isocyanobutane (0.3 mmol, 25 
mg) the mixture was stirred at room temperature overnight. Removal of the solvent gave 
the crude substance which was purified by RP-HPLC (Table 5.19, method 2). Yield 
(preparative HPLC): 17.1 mg (16.0 %, pale yellow solid). MS (CI-MS) m/z (rel. int. in %) = 
356.2 ([M + H]+, 100). C19H21N3O4 (Mr = 355.39 g/mol). 
 
4-(sec-Butylamino)-5-(3,5-dihydroxyphenyl)-1-(3-hydroxyphenyl)-1H-imidazole-
2(5H)-thione (5.15)52 
The title compound was prepared from 3,5-dihydroxybenzaldehyde (0.3 mmol, 41 mg) 
and 3-aminophenol (0.3 mmol, 33 mg) in anhydrous MeOH (1 mL per mmol). The solution 
was stirred for 1 h at room temperature and was subsequently cooled to 0 °C. After the 
addition of KSCN (4 eq), pyridinium chloride (4 eq) and 2-isocyanobutane (0.3 mmol, 25 
mg) the mixture was stirred at room temperature overnight. Removal of the solvent gave 
the crude substance, which was purified by RP-HPLC (Table 5.19, method 2). Yield 
(preparative HPLC): 17.1 mg (16.0 %, yellow solid). MS (CI-MS) m/z (rel. int. in %) = 
372.1 ([M + H]+, 100). C19H21N3O3S (Mr = 371.45 g/mol). 
 
5.8.2.3 Preparation of the compounds 5.16-5.25 
General procedure52  
A solution of the pertinent aldehyde (1 eq) and amine (1 eq) in anhydrous MeOH (1 mL 
per mmol) was stirred for 1 h at room temperature and was subsequently cooled to 0 °C. 
After the addition of KSCN (4 eq), pyridinium chloride (4 eq) and the corresponding 
isocyanide (1 eq), the mixture was stirred overnight below 20 °C. Insoluble material was 
removed by filtration, and the solvent (MeOH) was removed under reduced pressure. 
After addition of ethyl acetate as solvent, precipitated material was removed by filtration 
118 Experimental section  
and the crude product was obtained as residue after evaporation. The crude substance 
was submitted to preparative HPLC (method indicated) yielding the corresponding {[M + 
H]+ + 16} product.a 
a 
molecular [M + H]
+ 
species of compounds 5.26-5.35 showed complete autoxidation to the corresponding 
{[M + H]
+
 + 16} derivatives within the first 48 h. HPLC isolation of “{[M + H]
+
 + 16} substances” was performed 
not before 72 h after completion of the experiment. 
 
5-(2,5-Dihydroxyphenyl)-5-hydroxy-1-(4-hydroxyphenyl)-4-[4-(trifluoromethyl)benzyl 
amino]-1H-imidazole-2(5H)-thione (5.16) 
The title compound was prepared from 2,3-dihydroxybenzaldehyde (0.3 mmol, 41 mg), 4-
aminophenol (0.3 mmol, 33 mg) and 1-(isocyanomethyl)-4-(trifluoromethyl)benzene 
(0.3 mmol, 56 mg) according to the general procedure. The crude product was obtained 
as residue after evaporation from ethyl acetate, and gave yellow oil which was stored at -
20 °C for 7 days. A full conversion to the corresponding {[M + H]+ + 16} derivative was 
observed under the specified conditions. Separation by RP-HPLC (Table 5.19, method 1) 
yielded the autoxidized species {[M + H]+ + 16} as a pale yellow solid. Yield (precipitation): 
65 mg, 44 %; yield (preparative HPLC): 6.9 mg, 4.7 %. MS (CI-MS)b m/z (rel. int. in %) = 
496.1 (10), 474.1 ([M + H]+, 100), 385.1 (5), 218.1 (5). MS (CI-MS)d m/z (rel. int. in %) = 
512.0 (5), 496.1 (20), 490.1 ({[M + H]+ + 16}, 10), 474.1 ([M + H]+, 100). C23H18F3N3O4S 
(Mr* = 489.47 g/mol). 
Note: mass spectral data refer to [M + H]
+
 (Mr  = 473.47 g/mol) and {[M + H]
+
 + 16} (Mr* = 489.47 g/mol). 
b
 4 h 
after completion of the experiment; relative abundance (TIC): Mr (473.47 g/mol) = 50 %; relative abundance 
(TIC): Mr* (489.47 g/mol) = 4 %; 
d
 48 h after completion of the experiment; relative abundance (TIC): 
Mr (473.47 g/mol) = 50 %; relative abundance (TIC): Mr* (489.47 g/mol) = 10 %. 
 
5-(2,3-Dihydroxyphenyl)-5-hydroxy-1-(3-hydroxyphenyl)-4-[4-(trifluoromethyl)benzyl 
amino]-1H-imidazole-2(5H)-thione (5.17) 
The title compound was prepared from 2,3-dihydroxybenzaldehyde (0.3 mmol, 41 mg), 3-
aminophenol (0.3 mmol, 33 mg) and 1-(isocyanomethyl)-4-(trifluoromethyl)benzene 
(0.3 mmol, 56 mg) according to the general procedure. The crude product was obtained 
as residue after evaporation from ethyl acetate, and gave yellow oil, which was stored at -
20 °C for 7 days. A full conversion to the corresponding {[M + H]+ + 16} derivative was 
observed under the specified conditions. Separation by RP-HPLC (Table 5.19, method 1) 
yielded the autoxidized species {[M + H]+ + 16} as a pale yellow solid. Yield (precipitation): 
95 mg, 65 %; yield (preparative HPLC): 4.9 mg, 3.3 %. MS (CI-MS)b m/z (rel. int. in %) = 
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496.1 (5), 474.1 ([M + H]+, 100), 385.1 (5). MS (CI-MS)d m/z (rel. int. in %) = 496.1 (15), 
490.1 ({[M + H]+ + 16}, 10), 474.1 ([M + H]+, 100). C23H18F3N3O4S (Mr* = 489.47 g/mol). 
Note: mass spectral data refer to [M + H]
+
 (Mr  = 473.47 g/mol) and {[M + H]
+
 + 16} (Mr* = 489.47 g/mol). 
b
 4 h 
after completion of the experiment; relative abundance (TIC): Mr (473.47 g/mol) = 65 %; relative abundance 
(TIC): Mr* (489.47 g/mol) = 10 %; 
d
 48 h after completion of the experiment; relative abundance (TIC): 
Mr (473.47 g/mol) = 50 %; relative abundance (TIC): Mr* (489.47 g/mol) = 12 %. 
 
4-(4-tert-Butylbenzylamino)-5-(2,3-dihydroxyphenyl)-5-hydroxy-1-(3-hydroxyphenyl)-
1H-imidazole-2(5H)-thione (5.18) 
The title compound was prepared from 2,5-dihydroxybenzaldehyde (0.3 mmol, 41 mg), 3-
aminophenol (0.3 mmol, 33 mg) and 1-tert-butyl-4-(isocyanomethyl)benzene (0.3 mmol, 
52 mg) according to the general procedure. The crude product was obtained as residue 
after evaporation from ethyl acetate, and gave yellow oil, which was stored at -20 °C for 7 
days. A full conversion to the corresponding {[M + H]+ + 16} derivative was observed 
under the specified conditions. Separation by RP-HPLC (Table 5.19, method 1) yielded 
the autoxidized species {[M + H]+ + 16} as a pale yellow solid. Yield (precipitation): 95 mg, 
66 %; yield (preparative HPLC): 4.2 mg, 2.9 %. MS (CI-MS)b m/z (rel. int. in %) = 484.1 
(5), 462.2 ([M + H]+, 100). MS (CI-MS)d m/z (rel. int. in %) = 484.1 (5), 476.2 ({[M + H]+ + 
16}, 10), 462.2 ([M + H]+, 100). C26H27N3O4S (Mr* = 477.58 g/mol). 
Note: mass spectral data refer to [M + H]
+
 (Mr  = 461.58 g/mol) and {[M + H]
+
 + 16} (Mr* = 477.58 g/mol). 
b
 4 h 
after completion of the experiment; relative abundance (TIC): Mr (461.58 g/mol) = 60 %; relative abundance 
(TIC): Mr* (477.58 g/mol) = 6 %; 
d
 48 h after completion of the experiment; relative abundance (TIC): 
Mr (461.58 g/mol) = 60 %; relative abundance (TIC): Mr* (477.58 g/mol) = 8 %. 
 
4-(4-Chlorobenzylamino)-5-(3,5-dihydroxyphenyl)-5-hydroxy-1-(3-hydroxyphenyl)-
1H-imidazole-2(5H)-thione (5.19) 
The title compound was prepared from 2,4,5-trihydroxybenzaldehyde (0.3 mmol, 46 mg), 
3-aminophenol (0.3 mmol, 33 mg) and 1-tert-butyl-4-(isocyanomethyl)benzene (0.3 mmol, 
52 mg) according to the general procedure. The crude product was obtained as residue 
after evaporation from ethyl acetate, and gave yellow oil, which was stored at -20 °C for 7 
days. A full conversion to the corresponding {[M + H]+ + 16} derivative was observed 
under the specified conditions. Separation by RP-HPLC (Table 5.19, method 1) yielded 
the autoxidized species {[M + H]+ + 16} as a pale yellow solid. Yield (precipitation): 70 mg, 
47 %; yield (preparative HPLC): 6.1 mg, 4.1 %. MS (CI-MS)b m/z (rel. int. in %) = 547.1 
(5), 494.0 (5), 478.0 (20), 456.1 ({[M + H]+ + 16}, 95) 440.1 ([M + H]+, 100). MS (CI-MS)d 
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m/z (rel. int. in %) = 478.0 (15), 476.2 ({[M + H]+ + 16}, 100), 440.1 ([M + H]+, 90). 
C22H18ClN3O4S (Mr* = 455.91 g/mol). 
Note: mass spectral data refer to [M + H]
+
 (Mr  = 439.91 g/mol) and {[M + H]
+
 + 16} (Mr* = 455.91 g/mol). 
b
 4 h 
after completion of the experiment; relative abundance (TIC): Mr (439.91 g/mol) = 35 %; relative abundance 
(TIC): Mr* (455.91 g/mol) = 25 %; 
d
 48 h after completion of the experiment; relative abundance (TIC): 
Mr (439.91 g/mol) = 35 %; relative abundance (TIC): Mr* (455.91 g/mol) = 35 %. 
 
5-Hydroxy-1-(3-hydroxyphenyl)-4-(4-(trifluoromethyl)benzylamino)-5-(2,4,5-
trihydroxy phenyl)-1H-imidazole-2(5H)-thione (5.20) 
The title compound was prepared from 2,4,5-trihydroxybenzaldehyde (0.3 mmol, 46 mg), 
3-aminophenol (0.3 mmol, 33 mg) and 1-(isocyanomethyl)-4-(trifluoromethyl)benzene 
(0.3 mmol, 56 mg) according to the general procedure. The crude product was obtained 
as residue after evaporation from ethyl acetate, and gave brown oil, which was stored at -
20 °C for 7 days. A full conversion to the corresponding {[M + H]+ + 16} derivative was 
observed under the specified conditions. Separation by RP-HPLC (Table 5.19, method 1) 
yielded the autoxidized species {[M + H]+ + 16} as a pale yellow solid. Yield (precipitation): 
80 mg, 53 %; yield (preparative HPLC): 1.6 mg, 1.1 %. MS (CI-MS)b m/z (rel. int. in %) = 
565.1 (15), 512.1 (10), 491.1 ([M + H]+, 100). MS (CI-MS)c m/z (rel. int. in %) = 508.4 (20), 
506.4 ({[M + H]+ + 16}, 100). C23H18F3N3O5S (Mr* = 505.47 g/mol). 
Note: mass spectral data refer to [M + H]
+
 (Mr  = 489.47 g/mol) and {[M + H]
+
 + 16} (Mr* = 505.47 g/mol). 
b
 4 h 
after completion of the experiment; relative abundance (TIC): Mr (489.47 g/mol) = 50 %; relative abundance 
(TIC): Mr* (505.47 g/mol) = 1.5 %; 
c
 7 d after completion of the experiment; relative abundance (TIC): 
Mr (489.47 g/mol) = 0 %; relative abundance (TIC): Mr* (505.47 g/mol) = 40 %. 
 
4-(4-tert-Butylbenzylamino)-5-hydroxy-1-(3-hydroxyphenyl)-5-(2,4,5-
trihydroxyphenyl)-1H-imidazole-2(5H)-thione (5.21) 
The title compound was prepared from 2,4,5-trihydroxybenzaldehyde (0.3 mmol, 46 mg), 
3-aminophenol (0.3 mmol, 33 mg) and 1-tert-butyl-4-(isocyanomethyl)benzene (0.3 mmol, 
52 mg) according to the general procedure. The crude product was obtained as residue 
after evaporation from ethyl acetate, and gave brown oil, which was stored at -20 °C for 7 
days. A full conversion to the corresponding {[M + H]+ + 16} derivative was observed 
under the specified conditions. Separation by RP-HPLC (Table 5.19, method 1) yielded 
the autoxidized species {[M + H]+ + 16} as a yellow solid. Yield (precipitation): 70 mg, 47 
%; yield (preparative HPLC): 4.6 mg, 3.1 %. MS (CI-MS)b m/z (rel. int. in %) = 500.2 (15), 
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479.2 ([M + H]+, 100). MS (CI-MS)c m/z (rel. int. in %) = 495.9 (30), 494.9 ({[M + H]+ + 16}, 
100). C26H27N3O5S (Mr* = 493.57 g/mol). 
Note: mass spectral data refer to [M + H]
+
 (Mr  = 477.57 g/mol) and {[M + H]
+
 + 16} (Mr* = 493.57 g/mol). 
b
 4 h 
after completion of the experiment; relative abundance (TIC): Mr (477.57 g/mol) = 65 %; relative abundance 
(TIC): Mr* (493.57 g/mol) = 4.5 %; 
c
 7 d after completion of the experiment; relative abundance (TIC): 
Mr (477.57 g/mol) = 0 %; relative abundance (TIC): Mr* (493.57 g/mol) = 40 %. 
 
1-(3,5-Dichloro-4-hydroxyphenyl)-5-hydroxy-4-[4-(trifluoromethyl)benzylamino]-5-
(2,4,5-trihydroxyphenyl)-1H-imidazole-2(5H)-thione (5.22) 
The title compound was prepared from 2,4,5-trihydroxybenzaldehyde (0.3 mmol, 46 mg), 
3,5-dichloro-4-(trifluoromethyl)aniline (0.3 mmol, 53 mg) and 1-(isocyanomethyl)-4-
(trifluoromethyl)benzene (0.3 mmol, 56 mg) according to the general procedure. The 
crude product was obtained as residue after evaporation from ethyl acetate, and gave 
brown oil, which was stored at -20 °C for 7 days. A full conversion to the corresponding 
{[M + H]+ + 16} derivative was observed under the specified conditions. Separation by RP-
HPLC (Table 5.19, method 1) yielded the autoxidized species {[M + H]+ + 16} as a gray 
solid. Yield (precipitation): 115 mg, 67 %; yield (preparative HPLC): 6.1 mg, 3.7 %. 1H-
NMR (600 MHz, DMSO-d6): δ [ppm] = 10.24 (s, 1H, OH-4’), 9.32 – 9.11 (m, 2H, Ph-OH), 
9.03 – 8.88 (m, 1H, NHCH2-p-C6H4-CF3), 8.15 (s, 1H, OH-5), 7.75 – 7.64 (m, 2H, Ph-H), 
7.60 – 7.49 (m, 2H, Ph-H), 7.06 (s, 2H, Ph-H), 6.90 – 6.79 (m, 1H, Ph-H), 6.25 (s, 1H, Ph-
H), 4.75 – 4.53 (m, 2H, NHCH2-p-C6H4-CF3). MS (CI-MS)
b m/z (rel. int. in %) = 580.0 (10), 
558.0 ([M + H]+, 100), 485.2 (15), 423.0 (5), 385 (10). MS (CI-MS)c m/z (rel. int. in %) = 
614.9 ([M + H + MeCN]+ + 16, 25), 575.9 ({[M + H]+ + 16}, 60), 573.9 (100). 
C23H16Cl2F3N3O4S (Mr* = 574.36 g/mol). 
Note: mass spectral data refer to [M + H]
+
 (Mr  = 558.36 g/mol) and {[M + H]
+
 + 16} (Mr* = 574.36 g/mol). NMR 
spectral data (
1
H-NMR, 
13
C-NMR) refer to Mr*. 
b
 4 h after completion of the experiment; relative abundance 
(TIC): Mr (558.36 g/mol) = 35 %; relative abundance (TIC): Mr* (574.36 g/mol) = 3.5 %; 
c
 7 d after completion 
of the experiment; relative abundance (TIC): Mr (558.36 g/mol) = 0 %; relative abundance (TIC): Mr* (574.36 
g/mol) = 75 %. 
 
1-(3,5-Dichloro-4-hydroxyphenyl)-5-hydroxy-4-(4-methylbenzylamino)-5-(2,4,5-
trihydroxyphenyl)-1H-imidazole-2(5H)-thione (5.23) 
The title compound was prepared from 2,4,5-trihydroxybenzaldehyde (0.3 mmol, 46 mg), 
3,5-dichloro-4-(trifluoromethyl)aniline (0.3 mmol, 53 mg) and 1-(isocyanomethyl)-4-
methylbenzene (0.3 mmol, 40 mg) according to the general procedure. The crude product 
was obtained as residue after evaporation from ethyl acetate, and gave orange oil, which 
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was stored at -20 °C for 7 days. A full conversion to the corresponding {[M + H]+ + 16} 
derivative was observed under the specified conditions. Separation by RP-HPLC (Table 
5.19, method 1) yielded the autoxidized species {[M + H]+ + 16} as a pale yellow solid. 
Yield (precipitation): 80 mg, 51 %; yield (preparative HPLC): 4.6 mg, 3.0 %. MS (CI-MS)b 
m/z (rel. int. in %) = 649.0 (35), 576.1 (10), 526.0 (10), 504.9 ([M + H]+, 100), 428.2 (60), 
415.2 (20), 373.2 (25), 335.1 (90), 253.2 (25). MS (CI-MS)c m/z (rel. int. in %) = 522.9 
(70), 520.9 ({[M + H]+ + 16}, 100). C26H19Cl2N3O5S (Mr* = 520.39 g/mol). 
Note: mass spectral data refer to [M + H]
+
 (Mr  = 504.39 g/mol) and {[M + H]
+
 + 16} (Mr* = 520.39 g/mol). 
b
 4 h 
after completion of the experiment; relative abundance (TIC): Mr (504.39 g/mol) = 25 %; relative abundance 
(TIC): Mr* (520.39 g/mol) = 1.5 %; 
c
 7 d after completion of the experiment; relative abundance (TIC): 
Mr (504.39 g/mol) = 10 %; relative abundance (TIC): Mr* (520.39 g/mol) = 25 %. 
 
1-(3,5-Difluoro-4-hydroxyphenyl)-5-(2,5-dihydroxyphenyl)-5-hydroxy-4-[4-(trifluoro 
methyl)benzylamino]-1H-imidazole-2(5H)-thione (5.24) 
The title compound was prepared from 2,5-dihydroxybenzaldehyde (0.3 mmol, 41 mg), 
3,5-difluoro-4-(trifluoromethyl)aniline (0.3 mmol, 44 mg) and 1-(isocyanomethyl)-4-
(trifluoromethyl)benzene (0.3 mmol, 56 mg) according to the general procedure. The 
crude product was obtained as residue after evaporation from ethyl acetate, and gave 
orange oil, which was stored at -20 °C for 7 days. A full conversion to the corresponding 
{[M + H]+ + 16} derivative was observed under the specified conditions. Separation by RP-
HPLC (Table 5.19, method 1) yielded the autoxidized species {[M + H]+ + 16} as yellow 
solid. Yield (precipitation): 150 mg, 95 %; yield (preparative HPLC): 7.3 mg, 4.6 %. 1H-
NMR (600 MHz, DMSO-d6): δ [ppm] = 10.17 (s, 1H, OH-4’), 9.30 – 9.14 (m, 1H, Ph-OH), 
9.01 – 8.91 (m, 1H, NHCH2-p-C6H4-CF3), 8.73 – 8.63 (m, 1H, Ph-OH), 7.81 (s, 1H, OH-5), 
7.74 – 7.49 (m, 4H, Ph-H), 7.05 – 6.88 (m, 1H, Ph-H), 6.82 – 6.71 (m, 2H, Ph-H), 6.61 – 
6.49 (m, 2H, Ph-H), 4.76 – 4.51 (m, 2H, NHCH2-p-C6H4-CF3). MS (CI-MS)
b m/z (rel. int. in 
%) = 532.1 (22), 510.1 ([M + H]+, 100), 485.2 (19). MS (CI-MS)c m/z (rel. int. in %) = 567.9 
([[M + H + MeCN]+ + 16}, 30), 526.9 (35), 525.9 ({[M + H]+ + 16}, 100). C23H16F5N3O4S 
(Mr* = 525.45 g/mol). 
Note: mass spectral data refer to [M + H]
+
 (Mr  = 509.45 g/mol) and {[M + H]
+
 + 16} (Mr* = 525.45 g/mol). NMR 
spectral data (
1
H-NMR, 
13
C-NMR) refer to Mr*. 
b
 4 h after completion of the experiment; relative abundance 
(TIC): Mr (509.45 g/mol) = 50 %; relative abundance (TIC): Mr* (525.45 g/mol) = 0.5 %; 
c
 7 d after completion 
of the experiment; relative abundance (TIC): Mr (509.45 g/mol) = 0 %; relative abundance (TIC): Mr* (525.45 
g/mol) = 90 %. 
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5-(2,5-Dihydroxyphenyl)-5-hydroxy-1-(3-hydroxy-4-methoxyphenyl)-4-(4-(trifluoro-
methyl)benzylamino)-1H-imidazole-2(5H)-thione (5.25) 
The title compound was prepared from 2,5-dihydroxybenzaldehyde (0.3 mmol, 41 mg), 5-
amino-2-methoxyphenol (0.3 mmol, 42 mg) and 1-(isocyanomethyl)-4-(trifluoro-
methyl)benzene (0.3 mmol, 56 mg) according to the general procedure. The crude 
product was obtained as residue after evaporation from ethyl acetate, and gave yellow oil, 
which was stored at -20 °C for 2 days. A full conversion to the corresponding {[M + H]+ + 
16} derivative was observed under the specified conditions. Separation by RP-HPLC 
(Table 5.19, method 1) yielded the autoxidized species {[M + H]+ + 16] as a pale yellow 
solid. Yield (precipitation): 110 mg, 71 %; yield (preparative HPLC): 5.6 mg, 3.6 %. MS 
(CI-MS)b m/z (rel. int. in %) = 542.0 (5), 526.1 (15), 503.9 ([M + H]+, 100), 385.1 (10), 
218.1 (5). MS (CI-MS)d m/z (rel. int. in %) = 542.0 (15), 526.1 (25), 519.9 ({[M + H]+ + 16}, 
10), 503.9 ([M + H]+, 100), 385.1 (20), 361.1 (5), 240.1 (5), 218.1 (10). C24H20F3N3O5S (Mr* 
= 519.49 g/mol). 
Note: mass spectral data refer to [M + H]
+
 (Mr  = 503.49 g/mol) and {[M + H]
+
 + 16} (Mr* = 519.49 g/mol). NMR 
spectral data (
1
H-NMR, 
13
C-NMR) refer to Mr*. 
b
 4 h after completion of the experiment; relative abundance 
(TIC): Mr (503.49 g/mol) = 40 %; relative abundance (TIC): Mr* (519.49 g/mol) = 7 %; 
d
 48 h after completion of 
the experiment; relative abundance (TIC): Mr (503.49 g/mol) = 10 %; relative abundance (TIC): Mr* (519.49 
g/mol) = 25 %. 
 
5.8.2.4 Preparation of the compounds 5.26-5.35 
General procedure52 
A solution of the pertinent aldehyde (1 eq) and 4-amino-2,6-dichlorophenol (1 eq) in 
anhydrous MeOH (1 mL per mmol) was stirred for 1 h at room temperature and was 
subsequently cooled to 0 °C. After the addition of KSCN (4 eq), pyridinium chloride (4 eq) 
and 1-(isocyanomethyl)-4-(trifluoromethyl)benzene (1 eq), the mixture was stirred 
overnight below 20 °C. Insoluble material was removed by filtration, and the solvent 
(MeOH) was removed under reduced pressure. After addition of ethyl acetate as solvent, 
precipitated material was removed by filtration and the crude product was obtained as 
residue after evaporation. The crude substance was subjected to preparative HPLC 
(method indicated) yielding the corresponding {[M + H]+ + 16] product.a 
a 
molecular [M + H]
+ 
species of compounds 5.26-5.35 showed complete autoxidation to the corresponding 
{[M + H]
+
 + 16} derivatives within the first 48 h. HPLC isolation of {[M + H]
+
 + 16} substances was performed 
no earlier than 72 h after completion of the experiment. 
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Labeling of atoms (4-amino-1H-imidazole-2(5H)-ones derivatives) 
 
 
1-(3,5-Dichloro-4-hydroxyphenyl)-5-hydroxy-5-phenyl-4-[4-(trifluoromethyl)benzyl 
amino]-1H-imidazole-2(5H)-thione (5.26) 
The title compound was prepared from benzaldehyde (0.4 mmol, 58 mg) according to the 
general procedure. The crude product was obtained as residue after evaporation (ethyl 
acetate), and gave red oil, which was stored at -20 °C for 19 days. A full conversion to the 
corresponding {[M + H]+ + 16} derivative was observed under the specified conditions. 
Separation by RP-HPLC (Table 5.19, method 1) yielded the autoxidized species 
{[M + H]+ + 16} as an orange solid. Yield (precipitation): 170 mg, 39 %; yield (preparative 
HPLC): 18.6 mg, 4.2 %. 1H-NMR (600 MHz, DMSO-d6): δ [ppm] = 10.30 (s, 1H, OH-4’), 
9.31 (t, J = 6.2 Hz, 1H, NHCH2-p-C6H4-CF3), 8.19 (s, 1H, OH-5), 7.68 (t, J = 10.4 Hz, 2H, 
Ph-H-3’’,5’’), 7.44 (d, J = 8.1 Hz, 2H, Ph-H-2’’,6’’), 7.41 – 7.33 (m, 3H, Ph-H-3’’’,4’’’,5’’’), 
7.29 – 7.26 (m, 2H, Ph-H-2’’’,6’’’), 6.99 (s, 2H, Ph-H-2’,6’), 4.68 – 4.59 (m, 2H, NHCH2-p-
C6H4-CF3). 
13C-NMR (151 MHz, DMSO-d6): δ [ppm] = 195.49 (Cquat, CS), 177.45 (Cquat, C-
4), 148.39 (Cquat, Ph-C-4’), 142.47 (Cquat, Ph-C-1‘‘), 136.17 (Cquat, Ph-C-1’’’), 129.17 (+, Ph-
C-2’,6’), 129.04 (Cquat, Ph-C-3’,5’), 128.59 (+, Ph-C-3’’’,4’’’,5’’’), 128.01 (+, Ph-C-2’’,6’’), 
125.54 (+, Ph-C-2’’’,6’’’), 125.17 (+, Ph-C-3’’,5’’), 123.34 (Cquat, Ph-C-4’’), 121.20 (Cquat, 
Ph-C-1’), 93.94 (Cquat, 5-C), 45.02 (-, NHCH2-p-C6H4-CF3). MS (CI-MS) m/z (rel. int. in %) 
= 568.9 (35), 566.9 ([M* + H + MeCN]+, 55), 528.9 (15), 527.9 (75), 525.8 ([M* + H]+, 100). 
HRMS (ESI-MS) m/z calcd. [M* + H]+ 526.0365, found [M* + H]+ 526.03696. 
C23H16Cl2F3N3O2S (Mr* = 526.36 g/mol). 
Note: NMR spectral data (
1
H-NMR, 
13
C-NMR) and mass spectral data refer to the stable {[M + H]
+
 + 16} 
species (Mr* = 526.36 g/mol). 
 
1-(3,5-Dichloro-4-hydroxyphenyl)-5-hydroxy-4-[4-(trifluoromethyl)benzylamino]-5-
(2,4,5-trimethoxyphenyl)-1H-imidazole-2(5H)-thione (5.27) 
The title compound was prepared from 2,4,5-trimethoxybenzaldehyde (0.4 mmol, 59 mg) 
according to the general procedure. The crude product was obtained as residue after 
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evaporation (ethyl acetate), and gave a dark solid, which was stored at -20 °C for 19 days. 
A full conversion to the corresponding {[M + H]+ + 16} derivative was observed under the 
specified conditions. Separation by RP-HPLC (Table 5.19, method 1) yielded the 
autoxidized species {[M + H]+ + 16} as a yellow solid. Yield (precipitation): 175 mg, 71 %; 
yield (preparative HPLC): 14.8 mg, 6.0 %. 1H-NMR (600 MHz, DMSO-d6): δ [ppm] = 10.10 
(s br, 1H, OH-4’), 9.00 (t, J = 6.2 Hz, 1H NHCH2-p-C6H4-CF3), 8.06 (s, 1H, OH-5), 7.72 (d, 
J = 8.2 Hz, 2H, Ph-H-3’’,5’’), 7.49 (d, J = 8.1 Hz, 2H, Ph-H-2’’,6’’), 7.11 (s, 1H, Ph-H-6’’’), 
7.05 (s, 2H, Ph-H-2’,6’), 6.65 (s, J = 6.3 Hz, 1H, Ph-H-3’’’), 4.62 (ddd, J = 97.8, 15.4, 6.1 
Hz, 2H, NHCH2-p-C6H4-CF3), 3.76 (s, 3H, OCH3-2’’’), 3.65 (s, 3H, OCH3-4’’’), 3.59 (s, 3H, 
OCH3-5’’’). 
13C-NMR (151 MHz, DMSO-d6): δ [ppm] = 195.45 (Cquat, CS), 177.87 (Cquat, C-
4), 150.67 (Cquat, Ph-C-2’’’), 150.42 (Cquat, Ph-C-4’’’), 142.80 (Cquat, Ph-C-1’’), 142.55 (Cquat, 
Ph-C-4’), 141.72 (Cquat, Ph-C-5’’’), 128.13 (+, Ph-C-2’,6’), 127.95 (+, Ph-C-2’’,6’’), 125.14 
(+, Ph-C-3’’,5’’), 125.10 (Cquat, Ph-C-3’,5’), 123.40 (Cquat, Ph-C-4’’), 121.04 (Cquat, Ph-C-1’), 
114.34 (Cquat, Ph-C-1’’’), 112.71 (+, Ph-C-6’’’), 97.58 (+, Ph-C-3’’’), 66.91 (Cquat, C-5), 
56.22 (OCH3-4’’’), 56.12 (+, OCH3-5’’’), 55.75 (+, OCH3-2’’’), 44.89 (-, NHCH2-p-C6H4-CF3). 
MS (CI-MS) m/z (rel. int. in %) = 659.1 (20), 657.0 ([M* + H + MeCN]+, 30), 620.0 (15), 
619.0 (20), 617.9 (80), 615.9 ([M* + H]+, 100). HRMS (ESI-MS) m/z calcd. [M* + H]+ 
616.0682, found [M* + H]+ 616.0699. C26H22Cl2F3N3O5S (Mr* = 616.44 g/mol). 
Note: NMR spectral data (
1
H-NMR, 
13
C-NMR) and mass spectral data refer to the stable {[M + H]
+
 + 16} 
species (Mr* = 616.44 g/mol). 
 
4-(1-(3,5-Dichloro-4-hydroxyphenyl)-5-hydroxy-2-thioxo-4-[4-(trifluoromethyl) 
benzylamino]-2,5-dihydro-1H-imidazol-5-yl)benzoic acid (5.28) 
The title compound was prepared from 4-formylbenzoic acid (0.4 mmol, 60 mg) according 
to the general procedure. The crude product was obtained as residue after evaporation 
(ethyl acetate), and gave a brown solid, which was stored at -20 °C for 19 days. A full 
conversion to the corresponding {[M + H]+ + 16} derivative was observed under the 
specified conditions. Separation by RP-HPLC (Table 5.19, method 1) yielded the 
autoxidized species {[M + H]+ + 16} as a pale yellow solid. Yield (precipitation): 215 mg, 
94 %; yield (preparative HPLC): 39.8 mg, 17.4 %. 1H-NMR (600 MHz, DMSO-d6): δ [ppm] 
= 9.40 (s, 1H, NHCH2-p-C6H4-CF3), 8.37 (s, 1H, OH-5), 7.93 (d, J = 8.5 Hz, 2H, Ph-H-
3’’’,5’’’), 7.70 (d, J = 8.1 Hz, 2H, Ph-H-3’’,5’’), 7.44 (d, J = 8.0 Hz, 2H, Ph-H-2’’,6’’), 7.41 (d, 
J = 8.4 Hz, 2H, Ph-H-2’’’,6’’’), 7.03 (s, J = 8.5 Hz, 2H, Ph-H-2’,6’), 4.64 (s, 2H, NHCH2-p-
C6H4-CF3). 
13C-NMR (151 MHz, DMSO-d6): δ [ppm] = 195.65 (Cquat, CS), 177.09 (Cquat, C-
4), 166.80 (Cquat, Ph-COOH), 148.62 (Cquat, Ph-C-4’), 142.35 (Cquat, Ph-C-1’’), 140.53 
(Cquat, Ph-C-4’’’), 131.53 (Cquat, Ph-C-1’’’), 129.59 (+, Ph-C-3’’’,5’’’), 129.32 (Cquat, Ph-C-
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3’,5’), 129.21 (+, Ph-C-2’,6’), 128.02 (+, Ph-C-2’’’,6’’’), 125.98 (+, Ph-C-2’’,6’’), 125.23 (+, 
Ph-C-3’’,5’’), 123.46 (Cquat, Ph-C-4’’), 121.28 (Cquat, Ph-C-1’), 93.63 (Cquat, C-5), 45.11 (-, 
NHCH2-p-C6H4-CF3). MS (CI-MS) m/z (rel. int. in %) = 614.9 (10), 614.0 (15), 612.9 (40), 
610.9 ([M* + H + MeCN]+, 70), 574.1 (15), 573.0 (20), 571.9 (70), 569.9 ([M* + H]+, 100). 
HRMS (ESI-MS) m/z calcd. [M* + H]+ 570.0263, found [M* + H]+ 570.0263. 
C24H16Cl2F3N3O4S (Mr* = 570.37 g/mol). 
Note: NMR spectral data (
1
H-NMR, 
13
C-NMR) and mass spectral data refer to the stable {[M + H]
+
 + 16} 
species (Mr* = 570.37 g/mol). 
 
1-(3,5-Dichloro-4-hydroxyphenyl)-5-hydroxy-5-(1H-indol-5-yl)-4-[4-(trifluoromethyl) 
benzylamino]-1H-imidazole-2(5H)-thione (5.29) 
The title compound was prepared from 1H-indole-5-carbaldehyde (0.4 mmol, 44 mg) 
according to the general procedure. The crude product was obtained as residue after 
evaporation (ethyl acetate), and gave a dark brown solid, which was stored at -20 °C for 
19 days. A full conversion to the corresponding {[M + H]+ + 16} derivative was observed 
under the specified conditions. Separation by RP-HPLC (Table 5.19, method 1) yielded 
the autoxidized species {[M + H]+ + 16} as a yellow solid. Yield (precipitation): 165 mg, 73 
%; yield (preparative HPLC): 11.6 mg, 5.1 %. 1H-NMR (600 MHz, DMSO-d6): δ [ppm] = 
11.18 (s, 1H, indole-NH), 10.21 (s br, 1H, OH-4’), 9.12 (t, J = 6.3 Hz, 1H, NHCH2-p-C6H4-
CF3), 8.04 (s, 1H, OH-5), 7.66 (d, J = 8.2 Hz, 2H, Ph-H-3’’,5’’), 7.60 (s, 1H, Ar-H-4’’’), 7.42 
(d, J = 8.1 Hz, 2H, Ph-H-2’’,6’’), 7.39 (d, J = 8.5 Hz, 1H, Ar-H-7’’’), 7.35 (d, J = 2.7 Hz, 1H, 
Ar-H-2’’’), 7.04 (s, 2H, Ph-H-2’,6’), 6.88 (dd, J = 8.5, 1.6 Hz, 1H, Ar-H-6’’’), 6.44 – 6.42 (m, 
1H, Ar-H-3’’’), 4.60 (tt, J = 15.4, 7.7 Hz, 2H, NHCH2-p-C6H4-CF3). 
13C-NMR (151 MHz, 
DMSO-d6): δ [ppm] = 195.25 (Cquat, CS), 178.18 (Cquat, C-4), 148.13 (Cquat, Ph-C-4’), 
142.71 (Cquat, Ph-C-1’’), 135.78 (Cquat, indole-C), 129.75 (Cquat, Ph-C-3’,5’), 129.47 (Cquat, 
indole-C), 129.00 (+, Ph-C-2’,6’), 127.95 (+, Ph-C-2’’,6’’), 127.14 (Cquat, indole-C), 126.23 
(+, Ar-C-2’’’), 126.18 (Cquat, Ph-C-4’’), 125.11 (+, Ph-C-3’’,5’’), 121.03 (Cquat, Ph-C-1’), 
118.15 (+, Ar-C-6’’’), 117.80 (+, Ar-C-4’’’), 111.52 (+, Ar-C-7’’’), 101.68 (+, Ar-C-3’’’), 94.71 
(Cquat, C-5), 45.02 (-, NHCH2-p-C6H4-CF3). MS (CI-MS) m/z (rel. int. in %) = 606.2 ([M* + H
 
+ MeCN]+, 10), 568.9 (20), 566.9 (70), 564.9 ([M* + H]+, 100). HRMS (ESI-MS) m/z calcd. 
[M* + H]+ 564.0401, found [M* + H]+ 564.05001. C25H17Cl2F3N4O2S (Mr* = 565.39 g/mol). 
Note: NMR spectral data (
1
H-NMR, 
13
C-NMR) and mass spectral data refer to the stable {[M + H]
+
 + 16} 
species (Mr* = 565.39 g/mol). 
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1-(3,5-Dichloro-4-hydroxyphenyl)-5-hydroxy-5-(1H-indol-6-yl)-4-[4-(trifluoromethyl) 
benzylamino]-1H-imidazole-2(5H)-thione (5.30) 
The title compound was prepared from 1H-indole-6-carbaldehyde (0.4 mmol, 44 mg) 
according to the general procedure. The crude product was obtained as residue after 
evaporation (ethyl acetate), and gave a dark brown solid which was stored at -20 °C for 19 
days. A full conversion to the corresponding {[M + H]+ + 16} derivative was observed 
under the specified conditions. Separation by RP-HPLC (Table 5.19, method 1) yielded 
the autoxidized species {[M + H]+ + 16} as a yellow solid. Yield (precipitation): 190 mg, 84 
%; yield (preparative HPLC): 13.7 mg, 6.1 %. 1H-NMR (600 MHz, DMSO-d6): δ [ppm] = 
11.17 (s, 1H, indole-NH), 10.23 (s br, 1H, OH-4’), 9.15 (t, J = 6.2 Hz, 1H, NHCH2-p-C6H4-
CF3), 8.09 (s, 1H, OH-5), 7.66 (d, J = 8.2 Hz, 2H, Ph-H-3‘‘,5‘‘), 7.55 (d, J = 8.4 Hz, 1H, Ar-
H-4’’’), 7.49 (s, 1H, Ar-H-7’’’), 7.41 (d, J = 8.0 Hz, 2H, Ph-H-2’’,6’’), 7.40 – 7.38 (m, 1H, Ar-
H-2’’’), 7.05 (s, 2H, Ph-H-2’,6’), 6.81 – 6.77 (m, 1H, Ar-H-5’’’), 6.44 – 6.40 (m, 1H, Ar-H-
3’’’), 4.61 (qd, J = 15.3, 6.1 Hz, 2H, NHCH2-p-C6H4-CF3). 
13C-NMR (151 MHz, DMSO-d6): 
δ [ppm] = 195.39 (Cquat, CS), 177.99 (Cquat, C-4), 148.18 (Cquat, Ph-C-4’), 142.57 (Cquat, Ph-
C-1’’), 135.35 (Cquat, indole-C), 129.63 (Cquat, Ph-C-3’,5’), 129.42 (Cquat, indole-C), 129.07 
(+, Ph-C-2’,6’), 128.48 (Cquat, indole-C), 127.88 (+, Ph-C-2’’,6’’), 126.61 (+, Ar-C-2’’’), 
125.12 (+, Ph-C-3’’,5’’), 123.34 (Cquat, Ph-C-4’’), 121.05 (Cquat, Ph-C-1’), 120.15 (+, Ar-C-
4’’’), 115.91 (+, Ar-C-5’’’), 109.35 (+, Ar-C-7’’’), 101.07 (+, Ar-C-3’’’), 94.61 (Cquat, C-5), 
44.92 (-, NHCH2-p-C6H4-CF3). MS (CI-MS) m/z (rel. int. in %) = 607.9 (20), 605.9 ([M* + H
 
+ MeCN]+, 30), 568.8 (15), 567.9 (20), 566.9 (80), 564.9 ([M* + H]+, 100). HRMS (ESI-MS) 
m/z calcd. [M* + H]+ 565.0474, found [M* + H]+ 565.0476. C25H17Cl2F3N4O2S (Mr* = 565.39 
g/mol). 
Note: NMR spectral data (
1
H-NMR, 
13
C-NMR) and mass spectral data refer to the stable {[M + H]
+
 + 16} 
species (Mr* = 565.39 g/mol). 
 
5-(1H-Benzo[d]imidazol-5-yl)-1-(3,5-dichloro-4-hydroxyphenyl)-5-hydroxy-4-[4-
(trifluoro methyl)benzylamino]-1H-imidazole-2(5H)-thione (5.31) 
The title compound was prepared from 1H-benzo[d]imidazole-5-carbaldehyde (0.4 mmol, 
44 mg) according to the general procedure. The crude product was obtained as residue 
after evaporation (ethyl acetate), and gave beige solid, which was stored at -20 °C for 19 
days. A full conversion to the corresponding {[M + H]+ + 16} derivative was observed 
under the specified conditions. Separation by RP-HPLC (Table 5.19, method 1) yielded 
the autoxidized species {[M + H]+ + 16} as a yellow solid. Yield (precipitation): 170 mg, 85 
%; yield (preparative HPLC): 13.7 mg, 6.9 %. 1H-NMR (600 MHz, DMSO-d6): δ [ppm] = 
12.50 (s, 1H, benzimidazole-NH), 9.22 (t, J = 6.1 Hz, 1H, NHCH2-p-C6H4-CF3), 8.26 – 8.23 
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(m, 1H, Ar-H-2’’’), 8.19 (s, 1H, OH-5), 7.82 (d, J = 8.1 Hz, 1H, Ar-H-6’’’), 7.66 (d, J = 8.1 
Hz, 2H, Ph-H-3’’,5’’), 7.42 (d, J = 8.0 Hz, 2H, Ph-H-2’’,6’’), 7.11 (s, 1H, Ar-H-4’’’), 7.04 (s, 
2H, Ph-H-2’,6’), 6.99 (d, J = 8.5 Hz, 1H, Ar-H-7’’’), 4.67 – 4.57 (m, 2H, NHCH2-p-C6H4-
CF3). 
13C-NMR (151 MHz, DMSO-d6): δ [ppm] = 195.44 (Cquat, CS), 177.81 (Cquat, C-4), 
149.16 (Cquat, benzimidazole-C), 148.26 (Cquat, Ph-C-4’), 143.13 (+, Ar-C-2’’’), 142.51 
(Cquat, Ph-C-1’’), 138.65 (Cquat, benzimidazole-C), 129.62 (Cquat, Ph-C-3’,5’), 129.26 (+, Ph-
C-2’,6’), 129.17 (+, Ar-C-7’’’), 128.98 (+, Ar-C-4’’’), 127.93 (+, Ph-C-2’’,6’’), 127.84 (Cquat, 
benzimidazole-C), 125.49 (+, Ar-C-6’’’), 125.15 (+, Ph-C-3’’,5’’), 123.34 (Cquat, Ph-C-4’’), 
121.11 (Cquat, Ph-C-1’), 94.32 (Cquat, C-5), 44.97 (-, NHCH2-p-C6H4-CF3). MS (CI-MS) m/z 
(rel. int. in %) = 647.9 (10), 610.9 (10), 609.9 (15), 608.9 (70), 606.9 ([M* + H + MeCN]+, 
100), 569.1 (10), 567.9 (40), 565.9 ([M* + H]+, 55). HRMS (ESI-MS) m/z calcd. [M* + H]+ 
566.0427, found [M* + H]+ 566.0430. C24H16Cl2F3N5O2S (Mr* = 566.38 g/mol). 
Note: NMR spectral data (
1
H-NMR, 
13
C-NMR) and mass spectral data refer to the stable {[M + H]
+
 + 16} 
species (Mr* = 566.38 g/mol). 
 
 
1-(3,5-Dichloro-4-hydroxyphenyl)-5-hydroxy-5-(1H-indazol-5-yl)-4-[4-
(trifluoromethyl) benzylamino]-1H-imidazole-2(5H)-thione (5.32) 
The title compound was prepared from 1H-indazole-5-carbaldehyde (0.4 mmol, 44 mg) 
according to the general procedure. The crude product was obtained as residue after 
evaporation (ethyl acetate), and gave a dark oil which was stored at -20 °C for 19 days. A 
full conversion to the corresponding {[M + H]+ + 16} derivative was observed under the 
specified conditions. Separation by RP-HPLC (Table 5.19, method 1) yielded the 
autoxidized species {[M + H]+ + 16} as a pale yellow solid. Yield (precipitation): 200 mg, 
90 %; yield (preparative HPLC): 11.9 mg, 5.3 %. 1H-NMR (600 MHz, DMSO-d6): δ [ppm] = 
13.15 (s, 1H, indazole-NH), 10.21 (s br, 1H, OH-4’), 9.23 (t, J = 6.2 Hz, 1H, NHCH2-p-
C6H4-CF3), 8.21 (s, 1H, OH-5), 8.09 (s, 1H, Ar-H-3’’’), 7.84 (s, 1H, Ar-H-4’’’), 7.67 (d, J = 
8.2 Hz, 2H, Ph-H-3’’,5’’), 7.55 (d, J = 8.8 Hz, 1H, Ar-H-7’’’), 7.43 (d, J = 8.0 Hz, 2H, Ph-H-
2’’,6’’), 7.09 (d, J = 8.0 Hz, 1H, Ar-H-6’’’), 7.04 (s, 2H, Ph-H-2’,6’), 4.68 – 4.57 (m, 2H, 
NHCH2-p-C6H4-CF3). 
13C-NMR (151 MHz, DMSO-d6): δ [ppm] = 195.47 (Cquat, CS), 177.68 
(Cquat, C-4), 148.29 (Cquat, Ph-C-4’), 142.48 (Cquat, Ph-C-1’’), 139.71 (Cquat, indazole-C), 
134.19 (+, 3’’’-ArC), 129.62 (Cquat, Ph-C-3’,5’), 129.20 (Cquat, indazole-C), 129.08 (+, Ph-C-
2’,6’), 127.93 (+, Ph-C-2’’,6’’), 125.16 (+, Ph-C-3’’,5’’), 123.33 (Cquat, Ph-C-4’’), 123.11 (+, 
Ar-C-6’’’), 122.44 (Cquat, indazole-C), 121.14 (Cquat, Ph-C-1’), 118.58 (+, Ar-C-4’’’), 110.49 
(+, Ar-C-7’’’), 94.19 (Cquat, C-5), 44.99 (-, NHCH2-p-C6H4-CF3). MS (CI-MS) m/z (rel. int. in 
%) = 610.1 (10), 608.9 (35), 606.9 ([M* + H + MeCN]+, 60), 569.9 (15), 568.9 (20), 567.9 
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(80), 565.9 ([M* + H]+, 100). HRMS (ESI-MS) m/z calcd. [M* + H]+ 566.0427, found [M* + 
H]+ 566.0427. C24H16Cl2F3N5O2S (Mr* = 566.38 g/mol). 
Note: NMR spectral data (
1
H-NMR, 
13
C-NMR) and mass spectral data refer to the stable {[M + H]
+
 + 16} 
species (Mr* = 566.38 g/mol). 
 
5-[4-(1H-Imidazol-1-yl)phenyl]-1-(3,5-dichloro-4-hydroxyphenyl)-5-hydroxy-4-[4-
(trifluoromethyl)benzylamino]-1H-imidazole-2(5H)-thione (5.33) 
The title compound was prepared from 4-(1H-imidazol-1-yl)benzaldehyde (0.4 mmol, 69 
mg) according to the general procedure. The crude product was obtained as residue after 
evaporation (ethyl acetate), and gave a pale brown solid, which was stored at -20 °C for 
19 days. A full conversion to the corresponding {[M + H]+ + 16} derivative was observed 
under the specified conditions. Separation by RP-HPLC (Table 5.19, method 1) yielded 
the autoxidized species {[M + H]+ + 16} as a colorless solid. Yield (precipitation): 125 mg, 
53 %; yield (preparative HPLC): 12.1 mg, 5.1 %. 1H-NMR (600 MHz, DMSO-d6): δ [ppm] = 
10.33 (s, 1H, OH-4’), 9.40 (t, J = 5.9 Hz, 1H, NHCH2-p-C6H4-CF3), 8.41 (s, 1H, imidazole-
H), 8.36 (s, 1H, OH-5), 7.81 (s, 1H imidazole-H), 7.71 (t, J = 7.7 Hz, 4H, Ph-H-3’’,5’’, Ph-
H-3’’’,5’’’), 7.46 (d, J = 8.0 Hz, 2H, Ph-H-2’’,6’’), 7.42 (d, J = 8.6 Hz, 2H, Ph-H-2’’’,6’’’), 7.17 
(s, 1H, imidazole-H), 7.10 (s, 2H, Ph-H-2’,6’), 4.70 – 4.60 (m, 2H, NHCH2-p-C6H4-CF3). 
13C-NMR (151 MHz, DMSO-d6): δ [ppm] = 195.56 (Cquat, CS), 177.16 (Cquat, C-4), 148.42 
(Cquat, Ph-C-4’), 142.39 (Cquat, Ph-C-1’’), 137.06 (Cquat, Ph-C-1’’’), 135.42 (+, imidazole-C), 
134.72 (Cquat, Ph-C-4’’), 129.26 (+, Ph-C-2’,6’), 129.12 (+, imidazole-C), 129.00 (Cquat, Ph-
C-3’,5’), 128.00 (+, Ph-C-2’’,6’’), 127.33 (+, Ph-C-2’’’,6’’’), 125.25 (+, Ph-C-3’’’,5’’’), 123.34 
(Cquat, Ph-C-4’’), 121.29 (Cquat, Ph-C-1’), 120.26 (+, Ph-C-2’’’,6’’’), 118.07 (+, imidazole-C), 
93.54 (Cquat, C-5), 45.08 (-, NHCH2-p-C6H4-CF3). MS (CI-MS) m/z (rel. int. in %) = 637.1 
(10), 636.0 (20), 635.0 (55), 632.9 ([M* + H + MeCN]+, 75), 596.0 (15), 595.0 (20), 593.9 
(60), 591.9 ([M* + H]+, 100), 358.9 (30), 337.4 (20). HRMS (ESI-MS) m/z calcd. [M* + H]+ 
592.0583, found [M* + H]+ 592.0585. C26H18Cl2F3N5O2S (Mr* = 592.42 g/mol). 
Note: NMR spectral data (
1
H-NMR, 
13
C-NMR) and mass spectral data refer to the stable {[M + H]
+
 + 16} 
species (Mr* = 592.42 g/mol). 
 
1-(3,5-Dichloro-4-hydroxyphenyl)-5-hydroxy-5-[4-(2-methylthiazol-4-yl)phenyl]-4-(4-
(trifluoromethyl)benzylamino)-1H-imidazole-2(5H)-thione (5.34) 
The title compound was prepared from 4-(2-methylthiazol-4-yl)benzaldehyde (0.4 mmol, 
81 mg) according to the general procedure. The crude product was obtained as residue 
after evaporation (ethyl acetate), and gave a dark yellow solid which was stored at -20 °C 
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for 19 days. A full conversion to the corresponding {[M + H]+ + 16} derivative was 
observed under the specified conditions. Separation by RP-HPLC (Table 5.19, method 1) 
yielded the autoxidized species {[M + H]+ + 16} as a yellow solid. Yield (precipitation): 220 
mg, 88 %; yield (preparative HPLC): 45.3 mg, 18.2 %. Note: NMR spectral data (1H-NMR, 
13C-NMR) and mass data refer to the stable MH+ + 16 species (abbreviation: M*). 1H-NMR 
(600 MHz, DMSO-d6): δ [ppm] = 10.31 (s, 1H, OH-4’), 9.39 (t, J = 6.2 Hz, 1H, NHCH2-p-
C6H4-CF3), 8.29 (s, 1H, OH-5), 7.96 (s, 1H, thiazole-H), 7.93 (d, J = 8.6 Hz, 2H, Ph-H-
3’’’,5’’’), 7.69 (d, J = 8.2 Hz, 2H, Ph-H-3’’,5’’), 7.47 (d, J = 8.1 Hz, 2H, Ph-H-2’’,6’’), 7.33 (d, 
J = 8.5 Hz, 2H, Ph-H-2’’’,6’’’), 7.05 (s, 2H, Ph-H-2’,6’), 4.68 – 4.61 (m, 2H, NHCH2-p-C6H4-
CF3), 2.70 – 2.67 (m, 3H, thiazole-CH3). 
13C-NMR (151 MHz, DMSO-d6): δ [ppm] = 195.50 
(Cquat, CS), 177.38 (Cquat, C-4), 165.75 (Cquat, thiazole-C), 152.95 (Cquat, thiazole-C), 
148.39 (Cquat, Ph-C-4’), 142.47 (Cquat, Ph-C-1’’), 135.51 (Cquat, Ph-C-4’’’), 134.78 (Cquat, Ph-
C-1’’’), 129.17 (+, Ph-C-2’,6’), 129.10 (Cquat, Ph-C-3’,5’), 128.00 (Cquat, Ph-C-4’’), 126.10 
(+, Ph-C-2’’’,6’’’), 126.04 (+, Ph-C-3’’’,5’’’), 125.22 (+, Ph-C-3’’,5’’), 125.18 (+, Ph-C-2’’,6’’), 
121.22 (Cquat, Ph-C-1’), 114.72 (+, thiazole-C), 93.87 (Cquat, C-5), 45.06 (-, NHCH2-p-C6H4-
CF3), 18.89 (+, thiazole-CH3). MS (CI-MS) m/z (rel. int. in %) = 665.9 (20), 663.9 ([M* + H
 
+ MeCN]+, 25), 625.9 (15), 625.0 (65), 622.9 ([M* + H]+, 100). HRMS (ESI-MS) m/z calcd. 
[M* + H]+ 623.0351, found [M* + H]+ 623.0355. C27H19Cl2F3N4O2S2 (Mr* = 623.50 g/mol). 
Note: NMR spectral data (
1
H-NMR, 
13
C-NMR) and mass data spectral refer to the stable {[M + H]
+
 + 16} 
species (Mr* = 623.50 g/mol). 
 
1-(3,5-Dichloro-4-hydroxyphenyl)-5-hydroxy-5-[4-(4-methylpiperazin-1-yl)phenyl]-4-
(4-(trifluoromethyl)benzylamino)-1H-imidazole-2(5H)-thione (5.35) 
The title compound was prepared from 4-(4-methylpiperazin-1-yl)benzaldehyde (0.4 
mmol, 82 mg) according to the general procedure. The crude product was obtained as 
residue after evaporation (ethyl acetate), and gave a yellow solid which was stored at -20 
°C for 19 days. A full conversion to the corresponding {[M + H]+ + 16} derivative was 
observed under the specified conditions. Separation by RP-HPLC (Table 5.19, method 1) 
yielded the autoxidized species {[M + H]+ + 16} as a pale yellow solid. Yield (precipitation): 
225 mg, 90 %; yield (preparative HPLC): 37.7 mg, 15.1 %. 1H-NMR (600 MHz, DMSO-d6): 
δ [ppm] = 9.19 (t, J = 6.2 Hz, 1H, NHCH2-p-C6H4-CF3), 8.06 (s, 1H, OH-5), 7.69 (d, J = 8.2 
Hz, 2H, Ph-H-3’’,5’’), 7.44 (d, J = 8.0 Hz, 2H, Ph-H-2’’,6’’), 7.13 (d, J = 8.9 Hz, 2H, Ph-H-
2’’’,6’’’), 7.04 (s, 2H, Ph-H-2’,6’), 6.95 (d, J = 9.0 Hz, 2H, Ph-H-3’’’,5’’’), 4.62 (d, J = 6.1 Hz, 
2H, NHCH2-p-C6H4-CF3), 3.26 (s br, 4H, piperazine-H), 2.88 (s br, 4H, piperazine-H), 2.53 
(s, 3H, piperazine-CH3). 
13C-NMR (151 MHz, DMSO-d6): δ [ppm] = 195.23 (Cquat, CS), 
177.63 (Cquat, C-4), 150.47 (Cquat, Ph-C-4’’’), 148.27 (Cquat, Ph-C-4’), 142.56 (Cquat, Ph-C-
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1’’), 129.63 (Cquat, Ph-C-1’’’), 129.52 (Cquat, Ph-C-3’,5’), 129.05 (+, Ph-C-2’,6’), 127.99 (+, 
Ph-C-2’’,6’’), 126.46 (+, Ph-C-2’’’,6’’’), 125.18 (+, Ph-C-3’’,5’’), 123.36 (Cquat, Ph-C-4’’), 
121.15 (Cquat, Ph-C-1’), 114.97 (+, Ph-C-3’’’,5’’’), 94.08 (Cquat, C-5), 53.30 (-, piperazine-
CH2), 46.20 (-, piperazine-CH2), 44.98 (-, NHCH2-p-C6H4-CF3), 43.81 (+, piperazine-CH3). 
MS (CI-MS) m/z (rel. int. in %) = 669.0 (20), 668.0 (25), 667.0 (80), 665.0 ([M* + H + 
MeCN]+, 100), 627.0 (15), 626.0 (65), 624.0 ([M* + H]+, 50), 413.3 (10), 412.5 (30), 411.5 
(25), 373.9 (40), 354.3 (85), 353.4 (90), 332.9 (10). HRMS (ESI-MS) m/z calcd. [M* + H]+ 
624.1209, found [M* + H]+ 624.1212. C28H26Cl2F3N5O2S (Mr* = 624.50 g/mol). 
Note: NMR spectral data (
1
H-NMR, 
13
C-NMR) and mass spectral data refer to the stable {[M + H]
+
 + 16} 
species (Mr* = 624.50 g/mol). 
 
5.8.2.5 Preparation of the compounds 5.36-5.70 
General procedure 
Method A: A solution of the pertinent methyl ketone (1 eq) and 4-amino-2,6-
dichlorophenol (1 eq) in anhydrous MeOH (1 mL per mmol) was stirred for 2.5 h at room 
temperature and was subsequently cooled to 0 °C. After the addition of KSCN (4 eq), 
pyridinium chloride (4 eq) and 1-(isocyanomethyl)-4-(trifluoromethyl)benzene (1 eq), the 
mixture was stirred overnight below 20 °C. Insoluble material was removed by filtration, 
and the solvent (MeOH) was removed under reduced pressure. After addition of ethyl 
acetate as solvent, precipitated material was removed by filtration and the crude product 
was obtained as residue after evaporation. The crude substance was subjected to RP-
HPLC (method indicated) yielding the target molecules. 
Method B: A solution of the pertinent methyl ketone (1 eq) and amine (1 eq) in anhydrous 
MeOH (1 mL per mmol) was stirred for 3.0 h at room temperature and was subsequently 
cooled to 0 °C. After the addition of KSCN (4 eq), pyridinium chloride (4 eq) and the 
corresponding isocyanide (1 eq), the mixture was stirred overnight below 20 °C. After 
stirring at 0 °C overnight, solids were removed by filtration, the crude product was 
precipitated as described and subjected to RP-HPLC. Insoluble material was removed by 
filtration, and the solvent (MeOH) was removed under reduced pressure. After addition of 
ethyl acetate as solvent, precipitated material was removed by filtration and the crude 
product was obtained as residue after evaporation. The crude substance was subjected to 
preparative HPLC (method indicated) yielding the target molecules. 
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Labeling of atoms (4-amino-5-methyl-1H-imidazole-2(5H)-thiones derivatives) 
 
 
1-(3,5-Dichloro-4-hydroxyphenyl)-5-(4-hydroxyphenyl)-5-methyl-4-[4-
(trifluoromethyl) benzylamino]-1H-imidazole-2(5H)-thione (5.36) 
The title compound was prepared from 1-(4-hydroxyphenyl)ethanone (0.3 mmol, 41 mg) 
according to method A of the general procedure. The crude product was obtained as 
residue after evaporation (ethyl acetate), and gave brown solid, which was subjected to 
RP-HPLC (Table 5.19, method 2). Yield (crude product): 115 mg, 71 %; yield (preparative 
HPLC): beige solid, 2.6 mg, 1.6 %. 1H-NMR (600 MHz, DMSO-d6): δ [ppm] = 10.38 (s, 1H, 
OH-4’), 9.74 (s, 1H, Ph-OH-4’’’), 9.13 (t, J = 6.0 Hz, 1H, NHCH2-p-C6H4-CF3), 7.71 (d, J = 
8.2 Hz, 2H, Ph-H-3’’,5’’), 7.46 (d, J = 8.1 Hz, 2H, Ph-H-2’’,6’’), 6.99 (d, J = 8.7 Hz, 2H, Ph-
H-2’’’,6’’’), 6.82 – 6.78 (m, 2H, Ph-H-3’’’,5’’’), 6.70 (s, 2H, Ph-H-2’,6’), 4.66 (qd, J = 15.6, 
6.0 Hz, 2H, NHCH2-p-C6H4-CF3), 1.73 (s, J = 9.5 Hz, 3H, CH3-5). 
13C-NMR (151 MHz, 
DMSO-d6): δ [ppm] = 195.67 (Cquat, CS), 180.38 (Cquat, C-4), 158.32 (Cquat, Ph-C-4’’’), 
146.40 (Cquat, Ph-C-4’), 143.14 (Cquat, Ph-C-1’’), 133.88 (Cquat, Ph-C-1’’’), 129.69 (+, Ph-C-
2’,6’), 127.92 (+, Ph-C-2’’,6’’), 127.62 (+, Ph-C-2’’’,6’’’), 127.60 (Cquat, Ph-C-3’,5’), 125.00 
(+, Ph-C-3’’,5’’), 124.48 (Cquat, Ph-C-4’’), 121.43 (Cquat, Ph-C-1’), 115.11 (+, Ph-C-3’’’,5’’’), 
73.05 (Cquat, C-5), 44.88 (-, NHCH2-p-C6H4-CF3), 17.13 (+, CH3-5). MS (EI-MS, 70 eV) 
m/z (rel. int. in %) = 541.0 (20), 539.0 ([M+●], 35), 389.9 (35), 202.0 (30), 176.2 (40), 159.0 
(100), 146.0 (70), 121.0 (40), 109.1 (35), 72.1 (40), 59.1 (50). HRMS (ESI-MS) m/z calcd. 
[M + H]+ 539.0449, found [M + H]+ 539.0436. C24H18Cl2F3N3O2S (Mr = 540.38 g/mol). 
 
(E)-N'-(3,5-Dichloro-4-hydroxyphenyl)-N-[4-(trifluoromethyl)benzyl]formimidamide 
(5.37a) 
1-(2,5-Dihydroxyphenyl)ethanone (0.6 mmol, 91 mg) was treated with 4-amino-2,6-
dichlorophenol according to method A of the general procedure. Under these conditions 
the target molecule 1-(3,5-dichloro-4-hydroxyphenyl)-5-(2,5-dihydroxyphenyl)-5-methyl-4-
[4-(trifluoromethyl)benzylamino]-1H-imidazole-2(5H)-thione 5.40 was not obtained after 
the addition of the corresponding isocyanide. However, a full conversion to (E)-N'-(3,5-
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dichloro-4-hydroxyphenyl)-N-[4-(trifluoromethyl)benzyl]formimidamide occurred. The 
crude product was obtained as residue after evaporation (ethyl acetate), and gave orange 
oil which was subjected to RP-HPLC (Table 5.19, method 2) to yield a yellow solid. Yield 
(precipitation): 100 mg, 92 %; yield (preparative HPLC): 9.6 mg, 8.8 %. 1H-NMR (600 
MHz, DMSO-d6): δ [ppm] = 7.90 (s, 1H, Ph-OH), 7.83 (d, J = 8.0 Hz, 1H, NHCH2-p-C6H4-
CF3), 7.71 (d, J = 8.2 Hz, 2H, Ph-H), 7.60 (s, 1H, N=CHNHCH2-p-C6H4-CF3), 7.56 (d, 2H, 
Ph-H), 6.94 (s, 2H, Ph-H), 4.54 (s, 2H, NHCH2-p-C6H4-CF3). 
13C-NMR (151 MHz, DMSO-
d6): δ [ppm] = 151.01 (+, N=CHNHCH2-p-C6H4-CF3), 142.69 (Cquat, Ph-C), 136.96 (Cquat, 
Ph-C), 134.61 (Cquat, Ph-C), 129.44 (Cquat, Ph-C), 127.99 (+, Ph-C), 124.93 (+, Ph-C), 
122.45 (+, Ph-C), 118.98 (+, Ph-C), 56.40 (-, NHCH2-p-C6H4-CF3). MS (EI-MS, 70 eV) m/z 
(rel. int. in %) = 364.0 (52), 363.1 (20), 362.0 ([M]+●, 90), 334.0 (64), 207.0 (40), 204.9 
(66), 179.0 (52), 177.0 (85), 175.1 (45), 174.0 (100), 159.0 (80), 127.0 (30), 115.0 (25), 
113.0 (69), 109.0 (46), 106.1 (33), 78.1 (53), 52.1 (23). HRMS (ESI-MS) m/z calcd. [M + 
H]+ 362.0201, found [M + H]+ 362.0195. C15H11Cl2F3N2O (Mr* = 363.16 g/mol). 
Note: NMR spectral data (
1
H-NMR, 
13
C-NMR) and mass data refer to the isolated (E)-N'-(3,5-dichloro-4-
hydroxyphenyl)-N-(4-(trifluoromethyl)benzyl)formimidamide species (Mr* = 363.16 g/mol). 
 
(E)-N'-(3,5-Dichloro-4-hydroxyphenyl)-N-[4-(trifluoromethyl)benzyl]formimidamide 
(5.38a) 
1-(2,6-Dihydroxyphenyl)ethanone (0.6 mmol, 91 mg) was treated with 4-amino-2,6-
dichlorophenol according to method A of the general procedure. Under these conditions 
the target molecule 1-(3,5-dichloro-4-hydroxyphenyl)-5-(2,6-dihydroxyphenyl)-5-methyl-4-
[4-(trifluoromethyl)benzylamino]-1H-imidazole-2(5H)-thione 5.42 was not obtained after 
addition of the corresponding isocyanide. Instead, a full conversion to (E)-N'-(3,5-dichloro-
4-hydroxyphenyl)-N-[4-(trifluoromethyl)benzyl]formimidamide occurred. The crude product 
was obtained as residue after evaporation (ethyl acetate), and gave orange oil. Yield 
(precipitation): 95 mg, 87 %. MS (CI-MS) m/z (rel. int. in %) = 363.1 ([M + H]+, 100), 156.1 
(5). C15H11Cl2F3N2O (Mr = 363.16 g/mol). 
Note: NMR spectral data (
1
H-NMR, 
13
C-NMR) and mass data refer to the isolated (E)-N'-(3,5-dichloro-4-
hydroxyphenyl)-N-(4-(trifluoromethyl)benzyl)formimidamide species (Mr* = 363.16 g/mol). 
 
(E)-N'-(3,5-Dichloro-4-hydroxyphenyl)-N-[4-(trifluoromethyl)benzyl]formimidamide 
(5.39a) 
1-(2,4,5-Trihydroxyphenyl)ethanone (0.6 mmol, 101 mg) was treated with 4-amino-2,6-
dichlorophenol according to method A of the general procedure. Under these conditions 
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the target molecule 1-(3,5-dichloro-4-hydroxyphenyl)-5-(2,4,5-trihydroxyphenyl)-5-methyl-
4-(4-(trifluoromethyl)benzylamino)-1H-imidazole-2(5H)-thione 5.41 was not obtained after 
the addition of the corresponding isocyanide. Instead, a full conversion to (E)-N'-(3,5-
dichloro-4-hydroxyphenyl)-N-(4-(trifluoromethyl)benzyl)formimidamide occurred. The 
crude product was obtained as residue after evaporation (ethyl acetate), and gave orange 
oil. Yield (precipitation): 75 mg, 69 %. MS (CI-MS) m/z (rel. int. in %) = 363.1 ([M + H]+, 
100), 156.1 (10). C15H11Cl2F3N2O (Mr* = 363.16 g/mol). 
Note: NMR spectral data (
1
H-NMR, 
13
C-NMR) and mass data refer to the isolated (E)-N'-(3,5-dichloro-4-
hydroxyphenyl)-N-(4-(trifluoromethyl)benzyl)formimidamide species (Mr* = 363.16 g/mol). 
 
4-(1-(4-Hydroxyphenyl)-5-methyl-2-thioxo-4-[4-(trifluoromethyl)benzylamino]-2,5-
dihydro-1H-imidazol-5-yl)benzoic acid (5.40) 
The title compound was prepared from 4-acetylbenzoic acid (0.8 mmol, 131 mg), 4-
aminophenol (0.8 mmol, 87 mg) and 1-(isocyanomethyl)-4-(trifluoromethyl)benzene 
(0.8 mmol, 148 mg) according to method B of the general procedure. The crude product 
was obtained as residue after evaporation (ethyl acetate), and gave beige solid, which 
was subjected to RP-HPLC (Table 5.19, method 2). Yield (crude product): 195 mg, 49 %; 
yield (preparative HPLC): dark oil, 13.2 mg, 3.3 %. 1H-NMR (600 MHz, DMSO-d6): δ [ppm] 
= 9.52 (s, 1H, NHCH2-p-C6H4-CF3), 8.24 (s, 1H, OH-5), 7.98 – 7.96 (m, 2H, Ph-H-3’’’,5’’’), 
7.72 (d, J = 8.1 Hz, 2H, Ph-H-3’’,5’’), 7.46 (d, J = 8.0 Hz, 2H, Ph-H-2’’,6’’), 7.33 (d, J = 8.5 
Hz, 2H, Ph-H-2’’’,6’’’), 6.61 (d, J = 8.9 Hz, 2H, Ph-H-3’,5’), 6.55 – 6.53 (m, 2H, Ph-H-2’,6’), 
4.75 – 4.64 (m, 2H, NHCH2-p-C6H4-CF3), 1.84 (s, 3H, CH3-5). 
13C-NMR (151 MHz, DMSO-
d6): δ [ppm] = 195.24 (Cquat, CS), 175.69 (Cquat, C-4), 166.75 (Cquat, Ph-COOH), 157.12 
(Cquat, Ph-C-4’), 142.21 (Cquat, Ph-C-1’’), 141.33 (Cquat, Ph-C-4’’’), 131.24 (Cquat, Ph-C-1’’’), 
130.67 (Cquat, Ph-C-1’), 130.59 (+, Ph-C-2’,6’), 129.78 (+, Ph-C-3’’’,5’’’), 128.04 (+, Ph-C-
2’’,6’’), 127.37 (Cquat, Ph-C-4’’), 127.06 (+, Ph-C-2’’’,6’’’), 125.39 (+, Ph-C-3’’,5’’), 115.32 
(+, Ph-C-3’,5’), 66.91 (Cquat, C-5), 45.71 (-, NHCH2-p-C6H4-CF3), 20.00 (+, CH3-5). MS (CI-
MS) m/z (rel. int. in %) = 575.2 (5), 500.1 ([M + H]+, 100). HRMS (ESI scan) m/z calcd. [M 
+ H]+ 500.1177, found [M + H]+ 500.1189. C25H20F3N3O3S (Mr = 499.50 g/mol). 
 
4-[4-(4-Chlorobenzylamino)-1-(4-hydroxyphenyl)-5-methyl-2-thioxo-2,5-dihydro-1H-
imidazol-5-yl]benzoic acid (5.41) 
The title compound was prepared from 4-acetylbenzoic acid (0.8 mmol, 131 mg), 4-
aminophenol (0.8 mmol, 87 mg) and 1-chloro-4-(isocyanomethyl)benzene (0.8 mmol, 
121 mg) according to method B of the general procedure. The crude product was 
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obtained as residue after evaporation (ethyl acetate), and gave brown oil, which was 
subjected to RP-HPLC (Table 5.19, method 2). Yield (crude product): 290 mg, 78 %; yield 
(preparative HPLC): pale red solid, 4.6 mg, 1.2 %. 1H-NMR (600 MHz, DMSO-d6): δ [ppm] 
= 9.54 (s, 1H, OH-4’), 9.03 (t, J = 6.0 Hz, 1H, NHCH2-p-C6H4-Cl), 8.08 – 8.00 (m, 1H, Ph-
COOH), 7.95 (dd, J = 10.4, 3.6 Hz, 2H, Ph-H-3’’’,5’’’), 7.41 – 7.38 (m, 2H, Ph-H-2’’’,6’’’), 
7.27 (dd, J = 12.3, 8.5 Hz, 4H, Ph-H-2’’,6’’, Ph-H-3’’,5’’), 6.60 – 6.58 (m, 2H, Ph-H-3’,5’), 
6.54 – 6.51 (m, 2H, Ph-H-2’,6’), 4.56 (qd, J = 15.2, 5.9 Hz, 2H, NHCH2-p-C6H4-Cl), 1.77 (s, 
3H, CH3-5). 
13C-NMR (151 MHz, DMSO-d6): δ [ppm] = 195.72 (Cquat, CS), 180.11 (Cquat, C-
4), 166.72 (Cquat, Ph-COOH), 156.90 (Cquat, Ph-C-4’), 141.83 (Cquat, Ph-C-4’’’), 136.90 
(Cquat, Ph-C-1’’’), 131.83 (Cquat, Ph-C-1’’), 131.05 (Cquat, Ph-C-1’), 130.62 (+, Ph-C-2’,6’), 
129.70 (+, Ph-C-3’’’,5’’’), 129.53 (Cquat, Ph-C-4’’), 129.16 (+, Ph-C-2’’,6’’), 128.39 (+, Ph-C-
2’’’,6’’’), 126.95 (+, Ph-C-3’’,5’’), 115.21 (+, Ph-C-3’,5’), 73.55 (Cquat, C-5), 44.72 (-, 
NHCH2-p-C6H4-Cl), 19.95 (+, CH3-5). MS (CI-MS) m/z (rel. int. in %) = 509.1 (10), 507.1 
([M + H + MeCN]+, 20), 467.8 (40), 465.9 ([M + H]+, 100). HRMS (ESI-MS) m/z calcd. [M + 
H]+ 565.0474, found [M + H]+ 565.0476. C24H20ClN3O3S (Mr = 465.95 g/mol). 
 
4-[4-(Benzylamino)-1-(3-hydroxy-4-methoxyphenyl)-5-methyl-2-thioxo-2,5-dihydro-
1H-imidazol-5-yl]benzoic acid (5.42) 
The title compound was prepared from 4-acetylbenzoic acid (0.8 mmol, 131 mg), 5-amino-
2-methoxyphenol (0.8 mmol, 111 mg) and (isocyanomethyl)benzene (0.8 mmol, 94 mg) 
according to method B of the general procedure. The crude product was obtained as 
residue after evaporation (ethyl acetate), and gave pale brown solid which was subjected 
to RP-HPLC (Table 5.19, method 2). Yield (crude product): 210 mg, 57 %; yield 
(preparative HPLC): pale brown solid, 11.9 mg, 3.2 %. 1H-NMR (600 MHz, DMSO-d6): δ 
[ppm] = 9.03 (t, J = 5.9 Hz, 1H, NHCH2-p-Ph), 7.96 (d, J = 8.5 Hz, 2H, Ph-H-3’’’,5’’’), 7.36 
– 7.24 (m, 5H, Ph-H-2’’,3’’,4’’,5’’,6’’), 7.22 (d, J = 7.3 Hz, 2H, Ph-H-2’’’,6’’’), 6.75 (d, J = 8.7 
Hz, 1H, Ph-H-5’), 6.19 (d, J = 2.4 Hz, 1H, Ph-H-2’), 6.12 (dd, J = 8.6, 2.4 Hz, 1H, Ph-H-6’), 
4.57 (ddd, J = 53.0, 15.1, 5.9 Hz, 2H, NHCH2-p-Ph), 3.69 (s, 3H, OCH3-4’’’), 1.78 (s, 3H, 
CH3-5). 
13C-NMR (151 MHz, DMSO-d6): δ [ppm] = 195.58 (Cquat, CS), 180.09 (Cquat, C-4), 
166.82 (Cquat, Ph-COOH), 147.27 (Cquat, Ph-C-4’), 146.07 (Cquat, Ph-C-3’), 141.96 (Cquat, 
Ph-C-4’’’), 137.77 (Cquat, Ph-C-1’’), 131.02 (Cquat, Ph-C-1’’’), 129.64 (+, Ph-C-3’’’,5’’’), 
129.61 (Cquat, Ph-C-1’), 128.41 (+, Ph-C-3’’,4’’,5’’), 127.23 (+, Ph-C-2’’’,6’’’), 126.93 (+, Ph-
C-2’’,6’’), 120.18 (+, Ph-C-6’), 116.94 (+, Ph-C-2’), 111.45 (+, Ph-C-5’), 73.55 (Cquat, C-5), 
55.45 (+, OCH3-4’), 45.48 (-, NHCH2-p-Ph), 19.88 (+, CH3-5). MS (CI-MS) m/z (rel. int. in 
%) = 504.1 ([M + H + MeCN]+, 10), 464.0 (10), 462.9 (30), 462.0 ([M + H]+, 100). HRMS 
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(ESI-MS) m/z calcd. [M + H]+ 462.1482, found [M + H]+ 462.1485. C25H23N3O4S (Mr = 
461.53 g/mol). 
 
4-[1-(3-Hydroxyphenyl)-5-methyl-4-(4-methylbenzylamino)-2-thioxo-2,5-dihydro-1H-
imidazol-5-yl]benzoic acid (5.43) 
The title compound was prepared from 4-acetylbenzoic acid (0.8 mmol, 131 mg), 3-
aminophenol (0.8 mmol, 88 mg) and 1-(isocyanomethyl)-4-methylbenzene (0.8 mmol, 
105 mg) according to method B of the general procedure. The crude product was 
obtained as residue after evaporation (ethyl acetate), and gave a pale yellow solid which 
was subjected to RP-HPLC (Table 5.19, method 2). Yield (crude product): 320 mg, 89 %; 
yield (preparative HPLC): colorless solid, 7.4 mg, 2.1 %. 1H-NMR (600 MHz, DMSO-d6): δ 
[ppm] = 9.45 (s br, 1H, OH-3’), 9.00 (t, J = 5.9 Hz, 1H, NHCH2-p-C6H4-CH3), 7.96 (d, J = 
8.4 Hz, 2H, Ph-H-3’’’,5’’’), 7.29 (d, J = 8.4 Hz, 2H, Ph-H-2’’’,6’’’), 7.11 (q, J = 8.1 Hz, 4H, 
Ph-H-2’’,6’’, Ph-H-3’’,5’’), 7.02 (dd, J = 13.1, 5.1 Hz, 1H, Ph-H-5’), 6.63 (dd, J = 8.1, 1.7 
Hz, 1H, Ph-H-4’), 6.21 – 6.15 (m, 2H, Ph-H-2’, Ph-H-6’), 4.62 – 4.43 (m, 2H, NHCH2-p-
C6H4-CH3), 2.26 (s, 3H, NHCH2-p-C6H4-CH3), 1.77 (s, 3H, CH3-5). 
13C-NMR (151 MHz, 
DMSO-d6): δ [ppm] = 195.34 (Cquat, CS), 180.05 (Cquat, C-4), 166.88 (Cquat, Ph-COOH), 
157.33 (Cquat, Ph-C-3’), 141.73 (Cquat, Ph-C-4’’’), 138.01 (Cquat, Ph-C-1’), 136.40 (Cquat, Ph-
C-4’’), 134.68 (Cquat, Ph-C-1’’), 129.68 (+, Ph-C-3’’’,5’’’), 129.13 (+, Ph-C-2’’,6’’), 128.94 (+, 
Ph-C-5’), 128.58 (Cquat, Ph-C-1’’’), 127.22 (+, Ph-C-3’’,5’’), 126.83 (+, Ph-C-2’’’,6’’’), 119.89 
(+, Ph-C-6’), 116.52 (+, Ph-C-2’), 114.85 (+, Ph-C-4’), 73.62 (Cquat, C-5), 45.25 (-, NHCH2-
p-C6H4-CH3), 20.64 (+, NHCH2-p-C6H4-CH3), 19.89 (+, CH3-5). MS (CI-MS) m/z (rel. int. in 
%) = 488.1 ([M + H + MeCN]+, 10), 448.0 (10), 446.9 (25), 445.9 ([M + H]+, 100). HRMS 
(ESI-MS) m/z calcd. [M + H]+ 446.1533, found [M +H]+ 446.1532. C25H23N3O3S (Mr = 
445.53 g/mol). 
 
1-(3,5-Dichloro-4-hydroxyphenyl)-5-methyl-5-phenyl-4-[4-(trifluoromethyl)benzyl 
amino]-1H-imidazole-2(5H)-thione (5.44) 
The title compound was prepared from acetophenone (0.6 mmol, 72 mg) according to 
method A of the general procedure. The crude product was obtained as residue after 
evaporation (ethyl acetate), and gave pale red oil, which was subjected to preparative 
HPLC (Table 5.19, method 1). Yield (crude product): 175 mg, 33 %; yield (preparative 
HPLC): colorless solid, 2.9 mg, 0.9 %. 1H-NMR (600 MHz, DMSO-d6): δ [ppm] = 10.39 (s, 
1H, OH-4’), 9.22 (t, J = 6.0 Hz, 1H, NHCH2-p-C6H4-CF3), 7.71 (d, J = 8.1 Hz, 2H, Ph-H-
3’’,5’’), 7.49 – 7.41 (m, 5H, Ph-H), 7.20 (d, J = 8.0 Hz, 2H, Ph-H-2’’,6’’), 6.69 (s, 2H, Ph-H-
4-Amino-1H-imidazole-2(5H)-thiones as inhibitors of bacterial hyaluronidase: a computer-assisted 
and multicomponent synthesis approach 137 
2’,6’), 4.74 – 4.61 (m, 2H, NHCH2-p-C6H4-CF3), 1.81 (s, 3H, CH3-5). 
13C-NMR (151 MHz, 
DMSO-d6): δ [ppm] = 195.52 (Cquat, CS), 180.70 (Cquat, C-4), 148.93 (Cquat, Ph-C-4’), 
142.65 (Cquat, Ph-C-1’’), 136.96 (Cquat, Ph-C-1’’’), 129.80 (+, Ph-C-2’,6’), 129.17 (Cquat, Ph-
C-3’,5’), 129.00 (+, Ph-C), 127.92 (+, 4C, Ph-C), 126.54 (+, Ph-C-3’’,5’’), 125.32 (+, Ph-C-
2’’,6’’), 123.33 (Cquat, Ph-C-4’’), 121.51 (Cquat, Ph-C-1’), 73.98 (Cquat, C-5), 44.96 (-, 
NHCH2-p-C6H4-CF3), 19.65 (+, CH3-5). MS (EI-MS, 70 eV) m/z (rel. int. in %) = 525.0 
([M+●], 31), 524.1 ([M+●], 21), 523.0 ([M+●], 53), 159.0 (100), 130.1 (44), 103.1 (33), 69.2 
(31), 57.2 (49), 55.1 (46). HRMS (ESI-MS) m/z calcd. [M + H]+ 524.0572, found [M + H]+ 
524.0581. C24H18Cl2F3N3OS (Mr = 524.39 g/mol). 
 
1-(3,5-Dichloro-4-hydroxyphenyl)-5-methyl-4-[4-(trifluoromethyl)benzylamino]-5-
(2,4,5-trimethoxyphenyl)-1H-imidazole-2(5H)-thione (5.45) 
The title compound was prepared from 1-(2,4,5-trimethoxyphenyl)ethanone (0.6 mmol, 
126 mg) according to method A of the general procedure. The crude product was 
obtained as residue after evaporation (ethyl acetate), and gave a pale yellow solid, which 
was subjected to RP-HPLC (Table 5.19, method 1). Yield (crude product): 230 mg, 62 %; 
yield (preparative HPLC): pale red solid, 15.9 mg, 4.3 %. Single crystals of 5.48 were 
grown from a solution of 10 mg HPLC-purified product in anhydrous methanol (1.5 mL) in 
a 2 mL plastic vial. The solvent was slowly evaporated at room temperature over 14 days. 
1H-NMR (600 MHz, DMSO-d6): δ [ppm] = 10.30 (s, 1H, OH-4’), 8.88 (t, J = 5.9 Hz, 1H, 
NHCH2-p-C6H4-CF3), 7.73 (d, J = 8.2 Hz, 2H, Ph-H-3’’,5’’), 7.49 (d, J = 8.1 Hz, 2H, Ph-H-
2’’,6’’), 6.84 – 6.65 (m, 4H, Ph-H-2’,6’, Ph-H-3’’’,6’’’), 4.71 (dd, J = 15.5, 6.3 Hz, 1H, 
NHCH2-p-C6H4-CF3), 4.57 (dd, J = 15.5, 6.3 Hz, 1H, NHCH2-p-C6H4-CF3), 3.81 (d, J = 6.6 
Hz, 3H, OCH3-2’’’), 3.69 (d, J = 10.1 Hz, 3H, OCH3-4’’’), 3.63 (s, 3H, OCH3-5’’’), 1.74 (s, 
3H, CH3-5). 
13C-NMR (151 MHz, DMSO-d6): δ [ppm] = 195.03 (Cquat, CS), 181.57 (Cquat, C-
4), 152.31 (Cquat, Ph-C-2’’’), 150.99 (Cquat, Ph-C-4’’’), 148.52 (Cquat, Ph-C-4’), 143.06 (Cquat, 
Ph-C-1’’), 142.04 (Cquat, Ph-C-5’’’), 129.88 (+, Ph-C-2’,6’), 129.53 (Cquat, Ph-C-3’,5’), 
127.91 (+, Ph-C-3’’,5’’), 125.23 (+, Ph-C-2’’,6’’), 123.5 (Cquat, Ph-C-4’’), 121.36 (Cquat, Ph-
C-1’), 114.86 (+, Ph-C-6’’’), 114.47 (Cquat, Ph-C-1’’’), 98.25 (+, Ph-C-3’’’), 71.53 (Cquat, C-
5), 56.84 (+, OCH3-4’’’), 56.40 (+, OCH3-5’’’), 55.93 (+, OCH3-2’’’), 44.82 (-, NHCH2-p-
C6H4-CF3), 23.07 (+, CH3-5). MS (EI-MS, 70 eV) m/z (rel. int. in %) = 613.0 ([M
+●], 16), 
447.0 (28), 445.0 (49), 220.1 (30), 193.1 (22), 159.1 (43), 123.0 (38), 83.2 (56), 69.1 (87), 
55.1 (100). HRMS (ESI-MS) m/z calcd. [M + H]+ 614.0889, found [M + H]+ 614.0894. 
C27H24Cl2F3N3O4S (Mr = 614.46 g/mol). 
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4-{1-(3,5-Dichloro-4-hydroxyphenyl)-5-methyl-2-thioxo-4-[4-(trifluoromethyl) 
benzylamino]-2,5-dihydro-1H-imidazol-5-yl}benzoic acid (5.46) 
The title compound was prepared from 4-acetylbenzoic acid (0.8 mmol, 131 mg) 
according to method A of the general procedure. The crude product was obtained as 
residue after evaporation (ethyl acetate), and gave a brown solid, which was subjected to 
RP-HPLC (Table 5.19, method 2). Yield (crude product): 320 mg, 70 %; yield (preparative 
HPLC): gray solid, 14.1 mg, 3.1 %. 1H-NMR (600 MHz, DMSO-d6): δ [ppm] = 10.43 (s, 1H, 
OH-4’), 9.26 (t, J = 6.0 Hz, 1H, NHCH2-p-C6H4-CF3), 8.00 (d, J = 8.5 Hz, 2H, Ph-H-3’’’,5’’’), 
7.71 (d, J = 8.2 Hz, 2H, Ph-H-3’’,5’’), 7.45 (d, J = 8.0 Hz, 2H, Ph-H-2’’,6’’), 7.34 (d, J = 8.5 
Hz, 2H, Ph-H-2’’’,6’’’), 6.74 (s, 2H, Ph-H-2’,6’), 4.67 (d, J = 5.9 Hz, 2H, NHCH2-p-C6H4-
CF3), 1.85 (s, 3H, CH3-5). 
13C-NMR (151 MHz, DMSO-d6): δ [ppm] = 195.77 (Cquat, CS), 
180.30 (Cquat, C-4), 166.72 (Cquat, Ph-COOH), 149.06 (Cquat, Ph-C-4’), 142.52 (Cquat, Ph-C-
1’’), 141.39 (Cquat, Ph-C-4’’’), 131.30 (Cquat, Ph-C-1’’’), 129.91 (+, Ph-C-3’’’,5’’’), 129.89 (+, 
Ph-C-2’,6’), 129.06 (Cquat, Ph-C-3’,5’), 128.05 (+, Ph-C-2’’,6’’), 126.99 (+, Ph-C-2’’’,6’’’), 
125.36 (+, Ph-C-3’’,5’’), 123.32 (Cquat, Ph-C-4’’), 121.60 (Cquat, Ph-C-1’), 73.73 (Cquat, C-5), 
45.06 (-, NHCH2-p-C6H4-CF3), 19.77 (+, CH3-5). MS (CI-MS) m/z (rel. int. in %) = 611.9 
(10), 610.9 (40), 608.9 ([M + H + MeCN]+, 30), 571.9 (10), 570.9 (20), 569.9 (70), 567.9 
([M + H]+, 100). HRMS (ESI-MS) m/z calcd. [M + H]+ 568.0471, found [M + H]+ 568.0468. 
C25H18Cl2F3N3O3S (Mr = 568.39 g/mol). 
 
4-[4-(4-tert-Butylbenzylamino)-1-(3,5-dichloro-4-hydroxyphenyl)-5-methyl-2-thioxo-
2,5-dihydro-1H-imidazol-5-yl]benzoic acid (5.47) 
The title compound was prepared from 4-acetylbenzoic acid (0.8 mmol, 131 mg), 4-amino-
2,6-dichlorophenol (0.8 mmol, 142 mg) and 1-tert-butyl-4-(isocyanomethyl)benzene 
(0.8 mmol, 139 mg) according to method B of the general procedure. The crude product 
was obtained as residue after evaporation (ethyl acetate), and gave a green solid, which 
was subjected to RP-HPLC (Table 5.19, method 2). Yield (crude product): 200 mg, 45 %; 
yield (preparative HPLC): pale lilac solid, 12.0 mg, 2.7 %. 1H-NMR (600 MHz, DMSO-d6): 
δ [ppm] = 13.07 (s, 1H, Ph-COOH), 10.41 (s, 1H, OH-4’), 9.13 (t, J = 5.8 Hz, 1H, NHCH2-
p-C6H4-C(CH3)3), 7.98 (d, J = 8.6 Hz, 2H, Ph-H-3’’’,5’’’), 7.36 – 7.31 (m, 4H, Ph-H-3’’,5’’, 
Ph-H-2’’’,6’’’), 7.15 (d, J = 8.3 Hz, 2H, Ph-H-2’’,6’’), 6.74 (s, 2H, Ph-H-2’,6’), 4.62 – 4.46 
(m, 2H, NHCH2-p-C6H4-C(CH3)3), 1.83 (s, J = 5.8 Hz, 3H, CH3-5), 1.25 (s, 9H, C(CH3)3). 
13C-NMR (151 MHz, DMSO-d6): δ [ppm] = 195.80 (Cquat, CS), 180.04 (Cquat, C-4), 166.72 
(Cquat, Ph-COOH), 149.80 (Cquat, Ph-C-4’’), 148.99 (Cquat, Ph-C-4’), 141.63 (Cquat, Ph-C-
4’’’), 134.42 (Cquat, Ph-C-1’’), 131.18 (Cquat, Ph-C-1’’’), 129.92 (+, Ph-C-3’’’,5’’’), 129.68 (+, 
Ph-C-2’,6’), 129.16 (Cquat, Ph-C-3’,5’), 127.15 (+, Ph-C-2’’,6’’), 126.99 (+, Ph-C-3’’,5’’), 
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125.17 (+, Ph-C-2’’’,6’’’), 121.56 (Cquat, Ph-C-1’), 73.61 (Cquat, C-5), 45.38 (-, NHCH2-p-
C6H4-C(CH3)3), 34.19 (Cquat, C(CH3)3), 31.19 (+, C(CH3)3), 19.73 (+, CH3-5). MS (CI-MS) 
m/z (rel. int. in %) = 597.0 ([M + H + MeCN]+, 5), 560.0 (10), 559.0 (20), 557.9 (70), 556.0 
([M + H]+, 100). HRMS (ESI-MS) m/z calcd. [M + H]+ 556.1223, found [M + H]+ 556.1223. 
C28H27Cl2N3O3S (Mr = 556.50 g/mol). 
 
4-[4-(Benzylamino)-1-(3,5-dichloro-4-hydroxyphenyl)-5-methyl-2-thioxo-2,5-dihydro-
1H-imidazol-5-yl]benzoic acid (5.48) 
The title compound was prepared from 4-acetylbenzoic acid (0.8 mmol, 131 mg), 4-amino-
2,6-dichlorophenol (0.8 mmol, 142 mg) and (isocyanomethyl)benzene (0.8 mmol, 94 mg) 
according to method B of the general procedure. The crude product was obtained as 
residue after evaporation (ethyl acetate), and gave a pale brown solid, which was 
subjected to RP-HPLC (Table 5.19, method 2). Yield (crude product): 280 mg, 70 %; yield 
(preparative HPLC): pale yellow solid, 23.2 mg, 5.8 %. 1H-NMR (600 MHz, DMSO-d6): δ 
[ppm] = 9.20 (t, J = 5.9 Hz, 1H, NHCH2-p-Ph), 7.98 (d, J = 8.5 Hz, 2H, Ph-H-3’’’,5’’’), 7.33 
(t, J = 7.8 Hz, 4H, Ph-H-3’’,5’’, Ph-H-2’’’,6’’’), 7.27 (t, J = 7.3 Hz, 1H, Ph-H-4’’), 7.23 (d, J = 
7.2 Hz, 2H, Ph-H-2’’,6’’), 6.74 (s, 2H, Ph-H-2’,6’), 4.59 (ddd, J = 42.0, 15.0, 5.9 Hz, 2H, 
NHCH2-p-Ph), 1.84 (s, 3H, CH3-5). 
13C-NMR (151 MHz, DMSO-d6): δ [ppm] = 195.83 
(Cquat, CS), 180.16 (Cquat, C-4), 166.74 (Cquat, Ph-COOH), 149.16 (Cquat, Ph-C-4’), 141.53 
(Cquat, Ph-C-4’’’), 137.58 (Cquat, Ph-C-1’’), 131.34 (Cquat, Ph-C-1’’’), 129.90 (+, Ph-C-3’’’,5’’’), 
129.82 (+, Ph-C-2’,6’), 129.60 (Cquat, Ph-C-3’,5’), 128.98 (+, Ph-C-4’’), 128.44 (+, Ph-C-
2’’’,6’’’), 127.31 (+, Ph-C-2’’,6’’), 126.95 (+, Ph-C-3’’,5’’), 121.59 (Cquat, Ph-C-1’), 73.63 
(Cquat, C-5), 45.56 (-, NHCH2-p-Ph), 19.75 (+, CH3-5). MS (CI-MS) m/z (rel. int. in %) = 
545.1 (10), 543.0 (20), 540.9 ([M + H + MeCN]+, 35), 502.0 (75), 499.9 ([M + H]+, 100). 
HRMS (ESI scan) m/z calcd. [M + H]+ 500.0597, found [M + H]+ 500.0598. 
C24H19Cl2N3O3S (Mr = 500.40 g/mol). 
 
1-(3,5-Dichloro-4-hydroxyphenyl)-5-(1H-indol-5-yl)-5-methyl-4-[4-(trifluoromethyl) 
benzylamino]-1H-imidazole-2(5H)-thione (5.49) 
The title compound was prepared from 1-(1H-indol-5-yl)ethanone (0.8 mmol, 127 mg) 
according to method A of the general procedure. The crude product was obtained as 
residue after evaporation (ethyl acetate), and gave dark oil, which was subjected to RP-
HPLC (Table 5.19, method 1). Yield (crude product): 280 mg, 62 %; yield (preparative 
HPLC): pale gray solid, 10.5 mg, 1.9 %. 1H-NMR (600 MHz, DMSO-d6): δ [ppm] = 11.25 
(s, 1H, indole-NH), 10.32 (s, 1H, OH-4’), 9.08 (t, J = 5.7 Hz, 1H, NHCH2-p-C6H4-CF3), 7.67 
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(d, J = 8.1 Hz, 2H, Ph-H-3’’,5’’), 7.50 – 7.45 (m, 2H, Ph-H-6’’’,7’’’), 7.43 (d, J = 8.1 Hz, 2H, 
Ph-H-2’’,6’’), 7.41 – 7.39 (m, 1H, Ph-H-2’’’), 7.09 (s, 1H, Ph-H-4’’’), 6.71 (s, 2H, Ph-H-
2’,6’), 6.47 – 6.43 (m, 1H, Ph-H-3’’’), 4.75 – 4.54 (m, 2H, NHCH2-p-C6H4-CF3), 1.86 (s, 3H, 
CH3-5). 
13C-NMR (151 MHz, DMSO-d6): δ [ppm] = 195.22 (Cquat, CS), 181.44 (Cquat, C-4), 
148.72 (Cquat, Ph-C-4’), 142.80 (Cquat, Ph-C-1’’), 140.79 (Cquat, indole-C), 135.54 (Cquat, 
indole-C), 129.59 (+, Ph-C-2’,6’), 129.50 (Cquat, Ph-C-3’,5’), 127.86 (+, Ph-C-2’’,6’’), 127.39 
(Cquat, indole-C), 126.95 (Cquat, Ph-C-4’’), 126.47 (+, Ar-C-2’’’), 125.23 (+, Ph-C-3’’,5’’), 
121.37 (Cquat, Ph-C-1’), 120.87 (+, Ar-C-4’’’), 112.01 (+, Ar-C-6’’’), 111.85 (+, Ar-C- 7’’’), 
101.69 (+, Ar-C-3’’’), 74.54 (Cquat, C-5), 44.87 (-, NHCH2-p-C6H4-CF3), 20.20 (+, CH3-5). 
MS (CI-MS) m/z (rel. int. in %) = 606.0 ([M + H + MeCN]+, 10), 566.0 (20), 564.9 (75), 
562.9 ([M + H]+, 100). HRMS (ESI scan) m/z calcd. [M + H]+ 563.0681, found [M + H]+ 
563.0681. C26H19Cl2F3N4OS (Mr = 563.42 g/mol). 
 
1-(3,5-Dichloro-4-hydroxyphenyl)-5-(1H-indazol-5-yl)-5-methyl-4-[4-(trifluoromethyl) 
benzylamino]-1H-imidazole-2(5H)-thione (5.50) 
The title compound was prepared from 1-(1H-indazol-5-yl)ethanone (0.8 mmol, 128 mg) 
according to method A of the general procedure. The crude product was obtained as 
residue after evaporation (ethyl acetate), and gave dark oil which was subjected to RP-
HPLC (Table 5.19, method 2). Yield (crude product): 240 mg, 53 %; yield (preparative 
HPLC): pale yellow solid, 7.3 mg, 1.6 %. 1H-NMR (600 MHz, DMSO-d6): δ [ppm] = 13.22 
(s, 1H, indazole-NH), 10.36 (s, 1H, OH-4’), 9.15 (t, J = 6.0 Hz, 1H, NHCH2-p-C6H4-CF3), 
8.11 (d, J = 14.0 Hz, 1H, Ar-H-3’’’), 7.71 (d, J = 1.1 Hz, 1H, Ar-H-4’’’), 7.69 (d, J = 8.2 Hz, 
2H, Ph-H-3’’,5’’), 7.66 (d, J = 8.8 Hz, 1H, Ar-H-7’’’), 7.44 (d, J = 6.6 Hz, 2H, Ph-H-2’’,6’’), 
7.05 (dd, J = 8.8, 1.4 Hz, 1H, Ar-H-6’’’), 6.72 (s, 2H, Ph-H-2’,6’), 4.71 – 4.60 (m, 2H, 
NHCH2-p-C6H4-CF3), 1.87 (s, 3H, CH3-5). 
13C-NMR (151 MHz, DMSO-d6): δ [ppm] = 
195.46 (Cquat, CS), 180.98 (Cquat, C-4), 148.87 (Cquat, Ph-C-4’), 142.67 (Cquat, Ph-C-1’’), 
139.42 (Cquat, indazole-C), 134.16 (+, Ar-C-3’’’), 129.73 (+, Ph-C-2’,6’), 129.32 (Cquat, Ph-
C-3’,5’), 128.59 (Cquat, indazole-C), 127.87 (+, Ph-C-2’’,6’’), 125.29 (+, Ph-C-3’’,5’’), 125.11 
(Cquat, Ph-C-4’’), 124.37 (+, Ar-C-6’’’), 122.53 (Cquat, indazole-C), 121.48 (Cquat, Ph-C-1’), 
119.31 (+, Ar-C-4’’’), 111.18 (+, Ar-C-7’’’), 74.18 (Cquat, C-5), 44.94 (-, NHCH2-p-C6H4-
CF3), 20.10 (+, CH3-5). MS (CI-MS) m/z (rel. int. in %) = 606.9 (25), 605.0 ([M + H + 
MeCN]+, 40), 566.0 (65), 564.0 ([M + H]+, 100). HRMS (ESI-MS) m/z calcd. [M + H]+ 
564.0634, found [M + H]+ 564.0639. C25H18Cl2F3N5OS (Mr = 564.41 g/mol). 
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1-(3,5-Dichloro-4-hydroxyphenyl)-5-(2-methoxyphenyl)-5-methyl-4-[4-
(trifluoromethyl) benzylamino])-1H-imidazole-2(5H)-thione (5.51) 
The title compound was prepared from 1-(2-methoxyphenyl)ethanone (0.6 mmol, 90 mg) 
according to method A of the general procedure. The crude product was obtained as 
residue after evaporation (ethyl acetate), and gave yellow oil which was subjected to RP-
HPLC (Table 5.19, method 1). Yield (crude product): 145 mg, 39 %; yield (preparative 
HPLC): pale gray solid, 7.7 mg, 2.3 %. 1H-NMR (600 MHz, DMSO-d6): δ [ppm] = 10.28 (s, 
1H, OH-4’), 8.97 (t, J = 6.0 Hz, 1H, NHCH2-p-C6H4-CF3), 7.72 (t, J = 9.2 Hz, 2H, Ph-H-
3’’,5’’), 7.48 (d, J = 8.0 Hz, 2H, Ph-H-2’’,6’’), 7.42 (t, J = 8.5 Hz, 1H, Ph-H-4’’’), 7.26 (d, J = 
8.3 Hz, 1H, Ph-H-6’’’), 7.10 (d, J = 8.3 Hz, 1H, Ph-H-3’’’), 6.93 (d, J = 7.7 Hz, 1H, Ph-H-
5’’’), 6.70 (s, 2H, Ph-H-2’,6’), 4.75 (dd, J = 15.4, 6.5 Hz, 1H, NHCH2-p-C6H4-CF3), 4.54 
(dd, J = 15.4, 5.5 Hz, 1H, NHCH2-p-C6H4-CF3), 3.69 (s, 3H, OCH3-2’’’), 1.76 (s, 3H, CH3-
5). 13C-NMR (151 MHz, DMSO-d6): δ [ppm] = 195.34 (Cquat, CS), 181.40 (Cquat, C-4), 
157.33 (Cquat, Ph-C-2’’’), 148.65 (Cquat, Ph-C-4’), 143.03 (Cquat, Ph-C-1’’), 131.10 (+, Ph-C-
4’’’), 129.66 (+, Ph-C-2’,6’), 129.18 (+, Ph-C-6’’’), 127.92 (+, Ph-C-2’’,6’’), 127.70 (Cquat, 
Ph-C-3’,5’), 125.21 (+, Ph-C-3’’,5’’), 123.72 (Cquat, Ph-C-1’’’), 123.37 (Cquat, Ph-C-4’’), 
121.41 (Cquat, Ph-C-1’), 120.44 (+, Ph-C-5’’’), 111.55 (+, Ph-C-3’’’), 71.56 (Cquat, C-5), 
55.74 (+, OCH3-2‘‘‘), 44.86 (-, NHCH2-p-C6H4-CF3), 22.91 (+, CH3-5). MS (EI-MS, 70 eV) 
m/z (rel. int. in %) = 555.1 (29), 553.0 ([M+●], 61), 318.1 (57), 160.1 (54), 159.0 (100), 
133.1 (51), 105.1 (54), 57.1 (27), 55.1 (27). HRMS (ESI-MS) m/z calcd. [M + H]+ 
553.0605, found [M + H]+ 553.0592. C25H20Cl2F3N3O2S (Mr = 554.41 g/mol). 
 
1-(3,5-Dichloro-4-hydroxyphenyl)-5-(4-methoxyphenyl)-5-methyl-4-[4-
(trifluoromethyl) benzylamino]-1H-imidazole-2(5H)-thione (5.52) 
The title compound was prepared from 1-(4-methoxyphenyl)ethanone (0.6 mmol, 90 mg) 
according to method A of the general procedure. The crude product was obtained as 
residue after evaporation (ethyl acetate), and gave dark yellow oil which was subjected to 
RP-HPLC (Table 5.19, method 2). Yield (crude product): 170 mg, 31 %; yield (preparative 
HPLC): colorless solid, 12.8 mg, 2.3 %; mp 137-138 °C. 1H-NMR (600 MHz, DMSO-d6): δ 
[ppm] = 10.31 (s, 1H, OH-4’), 8.98 (t, J = 5.9 Hz, 1H, NHCH2-p-C6H4-CF3), 7.73 (d, J = 8.2 
Hz, 2H, Ph-H-3’’,5’’), 7.48 (d, J = 8.1 Hz, 2H, Ph-H-2’’,6’’), 7.42 (t, J = 7.7 Hz, 1H, Ph-H-
3’’’), 7.26 (d, J = 7.5 Hz, 1H, Ph-H-2’’’), 7.10 (d, J = 8.1 Hz, 1H, Ph-H-6’’’), 6.93 (t, J = 7.7 
Hz, 1H, Ph-H-5’’’), 6.70 (s, 2H, Ph-H-2’,6’), 4.75 (dd, J = 15.4, 6.4 Hz, 1H, NHCH2-p-C6H4-
CF3), 4.54 (dd, J = 15.4, 5.4 Hz, 1H, NHCH2-p-C6H4-CF3), 3.69 (s, 3H, OCH3-4’’’), 1.76 (s, 
3H, CH3-5). 
13C-NMR (151 MHz, DMSO-d6): δ [ppm] = 195.33 (Cquat, CS), 181.40 (Cquat, C-
4), 157.34 (Cquat, Ph-C-4’’’), 148.64 (Cquat, Ph-C-4’), 143.03 (Cquat, Ph-C-1’’), 131.12 (+, Ph-
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C-3’’’), 129.68 (+, Ph-C-2’,6’), 129.19 (+, Ph-C-2’’’), 127.93 (+, Ph-C-2’’,6’’), 127.72 (Cquat, 
Ph-C-4’’), 125.22 (+, Ph-C-3’’,5’’), 123.73 (Cquat, Ph-C-1’’’), 123.37 (Cquat, Ph-C-3’,5’), 
121.42 (Cquat, Ph-C-1’), 120.45 (+, Ph-C-5’’’), 111.56 (+, Ph-C-6’’’), 71.58 (Cquat, C-5), 
55.75 (+, OCH3-4’’’), 44.87 (-, NHCH2-p-C6H4-CF3), 22.92 (+, CH3-5). MS (EI-MS, 70 eV) 
m/z (rel. int. in %) = 555.3 (20), 553.0 ([M+●], 44), 447.1 (24), 445.1 (20), 319.1 (28), 310.1 
(22), 207.1 (37), 148.9 (22), 111.1 (27), 105.0 (22), 95.1 (35), 85.1 (35), 71.1 (54), 69.1 
(67), 57.1 (100), 55.1 (85). HRMS (ESI-MS) m/z calcd. [M + H]+ 553.0605, found [M + H]+ 
553.0599. C25H20Cl2F3N3O2S (Mr = 554.41 g/mol). 
 
1-(3,5-Dichloro-4-hydroxyphenyl)-5-(3,4-dimethoxyphenyl)-5-methyl-4-[4-(trifluoro 
methyl)benzylamino]-1H-imidazole-2(5H)-thione (5.53) 
The title compound was prepared from 1-(3,4-dimethoxyphenyl)ethanone (0.6 mmol, 
108 mg) according to method A of the general procedure. The crude product was 
obtained as residue after evaporation (ethyl acetate), and gave yellow oil which was 
subjected to RP-HPLC (Table 5.19, method 2). Yield (crude product): 110 mg, 31 %; yield 
(preparative HPLC): pale yellow solid, 4.9 mg, 1.4 %. 1H-NMR (600 MHz, DMSO-d6): δ 
[ppm] = 10.39 (s, 1H, OH-4’), 9.19 (t, J = 6.0 Hz, 1H, NHCH2-p-C6H4-CF3), 7.71 (d, J = 8.0 
Hz, 2H, Ph-H-3’’,5’’), 7.53 (d, J = 7.9 Hz, 2H, Ph-H-2’’,6’’), 6.90 (d, J = 8.9 Hz, 1H, Ph-H-
5’’’), 6.74 (s, 2H, Ph-H-2’,6’), 6.32 (s, 2H, Ph-H-2’’’,6’’’), 4.74 (dd, J = 15.2, 6.4 Hz, 1H, 
NHCH2-p-C6H4-CF3), 4.62 (dd, J = 15.2, 5.7 Hz, 1H, NHCH2-p-C6H4-CF3), 3.78 – 3.71 (m, 
6H, OCH3-3’’’,4’’’), 1.70 (s, J = 7.8 Hz, 3H, CH3-5).
 13C-NMR (151 MHz, DMSO-d6): δ 
[ppm] = 195.32 (Cquat, CS), 181.09 (Cquat, C-4), 151.77 (Cquat, Ph-C-3’’’), 148.89 (Cquat, Ph-
C-4’), 148.21 (Cquat, Ph-C-4’’’), 142.73 (Cquat, Ph-C-1’’), 129.79 (+, Ph-C-2’,6’), 129.44 
(Cquat, Ph-C-1’’’), 128.25 (+, Ph-C-2’’,6’’), 127.91 (Cquat, Ph-C-3’,5’) 125.27 (+, Ph-C-3’’,5’’), 
123.61 (+, Ph-C-5’’’), 123.30 (Cquat, Ph-C-4’’), 121.46 (Cquat, Ph-C-1’), 104.24 (+, Ph-C-
2’’’,6’’’), 74.14 (Cquat, C-5), 60.17 (+, OCH3-4’’’), 56.15 (+, OCH3-3’’’), 44.99 (-, NHCH2-p-
C6H4-CF3), 20.89 (+, CH3-5). MS (CI-MS) m/z (rel. int. in %) = 759.2 (20), 662.0 (5), 606.0 
(15), 584.1 ([M + H]+, 100). HRMS (ESI-MS) m/z calcd. [M + H]+ 584.0711, found [M + H]+ 
584.0910. C26H22Cl2F3N3O3S (Mr = 584.44 g/mol). 
 
1-(3,5-Dichloro-4-hydroxyphenyl)-5-methyl-4-[4-(trifluoromethyl)benzylamino]-5-
(2,3,4-trimethoxyphenyl)-1H-imidazole-2(5H)-thione (5.54) 
The title compound was prepared from 1-(2,3,4-trimethoxyphenyl)ethanone (0.6 mmol, 
126 mg) according to method A of the general procedure. The crude product was 
obtained as residue after evaporation (ethyl acetate), and gave red oil which was 
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subjected to RP-HPLC (Table 5.19, method 1). Yield (crude product): 145 mg, 43 %; yield 
(preparative HPLC): beige solid, 8.4 mg, 2.3 %. 1H-NMR (600 MHz, DMSO-d6): δ [ppm] = 
10.33 (s, 1H, OH-4’), 9.04 (t, J = 5.7 Hz, 1H, NHCH2-p-C6H4-CF3), 7.72 (d, J = 8.2 Hz, 2H, 
Ph-H-3’’,5’’), 7.55 (d, J = 8.1 Hz, 2H, Ph-H-2’’,6’’), 6.93 (d, J = 8.9 Hz, 1H, Ph-H-5’’’), 6.77 
(s, 2H, Ph-H-2’,6’), 6.74 (d, J = 8.9 Hz, 1H, Ph-H-6’’’), 4.74 (dd, J = 15.3, 6.1 Hz, 1H, 
NHCH2-p-C6H4-CF3), 4.62 (dd, J = 15.3, 5.7 Hz, 1H, NHCH2-p-C6H4-CF3), 3.78 (s, 3H, 
OCH3-4’’’), 3.72 (s, 3H, OCH3-3’’’), 3.70 (s, 3H, OCH3-2’’’), 1.70 (s, 3H, CH3-5). 
13C-NMR 
(151 MHz, DMSO-d6): δ [ppm] = 195.35 (Cquat, CS), 181.66 (Cquat, C-4), 154.64 (Cquat, Ph-
C-4’’’), 151.77 (Cquat, Ph-C-3’’’), 148.79 (Cquat, Ph-C-4’), 142.79 (Cquat, Ph-C-1’’), 141.61 
(Cquat, Ph-C-2’’’), 129.67 (+, Ph-C-2’,6’), 128.25 (+, Ph-C-2’’,6’’), 127.89 (Cquat, Ph-C-3’,5’), 
125.21 (+, Ph-C-3’’,5’’), 123.62 (+, Ph-C-5’’’), 123.27 (Cquat, Ph-C-4’’), 121.44 (Cquat, Ph-C-
1’’’), 120.91 (Cquat, Ph-C-1’), 106.84 (+, Ph-C-6’’’), 71.50 (Cquat, C-5), 60.44 (+, OCH3-2’’’), 
60.15 (+, OCH3-3’’’), 55.93 (+, OCH3-4’’’), 44.97 (-, NHCH2-p-C6H4-CF3), 22.89 (+, CH3-5). 
MS (EI-MS, 70 eV) m/z (rel. int. in %) = 613.2 ([M+●], 8), 447.0 (47), 445.0 (70), 378.2 (26), 
363.1 (33), 220.1 (24), 174.1 (37), 159.1 (80), 109.1 (38), 85.1 (48), 71.2 (60), 69.1 (62), 
57.1 (100). HRMS (ESI-MS) m/z calcd. [M + H]+ 614.0889, found [M + H]+ 614.0889. 
C27H24Cl2F3N3O4S (Mr = 614.46 g/mol). 
 
1-(3,5-Dichloro-4-hydroxyphenyl)-5-methyl-4-[4-(trifluoromethyl)benzylamino]-5-
(3,4,5-trimethoxyphenyl)-1H-imidazole-2(5H)-thione (5.55) 
The title compound was prepared from 1-(3,4,5-trimethoxyphenyl)ethanone (0.3 mmol, 
63 mg) according to method A of the general procedure. The crude product was obtained 
as residue after evaporation (ethyl acetate), and gave pale yellow solid which was 
subjected to RP-HPLC (Table 5.19, method 2). Yield (crude product): 90 mg, 49 %; yield 
(preparative HPLC): colorless solid, 5.0 mg, 2.7 %. 1H-NMR (600 MHz, DMSO-d6): δ 
[ppm] = 10.41 (s, 1H, OH-4’), 9.22 (t, J = 6.1 Hz, 1H, NHCH2-p-C6H4-CF3), 7.72 (d, J = 8.1 
Hz, 2H, Ph-H-3’’,5’’), 7.51 (d, J = 8.0 Hz, 2H, Ph-H-2’’,6’’), 6.74 (s, 2H, Ph-H-2’,6’), 6.34 (s, 
2H, Ph-H-2’’’,6’’’), 4.77 (dd, J = 15.2, 6.4 Hz, 1H, NHCH2-p-C6H4-CF3), 4.61 (dd, J = 15.2, 
5.7 Hz, 1H, NHCH2-p-C6H4-CF3), 3.67 – 3.61 (m, 9H, OCH3-3’’’,4’’’,5’’’), 1.78 (s, J = 7.8 
Hz, 3H, CH3-5). 
13C-NMR (151 MHz, DMSO-d6): δ [ppm] = 195.23 (Cquat, CS), 180.29 
(Cquat, C-4), 153.00 (Cquat, Ph-C-3’’’,5’’’), 148.90 (Cquat, Ph-C-4’), 142.72 (Cquat, Ph-C-1’’), 
138.22 (Cquat, Ph-C-4’’’), 132.45 (Cquat, Ph-C-1’’’), 129.84 (+, Ph-C-2’,6’), 129.19 (Cquat, Ph-
C-3’,5’), 128.25 (+, Ph-C-2’’,6’’), 125.35 (+, Ph-C-3’’,5’’), 123.30 (Cquat, Ph-C-4’’), 121.46 
(Cquat, Ph-C-1’), 104.34 (+, Ph-C-2’’’,6’’’), 74.04 (Cquat, C-5), 60.17 (+, OCH3-4’’’), 56.09 (+, 
OCH3-3’’’,5’’’), 45.01 (-, NHCH2-p-C6H4-CF3), 20.19 (+, CH3-5). MS (EI-MS, 70 eV) m/z 
(rel. int. in %) = 613.1 ([M+●], 10), 444.9 (35), 159.0 (32), 97.1 (34), 83.1 (38), 74.0 (63), 
144 Experimental section  
73.1 (35), 71.1 (58), 69.1 (59), 60.1 (74), 57.1 (100), 55.1 (75). HRMS (ESI-MS) 
m/z calcd. [M + H]+ 614.0889, found [M + H]+ 614.0891. C27H24Cl2F3N3O4S (Mr = 614.46 
g/mol). 
 
1-(3,5-Dichloro-4-hydroxyphenyl)-5-(4-fluorophenyl)-5-methyl-4-[(4-(trifluoromethyl)-
benzylamino]-1H-imidazole-2(5H)-thione (5.56) 
The title compound was prepared from 1-(4-fluorophenyl)ethanone (0.6 mmol, 83 mg) 
according to method A of the general procedure. The crude product was obtained as 
residue after evaporation (ethyl acetate), and gave pale red oil which was subjected to 
RP-HPLC (Table 5.19, method 1). Yield (crude product): 240 mg, 74 %; yield (preparative 
HPLC): colorless solid, 9.2 mg, 1.7 %. 1H-NMR (600 MHz, DMSO-d6): δ [ppm] = 10.27 (s, 
1H, OH-4’), 9.24 (t, J = 5.9 Hz, 1H, NHCH2-p-C6H4-CF3), 7.72 (d, J = 8.1 Hz, 2H, Ph-H-
3’’,5’’), 7.45 (d, J = 8.0 Hz, 2H, Ph-H-2’’,6’’), 7.32 – 7.23 (m, 4H, p-C6H4-F), 6.71 (s, 2H, 
Ph-H-2’,6’), 4.68 (d, J = 5.8 Hz, 2H, NHCH2-p-C6H4-CF3), 1.81 (s, 3H, CH3-5). 
13C-NMR 
(151 MHz, DMSO-d6): δ [ppm] = 195.51 (Cquat, CS), 180.49 (Cquat, C-4), 161.35 (Cquat, Ph-
C-4’’’), 149.81 (Cquat, Ph-C-4’), 142.60 (Cquat, Ph-C-1’’), 133.27 (Cquat, Ph-C-1’’’), 129.83 (+, 
Ph-C-2’,6’), 129.10 (Cquat, Ph-C-3’,5’), 129.01 (+, Ph-C-2’’’,6’’’), 127.86 (+, Ph-C-3’’,5’’), 
125.35 (+, Ph-C-2’’,6’’), 123.33 (Cquat, Ph-C-4’’), 121.61 (Cquat, Ph-C-1’), 115.81 (+, Ph-C-
3’’’,5’’’), 73.45 (Cquat, C-5), 44.98 (-, NHCH2-p-C6H4-CF3), 19.99 (+, CH3-5). MS (EI-MS, 70 
eV) m/z (rel. int. in %) = 541.0 ([M+●], 5), 309.0 (46), 306.9 (73), 221.0 (63), 218.9 (100), 
159.1 (30), 120.0 (92), 55.2 (78). HRMS (ESI-MS) m/z calcd. [M + H]+ 542.0478, found 
[M + H]+ 542.0486. C24H17Cl2F4N3OS (Mr = 542.38 g/mol). 
 
5-(4-Chlorophenyl)-1-(3,5-dichloro-4-hydroxyphenyl)-5-methyl-4-[4-(trifluoromethyl) 
benzylamino]-1H-imidazole-2(5H)-thione (5.57) 
The title compound was prepared from 1-(4-chlorophenyl)ethanone (0.6 mmol, 93 mg) 
according to method A of the general procedure. The crude product was obtained as 
residue after evaporation (ethyl acetate), and gave yellow oil, which was subjected to RP-
HPLC (Table 5.19, method 1). Yield (crude product): 80 mg, 24 %; yield (preparative 
HPLC): colorless solid, 3.2 mg, 0.9 %. 1H-NMR (600 MHz, DMSO-d6): δ [ppm] = 10.43 (s, 
1H, OH-4’), 9.23 (t, J = 6.0 Hz, 1H, NHCH2-p-C6H4-CF3), 7.72 (d, J = 8.2 Hz, 2H, Ph-H-
3’’,5’’), 7.54 – 7.50 (m, 2H, Ph-H-3’’’,5’’’), 7.45 (d, J = 8.0 Hz, 2H, Ph-H-2’’,6’’), 7.24 – 7.21 
(m, 2H, Ph-H-2’’’,6’’’), 6.76 (s, 2H, Ph-H-2’,6’), 4.67 (d, J = 5.9 Hz, 2H, NHCH2-p-C6H4-
CF3), 1.81 (s, 3H, CH3-5). 
13C-NMR (151 MHz, DMSO-d6): δ 195.66 (Cquat, CS), 180.34 
(Cquat, C-4), 149.04 (Cquat, Ph-C-4’), 142.54 (Cquat, Ph-C-1’’), 135.90 (Cquat, Ph-C-1’’’), 
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133.74 (Cquat, Ph-C-4’’’), 129.90 (+, Ph-C-2’,6’), 129.07 (Cquat, Ph-C-3’,5’), 128.95 (+, Ph-
C-3’’’,5’’’), 128.67 (+, Ph-C-2’’’,6’’’), 127.92 (+, Ph-C-3’’,5’’), 125.36 (+, Ph-C-2’’,6’’), 123.34 
(Cquat, Ph-C-4’’), 121.61 (Cquat, Ph-C-1’), 73.48 (Cquat, C-5), 45.02 (-, NHCH2-p-C6H4-CF3), 
19.83 (+, CH3-5). MS (EI-MS, 70 eV) m/z (rel. int. in %) = 559.0 ([M
+●], 30), 557.2 ([M]+●, 
15), 314.0 (18), 164.1 (31), 159.1 (100), 97.2 (40), 71.2 (51), 57.2 (82), 55.1 (56). HRMS 
(ESI-MS) m/z calcd. [M + H]+ 558.0183, found [M + H]+ 558.0184. C24H17Cl3F3N3OS (Mr = 
558.83 g/mol). 
 
5-(4-Bromophenyl)-1-(3,5-dichloro-4-hydroxyphenyl)-5-methyl-4-[4-(trifluoromethyl) 
benzylamino])-1H-imidazole-2(5H)-thione (5.58) 
The title compound was prepared from 1-(4-bromophenyl)ethanone (0.6 mmol, 119 mg) 
according to method A of the general procedure. The crude product was obtained as 
residue after evaporation (ethyl acetate), and gave yellow oil, which was subjected to RP-
HPLC (Table 5.19, method 1). Yield (crude product): 135 mg, 37 %; yield (preparative 
HPLC): colorless solid, 6.4 mg, 1.8 %. 1H-NMR (600 MHz, DMSO-d6): δ [ppm] = 9.22 (t, J 
= 5.7 Hz, 1H, NHCH2-p-C6H4-CF3), 7.72 (d, J = 8.1 Hz, 2H, Ph-H-3’’,5’’), 7.65 (d, J = 8.5 
Hz, 2H, Ph-H-3’’’,5’’’), 7.45 (d, J = 7.9 Hz, 2H, Ph-H-2’’,6’’), 7.16 (d, J = 8.5 Hz, 2H, Ph-H-
2’’’,6’’’), 6.75 (s, 2H, Ph-H-2’,6’), 4.67 (d, J = 5.4 Hz, 2H, NHCH2-p-C6H4-CF3), 1.80 (s, 3H, 
CH3-5). 
13C-NMR (151 MHz, DMSO-d6): δ [ppm] = 195.69 (Cquat, CS), 180.29 (Cquat, C-4), 
149,39 (Cquat, Ph-C-4’), 142.54 (Cquat, Ph-C-1’’), 136.32 (Cquat, Ph-C-4’’’-ArC), 131.89 (+, 
Ph-C-3’’’,5’’’), 129.86 (+, Ph-C-2’,6’), 129.07 (Cquat, Ph-C-3’,5’), 128.94 (+, Ph-C-2’’’,6’’’), 
127.91 (+, Ph-C-2’’,6’’), 125.36 (+, Ph-C-3’’,5’’), 123.46 (Cquat, Ph-C-4’’), 122.37 (Cquat, Ph-
C-1’’’), 121.62 (Cquat, Ph-C-1’), 73.54 (Cquat, C-5), 45.02 (-, NHCH2-p-C6H4-CF3), 19.78 (+, 
CH3-5). MS (EI-MS, 70 eV) m/z (rel. int. in %) = 603.0 ([M
+●], 40), 601.0 ([M+●], 24), 358.9 
(20), 343.8 (28), 210.0 (26), 159.0 (100), 109.1 (32), 60.1 (48). HRMS (ESI-MS) m/z 
calcd. [M + H]+ 602.9708, found [M + H]+ 602.9716. C24H17BrCl2F3N3OS (Mr = 603.28 
g/mol). 
 
1-(3,5-Dichloro-4-hydroxyphenyl)-5-methyl-4-[4-(trifluoromethyl)benzylamino]-5-(4-
(trifluoromethyl)phenyl)-1H-imidazole-2(5H)-thione (5.59) 
The title compound was prepared from 1-(4-(trifluoromethyl)phenyl)ethanone (0.6 mmol, 
113 mg) according to method A of the general procedure. The crude product was 
obtained as residue after evaporation (ethyl acetate), and gave yellow oil, which was 
subjected to RP-HPLC (Table 5.19, method 1). Yield (crude product): 190 mg, 53 %; yield 
(preparative HPLC): beige solid, 7.6 mg, 2.1 %. 1H-NMR (600 MHz, DMSO-d6): δ [ppm] = 
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10.45 (s, 1H, OH-4’), 9.27 (t, J = 5.9 Hz, 1H, NHCH2-p-C6H4-CF3), 7.83 (d, J = 8.4 Hz, 2H, 
Ph-H-3’’’,5’’’), 7.71 (d, J = 8.1 Hz, 2H, Ph-H-3’’,5’’), 7.45 (d, J = 7.5 Hz, 4H, Ph-H-2’’,6’’, 
Ph-H-2’’’,6’’’), 6.74 (s, 2H, Ph-H-2’,6’), 4.75 – 4.61 (m, 2H, NHCH2-p-C6H4-CF3), 1.87 (s, 
3H, CH3-5). 
13C-NMR (151 MHz, DMSO-d6): δ [ppm] = 195.85 (Cquat, CS), 180.10 (Cquat, C-
4), 149.11 (Cquat, Ph-C-4’), 142.47 (Cquat, Ph-C-1’’), 141.39 (Cquat, Ph-C-1’’’), 129.93 (+, Ph-
C-2’,6’), 128.96 (Cquat, Ph-C-3’,5’), 127.94 (+, Ph-C-2’’,6’’), 127.76 (+, Ph-C-2’’’,6’’’), 
125.93 (+, Ph-C-3’’’,5’’’), 125.35 (+, Ph-C-3’’,5’’), 123.31 (Cquat, Ph-C-4’’), 123.00 (Cquat, 
Ph-C-4’’’), 121.65 (Cquat, Ph-C-1’), 73.59 (Cquat, C-5), 45.07 (-, NHCH2-p-C6H4-CF3), 19.71 
(+, CH3-5). MS (EI-MS, 70 eV) m/z (rel. int. in %) = 593.0 ([M
+●], 19), 592.0 ([M+●], 12), 
591.1 ([M+●], 25), 348.0 (14), 332.0 (14), 204.0 (13), 159.0 (100), 109.1 (16). HRMS (ESI-
MS) m/z calcd. [M + H]+ 592.0446, found [M + H]+ 592.0450. C25H17Cl2F6N3OS (Mr = 
592.38 g/mol). 
 
1-(3,5-Dichloro-4-hydroxyphenyl)-5-methyl-5-(4-nitrophenyl)-4-[4-(trifluoromethyl) 
benzylamino]-1H-imidazole-2(5H)-thione (5.60) 
The title compound was prepared from 1-(4-nitrophenyl)ethanone (0.6 mmol, 99 mg) 
according to method A of the general procedure. The crude product was obtained as 
residue after evaporation (ethyl acetate), and gave orange oil, which was subjected to RP-
HPLC (Table 5.19, method 1). Yield (crude product): 215 mg, 63 %; yield (preparative 
HPLC): pale yellow solid, 6.7 mg, 1.4 %. 1H-NMR (600 MHz, DMSO-d6): δ [ppm] = 10.46 
(s, 1H, OH-4’), 9.32 (t, J = 5.9 Hz, 1H, NHCH2-p-C6H4-CF3), 8.33 – 8.26 (m, 2H, Ph-H-
3’’’,5’’’), 7.72 (d, J = 8.1 Hz, 2H, Ph-H-3’’,5’’), 7.53 – 7.49 (m, 2H, Ph-H-2’’’,6’’’), 7.44 (d, J 
= 8.0 Hz, 2H, Ph-H-2’’,6’’), 6.82 (s, 2H, Ph-H-2’,6’), 4.73 – 4.62 (m, 2H, NHCH2-p-C6H4-
CF3), 1.90 (s, 3H, CH3-5). 
13C-NMR (151 MHz, DMSO-d6): δ [ppm] = 196.03 (Cquat, CS), 
179.84 (Cquat, C-4), 149.21 (Cquat, Ph-C-4’), 147.66 (Cquat, Ph-C-1’’’), 143.80 (Cquat, Ph-C-
4’’’), 142.39 (Cquat, Ph-C-1’’), 129.99 (+, Ph-C-2’,6’), 128.89 (Cquat, Ph-C-3’,5’), 128.40 (+, 
Ph-C-2’’’,6’’’), 127.85 (+, Ph-C-2’’,6’’), 125.41 (+, Ph-C-3’’,5’’), 124.07 (+, Ph-C-3’’’,5’’’), 
123.32 (Cquat, Ph-C-4’’), 121.71 (Cquat, Ph-C-1’), 73.45 (Cquat, C-5), 45.10 (-, NHCH2-p-
C6H4-CF3), 19.84 (+, CH3-5). MS (EI-MS, 70 eV) m/z (rel. int. in %) = 568.0 ([M
+●], 27), 
159.0 (94), 131.1 (20), 109.1 (36), 91.1 (45), 83.2 (49), 71.2 (48), 69.1 (70), 57.2 (99), 
55.2 (100). HRMS (ESI-MS) m/z calcd. [M + H]+ 569.0423, found [M + H]+ 569.0432. 
C24H17Cl2F3N4O3S (Mr = 569.38 g/mol). 
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4-{1-(3,5-Dichloro-4-hydroxyphenyl)-5-methyl-2-thioxo-4-[4-(trifluoromethyl) 
benzylamino]-2,5-dihydro-1H-imidazol-5-yl}phenylboronic acid (5.61) 
The title compound was prepared from 4-acetylphenylboronic acid (0.6 mmol, 98 mg) 
according to method A of the general procedure. The crude product was obtained as 
residue after evaporation (ethyl acetate), and gave pale yellow oil, which was subjected to 
RP-HPLC (Table 5.19, method 1). Yield (crude product): 140 mg, 40 %; yield (preparative 
HPLC): pale yellow solid, 3.1 mg, 0.9 %. 1H-NMR (600 MHz, DMSO-d6): δ 10.39 (s, 1H, 
OH-4’), 9.19 (t, J = 6.0 Hz, 1H, NHCH2-p-C6H4-CF3), 8.16 (s, 2H, B(OH)2), 7.84 (d, J = 8.2 
Hz, 2H, Ph-H-2’’’,6’’’), 7.70 (d, J = 8.2 Hz, 2H, Ph-H-3’’,5’’), 7.44 (d, J = 7.9 Hz, 2H, Ph-H-
2’’,6’’), 7.17 (d, J = 8.3 Hz, 2H, Ph-H-3’’’,5’’’), 6.71 (s, 2H, Ph-H-2’,6’), 4.71 – 4.61 (m, 2H, 
NHCH2-p-C6H4-CF3), 1.81 (s, 3H, 5-CH3). 
13C-NMR (151 MHz, DMSO-d6): δ 195.57 (Cquat, 
CS), 180.71 (Cquat, C-4), 148.89 (Cquat, Ph-C-4’), 146.76 (Cquat, Ph-C-1’’’), 142.65 (Cquat, 
Ph-C-1’’), 138.51 (Cquat, Ph-C-4’’’), 134.68 (+, Ph-C-2’’’,6’’’), 129.76 (+, Ph-C-3’,5’), 129.26 
(+, Ph-C-2’,6’), 127.91 (+, Ph-C-2’’,6’’), 125.49 (+, Ph-C-3’’’,5’’’), 125.30 (+, Ph-C-3’’,5’’), 
123.32 (Cquat, Ph-C-4’’), 121.49 (Cquat, Ph-C-1’), 74.00 (Cquat, C-5), 44.96 (-, NHCH2-p-
C6H4-CF3), 19.66 (+, CH3-5). MS (CI-MS) m/z (rel. int. in %) = 590.0 (5), 568.1 ([M + H]
+, 
100), 180.1 (3), 158.2 (4). HRMS (ESI scan) m/z calcd. [M + H]+ 568.0642, found [M + H]+ 
568.0652. C24H19BCl2F3N3O3S (Mr = 568.20 g/mol). 
 
5-(Biphenyl-4-yl)-1-(3,5-dichloro-4-hydroxyphenyl)-5-methyl-4-[4-(trifluoromethyl)-
benzylamino]-1H-imidazole-2(5H)-thione (5.62) 
The title compound was prepared from 1-(biphenyl-4-yl)ethanone (0.8 mmol, 157 mg) 
according to method A of the general procedure. The crude product was obtained as 
residue after evaporation (ethyl acetate), and gave brown solid, which was subjected to 
RP-HPLC (Table 5.19, method 2). Yield (crude product): 260 mg, 54 %; yield (preparative 
HPLC): pale yellow solid, 4.8 mg, 1.0 %. 1H-NMR (600 MHz, DMSO-d6): δ [ppm] = 10.41 
(s, 1H, OH-4’), 9.26 (t, J = 6.0 Hz, 1H, NHCH2-p-C6H4-CF3), 8.04 – 8.02 (m, 2H, Ph-H-
2’’,6’’), 7.83 – 7.81 (m, 2H, Ph-H-3’’,5’’), 7.77 (d, J = 8.5 Hz, 2H, Ph-H-3’’’,5’’’), 7.75 – 7.73 
(m, 2H, Ph-H-8’’’,12’’’), 7.71 (s, 1H, Ph-H-10’’’), 7.69 (dd, J = 8.2, 1.1 Hz, 2H, Ph-H-
9’’’,11’’’), 7.29 (d, J = 8.5 Hz, 2H, Ph-H-2’’’,6’’’), 6.76 (s, 2H, Ph-H-2’,6’), 4.70 (d, J = 5.9 
Hz, 2H, NHCH2-p-C6H4-CF3), 1.85 (s, 3H, CH3-5). 
13C-NMR (151 MHz, DMSO-d6): δ [ppm] 
= 195.57 (Cquat, CS), 180.66 (Cquat, C-4), 148.97 (Cquat, Ph-C-4’), 144.52 (Cquat, Ph-C-1’’), 
142.64 (Cquat, Ph-C-7’’), 140.74 (Cquat, Ph-C-1’’’), 138.70 (Cquat, Ph-C-4’’’), 129.87 (+, Ph-C-
2’,6’), 129.22 (Cquat, Ph-C-3’,5’), 128.89 (+, Ph-C-9’’’,11’’’), 127.90 (+, Ph-C-2’’,6’’), 127.23 
(+, Ph-C-8’’’,12’’’), 126.98 (+, Ph-C-2’’’,6’’’), 126.84 (+, Ph-C-3’’’,5’’’), 126.70 (+, Ph-C-
3’’,5’’), 125.35 (+, Ph-C-10’’’), 123.35 (Cquat, Ph-C-4’’), 121.56 (Cquat, Ph-C-1’), 73.82 (Cquat, 
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C-5), 45.01 (-, NHCH2-p-C6H4-CF3), 19.78 (+, CH3-5). MS (CI-MS) m/z (rel. int. in %) = 
643.1 (10), 641.1 ([M + H + MeCN]+, 20), 602.0 (60), 600.0 ([M + H]+, 100). HRMS (ESI-
MS) m/z calcd. [M + H]+ 600.0885, found [M + H]+ 600.0892. C30H22Cl2F3N3OS (Mr = 
600.48 g/mol). 
 
3-{1-(3,5-Dichloro-4-hydroxyphenyl)-5-methyl-2-thioxo-4-[4-(trifluoromethyl) 
benzylamino]-2,5-dihydro-1H-imidazol-5-yl}benzonitrile (5.63) 
The title compound was prepared from 3-acetylbenzonitrile (0.8 mmol, 116 mg) according 
to method A of the general procedure. The crude product was obtained as residue after 
evaporation (ethyl acetate), and gave gray solid, which was subjected to RP-HPLC (Table 
5.19, method 2). Yield (crude product): 280 mg, 64 %; yield (preparative HPLC): colorless 
solid, 19.3 mg, 4.4 %. 1H-NMR (600 MHz, DMSO-d6): δ [ppm] = 10.53 (s, 1H, OH-4’), 9.26 
(t, J = 5.6 Hz, 1H, NHCH2-p-C6H4-CF3), 7.92 (d, J = 7.8 Hz, 1H, Ph-H-2’’’), 7.71 (d, 2H, 
Ph-H-3’’,5’’), 7.68 (m, 2H, Ph-H-4’’’,6’’’), 7.49 (dd, J = 19.6, 7.5 Hz, 1H, Ph-H-5’’’), 7.44 (d, 
J = 8.0 Hz, 2H, Ph-H-2’’,6’’), 6.77 (s, 2H, Ph-H-2’,6’), 4.67 (d, J = 5.2 Hz, 2H, NHCH2-p-
C6H4-CF3), 2.07 (s, 3H, CH3-5). 
13C-NMR (151 MHz, DMSO-d6): δ [ppm] = 195.86 (Cquat, 
CS), 179.93 (Cquat, C-4), 149.17 (Cquat, Ph-C-4’), 142.49 (Cquat, Ph-C-1’’), 133.05 (+, Ph-C-
2’’’), 131.72 (+, Ph-C-5’’’), 130.50 (+, Ph-C-4’’’,6’’’), 130.36 (Cquat, Ph-C-1’’’), 130.07 (+, 
Ph-C-2’,6’), 128.89 (Cquat, Ph-C-3’,5’), 128.00 (+, Ph-C-2’’,6’’), 125.37 (+, Ph-C-3’’,5’’), 
123.32 (Cquat, Ph-C-4’’), 121.68 (Cquat, Ph-C-1’), 118.26 (CN-3’’’), 111.93 (Cquat, Ph-C-3’’), 
73.46 (Cquat, C-5), 44.98 (-, NHCH2-p-C6H4-CF3), 19.77 (+, CH3-5). MS (ESI-MS) m/z (rel. 
int. in %) = 593.0 (10), 592.0 (65), 589.9 ([M + H + MeCN]+, 100), 548.9 ([M + H]+, 60). 
HRMS (ESI scan) m/z calcd. [M + H]+ 549.0525, found [M + H]+ 549.0526. 
C25H17Cl2F3N4OS (Mr = 549.39 g/mol). 
 
1-(3,5-Dichloro-4-hydroxyphenyl)-5-methyl-5-(naphthalen-2-yl)-4-[4-(trifluoromethyl) 
benzylamino]-1H-imidazole-2(5H)-thione (5.64) 
The title compound was prepared from 1-(naphthalen-2-yl)ethanone (0.6 mmol, 102 mg) 
according to method A of the general procedure. The crude product was obtained as 
residue after evaporation (ethyl acetate), and gave yellow oil, which was subjected to RP-
HPLC (Table 5.19, method 2). Yield (crude product): 205 mg, 60 %; yield (preparative 
HPLC): colorless solid, 4.8 mg, 1.4 %. 1H-NMR (600 MHz, DMSO-d6): δ [ppm] = 10.37 (s, 
1H, OH-4’), 9.20 (t, J = 6.0 Hz, 1H, NHCH2-p-C6H4-CF3), 8.02 (t, J = 9.5 Hz, 1H, Ar-H-4’’’), 
7.96 (t, J = 8.3 Hz, 2H, Ar-H-5’’’,8’’’), 7.86 (s, 1H, Ar-H-2’’’), 7.68 (d, J = 8.2 Hz, 2H, Ph-H-
3’’,5’’), 7.57 (pd, J = 6.9, 1.5 Hz, 2H, Ar-H-6’’’,7’’’), 7.44 (d, J = 8.0 Hz, 2H, Ph-H-2’’,6’’), 
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7.20 (d, J = 8.6 Hz, 1H, Ar-H-3’’’), 6.76 (s, 2H, Ph-H-2’,6’), 4.67 (qd, J = 15.5, 6.0 Hz, 2H, 
NHCH2-p-C6H4-CF3), 1.94 (s, 3H, CH3-5). 
13C-NMR (151 MHz, DMSO-d6): δ [ppm] = 
195.79 (Cquat, CS), 180.63 (Cquat, C-4), 148.94 (Cquat, Ph-C-4’), 142.61 (Cquat, Ph-C-1’’), 
133.94 (Cquat, Ar-C-2’’’), 132.68 (Cquat, naphthalene-C), 132.52 (Cquat, naphthalene-C), 
129.79 (+, Ph-C-2’,6’), 129.26 (+, Ph-C-3’,5’), 128.86 (+, Ar-C-4’’’), 128.30 (+, Ar-C-5’’’), 
127.91 (+, Ph-C-2’’,6’’), 127.57 (+, Ar-C-8’’’), 127.13 (+, Ar-C-7’’’), 126.82 (+, Ar-C-6’’’), 
126.24 (+, Ar-C-1’’’), 125.29 (+, Ph-C-3’’,5’’), 123.74 (+, Ar-C-3’’’), 123.31 (Cquat, Ph-C-4’’), 
121.53 (Cquat, Ph-C-1’), 74.12 (Cquat, C-5), 45.00 (-, NHCH2-p-C6H4-CF3), 19.91 (+, CH3-5). 
RP-HPLC (220 nm, gradient 1): 97.5 % (tR = 26.7 min, k = 2.5). MS (EI-MS, 70 eV) m/z 
(rel. int. in %) = 576.1 ([M+●], 5), 573.0 ([M+●], 28), 445.0 (6), 330.1 (16), 285.0 (18), 218.9 
(20), 180.1 (48), 159.0 (100), 155.1 (42), 127.1 (40), 57.2 (28). HRMS (ESI-MS) m/z 
calcd. [M + H]+ 574.0729, found [M + H]+ 574.0736. C28H20Cl2F3N3OS (Mr = 577.44 g/mol). 
 
5-(Benzo[d][1,3]dioxol-5-yl)-1-(3,5-dichloro-4-hydroxyphenyl)-5-methyl-4-[4-(trifluoro 
methyl)benzylamino]-1H-imidazole-2(5H)-thione (5.65) 
The title compound was prepared from 1-(benzo[d][1,3]dioxol-5-yl)ethanone (0.6 mmol, 
98 mg) according to method A of the general procedure. The crude product was obtained 
as residue after evaporation (ethyl acetate), and gave orange oil, which was subjected to 
RP-HPLC (Table 5.19, method 1). Yield (crude product): 170 mg, 50 %; yield (preparative 
HPLC): pale yellow solid, 5.4 mg, 1.6 %. 1H-NMR (600 MHz, DMSO-d6): δ [ppm] = 10.41 
(s, 1H, OH-4’), 9.26 (t, J = 5.9 Hz, 1H, NHCH2-p-C6H4-CF3), 7.71 (d, J = 8.2 Hz, 2H, Ph-H-
3’’,5’’), 7.46 (d, J = 8.0 Hz, 2H, Ph-H-2’’,6’’), 6.99 (d, J = 8.0 Hz, 1H, Ar-H-4’’’), 6.77 (s, 2H, 
Ph-H-2’,6’), 6.71 – 6.67 (m, 2H, Ar-H-6’’’,7’’’), 6.06 (d, J = 8.4 Hz, 2H, Ar-H-2’’’), 4.71 – 
4.62 (m, 2H, NHCH2-p-C6H4-CF3), 1.77 (s, 3H, CH3-5). 
13C-NMR (151 MHz, DMSO-d6): δ 
[ppm] = 195.57 (Cquat, CS), 180.40 (Cquat, C-4), 148.93 (Cquat, Ph-C-4’), 147.69 (Cquat, 
dioxole-C), 147.58 (Cquat, dioxole-C), 142.59 (Cquat, Ph-C-1’’), 130.73 (Cquat, Ph-C-5’’), 
129.74 (+, Ph-C-2’,6’), 129.19 (+, Ph-C-3’,5’), 127.93 (+, Ph-C-2’’,6’’), 125.30 (+, Ph-C-
3’’,5’’), 123.27 (Cquat, Ph-C-4’’), 121.54 (Cquat, Ph-C-1’), 120.57 (+, Ar-C-6’’’), 108.50 (+, Ar-
C-4’’’), 106.92 (+, Ar-C-7’’’), 101.57 (+, Ar-C-2’’’), 73.79 (Cquat, C-5), 45.89 (-, NHCH2-p-
C6H4-CF3), 20.10 (+, CH3-5). MS (EI-MS, 70 eV) m/z (rel. int. in %) = 569.1 ([M
+●], 22), 
567.0 ([M+●], 29), 444.9 (14), 334.1 (51), 308.0 (17), 279.0 (27), 174.0 (100), 159.0 (82), 
149.1 (29), 109.0 (25), 55.2 (36). HRMS (ESI-MS) m/z calcd. [M + H]+ 568.0471, found [M 
+ H]+ 568.0482. C25H18Cl2F3N3O3S (Mr = 568.39 g/mol). 
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1-(3,5-Dichloro-4-hydroxyphenyl)-5-(1H-indazol-6-yl)-5-methyl-4-[(4-
(trifluoromethyl)benzylamino]-1H-imidazole-2(5H)-thione (5.66) 
The title compound was prepared from 1-(1H-indol-6-yl)ethanone (0.8 mmol, 128 mg) 
according to method A of the general procedure. The crude product was obtained as 
residue after evaporation (ethyl acetate), and gave dark oil, which was subjected to RP-
HPLC (Table 5.19, method 2). Yield (crude product): 360 mg, 80 %; yield (preparative 
HPLC): pale gray solid, 11.0 mg, 1.9 %. 1H-NMR (600 MHz, DMSO-d6): δ [ppm] = 13.18 
(s, 1H, indazole-NH), 10.38 (s, 1H, OH-4’), 9.17 (t, J = 6.0 Hz, 1H, NHCH2-p-C6H4-CF3), 
8.13 (s, 1H, Ar-H-3’’’), 7.88 (d, J = 8.5 Hz, 1H, Ar-H-4’’’), 7.68 (d, J = 8.1 Hz, 2H, Ph-H-
3’’,5’’), 7.44 (s, 1H, Ar-H-7’’’), 7.42 (d, J = 6.7 Hz, 2H, Ph-H-2’’,6’’), 6.85 (d, J = 8.6 Hz, 1H, 
Ar-H-5’’’), 6.75 (s, 2H, Ph-H-2’,6’), 4.72 – 4.60 (m, 2H, NHCH2-p-C6H4-CF3), 1.88 (s, 3H, 
CH3-5). 
13C-NMR (151 MHz, DMSO-d6): δ [ppm] = 195.68 (Cquat, CS), 180.74 (Cquat, C-4), 
148.93 (Cquat, Ph-C-4’), 142.62 (Cquat, Ph-C-1’’), 134.53 (Cquat, indazole-C), 133.54 (+, Ar-
C-3’’’), 129.68 (+, Ph-C-2’,6’), 129.28 (Cquat, Ph-C-3’,5’), 127.99 (Cquat, indazole-C), 127.80 
(+, Ph-C-2’’,6’’), 125.30 (+, Ph-C-3’’,5’’), 125.12 (Cquat, indazole-C), 123.32 (Cquat, Ph-C-
4’’), 122.59 (Cquat, Ph-C-1’), 121.50 (+, Ar-C-4’’’), 118.53 (+, Ar-C-5’’’), 108.67 (+, Ar-C-
7’’’), 74.17 (Cquat, C-5), 44.93 (-, NHCH2-p-C6H4-CF3), 19.88 (+, CH3-5). MS (CI-MS) m/z 
(rel. int. in %) = 608.0 (10), 607.0 (30), 604.9 ([M + H + MeCN]+, 40), 565.9 (75), 563.9 ([M 
+ H]+, 100). HRMS (ESI-MS) m/z calcd. [M + H]+ 564.0634, found [M + H]+ 564.0635. 
C25H18Cl2F3N5OS (Mr = 564.41 g/mol). 
 
4-[1-(3-Hydroxy-4-methoxyphenyl)-5-methyl-4-(4-methylbenzylamino)-2-thioxo-2,5-
dihydro-1H-imidazol-5-yl]benzoic acid (5.67) 
The title compound was prepared from 4-acetylbenzoic acid (0.8 mmol, 131 mg), 5-amino-
2-methoxyphenol (0.8 mmol, 111 mg) and 1-(isocyanomethyl)-4-methylbenzene (0.8 
mmol, 105 mg) according to method B of the general procedure. The crude product was 
obtained as residue after evaporation (ethyl acetate), and gave brown solid, which was 
subjected to RP-HPLC (Table 5.19, method 2). Yield (crude product): 265 mg, 70 %; yield 
(preparative HPLC): yellow solid, 11.1 mg, 2.9 %. 1H-NMR (600 MHz, DMSO-d6): δ [ppm] 
= 8.98 (t, J = 5.9 Hz, 1H, NHCH2-p-C6H4-CH3), 7.95 (d, J = 8.5 Hz, 2H, Ph-H-3’’’,5’’’), 7.28 
(d, J = 8.5 Hz, 2H, Ph-H-2’’’,6’’’), 7.11 (q, J = 8.3 Hz, 4H, Ph-H-2’’,6’’, Ph-H-3’’,5’’), 6.75 (d, 
J = 8.7 Hz, 1H, Ph-H-5’), 6.19 (d, J = 2.5 Hz, 1H, Ph-H-2’), 6.11 (dd, J = 8.6, 2.5 Hz, 1H, 
Ph-H-6’), 4.59 – 4.45 (m, 2H, NHCH2-p-C6H4-CH3), 3.69 (s, 3H, OCH3-4’’’), 2.26 (s, 3H, 
NHCH2-p-C6H4-CH3), 1.77 (s, 3H, CH3-5). 
13C-NMR (151 MHz, DMSO-d6): δ [ppm] = 
195.59 (Cquat, CS), 180.01 (Cquat, C-4), 166.85 (Cquat, Ph-COOH), 147.26 (Cquat, Ph-C-4’), 
146.06 (Cquat, Ph-C-3’), 141.94 (Cquat, Ph-C-4’’’), 136.39 (Cquat, Ph-C-1’’), 134.73 (Cquat, Ph-
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C-4’’), 131.08 (Cquat, Ph-C-1’’’), 129.64 (+, Ph-C-3’’’,5’’’), 128.83 (+, Ph-C-2’’,6’’), 128.65 
(Cquat, Ph-C-1’), 127.23 (+, Ph-C-3’’,5’’), 126.91 (+, Ph-C-2’’’,6’’’), 120.17 (+, Ph-C-6’), 
116.95 (+, Ph-C-2’), 111.44 (+, Ph-C-5’), 73.50 (Cquat, C-5), 55.44 (+, OCH3-4’), 45.20 (-, 
NHCH2-p-C6H4-CH3), 20.64 (+, NHCH2-p-C6H4-CH3), 19.88 (+, CH3-5). MS (CI-MS) m/z 
(rel. int. in %) = 517.0 ([M + H + MeCN]+, 10), 478.0 (10), 477.0 (30), 475.9 ([M + H]+, 
100). HRMS (ESI-MS) m/z calcd. [M + H]+ 476.1639, found [M + H]+ 476.1642. 
C26H25N3O4S (Mr = 475.56 g/mol). 
 
4-[4-(4-Chlorobenzylamino)-1-(3-hydroxy-4-methoxyphenyl)-5-methyl-2-thioxo-2,5-
dihydro-1H-imidazol-5-yl]benzoic acid (5.68) 
The title compound was prepared from 4-acetylbenzoic acid (0.8 mmol, 131 mg), 5-amino-
2-methoxyphenol (0.8 mmol, 111 mg) and 1-chloro-4-(isocyanomethyl)benzene (0.8 
mmol, 121 mg) according to method B of the general procedure. The crude product was 
obtained as residue after evaporation (ethyl acetate), and gave a brown solid, which was 
subjected to RP-HPLC (Table 5.19, method 2). Yield (crude product): 280 mg, 71 %; yield 
(preparative HPLC): gray solid, 11.3 mg, 2.8 %. 1H-NMR (600 MHz, DMSO-d6): δ [ppm] = 
9.02 (t, J = 5.9 Hz, 1H, NHCH2-p-C6H4-Cl), 7.96 (d, J = 8.5 Hz, 2H, Ph-H-3’’’,5’’’), 7.42 – 
7.38 (m, 2H, Ph-H-3’’,5’’), 7.28 (d, J = 8.5 Hz, 2H, Ph-H-2’’’,6’’’), 7.25 (d, J = 8.4 Hz, 2H, 
Ph-H-2’’,6’’), 6.75 (d, J = 8.7 Hz, 1H, Ph-H-5’), 6.18 (d, J = 2.5 Hz, 1H, Ph-H-2’), 6.11 (dd, 
J = 8.6, 2.4 Hz, 1H, Ph-H-6’), 4.54 (qt, J = 21.4, 10.8 Hz, 2H, NHCH2-p-C6H4-Cl), 3.69 (s, 
3H, OCH3-4’’’), 1.77 (s, 3H, CH3-5). 
13C-NMR (151 MHz, DMSO-d6): δ [ppm] = 195.51 
(Cquat, CS), 180.12 (Cquat, C-4), 166.89 (Cquat, Ph-COOH), 147.29 (Cquat, Ph-C-4’), 146.07 
(Cquat, Ph-C-3’), 141.66 (Cquat, Ph-C-4’’’), 136.89 (Cquat, Ph-C-1’’), 131.82 (Cquat, Ph-C-4’’), 
129.71 (+, Ph-C-3’’’,5’’’), 129.53 (Cquat, Ph-C-1’), 129.14 (+, Ph-C-2’’,6’’), 128.39 (+, Ph-C-
3’’,5’’), 127.92 (Cquat, Ph-C-1’’’), 126.85 (+, Ph-C-2’’’,6’’’), 120.16 (+, Ph-C-6’), 116.92 (+, 
Ph-C-2’), 111.46 (+, Ph-C-5’), 73.58 (Cquat, C-5), 55.45 (+, OCH3-4’), 44.71 (-, NHCH2-p-
C6H4-Cl), 19.88 (+, CH3-5). MS (CI-MS) m/z (rel. int. in %) = 536.9 ([M + H + MeCN]
+, 10), 
497.9 (40), 496.0 ([M + H]+, 100). HRMS (ESI-MS) m/z calcd. [M + H]+ 496.1092, found 
[M + H]+ 496.1093. C25H22ClN3O4S (Mr = 495.98 g/mol). 
 
4-{5-Methyl-1-phenyl-2-thioxo-4-[4-(trifluoromethyl)benzylamino]-2,5-dihydro-1H-
imidazol-5-yl}benzoic acid (5.69) 
The title compound was prepared from 4-acetylbenzoic acid (0.8 mmol, 128 mg), aniline 
(0.8 mmol, 75 mg) and 1-(isocyanomethyl)-4-(trifluoromethyl)benzene (0.8 mmol, 148 mg) 
according to method B of the general procedure. The crude product was obtained as 
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residue after evaporation (ethyl acetate), and gave pale brown solid, which was subjected 
to RP-HPLC (Table 5.19, method 2). Yield (crude product): 290 mg, 70 %; yield 
(preparative HPLC): yellow solid, 8.7 mg, 2.3 %. 1H-NMR (600 MHz, DMSO-d6): δ [ppm] = 
9.16 (t, J = 6.0 Hz, 1H, NHCH2-p-C6H4-CF3), 7.98 (d, J = 8.5 Hz, 2H, Ph-H-3’’’,5’’’), 7.71 
(d, J = 8.2 Hz, 2H, Ph-H-3’’,5’’), 7.44 (t, J = 10.0 Hz, 2H, Ph-H-2’’,6’’), 7.33 (d, J = 8.5 Hz, 
2H, Ph-H-2’’’,6’’’), 7.29 – 7.23 (m, 3H, Ph-H-2’,4’,6’), 6.80 – 6.75 (m, 2H, Ph-H-3’,5’), 4.73 
– 4.62 (m, 2H, NHCH2-p-C6H4-CF3), 1.83 (s, 3H, CH3-5). 
13C-NMR (151 MHz, DMSO-d6): 
δ [ppm] = 195.53 (Cquat, CS), 180.30 (Cquat, C-4), 166.77 (Cquat, Ph-COOH), 142.65 (Cquat, 
Ph-C-4’’), 141.70 (Cquat, Ph-C-4’’’), 137.04 (Cquat, Ph-C-1’), 131.19 (Cquat, Ph-C-1’’’), 129.83 
(+, Ph-C-3’’’,5’’’), 129.47 (+, Ph-C-3’,5’), 128.72 (+, Ph-C-2’,4’,6’), 127.85 (+, Ph-C-2’’,6’’), 
126.95 (+, Ph-C-2’’’,6’’’), 125.35 (+, Ph-C-3’’,5’’), 123.34 (Cquat, Ph-C-1’’), 73.81 (Cquat, C-
5), 45.01 (-, NHCH2-p-C6H4-CF3), 20.02 (+, CH3-5). MS (CI-MS) m/z (rel. int. in %) = 526.0 
(10), 525.0 ([M + H + MeCN]+, 50), 483.9 ([M + H]+, 100). HRMS (ESI-MS) m/z calcd. 
[M + H]+ 484.1301, found [M + H]+ 484.1304. C25H20F3N3O2S (Mr = 483.51 g/mol). 
 
4-[4-(4-tert-Butylbenzylamino)-5-methyl-1-phenyl-2-thioxo-2,5-dihydro-1H-imidazol-
5-yl]benzoic acid (5.70) 
The title compound was prepared from 4-acetylbenzoic acid (0.8 mmol, 131 mg), aniline 
(0.8 mmol, 75 mg) and 1-tert-butyl-4-(isocyanomethyl)benzene (0.8 mmol, 139 mg) 
according to method B of the general procedure. The crude product was obtained as 
residue after evaporation (ethyl acetate), and gave yellow solid, which was subjected to 
RP-HPLC (Table 5.19, method 2). Yield (crude product): 290 mg, 70 %; yield (preparative 
HPLC): pale yellow solid, 8.7 mg, 2.3 %. 1H-NMR (600 MHz, DMSO-d6): δ [ppm] = 9.04 (t, 
J = 5.8 Hz, 1H, NHCH2-p-C6H4-C(CH3)3), 7.97 (t, J = 6.4 Hz, 2H, Ph-H-3’’’,5’’’), 7.36 – 7.33 
(m, 2H, Ph-H-2’’,6’’), 7.31 (d, J = 8.5 Hz, 2H, Ph-H-2’’’,6’’’), 7.26 – 7.23 (m, 3H, Ph-H-
3’,4’,5’), 7.16 (t, J = 8.7 Hz, 2H, Ph-H-3’’,5’’), 6.79 – 6.76 (m, 2H, Ph-H-2’,6’), 4.62 – 4.47 
(m, 2H, NHCH2-p-C6H4-C(CH3)3), 1.81 (s, 3H, CH3-5), 1.25 (s, 9H, C(CH3)3). 
13C-NMR 
(151 MHz, DMSO-d6): δ [ppm] = 195.58 (Cquat, CS), 180.07 (Cquat, C-4), 166.81 (Cquat, Ph-
COOH), 149.75 (Cquat, Ph-C-4’’), 141.87 (Cquat, Ph-C-4’’’), 137.12 (Cquat, Ph-C-1’), 134.55 
(Cquat, Ph-C-1’’), 131.22 (Cquat, Ph-C-1’’’), 129.73 (+, Ph-C-3’’’,5’’’), 129.50 (+, Ph-C-2’,6’), 
127.81 (+, Ph-C-3’,4’,5’), 127.12 (+, Ph-C-3’’,5’’), 126.94 (+, Ph-C-2’’’,6’’’), 125.17 (+, Ph-
C-2’’,6’’), 73.70 (Cquat, C-5), 45.33 (-, NHCH2-p-C6H4-C(CH3)3), 34.19 (Cquat, C(CH3)3), 
31.19 (+, C(CH3)3), 19.99 (+, CH3-5). MS (CI-MS) m/z (rel. int. in %) = 513.0 ([M + H + 
MeCN]+, 10), 474.1 (10), 473.0 (30), 472.0 ([M + H]+, 100). HRMS (ESI-MS) m/z calcd. 
[M + H]+ 472.2053, found [M + H]+ 472.2055. C28H29N3O2S (Mr = 471.61 g/mol). 
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5.8.2.6 Preparation of the compounds 5.81-5.83 
4-[4-(Benzylamino)-1-(3,5-dichloro-4-hydroxyphenyl)-2-thioxo-2,5-dihydro-1H-
imidazol-5-yl]benzoic acid (5.81) 
The title compound was prepared from 4-formylbenzoic acid (0.8 mmol, 120 mg) and 4-
amino-2,6-dichlorophenol (0.8 mmol, 142 mg) in 8 mL anhydrous MeOH under an 
atmosphere of nitrogen in a septum-equipped glass vessel. The solution was stirred for 1 
h at room temperature and was subsequently cooled to 0 °C. After the addition of KSCN 
(4 eq) and pyridinium chloride (4 eq) the mixture was bubbled with argon and evacuated. 
(Isocyanomethyl)benzene (0.8 mmol, 94 mg) was added with a syringe, and the mixture 
was stirred at ambient temperature overnight. For mass spectral analysis a sample from 
the supernatant (10 µL diluted with 990 µL MeOH) was subjected to LC-MS. According to 
this procedure, the crude product was analyzed 2 h and 72 h, respectively, after the 
completion of the experiment. 
 
LC-MS analysis (parameters cf. Table 5.17) 2 h after completion of the experiment is 
illustrated in Figure 5.48.  
  
  
  
Figure 5.48 LC-MS analysis of 5.81 recorded 2 hours after completion of the experiment. Counts vs. 
acquisition time plot and counts vs. mass-to-charge plot of “compound 1” (5.81 ([M + H]
+
)) shown on the left; 
counts vs. acquisition time plot and counts vs. mass-to-charge plot of “compound 2” (5.81, {[M + H]
+
 + 16}) 
indicated on the right; LC-MS column: Zorbax Eclipse Plus C18 Rapid Solution HD (Agilent Technologies, 
Santa Clara, USA). 
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The counts vs. acquisition time plot indicated a single peak (tR = 2.7583 min). The 
corresponding counts vs. mass-to-charge (m/z) plot displayed a mass of 486.0443 g/mol 
(“compound 1”, 5.81 ([M + H]+)) as predominant species. The signal for the C-5 
hydroxylated species (“compound 2”, 5.81 ({[M + H]+ +16})) was not detected. 
LC-MS analysis (parameters cf. Table 5.18) 72 h after completion of the experiment is 
illustrated in Figure 5.49. 
  
  
  
Figure 5.49 LC-MS analysis of 5.81 recorded 72 hours after completion of the experiment. Counts vs. 
acquisition time plot and counts vs. mass-to-charge plot of “compound 1” (5.81, ([M + H]
+
)) shown on the left; 
counts vs. acquisition time plot and counts vs. mass-to-charge plot of “compound 2” (5.81, {[M + H]
+
 + 16}) 
indicated on the right; LC-MS column: Accucore aQ (Thermo Scientific, Santa Clara, USA). 
 
The counts vs. acquisition time plot indicated a double-peak (tR = 2.5027 min, 2.6116 
min). The corresponding counts vs. mass-to-charge (m/z) plot displayed a mass of 
486.0443 g/mol (“compound 1”, 5.81 ([M + H]+)) and a mass of 502.0396 g/mol 
(“compound 2”, 5.81 ({[M + H]+ +16})). 
 
4-[4-(Benzylamino)-1-(3,5-dichloro-4-hydroxyphenyl)-5-hydroxy-2-thioxo-2,5-
dihydro-1H-imidazol-5-yl]benzoic acid (5.82) 
The title compound was prepared from 4-formylbenzoic acid (0.8 mmol, 120 mg) and 4-
amino-2,6-dichlorophenol (0.8 mmol, 142 mg) in 8 mL anhydrous MeOH under an 
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atmosphere of nitrogen in a septum-equipped glass vessel. The solution was stirred for 1 
h at room temperature and was subsequently cooled to 0 °C. After the addition of KSCN 
(4 eq) and pyridinium chloride (4 eq) the mixture was bubbled with air. 
(Isocyanomethyl)benzene (0.8 mmol, 94 mg) was added and the mixture was stirred at 
ambient temperature overnight. For mass spectral analysis a sample from the supernatant 
(10 µL diluted with 990 µL MeOH) was subjected to LC-MS. Following this method, the 
crude product was analyzed 2 h and 72 h, respectively, after the completion of the 
experiment. 
LC-MS analysis (parameters cf. Table 5.17) 2 h after completion of the experiment is 
illustrated in Figure 5.50. 
  
  
Figure 5.50 LC-MS analysis of 5.82 recorded 2 hours after completion of the experiment. “Compound 1” (5.82, 
([M + H]
+
)) non-existent; counts vs. acquisition time plot of “compound 2” (5.82, {[M + H]
+
 + 16}) indicated on 
the left, counts vs. mass-to-charge plot of “compound 2” indicated on the right; LC-MS column: Zorbax Eclipse 
Plus C18 Rapid Solution HD (Agilent Technologies, Santa Clara, USA). 
 
The counts vs. acquisition time plot indicated a single peak (tR = 2.6526 min). The 
corresponding counts vs. mass-to-charge (m/z) plot displayed only a mass of 502.0396 
g/mol (“compound 2”, 5.82 ({[M + H]+ +16})). 
 
 
 
 
 
156 Experimental section  
LC-MS analysis (parameters cf. Table 5.18) 72 h after completion of the experiment is 
illustrated in Figure 5.51. 
  
  
Figure 5.51 LC-MS analysis of 5.82 recorded 72 hours after completion of the experiment. “Compound 1” 
(5.82, ([M + H]
+
)) non-existent; counts vs. acquisition time plot of “compound 2” (5.82, {[M + H]
+
 + 16}) (M: 
non-existent); counts vs. mass-to-charge plot of “compound 2” indicated on the right; LC-MS column: 
Accucore aQ (Thermo Scientific, Santa Clara, USA). 
 
The counts vs. acquisition time plot indicated a single peak (tR = 2.5006 min). The 
corresponding counts vs. mass-to-charge (m/z) plot displayed a mass of 502.0396 g/mol 
(“compound 2”, 5.82 ({[M + H]+ +16})). 
 
4-[4-(Benzylamino)-1-(3,5-dichloro-4-hydroxyphenyl)-5-[18O]hydroxy-2-thioxo-2,5-
dihydro-1H-imidazol-5-yl]benzoic acid (5.83) 
18O2 oxygen gas was generated from H2
18O in an electrolysis apparatus (Figure 5.52).e  
e
 H2
18
O (20 mL) was a gift from G. Bernhardt, University of Regensburg 
 
 
 
 
 
 
Figure 5.52 Electrolysis apparatus 
for the generation of 
18
O2 oxygen 
gas 
 
10 mL of H2
18O were filled in an “u pipe”, which was connected (three-way valves) to gas 
syringes. Six drops of concentrated sulfuric acid were added to H2
18O. Platinum 
electrodes were assembled to both sides of the u pipe and hermetically sealed. 
Subsequently, the apparatus was purged with argon. Platinum electrodes were connected 
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to direct-current (14 V). During electrolysis (3 hours), a total volume of 30 mL of 18O2 
oxygen gas was collected in the gas syringe next to positive electrode (anode). Hydrogen 
gas was collected in the opposite syringe. The 18O2 oxygen gas fraction was transferred to 
an aerostat and instantly used for the experiment. 
The title compound was prepared from 4-formylbenzoic acid (0.8 mmol, 120 mg) and 4-
amino-2,6-dichlorophenol (0.8 mmol, 142 mg) in 8 mL anhydrous MeOH under an 
atmosphere of nitrogen in a septum-equipped glass vessel. The solution was stirred for 1 
h at room temperature and was subsequently cooled to 0 °C. After addition of KSCN (4 
eq) and pyridinium chloride (4 eq) the mixture was bubbled with argon and evacuated. A 
portion of 18O2 (30 mL, 2.4 mmol) was added to the glass vessel. 
(Isocyanomethyl)benzene (0.8 mmol, 94 mg) was added with a syringe and the mixture 
was stirred at ambient temperature overnight. For mass spectral analysis a sample from 
the supernatant (10 µL diluted with 990 µL MeOH) was subjected to LC-MS. Following 
this method, the crude product was analyzed 2 h and 72 h, respectively, after the 
completion of the experiment. 
LC-MS analysis (parameters cf. Table 5.17) 2 h after completion of the experiment is 
illustrated in Figure 5.53. 
  
  
  
Figure 5.53 LC-MS analysis of 5.83 recorded 2 hours after completion of the experiment. Counts vs. 
acquisition time plot and counts vs. mass-to-charge plot of “compound 1” (5.83, ([M + H]
+
) shown on the left 
(detection exclusively of “compound 2”); counts vs. acquisition plot and counts vs. mass-to-charge plot of 
“compound 2” (5.83, {[M + H]
+
 + 18}) indicated on the right; LC-MS column: Zorbax Eclipse Plus C18 Rapid 
Solution HD (Agilent Technologies, Santa Clara, USA). 
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The counts vs. acquisition time plot indicated a single peak (tR = 2.6398 min). The 
corresponding counts vs. mass-to-charge (m/z) plot displayed a mass of 504.0416 g/mol 
(“compound 2”, 5.83 ({[M + H]+ +18})). 
LC-MS analysis (parameters cf. Table 5.18) 72 h after completion of the experiment is 
illustrated in Figure 5.54. 
  
  
  
Figure 5.54 LC-MS analysis of 5.83 recorded 72 hours after completion of the experiment. Counts vs. 
acquisition time plot and counts vs. mass-to-charge plot of “compound 1” (5.83, ([M + H]
+
) shown on the left 
(detection exclusively of “compound 2”); counts vs. acquisition plot and counts vs. mass-to-charge plot of 
“compound 2” (5.83, {[M + H]
+
 + 18}) indicated on the right; LC-MS column: Accucore aQ (Thermo Scientific, 
Santa Clara, USA). 
 
The counts vs. acquisition time plot indicated a single peak (tR = 2.5020 min). The 
corresponding counts vs. mass-to-charge (m/z) displayed a mass of 504.0416 g/mol 
(“compound 2”, 5.83 ({[M + H]+ +18})). 
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6 Screening of 3-amino substituted imidazo 
[1,2-a]pyridines for the inhibition of 
streptococcal hyaluronidases 
  
166 Introduction  
6.1 Introduction 
Previously, hydroxylated 2-phenylindoles have been identified as inhibitors of 
streptococcal hyaluronidases.1 Besides, moderate inhibition was observed for some 
related benzimidazole derivatives bearing a similar substitution pattern.2 In Figure 6.1 
structures and SagHyal4755 inhibitory activities of representative hydroxylated 2-
phenylindoles (1, 2, 4, 5) and 2-phenylbenzimidazoles (3, 6) are summarized. Chloro 
substituents (cf. 2, 5) were found to enhance the biological activity of phenylindoles. 
Similarly, in the benzimidazole series, hyaluronidase inhibiton correlated with lipophilicity 
(cf. 3, 6). 
 
Figure 6.1 Structures of selected hydroxlated 2-phenylindoles (1, 2, 4, 5) and 2-phenylbenzimidazoles (3, 6) 
with inhibitory activity on SagHyal4755. 
 
These findings motivated us to explore novel heterocycles as hyaluronidase inhibitors. 
Only molecules accessible by multicomponent synthesis were taken into account. 
Moreover, the designed substances should possess drug-like properties. Under these 
premisses, imidazo[1,2-a]pyridines were selected as novel structural motifs. 
The structural motif of imidazo[1,2-a]pyridine can be found in a broad variety of 
biologically active compounds, including drugs for the treatment of gastric disorders3, 4, 
viral diseases5-8 and bacterial infections.9, 10 The imidazopyridine-type drug zolpidem is 
used as a medication for insomnia. In addition, the closely related heterocyclic substances 
alpidem, necopidem and saripidem demonstrate the importance of this structural moiety 
(Figure 6.2). 
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Figure 6.2 Structures of zolpidem, alpidem, necopidem and saripidem. 
 
Aiming at lyase inhibitors with improved drug-like properties, two different strategies were 
pursued. For the first approach, the focus was set on computer-assisted drug-design 
accompanied with multicomponent reaction synthesis of compound libraries. The 
evaluation of these compounds was performed according to electronic similarity. 
In a second approach, the imidazo[1,2-a]pyridine scaffold was maintained. In contrast to 
the previous strategy, the selection of starting materials was primarily based on 
experience and rational decision. To avoid the synthesis of unsuitable compounds, it 
became necessary to carefully analyze the chemical properties, for example lipophilicity. 
To estimate appropriate substituents, a series of structurally related heterocyles was 
considered. As shown Figure 6.3, correlating 2-phenylindoles (7a-d), 2-
phenylbenzimidazoles (8a-d) and 3-amino substituted 2-phenylimidazo[1,2-a]pyridines 
(9a-d) were tabulated and compared based on logD5.0 values. All compounds were 
virtually substituted with conserved residues (chlorine, pentyl) to increase logD5.0 values 
(Figure 6.3.). 
 
Figure 6.3 Arrangement of in silico designed and analyzed heterocycles bearing indole, benzimidazole and 
imidazo[1,2a]pyridine scaffold. 
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6.2 Chemistry 
For the first screening campaign, the reaction of aminopyridines 10, aldehydes 11 and 
isocyanides 12 was utilized for the construction of a series of 3-amino substituted 2-
phenylimidazo[1,2-a]pyridines of general structure 13 (c.f. Figure 6.4). 
 
Figure 6.4 General synthesis (multicomponent synthesis) of 3-amino substituted imidazo[1,2-a]pyridines (13). 
Reagents and conditions: anhydrous EtOH, (cat.) acetic acid, 48 h, rt. 
 
According to the method described by Groebke et al., target molecules were available 
from one-pot three component condensation.11 In parallel synthesis, aminopyridines and 
aldehydes were dissolved in anhydrous methanol and transformed to 96-deep well plates 
with an automated liquid handling system. After the generation of the corresponding imine 
species, isocyanides and a catalytic amount of acetic acid were added. The mixture was 
allowed to react for 48 hours at ambient temperature to give the target molecules. 
A selection of 26 aminopyridines, 27 aldehydes and 20 isocyanides was used to set up a 
library of 792 3-amino substituted imidazo[1,2-a]pyridines (ori.hya.1-9). All starting 
materials were commercially available chemicals. After HPLC mass spectral analysis 
(ESI-TOF), the solvent was evaporated and the crude substances were dispensed in 
DMSO, adjusting a concentration of 20 mM. Deep-well plates were sealed and stored at -
20 °C. For biological tests, the compounds were diluted and transferred by an automated 
system to 96-well screening plates. Starting materials and mass spectral analysis for 
compounds of plates ori.hya.1-9 are shown in section B.2 (appendix II). 
By analogy with the protocol shown in Figure 6.4, 3-amino substituted 2-
phenylimidazo[1,2-a]pyridines were synthesized in a second screening campaign. The 
corresponding starting materials are shown in Figure 6.5. A screening library of 560 
substances was obtained by combinatorial variation of 11 aminopyridines, 13 aldehydes 
and 35 isocyanides (ori.hya.48-54). Details for mass spectral analysis of the 
corresponding compounds are given in section B.7 (appendix II). 
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Figure 6.5 Aminopyridines 10{1}-{11}, aldehydes 11{1}-{13} and isocyanides 12{1}-{35} used to construct a 
library of 560 potential hyaluronidase inhibitors. 
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160 compounds were synthesized on plates ori.hya.48, 49. Aminopyridines 10{1}-{4}, 
aldehydes 11{1}-{2} and isocyanides 12{1}-{20} served as starting materials. A 
combination of 6-aminopyridin-3-ol 10{1} with aldehydes 11{1}, {2} was superior to the 
comparable aminopyridines 10{1}, {2}, {4}. The latter showed no conversion to the target 
molecules. No reaction was observed for isocyanides 12{9}, {11}. 
A matrix of 240 compounds was used for the miniaturized synthesis performed on plates 
ori.hya.50-52. Aminoyridines 10{5}-{10}, hydroxylated aldehydes 11{2}-{10} and 
isocyanides 12{1}, {2}, {4}, {6}, {15} served as starting materials. The reaction worked well. 
Merely, when 10{10} and 11{6} were used as starting materials, a significant lower 
occurrence of the target molecules was observed. 
The synthesis of an ensemble of 160 compounds was performed on screening plates 
ori.hya.53, 54 by variation of aminopyridines 10{5}-{10}, aldehydes 11{2}, {11}-{13} and 
isocyanides 12{1}, {2}, {4}, {11}, {15}, {21}-{35}. The usage of 12{21}, {34} and 12{28}, 
{29}, {32}, {33} as starting material gave either low or no conversion to the products. 
In total, 1352 3-amino substituted imidazo[1,2-a]pyridines were synthesized in both 
campaigns. The substances were synthesized by one-pot reactions on a miniaturized 
scale in 96 deep-well plates. 
 
6.3 Pharmacological results and discussion 
6.3.1 General conditions and screening mode 
Cf. section 5.3.1 
 
6.3.2 Inhibitory activities of screening compounds on 
SagHyal4755 
Among the tested 1352 3-amino substituted 2-phenylimidazo[1,2-a]pyridines, four 
compounds (6.1-6.4) were identified as screening hits. Referred to the size of the 
substance library, this equals a hit rate of 0.3 %. In appendix II, a detailed on-screen 
assay validation (cf. sections B.8.1, B.8.4) and representation of screening data (cf. 
sections B.9.2, B.9.5) is given. Chemical structures of identified hits (6.1-6.4) are shown in 
Figure 6.6. 
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Figure 6.6 Structures of identified screening hits 6.1-6.4. 
 
At this stage, the criteria to denote a compound as hit (inhibitory effect > 50 %, weighted 
effect ≥ 1 (cf. section 4.3.2)) were loosened to some extent (inhibitory effect 20 % - 50 %, 
weighted effect ≥ 1). Accordingly, 4 additional substances (6.5-6.8, Figure 6.7) with 
certified mass were pharmacologically characterized. These molecules were investigated 
to gain new ideas for novel inhibitors. 
 
Figure 6.7 Structures of additional compounds of the screening campaign displaying inhibitory activity 
between 20 % and 50 % (6.5-6.8). 
 
The inhibitory activities of compounds 6.1-6.8 are summarized in Table 5.1. 
Table 6.1 Inhibitory activities of compounds 6.1-6.8 on SagHyal4755, BTH and SpnHyl. 
Compound SagHyal4755 
IC50 (µM)
a
 
BTH 
% inhibition 
SpnHyl 
IC50 (µM)
a
 
Comment 
6.1 67 ± 5 inactive 90 ± 13 hit 
6.2 59 ± 5 inactive 99 ± 11 hit 
6.3 62 ± 4 inactive 95 ± 15 hit 
6.4 99 ± 1 inactive 7 ± 1 hit 
6.5 73 ± 7 inactive 21 ± 1 missed hit criteria 
6.6 99 ± 2 inactive 8 ± 0.3 missed hit criteria 
6.7 99 ± 6 inactive inactive missed hit criteria 
6.8 97 ± 11 inactive inactive missed hit criteria 
a
 mean values SEM (N = 2, experiments performed in duplicate); IC50 values determined at pH 5.0 in the 96-
well turbidimetric assay. 
 
The values determined for SagHyal4755 were compared to screening data on SpnHyl (data 
provided by Dr. J. Hamberger from our workgroup).12 For the SpnHyl screening campaign 
the assay parameters (ingredients, pH, microtiter plates, incubation time) were not 
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modified or changed. In addition, compounds 6.1-6.8 were tested on the mammalian 
hyaluronidase BTH. 
Screening hits 6.1 and 6.8 were subjected to preparative synthesis and were retested as 
purified compounds on SagHyal4755 using the turbidimetric assay. The compounds 
showed IC50 values of 630 µM (6.1) and 255 µM (6.8), respectively (Figure 6.8).  
log c
-4,8 -4,6 -4,4 -4,2 -4,0 -3,8 -3,6 -3,4 -3,2 -3,0 -2,8
e
n
zy
m
a
ti
c
 a
c
ti
vi
ty
 (
%
)
0
20
40
60
80
100
6.1
6.8
 
 
 
Figure 6.8 Concentration dependant inhibition of SagHyal4755 by 6.1 and 6.8. 
 
The results on the purified compounds 6.1 and 6.8 did not support the screening results, 
which suggested higher inhibitory potency for both compounds at SagHyal4755 and in 
particular at SpnHyl (cf. Table 5.1). According to the screening data, the inhibitory activity 
on SpnHyl appeared to be even higher. In the case of 6.1, most likely, the aldehyde 
(2,4,5-trihydroxybenzaldehyde) was responsible for this result, as similar discrepencies 
were observed before for screening compounds, bearing trihydroxylated groups. Most 
likely, substances 6.2 and 6.3, bearing an identical moiety, show the same phenomenon. 
In the case of 6.8, at least a lower difference between the results of the screening data 
and the testing of the purified substance was observed. False positive results became not 
obvious in case of other dihydroxylated compounds. Substances 6.4 and 6.6 pretend 
strong inhibition of SagHyal4755 but were found almost inactive on SpnHyl. To corroborate 
these results, the molecules should be synthesized in pure form.. Compounds bearing 
aromatic or heterocyclic residues in position 3 were not among the screening hits, except 
for 6.5, which showed moderate inhibition on SagHyal4755 (IC50 = 73 µM) and SpnHyl 
(IC50 = 21 µM). 
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6.4 Outlook 
For multicomponent synthesis, additional structural modifications of imidazopyridines as 
potential hyaluronidase inhibitors could be suggested. The concepts (concept 1, 
concept 2) were drafted in Figure 6.9. 
 
Figure 6.9 Proposed multicomponent synthesis of additional 3-amino substituted imidazo[1,2a]pyridines. 
 
Here, the introduction of a carboxylic moiety is recommended, either attached to the 
aminopyridine (concept 1) or to the aldehyde building block (concept 2). Synthesis of 
structurally related compounds was recently reported in literature.13-15 Eventually, this may 
promote the discovery of additional inhibitors of SagHyal4755. 
 
6.5 Summary 
3-Amino substituted imidazo[1,2a]pyridines were designed, synthesized in parallel and 
tested for the first time for inhibition of the bacterial hyaluronidase SagHyal4755. The 
achievement of drug-like properties was a key demand for the design and synthesis of 
imidazopyridines described in this chapter. Hence, the considered substances were 
predicted to be in accordance to criteria of druglikeness e.g. Lipinski’s rule of five. As 
lipophilicity was taken into account, plasma protein binding, which was found to be very 
high for previously sythesized hyaluronidase, inhibitors might be reduced. 
In two screening campaigns a total of 1352 3-amino substituted 2-phenylimidazo[1,2-
a]pyridines was prepared via multicomponent reactions. Four molecules were identified as 
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screening hits, with highest inhibitory activities residing in screening compounds 6.1 (67 % 
inhibition) and 6.4 (99 % inhibition). 
However, re-investigation of the purified compounds 6.1 and 6.8 did not confirm the 
inhibitory potency of the screening hits. In the case of 6.1 (IC50 = 630 µM) the discrepancy 
between screening of the mixture from the microtiter plates and the investigation of the 
pure compound appears to be associated with the presence of a trihydroxylated phenyl 
moiety. For 6.8, the purified compound had an IC50 value of 255 µM corresponding to 
moderate inhibition of the target enzyme.  
Taken together, the concept of molecular modeling, rational scaffold-orientated design 
and synthesis of hyaluronidase inhibitors led to new chemical entities, which were 
biologically active under assay conditions. This is supported by the results of 
investigations on SpnHyl, where other imidazopyridines were recently identified as 
screening hits.12 Further investigations with purified 3-amino-substituted 
imidazo[1,2a]pyridines, including studies on SpnHyl and plasma protein binding, have to 
be performed to substantiate the results and to prove the working hypothesis.  
 
6.6 Experimental section 
6.6.1 General conditions 
Cf. section 5.8.1 
 
6.6.2 Chemistry 
6.6.2.1 Parallel synthesis 
6.6.2.1.1 General conditions 
Cf. section 5.8.2.1.1 
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6.6.2.1.2 Preparation of 3-aminoimidazo[1,2a]pyridines (ori.hya.1-9, 48-54) 
Aminopyridines (0.2 M, 50 µL, 1 eq) in anhydrous MeOH) were dispensed on 96 deep-
well plates, the pertinent aldehydes (0.2 M, 50 µL, 1 eq) in anhydrous MeOH and 10 µL of 
acetic acid were added. The plates were stacked for 30 min at ambient temperature, 
before the isocyanides (0.3 M, 50 µL, 1.5 eq) in anhydrous MeOH were added. The well 
plates were sealed and stored for 48 h at room temperature. The solvent was evaporated 
and 500 µL of DMSO were added to adjust to a theoretical concentration of 20 mM. 
 
6.6.2.2 Preparation of the compounds 6.1, 6.8 
5-[3-(tert-Butylamino)-6-fluoroimidazo[1,2-a]pyridin-2-yl]benzene-1,2,4-triol (6.1) 
The title compound was prepared by analogy with the procedure described in 6.6.2.1.2 
using 5-fluoropyridin-2-amine (1 mmol, 114 mg), 2,4,5-trihydroxybenzaldehyde (1 mmol, 
154 mg), 100 µL of acetic acid in 6 mL of anhydrous MeOH. 2-Isocyano-2-methylpropane 
(1.5 mmol, 125 mg) was added subsequently. The crude product was subjected to 
automated flash-chromatography (column: SF10-4g, UV detection: 254 nm, DCM/MeOH 
98/2 v/v) to yield an orange solid (90 mg, 27 %). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 
8.52 (dd, J = 4.4, 2.2 Hz, 1H, Ar-H), 8.01 (d, J = 8.4 Hz, 1H, Ar-H), 7.30 (dd, J = 9.8, 2.4 
Hz, 1H, Ar-H), 6.29 (dd, J = 8.7, 2.4 Hz, 1H, Ar-H), 6.21 (d, J = 2.4 Hz, 1H, Ar-H), 3.34 (s, 
1H, NHC(CH3)3), 1.29 (s, 9H, NHC(CH3)3). 
13C-NMR (75 MHz, CDCl3): δ [ppm] = 157.87 
(Cquat, Ar-C), 157.70 (Cquat, Ar-C), 154.23 (Cquat, Ar-C), 151.10 (Cquat, Ar-C), 141.25 (Cquat, 
Ar-C), 136.69 (Cquat, Ar-C), 136.60 (+, Ar-C), 128.16 (Cquat, Ar-C), 124.36 (Cquat, Ar-C), 
116.53 (+, Ar-C), 116.35 (+, Ar-C), 115.60 (+, Ar-C), 109.90 (+, Ar-C), 59.31 (Cquat, 
NHC(CH3)3), 29.49 (+, NHC(CH3)3). MS (ESI-MS, 70 eV) m/z (rel. int. in %) = 331.9 ([M
+●], 
100), 332.9 ([M + H]+, 20). C17H18FN3O3 (Mr = 331.34 g/mol). 
 
4-[6-Fluoro-3-(isopropylamino)imidazo[1,2-a]pyridin-2-yl]benzene-1,2-diol (6.8) 
The title compound was prepared according to the procedure described in 6.6.2.1.2 using 
5-fluoropyridin-2-amine (1 mmol, 114 mg), 3,4-dihydroxybenzaldehyde (1 mmol, 138 mg), 
100 µL acetic acid in 6 mL MeOH (dry). 2-Isocyanopropane (1.5 mmol, 104 mg) was 
added subsequently. The crude product was subjected to automated flash-
chromatography (column: SF10-4g, UV detection: 254 nm, DCM/MeOH 97/3 v/v) to yield 
a colorless oil (100 mg, 33 %). 1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 8.50 (dd, J = 4.4, 
2.2 Hz, 1H, Ar-H), 8.05 (d, J = 8.6 Hz, 1H, Ar-H), 7.62 (dd, J = 9.9, 4.9 Hz, 1H, Ar-H), 7.33 
(ddd, J = 9.8, 8.3, 2.4 Hz, 1H, Ar-H), 6.34 (dd, J = 8.6, 2.5 Hz, 1H, Ar-H), 6.28 (d, J = 
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2.4 Hz, 1H, Ar-H), 3.35 (s, 1H, NHCH(CH3)2), 3.26 (dq, J = 12.2, 6.2 Hz, 1H, 
NHCH(CH3)2), 1.04 (d, J = 6.3 Hz, 6H, NHCH(CH3)2). 
13C-NMR (75 MHz, DMSO-d6): 
δ [ppm] = 158.27 (Cquat, Ar-C), 157.70 (Cquat, Ar-C), 154.23 (Cquat, Ar-C), 151.10 (Cquat, Ar-
C), 136.69 (Cquat, Ar-C), 136.60 (+, Ar-C), 128.16 (Cquat, Ar-C), 124.36 (Cquat, Ar-C), 116.53 
(+, Ar-C), 116.35 (+, Ar-C), 115.95 (+, Ar-C), 115.60 (+, Ar-C), 109.90 (+, Ar-C), 48.28 (+, 
NHCH(CH3)2), 22.59 (+, NHCH(CH3)2). MS (ESI-MS, 70 eV) m/z (rel. int. in %) = 301.9 
([M+●], 100), 302.9 ([M + H]+, 25). C16H16FN3O2 (Mr = 301.32 g/mol). 
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7.1 Introduction 
Recently (2009), Girish et al. published a comprehensive, but uncritical, review on the 
biological and therapeutic perspective of inhibitors of hyaluronidases.1 According to this 
survey, inhibitors of bacterial and mammalian hyaluronidases were found among proteins, 
glycosaminoglycans, polysaccharides, fatty acids, lanostanoids, antibiotics, 
antinematodal, synthetic organic and plant derived bioactive compounds such as 
alkaloids, antioxidants, polyphenols, flavonoids, terpenoids and anti-inflammatory drugs.1 
It should be noted, that classifications as competitive or noncompetitive inhibitors as well 
as IC50 values were not given by Girish et al. for the various hyaluronidase inhibitors. 
Nevertheless, IC50 values strongly depend on the method of the assay and are often 
difficult to compare. It is documented that incubation conditions, different isoenzymes or 
enzyme concentrations, substrate concentrations or pH value can cause huge 
discrepancies between inhibitory activities determined in different laboratories. 
In search for novel lead inhibitors of the bacterial hyaluronidase SagHyal4755, some 
purported hyaluronidase inhibitors, included in the review by Girish et al., were analyzed 
in our laboratory under standardized conditions in the turbidimetric assay. In addition, 
heterocyclic compounds resembling reported inhibitors, but having a different substitution 
pattern, and newe chemical entities were investigated for their inhibitory activity on 
SagHyal4755. The compounds were also analyzed on a mammalian hyaluronidase, bovine 
testicular hyaluronidase (BTH). In this context, hyaluronidases from prokaryotes and 
mammals must be clearly distinguished, as these enzymes cleave the substrate 
hyaluronan by a different catalytic mechanism. BTH is an ortholog of the human spam 
adhesion molecule (SPAM 1), also termed PH-20. Hence, the investigation on BTH was 
regarded as an approach to evaluate potential inhibitors of the human hyaluronidase PH-
20. 
The selected compounds were small molecules. The aim was to identify substances, 
which might serve as basis for the development of drug-like inhibitors. A number of 
compounds included in this screening were previously synthesized in our workgroup. In 
many cases, these agents were initially designed to target different biomolecules. 
Accordingly, activities at biological targets other than hyaluronidases must be kept in 
mind. 
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7.2 Inhibitory activity of screening compounds 
7.2.1 Benzo[b]furane derivatives 
Braun et al. identified a number of benzoxazole-2-thiones as potent and selective 
inhibitors of the streptococcal lyase SagHyal4755. Within this series, 3-phenyl-1-(2-
thioxobenzo[d]oxazol-3(2H)-yl)propan-1-one proved to be the most potent inhibitor with an 
IC50 value of 15 µM at a pH value of 5.0.
2, 3 Disadvantage of the 3-acylbenzoxazoles was 
their limited stability against hydrolysis, resulting in N-deacylated degradation products. In 
search for bioisosteric replacements of the heterocyclic core, a number of 2-
methylbenzo[b]furanes were investigated by Braun for inhibition of SagHyal4755 activity. 
These special compounds proved to be much less potent than expected,2 however, based 
on these results, the scaffold should not yet be considered inappropriate. To elucidate the 
impact of structural modifications, a set of six benzo[b]furans (Figure 7.1) was screened 
for hyaluronidase inhibition. 
 
Figure 7.1 Structures of investigated benzo[b]furanes. 
 
The hyaluronidase inhibitory activities of compounds 1-6 are summarized in Table 7.1. 
Table 7.1 Inhibitory activity on hyaluronidases and logD5.0 values of benzo[b]furanes 1-6. 
Compound SagHyal4755 
IC50 (µM)
a
 
BTH 
IC50 (µM) 
logD5.0
b
 
1 60 ± 8 inactive 4.9 
2 73 ± 6 inactive 5.4 
3 21 ± 4 inactive 3.9 
4 120 ± 10 inactive 5.3 
5 227 ± 3 inactive 3.4 
6 9.2 ± 2 inactive 6.5 
a
 mean values ± SEM (N = 2, experiments performed in duplicate), highest concentration of the test 
compounds in the assay was 1 mM; IC50 values determined at pH 5.0 in the turbidimetric assay (cuvettes);
 
b 
calculated with ACD-Labs (Advanced Chemistry Development Inc., Toronto, Canada) product version 12.00. 
182 Inhibitory activity of screening compounds  
Previously, compounds 1-6 were synthesized in our workgroup as antiestrogens and 
investigated for estrogen receptor binding. The following substances were published 
before: 14, 5, 24, 5, 44, 65. When investigated on SagHyal4755, surprisingly, the 3-alkyl-2-(4-
hydroxyphenyl)benzofuranes 1-3 turned out to be rather potent hyaluronidase inhibitors. 
The 3-benzyl-substituted benzofurane 4 was a moderate inhibitor. Dislocation of the 4-
hydroxyphenyl moiety from position 2 to 3 (cf. 5) resulted in a decrease in inhibitory 
potency. The most potent derivative was found with 6 (IC50 = 9 µM), bearing a 6-
bromohexyl moiety. All six substances were inactive on BTH. 
In conclusion, small molecules incorporating the 2-(4-hydroxyphenyl)-benzofuran-5-ol 
motif might be regarded as promising scaffolds for the inhibition of streptococcal 
hyaluronidases. A potential binding of structurally modified inhibitors bearing a 
hydroxylated 2-phenylbenzo[b]furan motif to the estrogen receptor (ER) or cytotoxic 
effects should be kept in mind. 
 
7.2.2 Benzo[b]thiophene derivatives 
For the first time, derivatives of benzo[b]thiophenes (Figure 7.2), structural analogs of 2-
phenylindoles and 2-phenylbenzo[b]furanes, were investigated as inhibitors of bacterial 
and mammalian hyaluronidases. 
 
Figure 7.2 Structures of investigated benzo[b]thiophene-type derivatives. 
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The hyaluronidase inhibitory activities of compounds 7-14 are summarized in Table 7.2. 
Table 7.2 Inhibitory activity on hyaluronidases and logD5.0 values of benzo[b]thiophenes 7-14. 
Compound SagHyal4755 
IC50 (µM)
a
 
BTH 
IC50 (µM) 
logD5.0
b
 
7 950 inactive 3.0 
8 38 ± 2 inactive 4.8 
9 24 ± 2 inactive 4.4 
10 16 ± 1 inactive 4.9 
11 145 ± 13 inactive 4.0 
12 20 ± 4 inactive 3.9 
13 inactive inactive 5.5 
14 700 inactive 3.9 
a
 mean values ± SEM (N = 2, experiments performed in duplicate), highest concentration of the test 
compounds in the assay was 1 mM; IC50 values determined at pH 5.0 in the turbidimetric assay (cuvettes);
 
b 
calculated with ACD-Labs (Advanced Chemistry Development Inc., Toronto, Canada) product version 12.00. 
Previously, the selected compounds were synthesized in our workgroup. The 
benzothiophenes 86, 137, 147 are published and described as ligands of the estrogen 
receptor (ER).7 By analogy with the related benzo[b]furanes, the 4-hydroxyphenyl moiety 
was identified as an effective motif to gain inhibitory activity on the bacterial hyaluronate 
lyase SagHyal4755. Among the 2-(4-hydroxyphenyl)benzo[b]furanes, the lipophilic 
compounds 9 (IC50 = 24 µM, logD5.0 = 4.4) and 10 (IC50 = 16 µM, logD5.0 = 4.9) were most 
active. With a 4-hydroxyphenyl group attached to position 3, best results were obtained for 
substance 12 with an IC50 value of 20 µM (logD5.0 = 3.9). Interestingly, the introduction of 
alkyl spacers (cf. 13, 14) resulted in a (total) loss of inhibition. None of these compounds 
inhibited the activity of the mammalian hyaluronidase BTH. Single crystals of 10, suitable 
for X-ray diffraction studies, were grown by evaporation of the solvent (anhydrous 
methanol). The packing arrangement of a single crystalline phase contained symmetric 
dimers in which two molecules were present. To illustrate the configuration, an ORTEP-
style plot and labeling scheme of 10 is given in Figure 7.3. 
 
Figure 7.3 Molecular structure (ORTEP-style) of 10 including atomic numbering scheme. 
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Experimental details (crystal data and structure refinement) including atomic coordinates, 
bond lengths and angles, anisotropic displacement parameters, hydrogen coordinates, 
torsion angles and hydrogen bonds are given in section A.3.2 (appendix I). The molecular 
structure of 10 shows the planar geometry of the benzo[b]thiophen scaffold with C(7)-S(1)-
C(10)-C(11) lying in plane. The torsion angle between the phenyl residue and the thiophene 
moiety along C(5)-C(4)-C(7)-C(8) is at 122.3 °. 
It is noteworthy that small molecules incorporating the 2-(4-hydroxyphenyl)benzothiophen-
5-ol motif are among the most promising scaffolds for the inhibition of streptococcal 
hyaluronidase identified so far. Potential binding of hydroxylated 2-phenyl-
benzo[b]thiophenes to the estrogen receptor (ER) or cytotoxic effects should be kept in 
mind. 
 
7.2.3 Benzimidazole derivatives 
Benzimidazole-type substances were shown as inhibitors for the hyaluronate lyase from 
S. agalactiae strain 4755 (SagHyal4755).
2, 3 The compounds are selective for the bacterial 
enzyme, whereas bovine testicular hyaluronidase was not affected.2 Hence, for the 
current selection, an ensemble of four molecules bearing the 2-(4-hydroxyphenyl) motif 
was investigated. The structures of the analyzed molecules are shown in Figure 7.4. 
 
 
Figure 7.4 Structures of investigated benzimidazole-type substances. 
 
The hyaluronidase inhibitory activities of compounds 15-18 are summarized in Table 7.3. 
Table 7.3 Inhibitory activity of benzimidazole-type derivatives. 
Compound SagHyal4755 
IC50 (µM)
a
 
BTH 
IC50 (µM) 
logD5.0
b
 
15 220 ± 70 inactive 1.2 
16 inactive inactive 1.7 
17 inactive inactive 1.7 
18 80 ± 17 inactive 2.0 
a
 mean values ± SEM (N = 2, experiments performed in duplicate), highest concentration of the test 
compounds in the assay was 1 mM; IC50 values determined at pH 5.0 in the turbidimetric assay (cuvettes);
 
b 
calculated with ACD-Labs (Advanced Chemistry Development Inc., Toronto, Canada) product version 12.00. 
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The following substances were published before: 168, 178. Compound 18 was provided by 
P. Baumeister from our workgroup. Among the investigated benzimidazole derivatives, 
only compound 18 showed noteworthy inhibition of the bacterial hyaluronidase. Probably, 
the benzo[b]furane and the benzo[b]thiphene scaffold harbor a higher potential the 
development of novel lead inhibitors. Compared to the latter, the benzimidazole skeleton 
causes a strong decrease in lipophilicity (cf. logD5.0 values of 15-18), which is supposed to 
determine the binding affinity for hyaluronidases. 
 
7.2.4 Alkanoic acid derivatives 
Previously, Salmen identified derivatives of diphenylpropionic acid as inhibitors of 
SagHyal4755 and BTH.
1, 9 Based on these observations, additional alkanoic acids (acetic 
acid, propanoic acid, butanoic acid and pentanoic acid derivatives) were tested for 
inhibition of hyaluronidases. The hyaluronidase inhibitory activities of compounds 19-36 
(Figure 7.5) are summarized in Table 7.4. 
 
Figure 7.5 Structures of investigated (het)arylalkanoic acids. 
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Table 7.4 Inhibition of hyaluronidases by (het)arylalkanoic acids. 
Compound SagHyal4755 
IC50 (µM)
a
 
BTH 
IC50 (µM) 
19 92 ± 4 inactive 
20 >1000 inactive 
21 >1000 inactive 
22 >1000 inactive 
23 >1000 inactive 
24 240 ± 22 inactive 
25 260 ± 40 inactive 
26 345 ± 15 inactive 
27 >1000 inactive 
28 inactive inactive 
29 115 ± 9 inactive 
30 290 ± 17 inactive 
31 700 inactive 
32 inactive inactive 
33 410 inactive 
34 850 inactive 
35 inactive inactive 
36 inactive inactive 
a
 mean values ± SEM (N = 2, experiments performed in duplicate), highest concentration of the test 
compounds in the assay was 1 mM; IC50 values determined at pH 5.0 in the turbidimetric assay (cuvettes). 
 
The following substances were published before: 1910, 2011, 2311, 2612, 2713, 3014, 3114, 
3215, 3316, 34. Substances 28, 29, 34-36 were commercially available. Among the 
carboxylic acids, compounds 19 (IC50 = 92 µM) and 29 (IC50 = 115 µM) were identified as 
the most potent inhibitors of SagHyal4755. Inhibition of the mammalian enzyme BTH was 
not observed. 
Taken together, several of the investigated (het)arylalkanoic acids revealed moderate to 
weak inhibitory activity on the bacterial hyaluronidase. Attempts to optimize the structures 
were not performed in this thesis. However, the results added knowledge to the project: 
Based on these observations, several commercially available non-steroidal anti-
inflammatory drugs (NSAIDs) were predicted as potential inhibitors of SagHyal4755. These 
studies are subject of ongoing projects in our workgroup. 
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7.2.5 Miscellaneous substances 
To study additional small-molecules, compounds 37-53 were tested for hyaluronidase 
inhibitory activity. The structures are displayed in Figure 7.6. 
 
 
Figure 7.6 Structures of investigated miscellaneous substances. 
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The hyaluronidase inhibitory activities of compounds 19-29 are summarized in Table 7.5. 
Table 7.5 Inhibitory activity of miscellaneous substances on hyaluronidases. 
Compound SagHyal4755 
IC50 (µM)
a
 
BTH 
IC50 (µM)
a
 
37 120 ± 36 inactive 
38 500 inactive 
39 Inactive inactive 
40 Inactive inactive 
41 Inactive inactive 
42 480 inactive 
43 >1000 inactive 
44 >1000 inactive 
45 Inactive inactive 
46 690 inactive 
47 Inactive inactive 
48 >1000 inactive 
49 10 ± 8 inactive 
50 480 inactive 
51 100 ± 8 >1000 
52 17 ± 3 41 ± 5 
53 Inactive inactive 
a
 mean values ± SEM (N = 2, experiments performed in duplicate), highest concentration of the test 
compounds in the assay was 1 mM; IC50 values determined at pH 5.0 in the turbidimetric assay (cuvettes). 
 
Compound 41 was published before17, substances 38-40, 42-53 were commercially 
available. Most of these compounds were inactive or showed weak inhibition of 
SagHyal4755 and BTH. As expected, the inhibitory activity of the dicarboxylic acids 50-52 
correlated with the length of the alkyl spacer. Accordingly, hexadecanedioic acid (52) was 
the most active inhibitor in this series. Besides, 52 showed relatively strong inhibition of 
the mammalian enzyme BTH. Remarkably, the loss of the carboxylic moiety led to inactive 
compounds, as, e.g., in case of 53. However, these molecules are far from being drug-
like, due to surfactant-like structural features. 
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7.2.6 Screening of bioactive natural products for hyaluronidase 
inhibition 
Natural products (bioactive compounds) and medicinal plants represent a promising 
source of potential hyaluronidase inhibitors.18 As an example, rosmarinic acid, was 
reported to possess various biological activities including inhibition of hyaluronidase.1, 19 
Very recently, novel phenylpropanoids from herbal plants Lycopus lucidas19, Cimicifuga 
dahurica and Cimicifuga heracleifolia20, Meehania urticifolia21 and Keiskea japonica22 were 
purported to have hyaluronidase inhibiting activities. The structures of the selected 
molecules are displayed in Figure 7.7. 
 
Figure 7.7 Structures of natural products investigated for hyaluronidase inhibition. 
 
The substances 54-63 were commercially available and investigated with respect to 
hyaluronidase inhibition. In this series, rosmarinic acid (54) served as reference. 
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The hyaluronidase inhibitory activities of compounds 54-63 are summarized in Table 7.6. 
Table 7.6 Inhibitory activity of investigated natural products. 
Compound SagHyal4755 
IC50 (µM)
a
 
BTH 
IC50 (µM) 
Notation 
54 325 ± 55 inactive rosmarinic acid 
55 inactive inactive menthol 
56 >1000 inactive thymol 
57 inactive inactive scopoletin 
58 inactive inactive chlorogenic acid 
59 inactive inactive D-(-)-quinic acid 
60 inactive inactive shikimic acid 
61 inactive inactive gallic acid 
62 inactive inactive scopolaminiumbromide 
63 inactive inactive emetine dihydrochloride 
a
 mean values ± SEM (N = 2, experiments performed in duplicate), highest concentration of the test 
compounds in the assay was 1 mM; IC50 values determined at pH 5.0 in the turbidimetric assay (cuvettes). 
 
Except for rosmarinic acid, the investigated substances, proved to be inactive on both 
SagHyal4755 and BTH, rosmarinic acid was inactive on BTH (turbidimetric acid, pH 5.0). As 
discussed before, the selection of compound was restricted to small molecules. Hence, a 
screening of more complex structures was not attempted. 
 
7.2.7 Screening of (approved) drugs for hyaluronidase inhibition 
In the review by Girish et al. , anti-inflammatory, anti-allergic and antibiotic drugs are listed 
as hyaluronidase inhibitors.1 This was confirmed in our laboratory in case of indomethacin, 
which is used as a reference inhibitor in this thesis. Besides, the anti-inflammatory agents 
phenylbutazone and oxyphenbutazone were stated to be potent hyaluronidase 
inhibitors.23 This hint and the discovery of active compounds incorporating a 
“thiohydantoin” scaffold (see chapter 5) inspired us to investigate a small library containing 
structurally related five-membered heterocycles (cf. Figure 7.8). 
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Figure 7.8 Structures of investigated drugs and related substances. 
 
The hyaluronidase inhibitory activities of compounds 64-72 are summarized in Table 7.7. 
Table 7.7 Inhibitory activity of investigated drugs and related substances. 
Compound SagHyal4755 
IC50 (µM)
a
 
BTH 
IC50 (µM) 
Notation 
64 650 inactive phenylbutazone 
65 inactive inactive propyphenazone 
66 inactive inactive phenazone (antipyrine) 
67 inactive inactive aminophenazone 
68 inactive inactive metamizole 
69 inactive inactive ethosuximide 
70 inactive inactive phenytoin 
71 inactive inactive hydantoin-5-acetic acid 
72 inactive inactive  
a
 mean values ± SEM (N = 2, experiments performed in duplicate), highest concentration of the test 
compounds in the assay was 1 mM; IC50 values determined at pH 5.0 in the turbidimetric assay (cuvettes). 
 
The substances 64-71 were commercially available. Compound 72 was provided by N. 
Pluym from our workgroup. Phenylbutazone (64) served as reference inhibitor. Under the 
present screening conditions, except for phenylbutazone, the investigated substances, 
were inactive on SagHyal4755 and BTH. 
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7.2.8 Peptide-based substances  
Over the past decade, a number of peptide-based therapeutics that block the binding of 
CD44 or RHAMM-specific ligands have been developed and tested in experimental 
models of disease.24 For example, peptide mimetics of HA with affinity to RHAMM were 
identified.25 This demonstrated that non-HA ligands specific to a given HA binding protein 
can be engineered.25 Hits were identified among HA-mimetic peptide libraries containing a 
number of negatively charged (R)- and (S)-amino acids. Strikingly, the most active 
peptides consisted of 8 to 12 amino acids.25, 26 These peptides were predicted to bind 
closely to basic amino acids in RHAMM which were known to be involved in the 
interaction with HA.27 As peptide mimetics offer a novel therapeutic strategy to block 
specific functions of CD44 and RHAMM, the idea arose to characterize octapeptides with 
regard to inhibition of hyaluronidases (SagHyal4755 and BTH). The structures of the 
selected peptide-ligands are displayed in Figure 7.9. 
 
Figure 7.9 Structures of investigated peptides. 
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The hyaluronidase inhibitory activities of compounds 73-76 are summarized in Table 7.8. 
Table 7.8 Inhibitory activity of peptides 73-76 on SagHyal4755 and BTH. 
Compound SagHyal4755 
IC50 (µM)
a
 
BTH 
IC50 (µM) 
Notation 
73 570 ± 20 inactive H-MdYEPeQe-NH2 
74 640 ± 35 inactive H-YDSeYeSe-NH2 
75 930 ± 10 inactive H-EGEWPVYP-NH2 
76 610 ± 20 inactive H-MdYePEQe-NH2 
a
 mean values ± SEM (N = 2, experiments performed in duplicate), highest concentration of the test 
compounds in the assay was 1 mM; IC50 values determined at pH 5.0 in the turbidimetric assay (cuvettes). 
 
The peptides were kindly provided by Prof. Dr. C. Cabrele (Institute of Organic Chemistry, 
University of Bochum). The peptide sequences were adopted from Ziebell et al. (7327, 
7427, 7525, 7625). All peptides (73-76) were identified as weak inhibitors of SagHyal4755. By 
contrast, inhibitory activity on the bovine testicular hyaluronidase was not observed. The 
inhibition of the bacterial enzyme is rather poor, probably due to major structural 
differences of the HA-binding site in SagHyal4755 compared to RHAMM. Nevertheless, 
such peptides might offer a molecular approach to the mimicry of the natural ligand HA. 
Most likely, computer-assisted design of peptides containing 8 to 12 amino acids is key to 
the rational discovery of more active and selective protein-based inhibitors. 
 
7.2.9 Conformationally restricted 2-phenylindole derivatives 
To explore conformationally restricted 2-phenylindoles (Figure 7.10), 6-alkyl-5,6-
dihydroindolo[2,1-a]isoquinolines (77-84), 11-alkyl-6,11-dihydro-5H-benzo[a]carbazoles 
(85, 86) and 5,10-diethyl-5,10-dihydroindeno[1,2-b]indole-2,8-diol (87), were selected for 
investigation on SagHyal4755 and BTH. Here, the indole and the 2-(4-hydroxyphenyl) 
substituent were bridged by a methylene or an ethylene group to constrain the rotation 
around the sigma bond between indole-C-2 and phenyl residue, resulting in a more planar 
shape of the core structure. Previously, the selected compounds were synthesized in our 
workgroup and investigated for their estrogen receptor affinity. The following substances 
were published before: 7717, 28, 7829, 8430, 8531. 
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Figure 7.10 Structures of investigated conformationally restricted 2-phenylindoles. 
 
The compounds 77-87 were investigated for inhibition of SagHyal4755 and BTH (Table 7.9). 
Table 7.9 Activity of conformationally restricted 2-phenylindoles 77-87 on SagHyal4755 and BTH. 
Compound SagHyal4755 
IC50 (µM)
a
 
BTH 
IC50 (µM) 
77 inactive inactive 
78 inactive inactive 
79 inactive inactive 
80 inactive inactive 
81 inactive inactive 
82 inactive inactive 
83 inactive inactive 
84 inactive inactive 
85 inactive inactive 
86 inactive inactive 
87 inactive inactive 
a
 mean values ± SEM (N = 2, experiments performed in duplicate), highest concentration of the test 
compounds in the assay was 1 mM; IC50 values determined at pH 5.0 in the turbidimetric assay (cuvettes). 
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None of the investigated compounds 77-87 showed an inhibitory effect on SagHyal4755 
and BTH. Obviously, the rigid three-dimensional structure is incompatible with binding to 
the enzymes. 
 
7.2.10 2-Phenylindolecarbaldehyde derivatives 
A series of hydrazones (88-93, 96) and Knoevenagel condensation products of 2-
phenylindole-3-carbaldehydes (94, 95, 97) was tested for inhibition of hyaluronidases. 
Previously, the selected compounds were synthesized in our workgroup and investigated 
for their estrogen receptor affinity. For substance 88 cf. ref.32 The corresponding 
structures are shown in Figure 7.11. 
 
Figure 7.11 Structures of hydrazones and Knoevenagel condensation products of 2-phenylindole-3-
carbaldehydes. 
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The results of the investigations of compounds 88-97 on SagHyal4755 and BTH are 
summarized in Table 7.10. 
Table 7.10 Activities of 2-phenylindole-3-carbaldehyde derivatives on SagHyal4755 and BTH. 
Compound SagHyal4755 
IC50 (µM)
a
 
BTH 
IC50 (µM)
a
 
88 inactive inactive 
89 inactive inactive 
90 inactive inactive 
91 inactive inactive 
92 inactive inactive 
93 inactive inactive 
94 inactive inactive 
95 inactive inactive 
96 inactive inactive 
97 380 ± 45 inactive 
98 37% (200 µM)
b
 inactive 
a
 mean values ± SEM (N = 2, experiments performed in duplicate), highest concentration of the test 
compounds in the assay was 1 mM; IC50 values determined at pH 5.0 in the turbidimetric assay (cuvettes);
 
b
 % inhibition of SagHyal4755 at indicated inhibitor concentration. 
 
As a result, most of the investigated compounds did not affect SagHyal4755 and BTH. An 
exception was substance 97. In this case, presumably, the carboxylic moiety plays a key 
role in enhancing the binding to the bacterial hyaluronate lyase. Moreover, cleavage of the 
methyl ether to the corresponding phenolic hydroxyl group as in 98 can increase binding 
affinity for hyaluronidase. 
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7.2.11 N-Alkylated 2-phenylindoles 
A small library of N-alkylated 2-phenylindoles was tested for the inhibition of SagHyal4755 
and BTH. Previously, the selected compounds were synthesized in our workgroup and 
investigated for their estrogen receptor affinity. The following substances were published 
before: 99-10233, 10334, 10434, 10534, 10635, 10736, 10937. The corresponding molecules 
are shown in Figure 7.12. 
 
Figure 7.12 Structures of N-alkylated 2-phenylindoles 99-112. 
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The hyaluronidase inhibitory activities of compounds 98-111 are summarized in Table 
7.11. 
Table 7.11 Inhibitory activity on SagHyal4755 and BTH and logD5.0 values of N-alkylated 2-phenylindoles. 
Compound SagHyal4755 
IC50 (µM)
a
 
BTH 
IC50 (µM) 
logD5.0
b
 
99 320 ± 25 inactive 3.6 
100 66 ± 17 inactive 4.6 
101 18.2 ± 9.6 inactive 6.1 
102 15 ± 5.8 inactive 7.6 
103 inactive inactive 5.1 
104 8.5 ± 1.3 inactive 5.2 
105 10 ± 3.6 inactive 5.7 
106 inactive inactive 2.2 
107 inactive inactive 3.7 
108 460 ± 44 inactive 2.9 
109 inactive inactive 5.6 
110 inactive inactive not calculated 
111 inactive inactive 5.2 
112 620 ± 26 inactive 3.3 
a
 mean values ± SEM (N = 2, experiments performed in duplicate), highest concentration of the test 
compounds in the assay was 1 mM; IC50 values determined at pH 5.0 in the turbidimetric assay (cuvettes).
 
b 
calculated with ACD-Labs (Advanced Chemistry Development Inc., Toronto, Canada) product version 12.00. 
 
The inhibitory potency of 99-102 for SagHyal4755 increased with elongation of the carbon 
chain. Interestingly, compound 101 (7 carbon atoms) and compound 102 (10 carbon 
atoms) were almost equipotent. In agreement with previous investigations,9, 38, 39 the 
results suggest a positive correlation between lipophilicity and enzyme inhibition. 
However, compound 109, containing a 10-(pentylsulfonyl)decyl substituent at the indole-
nitrogen, did not show inhibitory activities. 
Aiming at drug-like properties, the weak inhibitor 99, containing a relatively short aliphatic 
chain, was considered a structural basis for the search of structurally derived analogs. 
Accordingly, compounds 103-108 and 110-112 were selected for biological tests. By 
trend, only hydroxylated compounds were capable of inhibiting hyaluronidase SagHyal4755. 
Strikingly, compounds 104 and 105 were identified as one-digit micromolar inhibitors of 
SagHyal4755. Remarkably, these small molecules turned out to be even more potent than 
2-phenylindole bearing lipophilic N-alkyl chains (see compounds 101, 102). Replacement 
of the hydroxyl (cf. 104) by a methyl ether group (cf. 103) led to a total loss of inhibition. 
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Single crystals of 104, suitable for X-ray diffraction studies were grown by evaporation of 
the solvent (anhydrous methanol). The packing arrangement of a single crystalline phase 
contained monomers. To illustrate the configuration, an ORTEP-style plot and labeling 
scheme of 104 is given in Figure 7.13. 
 
Figure 7.13 Molecular structure (ORTEP-style) of 104 including atomic numbering scheme. 
 
Experimental details (crystal data and structure refinement) including atomic coordinates, 
bond lengths and angles, anisotropic displacement parameters, hydrogen coordinates, 
torsion angles and hydrogen bonds are given in section A.3.3 (appendix I). The molecular 
structure of 104 shows the indole scaffold with C(7)-N(1)-C(10)-C(11) lying in plane. The 
torsion angle between the phenyl ring and indole ring along C(1)-C(6)-C(7)-C(8) is 68.8 °. 
In summary, the discovery of the potent inhibitors 104, 105 became a valuable source for 
the design and development of novel, drug-like inhibitors of streptococcal enzymes. 
 
7.2.12 N-Alkylated 3-methyl-2-phenylindole derivatives 
A small library of N-alkylated 3-methyl-2-phenylindoles was tested for the inhibition of 
SagHyal4755 and BTH. Previously, the selected compounds were synthesized in our 
workgroup and investigated for their estrogen receptor affinity. The following substances 
were published before: 11340, 11535, 11635, 11741, 11841, 119-12135, 12242, 12343, 12443, 
12544, 12745, 12836, 13036, 13336. The corresponding molecules are shown in Figure 7.14. 
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Figure 7.14 Structures of N-alkylated 3-methyl-2-phenylindoles 113-133. 
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The hyaluronidase inhibitory activities of compounds 113-133 are summarized in Table 
7.12. 
Table 7.12 Inhibitory activities on SagHyal4755 and BTH and logD5.0
 
 values of N-alkyl-3-methyl-2-phenyl-
indoles. 
Compound SagHyal4755 
IC50 (µM)
a
 
BTH 
IC50 (µM) 
logD5.0
c
 
113 inactive inactive 5.3 
114 140 ± 11 inactive 1.2 
115 318 ± 10 inactive 1.4 
116 300 ± 32 inactive 2.1 
117 15% (200 µM)
b
 inactive 3.3 
118 20% (200 µM)
b
 inactive 3.8 
119 60% (200 µM)
b
 inactive 0.4 
120 70% (200 µM)
b
 inactive 0.9 
121 30% (200 µM)
b
 inactive 1.5 
122 inactive inactive 4.8 
123 570 ± 14 inactive 4.2 
124 750 ± 39 inactive 4.2 
125 95 ± 5 inactive 3.4 
126 16.4 ± 7 inactive 3.0 
127 79% (200 µM)
b
 inactive 3.5 
128 370 ± 48 inactive 3.7 
129 inactive inactive 3.1 
130 inactive inactive 4.5 
131 inactive inactive 4.0 
132 inactive inactive 4.3 
133 103 ± 21 inactive 4.2 
a
 mean values ± SEM (N = 2, experiments performed in duplicate), highest concentration of the test 
compounds in the assay was 1 mM; IC50 values determined at pH 5.0 in the turbidimetric assay (cuvettes); 
b
 % inhibition of SagHyal4755 at indicated inhibitor concentration;
 c 
calculated with ACD-Labs (Advanced 
Chemistry Development Inc., Toronto, Canada) product version 12.00. 
 
N-Alkylated 3-methyl-2-phenylindoles comprising chains of 5 to 10 carbon atoms were 
identified as potent inhibitors of SagHyal4755.
9 The attachment of bromo- (113), pyrrolidino- 
(114-116), pyrrolidinocarbonyl- (117, 118) and amino groups (119-121) at the aliphatic 
chain resulted in weak hyaluronidase inhibitors. 
Single crystals of 128, suitable for X-ray diffraction studies were grown by evaporation of 
the solvent (methanol). The packing arrangement of a single crystalline phase contained 
symmetric dimers in which two molecules were present. To illustrate the configuration, an 
ORTEP-style plot and labeling scheme of 128 is given in Figure 7.15. 
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Figure 7.15 Molecular structure (ORTEP-style) of 128 including atomic numbering scheme. 
 
Experimental details (crystal data and structure refinement) including atomic coordinates, 
bond lengths and angles, anisotropic displacement parameters, hydrogen coordinates, 
torsion angles and hydrogen bonds are given in section A.3.4 (appendix I). The molecular 
structure of 128 shows the planar indole scaffold with C(7)-N(1)-C(10)-C(9) lying in plane. The 
torsion angle between the phenyl ring and indole ring along C(5)-C(4)-C(7)-C(8) is at 55.0°. 
To investigate the influence on potency by different positioning of the hydroxyl groups on 
the 3-methyl-2-phenylindole skeleton, compounds 122-128 were compared under 
standardized conditions. The core structure (122) and mono-hydroxylated 3-methyl-2-
phenylindoles (123, 124) were inactive or weak inhibitors, respectively. Compared to 128, 
two hydroxyl groups significantly increased inhibitory activity. In addition, vicinal hydroxyl 
residues in position 5 and 6 of the indole skeleton (cf. 126) were tolerated and led to a 
potent inhibitor. By contrast, replacement of hydroxyl groups by methoxy- (129, 130) and 
fluoro-substituents (131, 132) resulted in inactive compounds. As suggested by 133, the 
position of the hydroxy group in the phenyl residue of 3-methyl-2-phenylindoles is of minor 
importance. 
 
7.2.13 N-Benzyl-3-methyl-2-phenylindole derivatives 
To get additional hints to promising structural modifications of inhibitors bearing a 2-
phenylindoles scaffold, N-benzylated 3-methyl-2-phenylindoles compounds 134-142 were 
tested for hyaluronidase inhibition. The molecular structures are shown Figure 7.16. 
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Figure 7.16 Structures of N-benzylated 3-methyl-2-phenylindoles 134-142. 
 
The hyaluronidase inhibitory activities of compounds 134-142 are summarized in Table 
7.13. 
Table 7.13 Activities of N-benzyl-3-methyl-2-phenylindoles on hyaluronidases and calculated logD5.0 values. 
Compound SagHyal4755 
IC50 (µM)
a
 
BTH 
IC50 (µM) 
logD5.0
b
 
134 9 ± 2 inactive 4.9 
135 5.2 ± 1.2 inactive 5.7 
136 5.7 ± 0.8 inactive 6.9 
137 27 ± 5 inactive 3.8 
138 27 ± 7 inactive 3.8 
139 20.1 ± 2 inactive 5.7 
140 18.5 ± 3 inactive 5.7 
141 22 ± 7 inactive 5.9 
142 120 ± 19 inactive 3.2 
a
 mean values ± SEM (N = 2, experiments performed in duplicate), highest concentration of the test 
compounds in the assay was 1 mM; IC50 values determined at pH 5.0 in the turbidimetric assay (cuvettes);
 
b 
calculated with ACD-Labs (Advanced Chemistry Development Inc., Toronto, Canada) product version 12.00. 
 
Previously, the selected compounds were synthesized in our workgroup and investigated 
for their estrogen receptor affinity and as inhibitors of the steroid sulfatase (EC 3.1.6.2.). 
For substance 135 (cf. ref.44). 
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Comparing 134-136 on SagHyal4755, sequential cleavage of the sulfamic ester groups 
resulted in equipotent inhibitors. This also holds for the indoles 137 and 138 compared to 
139 and 140, respectively. Calculation of the calculated logD5.0 values revealed significant 
lower lipophilicity of the sulfamates relative to the corresponding phenols. There is no 
correlation between the observed IC50 values and logD5.0 values for compounds 134-141. 
In this context, the chemical and enzymatic stability of the sulfamic ester group has to be 
considered. Golob and Walter reported that sulfatase inhibitors were at least partly 
converted to the free hydroxyl derivatives.33, 37 In particular, they found that the sulfamate 
moitey was hydrolyzed to the free hydroxyl derivative within a few days when kept under 
tissue culture conditions. The authors speculate that this conversion might occur 
especially in vivo, i. e. the sulfamates are prodrug-like compounds.33 Taking into 
consideration these observations, it was conceivable that the inhibition of hyaluronate 
lyase had to be mainly attributed to hydroxylated 2-phenylindole derivatives. 
A qualitative HPLC-MS experiment was performed to analyze the chemical stability of 
substances 134-136 under assay conditions. The compounds (c = 100 µM) were 
incubated in buffer medium (c(BSA) = 0.2 mg/mL, c(HA) = 2.0 mg/mL, pH 5.0) at 37 °C for 
30 minutes. Compound 136 served as reference compound. Subsequently, the assay 
incubation mixture was subjected to HPLC and analyzed by means of mass spectroscopy 
(Table 7.14). 
Table 7.14 HPLC-MS spectral data of 134-136 (concentration: 100 µM) after incubation under assay 
conditions at 37 °C for 30 minutes. 
Compound MS-scan for 134 MS-scan for 135 MS-scan for 136 
134 (Mr = 645.5) 646.1 ([M + H]
+
, 100 %) n.d. n.d. 
135 (Mr = 566.4)  567.1 ([M + H]
+
, 100 %) n.d. 
136 (Mr = 487.3)   488.1 ([M + H]
+
, 100 %) 
 
As a result, for the incubation of the substances under in vitro assay conditions in the 
buffer medium, according to HPLC-MS, hydrolysis of the sulfamated residues was not 
observed. This data suggests that the indole derivatives bearing one or two sulfamate 
groups are actually equipotent to the corresponding hydroxy compounds. As discussed 
above, the situation might be different under in vivo conditions. 
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7.2.14 N-Alkyl-3-ethyl-2-phenylindole derivatives 
A set of three N-alkylated 3-ethyl-2-phenylindoles was tested for inhibition of SagHyal4755 
and BTH. The corresponding molecules are shown in Figure 7.17. 
 
Figure 7.17 Structures of N-alkylated 3-ethyl-2-phenylindoles 143-145. 
 
Previously, the compounds 143-145 were synthesized in our workgroup and investigated 
for estrogen receptor affinity. For compounds 144 and 145 (cf. ref.36). 
The hyaluronidase inhibitory activities of compounds 143-145 are summarized in Table 
7.15. 
Table 7.15 Hyaluronidase inhibitory activity and logD5.0 values of N-alkyl-3-ethyl-2-phenylindoles 143-145. 
Compound SagHyal4755 
IC50 (µM)
a
 
BTH 
IC50 (µM) 
logD5.0
b
 
143 inactive inactive 4.2 
144 inactive inactive 4.7 
145 67 ± 13 inactive 4.6 
a
 mean values ± SEM (N = 2, experiments performed in duplicate), highest concentration of the test 
compounds in the assay was 1 mM; IC50 values determined at pH 5.0 in the turbidimetric assay (cuvettes);
 
b 
calculated with ACD-Labs (Advanced Chemistry Development Inc., Toronto, Canada) product version 12.00. 
 
The hydroxylated 3-ethyl-2-phenylindole 145 displayed inhibitory activity on SagHyal4755. 
Nevertheless, the focus for structural modifications was set to less lipophilic 3-methyl-2-
phenylindole derivatives. 
 
7.2.15 Sulfamoyloxy-substituted 3-methyl-2-phenylindoles 
Previously, the indole-type inhibitor 146 (Figure 7.18) from our workgroup was crystallized 
in complex with S. pneumonia hyaluronidase (SpnHyl) and the binding mode was 
determined by X-ray crystallography.38 As the indole moiety binds to the catalytic site of 
the enzyme, this phenylindole was tested for inhibition of the related hyaluronate lyase 
from S. agalactiae (SagHyal4755) resulting in an IC50 value of 11 µM.
38 
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Figure 7.18 Structures of the sulfamoyloxy-substituted N-alkylated 3-methyl-2-phenylindoles 146, 147 and the 
partent compound 148. 
 
The hyaluronidase inhibitory activities of compounds 146-148 are summarized in Table 
7.16. 
Table 7.16 Inhibitory activity of N-alkylated 3-methyl-2-phenylindoles 146-148 on hyaluronidases 
Compound SagHyal4755 
IC50 (µM)
a
 
BTH 
IC50 (µM) 
logD5.0
b
 
146 11 ± 5 inactive 4.9 
147 8 ± 3 inactive 5.8 
148 13 ± 6 inactive 6.9 
a
 mean values ± SEM (N = 2, experiments performed in duplicate), highest concentration of the test 
compounds in the assay was 1 mM; IC50 values determined at pH 5.0 in the turbidimetric assay (cuvettes);
 
b 
calculated with ACD-Labs (Advanced Chemistry Development Inc., Toronto, Canada) product version 12.00. 
 
To optimize 2-phenylindole of general structure 146 with respect to drug-likeness, the 
contribution of the sulfamate moieties, the effect of the length of the alkyl chains and the 
influence of novel substitution patterns (N-benzyl substituent, methyl group in position 3 of 
the 2-phenylindole scaffold) were investigated systematically. At first, to analyze the effect 
of sequential replacement of the sulfamoyl with hydroxyl groups, compounds 146-148 
were tested towards inhibition of SagHyal4755. In accordance to Salmen, the hydroxylated 
analogs (147, 148) were about as active as the parent molecule 146. In agreement with 
previous studies, inhibition of the mammalian hyaluronidase BTH was not observed. 
In continuation of these studies, a small library of N-alkylated 2-phenylindoles (149-154) 
related to 146-148 was tested for inhibition of SagHyal4755 and BTH. The following 
substances were published before: 14937, 15037, 152-15437. The corresponding molecules 
are shown in Figure 7.19. 
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Figure 7.19 Structures of sulfamoyloxy-substituted 3-methyl-2-phenylindoles 149-154. 
 
The hyaluronidase inhibitory activities of compounds 149-154 are summarized in Table 
7.17. 
Table 7.17 Inhibitory activity of sulfamoyloxy-substituted 3-methyl-2-phenylindoles 149-154. 
Compound SagHyal4755 
IC50 (µM)
a
 
BTH 
IC50 (µM) 
logD5.0
b
 
149 124 ± 26 inactive 1.8 
150 109 ± 10 inactive 1.8 
151 20.9 ± 6 inactive 2.9 
152 219 ± 41 inactive 0.2 
153 inactive inactive 7.2 
154 550 ± 52 inactive 3.3 
a
 mean values ± SEM (N = 2, experiments performed in duplicate), highest concentration of the test 
compounds in the assay was 1 mM; IC50 values determined at pH 5.0 in the turbidimetric assay (cuvettes);
 
b 
calculated with ACD-Labs (Advanced Chemistry Development Inc., Toronto, Canada) product version 12.00. 
 
Compounds 149, 150, 152 and 154 displayed moderate inhibition of the bacterial 
hyaluronate lyase, whereas substance 153 was inactive. Highest activity resided in 151. 
Again, a 2-phenylindole, bearing a short aliphatic chain on the indole-nitrogen, was 
identified as potent inhibitor. 
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7.2.16 6,7-Dichloro-1H-indoles 
In search for novel phenylindoles and structurally related indole-based heterocycles, 6,7-
dichloro-1H-indoles derivatives 155-165 were tested for inhibitory activity on SagHyal4755 
and BTH. The structures are illustrated in Figure 7.20. The molecules were structurally 
derived from the -carboline alkaloid bauerine C, having a unique 7,8-dichloro substitution 
pattern.46 Bauerine C was first isolated from the blue-green alga Dichothrix baueriana and 
has been reported to possess antiproliferative as well as antiviral properties.47 Very 
recently, such scaffolds were characterized as versatile chemotypes for the development 
of potent and selective kinase inhibitors.48, 49 However, the selected compounds were not 
reported to possess kinase inhibitory activity. 
 
 
Figure 7.20 Structures of bauerine C and 6,7-dichloro-1H-indole derivatives 155-165. 
 
The hyaluronidase inhibitory activities of compounds 155-165 are summarized in Table 
7.18. 
 
Table 7.18 Inhibitory activity of 6,7-dichloro-1H-indole derivatives 155-165. 
Compound SagHyal4755 
IC50 (µM)
a
 
BTH 
IC50 (µM) 
logD5.0
b
 
155 inactive inactive 3.8 
156 inactive inactive 4.3 
157 152 ± 32 20% (1 mM) 2.7 
158 inactive inactive 4.2 
159 196 ± 34 inactive 5.9 
160 inactive inactive 2.4 
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161 70% (1 mM) inactive 4.1 
162 inactive inactive 3.9 
163 172 ± 38 15% (1 mM) 1.0 
164 40% (300 µM) inactive 2.2 
165 50% (200 µM) inactive 2.1 
a
 mean values ± SEM (N = 2, experiments performed in duplicate), highest concentration of the test 
compounds in the assay was 1 mM; IC50 values determined at pH 5.0 in the turbidimetric assay (cuvettes);
 
b 
calculated with ACD-Labs (Advanced Chemistry Development Inc., Toronto, Canada) product version 12.00. 
 
The compounds were kindly provided by Prof. Dr. F. Bracher (Department of Pharmacy, 
LMU Munich). Among the investigated small molecules, substances 157, 159 and 163 
were identified as moderate inhibitors of SagHyal4755, whereas potent inhibitors of BTH 
were not observed identified among the 6,7-dichloro-1H-indoles.  
 
7.3 Conclusion 
For the current screening, heterogeneous synthetic organic molecules, bioactive 
compounds and peptide mimetics of hyaluronan were analyzed under standardized 
conditions. All substances were elucidated in the presence of SagHyal4755 and BTH. 
It should be stressed that the selection of these compounds was not the result of random 
search, but inspired by reports from the literature and the results from our workgroup 
including the present doctoral project. Moreover, aiming at drug-like inhibitors, based on 
the experience with previously identified hyaluronidase inhibitors, the physicochemical 
properties and were taken into account. For example, compounds meeting the 
characteristic requirements of formerly discovered highly potent inhibitors, i.e. combining 
lipophilic moieties and negatively charged groups, were mostly excluded, because such 
compounds usually possess high plasma protein binding affinity as well as surfactant 
properties. In addition, with respect to the application of computer-assisted drug design 
methods, the idea was to identify promising molecular scaffolds or, if possible, lead 
compounds and pharmacophoric groups. 
This strategy led to the discovery of novel inhibitors among the previously investigated 2-
phenylindoles. Also, isosteric heterocycles, e.g. derivatives of benzo[b]thiophen were 
identified as streptococcal hyaluronidase inhibitors for the first time. Some of the most 
potent inhibitors of SagHyal4755 (i.e. compounds 9, 10, 104, 105 and 128), discovered by 
this screening approach, are displayed in Figure 7.21. 
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Figure 7.21 Concentration dependent activity of SagHyal4755 in the presence of 9, 10, 104, 105 and 128. 
 
Moreover, molecules bearing a N-benzylated 3-methyl-2-phenylindole scaffold were found 
as highly potent inhibitors of SagHyal4755. Here, hydoxylated molecules (134-136) were 
found as equipotent to substances bearing one or two sulfamoyl residues (138, 140) 
(Figure 7.22). 
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Figure 7.22 Concentration dependent activity of SagHyal4755 in the presence of 134-136, 138 and 140. 
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Previously, the skeleton of the investigated 2-phenylindoles proved to be a versatile 
structure for the development of compounds with antiproliferative activity against breast 
cancer cells. Therefore, depending on the chemical nature and the position of the 
substituents, it must be kept in mind, that 2-phenylindoles inhibit the growth of tumor cells 
by different mechanisms.50 Hence, chemical modifications of this pharmacophore must be 
evaluated to overcome the “off-target” estrogen receptor (ER) and to reduce the cytotoxic 
effects. 
Under the current conditions, only inhibitors of SagHyal4755 were identified. The 
mammalian hyaluronidase BTH was not affected by the small molecule inhibitors included 
in this section. This suggests inactivity of these compounds at the related human PH-20 
hyaluronidase. 
In summary, 4-chloro-2-(2,6-dichloro-4-hydroxyphenyl)-1-ethyl-1H-indol-6-ol (104, IC50 = 
8.5 µM) was classified as a novel lead compound for the inhibition of SagHyal4755. 
Furthermore, the related benzo[b]thiophen derivatives 9 and 10 were identified as hits, but 
were not further investigated in this thesis. The 2-phenylindole scaffold is considered a 
pharmacophoric core structure of inhibitors of SagHyal4755. Compared to previously 
developed inhibitors of the hyaluronate lyase SagHyal4755, lead compound 104 is 
characterized by major structural differences, in particular, the lack of long, lipophilic 
carbon chains. This is of special relevance with respect to the development of selective 
hyaluronate lyase inhibitors with drug-like properties. The structural features of 104 
inspired the rational development of related 3-methyl-2-phenylindoles. Aiming at 
overcoming side-effects due to nanomolar affinity to the estrogen receptor, the 6,7-
dichloro-1H-indole motif (cf. inhibitors 157 (IC50 = 152 µM), 159 (IC50 = 196 µM) and 163 
(IC50 = 172 µM)) is a promising discovery. Accordingly, the introduction of chloro 
substituents in positions 6 and 7 of the 2-phenylindole scaffold might provide access to 
potent inhibitors of SagHyal4755 and simultaneously avoid anti-estrogenic activity. 
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7.4 Experimental data 
7.4.1 Pharmacological parameters 
The structures of all synthesized compounds were confirmed by means of NMR and 
HPLC-MS analysis prior the testing of hyaluronidase inhibition. All data are presented as 
mean values ± SEM of two independent experiments performed in duplicate. Inhibitory 
activities are given as IC50 values (molar concentration of the inhibitor causing 50 % 
inhibition of the enzymatic activity) or % inhibition of the inhibitor at concentration of the 
compound indicated in brackets. The maximum inhibitor concentration in the assay was 
set to 1 mM. Poorly soluble or colored compounds were used at lower concentrations. All 
measurements were performed in cuvettes, using the turbidimetric assay (pH 5.0). 
 
7.4.2 Chemistry 
4-Chloro-3-ethyl-2-(4-hydroxyphenyl)benzo[b]thiophen-5-ol (10) 
Compound 10 was previously synthesized and published from our workgroup. Single 
crystals of 10 were grown from a solution of 10 mg product in anhydrous methanol 
(1.5 mL) in a 2 mL plastic vial. The solvent was slowly evaporated at room temperature 
over 7 days. 1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 10.06 (s, 1H, indole-OH-5), 9.79 (s, 
1H, Ph-OH-4), 7.67 (d, J = 8.6 Hz, 1H, indole-H-7), 7.35 – 7.23 (m, 2H, Ph-H-2,6), 7.05 (d, 
J = 8.6 Hz, 1H, indole-H-6), 6.98 – 6.79 (m, 2H, Ph-H-3,5), 2.97 (q, J = 7.2 Hz, 2H, 
CH2CH3), 1.20 (t, J = 7.3 Hz, 3H, CH2CH3). 
13C-NMR (75 MHz, DMSO-d6): δ [ppm] = 
157.62 (Cquat, Ph-C-4), 150.99 (Cquat, indole-C-5), 140.62 (Cquat, indole-C), 136.12 (Cquat, 
indole-C), 133.24 (Cquat, indole-C), 130.71 (+, Ph-C-2,6), 130.66 (Cquat, indole-C), 124.22 
(Cquat, Ph-C-1), 121.31 (+, indole-C-6), 115.42 (+, Ph-C-3,5), 114.39 (+, indole-C-7), 
112.96 (Cquat, indole-C-4), 20.89 (-, CH2CH3), 16.86 (+, CH2CH3). MS (EI-MS, 70 eV) m/z 
(rel. int. in %) = 306.2 (32), 304.2 ([M]+●, 86), 289.1 (55), 254.2 (100), 253.1 (25). HRMS 
(ESI-MS) m/z calcd. [M + H]+ 305.0398, found [M + H]+ 305.0396. C16H13ClO2S (Mr = 
304.79 g/mol). 
 
4-Chloro-2-(2,6-dichloro-4-hydroxyphenyl)-1-ethyl-1H-indol-6-ol (104) 
Compound 104 was previously synthesized and published from workgroup.34, 51 Single 
crystals of 104 were grown from a solution of 10 mg product in dry methanol (1.5 mL) in a 
2 mL plastic vial. The solvent was slowly evaporated at room temperature over 7 days. 1H-
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NMR (300 MHz, DMSO-d6): δ [ppm] = 10.75 (s, 1H, indole-OH-5), 9.49 (s, 1H, Ph-OH-4), 
7.03 (d, J = 9.1 Hz, 2H, Ph-H-3,5), 6.80 (d, J = 1.0 Hz, 1H, indole-H-5), 6.69 (d, J = 
1.8 Hz, 1H, indole-H-7), 6.26 (s, 1H, indole-H-3), 3.79 (q, J = 7.0 Hz, 2H, NCH2CH3), 1.19 
– 1.02 (m, 3H, NCH2CH3). 
13C-NMR (75 MHz, DMSO-d6): δ [ppm] = 159.14 (Cquat, Ph-C-4 
C), 153.54 (Cquat, indole-C-6), 136.92 (Cquat, indole-C), 136.32 (Cquat, Ph-C-2,6), 132.79 
(Cquat, indole-C-4), 124.32 (Cquat, Ph-C-1), 120.22 (Cquat, indole-C), 119.33 (Cquat, indole-C), 
115.27 (+, Ph-C-3,5), 109.37 (+, indole-C-5), 100.30 (+, indole-C-3), 94.45 (+, indole-C-7), 
38.41 (-, NCH2CH3), 14.54 (+, NCH2CH3). MS (EI-MS, 70 eV) m/z (rel. int. in %) = 359.1 
(33), 357.1 (100), 356.1 (25), 355.1 ([M]+●, 99), 342.1 (33), 340.0 (37). HRMS (ESI-MS) 
m/z calcd. [M + H]+ 357.9979, found [M + H]+ 357.9978. C16H12Cl3NO2 (Mr = 
356.63 g/mol). 
 
1-Ethyl-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol (128) 
Compound 128 was previously synthesized and published from our workgroup.43 Single 
crystals of 5.48 were grown from a solution of 10 mg product in dry methanol (1.5 mL) in a 
2 mL plastic vial. The solvent was slowly evaporated at room temperature over 5 days. 1H-
NMR (300 MHz, DMSO-d6): δ [ppm] = 9.75 (s, 1H, Ph-OH-4), 8.75 (s, 1H, indole-OH-5), 
7.21 (d, J = 5.9 Hz, 1H, indole-H-7), 7.19 – 7.15 (m, 2H, Ph-H-2,6), 6.89 (d, J = 8.5 Hz, 
2H, Ph-H-3,5), 6.78 (d, J = 2.2 Hz, 1H, indole-H-4), 6.64 (dd, J = 8.6, 2.3 Hz, 1H, indole-
H-6), 3.94 (q, J = 7.0 Hz, 2H, NCH2CH3), 2.04 (s, 3H, indole-CH3-3), 1.13 – 0.94 (m, 3H, 
NCH2CH3). 
13C-NMR (75 MHz, DMSO-d6): δ [ppm] = 156.92 (Cquat, Ph-C-4), 150.42 (Cquat, 
indole-C-5), 137.38 (Cquat, indole-C), 131.19 (+, Ph-C-2,6), 130.03 (Cquat, indole-C), 122.25 
(Cquat, Ph-C-1), 115.25 (+, Ph-C-3,5), 110.95 (+, indole-C-6), 109.97 (+, indole-C-7), 
105.97 (Cquat, indole-C), 102.32 (+, indole-C-4), 93.62 (Cquat, indole-C), 38.39 (-, 
NCH2CH3), 15.02 (+, NCH2CH3), 9.18 (+, indole-CH3-3). MS (EI-MS, 70 eV) m/z (rel. int. in 
%) = 267.2 ([M]+●, 100), 266.2 (27), 252.1 (59). HRMS (ESI-MS) m/z calcd. [M + H]+ 
268.1332, found [M + H]+ 268.1333. C17H17NO2 (Mr = 267.32 g/mol). 
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8.1 Introduction 
In 1975, the anti-inflammatory drug indomethacin was reported for the first time as a 
hyaluronidase inhibitor.1 As shown by Spickenreither, under standardized conditions, 
indomethacin is an inhibitor of the bacterial hyaluronidase SagHyal4755 and the 
mammalian enzymes BTH, Hyal-1 and PH-20.2 Accordingly, aiming at derivatives of 
indomethacin, several structurally related substances were synthesized and tested for 
inhibition of hyaluronidase in our laboratory. This approach led to the discovery of 
compounds, which were among the most potent inhibitors of bacterial and mammalian 
hyaluronidases known so far. Besides, retaining the indole skeleton, an additional 
structural motif was found with 2-phenylindoles. As shown for the bacterial hyaluronidase 
SagHyal4755, compounds incorporating hydroxylated 2-phenylindoles displayed inhibitory 
activity in the lower micromolar range. Moreover, these molecules, as evidenced by X-ray 
crystallography, bind the active site of the streptococcal hyaluronidase SpnHyl (PDB code: 
2BRP).3, 4 
A common structural feature of potent indole-based inhibitors includes aliphatic carbon 
chains, directly attached to the indole moiety. Typically, the potency correlated 
significantly with the length of the aliphatic chain. To illustrate indole-based inhibitors, 
some of the most potent molecules are displayed in Figure 8.1. 
 
Figure 8.1 Structures of indole-type hyaluronidase inhibitors. 
 
Interestingly, 2-phenylindole-type copmounds displayed selectivity for SagHyal4755. The 
mammalian enzyme BTH was not or only very weakly affected by these molecules. In 
contrast, inhibitors derived from indomethacin, addressed both bacterial and mammalian 
enzymes. By trend, highest inhibitory potency at bacterial enzymes resided in indole-
based substances. 
Despite the high potency of indole-based hyaluronidase inhibitors, the discussed 
compounds are most probably unfavorable for in vivo application by various reasons. 
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Firstly, in terms of drug-likeness, long lipophilic alkyl residues are unsuited, e.g., due to 
extremely high plasma protein binding of the respective compounds. This is a dilemma, as 
lipophilicity positively correlates with potency. Hence, the truncation of an alkyl chain will 
result in less active compounds. Secondly, N-alkylated indoles bearing negatively charged 
groups might possess surfactant properties. To avoid such unfavorable properties, 
hydroxylated 2-phenylindoles might harbor the potential as a template for the 
development of highly potent hyaluronidase inhibitors. However, depending on the N-
substituent, compounds derived from the 2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol 
scaffold are known for antiestrogenic activity in the low nanomolar range.5-7 Hence, 
potential binding of hyaluronidase inhibitors bearing a hydroxylated 2-phenylindole motif to 
the estrogen receptor (ER) should be kept in mind. 
Inspired by the compound 104 (see section 7.2.11) and N-benzylated 2-phenylindoles 
134-142 (see section 7.2.13), new 2-phenylindole derivatives were explored in the current 
section. The intention was to elaborate new ideas for the design of structurally modified 2-
phenylindole-based inhibitors of SagHyal4755. For the current investigations, the 2-(4-
hydroxyphenyl)-3-methyl-1H-indol-5-ol moiety was regarded as an appropriate core 
structure for the design of small molecules with drug-like properties. The synthesis and 
structure-activity relationships of N-alkylated and N-benzylated indoles will be reported in 
this chapter. 
 
8.2 Chemistry 
The N-substituted 3-methyl-2-phenylindoles were synthesized as outlined in Figure 8.2. 
 
Figure 8.2 Synthesis of the hydroxylated 2-phenylindoles 8.18a-8.32a, 8.27b, 8.29b and 8.32b. Reagents and 
conditions: (i) acetic acid, 48 % HBr, Br2, 0 °C; (ii) 4-methoxyaniline or 3-methoxyaniline, N,N-dimethylaniline, 
xylene, 170 °C; (iii) NaH, DMF, R-X (X= Cl, Br, I), 0 °C; (iv) BBr3, DCM, -20 °C. 
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Bromination of 1-(4-methoxyphenyl)propan-1-one afforded the 2-bromo-1-(4-
methoxyphenyl)propan-1-one derivative 8.1.8 For the synthesis of the 2-phenylindole 
building blocks (8.2a, 8.2b), the Bischler-Möhlau indole synthesis method was applied.5, 9, 
10 For this procedure, the reaction of primary aromatic amines (methoxyanilines) with the 
-bromoacylbenzene afforded the desired 2-phenylindole scaffold.8 The ring closure 
reaction was achieved at high temperature (170 °C) in the presence of N,N-
dimethylaniline. For the preparation of the building block 8.2a (5-methoxy-2-(4-
methoxyphenyl)-3-methyl-1H-indole), 4-methoxyaniline was used. For the synthesis of 
8.2b (6-methoxy-2-(4-methoxyphenyl)-3-methyl-1H-indole), the primary amine 3-
methoxyaniline was used. After removal of side-products by flash-chromatography and 
recrystallization, building blocks 8.2a, 8.2b were obtained in moderate yields. 
The mechanism of the Bischler-method was described as a multi-step reaction.11 In detail, 
in the primary step, nucleophilic substitution of -bromoacylbenzene and methoxyaniline 
results in a -aminoketone. The ketone is converted to a Schiff's base by condensation 
with a second methoxyaniline molecule. The cyclisation of the intermediate endiamine 
structure takes place under displacement of the “first” charged aniline molecule. After a 
1,3-H-shift, aromatization yields the 2-phenylindole. 
The N-alkylated indoles 8.3a-8.8a were prepared from the parent indole 8.2a by 
deprotonation with sodium hydride in dimethylformamide and subsequent addition of alkyl 
halide at 0 °C.5 By analogy with this procedure, N-substitution of 8.2a and 8.2b with 
benzylic residues was accomplished to yield substances 8.9a-8.17a, 8.12b, 8.14b and 
8.17b.6 In the last step, cleavage of the methyl ether groups was performed with boron 
tribromide in anhydrous dichloromethane.12 The corresponding hydroxylated 3-methyl-2-
phenylindoles 8.18a-8.32a, 8.27b, 8.29b and 8.32b were purified by flash-
chromatography. 
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The N-substituted 2-phenylindoles 8.41-8.43 were synthesized as outlined in Figure 8.3.  
 
Figure 8.3 Synthesis of the 2-phenylindoles 8.41-8.43. Reagents and conditions: (i) 8.33: acetic acid, 48 % 
HBr, Br2, 0 °C; 8.34: Et2O, dioxane, Br2, 0 °C; (ii) aniline, N,N-dimethylaniline, xylene, 170 °C; (iii) NaH, DMF, 
ethyl 4-(bromomethyl)benzoate, 0 °C; (iv) BBr3, DCM, -20 °C. 
 
Bromination of 1-(4-methoxyphenyl)ethanone 8.34 was achieved with bromine in a 
mixture of dioxane and diethyl ether at ambient temperature.13 The 2-phenylindole 
building blocks 8.35-8.37 were obtained by the Bischler method and purified as described 
previously. Because of the harsh conditions of the ether cleavage with boron tribromide, at 
this stage the reaction was performed with the indolylmethylbenzoic esters 8.38-8.40, 
which were obtained by reacting the 2-phenylindoles with ethyl 4-(bromomethyl)benzoate 
in the presence of sodium hydride.14 Since the ester function was cleaved as well, the 
products 8.41-8.43 were obtained as the corresponding indolylmethylbenzoic acids after 
column chromatography. 
The synthesis of the 6,7-dichloro-2-(4-methoxyphenyl)-3-methyl-1H-indole building block 
(8.45) was performed as displayed in Figure 8.4. 
 
Figure 8.4 Synthesis of the 6,7-dichloro-2-(4-methoxyphenyl)-3-methyl-1H-indole 8.45. Reagents and 
conditions: (i) a) NaNO2, HCl; b) SnCl2 ●  2H2O, conc. HCl; (ii) EtOH, 32 % HCl, reflux, 2h. 
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The Bischler method, which involved the condensation of substituted anilines with -
bromoacyl derivatives, did not afford the building block 6,7-dichloro-2-(4-methoxyphenyl)-
3-methyl-1H-indole 8.45 (Figure 8.4). A versatile route of synthesis was found in the 
Fischer indole synthesis.15, 16 Commercially available 2,3-dichloroaniline was diazotized 
and reduced with stannous chloride in one pot to give the corresponding (2,3-
dichlorophenyl)hydrazine 8.44 in good yield.17-21 The building block 8.45 was separated 
from starting materials and isolated by flash-chromatography in acceptable yields. 
The synthesis of the target compound 8.47 was performed as shown in Figure 8.5. 
 
Figure 8.5 Synthesis of the 4-{[6,7-dichloro-2-(4-hydroxyphenyl)-3-methyl-1H-indol-1-yl]methyl}benzoic acid 
8.47. Reagents and conditions: (i) NaH, DMF, ethyl 4-(bromomethyl)benzoate, 0 °C; (ii) BBr3, DCM, -20 °C. 
 
N-Benzylation with ethyl 4-(bromomethyl)benzoate was performed as described before. 
Deprotection of the ether and the ester group in 8.46 with boron tribromide and 
subsequent flash-chromatography afforded 8.47.14 
 
8.3 Pharmacological results and discussion 
8.3.1 General conditions 
All synthesized 2-phenylindole derivatives were investigated for inhibition of the bacterial 
hyaluronan lyase SagHyal4755 and the bovine testicular enzyme BTH (Neopermease
®) in a 
turbidimetric assay based on the method of Di Ferrante22 as described in chapter 3.5.3. 
It is important to mention that the Morgan Elson assay is not suitable for the investigation 
of indole or 2-phenylindole derivatives.3  
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8.3.2 Inhibitory activities of N-alkylated 2-phenylindole 
derivatives 
The IC50-values determined for the N-alkylated 2-phenylindole (8.18a-8.23a) derivatives 
are summarized in Table 8.1. 
Table 8.1 Inhibitory activity
a
 and calculated logD5.0 values
b
 of N-alkylated 2-(4-hydroxyphenyl)-3-methyl-1H-
indol-5-ol derivatives 8.18a-8.23a. 
Compound SagHyal4755 
IC50 (µM)
a
 
BTH 
IC50 (µM)
a
 
logD5.0
b
 
8.18a 510 ± 47 inactive 3.2 
8.19a 130 ± 15 inactive 4.1 
8.20a 22 ± 4.1 inactive 6.2 
8.21a 29 ± 3.3 inactive 7.3 
8.22a 180 ± 20 inactive 9.8 
8.23a 120 ± 53 inactive 10.8 
a
 mean values ± SEM (N = 2, experiments performed in duplicate), IC50 values determined at pH 5.0 in the 
automated 96-well turbidimetric assay; 
b 
calculated with ACD-Labs (Advanced Chemistry Development Inc., 
Toronto, Canada) product version 12.00. 
 
Previously, N-alkylated 3-methyl-2-phenylindoles were identified as selective inhibitors of 
SagHyal4755. Inhibitory activity correlated with the length of the alkyl chain. This was 
examined for compounds bearing hydrogen, methyl, n-propyl, n-pentyl and n-heptyl 
substituents at the indole-nitrogen. The most potent compounds (5, 6) are displayed in 
Figure 8.6. 
 
Figure 8.6 Structures of N-alkylated 3-methyl-2-phenylindole derivatives (5, 6), previously determined as 
inhibitors of SagHyal4755.
3
 
 
To further explore the structure-activity relationships, the analogs 8.18a-8.23a were 
analyzed. As expected, an increase in the length of the aliphatic chain led to a significant 
decrease in IC50 values. However, elongation of the aliphatic chain beyond 14 carbon 
atoms did not increase inhibitory potency in case of substances 8.22a and 8.23a. The 
latter highly lipophilic compounds suffered additionally from limited solubility. The 
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enzymatic activity of SagHyal4755 in the presence of 8.18a-8.21a is depicted as 
concentration-response curves in Figure 8.7. 
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Figure 8.7 Enzymatic activity of SagHyal4755 in the presence of 8.18a-8.21a. 
 
A positive correlation between inhibition of SagHyal4755 and lipophilicity was observed for 
N-alkylated 3-methyl-2-phenylindoles comprising a chain of 5 to 10 carbon atoms (cf. 
Figure 8.6, Table 8.1). Taken together, the most potent 2-phenylindoles containing 
aliphatic chains, were inhibitors of the bacterial hyaluronate lyase with IC50 values of 
approximately 20 µM. The mammalian enzyme BTH was not inhibited by molecules 
analyzed in this section. 
8.3.3 Inhibitory activity of N-benzylated 2-phenylindole 
derivatives 
 
The IC50 values determined for the N-benzylated 2-phenylindole derivatives are 
summarized in Table 8.2. 
Table 8.2 Inhibitory activity
a
 and calculated logD5.0 values
b
 of N-benzylated 2-phenylndol derivatives 8.24a-
8.32a, 8.27b, 8.29b, 8.32b, 8.40-8.43, 8.46, 8.47. 
Compound SagHyal4755 
IC50 (µM)
a
 
BTH 
IC50 (µM)
a
 
logD5.0
b
 
8.24a 30 ± 4.1 inactive 5.5 
8.25a 41 ± 3.3 inactive 5.6 
8.26a 21 ± 2.1 inactive 6.0 
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8.27a 19 ± 1.7 inactive 6.3 
8.27b 30 ± 2.6 inactive 6.2 
8.28a 46 ± 4.4 inactive 6.0 
8.29a 121 ± 7 inactive 7.4 
8.29b 115 ± 10 inactive 7.2 
8.30a 178 ± 34 inactive 5.9 
8.31a 49 ± 17 inactive 5.2 
8.17a inactive inactive 6.2
c
 
8.17b inactive inactive 5.9
c
 
8.32a 46.2 ± 2.2 605 ± 47 3.9 
8.32b 33.1 ± 5.0 415 ± 23 3.8 
8.40 575± 44 > 1000 8.8
c
 
8.41 420 ± 23 > 1000 4.6 
8.42 53.1 ± 6.7 465 ± 17 3.6 
8.43 8.5 ± 0.4 113 ± 34 6.3 
8.46 inactive inactive 7.4
c
 
8.47 6.3 ± 0.1 460 ± 53 5.0 
a
 mean values ± SEM (N = 2, experiments performed in duplicate); IC50 values determined at pH 5.0 in the 
automated 96-well turbidimetric assay; 
b 
calculated with ACD-Labs (Advanced Chemistry Development Inc., 
Toronto, Canada) product version 12.00; 
c
 the structure does not contain ionization centers calculated by 
ACD-Labs. LogP-value is indicated instead.  
 
Systematic screening of N-benzylated compounds (see section 7.2.13) led to the 
discovery of potent inhibitors of SagHyal4755. Two prototypical structures of this approach, 
140 and 141, are illustrated in Figure 8.8. 
 
Figure 8.8 Structures of N-benzylated 3-methyl-2-phenylindole derivatives (140, 141 (see chapter 7)), 
identified as inhibitors  of SagHyal4755. 
 
To study the influence of variously substituted benzyl residues, compounds 8.24a-8.32a, 
8.27b, 8.29b and 8.32b were compared in the turbidimetric assay. Compounds 8.17a, 
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8.17b, bearing methyl ether protecting groups and an ethyl benzoate moiety, were 
included to verify the contribution of the free phenolic and carboxylic groups, respectively. 
The enzymatic activity of SagHyal4755 in presence of 8.17a, 8.26a, 8.27a and 8.32a is 
depicted as concentrations-response curves in Figure 8.9. 
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Figure 8.9 Enzymatic activity of SagHyal4755 in the presence of 8.17a, 8.26a, 8.27a and 8.32a. 
 
The benzylindoles 8.24a-8.28a and 8.31a, bearing different substitutents in para-position 
of the benzyl residues, were equipotent inhibitors of SagHyal4755. For these inhibitors the 
calculated logD5.0 values covered the range from 5.2 to 6.3. A shift of the hydroxyl group 
from position 5 (cf. 8.27a, IC50 = 19 µM) to position 6 (cf. 8.27b, IC50 = 30 µM) was 
tolerated. As predicted, compounds 8.17a, 8.17b were inactive. The introduction of bulky, 
lipophilic groups (cf. compounds 8.29a (IC50 = 121 µM) and 8.29b (IC50 = 115 µM)) 
resulted in a decrease in inhibitory activity on the streptococcal hyaluronidase, regardless 
of the position of the hydroxyl group on the indole skeleton. A similar effect was observed 
for 8.30a (IC50 = 178 µM). 
Interestingly, the introduction of a negatively charged group (cf. 8.32a, 8.32b), i.e. a 
carboxyl group in position 4 of the benzyl residue did not enhance the activity at the 
bacterial enzyme (IC50 values: 46 µM (8.32a) and 33 µM (8.32b)). However, in these 
cases weak inhibition of the mammalian enzyme BTH by 2-phenylindoles was observed 
for the first time. Compared to the previously discussed phenylindoles, the calculated 
logD5.0 values of 8.32a, 8.32b were significantly lower and the solubility was improved. 
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Strikingly, the combination of lipophilic residues (N-benzyl substituents) and negatively 
charged groups (carboxylic group) was identified as conferring affinity to BTH, thus 
reducing selectivity for streptococcal hyaluronidases. This substantiates our working 
hypothesis regarding crucial structural features of inhibitors of bacterial and mammalian 
hyaluronidase inhibitors. 
Further modifications of 2-phenylindoles were performed to combine N-benzyl moieties 
and charged residues. Aiming at more potent inhibitors, structural features of other highly 
potent inhibitors of the bacterial hyaluronidase were also taken into consideration. For 
example, as shown compounds 104, 136 in Figure 8.10, electron withdrawing groups and 
bulky substituents at the indole core structure were investigated. 
 
Figure 8.10 Structures of N-benzylated 2-phenylindole derivatives (104, 136 (see chapter 7)) determined as 
inhibitors of SagHyal4755. 
 
A similar substitution pattern was included in a series of 6,7-dichloro-1H-indole derivatives 
(cf. section 7.2.16). As illustrated by 157, 163 (Figure 8.11), such compounds were 
confirmed to possess moderate inhibitory activity on SagHyal4755.  
 
Figure 8.11 Structures of indole derivatives (157, 163 (see chapter 7)) determined as inhibitors of SagHyal4755. 
 
Therefore, compounds 8.43 (bulky substituent instead indole-5-OH) and 8.47 (6,7-dichloro 
substituents instead of indole-5-OH) were synthesized. The enzymatic activity of 
SagHyal4755 in presence of 8.41-8.43 and 8.47 is depicted as concentration-response 
curves in Figure 8.12. 
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Figure 8.12 Enzymatic activity of SagHyal4755 in the presence of 8.41-8.43 and 8.47. 
 
The IC50 values of compounds 8.42 and 8.43 were in the two- and in the one-digit µM 
range. The weak inhibition of SagHyal4755 by 8.41 is mainly caused by the missing 
hydroxyl substitutent in position 4 of the phenyl residue. This is in agreement with results 
for structurally related potent inhibitors 8.32a, 8.32b and 8.42, which incorporate a 
hydroxyl group on the respective position. The replacement of the hydroxyl group in 
position 5 (cf. 8.42, IC50 = 53 µM, logD5.0 = 3.6) of the indole skeleton by an n-butyl moiety 
(cf. 8.43, IC50= 9 µM, logD5.0 = 6.3) was accompanied by a 5-fold increase in inhibitory 
activity. The introduction of chloro substituents in positions 6 and 7 (8.47, logD5.0 = 5.0) 
resulted in an IC50 value of 6 µM. With regard to BTH, compound 8.42 (IC50 = 463 µM) 
and 8.47 (IC50 = 460 µM) were identified as weak inhibitors. The more lipophilic 
substances 8.43 showed an IC50 value of 113 µM for BTH. Compounds 8.42 and 8.43 
were about 10-fold more potent on the bacterial enzyme, and the 6,7-dichloro-1H-indole 
motif in 8.47 resulted in 75-fold selectivity for SagHyal4755 compared to BTH. 
 
8.3.4 Inhibitory activities of selected compounds on SpnHyl 
To compare the results from SagHyal4755 with data from an additional bacterial enzyme, 
an ensemble of four inhibitors was tested by Dr. J. Hamberger from our workgroup on 
hyaluronidase from S. pneumonia, SpnHyl. Under identical assay conditions (including the 
pH value) these substances were inactive on SpnHyl (Table 8.3) except for compound 
8.47, which was identified as inhibitor of the streptococcal hyaluronate lyase SpnHyl. Most 
 2-Phenylindole derivatives as inhibitors of streptococcal hyaluronidases 231 
likely the inhibitory activity can be attributed to both, the lipophilic chloro substituent and 
the carboxylate group in 8.47. With an IC50 value of 93 µM, compound 8.47 is one of the 
most potent inhibitors of SpnHyl known to date. 
Table 8.3 Inhibitory activity
a
 of 104 (see chapter 7) and 3-methyl-2-phenylindoles derivatives 8.26a, 8.29a, 
8.47. 
Compound SagHyal4755 
IC50 (µM)
a
 
SpnHyl 
IC50 (µM)
a
 
104
b
 8.5 ± 1.3
C
 inactive 
8.26a 21 ± 2.1 inactive 
8.29a 121 ± 7 inactive 
8.47 6.3 ± 0.1 93 ± 1.1 
a
 mean values ± SEM (N = 2, experiments performed in duplicate); IC50 values determined at pH 5.0 in the 
automated 96-well turbidimetric assay; 
b
 see Figure 8.10; 
c
 see section 7.2.11. 
 
8.3.5 Investigation of selected indole derivatives for anti-
proliferative activity on MCF-7 mammary carcinoma cell  
Several 2-phenylindole compounds were reported to possess antiestrogenic activities and 
to show cytostatic effects on hormone sensitive breast cancer cells.5, 6, 23 Therefore three 
phenylindole-type hyaluronidase inhibitors were tested for antiproliferative activity  on 
human MCF-7 mammary carcinoma cells (Figure 8.13). The selective estrogen receptor 
modulator 4-hydroxytamoxifen was used as reference substance.24 
 
Figure 8.13 Structures of compounds investigated for cytotoxicity on mammary carcinoma cells. 
 
The investigation of the antiproliferative activity was performed in a kinetic cytotoxicity 
assay according to a well-established protocol.25 In principle, cell growth in the presence 
and in the absence of the test compounds are compared. To determine cytostatic effects 
of the analyzed compounds (see Figure 8.13), the change of cell mass is quantified by 
staining cells with crystal violet. Test compounds were investigated in five different 
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concentrations (10 µM, 3 µM, 1 µM, 300 nM, 100 nM). During the 14 day incubation 
period, tumor cells were fixed after 70, 120, 260 and 330 hours, respectively. To calculate 
the effect of the test compounds on cell proliferation, the following equation was used 
(Equation 8.1): 
              
    
    
      
Equation 8.1 
T:  mean ratio of the optical density of treated cells 
Co:  mean ratio of the initial optical density (first addition of test compound, t = 0) 
C:  mean ratio of the optical density of non-treated cells 
T/Ccorr. corrected value 
 
To calculate the cell growth for the non-treated cell population, Equation 8.2 was used: 
 
    
  
      
Equation 8.2 
T:  mean ratio of the optical density of treated cells 
Co:  mean ratio of the initial optical density (first addition of test compound, t = 0) 
 
Corrected values (T/Ccorr.) are calculated as the ratio of the optical densities of treated 
to non-treated cells. Each density is corrected by subtraction of the initial cell density 
T0. Accordingly, corrected T/Ccorr. values, obtained after maximal incubation periods 
(end points) were plotted as a function of the concentration. The corresponding plots, 
indicating the cell growth of MCF-7 cells upon treatment with compounds (cf. Figure 
8.13) compared to the vehicle control (non-treated cells) are given in Figure 8.14. 
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Figure 8.14 Sensitivity of MCF-7 cells against of 4-hydroxytamoxifen (A), 4-chloro-2-(2,6-dichloro-4-
hydroxyphenyl)-1-ethyl-1H-indol-6-ol (104 (see chapter 7), B), 2-(6,7-dichloro-1H-indol-2-yl)-1,3,4-oxadiazole 
(157, C) and 1-(4-chlorobenzyl)-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol (8.26a, D) compared to the 
vehicle control. MCF-7 passage 237; values represent means of at least 14 replicates ± SD; Errors of T/Ccorr. 
were calculated according to the Gaussian law of error propagation. 
 
Compound 104 (see chapter 7, IC50 (SagHyal4755) = 9 µM) showed strong growth inhibition 
on the estrogen-responsive MCF-7 cells at concentrations of 3 µM and 10 µM, 
respectively. Moderate inhibition of the cell growth was observed for 8.26a (IC50 
(SagHyal4755) = 21 µM) in the same concentration range. Thus, cytotoxic effects were 
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found for the 2-phenylindoles 104 and 8.26a, which were already described as mammary 
tumor inhibiting agents.6, 23 By contrast, 2-(6,7-dichloro-1H-indol-2-yl)-1,3,4-oxadiazole 
(157, see chapter 7, IC50 (SagHyal4755) = 152 µM) did not show cytotoxic effects against 
MCF-7 cells. Therefore, the 6,7-dichloroindole moiety may be considered a promising 
structural motif for the rational development of inhibitors of streptococcal hyaluronidases, 
devoid of effects on the estrogen receptor. 
 
8.4 Outlook 
As stated in the introduction, depending on the N-substituent, molecules incorporating a 2-
(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol scaffold are known for antiestrogenic activity in 
the low nanomolar range. Hydroxylated 2-phenylindoles carrying substituted benzyl 
groups or similar residues at the indole nitrogen were previously synthesized and tested 
for estrogen receptor affinity.6 The estrogenicity of the 1-benzylindoles is rather similar to 
that of 1-alkyl-5-hydroxy-2-(4-hydroxyphenyl)-3-methylindoles.5, 6 The compounds 8.24a-
8.31a, 8.27b and 8.29b turned out to be of interest as scaffolds for the development of 
hyaluronidase inhibitors. However, only 8.24a, 8.26a and 8.28a were documented to show 
binding affinity for the calf uterine estrogen receptor.6 Introducing negatively charged 
groups such as carboxylate (cf. 8.32a, 8.32b) appears to be an effective strategy to 
strongly decrease estrogen receptor binding. Furthermore, the substitution pattern of 157, 
163 (cf. Figure 8.11), bearing two chloro substituents in position 6 and 7, gives access to 
more potent and selective inhibitors of SagHyal4755. An overview of selected indole-based 
inhibitors is shown in Figure 8.15. 
 
Figure 8.15 Comparison of indole-based inhibitors of SagHyal4755 with focus on the contribution of chloro-
substituents to inhibitory potency. 
 
Previously, 1H-indole-2-carboxylic acid was scored as hit in a LUDI-based approach for 
the identification of hyaluronate lyase inhibitors.26 This molecule, proposed by computer-
assisted drug design (virtual screening), was confirmed as a weak inhibitor (IC50 = 4 mM) 
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of SagHyal4755 in the turbidimetric assay.
3 As shown for 163 (see chapter 7), the 
introduction of chloro-substituents in combination with methyl residues in position 1 and 3, 
resulted in an IC50 value of 172 µM. Most probably, the increase in potency compared to 
the parent compound indole-3-carboxylic acid has to be attributed to the chloro 
substituents. This is corroborated by further examples, for instance, comparing 1-ethyl-2-
(4-hydroxyphenyl)-1H-indol-6-ol (99) and 4-chloro-2-(2,6-dichloro-4-hydroxyphenyl)-1-
ethyl-1H-indol-6-ol (104). The latter was 35-fold more potent than the parent compound. 
Thus, the introduction of chloro substituents may be considered an alternative to aliphatic 
chains to provide the required level of lipophilicity for binding to hyaluronidase. However, 
the cytotoxic effects of 104 and interaction with the ER must be kept in mind. Inhibitors 
based on 157, 163 (cf. Figure 8.11) might pave the way to overcome these limitations. 
As an outlook for future developments, several structural modification of inhibitors 
containing the structural features of 157 (Figure 8.11) can be proposed. As outlined in 
Figure 8.16, three different concepts (concept 1-3) are exemplified in a schematic draft. In 
the current chapter, concept 1 was elaborated for the design of the potent inhibitor 8.47. 
Besides, additional modifications, e.g. the insertion of the 1,3,4-oxadiazole moiety to a 
hydroxylated 2-phenylindole (concept 2) or substituents on the core structure of 
157(concept 3) can be suggested. 
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Figure 8.16 Proposed structural modifications of 157 for the development of potent inhibitors of SagHyal4755. 
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8.5 Summary 
Aiming at inhibitors of the bacterial hyaluronate lyase SagHyal4755, the 3-methyl-2-
phenylindole skeleton was used as a pharmacophoric moiety. Structural modifications 
were performed taking into account to obtain compounds with drug-like properties. 
Starting from extensive studies on N-alkylated 3-methyl-2-phenylindoles, crucial structural 
features of compounds with retained activity in the micromolar range but significantly 
reduced lipophilicity were elaborated.  
This knowledge was transformed into the development of a library of N-benzylated 3-
methyl-2-phenylindoles. A stepwise variation of the substructures resulted in inhibitors 
with IC50 values for inhibition of SagHyal4755 in the lower micromolar range. Compared to 
N-alkylated analogs, the novel structures were not superior in terms of potency at the 
bacterial enzyme. In accordance to our expectations, these compounds were not capable 
of inhibiting the mammalian enzyme BTH. As structurally closely related molecules are 
known for antiestrogenic activity in the low nanomolar range, potential disadvantages, 
such as cytotoxic activity, have to be taken into account. 
To improve the solubility and to obtain more potent and selective hyaluronidase inhibitors, 
a negatively charged group was introduced in position 4 of the benzyl residue. In this way 
inhibition of the target enzyme was not improved, however, estrogen receptor mediated 
off-target effects were prevented. As a side-effect, charged 2-phenylindole derivatives 
proved to be weak inhibitors of BTH. i.e., inhibition of a mammalian enzyme by 2-
phenylindoles was observed for the first time. 
Bioisosteric replacement of a hydroxyl moiety by chlorine residues on the indole skeleton, 
resulted in a significant increase in inhibitory activity for the bacterial hyaluronate lyase. 
For example, an IC50 value of 6 µM was determined for one of the most potent inhibitors of 
SagHyal4755 known to date, 4-[(6,7-dichloro-2-(4-hydroxyphenyl)-3-methyl-1H-indol-1-
yl)methyl]benzoic acid (8.47). Moreover, an IC50 value of 93 µM was determined on the 
structurally related streptococcal hyaluronidase SpnHyl. The chloro-substituted 2-
phenylindole 157 (2-(6,7-dichloro-1H-indol-2-yl)-1,3,4-oxadiazole) was devoid of cytotoxic 
effects on human estrogen-responsive MCF-7 breast cancer cells. In summary, 
compound 8.47 can be considered as a new lead structure for the development of 
inhibitors of bacterial hyaluronate lyases. 
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8.6 Experimental section 
8.6.1 General conditions; 
Cf. 5.8.1 
Compounds 8.2a-8.4a5, 8.9a6, 8.11a6, 8.13a6, 8.24a6, 8.26a6, 8.28a6, 8.2b5 and 8.3727 
have been described before. Compound 8.33 was commercially available (Sigma-Aldrich 
Chemie GmbH, Munich, Germany). 
 
8.6.2 Chemistry 
8.6.2.1. Preparation of the compounds 8.1, 8.34 
2-Bromo-1-(4-methoxyphenyl)propan-1-one (8.1)8 
To a cooled solution of 1-(4-methoxyphenyl)propan-1-one (15.4 g, 93.6 mmol) in 80 mL 
glacial acetic acid, a few drops of aqueous hydrobromic acid (48 %, v/v) and bromine 
(15.0 g, 93.6 mmol) were slowly added under vigorous stirring at a temperature below 
20 °C. Subsequently, the reaction mixture was stirred at ambient temperature for 1 h. The 
mixture was poured into ice water (90 mL) and the precipitate was filtrated off and washed 
several times with ice-cold water. The product was purified by recrystallization from 
ethanol to give colorless crystals. Yield: 18.3 g (80 %, colorless crystals); mp 67 °C 
(ref:8 66-67 °C). 1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 8.06 – 7.99 (m, 2H, Ph-H-2,6), 
7.11 – 7.04 (m, 2H, Ph-H-3,5), 5.79 (q, J = 6.5 Hz, 1H, COCHBrCH3), 3.86 (s, 3H, OCH3-
4), 1.76 (d, J = 6.5 Hz, 3H, COCHBrCH3). 
13C-NMR (75 MHz, DMSO-d6): 
δ [ppm] = 191.92 (Cquat, COCHBrCH3), 163.48 (Cquat, Ph-C-4), 131.15 (+, Ph-C-3,5), 
126.27 (Cquat, Ph-C-1), 113.99 (+, Ph-C-2,6), 55.53 (+, OCH3-4), 42.88 (+, COCHBrCH3), 
19.99 (+, COCHBrCH3). MS (EI-MS, 70 eV) m/z (rel. int. in %) = 224.0 ([M
+●], 3), 135.0 
([p-OCH3-C6H4-CO]
+, 100). C10H11BrO2 (Mr = 243.10 g/mol). 
 
2-Bromo-1-(4-methoxyphenyl)ethanone (8.34)13 
Bromine (4.8 g, 30.0 mmol) was added dropwise to a solution of 4-methoxyacetophenone 
(4.5 g, 30.0 mmol) in dioxane (100 mL) and dichloromethane (50 mL) under vigorous 
stirring. The solution was cooled in an ice-bath to maintain the temperatures below 20 °C. 
Subsequently, the reaction mixture was stirred at ambient temperature for 1 h. After 
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washing with water (2 x 200 mL) the aqueous solution was extracted with EtOAc (4 x 
250 mL). The combined organic layers were combined and dried over Na2SO4 and the 
solvent was removed in vacuo. The crude product was recrystallized from ethanol to give 
a white solid. Yield: 4.8 g (70 %, colorless crystals); mp 71 °C (ref28: 73 °C). 1H-NMR (300 
MHz, DMSO-d6): δ [ppm] = 8.05 – 7.98 (m, 2H, Ph-H-2,6), 7.09 – 7.02 (m, 2H, Ph-H-3,5), 
4.79 (s, 2H, COCH2Br), 3.86 (s, 3H, OCH3-4). 
13C-NMR (75 MHz, DMSO-d6): δ [ppm] = 
191.73 (Cquat, COCHBrCH3), 162.99 (Cquat, Ph-C-4), 131.11 (+, Ph-C-3,5), 126.11 (Cquat, 
Ph-C-1), 113.95 (+, Ph-C-2,6), 55.49 (+, OCH3-4), 33.98 (-, COCH2Br). MS (EI-MS, 
70 eV) m/z (rel. int. in %) = 230.0 ([M+●], 10), 135.0 ([p-OCH3-C6H4-CO]
+, 100). C9H9BrO2 
(Mr = 229.07 g/mol). 
 
8.6.2.2. Preparation of the compounds 8.2a, 8.2b, 8.35-8.37 
General procedure27 
A solution of the pertinent ring-substituted 2-bromo-1-phenylethanone (1 eq) or 2-bromo-
1-phenyl)propan-1-one (1 eq) in xylene (60 mL per 0.1 mol) was added dropwise to a 
solution of the substituted aniline (2.1 eq) in N,N-dimethylaniline (20 mL per 0.1 mol) at a 
temperature of 170 °C over a period of 1h. After addition, the mixture was kept at a 
temperature of 170 °C for additional 2 h. After cooling to room temperature, the dark 
brown solution was poured into 2N HCl (150 mL per 0.1 mol). EtOAc was added and the 
aqueous phase was extracted three more times with EtOAc. After washing with 2N HCl, 
water and sat. NaHCO3, the organic layer was dried over Na2SO4. The solvent was 
removed under reduced pressure and the crude product was purified by column 
chromatography (SiO2) as indicated. 
 
5-Methoxy-2-(4-methoxyphenyl)-3-methyl-1H-indole (8.2a)8, 13 
The title compound was prepared from 4-methoxyaniline (11.7 g, 95 mmol), N,N-
dimethylaniline (18.8 mL) and 2-bromo-1-(4-methoxyphenyl)propan-1-one 8.1 (10.9 g, 
45 mmol) according to the general procedure. The crude product was purified by flash-
chromatography (PE/EtOAc 80/20, v/v). Yield: 5.8 g (48 %, white solid); mp 137 °C 
(ref:8 139 °C). 1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 10.88 (s, 1H, indole-NH), 7.61 – 
7.55 (m, 2H, Ph-H-2,6), 7.23 (dd, J = 8.7, 2.7 Hz, 1H, indole-H-7), 7.12 – 7.03 (m, 2H, Ph-
H-3,5), 6.98 (d, J = 2.4 Hz, 1H, indole-H-4), 6.73 (dd, J = 8.7, 2.4 Hz, 1H, indole-H-6), 
3.81 (s, 3H, OCH3-4), 3.79 (s, 3H, indole-OCH3-5), 2.36 (s, 3H, indole-CH3-3). 
13C-NMR 
(75 MHz, DMSO-d6): δ [ppm] = 158.20 (Cquat, Ph-C-4), 153.05 (Cquat, indole-C-5), 134.42 
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(Cquat, indole-C), 130.75 (Cquat, indole-C), 129.72 (Cquat, indole-C), 128.53 (+, Ph-C-2,6), 
125.63 (Cquat, Ph-C-1), 114.04 (+, Ph-C-3,5), 111.40 (+, indole-C-6), 111.04 (+, indole-C-
7), 105.37 (Cquat, indole-C), 99.90 (+, indole-C-4), 55.22 (+, OCH3-4), 55.04 (+, indole-
OCH3-5), 9.81 (+, indole-CH3-3). MS (ES-MS, DCM/MeOH + NH4OAc) m/z (rel. int. in %) 
= 268.0 ([M + H]+, 100). C17H17NO2 (Mr = 267.32 g/mol). 
 
6-Methoxy-2-(4-methoxyphenyl)-3-methyl-1H-indole (8.2b)13 
The title compound was prepared from 3-methoxyaniline (11.7 g, 95 mmol), N,N-
dimethylaniline (18.8 mL) and 2-bromo-1-(4-methoxyphenyl)propan-1-one 8.1 (10.9 g, 
45 mmol) according to the general procedure. The crude product was purified by flash-
chromatography (PE/EtOAc 80/20, v/v). Yield: 3.9 g (32 %, white solid); mp 134 °C (ref:8 
136 °C). 1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 10.86 (s, 1H, indole-NH), 7.55 (d, 
J = 8.8 Hz, 2H, Ph-H-2,6), 7.36 (d, J = 8.6 Hz, 1H, indole-H-4), 7.06 (d, J = 8.8 Hz, 2H, 
Ph-H-3,5), 6.82 (d, J = 2.2 Hz, 1H, indole-H-7), 6.65 (dd, J = 8.6, 2.2 Hz, 1H, indole-H-6), 
3.81 (s, 3H, OCH3-4), 3.77 (s, 3H, indole-OCH3-6), 2.33 (s, 3H, indole-CH3-3).
 13C-NMR 
(75 MHz, DMSO-d6): δ [ppm] = 158.14 (Cquat, Ph-C-4), 157.23 (Cquat, indole-C-6), 134.44 
(Cquat, indole-C), 130.81 (Cquat, indole-C), 130.03 (Cquat, indole-C), 128.53 (+, Ph-C-2,6), 
125.56 (Cquat, Ph-C-1), 114.03 (+, Ph-C-3,5), 110.77 (+, indole-C-7), 107.40 (+, indole-C-
5), 105.37 (Cquat, indole-C), 99.87 (+, indole-C-4), 55.34 (+, OCH3-4), 55.11 (+, indole-
OCH3-6), 9.77 (+, indole-CH3-3). MS (ES-MS, DCM/MeOH + NH4OAc) m/z (rel. int. in %) 
= 268.0 ([M + H]+, 100). C17H17NO2 (Mr = 267.32 g/mol). 
 
5-Methoxy-3-methyl-2-phenyl-1H-indole (8.35) 
The title compound was prepared from 4-methoxyaniline (5.2 g, 42 mmol), N,N-
dimethylaniline (8.3 mL) and 2-bromo-1-phenylpropan-1-one 8.33 (4.3 g, 20 mmol) 
according to the general procedure. The crude product was purified by flash-
chromatography (PE/EtOAc 80/20, v/v). Yield: 2.0 g (41 %, white solid); mp 117 °C (ref:29 
114-116 °C). 1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 10.99 (s, 1H, indole-NH), 7.65 (dt, 
J = 2.8, 1.6 Hz, 2H, Ph-H-3,5), 7.50 (dd, J = 10.5, 4.9 Hz, 2H, Ph-H-2,6), 7.38 – 7.30 (m, 
1H, Ph-H-4), 7.25 (d, J = 8.7 Hz, 1H, indole-H-7), 7.01 (d, J = 2.4 Hz, 1H, indole-H-4), 
6.75 (dd, J = 8.7, 2.4 Hz, 1H, indole-H-6), 3.79 (s, 3H, OCH3-4), 2.39 (s, 3H, indole-CH3-
3). 13C-NMR (75 MHz, DMSO-d6) δ [ppm] = 153.09 (Cquat, indole-C-5), 134.31 (Cquat, 
indole-C), 133.09 (Cquat, Ph-C-1), 130.95 (Cquat, indole-C), 129.59 (Cquat, indole-C), 128.56 
(+, Ph-C-3,5), 127.24 (+, Ph-C-2,6), 126.75 (+, Ph-C-4), 111.63 (+, indole-C-7), 108.20 
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(Cquat, indole-C), 106.50 (+, indole-C-6), 99.99 (+, indole-C-4), 55.22 (+, indole-OCH3-5), 
9.88 (+, indole-CH3-3). MS (EI-MS, 70 eV) m/z (rel. int. in %) = 237.1 ([M
+●], 100), 195.1 
(12), 105.1 (10). C16H15NO (Mr = 237.30 g/mol). 
 
5-Methoxy-2-(4-methoxyphenyl)-1H-indole (8.36)30 
The title compound was prepared from 4-methoxyaniline (5.2 g, 42 mmol), N,N-
dimethylaniline (8.3 mL) and 2-bromo-1-(4-methoxyphenyl)ethanone 8.34 (4.6 g, 
20 mmol) according to the general procedure. The crude product was purified by flash-
chromatography (PE/EtOAc 80/20, v/v). Yield: 2.5 g (49 %, beige solid); mp 211 °C (ref:31 
219-220 °C). 1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 11.25 (s, 1H, indole-NH), 7.80 – 
7.70 (m, 2H, Ph-H-2,6), 7.25 (d, J = 8.7 Hz, 1H, indole-H-7), 7.06 – 6.96 (m, 3H, indole-H-
4, Ph-H-3,5), 6.74 – 6.64 (m, 2H, indole-H-3, indole-H-6), 3.80 (s, 3H, OCH3-4), 3.75 (s, 
3H, indole-OCH3-6). 
13C-NMR (75 MHz, DMSO-d6): δ [ppm] = 158.57 (Cquat, Ph-C-4), 
153.42 (Cquat, indole-C-5), 138.16 (Cquat, indole-C), 131.92 (Cquat, indole-C), 129.12 (Cquat, 
Ph-C-1), 126.10 (+, Ph-C-2,6), 124.90 (Cquat, indole-C), 114.20 (+, Ph-C-3,5), 111.57 
(+, indole-C-7), 110.97 (+, indole-C-6), 101.28 (+, indole-C-4), 97.15 (+, indole-C-3), 55.32 
(+, OCH3-4), 55.09 (+, indole-OCH3-5). MS (EI-MS, 70 eV) m/z (rel. int. in %) = 253.1 
([M+●], 100), 238.1 (31), 210.1 (31), 195.1 (12), 167.1 (9), 126.6 (21), 105.1 (10). 
C16H15NO2 (Mr = 253.30 g/mol). 
 
5-sec-Butyl-2-(4-methoxyphenyl)-1H-indole (8.37)27 
The title compound was prepared from 4-sec-butylaniline (6.3 g, 42 mmol), N,N-
dimethylaniline (8.3 mL) and 2-bromo-1-(4-methoxyphenyl)ethanone 8.34 (4.6 g, 
20 mmol) according to the general procedure. The crude product was purified by flash-
chromatography (PE/EtOAc 80/20, v/v). Yield: 2.0 g (36 %, colorless crystals); mp 194 °C 
(ref:27 191 °C). 1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 11.15 (s, 1H, indole-NH), 7.42 
(m, 1H, indole-H-4), 7.25 (d, J = 8.7 Hz, 1H, indole-H-7), 7.06 – 6.96 (m, 4H, Ph-H-2,6, 
Ph-H-3,5), 6.94 – 6.82 (m, 1H, indole-H-6), 6.67 (s, 1H, indole-H-3), 3.80 (s, 3H, OCH3-4), 
2.68 (t, J = 7.1 Hz, 1H, CH(CH3)CH2CH3), 1.65 (quin, J = 7 Hz, 2H, CH(CH3)CH2CH3), 
1.27 (J = 7.0 Hz, 3H, CH(CH3)CH2CH3), 0.89 (t, J = 7.1 Hz, 3H, CH(CH3)CH2CH3). 
13C-
NMR (75 MHz, DMSO-d6): δ [ppm] = 158.57 (Cquat, Ph-C-4), 138.54 (Cquat, indole-C), 
133.32 (Cquat, indole-C-5), 131.94 (Cquat, indole-C), 129.12 (Cquat, Ph-C-1), 126.10 (+, Ph-
C-2,6), 125.21 (Cquat, indole-C), 118.98 (+, indole-C-4), 114.56 (+, Ph-C-3,5), 111.41 
(+, indole-C-7), 111.07 (+, indole-C-6), 98.05 (+, indole-C-3), 55.32 (+, OCH3-4), 45.09 
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(+, CH(CH3)CH2CH3), 32.89 (-, CH(CH3)CH2CH3), 21.01 (+, CH(CH3)CH2CH3), 11.89 
(+, CH(CH3)CH2CH3). MS (EI-MS, 70 eV) m/z (rel. int. in %) = 279.1 ([M
+●], 100), 126.6 
(15), 105.1 (10). C19H21NO2 (Mr = 279.38 g/mol). 
 
8.6.2.3. Preparation of the compounds 8.44, 8.45 
(2,3-Dichlorophenyl)hydrazine (8.44)19 
A solution of sodium nitrite (2.6 g, 37.4 mmol) in water (8 mL) was added dropwise to a 
solution of 2,3-dichloroaniline (6.1 g, 37.4 mmol) in 24 mL water and 24 mL concentrated 
HCl at 0 °C. The solution was stirred for 10 min and then slowly added dropwise to a 
rapidly stirred mixture of SnCl2●2H2O (33.7 g, 149.5 mmol) in concentrated HCl (140 mL) 
at 0 °C. The reaction was allowed to warm to room temperature, stirred for 15 min, and 
filtered. The precipitate was washed on the filter with large portions of ice-cold ether and 
dried under reduced pressure to give the target compound, which was used in the next 
step without further purification. Yield: 5.2 g (78 %, white solid). 
 
6,7-Dichloro-2-(4-methoxyphenyl)-3-methyl-1H-indole (8.45)18, 20 
(2,3-Dichlorophenyl)hydrazine (2.0 g, 11.3 mmol) and 1-(4-methoxyphenyl)propan-1-one 
(1.9 g, 11.3 mmol) were dissolved in anhydrous EtOH (80 mL). After the addition of 40 mL 
of 32 % HCl, the solution was boiled under reflux for at least 48 h. Subsequently, the 
mixture was allowed to cool to room temperature (precipitation occurred). After 
concentration of the solution, the aqueous phase was extracted with EtOAc (3 x 250 mL). 
The organic layers were combined and washed with brine. The precipitate (white solid, not 
product), formed in the organic phase, was removed by filtration. The remaining organic 
phase was dried over Na2SO4 and the solvent was evaporated yielding dark red oil. The 
crude product was tediously purified by column chromatography (SiO2). The product was 
finally isolated with 25-fold excess of SiO2 (relative to crude substance) at a PE/EtOAc 
gradient of 97/3 (v/v). Yield: 5.2 g (15 %, yellow crystals). 1H-NMR (300 MHz, DMSO-d6): 
δ [ppm] = 11.42 (s, 1H, indole-NH), 7.65 – 7.59 (m, 2H, Ph-H-2,6), 7.49 (d, J = 8.4 Hz, 1H, 
indole-H-4), 7.22 – 7.17 (m, 1H, indole-H-5), 7.12 – 7.05 (m, 2H, Ph-H-3,5), 3.83 (d, J = 
2.1 Hz, 3H, OCH3-4), 2.33 (s, 3H, indole-CH3-3). 
13C-NMR (75 MHz, DMSO-d6): δ [ppm] = 
158.77 (Cquat, Ph-C), 136.59 (Cquat, indole-C), 133.42 (Cquat, indole-C), 129.74 (+, Ph-C-
2,6), 129.55 (Cquat, indole-C-Cl), 124.13 (Cquat, Ph-C-1), 123.29 (Cquat, indole-C), 120.32 (+, 
indole-C-5), 117.87 (+, indole-C-4), 113.86 (+, Ph-C-3,5), 113.50 (Cquat, indole-C-Cl), 
107.38 (Cquat, indole-C), 55.12 (+, OCH3-4), 9.44 (+, indole-CH3-3). MS (EI-MS, 70 eV) 
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m/z (rel. int. in %) = 307.1 (62), 306.1 (38), 305.1 ([M+●], 100), 292.1 (15), 290.0 ([M -
 CH3
+●], 28). HRMS (ESI-MS) m/z calcd. [M + H]+ 306.0447, found [M + H]+ 306.0448. 
C16H13Cl2NO (Mr = 306.19 g/mol). 
 
8.6.2.4. Preparation of the compounds 8.3a-8.8a  
General procedure5, 6 
With ice cooling, NaH (60 % in paraffin, 1.9 eq) was suspended in anhydrous DMF (15 mL 
per 10 mmol NaH) and stirred for 15 min under an atmosphere of nitrogen. Subsequently, 
5-methoxy-2-(4-methoxyphenyl)-3-methyl-1H-indole (8.2a, 1.0 eq) in anhydrous DMF 
(22.5 mL per 10 mmol 2-phenylindole) was added dropwise at 0 °C under an atmosphere 
of nitrogen. After stirring for 45 min at 0 °C, the corresponding alkyl halide (1.2 eq) in 
anhydrous DMF (45 mL per 10 mmol alkyl halide) was slowly added. After removing of the 
cooling bath, the mixture was stirred for additional 2.5 h at ambient temperature and then 
poured into ice water. The aqueous solution was extracted at least three times with 
EtOAc. The combined organic layers were washed with water and dried over Na2SO4. The 
solvent was removed under reduced pressure, and the crude product was purified by flash 
chromatography (SiO2) as indicated. 
 
5-Methoxy-2-(4-methoxyphenyl)-3-methyl-1-ethyl-1H-indole (8.3a)32  
The title compound was prepared from 8.2a (400 mg, 1.5 mmol) and iodoethane (280 mg, 
1.8 mmol) according to the general procedure. Flash chromatography yielded a yellow oil 
(330 mg, 85 %). 1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 7.32 (ddd, J = 9.8, 6.0, 3.6 Hz, 
3H, indole-H-7, Ph-H-2,6), 7.11 – 7.04 (m, 2H, Ph-H-3,5), 6.99 (d, J = 2.4 Hz, 1H, indole-
H-4), 6.78 (dd, J = 8.8, 2.4 Hz, 1H, indole-H-6), 4.56 (q, J = 7.1 Hz, 2H, NCH2CH3), 3.82 
(s, 3H, OCH3-4), 3.79 (s, 3H, indole-OCH3-5), 2.11 (s, 3H, indole-CH3-3), 1.29 (t, J = 
7.2 Hz, 3H, NCH2CH3). 
13C-NMR (75 MHz, DMSO-d6): δ [ppm] = 158.72 (Cquat, Ph-C-4), 
153.22 (Cquat, indole-C-5), 137.46 (Cquat, indole-C), 131.32 (+, Ph-C-2,6), 131.16 (Cquat, 
indole-C), 128.25 (Cquat, Ph-C-1), 123.92 (Cquat, indole-C), 113.86 (+, Ph-C-3,5), 110.89 (+, 
indole-C-6), 110.56 (+, indole-C-7), 106.88 (Cquat, indole-C), 100.25 (+, indole-C-4), 55.29 
(+, OCH3-4), 55.00 (+, indole-OCH3-5), 35.71 (-, NCH2CH3), 15.40 (+, NCH2CH3), 9.17 (+, 
indole-CH3-3). MS (EI-MS, 70 eV) m/z (rel. int. in %) = 295.1 ([M
+●], 100), 174.1 (20). 
C19H21NO2 (Mr = 295.38 g/mol). 
 
244 Experimental section  
1-Isopropyl-5-methoxy-2-(4-methoxyphenyl)-3-methyl-1H-indole (8.4a)5 
The title compound was prepared from 8.2a (400 mg, 1.5 mmol) and 2-iodopropane 
(310 mg, 1.8 mmol) according to the general procedure. Flash chromatography yielded a 
dark yellow oil (330 mg, 85 %). 1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 7.42 (t, J = 
7.2 Hz, 1H, indole-H-6), 7.15 (dd, J = 8.9, 2.3 Hz, 2H, Ph-H-2,6), 6.90 – 6.79 (m, 2H, Ph-
H-3,5), 6.76 (d, J = 2.2 Hz, 1H, indole-H-4), 6.63 (dd, J = 8.8, 2.4 Hz, 1H, indole-H-7), 
3.86 (s, 3H, OCH3-4), 3.82 (s, 3H, indole-OCH3-5), 4.41 – 4.27 (m, 1H, NCH(CH3)2), 1.99 
(s, 3H, indole-CH3-3), 1.42 (d, J = 7.0 Hz, 6H, NCH(CH3)2). MS (EI-MS, 70 eV) m/z 
(rel. int. in %) = 310.2 (25), 309.2 ([M+●], 100). C20H23NO2 (Mr = 309.40 g/mol). 
 
5-Methoxy-2-(4-methoxyphenyl)-3-methyl-1-nonyl-1H-indole (8.5a) 
The title compound was prepared from 8.2a (300 mg, 1.1 mmol) and 1-chlorononane 
(210 mg, 1.3 mmol) according to the general procedure. Flash chromatography yielded a 
dark orange oil (200 mg, 46 %). 1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 7.33-7.28 (m, 
3H, indole-H-7, Ph-H-2,6), 7.09-7.04 (m, 2H, Ph-H-3,5), 6.78 (dd, J = 2.5, 7.9 Hz, 1H, 
indole-H-6), 6.98 (d, 1H, J = 2.5 Hz, indole-H-4), 3.98 (t, 2H, J = 7.1 Hz, 
NCH2CH2(CH2)6CH3), 3.79 (s, 3H, OCH3-4), 3.83 (s, 3H, indole-OCH3-5), 2.11 (s, 3H, 
indole-CH3-3), 1.46-1.35 (m, 2H, NCH2CH2(CH2)6CH3), 1.26 - 1.18 (m, 8H, 
NCH2CH2(CH2)6CH3), 1.16-1.00 (m, 4H, NCH2CH2(CH2)6CH3), 0.81 – 0.74 (m, 3H, 
NCH2CH2(CH2)6CH3). MS (ES-MS, DCM/MeOH + NH4OAc) m/z (rel. int. in %) = 393.3 
([M + H]+, 100). C26H35NO2 (Mr = 393.56 g/mol). 
 
1-Decyl-6-methoxy-2-(4-methoxyphenyl)-3-methyl-1H-indole (8.6a) 
The title compound was prepared from 8.2a (500 mg, 1.9 mmol) and 1-bromodecane 
(500 mg, 2.3 mmol) according to the general procedure. Flash chromatography yielded a 
yellow oil (310 mg, 40 %). 1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 7.36 (d, J = 8.5 Hz, 
1H, indole-H-7), 7.33 – 7.27 (m, 2H, Ph-H-2,6), 7.07 (t, J = 5.8 Hz, 2H, Ph-H-3,5), 6.95 (d, 
J = 2.1 Hz, 1H, indole-H-4), 6.69 (dd, J = 8.5, 2.2 Hz, 1H, indole-H-6), 3.99 (t, J = 7.2 Hz, 
2H, NCH2CH2(CH2)7CH3), 3.82 (s, 3H, OCH3-4), 3.80 (s, 3H, indole-OCH3-5), 2.09 (s, 3H, 
indole-CH3), 1.45 – 1.35 (m, 2H, NCH2CH2(CH2)7CH3), 1.28 – 1.20 (m, 10H, 
NCH2CH2(CH2)7CH3), 1.06 – 0.99 (m, 4H, NCH2CH2(CH2)7CH3), 0.87 – 0.83 (m, 3H, 
NCH2CH2(CH2)7CH3). MS (EI-MS, 70 eV) m/z (rel. int. in %) = 408.4 (24), 407.3 ([M
+●], 
100), 280.1 (17). C27H37NO2 (Mr = 407.59 g/mol). 
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5-Methoxy-2-(4-methoxyphenyl)-3-methyl-1-tetradecyl-1H-indole (8.7a) 
The title compound was prepared from 8.2a (300 mg, 1.1 mmol) and 1-chlorotetradecane 
(310 mg, 1.3 mmol) according to the general procedure. Flash chromatography yielded a 
yellow oil (170 mg, 37 %). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 7.32 – 7.27 (m, 2H, Ph-
H-2,6), 7.23 (d, J = 8.8 Hz, 1H, indole-H-7), 7.04 – 7.01 (m, 2H, Ph-H-3,5), 7.00 – 6.98 (m, 
1H, indole-H-4), 6.88 (dd, J = 8.5, 2.2 Hz, 1H, indole-H-6), 3.99 – 3.92 (m, 2H, 
NCH2CH2(CH2)11CH3), 3.89 (s, 3H, OCH3-4), 3.88 (s, 3H, indole-OCH3-5), 2.19 (s, 3H, 
indole-CH3), 2.05 (s, 2H, NCH2CH2(CH2)11CH3), 1.62 – 1.54 (m, 2H, 
NCH2CH2(CH2)11CH3), 1.27 – 1.20 (m, 16H, NCH2CH2(CH2)11CH3), 1.18 – 1.09 (m, 6H, 
NCH2CH2(CH2)11CH3), 0.90 – 0.85 (m, 3H, NCH2CH2(CH2)11CH3). MS (ES-MS, 
DCM/MeOH + NH4OAc) m/z (rel. int. in %) = 512.2 (60), 496.1 (85), 480.1 ([M
+●] + NH3, 
100), 464.2 ([M + H]+, 20), 462.2 ([M+●], 15). C31H45NO2 (Mr = 463.69 g/mol). 
 
1-Hexadecyl-5-methoxy-2-(4-methoxyphenyl)-3-methyl-1H-indole (8.8a)  
The title compound was prepared from 8.2a (300 mg, 1.1 mmol) and 1-chlorohexadecane 
(350 mg, 1.3 mmol) according to the general procedure. Flash chromatography yielded an 
orange oil (490 mg, 41 %). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 7.33 – 7.27 (m, 2H, Ph-
H-2,6), 7.23 (d, J = 8.8 Hz, 1H, indole-H-7), 7.04 – 7.02 (m, 2H, Ph-H-3,5), 7.00 – 6.98 (m, 
1H, indole-H-4), 6.88 (dd, J = 8.5, 2.5 Hz, 1H, indole-H-6), 3.99 – 3.92 (m, 2H, 
NCH2CH2(CH2)13CH3), 3.90 (s, 3H, OCH3-4), 3.89 (s, 3H, indole-OCH3-5), 2.20 (s, 3H, 
indole-CH3), 1.61 – 1.54 (s, 2H, NCH2CH2(CH2)13CH3), 1.39 – 1.22 (m, 4H, 
NCH2CH2(CH2)13CH3), 1.18 – 1.09 (m, 22H, NCH2CH2(CH2)13CH3), 0.92 – 0.85 (m, 3H, 
NCH2CH2(CH2)13CH3). MS (ES-MS, DCM/MeOH + NH4OAc) m/z (rel. int. in %) = 540.2 
(100), 524.2 (40), 508.2 ([M+●] + NH3, 75, 491.2 ([M + H]
+, 10), 490.1 ([M+●], 20). 
C33H49NO2 (Mr = 491.75 g/mol). 
 
8.6.2.5. Preparation of the compounds 8.9a-8.17a, 8.12b, 8.14b, 8.17b, 
8.38-8.40, 8.46 
General procedure5, 6 
With ice cooling, NaH (60 % in paraffin, 1.9 eq) was suspended in anhydrous DMF (15 mL 
per 10 mmol NaH) and stirred for 15 min under an atmosphere of nitrogen. Subsequently, 
the corresponding 2-phenylindole (1.0 eq) in anhydrous DMF (22.5 mL per 10 mmol 
indole) was added dropwise at 0 °C under an atmosphere of nitrogen. After stirring for 
45 min at 0 °C, the corresponding benzyl halide (1.2 eq) in anhydrous DMF (45 mL per 
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10 mmol alkyl halide) was slowly added. After removing of the cooling bath, the mixture 
stirred for additional 2.5 h at ambient temperature before it was poured into ice water. The 
aqueous solution was extracted three times with EtOAc. The combined organic layers 
were washed with water and dried (Na2SO4). The solvent was removed under vacuum 
and the crude product was purified by flash-chromatography (SiO2) as indicated. 
 
1-Benzyl-5-methoxy-2-(4-methoxyphenyl)-3-methyl-1H-indole (8.9a)6 
The title compound was prepared from 8.2a (900 mg, 3.4 mmol) and (bromomethyl)-
benzene (690 mg, 4.0 mmol) according to the general procedure. Flash chromatography 
yielded a yellow, viscous oil (970 mg, 81 %). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 7.40 – 
7.35 (m, 1H, indole-H-7), 7.27 – 7.18 (m, 5H, Ph-H-2,6, benzyl-H-3,4,5), 7.08 – 7.02 (m, 
2H, benzyl-H-2,6), 6.97 (d, J = 2.0 Hz, 1H, indole-H-4), 6.96 – 6.91 (m, 2H, Ph-H-3,5), 
6.81 (dd, J = 8.8, 2.5 Hz, 1H, indole-H-6), 5.19 (s, 2H, NCH2), 3.89 (s, 3H, OCH3-4), 3.84 
(s, 3H, indole-OCH3-5), 2.28 (s, 3H, indole-CH3-3). MS (EI-MS, 70 eV) m/z (rel. int. in %) = 
358.2 (23), 357.1 ([M+●], 100), 266.1 ([M+●] – ●C7H7, 30), 91.0 (
●C7H7, 16). C24H23NO2 (Mr = 
357.44 g/mol). 
 
1-(4-Fluorobenzyl)-5-methoxy-2-(4-methoxyphenyl)-3-methyl-1H-indole (8.10a) 
The title compound was prepared from 8.2a (250 mg, 0.9 mmol) and 1-(bromomethyl)-4-
fluorobenzene (215 mg, 1.1 mmol) according to the general procedure. Flash 
chromatography yielded a colorless oil (130 mg, 37 %). 1H-NMR (300 MHz, CDCl3): 
δ [ppm] = 7.25 – 7.18 (m, 2H, Ph-H-2,6), 7.08 – 7.01 (m, 2H, Ph-H-3,5), 6.98 – 6.92 (m, 
2H, benzyl-H), 6.92 - 6.87 (m, 4H, indole-H-4, indole-H-7, benzyl-H), 6.82 (dd, J = 8.8, 
2.5 Hz, 1H, indole-H-6), 5.14 (s, 2H, NCH2), 3.89 (s, 3H, OCH3-4), 3.84 (s, 3H, indole-
OCH3-5), 2.25 (s, 3H, indole-CH3-3). MS (ES-MS, DCM/MeOH + NH4OAc) m/z 
(rel. int. In %) = 377.1 (30), 376.1 ([M + H]+, 100). C24H22FNO2 (Mr = 375.44 g/mol). 
 
1-(4-Chlorobenzyl)-5-methoxy-2-(4-methoxyphenyl)-3-methyl-1H-indole (8.11a)6 
The title compound was prepared from 8.2a (300 mg, 1.1 mmol) and 1-chloro-4-
(chloromethyl)benzene (215 mg, 1.3 mmol) according to the general procedure. Flash 
chromatography yielded a yellow oil (210 mg, 48 %). 1H-NMR (300 MHz, CDCl3): 
δ [ppm] = 7.24 - 7.16 (s, 4H, benzyl-H, Ph-H-2,6), 7.06 (d, J = 2.4 Hz, 1H, indole-H-4), 
7.02 (d, J = 8.8 Hz, 1H, indole-H-7), 6.99 – 6.90 (m, 2H, benzyl-H), 6.86 (d, J = 8.5 Hz, 
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2H, Ph-H-3,5), 6.82 (dd, J = 8.8, 2.5 Hz, 1H, indole-H-6), 5.14 (s, 2H, NCH2), 3.89 (s, 3H, 
OCH3-4), 3.84 (s, 3H, indole-OCH3-5), 2.26 (s, 3H, indole-CH3-3). 
13C-NMR (75 MHz, 
CDCl3): δ [ppm] = 159.37 (Cquat, Ph-C-4), 154.19 (Cquat, indole-C-5), 138.27 (Cquat, benzyl-
C), 137.21 (Cquat, benzyl-C), 132.73 (Cquat, indole-C), 131.61 (+, Ph-C-2,6), 129.22 (Cquat, 
indole-C), 128.74 (+, benzyl-C), 127.40 (+, benzyl-C), 124.13 (Cquat, Ph-C-1), 113.90 (+, 
Ph-C-3,5), 111.77 (+, indole-C-6), 110.68 (+, indole-C-7), 108.72 (Cquat, indole-C), 100.88 
(+, indole-C-4), 55.98 (+, indole-OCH3-5), 55.31 (+, OCH3-4), 47.01 (-, NCH2), 9.51 (+, 
indole-CH3-3). MS (EI-MS, 70 eV) m/z (rel. int. in %) = 393.2 (30), 392.2 (25), 391.2 ([M
+●], 
100), 266.1 (68), 125.0 (16). C24H22ClNO2 (Mr = 391.89 g/mol). 
 
1-(4-Bromobenzyl)-5-methoxy-2-(4-methoxyphenyl)-3-methyl-1H-indole (8.12a) 
The title compound was prepared from 8.2a (300 mg, 1.1 mmol) and 1-bromo-4-
(bromomethyl)benzene (330 mg, 1.3 mmol) according to the general procedure. Flash 
chromatography yielded an orange oil (290 mg, 60 %). 1H-NMR (300 MHz, DMSO-d6): 
δ [ppm] = 7.43 – 7.35 (m, 2H, benzyl-H), 7.32 – 7.24 (m, 2H, Ph-H-2,6), 7.18 (d, J = 
8.8 Hz, 1H, indole-H-7), 7.07 – 6.99 (m, 3H, benzyl-H, indole-H-4), 6.79 – 6.70 (m, 3H, 
Ph-H-3,5, indole-H-6), 5.21 (s, 2H, NCH2), 3.78 (s, 6H, indole-OCH3-5, OCH3-4), 2.18 (s, 
3H, indole-CH3-3). 
13C-NMR (75 MHz, DMSO-d6): δ [ppm] = 158.88 (Cquat, Ph-C-4), 
153.58 (Cquat, indole-C-5), 138.02 (Cquat, benzyl-C), 137.63 (Cquat, indole-C), 131.27 (+, 
benzyl-C), 131.17 (+, benzyl-C), 128.67 (Cquat, indole-C), 127.99 (+, Ph-C-2,6), 123.29 
(Cquat, Ph-C-1), 119.80 (Cquat, benzyl-C), 117.55 (Cquat, indole-C), 113.97 (+, Ph-C-3,5), 
111.30 (+, indole-C-6), 110.90 (+, indole-C-7), 107.71 (Cquat, indole-C), 100.50 (+, indole-
C-4), 55.29 (+, indole-OCH3-5), 55.02 (+, OCH3-4), 45.95 (-, NCH2), 9.30 (+, indole-CH3-
3). MS (EI-MS, 70 eV) m/z (rel. int. in %) = 437.1 (70), 435.1 ([M+●], 72), 266.1 ([M+●] – 
●CH2C6H4Br, 100), 223.1 (22), 171.0 (25), 169.0 (26), 90.1 (21). C24H22BrNO2 (Mr = 
436.34 g/mol). 
 
1-(4-Bromobenzyl)-6-methoxy-2-(4-methoxyphenyl)-3-methyl-1H-indole (8.12b) 
The title compound was prepared from 8.2b (500 mg, 1.9 mmol) and 1-bromo-4-
(bromomethyl)benzene (570 mg, 2.3 mmol) according to the general procedure. Flash 
chromatography yielded an yellow oil (290 mg, 57 %). 1H-NMR (300 MHz, CDCl3): 
δ [ppm] = 7.54 – 7.45 (m, 1H, indole-H-4), 7.35 (d, J = 8.3 Hz, 2H, benzyl-H), 7.19 (d, J = 
8.8 Hz, 2H, Ph-H-2,6), 6.93 (d, J = 8.8 Hz, 2H, Ph-H-3,5), 6.86 – 6.78 (m, 3H, benzyl-H, 
indole-H-7), 6.61 (d, 1H, indole-H-5), 5.10 (s, 2H, NCH2), 3.84 (s, 3H, OCH3-4), 3.79 (s, 
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3H, indole-OCH3-6), 2.26 (s, 3H, indole-CH3-3). MS (EI-MS, 70 eV) m/z (rel. int. in %) = 
437.1 (56), 435.1 ([M+●], 65), 266.1 ([M+●] – ●CH2C6H4Br, 100), 223.1 (12). C24H22BrNO2 
(Mr = 436.34 g/mol). 
 
5-Methoxy-2-(4-methoxyphenyl)-3-methyl-1-(4-methylbenzyl)-1H-indole (8.13a)6 
The title compound was prepared from 8.2a (250 mg, 0.9 mmol) and 1-(bromomethyl)-4-
methylbenzene (210 mg, 1.1 mmol) according to the general procedure. Flash 
chromatography yielded a colorless oil (140 mg, 40 %). 1H-NMR (300 MHz, CDCl3): 
δ [ppm] = 7.27 – 7.23 (m, 2H, Ph-H-2,6), 7.07 – 7.01 (m, 4H, indole-H-4, indole-H-7, 
benzyl-H), 6.96 – 6.90 (m, 2H, Ph-H-3,5), 6.85 (d, J = 8.1 Hz, 2H, benzyl-H), 6.80 (dd, 
J = 8.8, 2.5 Hz, 1H, indole-H-6), 5.14 (s, 2H, NCH2), 3.89 (s, 3H, OCH3-4), 3.84 (s, 3H, 
indole-OCH3-5), 2.29 (s, 3H, benzyl-CH3), 2.27 (s, 3H, indole-CH3-3). MS (ES-MS, 
DCM/MeOH + NH4OAc) m/z (rel. int. in %) = 373.1 (25), 372.0 ([M + H]
+, 100). C25H25NO2 
(Mr = 371.47 g/mol). 
 
1-(Biphenyl-4-ylmethyl)-5-methoxy-2-(4-methoxyphenyl)-3-methyl-1H-indole (8.14a) 
The title compound was prepared from 8.2a (500 mg, 1.9 mmol) and 4-
(chloromethyl)biphenyl (450 mg, 2.2 mmol) according to the general procedure. Flash 
chromatography yielded a dark yellow oil (530 mg, 64 %). 1H-NMR (300 MHz, DMSO-d6): 
δ [ppm] = 7.71 – 7.64 (m, 1H, indole-H-7), 7.60 – 7.52 (m, 2H, Ph-H-2,6), 7.49 (dd, 
J = 7.6, 3.9 Hz, 3H, biphenyl-H), 7.45 – 7.38 (m, 2H, biphenyl-H), 7.37 – 7.31 (m, 2H, 
biphenyl-H), 7.26 – 7.19 (m, 1H, indole-H-4), 7.09 – 7.01 (m, 2H, biphenyl-H), 6.91 (d, 
J = 8.3 Hz, 2H, Ph-H-3,5), 6.74 (dd, J = 8.8, 2.4 Hz, 1H, indole-H-6), 5.29 (s, 2H, NCH2), 
3.80 (s, 3H, OCH3-4), 3.79 (s, 3H, indole-OCH3-5), 2.20 (s, 3H, indole-CH3-3). MS (EI-MS, 
70 eV) m/z (rel. int. in %) = 433.3 ([M+●], 100), 167.1 (100). C30H27NO2 (Mr = 
433.54 g/mol). 
 
1-(Biphenyl-4-ylmethyl)-6-methoxy-2-(4-methoxyphenyl)-3-methyl-1H-indole (8.14b) 
The title compound was prepared from 8.2b (350 mg, 1.3 mmol) and 4-
(chloromethyl)biphenyl (450 mg, 1.6 mmol) according to the general procedure. Flash 
chromatography yielded a dark yellow oil (350 mg, 62 %). 1H-NMR (300 MHz, DMSO-d6): 
δ [ppm] = 7.71 – 7.64 (m, 1H, indole-H-4), 7.61 – 7.56 (m, 2H, biphenyl-H), 7.55 – 7.47 
(m, 2H, Ph-H-2,6), 7.46 – 7.37 (m, 4H, biphenyl-H), 7.36 – 7.26 (m, 3H, biphenyl-H), 6.97-
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6.90 (m, 3H, indole-H-7, Ph-H-3,5), 6.74 (dd, J = 8.8, 2.4 Hz, 1H, indole-H-5), 5.31 (s, 2H, 
NCH2), 3.79 (s, 3H, OCH3-4), 3.72 (s, 3H, indole-OCH3-6), 2.19 (s, 3H, indole-CH3-3). MS 
(EI-MS, 70 eV) m/z (rel. int. in %) = 433.3 ([M+●], 100), 266.1 (80), 167.0 (68). C30H27NO2 
(Mr = 433.54 g/mol). 
 
5-Methoxy-2-(4-methoxyphenyl)-3-methyl-1-(3-phenylpropyl)-1H-indole (8.15a) 
The title compound was prepared from 8.2a (350 mg, 1.3 mmol) and (3-
chloropropyl)benzene (240 mg, 1.6 mmol) according to the general procedure. Flash 
chromatography yielded a yellow oil (160 mg, 32 %). 1H-NMR (300 MHz, CDCl3): δ [ppm] 
= 7.52 – 7.44 (m, 3H, indole-H-7, Ph-H), 7.27 – 7.18 (m, 5H, Ph-H), 6.97 (d, J = 2.0 Hz, 
1H, indole-H-4), 6.96 – 6.91 (m, 2H, Ph-H), 6.81 (dd, J = 8.8, 2.5 Hz, 1H, indole-H-6), 4.38 
(t, J = 7.1 Hz, 2H, NCH2CH2CH2), 3.83 (s, 3H, OCH3-4), 3.79 (s, 3H, indole-OCH3-5), 2.86 
(t, 2H, NCH2CH2CH2), 2.28 (s, 3H, indole-CH3-3), 2.09 – 2.01 (m, 2H, NCH2CH2CH2). MS 
(EI-MS, 70 eV) m/z (rel. int. in %) = 385.2 ([M+●], 100), 281.2 (60), 266.2 (80), 207.0 (55), 
91.0 (30). C26H27NO2 (Mr = 385.50 g/mol). 
 
5-Methoxy-2-(4-methoxyphenyl)-3-methyl-1-(4-nitrobenzyl)-1H-indole (8.16a) 
The title compound was prepared from 8.2a (500 mg, 1.9 mmol) and 1-(bromomethyl)-4-
nitrobenzene (490 mg, 2.2 mmol) according to the general procedure. Flash 
chromatography yielded a dark yellow solid (170 mg, 22 %); mp 152 °C. 1H-NMR 
(300 MHz, CDCl3): δ [ppm] = 8.22 – 8.11 (m, 2H, benzyl-H-3,5), 7.51 – 7.44 (m, 1H, 
indole-H-7), 7.38 – 7.34 (m, 1H, indole-H-4), 7.22 (d, J = 8.7 Hz, 1H, indole-H-6), 7.02 – 
6.86 (m, 4H, benzyl-H-2,6, Ph-H-2,6), 6.85 – 6.67 (m, 2H, Ph-H-3,5), 5.25 (s, 2H, NCH2), 
3.89 – 3.80 (m, 6H, indole-OCH3-5, OCH3-4), 1.59 – 1.53 (m, 3H, indole-CH3-3). MS (EI-
MS, 70 eV) m/z (rel. int. in %) = 404.1 (20), 403.1 ([M+●], 100), 402.0 (25). C24H22N2O4 
(Mr =  402.44 g/mol). 
 
Ethyl 4-{[5-methoxy-2-(4-methoxyphenyl)-3-methyl-1H-indol-1-yl]methyl}benzoate 
(8.17a) 
The title compound was prepared from 8.2a (300 mg, 1.1 mmol) and ethyl 4-(bromo-
methyl)benzoate (330 mg, 1.3 mmol) according to the general procedure. Flash chromato-
graphy yielded a yellow oil (320 mg, 68 %). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 7.94 – 
7.85 (m, 2H, benzoate-H-3,5), 7.23 – 7.18 (m, 2H, Ph-H-2,6), 7.08 (d, J = 2.4 Hz, 1H, 
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indole-H-4), 7.00 (d, J = 6.5 Hz, 1H, indole-H-7), 6.97 (d, J = 6.1 Hz, 2H, benzoate-H-2,6), 
6.94 – 6.88 (m, 2H, Ph-H-3,5), 6.80 (dd, J = 8.8, 2.4 Hz, 1H, indole-H-6), 5.19 (s, 2H, 
NCH2), 4.40 – 4.26 (m, 2H, COOCH2CH3), 3.87 (s, 3H, OCH3-4), 3.79 (s, 3H, indole-
OCH3-5), 2.28 (s, 3H, indole-CH3-3), 1.39 – 1.30 (m, 3H, COOCH2CH3). 
13C-NMR 
(75 MHz, CDCl3): δ [ppm] = 171.03 (Cquat, COOCH2CH3), 166.25 (Cquat, benzoate-C-4), 
159.42 (Cquat, Ph-C-4), 154.28 (Cquat, indole-C-5), 143.92 (Cquat, benzoate-C-1), 138.30 
(Cquat, indole-C), 131.92 (Cquat, indole-C), 131.59 (+, Ph-C-2,6), 129.88 (+, benzoate-C-
3,5), 129.34 (Cquat, indole-C), 125.96 (+, benzoate-C-2,6), 124.05 (Cquat, Ph-C-1), 113.91 
(+, Ph-C-3,5), 111.79 (+, indole-C-6), 110.65 (+, indole-C-7), 108.74 (Cquat, indole-C), 
100.90 (+, indole-C-4), 60.86 (-, COOCH2CH3), 55.85 (+, indole-OCH3-5), 55.19 (+, OCH3-
4), 47.43 (-, NCH2), 14.24 (+, COOCH2CH3), 9.51 (+, indole-CH3-3). MS (EI-MS, 70 eV) 
m/z (rel. int. in %) = 430.2 (34), 429.2 ([M+●], 100), 266.1 (62), 223.1 (23), 163.1 (23), 
107.1 (22). C27H27NO4 (Mr = 429.51 g/mol). 
 
Ethyl 4-{[6-methoxy-2-(4-methoxyphenyl)-3-methyl-1H-indol-1-yl]methyl}benzoate 
(8.17b) 
The title compound was prepared from 8.2b (300 mg, 1.1 mmol) and ethyl 4-(bromo-
methyl)benzoate (330 mg, 1.3 mmol) according to the general procedure. Flash 
chromatography yielded a yellow oil (340 mg, 72 %). 1H-NMR (600 MHz, CDCl3): 
δ [ppm] = 7.94 – 7.90 (m, 2H, benzoate-H-3,5), 7.52 – 7.48 (m, 1H, indole-H-4), 7.22 – 
7.17 (m, 2H, Ph-H-2,6), 7.02 (d, J = 8.5 Hz, 2H, benzoate-H-2,6), 6.94 – 6.89 (m, 2H, Ph-
H-3,5), 6.83 (dd, J = 8.6, 2.2 Hz, 1H, indole-H-5), 6.60 (d, J = 2.2 Hz, 1H, indole-H-7), 
5.20 (s, 2H, NCH2), 4.35 (q, J = 7.1 Hz, 2H, COOCH2CH3), 3.83 (s, 3H, OCH3-4), 3.77 (s, 
3H, indole-OCH3-6), 2.27 (s, 3H, indole-CH3-3), 1.37 (t, J = 7.1 Hz, 3H, COOCH2CH3). 
13C-NMR (151 MHz, CDCl3): δ [ppm] = 171.11 (Cquat, COOCH2CH3), 166.34 (Cquat, 
benzoate-C-4), 159.22 (Cquat, Ph-C-4), 156.48 (Cquat, indole-C-6), 143.64 (Cquat, benzoate-
C-1), 137.41 (Cquat, indole-C), 136.41 (Cquat, indole-C), 131.62 (+, Ph-C-2,6), 129.88 (+, 
benzonate-C-3,5), 125.97 (+, benzoate-C-2,6), 124.16 (Cquat, Ph-C-1), 123.44 (Cquat, 
indole-C), 119.46 (+, indole-C-4), 113.84 (+, Ph-C-3,5), 109.00 (Cquat, indole-C), 108.81 
(+, indole-C-5), 93.96 (+, indole-C-7), 60.89 (-, COOCH2CH3), 55.73 (+, indole-OCH3-6), 
55.24 (+, OCH3-4), 47.34 (-, NCH2), 14.23 (+, COOCH2CH3), 9.44 (+, indole-CH3-3). MS 
(EI-MS, 70 eV) m/z (rel. int. in %) = 430.2 (27), 429.2 ([M+●], 100), 266.1 (87), 220.1 (22), 
163.1 (26), 107.1 (21). C27H27NO4 (Mr = 429.51 g/mol). 
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Ethyl 4-[(5-methoxy-3-methyl-2-phenyl-1H-indol-1-yl)methyl]benzoate (8.38) 
The title compound was prepared from 8.35 (270 mg, 1.1 mmol) and ethyl 4-(bromo-
methyl)benzoate (330 mg, 1.3 mmol) according to the general procedure. Flash chromato-
graphy yielded a yellow oil (130 mg, 29 %). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 7.99 – 
7.91 (m, 2H, benzoate-H-3,5), 7.47 – 7.38 (m, 3H, Ph-H-2,4,6), 7.37 – 7.31 (m, 2H, Ph-H-
3,5), 7.13 (d, J = 2.4 Hz, 1H, indole-H-4), 7.08 – 6.09 (m, 3H, benzoate-H-2,6, indole-H-7), 
6.86 (dd, J = 8.8, 2.4 Hz, 1H, indole-H-6), 5.26 (s, 2H, NCH2), 4.38 (dt, J = 14.3, 5.3 Hz, 
2H, COOCH2CH3), 3.92 (s, 3H, indole-OCH3-5), 2.34 (s, 3H, indole-CH3-3), 1.39 (t, J = 
7.1 Hz, 3H, COOCH2CH3). 
13C-NMR (75 MHz, CDCl3): δ [ppm] = 166.36 (Cquat, 
COOCH2CH3), 154.34 (Cquat, indole-C-5), 143.81 (Cquat, benzoate-C-1), 138.49 (Cquat, Ph-
C-1), 132.10 (Cquat, indole-C), 131.92 (Cquat, indole-C), 130.44 (+, benzonate-C-3,5), 
129.95 (+, Ph-C-3,5), 129.45 (Cquat, benzoate-C-1), 129.34 (Cquat, indole-C), 128.49 (+, 
benzonate-C-2,6), 128.03 (+, Ph-C-4), 126.01 (+, Ph-C-2,6), 112.13 (+, indole-C-6), 
110.83 (+, indole-C-7), 109.19 (Cquat, indole-C), 101.03 (+, indole-C-4), 60.95 (-, 
COOCH2CH3), 55.97 (+, indole-OCH3-6), 47.61 (-, NCH2), 14.31 (+, COOCH2CH3), 9.58 
(+, indole-CH3-3). MS (EI-MS, 70 eV) m/z (rel. int. in %) = 400.3 (25), 399.2 ([M
+●], 100), 
236.2 (31), 193.2 (33), 163.1 (26). C26H25NO3 (Mr = 399.48 g/mol). 
 
Ethyl 4-{[5-methoxy-2-(4-methoxyphenyl)-1H-indol-1-yl]methyl}benzoate (8.39) 
The title compound was prepared from 8.36 (290 mg, 1.1 mmol) and ethyl 4-(bromo-
methyl)benzoate (330 mg, 1.3 mmol) according to the general procedure. Flash chromato-
graphy yielded a yellow oil (140 mg, 30 %). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 8.00 – 
7.93 (m, 2H, benzoate-H-3,5), 7.36 – 7.28 (m, 2H, Ph-H-2,6), 7.13 (d, J = 2.4 Hz, 1H, 
indole-H-4), 7.08 (d, J = 8.4 Hz, 2H, benzoate-H-2,6), 7.04 – 6.98 (m, 1H, indole-H-7), 
6.94 – 6.87 (m, 2H, Ph-H-3,5), 6.80 (dd, J = 8.8, 2.5 Hz, 1H, indole-H-6), 6.54 (s, 1H, 
indole-H-3), 5.34 (s, 2H, NCH2), 4.36 (q, J = 7.1 Hz, 2H, COOCH2CH3), 3.86 (s, 3H, 
OCH3-4), 3.82 (s, 3H, indole-OCH3-5), 1.37 (t, J = 7.1 Hz, 3H, COOCH2CH3). 
13C-NMR 
(75 MHz, CDCl3): δ [ppm] = 171.40 (Cquat, COOCH2CH3), 166.30 (Cquat, benzoate-C-4), 
159.62 (Cquat, Ph-C-4), 154.63 (Cquat, indole-C-5), 143.55 (Cquat, benzoate-C-1), 132.98 
(Cquat, indole-C), 130.35 (+, Ph-C-2,6), 130.07 (+, benzonate-C-3,5), 129.57 (Cquat, indole-
C), 128.83 (Cquat, indole-C), 125.89 (+, benzonate-C-2,6), 124.94 (Cquat, Ph-C-1), 114.07 
(+, Ph-C-3,5), 111.87 (+, indole-C-6), 110.95 (+, indole-C-7), 102.31 (+, indole-C-3), 
101.72 (+, indole-C-4), 60.95 (-, COOCH2CH3), 55.83 (+, OCH3-4), 55.30 (+, indole-OCH3-
5), 47.63 (-, NCH2), 14.26 (+, COOCH2CH3). MS (EI-MS, 70 eV) m/z (rel. int. in %) 
= 416.3 (24), 415.2 ([M+●], 78), 252.2 (100), 209.2 (33), 163.1 (18), 107.1 (19). C26H25NO4 
(Mr = 415.48 g/mol). 
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Ethyl 4-{[5-sec-butyl-2-(4-methoxyphenyl)-1H-indol-1-yl]methyl}benzoate (8.40) 
The title compound was prepared from 8.37 (300 mg, 1.1 mmol) and ethyl 4-(bromo-
methyl)benzoate (310 mg, 1.3 mmol) according to the general procedure. Flash chromato-
graphy yielded a yellow oil (150 mg, 31 %). 1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 7.84 
(d, J = 8.2 Hz, 2H, benzoate-H-3,5), 7.42 – 7.34 (m, 3H, indole-H-4, Ph-H-2,6), 7.19 (d, 
J = 8.4 Hz, 1H, indole-H-7), 7.04 (d, J = 8.2 Hz, 2H, benzoate-H-2,6), 7.02 – 6.98 (m, 2H, 
Ph-H-3,5), 6.94 (dd, J = 8.5, 1.3 Hz, 1H, indole-H-6), 6.52 (s, 1H, indole-H-3), 5.46 (s, 2H, 
NCH2), 4.27 (q, J = 7.1 Hz, 2H, COOCH2CH3), 3.77 (s, 3H, OCH3-4), 2.70 – 2.57 (m, 1H, 
indole-CH(CH3)(CH2CH3)), 2.02 – 1.97 (m, 3H, COOCH2CH3), 1.58 (p, J = 7.3 Hz, 2H, 
indole-CH(CH3)(CH2CH3)), 1.27 (t, J = 7.1 Hz, 3H, indole-CH(CH3)(CH2CH3)), 0.82 – 0.73 
(m, 3H, indole-CH(CH3)(CH2CH3)). 
13C-NMR (75 MHz, DMSO-d6): δ [ppm] = 172.10 (Cquat, 
COOCH2CH3), 166.30 (Cquat, benzoate-C-4), 159.62 (Cquat, Ph-C-4), 154.63 (Cquat, indole-
C), 151.42 (Cquat, benzoate-C-1), 138.41 (Cquat, indole-C), 130.26 (+, Ph-C-2,6), 129.21 (+, 
benzonate-C-3,5), 129.17 (Cquat, indole-C), 127.38 (Cquat, indole-C), 125.96 (+, benzoate-
C-2,6), 122.22 (Cquat, Ph-C-1), 121.11 (+, indole-C-4), 117.58 (+, indole-C-6), 115.49 (+, 
Ph-C-3,5), 110.23 (+, indole-C-7), 100.99 (+, indole-C-3), 60.95 (-, COOCH2CH3), 55.82 
(+, OCH3-4), 46.50 (-, NCH2), 40.94 (+, indole-CH(CH3)(CH2CH3)), 31.24 (-, indole-
CH(CH3)(CH2CH3)), 22.27 (+, indole-CH(CH3)(CH2CH3)), 14.13 (+, COOCH2CH3), 12.17 
(+, indole-CH(CH3)(CH2CH3)). MS (EI-MS, 70 eV) m/z (rel. int. in %) = 441.3 ([M
+●], 48), 
262.2 (18), 207.1 (22), 183.4 (51), 44.1 (100), 40.0 (55). C29H31NO3 (Mr = 441.56 g/mol). 
 
Ethyl 4-{[6,7-Dichloro-2-(4-methoxyphenyl)-3-methyl-1H-indol-1-yl]methyl}benzoate 
(8.46) 
The title compound was prepared from 8.45 (200 mg, 0.6 mmol) and ethyl 4-(bromo-
methyl)benzoate (190 mg, 0.8 mmol) according to the general procedure. Flash chromato-
graphy yielded an orange oil (150 mg, 48 %). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 7.92 
– 7.86 (m, 2H, benzoate-H-3,5), 7.43 – 7.38 (m, 1H, indole-H-4), 7.24 – 7.20 (m, 1H, 
indole-H-5), 7.20 – 7.14 (m, 2H, Ph-H-2,6), 6.94 – 6.87 (m, 2H, benzoate-H-2,6), 6.82 (d, 
J = 8.4 Hz, 2H, Ph-H-3,5), 5.63 (s, 2H, NCH2), 4.33 (q, J = 7.1 Hz, 2H, COOCH2CH3), 
3.81 (s, 3H, OCH3-4), 2.21 (s, 3H, indole-CH3-3), 1.35 (t, J = 7.1 Hz, 3H, COOCH2CH3). 
13C-NMR (75 MHz, CDCl3): δ [ppm] = 171.12 (Cquat, COOCH2CH3), 166.33 (Cquat, 
benzoate-C-4), 159.82 (Cquat, Ph-C-4), 145.23 (Cquat, benzoate-C-1), 140.51 (Cquat, indole-
C), 132.90 (Cquat, indole-C), 131.88 (+, benzoate-C-3,5), 130.21 (+, Ph-C-2,6), 129.83 (+, 
indole-C), 129.20 (Cquat, indole-C-Cl), 127.08 (Cquat, indole-C), 125.37 (+, benzoate-C-2,6), 
123.12 (Cquat, Ph-C-1), 117.81 (+, indole-C), 115.18 (Cquat, indole-C-Cl), 114.00 (+, Ph-C-
3,5), 110.33 (Cquat, indole-C), 60.87 (-, COOCH2CH3), 55.33 (+, OCH3-4), 48.77 (-, NCH2), 
14.32 (+, COOCH2CH3), 9.32 (+, indole-CH3-3). MS (EI-MS, 70 eV) m/z (rel. int. in %) = 
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469.1 (59), 468.2 (29), 467.1 ([M+●], 88), 306.1 (35), 304.1 (54), 269.1 (25), 163.1 (100), 
135.1 (36), 107.1 (46), 90.1 (25), 44.1 (36), 40.1 (23). C26H23Cl2NO3 (Mr = 468.37 g/mol). 
 
8.6.2.6. Preparation of the compounds 8.18a-8.32a, 8.27b, 8.29b, 8.32b, 
8.41-8.43, 8.47 
General procedure 18 
A solution of 4.0 eq of BBr3 (~ 1.0 M solution in CH2Cl2) in anhydrous CH2Cl2 (20 mL per 
4 mmol BBr3) was cooled to -20 °C under nitrogen atmosphere. A solution of the 
corresponding methoxy-substituted indole (1.0 eq) in anhydrous CH2Cl2 (20 mL per 
1 mmol indole) was added at -20 °C under nitrogen atmosphere within 15 min. After 
removal of the cooling bath, the mixture was stirred overnight. Under a nitrogen 
atmosphere and cooling (ice bath), a saturated solution of NaHCO3 was added slowly. 
The reaction mixture was extracted several times with EtOAc. The combined organic 
layers were washed with brine and dried over Na2SO4. After evaporation of the solvent, 
the residue was purified by flash chromatography (SiO2) as indicated. 
 
General procedure 214 
A solution of 5.5 eq of BBr3 (~ 1.0 M solution in CH2Cl2) in anhydrous CH2Cl2 (20 mL per 
4 mmol BBr3) was cooled to -20 °C under nitrogen atmosphere. A solution of the 
corresponding methoxy-substituted indole (1.0 eq) in anhydrous CH2Cl2 (20 mL per 
1 mmol indole) was added at -20 °C under nitrogen atmosphere within 15 min. After 
removal of the cooling bath, the mixture was stirred overnight. Under a nitrogen 
atmosphere and cooling with an ice bath, a saturated solution of NaHCO3 was added 
slowly until the vigorous reaction ceased. By dropwise addition of 32 % hydrochloric acid, 
the pH value was carefully adjusted to < 3. The reaction mixture was extracted several 
times with EtOAc. The combined organic layers were washed with brine and dried over 
Na2SO4. After evaporation of the solvent, the residue was purified by flash 
chromatography (SiO2) as indicated. 
 
1-Ethyl-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol (8.18a)5 
The title compound was prepared from 8.3a (210 mg, 0.7 mmol) according to general 
procedure 1. Flash chromatography yielded a yellow solid (160 mg, 85 %); mp 199 °C 
(ref:5 204 – 207 °C). 1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 9.67 (s, 1H, Ph-OH -4), 
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8.68 (s, 1H, indole-OH-5), 7.14 – 7.07 (m, 3H, Ph-H-2,6, indole-H-7), 6.90 (d, J = 8.6 Hz, 
2H, Ph-H-3,5), 6.79 (d, J = 2.2 Hz, 1H, indole-H-4), 6.65 (dd, J = 8.6, 2.3 Hz, 1H, indole-
H-6), 4.66 (q, J = 7.1 Hz, 2H, NCH2CH3), 2.09 (s, 3H, indole-CH3-3), 1.28 (t, J = 7.1 Hz, 
3H, NCH2CH3). 
13C-NMR (75 MHz, DMSO-d6): δ [ppm] = 156.89 (Cquat, Ph-C-4), 150.47 
(Cquat, indole-C-5), 137.79 (Cquat, indole-C), 131.36 (+, Ph-C-2,6), 131.31 (Cquat, indole-C), 
128.52 (Cquat, Ph-C-1), 121.99 (Cquat, indole-C), 115.17 (+, Ph-C-3,5), 111.00 (+, indole-C-
6), 109.81 (+, indole-C-7), 105.43 (Cquat, indole-C), 102.16 (+, indole-C-4), 37.57 (-, 
NCH2CH3), 17.51 (+, NCH2CH3), 9.30 (+, indole-CH3-3). MS (EI-MS, 70 eV) m/z (rel. int. in 
%) = 268.2 (16), 267.2 ([M+●], 100), 266.1 (73), 174.1 (27), 140.6 (15). C17H17NO2 (Mr = 
267.32 g/mol). 
 
2-(4-Hydroxyphenyl)-1-isopropyl-3-methyl-1H-indol-5-ol (8.19a)5 
The title compound was prepared from 8.4a (200 mg, 0.6 mmol) according to general 
procedure 1. Flash chromatography yielded and subsequent recrystallization (solvent: 
anhydrous EtOH) yielded pale yellow crystals (120 mg, 71 %); mp 157 -162 °C (ref:5 150 -
161 °C). 1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 9.67 (s, 1H, OH-4), 8.66 (s, 1H, indole-
OH-5), 7.38 (t, J = 7.2 Hz, 1H, indole-H-6), 7.14 (dd, J = 8.9, 2.3 Hz, 2H, Ph-H-2,6), 6.93 – 
6.84 (m, 2H, Ph-H-3,5), 6.77 (d, J = 2.3 Hz, 1H, indole-H-4), 6.61 (dd, J = 8.8, 2.4 Hz, 1H, 
indole-H-7), 4.42 – 4.23 (m, 1H, NCH(CH3)2), 1.99 (s, 3H, indole-CH3-3), 1.42 
(d, J = 7.0 Hz, 6H, NCH(CH3)2). 
13C-NMR (75 MHz, DMSO-d6): δ [ppm] = 156.98 (Cquat, 
Ph-C-4), 150.16 (Cquat, indole-C-5), 137.77 (Cquat, indole-C), 131.34 (+, Ph-C-2,6), 129.69 
(Cquat, indole-C), 128.32 (Cquat, indole-C), 122.74 (Cquat, Ph-C-1), 115.17 (+, Ph-C-3,5), 
112.12 (+, indole-C-6), 110.60 (+, indole-C-7), 105.60 (Cquat, indole-C), 102.42 (+, indole-
C-4), 46.95 (+, NCH(CH3)2), 21.17 (+, NCH(CH3)2), 9.22 (+, indole-CH3-3). MS (EI-MS, 
70 eV) m/z (rel. int. in %) =282.2 (20), 281.2 ([M+●], 100), 266.1 (44), 44.1 (67). C18H19NO2 
(Mr = 281.35 g/mol). 
 
2-(4-Hydroxyphenyl)-3-methyl-1-nonyl-1H-indol-5-ol (8.20a) 
The title compound was prepared from 8.5a (150 mg, 0.4 mmol) according to general 
procedure 1. Flash chromatography yielded a yellow oil (100 mg, 68 %). 1H-NMR 
(300 MHz, DMSO-d6): δ [ppm] = 9.62 (s, 1H, OH-4), 8.64 (s, 1H, indole-OH-5), 7.22 – 
7.15 (m, 3H, Ph-H-2,6, indole-H-7), 6.98 – 6.88 (m, 2H, Ph-H-3,5), 6.82 (d, J = 2.4 Hz, 1H, 
indole-H-4), 6.68 (dd, J = 8.5, 2.5 Hz, 1H, indole-H-6), 3.96 – 3.89 (m, 2H, 
NCH2CH2(CH2)6CH3), 2.11 (s, 3H, indole-CH3), 1.60 – 1.55 (m, 2H, NCH2CH2(CH2)6CH3), 
1.23 – 1.11 (m, 8H, NCH2CH2(CH2)6CH3), 1.10 – 1.03 (m, 4H, NCH2CH2(CH2)6CH3), 0.89 
– 0.75 (m, 3H, NCH2CH2(CH2)6CH3). 
13C-NMR (75 MHz, DMSO-d6): δ [ppm] = 158.08 
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(Cquat, Ph-C-4), 153.30 (Cquat, indole-C-5), 137.50 (Cquat, indole-C), 131.42 (+, Ph-C-2,6), 
131.21 (Cquat, indole-C), 128.44 (Cquat, indole-C), 124.04 (Cquat, Ph-C-1), 113.87 (+, Ph-C-
3,5), 110.89 (+, indole-C-6), 110.85 (+, indole-C-7), 106.85 (Cquat, indole-C), 100.42 
(+, indole-C-4), 42.94 (-, NCH2CH2(CH2)6CH3), 30.91 (-, NCH2CH2(CH2)6CH3), 27.89 (-, 
NCH2CH2(CH2)6CH3), 25.9 (-, NCH2CH2(CH2)6CH3), 21.86 (-, NCH2CH2(CH2)6CH3), 21.45 
(-, NCH2CH2(CH2)6CH3), 20.22 (-, NCH2CH2(CH2)6CH3), 20.13 (-, NCH2CH2(CH2)6CH3), 
13.80 (+, NCH2CH2(CH2)6CH3), 9.27 (+, indole-CH3-3). MS (ES-MS, DCM/MeOH + 
NH4OAc) m/z (rel. int. in %) = 366.2 ([M + H]
+, 100). C24H31NO2 (Mr = 365.51 g/mol). 
 
1-Decyl-2-(4-hydroxyphenyl)-3-methyl-1H-indol-6-ol (8.21a) 
The title compound was prepared from 8.6a (250 mg, 0.6 mmol) according to general 
procedure 1. Flash chromatography yielded an orange oil (120 mg, 53 %). 1H-NMR 
(300 MHz, DMSO-d6): δ [ppm] = 9.61 (s, 1H, Ph-OH-4), 8.94 (s, 1H, indole-OH-5), 7.24 (d, 
J = 8.4 Hz, 1H, indole-H-7), 7.15 (d, J = 8.5 Hz, 2H, Ph-H-2,6), 6.87 (d, J = 8.5 Hz, 2H, 
Ph-H-3,5), 6.70 (d, J = 1.8 Hz, 1H, indole-H-4), 6.55 (dd, J = 8.4, 1.9 Hz, 1H, indole-H-6), 
3.86 (t, J = 7.2 Hz, 2H, NCH2CH2(CH2)7CH3), 2.07 (s, 3H, indole-CH3), 1.48 – 1.37 (m, 2H, 
NCH2CH2(CH2)7CH3), 1.25 – 1.13 (m, 10H, NCH2CH2(CH2)7CH3), 1.10 – 1.02 (m, 4H, 
NCH2CH2(CH2)7CH3), 0.87 – 0.81 (m, 3H, NCH2CH2(CH2)7CH3). 
13C-NMR (75 MHz, 
DMSO-d6): δ [ppm] = 155.29 (Cquat, Ph-C-4), 148.87 (Cquat, indole-C-5), 138.22 (Cquat, 
indole-C), 131.80 (+, Ph-C-2,6), 128.67 (Cquat, indole-C), 125.01 (Cquat, Ph-C-1), 122.01 
(Cquat, indole-C), 115.37 (+, Ph-C-3,5), 110.86 (+, indole-C-6), 110.26 (+, indole-C-7), 
107.57 (Cquat, indole-C), 103.41 (+, indole-C-4), 43.97 (-, NCH2(CH2)8CH3), 31.94 (-, 
NCH2(CH2)8CH3), 30.06 (-, NCH2(CH2)8CH3), 29.73 (-, NCH2(CH2)8CH3), 29.69 (-, 
NCH2(CH2)8CH3), 29.46 (-, NCH2(CH2)8CH3), 29.36 (-, NCH2(CH2)8CH3), 29.13 (-, 
NCH2(CH2)8CH3), 22.71 (-, NCH2(CH2)8CH3), 14.14 (+, NCH2(CH2)8CH3), 9.30 (+, indole-
CH3-3). MS (EI-MS, 70 eV) m/z (rel. int. in %) = 380.3 (23), 379.2 ([M
+●], 100), 252.1 (35). 
C25H33NO2 (Mr = 379.54 g/mol). 
 
2-(4-Hydroxyphenyl)-3-methyl-1-tetradecyl-1H-indol-5-ol (8.22a) 
The title compound was prepared from 8.7a (100 mg, 0.2 mmol) according to general 
procedure 1. Flash chromatography yielded a yellow solid (80 mg, 92 %); mp 178 °C. 1H-
NMR (300 MHz, CDCl3): δ [ppm] = 7.26 – 7.21 (m, 2H, Ph-H-2,6), 7.18 (d, J = 8.6 Hz, 1H, 
indole-H-7), 6.98 (d, J = 2.4 Hz, 1H, indole-H-4), 6.95 – 6.91 (m, 2H, Ph-H-3,5), 6.78 (dd, 
J = 8.5, 2.5 Hz, 1H, indole-H-6), 4.89 (s, 1H, Ph-OH-4), 4.48 (s, 1H, indole-OH-5), 3.97 – 
3.88 (m, 2H, NCH2CH2(CH2)11CH3), 2.15 (s, 3H, indole-CH3), 1.60 – 1.55 (m, 2H, 
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NCH2CH2(CH2)11CH3), 1.28 – 1.21 (m, 18H, NCH2CH2(CH2)11CH3), 1.16 – 1.09 (m, 4H, 
NCH2CH2(CH2)11CH3), 0.91 – 0.85 (m, 3H, NCH2CH2(CH2)11CH3). 
13C-NMR (75 MHz, 
DMSO-d6): δ [ppm] = 155.36 (Cquat, Ph-C-4), 148.98 (Cquat, indole-C-5), 138.35 (Cquat, 
indole-C), 131.82 (+, Ph-C-2,6), 129.17 (Cquat, indole-C), 124.91 (Cquat, Ph-C-1), 121.99 
(Cquat, indole-C), 115.33 (+, Ph-C-3,5), 110.88 (+, indole-C-6), 110.27 (+, indole-C-7), 
107.65 (Cquat, indole-C), 103.40 (+, indole-C-4), 43.97 (-, NCH2(CH3)12CH3), 31.94 (-, 
NCH2(CH3)12CH3), 30.06 (-, NCH2(CH3)12CH3), 29.84 (-, NCH2(CH3)12CH3), 29.82 (-, 
NCH2(CH3)12CH3), 29.73 (-, NCH2(CH3)12CH3), 29.69 (-, NCH2(CH3)12CH3), 29.56 (-, 
NCH2(CH3)12CH3), 29.46 (-, NCH2(CH3)12CH3), 29.36 (-, NCH2(CH3)12CH3), 29.13 (-, 
NCH2(CH3)12CH3), 26.83 (-, NCH2(CH3)12CH3), 22.71 (-, NCH2(CH3)12CH3), 14.14 (+, 
NCH2(CH3)12CH3), 9.30 (+, indole-CH3-3). MS (ES-MS, DCM/MeOH + NH4OAc) m/z 
(rel. int. in %) = 437.2 (30), 436.1 ([M + H]+, 100). C29H41NO2 (Mr = 435.64 g/mol). 
 
1-Hexadecyl-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol (8.23a) 
The title compound was prepared from 8.8a (110 mg, 0.2 mmol) according to general 
procedure 1. Flash chromatography yielded a yellow solid (90 mg, 97 %); mp 189 °C. 1H-
NMR (300 MHz, CDCl3): δ [ppm] = 7.27 – 7.21 (m, 2H, Ph-H-2,6), 7.19 (d, J = 8.6 Hz, 1H, 
indole-H-7), 6.96 (d, J = 2.4 Hz, 1H, indole-H-4), 6.94 – 6.90 (m, 2H, Ph-H-3,5), 6.80 (dd, 
J = 8.5, 2.5 Hz, 1H, indole-H-6), 3.97 – 3.91 (m, 2H, NCH2CH2(CH2)13CH3), 2.15 (s, 3H, 
indole-CH3), 1.63 – 1.50 (m, 2H, NCH2CH2(CH2)13CH3), 1.31 – 1.21 (m, 20H, 
NCH2CH2(CH2)13CH3), 1.17 – 1.10 (m, 6H, NCH2CH2(CH2)13CH3), 0.92 – 0.87 (m, 3H, 
NCH2CH2(CH2)13CH3). 
13C-NMR (75 MHz, DMSO-d6): δ [ppm] = 155.20 (Cquat, Ph-C-4), 
149.04 (Cquat, indole-C-5), 138.23 (Cquat, indole-C), 131.86 (+, Ph-C-2,6), 128.06 (Cquat, 
indole-C), 125.06 (Cquat, Ph-C-1), 121.99 (Cquat, indole-C), 115.32 (+, Ph-C-3,5), 110.92 (+, 
indole-C-6), 110.29 (+, indole-C-7), 107.67 (Cquat, indole-C), 103.38 (+, indole-C-4), 43.94 
(-, NCH2(CH2)14CH3), 31.93 (-, NCH2(CH2)14CH3), 30.04 (-, NCH2(CH2)14CH3), 30.01 (-, 
NCH2(CH2)14CH3), 29.69 (-, NCH2(CH2)14CH3), 29.64 (-, NCH2(CH2)14CH3), 29.66 (-, 
NCH2(CH2)14CH3), 29.62 (-, NCH2(CH2)14CH3), 29.53 (-, NCH2(CH2)14CH3), 29.42 (-, 
NCH2(CH2)14CH3), 29.37 (-, NCH2(CH2)14CH3), 29.12 (-, NCH2(CH2)14CH3), 28.57 (-, 
NCH2(CH2)14CH3), 26.79 (-, NCH2(CH2)14CH3), 22.74 (-, NCH2(CH2)14CH3), 14.17 
(+, NCH2(CH2)14CH3), 9.31 (+, indole-CH3-3). MS (ES-MS, DCM/MeOH + NH4OAc) m/z 
(rel. int. in %) = 465.2 (30), 464.2 ([M + H]+, 100). C31H45NO2 (Mr = 463.69 g/mol). 
 
 
 
 2-Phenylindole derivatives as inhibitors of streptococcal hyaluronidases 257 
1-Benzyl-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol (8.24a)6 
The title compound was prepared from 8.9a (700 mg, 2.0 mmol) according to general 
procedure 1. Flash chromatography yielded a green oil (660 mg, 99 %). 1H-NMR 
(300 MHz, DMSO-d6): δ [ppm] = 9.66 (s, 1H, OH-4), 8.71 (s, 1H, indole-OH-5), 7.22 – 
7.11 (m, 5H, indole-H-7, Ph-H-2,6, benzyl-H-3,5), 7.05 (d, J = 8.7 Hz, 1H, indole-H-6), 
6.89 – 6.77 (m, 5H, Ph-H-3,5, benzyl-H-2,4,6), 6.59 (td, J = 9.0, 2.3 Hz, 1H, indole-H-4), 
5.18 (s, 2H, NCH2), 2.15 – 2.08 (m, 3H, indole-CH3-3). 
13C-NMR (75 MHz, DMSO-d6): 
δ [ppm] = 157.11 (Cquat, Ph-C-4), 150.75 (Cquat, indole-C-5), 138.69 (Cquat, benzyl-C), 
131.27 (+, Ph-C-2,6), 130.57 (Cquat, indole-C), 128.98 (Cquat, indole-C), 128.22 (+, benzyl-
C), 126.65 (+, benzyl-C), 125.88 (+, benzyl-C), 121.91 (Cquat, Ph-C-1), 115.23 (+, Ph-C-
3,5), 111.19 (Cquat, indole-C), 110.62 (+, indole-C-6), 106.43 (+, indole-C-7), 102.37 (+, 
indole-C-4), 88.96 (Cquat, indole-C), 46.45 (-, NCH2), 9.31 (+, indole-CH3-3). MS (EI-MS, 
70 eV) m/z (rel. int. in %) = 330.2 (21), 329.2 ([M+●], 100), 238.1 (33), 91.1 (50). HRMS 
(ESI-MS) m/z calcd. [M + H]+ 330.1489, found [M + H]+ 330.1492. C22H19NO2 (Mr = 
329.39 g/mol). 
 
1-(4-Fluorobenzyl)-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol (8.25a) 
The title compound was prepared from 8.10a (80 mg, 0.2 mmol) according to general 
procedure 1. Flash chromatography yielded a dark green oil (71 mg, 97 %). 1H-NMR 
(300 MHz, CDCl3): δ [ppm] = 7.19 – 7.13 (m, 2H, Ph-H-2,6), 7.02 – 6.98 (m, 2H, Ph-H-
3,5), 6.94 – 6.83 (m, 6H, indole-H-4, indole-H-7, benzyl-H), 6.72 (dd, J = 8.6, 2.5 Hz, 1H, 
indole-H-6), 5.12 (s, 2H, NCH2), 2.21 (s, 3H, indole-CH3-3). 
13C-NMR (75 MHz, CDCl3): 
δ [ppm] = 155.47 (Cquat, Ph-C-4), 149.44 (Cquat, indole-C-5), 144.29 (Cquat, benzyl-C), 
134.23 (Cquat, benzyl-C), 131.82 (+, Ph-C-2,6), 129.53 (Cquat, indole-C), 129.14 (Cquat, 
indole-C), 127.62 (+, benzyl-C), 127.56 (Cquat, indole-C), 124.26 (Cquat, Ph-C-1), 115.61 
(Cquat, indole-C), 115.36 (+, Ph-H-3,5), 115.29 (+, benzyl-C), 111.30 (+, indole-C-6), 
110.63 (+, indole-C-7), 103.50 (+, indole-C-4), 46.56 (-, NCH2), 9.25 (+, indole-CH3-3). MS 
(EI-MS, 70 eV) m/z (rel. int. in %) = 348.2 (20), 347.0 ([M+●], 100), 238.1 (66), 109.1 (82). 
HRMS (ESI-MS) m/z calcd. [M + H]+ 348.1394, found [M + H]+ 348.1394. C22H18FNO2 
(Mr = 347.38 g/mol). 
 
1-(4-Chlorobenzyl)-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol (8.26a)6 
The title compound was prepared from 8.11a (200 mg, 0.5 mmol) according to general 
procedure 1. Flash chromatography yielded a green oil (200 mg, 99 %). 1H-NMR 
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(300 MHz, DMSO-d6): δ [ppm] = 9.68 (s, 1H, OH-4), 8.74 (s, 1H, indole-OH-5), 7.32 – 
7.21 (m, 2H, Ph-H-2,6), 7.18 – 7.09 (m, 2H, benzyl-H), 7.05 (d, J = 8.7 Hz, 1H, indole-H-
7), 6.85 (d, J = 2.0 Hz, 1H, indole-H-4), 6.84 – 6.80 (m, 4H, Ph-H-3,5, benzyl-H), 6.58 (dd, 
J = 8.7, 2.3 Hz, 1H, indole-H-6), 5.17 (s, 2H, NCH2), 2.10 (s, 3H, indole-CH3-3). 
13C-NMR 
(75 MHz, CDCl3): δ [ppm] = 155.97 (Cquat, Ph-C-4), 149.62 (Cquat, indole-C-5), 138.64 
(Cquat, benzyl-C), 137.20 (Cquat, benzyl-C), 132.70 (Cquat, indole-C), 131.83 (+, Ph-H-2,6), 
129.62 (Cquat, indole-C), 128.71 (+, benzyl-C), 127.43 (+, benzyl-C), 123.85 (Cquat, Ph-C-
1), 115.44 (+, Ph-C-3,5), 111.39 (+, indole-C-6), 110.58 (+, indole-C-7), 108.32 (Cquat, 
indole-C), 103.57 (+, indole-C-4), 88.96 (Cquat, indole-C), 46.99 (-, NCH2), 9.45 (+, indole-
CH3-3). MS (EI-MS, 70 eV) m/z (rel. int. in %) = 365.1 (24), 363.2 ([M
+●], 76), 238.1 (54), 
125.0 (33), 44.0 (37), 40.0 (100). HRMS (ESI-MS) m/z calcd. [M + H]+ 364.1099, found 
[M + H]+ 364.1100. C22H18ClNO2 (Mr = 363.84 g/mol). 
 
1-(4-Bromobenzyl)-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol (8.27a)33 
The title compound was prepared from 8.12a (250 mg, 0.6 mmol) according to general 
procedure 1. Flash chromatography yielded a green oil (220 mg, 91 %). 1H-NMR 
(300 MHz, CDCl3): δ [ppm] = 7.37 – 7.30 (m, 2H, benzyl-H), 7.18 – 7.11 (m, 2H, Ph-H-
2,6), 7.01 (d, J = 2.4 Hz, 1H, indole-H-4), 6.97 (d, J = 8.7 Hz, 1H, indole-H-7), 6.89 – 6.83 
(m, 2H, Ph-H-3,5), 6.79 (d, J = 8.4 Hz, 2H, benzyl-H), 6.72 (dd, J = 8.6, 2.4 Hz, 1H, 
indole-H-6), 5.10 (s, 2H, NCH2), 2.21 (s, 3H, indole-CH3-3). 
13C-NMR (75 MHz, CDCl3): δ 
[ppm] = 155.61 (Cquat, Ph-C-4), 149.53 (Cquat, indole-C-5), 137.69 (Cquat, benzyl-C), 131.98 
(Cquat, indole-C), 131.79 (+, benzyl-C), 131.69 (+, Ph-C-2,6 Ar-C), 129.59 (Cquat, indole-C), 
127.76 (+, benzyl-C), 124.12 (Cquat, Ph-C-1), 120.78 (Cquat, benzyl-C), 115.41 (+, Ph-C-
3,5), 111.37 (+, indole-C-6), 110.59 (+, indole-C-7), 108.35 (Cquat, indole-C), 103.56 (+, 
indole-C-4), 89.65 (Cquat, indole-C), 47.06 (-, NCH2), 9.44 (+, indole-CH3-3). MS (EI-MS, 
70 eV) m/z (rel. int. in %) = 409.1 (67), 408.2 (32), 407.1 ([M+●], 100), 238.1 (80), 171.0 
(34), 169.0 (30). HRMS (ESI-MS) m/z calcd. [M + H]+ 408.0594, found [M + H]+ 408.0591. 
C22H18BrNO2 (Mr = 408.29 g/mol). 
 
1-(4-Bromobenzyl)-2-(4-hydroxyphenyl)-3-methyl-1H-indol-6-ol (8.27b) 
The title compound was prepared from 8.12b (250 mg, 0.6 mmol) according to general 
procedure 1. Flash chromatography yielded a yellow oil (220 mg, 90 %). 1H-NMR 
(300 MHz, DMSO-d6): δ [ppm] = 7.43 (d, J = 8.5 Hz, 2H, benzyl-H), 7.34 – 7.27 (m, 1H, 
indole-H-4), 7.12 (d, J = 8.5 Hz, 1H, Ph-H-2,6), 6.86 – 6.77 (m, 4H, benzyl-H, Ph-H-3,5), 
6.62 – 6.50 (m, 2H, indole-H-5, indole-H-7), 5.11 (s, 2H, NCH2), 2.14 (s, 3H, indole-CH3-
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3). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 155.59 (Cquat, Ph-C-4), 149.47 (Cquat, indole-C-5), 
137.61 (Cquat, benzyl-C), 131.98 (Cquat, indole-C), 131.21 (+, benzyl-C), 131.69 (+, Ph-C-
2,6 Ar-C), 129.66 (Cquat, indole-C), 128.03 (+, benzyl-C), 124.03 (Cquat, Ph-C-1), 120.28 
(Cquat, benzyl-C), 114.41 (+, Ph-C-3,5), 111.31 (+, indole-C-4), 110.09 (+, indole-C-5), 
108.35 (Cquat, indole-C), 99.42 (+, indole-C-7), 89.88 (Cquat, indole-C), 47.06 (-, NCH2), 
9.41 (+, indole-CH3-3). MS (EI-MS, 70 eV) m/z (rel. int. in %) = 409.1 (46), 407.0 ([M
+●], 
100), 238.1 (100). C22H18BrNO2 (Mr = 408.29 g/mol). 
 
2-(4-Hydroxyphenyl)-3-methyl-1-(4-methylbenzyl)-1H-indol-5-ol (8.28a)6 
The title compound was prepared from 8.13a (100 mg, 0.3 mmol) according to general 
procedure 1. Flash chromatography yielded a green solid (85 mg, 91 %). 1H-NMR 
(300 MHz, CDCl3): δ [ppm] = 7.23 – 7.15 (m, 2H, Ph-H-2,6), 7.09 – 6.97 (m, 4H, benzyl-
H), 6.91 – 6.80 (m, 4H, indole-H-4, indole-H-7, Ph-H-3,5), 6.70 (dd, J = 8.6, 2.5 Hz, 1H, 
indole-H-6), 5.12 (s, 2H, NCH2), 2.29 (s, 3H, benzyl-CH3), 2.22 (s, 3H, indole-CH3-3). 
13C-
NMR (75 MHz, CDCl3): δ [ppm] = 155.46 (Cquat, Ph-C-4), 149.31 (Cquat, indole-C-5), 
138.61 (Cquat, benzyl-C), 136.57 (Cquat, benzyl-C), 135.59 (Cquat, indole-C), 132.14 (Cquat, 
indole-C), 131.85 (+, Ph-C-2,6), 129.26 (+, benzyl-C-3,5), 125.94 (+, benzyl-C-2,6), 
124.41 (Cquat, Ph-C-1), 115.32 (+, Ph-C-3,5), 111.18 (+, indole-C-6), 110.87 (+, indole-C-
7), 107.91 (Cquat, indole-C), 103.39 (+, indole-C-4), 92.82 (Cquat, indole-C), 47.40 (-, NCH2), 
14.00 (+, benzyl-CH3), 9.50 (+, indole-CH3-3). MS (EI-MS, 70 eV) m/z (rel. int. in %) = 
344.2 (22), 343.2 ([M+●], 100), 238.1 (21), 105.1 (90). HRMS (ESI-MS) m/z calcd. [M + H]+ 
344.1645, found [M + H]+ 344.1645. C23H21NO2 (Mr = 343.42 g/mol). 
 
1-(Biphenyl-4-ylmethyl)-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol (8.29a) 
The title compound was prepared from 8.14a (250 mg, 0.6 mmol) according to general 
procedure 1. Flash chromatography yielded a white solid (230 mg, 98 %). 1H-NMR 
(300 MHz, DMSO-d6): δ [ppm] = 9.68 (s, 1H, OH-4), 8.73 (s, 1H, indole-OH-5), 7.58 (dd, 
J = 5.3, 3.3 Hz, 2H, biphenyl-H), 7.50 (d, J = 8.3 Hz, 2H, biphenyl-H), 7.45 – 7.37 (m, 2H, 
biphenyl-H), 7.35 – 7.30 (m, 1H, biphenyl-H), 7.19 (d, J = 8.5 Hz, 2H, Ph-H-2,6), 7.09 (d, 
J = 8.7 Hz, 1H, indole-H-7), 6.92 (d, J = 8.3 Hz, 2H, biphenyl-H), 6.90 – 6.81 (m, 3H, 
indole-H-4, Ph-H-3,5), 6.60 (dt, J = 8.6, 4.3 Hz, 1H, indole-H-6), 5.23 (s, 2H, NCH2), 2.13 
(s, 3H, indole-CH3-3). 
13C-NMR (75 MHz, DMSO-d6): δ [ppm] = 157.10 (Cquat, Ph-C-4), 
150.76 (Cquat, indole-C-5), 139.66 (Cquat, biphenyl-C), 138.57 (Cquat, biphenyl-C), 137.98 
(Cquat, biphenyl-C), 131.30 (+, Ph-C-2,6), 130.65 (Cquat, indole-C), 129.12 (Cquat, indole-C), 
128.76 (+, biphenyl-C), 127.23 (+, biphenyl-C), 126.54 (+, biphenyl-C), 126.48 
(+, biphenyl-C), 126.40 (+, biphenyl-C), 121.92 (Cquat, Ph-C-1), 115.28 (+, Ph-C-3,5), 
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111.20 (+, indole-C-6), 110.60 (+, indole-C-7), 106.49 (Cquat, indole-C), 102.33 (+, indole-
C-4), 93.53 (Cquat, indole-C), 45.97 (-, NCH2), 9.53 (+, indole-3 CH3). MS (EI-MS, 70 eV) 
m/z (rel. int. in %) = 407.1 (30), 405.0 ([M+●], 100). HRMS (ESI-MS) m/z calcd. [M + H]+ 
406.1802, found [M + H]+ 406.1803. C28H23NO2 (Mr = 405.49 g/mol). 
 
1-(Biphenyl-4-ylmethyl)-2-(4-hydroxyphenyl)-3-methyl-1H-indol-6-ol (8.29b) 
The title compound was prepared from 8.14b (250 mg, 0.6 mmol) according to general 
procedure 1. Flash chromatography yielded a white solid (220 mg, 96 %). 1H-NMR 
(300 MHz, CDCl3): δ [ppm] = 7.53 (dd, J = 7.6, 6.1 Hz, 2H, biphenyl-H), 7.50 (d, J = 
8.3 Hz, 2H, biphenyl-H), 7.49 – 7.34 (m, 2H, biphenyl-H), 7.36 – 7.24 (m, 1H, biphenyl-H), 
7.17 (d, J = 8.5 Hz, 2H, Ph-H-2,6), 7.00 (d, J = 8.2 Hz, 1H, indole-H-7), 6.89 – 6.82 (m, 
2H, biphenyl-H), 6.75 – 6.69 (m, 1H, indole-H-4), 6.65 (dd, J = 6.0, 2.5 Hz, 2H, Ph-H-3,5), 
6.31 – 6.16 (m, 1H, indole-H-6), 5.12 (s, 2H, NCH2), 2.27 (s, 3H, indole-CH3-3). 
13C-NMR 
(75 MHz, DMSO-d6): δ [ppm] = 155.61 (Cquat, Ph-C-4), 151.00 (Cquat, indole-C-5), 139.86 
(Cquat, biphenyl-C), 138.41 (Cquat, biphenyl-C), 137.60 (Cquat, biphenyl-C), 131.89 (+, Ph-C-
2,6), 132.03 (Cquat, indole-C), 128.79 (Cquat, indole-C), 127.68 (+, biphenyl-C), 127.31 
(+, biphenyl-C), 127.00 (+, biphenyl-C), 126.93 (+, biphenyl-C), 126.56 (+, biphenyl-C), 
120.81 (Cquat, Ph-C-1), 119.52 (+, Ph-C-3,5), 115.23 (+, indole-C-4), 109.22 (+, indole-C-
5), 108.71 (Cquat, indole-C), 100.91 (Cquat, indole-C), 96.27 (+, indole-C-7), 47.23 (-, NCH2), 
9.56 (+, indole-CH3-3). MS (EI-MS, 70 eV) m/z (rel. int. in %) = 406.2 (22), 405.1 ([M
+●], 
88), 238.1 (25), 167.0 (100). HRMS (ESI-MS) m/z calcd. [M + H]+ 406.1802, found 
[M + H]+ 406.1798. C28H23NO2 (Mr = 405.49 g/mol). 
 
2-(4-Hydroxyphenyl)-3-methyl-1-(3-phenylpropyl)-1H-indol-5-ol (8.30a) 
The title compound was prepared from 8.15a (200 mg, 0.5 mmol) according to general 
procedure 1. Flash chromatography yielded a yellow oil (130 mg, 36 %). 1H-NMR 
(300 MHz, DMSO-d6): δ [ppm] = 7.50 – 7.41 (m, 3H, indole-H-7, Ph-H), 7.24 – 7.12 (m, 
5H, Ph-H), 6.99 (d, J = 2.0 Hz, 1H, indole-H-4), 6.96 – 6.92 (m, 2H, Ph-H), 6.79 (dd, J = 
8.8, 2.5 Hz, 1H, indole-H-6), 4.25 (t, J = 7.1 Hz, 2H, NCH2CH2CH2), 2.83 (t, 2H, 
NCH2CH2CH2), 2.24 (s, 3H, indole-CH3-3), 2.00 – 1.96 (m, 2H, NCH2CH2CH2). 
13C-NMR 
(75 MHz, DMSO-d6): δ [ppm] = 157.03 (Cquat, Ph-C-4), 150.40 (Cquat, indole-C-5), 141.13 
(Cquat, benzyl-C), 132.68 (Cquat, indole-C), 131.27 (+, Ph-C-2,6), 130.57 (Cquat, indole-C), 
127.67 (+, benzyl-C), 127.53 (+, benzyl-C), 121.85 (Cquat, Ph-C-1), 118.97 (+, benzyl-C), 
115.29 (+, Ph-C-3,5), 111.30 (Cquat, indole-C), 110.55 (+, indole-C-6), 106.65 (+, indole-C-
7), 104.39 (+, indole-C-4), 90.18 (Cquat, indole-C), 53.21 (-, NCH2), 33.42 (-, 
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NCH2CH2CH2), 31.30 (-, NCH2CH2CH2), 9.30 (+, indole-CH3-3). MS (EI-MS, 70 eV) m/z 
(rel. int. in %) = 357.2 ([M+●], 100), 266.2 (25), 91.0 (30). C24H23NO2 (Mr = 357.44 g/mol). 
 
2-(4-Hydroxyphenyl)-3-methyl-1-(4-nitrobenzyl)-1H-indol-5-ol (8.31a) 
The title compound was prepared from 8.16a (300 mg, 0.7 mmol) according to general 
procedure 2. Flash chromatography yielded a pale yellow solid (240 mg, 92 %). Flash 
chromatography yielded a dark yellow solid (170 mg, 22 %); mp 152 °C. 1H-NMR (300 
MHz, CDCl3): δ [ppm] = 8.20 – 8.12 (m, 2H, benzyl-H-3,5), 7.49 – 7.43 (m, 1H, indole-H-
7), 7.36 – 7.32 (m, 1H, indole-H-4), 7.26 (d, J = 8.7 Hz, 1H, indole-H-6), 7.02 – 6.87 (m, 
4H, benzyl-H-2,6, Ph-H-2,6), 6.84 – 6.67 (m, 2H, Ph-H-3,5), 5.26 (s, 2H, NCH2), 1.57 (s, 
3H, indole-CH3-3). 
13C-NMR (75 MHz, CDCl3) δ [ppm] = 156.95 (Cquat, Ph-C-4), 150.57 
(Cquat, indole-C-5), 147.34 (Cquat, benzyl-C), 137.98 (Cquat, indole-C), 131.32 (+, benzyl-C), 
129.00 (+, benzyl-C), 126.88 (Cquat, indole-C), 125.47 (+, Ph-C-2,6), 122.21 (Cquat, Ph-C-
1), 121.08 Cquat, benzyl-C), 115.16 (Cquat, indole-C), 113.54 (+, Ph-C-3,5), 111.20 
(+, indole-C-6), 110.93 (+, indole-C-7), 106.03 (Cquat, indole-C), 102.17 (+, indole-C-4), 
47.43 (-, NCH2), 9.33 (+, indole-CH3-3). MS (EI-MS, 70 eV) m/z (rel. int. in %) = 374.1 
(30), 373.1 ([M+●], 100. C22H18N2O4 (Mr = 374.39 g/mol). 
 
4-{[5-Hydroxy-2-(4-hydroxyphenyl)-3-methyl-1H-indol-1-yl]methyl}benzoic acid 
(8.32a) 
The title compound was prepared from 8.14a (320 mg, 0.7 mmol) according to general 
procedure 2. Flash chromatography yielded a yellow oil (150 mg, 54 %). 1H-NMR 
(300 MHz, MeOD) δ [ppm] = 7.87 – 7.79 (m, 2H, benzyl-H-3,5), 7.13 – 7.07 (m, 2H, Ph-H-
2,6), 6.99 (d, J = 8.7 Hz, 1H, indole-H-4), 6.93 (d, J = 3.1 Hz, 1H, indole-H-7), 6.91 (d, J = 
2.7 Hz, 2H, benzyl-H-2,6), 6.84 – 6.78 (m, 2H, Ph-H-3,5), 6.65 (dd, J = 8.7, 2.3 Hz, 1H, 
indole-H-6), 5.25 (s, 2H, NCH2), 2.17 (s, 3H, indole-CH3-3). 
13C-NMR (75 MHz, MeOD) 
δ [ppm] = 168.07 (Cquat, COOH), 157.77 (Cquat, indole-C-6), 153.11 (Cquat, Ph-C-4), 147.01 
(Cquat, benzyl-C-1), 139.83 (Cquat, indole-C), 132.68 (+, Ph-C-2,6), 130.93 (Cquat, indole-C), 
130.80 (+, benzyl-C-3,5), 127.21 (Cquat, benzyl-C-4), 127.10 (+, benzyl-C-2,6), 124.44 
(Cquat, Ph-C-1), 124.30 (Cquat, indole-C), 116.30 (+, indole-C-6), 116.17 (+, Ph-C-3,5), 
112.31 (Cquat, indole-C), 111.23 (+, indole-C-7), 104.07 (+, indole-C-4), 47.82 (-, NCH2), 
9.52 (+, indole-CH3-3). MS (ES-MS, DCM/MeOH + NH4OAc) m/z (rel. int. in %) = 375.0 
(25), 374.0 ([M + H]+, 100). HRMS (ESI-MS) m/z calcd. [M + H]+ 374.1387, found [M + H]+ 
374.1387. C23H19NO4 (Mr = 373.40 g/mol). 
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4-{[6-Hydroxy-2-(4-hydroxyphenyl)-3-methyl-1H-indol-1-yl]methyl}benzoic acid 
(8.32b) 
The title compound was prepared from 8.14b (320 mg, 0.7 mmol) according to general 
procedure 2. Flash chromatography yielded a yellow oil (140 mg, 51 %). 1H-NMR 
(300 MHz, MeOD): δ [ppm] = 7.88 – 7.77 (m, 2H, benzyl-H-3,5), 7.34 (d, J = 8.4 Hz, 1H, 
indole-H-4), 7.11 – 7.01 (m, 2H, Ph-H-2,6), 6.93 (d, J = 8.3 Hz, 2H, benzyl-H-2,6), 6.83 – 
6.74 (m, 2H, Ph-H-3,5), 6.64 (dd, J = 8.4, 2.1 Hz, 1H, indole-H-5), 6.55 (d, J = 2.0 Hz, 1H, 
indole-H-7), 5.13 (s, 2H, NCH2), 2.18 (s, 3H, indole-CH3-3). 
13C-NMR (75 MHz, MeOD) 
δ [ppm] = 169.67 (Cquat, COOH), 158.46 (Cquat, indole-C-6), 154.49 (Cquat, Ph-C-4), 145.82 
(Cquat, benzyl-C-1), 139.20 (Cquat, indole-C), 137.62 (Cquat, indole-C), 132.92 (+, Ph-C-2,6), 
131.00 (+, benzyl-C-3,5), 130.58 (Cquat, benzyl-C-4), 127.28 (+, benzyl-C-2,6), 124.44 
(Cquat, Ph-C-1), 124.33 (Cquat, indole-C), 120.27 (+, indole-C-4), 116.31 (+, Ph-C-3,5), 
110.37 (+, indole-C-5), 109.65 (Cquat, indole-C), 96.74 (+, indole-C-7), 48.13 (-, NCH2), 
9.69 (+, indole-CH3-3). MS (EI-MS, 70 eV) m/z (rel. int. in %) = 391.0 (20), 390.0 (100), 
373.9 ([M+●], 70), 373.0 (15). HRMS (ESI-MS) m/z calcd. [M + H]+ 373.1309, found 
[M + H]+ 373.1304. C23H19NO4 (Mr = 373.40 g/mol). 
 
4-[(5-Hydroxy-3-methyl-2-phenyl-1H-indol-1-yl)methyl]benzoic acid (8.41) 
The title compound was prepared from 8.38 (130 mg, 0.3 mmol) according to general 
procedure 2. Flash chromatography yielded a yellow solid (110 mg, 96 %); mp 158 °C. 1H-
NMR (300 MHz, MeOD): δ [ppm] = 7.82 (d, J = 8.3 Hz, 2H, benzoate-H-3,5), 7.45 – 7.32 
(m, 3H, Ph-H-2,4,6), 7.29 (dd, J = 7.7, 1.7 Hz, 2H, benzoate-H-2,6), 7.02 (d, J = 8.7 Hz, 
1H, indole-H-7), 6.95 (d, J = 2.2 Hz, 1H, indole-H-4), 6.90 (d, J = 8.3 Hz, 2H, Ph-H-3,5), 
6.68 (dd, J = 8.7, 2.4 Hz, 1H, indole-H-6), 5.24 (s, 2H, NCH2), 2.19 (s, 3H, indole-3 CH3). 
13C-NMR (75 MHz, MeOD): δ [ppm] = 169.56 (Cquat, COOH), 152.01 (Cquat, indole-C-5), 
145.78 (Cquat, benzoate-C-1), 139.60 (Cquat, indole-C), 133.49 (Cquat, indole-C), 133.39 
(Cquat, indole-C), 131.60 (+, benzoate-C-3,5), 131.08 (Cquat, Ph-C-1), 130.95 (+, Ph-C-3,5), 
130.68 (Cquat, indole-C), 129.53 (+, Ph-C-4), 129.09 (+, benzoate-C-2,6), 127.18 (+, Ph-C-
2,6), 112.86 (+, indole-C-6), 111.58 (+, indole-C-7), 109.61 (Cquat, indole-C), 104.19 
(+, indole-C-4), 48.19 (-, NCH2), 9.57 (+, indole-CH3-3). MS (ES-MS, DCM/MeOH + 
NH4OAc) m/z (rel. int. in %) = 359.0 (26), 358.0 ([M + H]
+, 100). HRMS (ESI-MS) m/z 
calcd [M + H]+ 358.1438, found [M + H]+ 358.1440. C23H19NO3 (Mr = 357.40 g/mol). 
 
4-{[5-Hydroxy-2-(4-hydroxyphenyl)-1H-indol-1-yl]methyl}benzoic acid (8.42) 
The title compound was prepared from 8.39 (40 mg, 0.1 mmol) according to general 
procedure 2. Flash chromatography yielded a yellow solid (30 mg, 83 %); mp 147 °C. 1H-
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NMR (300 MHz, MeOD): δ [ppm] = 7.88 (d, J = 8.2 Hz, 2H, benzoate-H-3,5), 7.24 – 7.18 
(m, 2H, Ph-H-2,6), 7.01 (dd, J = 8.4, 2.0 Hz, 2H, benzoate-H-2,6), 6.95 (dd, J = 4.5, 
2.1 Hz, 1H, indole-H-7), 6.79 (dd, J = 6.7, 2.0 Hz, 2H, Ph-H-3,5), 6.68 – 6.62 (m, 2H, 
indole-H-4, indole-H-6), 6.36 (s, 1H, indole-H-3), 5.36 (s, 2H, NCH2). 
13C-NMR (75 MHz, 
MeOD): δ [ppm] = 172.88 (Cquat, COOH), 158.83 (Cquat, indole-C-5), 152.37 (Cquat, Ph-C-
4), 145.54 (Cquat, benzoate-C-1), 134.23 (Cquat, indole-C), 131.53 (+, Ph-C-2,6), 131.08 
(+, benzonate-C-3,5), 130.87 (Cquat, benzoate-C-4), 130.66 (Cquat, indole-C), 127.19 
(+, benzoate-C-2,6), 125.26 (Cquat, Ph-C-1), 116.42 (+, Ph-C-3,5), 115.56 (Cquat, indole-C), 
112.35 (+, indole-C-6), 111.73 (+, indole-C-7), 105.39 (+, indole-C-4), 85.18 (Cquat, indole-
C), 48.41 (-, NCH2). MS (ES-MS, DCM/MeOH + NH4OAc) m/z (rel. int. in %) = 361.0 (35), 
360.0 ([M + H]+, 100). C22H17NO4 (Mr = 359.37 g/mol). 
 
4-{[(5-sec-Butyl-2-(4-hydroxyphenyl)-1H-indol-1-yl]methyl}benzoic acid (8.43) 
The title compound was prepared from 8.40 (130 mg, 0.3 mmol) according to general 
procedure 2. Flash chromatography yielded yellow crystals (100 mg, 86 %); mp 137 °C. 
1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 12.88 (s, 1H, COOH), 9.71 (s, 1H, OH-4), 7.82 
(d, J = 8.2 Hz, 2H, benzoate-H-3,5), 7.36 (s, 1H, indole-H-4), 7.25 (d, J = 8.5 Hz, 2H, Ph-
H-2,6), 7.17 (d, J = 8.4 Hz, 1H, indole-H-7), 7.03 (d, J = 8.2 Hz, 2H, benzoate-H-2,6), 6.92 
(dd, J = 8.5, 1.3 Hz, 1H, indole-H-6), 6.82 (d, J = 8.5 Hz, 2H, Ph-H-3,5), 6.47 (s, 1H, 
indole-H-3), 5.43 (s, 2H, NCH2), 2.63 (h, J = 7.0 Hz, 1H, indole-CH(CH3)(CH2CH3)), 1.58 
(p, J = 7.3 Hz, 2H, indole-CH(CH3)(CH2CH3)), 1.22 (d, J = 6.9 Hz, 3H, indole-
CH(CH3)(CH2CH3)), 0.82 – 0.72 (m, 3H, indole-CH(CH3)(CH2CH3)). 
13C-NMR (75 MHz, 
DMSO-d6): δ [ppm] = 166.89 (Cquat, COOH), 157.42 (Cquat, Ph-C-4), 143.56 (Cquat, 
benzoate-C-1), 141.41 (Cquat, indole-C), 138.46 (Cquat, indole-C), 135.89 (Cquat, benzoate-
C-4), 130.06 (+, Ph-C-2,6), 129.51 (+, benzonate-C-3,5), 129.44 (Cquat, indole-C), 127.88 
(Cquat, indole-C), 125.96 (+, benzoate-C-2,6), 122.67 (Cquat, Ph-C-1), 120.71 (+, indole-C-
4), 117.56 (+, indole-C-6), 115.42 (+, Ph-C-3,5), 110.11 (+, indole-C-7), 100.98 (+, indole-
C-3), 46.52 (-, NCH2), 40.89 (+, indole-CH(CH3)(CH2CH3)), 31.19 (-, indole-
CH(CH3)(CH2CH3)), 22.36 (+, indole-CH(CH3)(CH2CH3)), 12.18 (+, indole-
CH(CH3)(CH2CH3)). MS (ES-MS, DCM/MeOH + NH4OAc) m/z (rel. int. in %) = 401.0 (25), 
400.0 ([M + H]+, 100). HRMS (ESI-MS) m/z calcd. [M - H]- 398.1770, found [M - H]- 
398.1762. C22H17NO4 (Mr = 399.48 g/mol). 
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4-{[6,7-Dichloro-2-(4-hydroxyphenyl)-3-methyl-1H-indol-1-yl]methyl}benzoic acid 
(8.47) 
The title compound was prepared from 8.46 (150 mg, 0.3 mmol) according to general 
procedure 2. Flash chromatography yielded orange crystals (120 mg, 88 %); mp 155 °C. 
1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 12.84 (s, 1H, COOH), 9.79 (s, 1H, OH-4), 7.79 
(d, J = 8.3 Hz, 2H, benzoate-H-3,5), 7.58 (d, J = 8.4 Hz, 1H, indole-H-4), 7.30 (d, J = 
8.4 Hz, 1H, indole-H-5), 7.16 (d, J = 8.4 Hz, 2H, Ph-H-2,6), 6.83 (dd, J = 8.4, 4.1 Hz, 4H, 
benzoate-H-2,6, Ph-H-3,5), 5.62 (s, 2H, NCH2), 2.17 (s, 3H, indole-CH3-3). 
13C-NMR 
(75 MHz, DMSO-d6): δ [ppm] = 166.87 (Cquat, COOH), 157.77 (Cquat, Ph-C-4), 144.76 
(Cquat, benzoate-C-1), 141.08 (Cquat, indole-C), 131.88 (Cquat, indole-C), 131.64 
(+, benzoate-C-3,5), 130.12 (Cquat, indole-C), 129.52 (+, Ph-C-2,6), 129.30 (Cquat, indole-
C-Cl), 125.40 (Cquat, benzoate-C-4), 125.04 (+, benzoate-C-2,6), 121.25 (+, indole-C-5), 
120.38 (Cquat, Ph-C-1), 118.40 (+, indole-C-4), 115.38 (+, Ph-C-3,5), 113.38 (Cquat, indole-
C-Cl), 109.26 (Cquat, indole-C), 48.11 (-, NCH2), 9.07 (+, indole-CH3-3). MS (ES-MS, 
DCM/MeOH + NH4OAc) m/z (rel. int. in %) = 428.9 (25), 427.6 (80), 425.9 ([M + H]
+, 100). 
HRMS (ESI-MS) m/z calcd. [M - H]- 424.0513, found [M - H]- 424.0520. C23H17Cl2NO3 
(Mr = 425.29 g/mol). 
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9.1 Introduction 
A fundamental strategic approach in medicinal chemistry involves the development and 
application of bioisosteres.1 The concept of bioisosterism can be summarized as the 
introduction of structural changes into a given active compound, leading to a derivative 
that broadly maintains the bioactivity on the biological target. The definition of bioisosteres 
implies compounds causing similar biological effects. Therefore, compounds bearing 
isosteric molecular features do not necessarily represent bioisosteres. A universal, 
rational prediction of bioisosteres is impossible as it strongly depends on the individual 
target, physicochemical parameters and biological mimicry. As a consequence, the 
evaluation of suitable structural modifications remains the most challenging step for a 
medicinal chemist. To quantify parameters of bioisosteric similarity, various methods and 
concepts such as size, shape, electronic distribution, polarizability, dipole, polarity, 
lipophilicity and pKa values play key roles.
1  
For the current approach, a computer-assisted prediction of bioisosteric properties for 
novel inhibitors was performed. For this purpose, a compound library containing 32 potent 
inhibitors of the target enzyme served as foundation. The selection of suitable inhibitors 
was based on experience and intuition. To quantify inhibitor similarity, or ideally bioiosteric 
molecular properties, the surface polarities of the library compounds were computed. 
Surface polarity, that is conductor surface polarization charge density represents an 
established parameter derived from quantum chemistry.2 In detail, the -profile 
measurement was defined by the conductor-like screening model for realistic solvation 
(COMSO-RS). The acronym for the -profile based drug similarity measurement was 
termed COSMOsim. 
Hence, the current approach was entirely based on the assumption that bioisosteres must 
have, to a certain extent, similar physiochemical properties that determine their 
interactions with different “environments” (solvents, membranes, biological targets). As a 
result, the COSMOsim based calculations proposed indolizines as novel, putatively 
bioisosteric molecules to possess inhibitory activity on the target enzyme. 
Indolizine was discovered by Angeli in 1890 and first prepared by Scholz in 1912 from -
picoline and acetic anhydride.3, 4 The generally accepted numbering system of indolizine is 
shown in Figure 9.1. Alternative notations for the molecular structure of indolizine 
derivatives are pyrrodine, pyrindole, 8-pyrrolopyridine, pyrrolo[1,2-a]pyridine or 
pyrrocoline. 
 
 Indolizines: a bioisosteric approach to inhibitors of bacterial hyaluronidases 269 
 
Figure 9.1 Molecular structure of indolizine (including atomic numbering system) and 2-phenylindolizine. 
 
Indolizine seems to play a minor role for drug development and discovery in comparison 
to its isomer indole, despite the fact that it is one of the fundamental nitrogen heterocyclic 
systems.4 Indolizine derivatives were discovered in natural products, for example among 
alkaloids such as pumiliotoxin or swainsonine. Synthetic organic molecules bearing an 
indolizine motif were reported as aromatase inhibitors,5 agonist of the estrogen receptor,6 
antibacterial agents,7 histamine H3 receptor antagonists,
8 hypoglycemic agents,9 inhibitors 
of 15-lipoxygenase10 and of secretory phospholipase A2.11 A comprehensive review on 
methods for the construction of the indolizine nucleus was published by Uchida and 
Matasumoto in 1976.4 Recently, organo-metal catalyzed isomerization reaction 
synthesis12-15 and multicomponent reaction synthesis16, 17 of indolizine derivatives were 
reported. 
For the virtual screening approach, structural requirements, e.g. drug-like properties, 
solubility and innovational character, were included. Commercially available or easily 
accessible starting materials were preferred for the construction of indolizine derivatives. 
Products available via multicomponent reaction synthesis (cf. chapter 5) were excluded. 
Accordingly, the target molecules, bearing an indolizine core structure, were mainly 
accessible via conventional synthesis. COSMOsim based calculations gave a total of 300 
hits which were ranked in terms of expected binding affinity on the target protein. To prove 
the suitability of COSMOsim based indolizine derivatives in principal, a single compound 
was synthesized and tested for inhibition of SagHyal4755. Besides, a “minimal 
pharmacophore”, that is a 2-phenylindolizine without substituents was synthesized as 
reference compound. The results are presented in the following sections. 
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9.2 COSMOsim based modeling of bioisosteric 
inhibitors for SagHyal4755 
For the computer-assisted evaluation of new inhibitors, a compound library containing 32 
selected inhibitors of SagHyal4755 served as foundation (see section B.1.2, (appendix II)). 
As ligand-protein interactions were not elucidated, the project was conceptualized entirely 
as a ligand-based approach. The evaluation of the electronic properties (COSMOsim) was 
performed for all compounds of the library. Accordingly, structural information from well-
established inhibitors was provided and abstracted for the de novo design of (bioisosteric) 
inhibitors. To illustrate the COSMO surface of such compounds, two examples were 
illustrated in this section. The surface models of 1-ethyl-2-(4-hydroxyphenyl)-3-methyl-1H-
indol-5-ol is shown in Figure 9.2. 
  
    
Figure 9.2 Surface polarity of 1-ethyl-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol
 a
. The regions of strongly 
negative molecular polarity are displayed in red. The strongly positive molecular regions carrying negative  
are colored blue, while the neutral parts of the molecules with  close to zero appear green; 
a
 cf. section 5.6. 
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As a second example, the COSMO surface color coded by the polarization charge density 
for 4-chloro-2-(2,6-dichloro-4-hydroxyphenyl)-1-ethyl-1H-indol-6-ol is given in Figure 9.3. 
  
    
Figure 9.3 Surface polarity of 4-chloro-2-(2,6-dichloro-4-hydroxyphenyl)-1-ethyl-1H-indol-6-ol
 a
. The regions of 
strongly negative molecular polarity are displayed in red. The strongly positive molecular regions carrying 
negative  are colored blue, while the neutral parts of the molecules with  close to zero appear green; 
a
 cf. section 5.6. 
 
The information on relevant parameters must be regarded as the most critical step and 
therefore strongly depends on an appropriate selection of compounds. This is even more 
significant for an ensemble of only 32 molecules. It must be reconsidered that an 
inappropriate selection of library molecules, e.g. molecules with low intermolecular 
similarity, might result in a failure of the entire method. To minimize such risks, the 
selection of ligands included two aspects. At first, substances bearing an identical 
chemical scaffold (2-phenylindoles) with IC50 values from 750 µM to 6 µM were selected. 
Hence, ligands of improved potency with a similar chemical scaffold were included. 
Secondly, benzo[b]thiophenes were selected as isosteric inhibitors to explore additional 
structural patterns. 
The structural information on the ligands was abstracted for subsequent molecular 
similarity calculations. As a result, computer-assisted molecular design involved the 
indolizine skeleton as novel structural scaffold. With respect to structural diversity, three 
subclasses including different substitution patterns were elaborated. Besides, indolizine-
based substances were ranked according to their proposed binding affinity on the target 
lyase. For each class of indolizines, the top 100 ranked molecules are illustrated in the 
following section. 
272 COSMOsim based modeling of bioisosteric inhibitors for SagHyal4755  
The indolizine derivatives of the first compound class, ranked according to their proposed 
binding affinity on SagHyal4755, are listed in Table 9.1. 
Table 9.1 Indolizine derivatives proposed by virtual chemistry as inhibitors of SagHyal4755 (compound class 1). 
No.
a
 SMILES-code
b
 
1 Cc1c(cc2cccc(C(=O)O)n12)c3ccc(Br)cc3  
2 CN(C)c1c(c(C)n2cccc(O)c12)c3ccc(Br)cc3  
3 Cc1c(cc2c(C(=O)O)c(C)ccn12)c3ccc(Br)cc3  
4 Cc1c(c(CCc2ccccc2)c3ccccn13)c4ccc(Cl)cc4  
5 Oc1ccn2c3CCc4ccccc4-c3cc2c1OCc5ccc(Cl)cc5 
6 Cc1c(cc2ccc3cccc([N+](=O)[O])c3n12)c4ccc(Br)cc4 
7 CCN(CC)c1c(c(C)n2cccc(O)c12)c3ccc(Br)cc3  
8 Cc1c(c(C(=O)O)c2c(cccn12)C(F)(F)F)c3ccc(Br)cc3  
9 Cc1c(c(n2cc(Br)cn2)c3ccccn13)c4ccc(Br)cc4  
10 Cc1c(c(O)c2ccc(O)c(Cl)n12)c3ccc(Br)cc3  
11 CCc1cc2c(OCc3ccc(Cl)cc3)c(O)ccn2c1C  
12 Cc1c(cc2cc(C#N)c3ccccc3n12)c4ccc(Br)cc4  
13 Cc1c(cc2cc(O)c(C(=O)O)c(O)n12)c3ccc(Br)cc3  
14 Cc1c(c(C(=O)O)c2ccc(Cl)cn12)c3ccc(Br)cc3  
15 Cc1c(cc2cc(ccn12)C(=O)O)c3ccc(Br)cc3  
16 Cc1c(c(C(=O)O)c2ccccn12)c3ccc(Br)cc3  
17 Cc1c(c(N2CCC[C@H](CO)C2)c3ccccn13)c4ccc(Br)cc4  
18 Oc1c(c([C@H](Br)c2ccc(Br)cc2)n3ccc(Cl)cc13)c4ccccc4O  
19 Cc1c(cc2c(OCc3ccc(Cl)cc3)c(O)ccn12)C(F)(F)F  
20 Cc1c(cc2c(cccn12)C(=O)O)c3ccc(Br)cc3  
21 Cc1c(c(C)n2c(S)c(C#N)cc(C)c12)c3ccc(Br)cc3  
22 Cc1c(cc2c(cc3cccnc3n12)C(=O)O)c4ccc(Br)cc4  
23 Cc1c(c(N2CCCC2)c3c(O)cccn13)c4ccc(Br)cc4  
24 Cc1c(cc2c(Br)c(C)c(C#N)c(O)n12)c3ccc(Br)cc3  
25 Cc1c(c(CN2CCCC2)c3ccc(cn13)C(=O)O)c4ccc(Br)cc4  
26 Oc1ccn2c3CCc4nonc4-c3cc2c1OCc5ccc(Cl)cc5 
27 Cc1c(cc2c3ccc(Cl)nc3ccn12)c4ccc(Br)cc4  
28 Cc1c(c(O)c2cccc(CO)n12)c3ccc(Br)cc3  
29 CCc1c(cc2c(OCc3ccc(Cl)cc3)c(O)ccn12)C(F)(F)F  
30 C[C@@H](Br)c1cc2c(OCc3ccc(Cl)cc3)c(O)ccn2c1C  
31 COC(=O)c1ccn2c(C)c(cc2c1)c3ccc(Br)cc3  
32 Cc1c(c(C(=O)O)c2cccc(n12)C(F)(F)F)c3ccc(Br)cc3  
33 Cc1c(cc2ccc(cn12)C(=O)O)c3ccc(Br)cc3  
34 Cc1c(cc2c(O)cc3ccccc3n12)c4ccc(Br)cc4  
35 Cc1c(cc2ccc3c(C)ccc(O)c3n12)c4ccc(Br)cc4  
36 Cc1c(c(c2ccc(Cl)nn2)c3ccccn13)c4ccc(Br)cc4  
37 Cc1c(cc2cc(O)c3ccc(C)c(C)c3n12)c4ccc(Br)cc4  
38 Cc1c(cc2cc(O)c3ccc(Cl)cc3n12)c4ccc(Br)cc4  
39 CCOC(=O)c1cccn2c(C)c(c(Br)c12)c3ccc(Br)cc3  
40 Cc1c(c(C(=O)O)c2ccc(Br)cn12)c3ccc(Br)cc3  
41 Oc1ccccc1c2c(Cl)c3cccc(Cl)n3c2[C@H](Br)c4ccc(Br)cc4  
42 Cc1cccn2c([C@H](Br)c3ccc(Br)cc3)c(c(Cl)c12)c4ccccc4O  
43 Cc1c(cc2cc(S)c3ccccc3n12)c4ccc(Br)cc4  
44 Cc1c(cc2cc(O)c3cc(C)ccc3n12)c4ccc(Br)cc4  
45 Cc1ccc(Cl)n2c([C@H](Br)c3ccc(Br)cc3)c(cc12)c4ccccc4O  
46 Cc1c(cc2cc(O)c3cc(C)c(C)cc3n12)c4ccc(Br)cc4  
47 CC(=O)Oc1c(c(C)n2ccc(Br)cc12)c3ccc(Br)cc3  
48 Oc1ccn2c3CCc4nonc4-c3cc2c1OCc5ccc(Cl)cc5Cl 
49 Cc1c(c(Br)c2cccc(C#N)n12)c3ccc(Br)cc3  
50 Cc1c(c(C(=O)O)c2c(Br)cccn12)c3ccc(Br)cc3  
51 Cc1cc2c(OCc3ccc(Cl)cc3)c(O)ccn2c1C  
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52 Cc1cc2c(OCc3ccc(Cl)cc3)c(O)ccn2c1c4ccccc4  
53 Cc1c(cc2c(cc3cc(C)ccc3n12)C(=O)O)c4ccc(Br)cc4  
54 Cc1c(cc2cc(C)cc(C(=O)O)n12)c3ccc(Br)cc3  
55 Cc1c(cc2cc(Cl)c([N+](=O)[O])c(C)n12)c3ccc(Br)cc3 
56 Cc1c(cc2cc(O)c3ccc4ccccc4c3n12)c5ccc(Br)cc5  
57 Cc1nc(sc1C(=O)O)c2c(c(C)n3ccccc23)c4ccc(Br)cc4  
58 CCc1c(cc2c(ccc(c3ccc(Br)cc3)n12)C(=O)O)C(F)(F)F  
59 CC(=O)c1ccn2c(C)c(cc2c1)c3ccc(Br)cc3  
60 Cc1c(c(N2CCC(CC2)C(=O)O)c3ccccn13)c4ccc(Br)cc4  
61 Cc1c(cc2cc(O)ccn12)c3ccc(Br)cc3  
62 Cc1c(cc2c3cc(Br)c(Cl)nc3ccn12)c4ccc(Br)cc4  
63 Cc1c(cc2cc(Cl)c(C(=O)O)c(C)n12)c3ccc(Br)cc3  
64 Cc1c(c(N2CCC[C@@H](C2)C(=O)O)c3ccccn13)c4ccc(Br)cc4  
65 Oc1ccccc1c2c(Cl)c3ccccn3c2[C@H](Br)c4ccc(Br)cc4  
66 Cc1c(c(SCC(=O)O)c2ccccn12)c3ccc(Br)cc3  
67 Cc1c(cc2cc(C)c(O)cn12)c3ccc(Br)cc3  
68 Cc1c(cc2ccc(O)c(CO)n12)c3ccc(Br)cc3  
69 Cc1c(cc2cc(O)c3cccc(c3n12)C(F)(F)F)c4ccc(Br)cc4  
70 COc1cn2c(C)c(c(O)c2c(I)c1O)c3ccc(Br)cc3  
71 C[C@H](O)c1ccc2cc(c(C)n2c1)c3ccc(Br)cc3  
72 Cc1c(cc2c(O)c(Br)c3ccccc3n12)c4ccc(Br)cc4  
73 Cc1c(cc2ccc3oc(S)nc3n12)c4ccc(Br)cc4  
74 CCOC(=O)c1ccn2c(C)c(cc2c1)c3ccc(Br)cc3  
75 Cc1c(cc2cc(O)c3cc(ccc3n12)C(F)(F)F)c4ccc(Br)cc4  
76 Cc1c(c(C(=O)c2ccsc2)c3ccccn13)c4ccc(Br)cc4  
77 Cc1c(c(N2CCC(=NO)CC2)c3ccccn13)c4ccc(Br)cc4  
78 Cc1c(c(n2cccc2)c3ccccn13)c4ccc(Br)cc4  
79 Cc1c(cc2ccc(O)c(Br)n12)c3ccc(Br)cc3  
80 Oc1ccn2c3C(=O)CCc3cc2c1OCc4ccc(Cl)cc4Cl  
81 Cc1cccn2c([C@H](Br)c3ccc(Br)cc3)c(c(O)c12)c4ccccc4O  
82 Oc1ccn2c3C(=O)CCCc3cc2c1OCc4ccc(Cl)cc4Cl  
83 COc1ccc([N+](=O)[O])c2cc(c(C)n12)c3ccc(Br)cc3 
84 Cc1c(c(C(=O)O)c2cccc(Cl)n12)c3ccc(Br)cc3  
85 COc1ccc(Cl)c2c(O)cc3cc(c(C)n3c12)c4ccc(Br)cc4  
86 Cc1c(cc2ccc(C(=O)O)c(O)n12)c3ccc(Br)cc3  
87 Cc1c(cc2c(Br)c(C)c(cn12)C(=O)O)c3ccc(Br)cc3  
88 Oc1ccn2c3CCCCc3cc2c1OCc4ccc(Cl)cc4  
89 COc1ccc([N+](=O)[O])n2c(C)c(cc12)c3ccc(Br)cc3 
90 Cc1cc(Br)n2c([C@H](Br)c3ccc(Br)cc3)c(cc2c1)c4ccccc4O  
91 Cc1c(c(CCc2ccccc2)c3ccccn13)c4cccc(Cl)c4  
92 Cc1c(c(Br)c2ccc3ccccc3n12)c4ccc(Br)cc4  
93 Cc1c(cc2cccc(CC(=O)O)n12)c3ccc(Br)cc3  
94 COC(=O)c1cc(Cl)n2c(C)c(c(C)c2c1)c3ccc(Br)cc3  
95 Cc1c(c(C(=O)C(C)(C)C)c2ccccn12)c3ccc(Br)cc3  
96 Cc1c(cc2cc(S)c3cc(C)ccc3n12)c4ccc(Br)cc4  
97 Oc1ccccc1c2cc3ccc4cccnc4n3c2[C@H](Br)c5ccc(Br)cc5  
98 COc1c(c([C@H](Br)c2ccc(Br)cc2)n3ccccc13)c4ccccc4O  
99 Cc1cccc2c(Cl)c(c([C@H](Br)c3ccc(Br)cc3)n12)c4ccccc4O  
100 Cc1c(cc2cc(O)c3ccc(cc3n12)C(F)(F)F)c4ccc(Br)cc4  
a
 the listed molecules were ranked according to the calculated binding affinity to SagHyal4755 (details not 
shown); accordingly, compound 1 represents the highest binding affinity, compound 100 the lowest binding 
affinity in this synopsis; 
b
 simplified molecular-input line-entry system (SMILES) code can be easily converted 
to the corresponding molecular structures e.g. with ChemDraw software (PerkinElmer Inc., Cambridge, USA), 
level: ultra, product version: 11. 
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The proposed molecules are encoded as SMILES-code. The SMILES (simplified 
molecular-input line-entry system) represents a coding system for simple or complex 
chemical structures that can be written down as a string of characters. The codes are 
designed to allow chemical structure definitions to be transferred between the various 
computer systems that are used to catalogue and design chemical compounds. A 
conversion to the corresponding molecular structure was simply achieved using 
ChemDraw software. The top ten ranked molecules of compound class 1 are illustrated in 
Figure 9.4. 
 
Figure 9.4 Top ten ranked indolizine derivatives proposed by virtual chemistry as inhibitors of SagHyal4755 
(compound class 1). 
 
Compound 3, predicted to possess high binding affinity to the target enzyme, was 
selected as molecular basis for the synthesis of a first indolizine derivative. For economic 
reasons, the methyl group in position 7 was skipped, resulting in the modified target 
molecule 2-(4-bromophenyl)-3-methylindolizine-8-carboxylic acid (Figure 9.5). 
 
Figure 9.5 Illustration of the target molecule 2-(4-bromophenyl)-3-methylindolizine-8-carboxylic acid; The 
substance was essentially originated from molecule No. 3 (compound class 1) but modified by elimination of 
the methyl group in position 7. 
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The indolizine derivatives of the second compound class, ranked according to their 
proposed binding affinity on SagHyal4755, are listed in Table 9.2. 
Table 9.2 Indolizine derivatives proposed by virtual chemistry as inhibitors of SagHyal4755 (compound class 2). 
No.
a
 SMILES-code
b
 
1 Cc1c(cc2c(Cl)cc(cn12)C(F)(F)F)c3ccc(O)cc3  
2 Cc1c(c(C#N)c2c(Cl)cc(cn12)C(F)(F)F)c3ccccc3F  
3 CCOC(=O)c1c(cc2c(Cl)cccn12)c3ccccc3F  
4 CCOC(=O)c1c(cc2c(Br)cccn12)c3ccccc3F  
5 Cc1c(cc2c(Br)cc(Br)c(Cl)n12)c3ccc(O)cc3  
6 CCOC(=O)c1c(cc2c(Br)cc(Br)cn12)c3ccccc3F  
7 CCOC(=O)c1c(cc2c(Cl)cc(cn12)C(F)(F)F)c3ccccc3F  
8 Cc1c(cc2c(I)cccn12)c3ccc(O)cc3  
9 Cc1c(cc2c(Cl)cc(cn12)C(F)(F)F)c3ccc(Cl)cc3  
10 Cc1c(cc2c(Cl)cc(cn12)C(F)(F)F)c3ccc(Br)cc3  
11 Cc1c(cc2c(Br)cccn12)c3ccc(O)cc3  
12 Cc1c(c(C#N)c2c(Cl)cc(cn12)C(F)(F)F)c3cccc(Cl)c3  
13 CCOC(=O)c1c(cc2c(Br)ccc(O)n12)c3ccccc3F  
14 Cc1c(c(Br)c2c3ccccc3ccn12)c4ccc(O)cc4  
15 COc1cc(C)c(cc1C)c2c(C)n3cc(F)cc(F)c3c2Br  
16 CCOC(=O)c1c(cc2c(Br)cc(Br)cn12)c3ccccc3  
17 COc1cc(C)c(cc1C)c2c(C)n3cc(F)cc(F)c3c2O  
18 Cc1c(c(Cl)c2c(F)cc(F)cn12)c3ccccc3F  
19 CCOC(=O)c1c(cc2ccc(F)cn12)c3ccccc3F  
20 Cc1c(c(O)c2c(Br)cccn12)c3ccccc3F  
21 CC1(C)C(=C(Br)c2cc3ccc4cc(O)ccc4n3c21)Br  
22 Cc1c(c(Cl)c2ccc(Cl)cn12)c3ccc(O)cc3  
23 CCOC(=O)c1c(cc2c(Cl)cccn12)c3cccc(F)c3  
24 CCOC(=O)c1c(cc2c(Br)ccc(Cl)n12)c3ccccc3F  
25 Cc1c(c(Br)c2c(F)cc(F)cn12)c3ccccc3F  
26 CCOC(=O)c1c(cc2c(Cl)cccn12)c3cc(F)ccc3F  
27 CCOC(=O)c1c(cc2c(Br)cccn12)c3cc(F)ccc3F  
28 Cc1c(c(Cl)c2c3ccccc3ccn12)c4ccc(O)cc4  
29 CCOC(=O)c1c(cc2c(I)cccn12)c3ccccc3  
30 Cc1c(c(Cl)c2c(Cl)cc(cn12)C(F)(F)F)c3ccc(O)cc3  
31 C[C@H](Br)c1cc2cc(C(=O)O)c3cccc(Br)c3n2c1C  
32 Cc1c(cc2c(I)ccc(O)n12)c3ccccc3F  
33 CCOC(=O)c1c(cc2c(I)ccc(O)n12)c3ccccc3F  
34 CC1(C)C(=C(Br)c2cc3cc(O)c4ccc(Cl)cc4n3c21)Br  
35 CCOC(=O)c1c(cc2ccc(Br)cn12)c3ccccc3F  
36 Cc1c(c(Br)c2c(F)cc(F)cn12)c3ccc(OC(F)F)cc3  
37 CCc1c(c(C)n2c(O)cc(cc12)C(F)(F)F)c3ccc(O)cc3  
38 Fc1cccn2c(c(c(Br)c12)c3ccc(Cl)cc3)c4ccccc4  
39 COc1cc(C)c(cc1C)c2cc3c(Cl)cc(cn3c2C)C(F)(F)F  
40 Cc1c(c(O)c2c3ccccc3ccn12)c4ccc(O)cc4  
41 Cc1c(cc2c(Br)ccc(O)n12)c3ccccc3F  
42 Cc1c(c(C#N)c2c(Br)cccn12)c3ccccc3F  
43 Cc1c(cc2c(I)cccn12)c3ccc(Br)cc3  
44 CCOC(=O)c1c(cc2c(Cl)cccn12)c3ccccc3  
45 CCc1c(cc2c(Br)cc(Br)c(Cl)n12)c3ccccc3  
46 Cc1c(cc2c3ccccc3c(Br)cn12)c4ccc(O)cc4  
47 CCOC(=O)c1c(c(Br)c2ccc(F)cn12)c3ccccc3F  
48 CCOC(=O)c1c(c(Cl)c2c(Cl)cc(cn12)C(F)(F)F)c3ccccc3F  
49 Cc1c(cc2c(Cl)cccn12)c3ccc(Cl)cc3  
50 Cc1c(c(C(=O)O)c2c(Cl)cc(cn12)C(F)(F)F)c3cccc(F)c3  
51 Cc1c(c(C(=O)O)c2cc3ccccc3cn12)c4ccccc4F  
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52 CCOC(=O)c1c(c(O)c2c(F)cc(F)cn12)c3ccccc3F  
53 Cc1c(cc2c(Br)cc(Br)cn12)c3ccc(O)cc3  
54 CCOC(=O)c1c(cc2c(Br)cc(Br)cn12)c3cc(F)ccc3F  
55 CCOC(=O)c1c(cc2c(I)cccn12)c3cc(F)ccc3F  
56 CCOC(=O)c1c(c(Cl)c2c(F)cccn12)c3ccccc3F  
57 Cc1c(cc2c(Br)cccn12)c3ccc(Br)cc3  
58 CCOC(=O)c1c(cc2c(Cl)cc(cn12)C(F)(F)F)c3cc(F)ccc3F  
59 Cc1c(c(C#N)c2c(Br)cccn12)c3ccc(Cl)cc3  
60 Cc1c(cc2c(Br)c(O)c3ccccc3n12)c4ccc(O)cc4  
61 COc1ccc(cc1)c2cc3c(Br)cc(Br)cn3c2C  
62 COc1ccc(cc1)c2cc3c(Cl)cc(cn3c2C)C(F)(F)F  
63 Cc1c(cc2c(Br)ccc(Br)n12)c3ccccc3F  
64 CCOC(=O)c1c(cc2c(Br)ccc(Br)n12)c3ccccc3  
65 Cc1c(c(C(=O)O)c2c(F)cc(cn12)C(F)(F)F)c3ccc(Cl)cc3  
66 COc1ccc2Cc3c(c(Cl)c4c(Cl)cc(cn34)C(F)(F)F) 
67 COc1ccc(cc1)c2c(C)n3cc(cc(Cl)c3c2Cl)C(F)(F)F  
68 Cc1c(c(Cl)c2c(F)cc(F)cn12)c3ccc(O)cc3  
69 Cc1c(c(Cl)c2c(F)cc(F)cn12)c3ccc(cc3)c4ccccc4F  
70 Cc1c(c(Cl)c2c(Cl)cc(cn12)C(F)(F)F)c3ccc(Br)cc3  
71 Cc1c(c(O)c2c(Cl)cc(cn12)C(F)(F)F)c3ccc(O)cc3  
72 CCc1c(c(C(=O)O)c2cccc(n12)C(F)(F)F)c3ccccc3  
73 CC(C)c1c(cc2c(Br)cc(Br)c(O)n12)c3ccccc3  
74 Cc1c(c(Br)c2ccc(F)cn12)c3ccccc3F  
75 Cc1ccc2Cc3c(cc4c(O)cc5cc(Br)cc(Br)c5n34)-c2c1 
76 CCOC(=O)c1c(c(O)c2c(cccn12)C(F)(F)F)c3ccccc3F  
77 COc1ccc(Br)c2c(O)c(c(C)n12)c3ccccc3F  
78 Cc1c(c(Cl)c2c(Cl)cc(cn12)C(F)(F)F)c3ccc(OC(F)F)cc3  
79 CC(C)c1c(cc2c(Br)cc(Br)c(Cl)n12)c3ccccc3  
80 Cc1c(cc2ccc(F)c(Br)n12)c3ccccc3F  
81 Fc1ccc(cc1)c2cc3c(Cl)cc(cn3c2c4ccccc4)C(F)(F)F  
82 Cc1c(cc2c(Cl)c(C)c(C#N)cn12)c3ccc(O)cc3  
83 Cc1c(cc2c(Br)c(C)ccn12)c3ccc(O)cc3  
84 Cc1cc(C)c2-c3c(O)c4c(F)cc(F)cn4c3C(C)(C)Cc2c1 
85 Cc1c(c(C)n2cc(cc(Cl)c12)C(F)(F)F)c3ccc(O)cc3  
86 Cc1c(c(C#N)c2c(Cl)cc(Cl)cn12)c3ccc(Cl)cc3  
87 Fc1ccc2Cc3c(c(Cl)c4c(Cl)cc(cn34)C(F)(F)F)-c2c1 
88 Cc1cc(C)c2-c3c(Cl)c4c(F)cc(F)cn4c3C(C)(C)Cc2c1 
89 Cc1c(c(Br)c2c(F)cccn12)c3ccccc3F  
90 Cc1cc(C)c2-c3cc4c(Br)cccn4c3C(C)(C)Cc2c1 
91 Cc1c(cc2c(Br)ccc(Cl)n12)c3ccccc3F  
92 CCOC(=O)c1c(c(Br)c2c(F)cccn12)c3ccccc3F  
93 COc1cc(C)c(cc1C)c2c(C)n3cccc(Br)c3c2C#N  
94 Cc1c(c(c2ccc(O)cc2)c3c(Cl)cc(cn13)C(F)(F)F)c4ccccc4F  
95 Cc1c(cc2ccc(F)c(Br)n12)c3ccc(Cl)cc3  
96 CCOC(=O)c1c(c(O)c2c(Br)cccn12)c3ccccc3F  
97 Cc1c(c(C(=O)O)c2cc3ccccc3cn12)c4ccc(Cl)cc4  
98 Cc1c(cc2c(Cl)c(C)c(C#N)cn12)c3ccccc3F  
99 Cc1c(cc2ccc(Br)c(Br)n12)c3ccccc3F  
100 Cc1c(c(O)c2cc3ccccc3cn12)c4ccc(Cl)cc4  
a
 the listed molecules were ranked according to the calculated binding affinity to SagHyal4755 (details not 
shown); accordingly, compound 1 represents the highest binding affinity, compound 100 the lowest binding 
affinity in this synopsis; 
b
 simplified molecular-input line-entry system (SMILES) code can be easily converted 
to the corresponding molecular structures e.g. with ChemDraw software (PerkinElmer Inc., Cambridge, USA), 
level: ultra, product version: 11. 
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The top ten ranked molecules of compound class 2 are illustrated in Figure 9.6. 
 
Figure 9.6 Top ten ranked indolizine derivatives proposed by virtual chemistry as inhibitors of SagHyal4755 
(compound class 2). 
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The indolizine derivatives of the third compound class, ranked according to their proposed 
binding affinity on SagHyal4755, are listed in Table 9.3. 
Table 9.3 Indolizine derivatives proposed by virtual chemistry as inhibitors of SagHyal4755 (compound class 3). 
No.
a
 SMILES-code
b
 
1 Cc1c(c([C@H](Br)c2ccccc2)n3ccccc13)c4ccccc4  
2 Cc1c(cc2c(Cl)cc(cn12)C(F)(F)F)c3ccc(O)cc3  
3 Fc1ccc(cc1)[C@@H](Br)c2c(cc3ccccn23)c4ccc(F)cc4  
4 Oc1ccc2cc(c([C@H](Br)c3ccc(F)cc3)n2c1)c4ccc(F)cc4  
5 OCc1c(c([C@H](Br)c2ccccc2)n3ccccc13)c4ccccc4  
6 Cc1c(cc2cccc(C=NO)n12)c3ccc(Br)cc3  
7 Cc1c(c(C#N)c2c(Cl)cc(cn12)C(F)(F)F)c3ccccc3F  
8 COc1cccn2c([C@H](Br)c3ccc(F)cc3)c(cc12)c4ccc(F)cc4  
9 CCOC(=O)c1c(cc2c(Cl)cccn12)c3ccccc3F  
10 CCOC(=O)c1c(cc2c(Br)cccn12)c3ccccc3F  
11 Cc1c(c(C(=O)c2ccsc2)c3ccccn13)c4ccc(Br)cc4  
12 Oc1ccn2c([C@H](Br)c3ccccc3)c(cc2c1)c4ccccc4  
13 Cc1ccn2c([C@H](Br)c3ccc(F)cc3)c(cc2c1)c4ccc(F)cc4  
14 Cc1cc2cc(c([C@H](Br)c3ccc(F)cc3)n2cc1O)c4ccc(F)cc4  
15 Cc1c(cc2c(Br)cc(Br)c(Cl)n12)c3ccc(O)cc3  
16 Fc1ccc(cc1)[C@@H](Br)c2c(cc3c(Cl)cccn23)c4ccc(F)cc4  
17 Br[C@@H](c1c(cc2ccccn12)c3ccccc3)c4ccccc4  
18 OCc1ccn2c([C@H](Br)c3ccc(F)cc3)c(cc2c1)c4ccc(F)cc4  
19 Oc1ccccc1c2cc3c(O)cccn3c2[C@H](Br)c4ccc(F)cc4  
20 Cc1c(cc2c(Br)c(C)c(cn12)C(=O)O)c3ccc(Br)cc3  
21 Br[C@@H](c1c(c(Br)c2ccccn12)c3ccccc3)c4ccccc4  
22 Cc1c(cc2cccc(C(=O)O)n12)c3ccc(Br)cc3  
23 CCOC(=O)c1c(cc2c(Br)cc(Br)cn12)c3ccccc3F  
24 Sc1cccc2cc(c(C(=O)c3ccc(Br)cc3)n12)c4ccc(Br)cc4  
25 CCOC(=O)c1c(cc2c(Cl)cc(cn12)C(F)(F)F)c3ccccc3F  
26 Cc1c(cc2c(Cl)c(C)c(C#N)cn12)c3ccc(Br)cc3  
27 Cc1cc(C)c2cc(c([C@H](Br)c3ccc(F)cc3)n2c1)c4ccc(F)cc4  
28 COCc1c(c([C@H](Br)c2ccccc2)n3ccccc13)c4ccccc4  
29 COC(=O)c1cc(Cl)n2c(C)c(c(C)c2c1)c3ccc(Br)cc3  
30 CN(C)c1c(c(C)n2cccc(O)c12)c3ccc(Br)cc3  
31 Cc1c(cc2c(cc3ccc(C)cc3n12)C(=O)O)c4ccc(Br)cc4  
32 Cc1c(cc2ccc3cccc([N+](=O)[O])c3n12)c4ccc(Br)cc4 
33 Cc1c(cc2c(ccc(c3ccc(Br)cc3)n12)C(=O)O)C(F)(F)F  
34 CN(C)Cc1c(c([C@H](Br)c2ccccc2)n3ccccc13)c4ccccc4  
35 COC(=O)c1ccn2c(C)c(cc2c1)c3ccc(Br)cc3  
36 Cc1c(cc2cc(O)c(cn12)C(=O)O)c3ccc(Br)cc3  
37 CSc1c(C#N)cc(C)c2c(C)c(c(C)n12)c3ccc(Br)cc3  
38 Cc1c(cc2c(C(=O)O)c(C)ccn12)c3ccc(Br)cc3  
39 Cc1c(cc2c(I)cccn12)c3ccc(O)cc3  
40 Cc1c(cc2cc(CO)c3ccccc3n12)c4ccc(Br)cc4  
41 Cc1c(cc2cc(O)c(C(=O)O)c(O)n12)c3ccc(Br)cc3  
42 Cc1c(cc2c(O)c(C)c(CO)cn12)c3ccc(Br)cc3  
43 Cc1c(cc2c(cccn12)C(=O)O)c3ccc(Br)cc3  
44 Cc1c(cc2ccc3cc(ccc3n12)C(=O)O)c4ccc(Br)cc4  
45 Oc1ccn2c3CCc4ccccc4-c3cc2c1OCc5ccc(Cl)cc5 
46 Cc1c(c(Oc2ccc(cc2)C(=O)O)c3ccccn13)c4ccc(Cl)cc4  
47 Cc1c(c(Oc2cccc(c2)C(=O)O)c3ccccn13)c4ccc(Br)cc4  
48 Cc1c(cc2ccc(CC(=O)O)cn12)c3ccc(Br)cc3  
49 Cc1c(cc2cc(Cl)c(cn12)C(=O)O)c3ccc(Br)cc3  
50 Cc1c(c(O)c2c(Cl)cc(cn12)C(F)(F)F)c3ccccc3F  
51 CCc1c(cc2c(OCc3ccc(Cl)cc3)c(O)ccn12)C(F)(F)F  
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52 CCN(CC)c1c(c(C)n2cccc(O)c12)c3ccc(Br)cc3  
53 Cc1c(cc2c(Cl)cc(cn12)C(F)(F)F)c3ccc(Cl)cc3  
54 Cc1c(c(C(=O)O)c2c(cccn12)C(F)(F)F)c3ccc(Br)cc3  
55 Cc1c(cc2cc(O)c3ccccc3n12)c4ccc(Br)cc4  
56 Cc1c(c(n2cc(Br)cn2)c3ccccn13)c4ccc(Br)cc4  
57 Cc1c(c(O)c2ccc(O)c(Cl)n12)c3ccc(Br)cc3  
58 CCc1c(cc2c(ccc(c3ccc(Br)cc3)n12)C(=O)O)C(F)(F)F  
59 Cc1cccn2c([C@H](Br)c3ccccc3)c(cc12)c4ccccc4  
60 Cc1c(cc2cc(C)c(O)cn12)c3ccc(Br)cc3  
61 CCc1cc2c(OCc3ccc(Cl)cc3)c(O)ccn2c1C  
62 Cc1c(cc2c(Cl)cc(cn12)C(F)(F)F)c3ccc(Br)cc3  
63 Cc1c(cc2c(Cl)cc(cn12)C(F)(F)F)c3ccc(F)cc3F  
64 Cc1c(c(C(=O)C(C)(C)C)c2ccccn12)c3ccc(Br)cc3  
65 Cc1c(cc2c(cc3cccnc3n12)C(=O)O)c4ccc(Br)cc4  
66 CCc1c(c([C@H](Br)c2ccccc2)n3ccc(Cl)cc13)c4ccccc4  
67 Cc1c(cc2cc(C#N)c3ccccc3n12)c4ccc(Br)cc4  
68 Cc1c(cc2cc(O)c3cc(C)ccc3n12)c4ccc(Br)cc4  
69 Cc1ccn2c(C(=O)c3ccc(Br)cc3)c(c(O)c2c1)c4ccc(Br)cc4  
70 CC(=O)c1ccc(c2ccc(Br)cc2)n3c(C)c(cc13)C(F)(F)F  
71 CN(CC(=O)O)c1c(c(C)n2ccccc12)c3ccc(Br)cc3  
72 COC(=O)c1cccc2c(Br)c(c(C)n12)c3ccc(Br)cc3  
73 Cc1c(c(N2CCC[C@H]2CO)c3ccccn13)c4ccc(Br)cc4  
74 Cc1c(c(C(=O)O)c2ccccn12)c3ccc(Br)cc3  
75 Cc1c(cc2c(Br)cccn12)c3ccc(O)cc3  
76 Cc1nc(sc1C(=O)O)c2c(c(C)n3ccccc23)c4ccc(Br)cc4  
77 Fc1ccc(cc1)[C@@H](Br)c2c(cc3c4ccccc4ccn23)c5ccc(F)cc5  
78 OCc1cccn2c([C@H](Br)c3ccc(F)cc3)c(cc12)c4ccc(F)cc4  
79 Cc1c(c(Cl)c2c(Cl)cc(cn12)C(F)(F)F)c3ccccc3F  
80 Cc1c(c(C(=O)O)c2ccc(Cl)cn12)c3ccc(Br)cc3  
81 Cc1c(cc2cc(ccn12)C(=O)O)c3ccc(Br)cc3  
82 Oc1ccccc1c2cc3cc(Br)ccn3c2[C@H](Br)c4ccc(Br)cc4  
83 Cc1c(cc2cc(O)c3ccc(F)cc3n12)c4ccc(Br)cc4  
84 Cc1c(c(N2CCC[C@H](CO)C2)c3ccccn13)c4ccc(Br)cc4  
85 Oc1ccn2c3CCc4nonc4-c3cc2c1OCc5ccc(Cl)cc5 
86 Cc1c(c(C(=O)C2CCC2)c3ccccn13)c4ccc(Br)cc4  
87 [O][N+](=O)c1ccn2c([C@H](Br)c3ccc(F)cc3)c(cc2c1)c4ccc(F)cc4 
88 Cc1c(cc2c(OCc3ccc(Cl)cc3)c(O)ccn12)C(F)(F)F  
89 OCc1ccc2cc(c([C@H](Br)c3ccc(F)cc3)n2c1)c4ccc(F)cc4  
90 Cc1c(c(C)n2c(S)c(C#N)cc(C)c12)c3ccc(Br)cc3  
91 Cc1c(c(c2ccc(Cl)cc2)c3ccccn13)c4ccc(Br)cc4  
92 Cc1c(cc2cc(C)c([N+](=O)[O])c(C)n12)c3ccc(Br)cc3 
93 CCc1ccc2cc(c([C@H](Br)c3ccc(F)cc3)n2c1)c4ccc(F)cc4  
94 Cc1c(c(N2CCCC2)c3c(O)cccn13)c4ccc(Br)cc4  
95 COc1c(C#N)c(C)cc2cc(c(C)n12)c3ccc(Br)cc3  
96 Cc1c(cc2c(Br)c(C)c(C#N)c(O)n12)c3ccc(Br)cc3  
97 Cc1c(cc2ccc3cc(O)ccc3n12)c4ccc(Br)cc4  
98 Cc1ccc(cc1)c2c(CO)c3ccccn3c2[C@H](Br)c4cccs4  
99 Cc1c(cc2ccc(O)c(C)n12)c3ccc(Br)cc3  
100 Cc1c(cc2c3ccc(Cl)nc3ccn12)c4ccc(Br)cc4  
a
 the listed molecules were ranked according to the calculated binding affinity to SagHyal4755 (details not 
shown); accordingly, compound 1 represents the highest binding affinity, compound 100 the lowest binding 
affinity in this synopsis;
 b
 simplified molecular-input line-entry system (SMILES) code can be easily converted 
to the corresponding molecular structures e.g. with ChemDraw software (PerkinElmer Inc., Cambridge, USA), 
level: ultra, product version: 11. 
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The top ten ranked molecules of compound class 3 are illustrated in Figure 9.7. 
 
Figure 9.7 Top ten ranked indolizine derivatives proposed by virtual chemistry as inhibitors of SagHyal4755 
(compound class 3). 
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9.3 Chemistry 
The synthesis of 2-(4-methoxyphenyl)indolizine (9.1) was performed as a condensation 
reaction as illustrated in Figure 9.8. 
 
Figure 9.8 Synthesis of 2-(4-methoxyphenyl)indolizine 9.1. Reagents and conditions: (i) acetone, microwave 
irradiation (130 °C, 4 min); (ii) K2CO3, H2O, microwave irradiation (150 °C, 4 min). 
 
A general method for the preparation of 2-alkyl- and 2-arylindolizines was discovered by 
Tschitschibabin in 1927.18 In detail, a reaction of quaternary pyridinium halides leads to 
the cyclization resulting in indolizines. In a two-step protocol, 2-methylpyridine was 
alkylated with 2-bromo-1-(4-methoxyphenyl)ethanone (8.34, cf. chapter 8), followed by 
ring closure in the presence of a base (potassium carbonate).4, 8 The synthesis was 
modified and optimized as a microwave assisted reaction, to promote the preparation of 
the product 9.1. 
Synthesis of ethyl 2-(4-bromophenyl)-3-methylindolizine-8-carboxylate was accomplished 
by the procedure outlined in Figure 9.9. 
 
Figure 9.9 Synthesis of 2-(4-bromophenyl)-3-methylindolizine-8-carboxylic acid 9.3. Reagents and conditions: 
(i) acetone, microwave irradiation (140 °C, 60 min); (ii) LiOH, THF/EtOH/H2O = 3:0.2:1 (v/v/v). 
 
Following a modified (one-step) and optimized (microwave assisted) reaction, ethyl 2-(4-
bromophenyl)-3-methylindolizine-8-carboxylate (9.2) became directly accessible without 
the addition of base.19 Saponification of the ester moiety with lithium hydroxide yielded the 
target molecule 9.3. 
It is important to mention, that the indolizine core structure was reported to be generally 
unstable against oxidation because of its electron-rich character. As reported by Hagishita 
et al., electron withdrawing groups on the indolizine nucleus make the compounds much 
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less susceptible to oxidation by air.11 As a fact, for the synthesized indolizines 9.1-9.3, 
autoxidation or decomposition was not observed. However, the documentation of 
chemical stability remains an important issue with regard to the indolizine derivatives 
proposed by virtual chemistry. 
Single crystals of 9.3, suitable for X-ray diffraction studies were grown by evaporation of 
the solvent (methanol). The obtained X-ray structure of 9.3 is shown in detail in section 
A.3.5 (appendix I). The crystal structure showed a disorder, which was calculated as “part 
1” and “part 2”. However, anisotropic calculations for the corresponding carbon atoms 
were not accessible. Consequently, the crystal structure showed a double arrangement 
for the 2-phenylindole residue. The packing arrangement of a single crystalline phase 
contained symmetric dimers in which two molecules were present. To illustrate the 
configuration, an ORTEP-style plot and labeling scheme of 9.3 is given in Figure 9.10. 
 
Figure 9.10 Molecular structure (ORTEP-style) of 9.3 including atomic numbering scheme (disorder in the 
crystal induces two calculations of the phenyl residue). 
 
9.4 Pharmacological results and discussion 
9.4.1 General conditions 
All synthesized 2-phenylindolizine derivatives were investigated for inhibition of the 
bacterial hyaluronate lyase SagHyal4755 and the bovine testicular enzyme BTH 
(Neopermease®) in a turbidimetric assay based on the method of Di Ferrante20 as 
described in chapter 3.5.3. 
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9.4.2 Hyaluronidase inhibitory activities of 2-phenylindolizine 
derivatives 
The IC50-values determined for the 2-phenylindolizine derivatives are summarized in 
Table 9.4. 
Table 9.4 Inhibitory activity
a
 and calculated logD5.0 values
b
 of 2-phenylindolizine derivatives 9.1-9.3. 
Compound SagHyal4755 
IC50 (µM)
a
 
BTH 
IC50 (µM) 
logD5.0
b
 
9.1 inactive
c
 inactive 4.4 
9.2 inactive
c
 inactive 6.0
d
 
9.3 85 ± 4.9 inactive 2.3 
a
 mean values ± SEM (N = 2, experiments performed in duplicate), IC50 values determined at pH 5.0 in the 
automated 96-well turbidimetric assay; 
b 
calculated with ACD-Labs (Advanced Chemistry Development Inc., 
Toronto, Canada) product version 12.00;
 c
 at concentrations between 1 µM and 200 µM, inhibition was 
pretended due to colored compounds. 
d
 the structure does not contain ionization centers calculated by ACD-
Labs, LogP-value is indicated instead. 
 
The concentration dependent enzymatic activity of SagHyal4755 in presence of 9.1-9.3 is 
depicted in Figure 9.11. 
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Figure 9.11 Enzymatic activity of SagHyal4755 in the presence of 9.1-9.3. 
 
As a result, inhibitory activity on the target enzyme was confirmed for the indolizine 
derivative 9.3. The “minimal pharmacophore” 2-phenylindolizine (9.1) and ethyl 2-(4-
bromophenyl)-3-methylindolizine-8-carboxylate (9.2) were inactive. Most likely, the 
negatively charged residue of 9.3 plays an important role for inhibitory activity, as the 
corresponding ester 9.2 was inactive on SagHyal4755. A similar behavior was observed for 
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2-phenylindoles (see chapter 8) and for indole-derivatives in previous studies.21-24 Based 
on these observations, 2-phenylindolizines bearing COSMOsim proposed substitution 
patterns represent a new and promising class of inhibitors of SagHyal4755. In particular, 
future investigations should consider indolizine derivatives with and without carboxylic 
groups. Such molecules should be closely related to compounds proposed for compound 
classes 1 to 3. 
 
9.5 Summary 
The molecules of the present chapter were designed with the aid of computational 
methods as bioisosteric molecules of previously identified potent hyaluronidase inhibitors. 
To minimize structural variability, a condensed inhibitor library of 32 substances, mainly 
representing 2-phenylindolizine derivatives, was selected. The streptococcal hyaluronate 
lyase SagHyal4755 was set as target enzyme. 
To quantify bioiosteric molecules, the electronic properties of the library compounds were 
investigated and served as templates for virtual chemistry. The corresponding 
COSMOsim based calculations suggested an indolizine skeleton as core structure of 
bioisosteric inhibitors. Consequently, the prediction of bioisosteric compounds was entirely 
based on physicochemical properties. 
By the aid of virtual chemistry, indolizine derivatives were validated according to their 
calculated binding affinity to the target enzyme SagHyal4755 in silico. The top ranked 
indolizine derivatives, predicted to possess the highest binding affinities, were selected as 
promising molecular structures for the design of novel inhibitors. As a result, a total of 300 
compounds, subdivided into 3 different classes were listed in the present chapter. 
To determine the ability of indolizine derivatives to inhibit the target enzyme under in vitro 
conditions, a single compound was selected and synthesized. As a result, in case of 2-(4-
bromophenyl)-3-methylindolizine-8-carboxylic acid (9.3), an IC50 value of 85 µM was 
determined for SagHyal4755 in the turbidimetric assay. 
This results may be regarded as promising starting point for the development of additional 
inhibitors. For this purpose, indolizine derivatives, bearing structural patterns suggested 
by virtual drug design, might be a valuable source for novel hyaluronidase inhibitors. 
Indolizines and indoles represent chemical isomers. Depending on the results of future 
investigations, indolizines might also be classified as bioisosteric hyaluronidase inhibitors. 
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9.6 Experimental section 
9.6.1 General conditions 
Cf. section 5.8.1 
Compound 8.34 has been described in section 8.6.2.1 
Compound 9.1 has been described before.18 
9.6.2 Chemistry 
2-(4-Methoxyphenyl)indolizine (9.1) 
Experimental details essentially adopted from ref8, 25; the procedure was modified and 
optimized for microwave irradiation. 
A mixture of 2-methylpyridine (0.09 mL, 1 mmol) and 2-bromo-1-(4-methoxyphenyl)-
ethanone 8.34 (229 mg, 1.0 mmol) was dissolved in 2 mL of anhydrous acetone. After 
microwave irradiation (130 °C, 4 min), the quaternary pyridinium halide was filtered off and 
collected to yield 270 mg of a pale gray solid. The precipitate was re-dissolved in 2 mL of 
hot H2O with the aid of sonication. Subsequently, K2CO3 (138 mg, 1mmol) was added to 
the solution. After microwave irradiation (150 °C, 4 min), the remaining precipitate was 
solved in DCM. The organic layer was washed with H2O and dried (Na2SO4). After 
evaporation of the solvent, the product was directly received from white crystals. Yield: 
190 mg (85 %, white crystals); mp 179 – 181 °C (ref25: 184 °C). 1H-NMR (300 MHz, 
DMSO-d6): δ [ppm] = 7.92 (d, J = 7.0 Hz, 1H, indolizine-H), 7.64 – 7.59 (m, 2H, Ph-H-2,6), 
7.45 (br s, indolizine-H), 7.38 – 7.37 (m, 1H, indolizine-H), 7.24 (s, 1H, indolizine-H), 6.64 
– 6.59 (m, 2H, Ph-H-3,5), 6.44 (t, J = 6.7 Hz, 1H, indolizine-H), 3.86 (s, 3H, OCH3-4). MS 
(EI-MS, 70 eV) m/z (rel. int. in %) = 359.0 (90), 356.9 ([M+●], 100), 330.0 (35), 328.0 (35), 
285.0 (20), 248.0 (30), 204.1 (40), 101.6 (30). C15H13BrNO (Mr = 223.27 g/mol). 
 
Ethyl 2-(4-bromophenyl)-3-methylindolizine-8-carboxylate (9.2) 
Experimental details essentially adopted from ref19; the procedure was modified and 
optimized for microwave irradiation. 
A mixture of ethyl 2-methylnicotinate (165 mg, 1.0 mmol) and 2-bromo-1-(4-
bromophenyl)propan-1-one (292 mg, 1.0 mmol) was dissolved in 1.5 mL of anhydrous 
acetone. After microwave irradiation (140 °C, 60 min), the solvent was evaporated (rotary 
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evaporator) to yield the crude product as a dark yellow oil. The product was purified by 
flash-chromatography (PE/EtOAc 80/20, v/v). Yield: 80 mg (20 %, yellow solid); mp 169 – 
171 °C. 1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 7.91 (d, J = 7.0 Hz, 1H, indolizine-H-5), 
7.61 (dd, J = 6.9, 0.7 Hz, 1H, indolizine-H-7), 7.59 – 7.53 (m, 2H, Ph-H-3,5), 7.43 – 7.37 
(m, 2H, Ph-H-2,6), 7.24 (d, J = 11.7 Hz, 1H, indolizine-H-1), 6.64 (t, 1H, J = 7.0 Hz, 
indolizine-H-6), 4.44 (q, J = 7.1 Hz, 2H, COOCH2CH3), 2.55 (s, 3H, indolizine-CH3-3), 1.44 
(t, J = 7.1 Hz, 3H, 3H, COOCH2CH3). MS (EI-MS, 70 eV) m/z (rel. int. in %) = 359.0 (90), 
356.9 ([M+●], 100), 330.0 (35), 328.0 (35), 285.0 (20), 248.0 (30), 204.1 (40), 101.6 (30). 
C18H16BrNO2 (Mr = 358.23 g/mol). 
 
2-(4-Bromophenyl)-3-methylindolizine-8-carboxylic acid (9.3) 
A suspension of ethyl 2-(4-bromophenyl)-3-methylindolizine-8-carboxylate 9.2 (60 mg, 
0.2 mmol) and LiOH (8 mg, 0.4 mmol) in a mixture 3:0.2:1 mixture of THF, EtOH, H2O 
(v/v/v) was stirred at room temperature for 14 days. Purification by flash chromatography 
(PE/EtOAc 80/20, v/v) gave 9.3 as a yellow powder. Yield: 50 mg (76 %, yellow solid); mp 
151 - 154 °C. Single crystals of 9.3 were grown from a solution of 10 mg product in 
anhydrous methanol (1.5 mL) in a 2 mL plastic vial. The solvent was slowly evaporated at 
room temperature over 14 days. 1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 13.00 (s, 1H, 
COOH), 8.32 (d, J = 7.1 Hz, 1H, indolizine-H-5), 7.66 – 7.60 (m, 2H, Ph-H-3,5), 7.53 (d, 
J = 6.5 Hz, 1H, indolizine-H-7), 7.51 – 7.45 (m, 2H, Ph-H-2,6), 7.12 (s, 1H, indolizine-H-1), 
6.76 (t, J = 7.0 Hz, 1H, indolizine-H-6), 2.56 (s, 3H, indolizine-CH3-3). 
13C-NMR (75 MHz, 
DMSO-d6) δ [ppm] = 166.18 (Cquat, COOH), 135.03 (Cquat, indolizine-C), 131.46 (+, Ph-C-
2,6), 130.54 (+, Ph-C-3,5), 128.31 (Cquat, Ph-C), 127.27 (+, indolizine-C-5), 126.22 (Cquat, 
indolizine-C), 122.63 (+, indolizine-C-7), 120.15 (Cquat, Ph-C), 119.51 (Cquat, indolizine-C), 
117.13 (Cquat, indolizine-C), 109.07 (+, indolizine-C-6), 100.01 (+, indolizine-C-1), 10.21 (+, 
indolizine-CH3-3). MS (ES-MS, DCM/MeOH + NH4OAc) m/z (rel. int. in %) = 329.9 
([M + H]+, 100), 328.8 (15). C16H12BrNO2 (Mr = 330.18 g/mol). 
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Hyaluronidases are enzymes that degrade hyaluronan, a major constituent of the 
extracellular matrix. As the role of hyaluronidases is far from being understood, potent and 
selective inhibitors are required as pharmacological tools. Moreover, inhibitors of the 
bacterial and mammalian enzymes might be useful agents in the treatment of various 
diseases, e.g. bacterial infections. 
Previously, we identified hyaluronidase inhibitors among lipophilic vitamin C, indole and 
benzoxazole derivatives. Unfortunately, such substances proved to be inappropriate for 
in vivo studies due to the lack of drug-like properties, in particular, due to extremely high 
plasma protein binding. Furthermore, substances bearing a 2-phenylindole scaffold were 
chemically derived from known antiestrogens. Hence, (anti)estrogenicity of phenylindole-
type hyaluronidase inhibitors had to be taken into account. 
The goal of this thesis was the design, synthesis, identification and pharmacological 
characterization of novel lead inhibitors for the bacterial hyaluronidase SagHyal4755. To 
give access to inhibitors suitable for in vivo characterization, the focus was set on small 
molecules with drug-like properties. 
In a first attempt, a target-based approach led to the development of novel lead inhibitors 
of the streptococcal lyase SagHyal4755. For this purpose, a convenient strategy, inspired 
by industrial pharmaceutical research, i.e. a computer-assisted and multicomponent 
synthesis approach was pursued in an interdisciplinary project. An existing turbidimetric 
assay for the investigation of hyaluronidase inhibitors was modified and adapted to 
automated screening in the 96 well and 384 well format. Decision criteria for the 
acceptance of “hit” compounds were elaborated. A compound library comprising 347 
substances was analyzed for inhibition of SagHyal4755. The structure activity relationships 
(SAR) were elucidated and models of the enzyme in complex with potential inhibitors were 
generated in silico. The suggested compounds were synthesized by parallel synthesis, 
analyzed and tested for biological activity in medium-throughput. Among 2640 screened 
samples, 4-amino-imidazolidine-2-thiones were identified as promising hits to develop 
inhibitors of SagHyal4755. Synthesis on the preparative scale and purification of hit 
compounds revealed inhibitory activity in the micromolar range. However, some 
derivatives proved to be prone to autoxidation and decomposition. To cope with this 
problem, the oxidation process was studied in detail by means of [18O] labeling and HPLC-
MS analysis. The results paved the way to the synthesis of more stable molecules. 4-{1-
(3,5-Dichloro-4-hydroxyphenyl)-5-hydroxy-2-thioxo-4-[4-(trifluoromethyl)benzylamino]-2,5-
dihydro-1H-imidazol-5-yl}benzoic acid (UR-CT574 with an IC50 value of 8 µM) was 
identified as one of the most potent inhibitors of the target enzyme known so far. 
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Furthermore, 1352 compounds with imidazopyridine scaffold were synthesized and 
tested. Screening for inhibition of the bacterial hyaluronate lyase revealed several hits, 
which will be subject of future studies. 
A subproject focused on the synthesis and pharmacological characterization of a small 
series of 2-phenylindoles bearing a benzyl substituent in position 1, aiming at less 
lipophilic compounds compared to the previously described N-alkylated indole-type 
inhibitors. The IC50 values of the novel compounds, especially when bearing chloro 
substituents, were in the micromolar range. For example, an IC50 value of 9 µM for 
inhibition of SagHyal4755 was determined for 4-{[6,7-dichloro-2-(4-hydroxyphenyl)-3-
methyl-1H-indol-1-yl]methyl}benzoic acid (UR-CT619). In addition, this compound proved 
to be the most potent inhibitor of a related bacterial hyaluronidase from S. pneumonia 
(SpnHyl) known so far (IC50 = 93 µM). These compounds are devoid of cytotoxicity against 
estrogen sensitive MCF-7 human breast cancer cells. 
Taken together, molecules from two different chemical classes were discovered as one-
digit micromolar inhibitors of the target enzyme SagHyal4755. Inhibitory activity was also 
observed for the streptococcal hyaluronidase SpnHyl. These compounds can be 
considered as lead structures for the development of inhibitors of bacterial hyaluronate 
lyases. Such agents might be useful in combination with antibiotics to combat bacteria 
producing hyaluronidase as a putative virulence factor. 
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A.1 Abbreviations 
A Ala, alanine 
Å Angstrom (unit) 
abs absolute 
Anal. Analysis 
aq aqueous 
Ar aromatic 
AU absorption units 
BSA  bovine serum albumin 
BTH bovine testicular hyaluronidase 
c concentration 
calcd. calculated 
cat. catalytical amounts 
CD44 cluster of differentiation 44 
CI chemical ionization 
conc. concentrated 
COSY correlated spectroscopy 
cpd compound 
Cquat quaternary carbon atom 
CTAB cetrimonium bromide, cetyltrimethylammonium bromide 
CV column volume 
4CC four component condensation 
d day(s) or doublet 
 chemical shift 
Da Dalton 
DCM dichloromethane 
DEPT distortionless enhancement by polarization transfer 
DMAB 4-(dimethylamino)benzaldehyde 
DMF N,N-dimethylformamide 
DMSO dimethylsulfoxide 
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DMSO-d6 per-deuterated DMSO 
EC enzyme commission 
ECM extracellular matrix 
E. coli Escherichia coli 
EDTA ethylenediaminetetraacetic acid 
EI electron impact ionization 
eq equivalent(s) 
ER estrogen receptor 
ESI electrospray ionization 
Et2O diethyl ether 
EtOAc ethyl acetate 
EtOH ethanol 
EWG electron withdrawing group 
F Phe, phenylalanine 
GAG glycosaminoglycan 
GlcNAc N-acetyl-D-glycosamine 
GlcUA D-glucuronic acid 
GPI glycosylphospatidylinositol 
h hour(s) 
HA hyaluronic acid, hyaluronan 
HAS hyaluronan synthase 
HMBC heteronuclear multiple bond correlation 
HPLC high performance liquid chromatography 
HRMS high resolution mass spectroscopy 
HSQC heteronuclear single quantum correlation 
HTS high-throughput screening 
Hyal-1 (human) hyaluronidase 1 
IC50  concentration of an inhibitor required to give 50% inhibition of 
enzymatic activity 
IMAC immobilized metal affinity chromatography 
IU international units 
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J coupling constant 
LB lysogeny broth 
m milli or multiplet 
M molar 
M  mass 
Mr  molecular mass 
MCF-7 Michigan Cancer Foundation – 7 (human breast cancer cell line) 
MCR multicomponent reaction 
Me methyl 
MeCN acetonitrile 
MeOH methanol 
min minute(s) 
mp melting point 
MS mass spectral or mass spectrum 
MTP microtiter plate 
mw molecular weight 
MWCO molecular weight cutoff 
m/z mass-to-charge ratio 
N number of experiments 
NCE new chemical entities 
NFU national formulatory unit 
NMR nuclear magnetic resonance 
NP normal phase 
NSAID non-steroidal anti-inflammatory drug 
OAc acetate 
OD optical density 
PAD proton acceptance and donation 
PAGE polyacrylamide gel electrophoresis 
PDB protein data bank 
PE petroleum ether 
PEGME poly(ethylene glycol)monoethyl ether 
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pH negative logarithm of the hydrogen ion concentration 
Ph phenyl 
ppm part per million 
q quartet 
ref reference 
RHAMM receptor for hyaluronate-mediated motility 
RP reversed phase 
rpm revolutions per minute 
rt room temperature 
s singulet 
SagHyal4755 hyaluronate lyase from Streptococcus agalagtiae strain 4755 
SAR structure-activity relationships 
sat. saturated 
SDS sodium dodecylsulfate 
SEM standard error of the mean 
SPAM1 spam adhesion molecule 1 (also termed PH-20) 
SpnHyl hyaluronate lyase from Streptococcus pneumoniae 
t triplet 
t0 dead time 
tR retention time 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
TIC total ion count 
TLC thin layer chromatography 
TMS trimethylsilyl 
(r)TRU (relative) turbidity reducing unit 
U unit(s) 
UV ultraviolet 
V Val, valine 
W Trp, tryptophan 
Y Tyr, tyrosine 
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A.2 HPLC purity data 
Cpd tR (min) k’ purity (%) Cpd tR (min) k’ purity (%) 
5.26
a
 12.33 4.29 90.3 5.62
b
 27.26 7.21 95.0 
5.27
a
 11.26 3.83 94.9 5.63
b
 24.80 6.47 95.8 
5.28
a
 10.87 3.67 95.1 5.64
b
 19.63 4.91 95.7 
5.29
a
 11.71 4.03 96.3 5.65
a
 13.79 4.92 92.9 
5.30
a
 12.14 4.21 94.8 5.66
a
 12.29 4.27 94.8 
5.31
a
 12.15 4.21 94.1 5.67
b
 26.72 7.05 97.5 
5.32
a
 10.93 3.69 95.8 5.68
b
 23.66 6.13 95.8 
5.33
a
 9.83 3.22 98.2 5.69
a
 11.54 3.95 95.3 
5.34
a
 12.73 4.46 99.1 5.70
a
 9.70 3.16 95.8 
5.35
a
 9.84 3.22 93.9 5.71
a
 9.95 3.27 97.8 
5.43
a
 8.30 2.56 95.0 5.72
a
 11.42 3.90 97.3 
5.44
a
 9.82 3.21 97.4 5.73
a
 12.13 4.21 99.1 
5.45
a
 9.17 2.94 95.1 8.24a
a
 12.14 4.21 95.9 
5.46
a
 9.79 3.20 96.7 8.25a
a
 12.91 4.54 99.5 
5.47
b
 24.26 6.31 95.1 8.26a
a
 12.78 4.48 97.7 
5.48
a
 11.71 4.03 98.9 8.27a
a
 11.19 3.80 98.3 
5.49
a
 11.35 3.87 98.1 8.27b
a
 8.54 2.67 95.7 
5.50
a
 12.09 4.19 94.9 8.28a
a
 12.97 4.57 97.4 
5.51
a
 10.37 3.45 99.8 8.29a
a
 13.61 4.84 98.3 
5.52
b
 24.82 6.48 95.4 8.29b
a
 9.74 3.18 95.3 
5.53
a
 11.34 3.87 95.7 8.30a
a
 11.89 4.10 94.8 
5.54
b
 20.20 5.08 96.1 8.31a
a
 12.67 4.44 97.0 
5.55
b
 24.13 6.27 95.0 8.32a
a
 10.25 3.40 94.7 
5.56
a
 9.82 3.21 96.2 8.32b
a
 10.58 3.54 97.4 
5.57
b
 21.54 5.49 95.9 8.41
a
 12.17 4.22 93.9 
5.58
b
 23.24 6.00 94.9 8.42
a
 12.18 4.23 95.1 
5.59
b
 24.82 6.48 95.4 8.43
a
 14.57 5.25 98.6 
5.60
b
 26.24 6.90 95.2 8.47
a
 14.63 5.28 97.8 
5.61
b
 26.58 7.01 96.2 9.3
a
 8.14 2.49 96.6 
a 
Eurospher-100 C18, 250 x 4.0 mm, 5 µm (Knauer, Berlin, Germany), t0 = 2.33 min, gradient mode: 
MeCN/H2O + 0.025% TFA: 0 min: 20/80, 15 min: 95/5, 21 min: 20/80, 25 min: 20/80; 
b
 Eurospher-100 C18, 
250 x 4.0 mm, 5 µm (Knauer, Berlin, Germany), t0 = 3.32 min, gradient mode: MeCN/H2O + 0.05% TFA: 0 
min: 20/80, 20 min: 90/10, 21 min: 95/5, 30 min: 95/5, 31 min: 10/90, 40 min 10/90. 
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A.3 X-ray crystallographic data 
A.3.1 rac-1-(3,5-Dichloro-4-hydroxyphenyl)-5-methyl-4-(4-
(trifluoromethyl)benzylamino)-5-(2,4,5-trimethoxy-phenyl)-
1H-imidazole-2(5H)-thione (5.45) 
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Table 1 Crystal data and structure refinement for 5.45. 
Crystal Data    
Empirical formula  C55H54Cl4F6N6O10S2 
Formula weight  1278.98  
Crystal size  0.1371 x 0.0373 x 0.0135 mm  
Crystal description  plate  
Crystal colour  colourless  
Crystal system Triclinic  
Space group  P -1  
Unit cell dimensions  a = 11.6049(5) Å alpha = 61.372(4) deg.  
 b = 17.0403(7) Å beta = 79.516(4) deg.  
 c = 17.3915(7) Å gamma = 74.160(4) deg.  
Volume  2898.8(2) Å
3
 
Z, Calculated density  2,  1.465 Mg/m
3
  
Absorption coefficient  3.239 mm
-1
  
F(000)  1320  
  
Data Collection    
Measurement device type  SuperNova, Single source at offset), Atlas  
Measurement method  \w scans  
Temperature  123 K  
Wavelength  1.54184 Å  
Monochromator  graphite  
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Theta range for data collection  3.03 to 76.60 deg.  
Index ranges  -14<=h<=10, -21<=k<=21, -21<=l<=21  
Reflections collected / unique  21495 / 11732 [R(int) = 0.0340]  
Reflections greater I>2\s(I) 9352  
Absorption correction  Analytical  
Max. and min. transmission  0.960 and 0.767  
Refinement  --- 
Refinement method  Full-matrix least-squares on F
2
  
Hydrogen treatment  --- 
Data / restraints / parameters  11732 / 2 / 746  
Goodness-of-fit on F
2
  1.033  
Final R indices [I>2sigma(I)]      R1 = 0.0546, wR2 = 0.1445  
R indices (all data)               R1 = 0.0682, wR2 = 0.1572  
Absolute structure parameter  --- 
Largest diff. peak and hole  1.073 and -0.648 e.A
-3
  
 
Table 2. Atomic coordinates (x 104) and equivalent isotropic displacement 
parameters (Å2 x 103) for 5.45. U(eq) is defined as one third of the trace of the 
orthogonalized Uij tensor. 
 x y z U(eq) 
     
Cl(1) -1425(1) 1016(1) 2294(1) 39(1) 
Cl(2) -3793(1) 4515(1) 569(1) 40(1) 
S(1) 1732(1) 3318(1) 290(1) 34(1) 
F(1) 8258(2) 1222(1) 4064(1) 45(1) 
F(2) 6975(2) 933(2) 5162(1) 61(1) 
F(3) 7030(2) 380(1) 4279(2) 49(1) 
O(1) 1769(2) 2187(1) 2960(1) 30(1) 
O(2) -866(2) 1470(1) 5607(1) 34(1) 
O(3) -1916(2) 3167(1) 5044(1) 40(1) 
O(4) -3402(2) 2429(1) 1414(1) 37(1) 
N(1) 2431(2) 4287(2) 2432(2) 29(1) 
N(2) 2370(2) 3869(2) 1344(2) 29(1) 
N(3) 449(2) 3701(1) 1566(1) 26(1) 
C(1) 6233(2) 1971(2) 3769(2) 33(1) 
C(2) 6447(3) 2833(2) 3477(2) 37(1) 
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C(3) 5616(3) 3611(2) 2993(2) 35(1) 
C(4) 4565(2) 3530(2) 2788(2) 29(1) 
C(5) 4360(3) 2665(2) 3076(2) 41(1) 
C(6) 5192(3) 1889(2) 3561(2) 41(1) 
C(7) 7110(3) 1136(2) 4308(2) 38(1) 
C(8) 3677(2) 4384(2) 2230(2) 31(1) 
C(9) 1878(2) 4050(2) 2005(2) 26(1) 
C(10) 1500(2) 3633(2) 1092(2) 28(1) 
C(11) 557(2) 4010(2) 2209(2) 25(1) 
C(12) -196(2) 4982(2) 1943(2) 28(1) 
C(13) 257(2) 3329(2) 3148(2) 25(1) 
C(14) 860(2) 2415(2) 3488(2) 26(1) 
C(15) 527(2) 1774(2) 4321(2) 28(1) 
C(16) -421(2) 2046(2) 4813(2) 28(1) 
C(17) -1014(2) 2971(2) 4498(2) 28(1) 
C(18) -669(2) 3594(2) 3671(2) 27(1) 
C(19) 2438(3) 1269(2) 3288(2) 37(1) 
C(20) -267(3) 535(2) 5964(2) 39(1) 
C(21) -2549(3) 4097(2) 4732(2) 48(1) 
C(22) -571(2) 3408(2) 1534(2) 26(1) 
C(23) -529(2) 2472(2) 1912(2) 28(1) 
C(24) -1490(2) 2183(2) 1858(2) 28(1) 
C(25) -2536(2) 2788(2) 1450(2) 29(1) 
C(26) -2538(2) 3716(2) 1094(2) 29(1) 
C(27) -1581(2) 4033(2) 1126(2) 28(1) 
Cl(3) -3727(1) -3312(1) 5082(1) 40(1) 
Cl(4) -3551(1) -3885(1) 2258(1) 36(1) 
S(2) 933(1) -4819(1) 3808(1) 32(1) 
F(4) 5423(3) 275(2) 2832(3) 118(2) 
F(5) 6966(2) -732(2) 3067(3) 87(1) 
F(6) 5551(4) -884(4) 4044(2) 132(2) 
O(5) -2390(2) 527(1) 88(1) 34(1) 
O(6) -1958(2) -204(1) -942(1) 37(1) 
O(7) 630(2) -2882(1) 1155(1) 30(1) 
O(8) -4572(2) -3870(2) 4001(2) 38(1) 
N(4) 2346(2) -1944(2) 1735(2) 32(1) 
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N(5) 1973(2) -3386(2) 2752(2) 29(1) 
N(6) -57(2) -3035(1) 2885(1) 26(1) 
C(28) 5257(3) -1061(2) 2841(2) 41(1) 
C(29) 5673(3) -1009(3) 2027(3) 51(1) 
C(30) 5145(3) -1374(2) 1656(2) 45(1) 
C(31) 4200(2) -1806(2) 2104(2) 31(1) 
C(32) 3801(3) -1868(2) 2930(2) 37(1) 
C(33) 4318(3) -1496(2) 3297(2) 40(1) 
C(34) 5793(3) -622(3) 3211(3) 50(1) 
C(35) 3653(2) -2217(2) 1698(2) 34(1) 
C(36) 1624(2) -2504(2) 2235(2) 26(1) 
C(37) 939(2) -3721(2) 3132(2) 26(1) 
C(38) 275(2) -2145(2) 2304(2) 27(1) 
C(39) 57(3) -1583(2) 2815(2) 32(1) 
C(40) -311(2) -1635(2) 1434(2) 26(1) 
C(41) -1078(2) -769(2) 1176(2) 27(1) 
C(42) -1612(2) -314(2) 388(2) 28(1) 
C(43) -1395(2) -720(2) -174(2) 28(1) 
C(44) -642(2) -1578(2) 63(2) 29(1) 
C(45) -103(2) -2027(2) 864(2) 26(1) 
C(46) -2535(3) 1015(2) 586(2) 36(1) 
C(47) -1981(3) -638(2) -1461(2) 45(1) 
C(48) 1220(3) -3180(2) 518(2) 31(1) 
C(49) -1256(2) -3170(2) 3129(2) 26(1) 
C(50) -1843(2) -3158(2) 3894(2) 30(1) 
C(51) -2973(2) -3359(2) 4139(2) 31(1) 
C(52) -3523(2) -3614(2) 3672(2) 32(1) 
C(53) -2915(2) -3592(2) 2893(2) 28(1) 
C(54) -1802(2) -3368(2) 2614(2) 26(1) 
O(9) -5408(2) 3225(2) 650(2) 53(1) 
C(55) -5319(17) 3216(13) -147(13) 325(11) 
O(10) -5872(2) -4571(2) 3466(2) 37(1) 
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Table 3. Bond lengths [Å] and angles [deg.] for 5.45. 
Cl(1)-C(24) 1.740(3) S(1)-C(10)-N(2) 123.8(2) 
Cl(2)-C(26) 1.737(3) N(3)-C(11)-C(12) 109.5(2) 
Cl(3)-C(51) 1.740(3) N(3)-C(11)-C(9) 97.8(2) 
Cl(4)-C(53) 1.742(3) C(9)-C(11)-C(13) 114.3(2) 
S(1)-C(10) 1.674(3) N(3)-C(11)-C(13) 111.7(2) 
S(2)-C(37) 1.667(3) C(9)-C(11)-C(12) 108.9(2) 
F(1)-C(7) 1.349(4) C(12)-C(11)-C(13) 113.5(2) 
F(2)-C(7) 1.342(4) C(14)-C(13)-C(18) 118.3(2) 
F(3)-C(7) 1.342(4) C(11)-C(13)-C(18) 121.1(3) 
F(4)-C(34) 1.317(7) C(11)-C(13)-C(14) 120.5(2) 
F(5)-C(34) 1.316(5) O(1)-C(14)-C(15) 122.7(3) 
F(6)-C(34) 1.295(6) C(13)-C(14)-C(15) 120.8(3) 
O(1)-C(19) 1.420(4) O(1)-C(14)-C(13) 116.5(2) 
O(1)-C(14) 1.369(3) C(14)-C(15)-C(16) 119.8(3) 
O(2)-C(16) 1.363(3) C(15)-C(16)-C(17) 120.4(2) 
O(2)-C(20) 1.418(4) O(2)-C(16)-C(15) 124.7(3) 
O(3)-C(17) 1.364(4) O(2)-C(16)-C(17) 114.9(2) 
O(3)-C(21) 1.425(4) C(16)-C(17)-C(18) 118.7(3) 
O(4)-C(25) 1.335(4) O(3)-C(17)-C(16) 115.6(2) 
O(4)-H(4) 0.8400 O(3)-C(17)-C(18) 125.7(3) 
O(5)-C(42) 1.374(4) C(13)-C(18)-C(17) 121.8(3) 
O(5)-C(46) 1.424(4) C(23)-C(22)-C(27) 120.1(2) 
O(6)-C(43) 1.364(3) N(3)-C(22)-C(27) 121.1(3) 
O(6)-C(47) 1.423(4) N(3)-C(22)-C(23) 118.7(2) 
O(7)-C(45) 1.370(4) C(22)-C(23)-C(24) 119.2(2) 
O(7)-C(48) 1.424(4) Cl(1)-C(24)-C(25) 117.4(2) 
O(8)-C(52) 1.340(3) Cl(1)-C(24)-C(23) 119.5(2) 
O(8)-H(8) 0.8400 C(23)-C(24)-C(25) 123.1(3) 
O(9)-C(55) 1.38(2) O(4)-C(25)-C(26) 126.7(3) 
O(9)-H(9) 0.8400 C(24)-C(25)-C(26) 115.5(2) 
O(10)-H(10O) 0.87(3) O(4)-C(25)-C(24) 117.8(3) 
O(10)-H(10P) 0.83(2) C(25)-C(26)-C(27) 123.1(3) 
N(1)-C(9) 1.314(4) Cl(2)-C(26)-C(27) 118.2(2) 
N(1)-C(8) 1.460(4) Cl(2)-C(26)-C(25) 118.7(2) 
N(2)-C(10) 1.388(4) C(22)-C(27)-C(26) 119.1(3) 
 Appendix I 305 
N(2)-C(9) 1.323(4) C(3)-C(2)-H(2) 120.00 
N(3)-C(22) 1.424(4) C(1)-C(2)-H(2) 120.00 
N(3)-C(10) 1.353(3) C(4)-C(3)-H(3) 120.00 
N(3)-C(11) 1.482(4) C(2)-C(3)-H(3) 120.00 
N(1)-H(1N) 0.78(5) C(6)-C(5)-H(5) 120.00 
N(4)-C(35) 1.459(4) C(4)-C(5)-H(5) 120.00 
N(4)-C(36) 1.322(4) C(5)-C(6)-H(6) 120.00 
N(5)-C(36) 1.317(4) C(1)-C(6)-H(6) 120.00 
N(5)-C(37) 1.388(4) C(4)-C(8)-H(8B) 109.00 
N(6)-C(49) 1.427(3) N(1)-C(8)-H(8B) 109.00 
N(6)-C(38) 1.476(4) N(1)-C(8)-H(8A) 109.00 
N(6)-C(37) 1.360(4) C(4)-C(8)-H(8A) 109.00 
N(4)-H(4N) 0.83(5) H(8A)-C(8)-H(8B) 108.00 
C(1)-C(7) 1.489(5) H(12B)-C(12)-H(12C) 110.00 
C(1)-C(6) 1.382(4) C(11)-C(12)-H(12A) 110.00 
C(1)-C(2) 1.384(5) H(12A)-C(12)-H(12B) 109.00 
C(2)-C(3) 1.387(5) C(11)-C(12)-H(12C) 110.00 
C(3)-C(4) 1.390(4) C(11)-C(12)-H(12B) 109.00 
C(4)-C(8) 1.520(4) H(12A)-C(12)-H(12C) 109.00 
C(4)-C(5) 1.386(5) C(14)-C(15)-H(15) 120.00 
C(5)-C(6) 1.387(5) C(16)-C(15)-H(15) 120.00 
C(9)-C(11) 1.522(4) C(17)-C(18)-H(18) 119.00 
C(11)-C(13) 1.527(4) C(13)-C(18)-H(18) 119.00 
C(11)-C(12) 1.531(4) O(1)-C(19)-H(19B) 110.00 
C(13)-C(18) 1.400(4) H(19A)-C(19)-H(19B) 109.00 
C(13)-C(14) 1.392(4) H(19A)-C(19)-H(19C) 109.00 
C(14)-C(15) 1.397(4) O(1)-C(19)-H(19C) 109.00 
C(15)-C(16) 1.384(4) O(1)-C(19)-H(19A) 109.00 
C(16)-C(17) 1.406(4) H(19B)-C(19)-H(19C) 110.00 
C(17)-C(18) 1.384(4) H(20A)-C(20)-H(20B) 109.00 
C(22)-C(27) 1.382(4) O(2)-C(20)-H(20A) 109.00 
C(22)-C(23) 1.394(4) H(20A)-C(20)-H(20C) 109.00 
C(23)-C(24) 1.369(4) O(2)-C(20)-H(20B) 109.00 
C(24)-C(25) 1.403(4) H(20B)-C(20)-H(20C) 109.00 
C(25)-C(26) 1.395(4) O(2)-C(20)-H(20C) 110.00 
C(26)-C(27) 1.381(4) H(21A)-C(21)-H(21C) 109.00 
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C(2)-H(2) 0.9500 O(3)-C(21)-H(21C) 109.00 
C(3)-H(3) 0.9500 H(21B)-C(21)-H(21C) 109.00 
C(5)-H(5) 0.9500 H(21A)-C(21)-H(21B) 110.00 
C(6)-H(6) 0.9500 O(3)-C(21)-H(21A) 109.00 
C(8)-H(8A) 0.9900 O(3)-C(21)-H(21B) 109.00 
C(8)-H(8B) 0.9900 C(24)-C(23)-H(23) 120.00 
C(12)-H(12B) 0.9800 C(22)-C(23)-H(23) 120.00 
C(12)-H(12A) 0.9800 C(22)-C(27)-H(27) 121.00 
C(12)-H(12C) 0.9800 C(26)-C(27)-H(27) 120.00 
C(15)-H(15) 0.9500 C(29)-C(28)-C(34) 119.6(3) 
C(18)-H(18) 0.9500 C(33)-C(28)-C(34) 120.6(3) 
C(19)-H(19B) 0.9800 C(29)-C(28)-C(33) 119.8(3) 
C(19)-H(19A) 0.9800 C(28)-C(29)-C(30) 120.3(4) 
C(19)-H(19C) 0.9800 C(29)-C(30)-C(31) 120.4(3) 
C(20)-H(20C) 0.9800 C(32)-C(31)-C(35) 121.5(3) 
C(20)-H(20B) 0.9800 C(30)-C(31)-C(35) 119.7(3) 
C(20)-H(20A) 0.9800 C(30)-C(31)-C(32) 118.8(3) 
C(21)-H(21A) 0.9800 C(31)-C(32)-C(33) 120.8(3) 
C(21)-H(21C) 0.9800 C(28)-C(33)-C(32) 119.8(3) 
C(21)-H(21B) 0.9800 F(5)-C(34)-C(28) 113.3(4) 
C(23)-H(23) 0.9500 F(4)-C(34)-F(5) 102.8(4) 
C(27)-H(27) 0.9500 F(4)-C(34)-C(28) 112.0(4) 
C(28)-C(29) 1.378(6) F(6)-C(34)-C(28) 114.6(4) 
C(28)-C(33) 1.389(5) F(4)-C(34)-F(6) 105.6(5) 
C(28)-C(34) 1.491(6) F(5)-C(34)-F(6) 107.7(4) 
C(29)-C(30) 1.384(6) N(4)-C(35)-C(31) 111.6(3) 
C(30)-C(31) 1.390(4) N(4)-C(36)-N(5) 125.3(3) 
C(31)-C(32) 1.389(4) N(5)-C(36)-C(38) 113.7(2) 
C(31)-C(35) 1.507(4) N(4)-C(36)-C(38) 120.9(3) 
C(32)-C(33) 1.380(5) N(5)-C(37)-N(6) 110.9(2) 
C(36)-C(38) 1.523(4) S(2)-C(37)-N(6) 125.0(2) 
C(38)-C(39) 1.540(4) S(2)-C(37)-N(5) 124.1(2) 
C(38)-C(40) 1.517(4) N(6)-C(38)-C(39) 109.1(2) 
C(40)-C(45) 1.395(4) N(6)-C(38)-C(36) 97.5(2) 
C(40)-C(41) 1.402(4) C(36)-C(38)-C(40) 114.3(2) 
C(41)-C(42) 1.375(4) N(6)-C(38)-C(40) 113.5(2) 
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C(42)-C(43) 1.401(4) C(39)-C(38)-C(40) 113.8(3) 
C(43)-C(44) 1.388(4) C(36)-C(38)-C(39) 107.3(2) 
C(44)-C(45) 1.396(4) C(38)-C(40)-C(45) 120.2(3) 
C(49)-C(50) 1.387(4) C(41)-C(40)-C(45) 117.9(2) 
C(49)-C(54) 1.388(4) C(38)-C(40)-C(41) 121.9(3) 
C(50)-C(51) 1.386(4) C(40)-C(41)-C(42) 121.5(3) 
C(51)-C(52) 1.391(4) O(5)-C(42)-C(41) 125.7(3) 
C(52)-C(53) 1.398(4) C(41)-C(42)-C(43) 119.8(3) 
C(53)-C(54) 1.383(4) O(5)-C(42)-C(43) 114.6(2) 
C(29)-H(29) 0.9500 C(42)-C(43)-C(44) 120.0(2) 
C(30)-H(30) 0.9500 O(6)-C(43)-C(44) 125.1(3) 
C(32)-H(32) 0.9500 O(6)-C(43)-C(42) 114.8(3) 
C(33)-H(33) 0.9500 C(43)-C(44)-C(45) 119.4(3) 
C(35)-H(35A) 0.9900 C(40)-C(45)-C(44) 121.4(3) 
C(35)-H(35B) 0.9900 O(7)-C(45)-C(40) 115.5(2) 
C(39)-H(39A) 0.9800 O(7)-C(45)-C(44) 123.0(3) 
C(39)-H(39C) 0.9800 C(50)-C(49)-C(54) 120.4(2) 
C(39)-H(39B) 0.9800 N(6)-C(49)-C(50) 120.6(2) 
C(41)-H(41) 0.9500 N(6)-C(49)-C(54) 118.9(2) 
C(44)-H(44) 0.9500 C(49)-C(50)-C(51) 118.8(3) 
C(46)-H(46A) 0.9800 Cl(3)-C(51)-C(52) 118.4(2) 
C(46)-H(46C) 0.9800 Cl(3)-C(51)-C(50) 118.8(2) 
C(46)-H(46B) 0.9800 C(50)-C(51)-C(52) 122.8(3) 
C(47)-H(47A) 0.9800 O(8)-C(52)-C(53) 125.2(3) 
C(47)-H(47B) 0.9800 C(51)-C(52)-C(53) 116.4(2) 
C(47)-H(47C) 0.9800 O(8)-C(52)-C(51) 118.4(3) 
C(48)-H(48B) 0.9800 C(52)-C(53)-C(54) 122.3(3) 
C(48)-H(48C) 0.9800 Cl(4)-C(53)-C(54) 118.3(2) 
C(48)-H(48A) 0.9800 Cl(4)-C(53)-C(52) 119.4(2) 
C(50)-H(50) 0.9500 C(49)-C(54)-C(53) 119.3(2) 
C(54)-H(54) 0.9500 C(30)-C(29)-H(29) 120.00 
C(55)-H(55C) 0.9800 C(28)-C(29)-H(29) 120.00 
C(55)-H(55A) 0.9800 C(29)-C(30)-H(30) 120.00 
C(55)-H(55B) 0.9800 C(31)-C(30)-H(30) 120.00 
  C(33)-C(32)-H(32) 120.00 
C(14)-O(1)-C(19) 118.7(2) C(31)-C(32)-H(32) 119.00 
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C(16)-O(2)-C(20) 116.8(2) C(32)-C(33)-H(33) 120.00 
C(17)-O(3)-C(21) 116.7(2) C(28)-C(33)-H(33) 120.00 
C(25)-O(4)-H(4) 110.00 C(31)-C(35)-H(35A) 109.00 
C(42)-O(5)-C(46) 116.7(2) N(4)-C(35)-H(35A) 109.00 
C(43)-O(6)-C(47) 117.8(3) N(4)-C(35)-H(35B) 109.00 
C(45)-O(7)-C(48) 117.9(2) C(31)-C(35)-H(35B) 109.00 
C(52)-O(8)-H(8) 109.00 H(35A)-C(35)-H(35B) 108.00 
C(55)-O(9)-H(9) 109.00 C(38)-C(39)-H(39A) 109.00 
H(10O)-O(10)-H(10P) 123(3) H(39A)-C(39)-H(39B) 109.00 
C(8)-N(1)-C(9) 123.8(3) H(39A)-C(39)-H(39C) 109.00 
C(9)-N(2)-C(10) 106.7(2) C(38)-C(39)-H(39C) 109.00 
C(11)-N(3)-C(22) 124.2(2) C(38)-C(39)-H(39B) 109.00 
C(10)-N(3)-C(11) 110.5(2) H(39B)-C(39)-H(39C) 110.00 
C(10)-N(3)-C(22) 124.9(2) C(40)-C(41)-H(41) 119.00 
C(9)-N(1)-H(1N) 119(3) C(42)-C(41)-H(41) 119.00 
C(8)-N(1)-H(1N) 117(3) C(45)-C(44)-H(44) 120.00 
C(35)-N(4)-C(36) 124.3(3) C(43)-C(44)-H(44) 120.00 
C(36)-N(5)-C(37) 106.7(2) O(5)-C(46)-H(46C) 109.00 
C(38)-N(6)-C(49) 125.0(2) H(46A)-C(46)-H(46B) 109.00 
C(37)-N(6)-C(49) 124.2(2) O(5)-C(46)-H(46B) 110.00 
C(37)-N(6)-C(38) 110.8(2) H(46B)-C(46)-H(46C) 109.00 
C(36)-N(4)-H(4N) 119(3) H(46A)-C(46)-H(46C) 110.00 
C(35)-N(4)-H(4N) 117(3) O(5)-C(46)-H(46A) 109.00 
C(6)-C(1)-C(7) 120.0(3) O(6)-C(47)-H(47A) 110.00 
C(2)-C(1)-C(7) 120.5(3) H(47A)-C(47)-H(47B) 109.00 
C(2)-C(1)-C(6) 119.5(3) H(47A)-C(47)-H(47C) 109.00 
C(1)-C(2)-C(3) 120.5(3) O(6)-C(47)-H(47C) 109.00 
C(2)-C(3)-C(4) 120.1(3) O(6)-C(47)-H(47B) 109.00 
C(5)-C(4)-C(8) 120.9(3) H(47B)-C(47)-H(47C) 109.00 
C(3)-C(4)-C(8) 119.9(3) O(7)-C(48)-H(48B) 109.00 
C(3)-C(4)-C(5) 119.1(3) O(7)-C(48)-H(48A) 109.00 
C(4)-C(5)-C(6) 120.6(3) H(48A)-C(48)-H(48C) 109.00 
C(1)-C(6)-C(5) 120.2(3) H(48B)-C(48)-H(48C) 109.00 
F(3)-C(7)-C(1) 113.6(3) H(48A)-C(48)-H(48B) 110.00 
F(1)-C(7)-C(1) 112.8(3) O(7)-C(48)-H(48C) 109.00 
F(1)-C(7)-F(3) 106.4(3) C(49)-C(50)-H(50) 121.00 
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F(2)-C(7)-C(1) 112.7(3) C(51)-C(50)-H(50) 121.00 
F(1)-C(7)-F(2) 105.2(3) C(53)-C(54)-H(54) 120.00 
F(2)-C(7)-F(3) 105.6(3) C(49)-C(54)-H(54) 120.00 
N(1)-C(8)-C(4) 113.8(2) O(9)-C(55)-H(55B) 110.00 
N(2)-C(9)-C(11) 113.4(2) O(9)-C(55)-H(55C) 109.00 
N(1)-C(9)-C(11) 121.7(2) O(9)-C(55)-H(55A) 109.00 
N(1)-C(9)-N(2) 124.8(2) H(55A)-C(55)-H(55C) 109.00 
S(1)-C(10)-N(3) 124.8(2) H(55B)-C(55)-H(55C) 109.00 
N(2)-C(10)-N(3) 111.4(2) H(55A)-C(55)-H(55B) 110.00 
           Symmetry transformations used to generate equivalent atoms 
 
Table 4. Anisotropic displacement parameters (Å2 x 103) for 5.45. The anisotropic 
displacement factor exponent takes the form:-2 pi2 [ h2 a*2 U11 +...+ 2 h k a* b* U12 ]. 
 U11 U22 U33 U23 U13 U12 
       
Cl(1) 52(1) 24(1) 42(1) -10(1) -14(1) -10(1) 
Cl(2) 27(1) 35(1) 45(1) -8(1) -9(1) -1(1) 
S(1) 38(1) 35(1) 34(1) -19(1) 3(1) -11(1) 
F(1) 29(1) 47(1) 64(1) -30(1) -11(1) 0(1) 
F(2) 61(1) 66(1) 40(1) -23(1) -14(1) 13(1) 
F(3) 44(1) 33(1) 66(1) -20(1) -15(1) -3(1) 
O(1) 27(1) 22(1) 33(1) -11(1) 0(1) -1(1) 
O(2) 45(1) 26(1) 27(1) -9(1) -1(1) -9(1) 
O(3) 46(1) 30(1) 35(1) -14(1) 8(1) -3(1) 
O(4) 31(1) 34(1) 44(1) -14(1) -5(1) -11(1) 
N(1) 26(1) 28(1) 34(1) -15(1) -2(1) -5(1) 
N(2) 25(1) 26(1) 33(1) -12(1) 0(1) -5(1) 
N(3) 26(1) 24(1) 28(1) -11(1) -3(1) -5(1) 
C(1) 29(1) 35(1) 34(1) -18(1) -4(1) -2(1) 
C(2) 29(1) 40(2) 47(2) -22(1) -8(1) -7(1) 
C(3) 32(1) 33(1) 44(2) -19(1) -4(1) -10(1) 
C(4) 27(1) 31(1) 32(1) -17(1) 1(1) -7(1) 
C(5) 33(2) 32(2) 58(2) -18(1) -13(1) -7(1) 
C(6) 39(2) 31(1) 56(2) -18(1) -12(1) -5(1) 
C(7) 34(2) 42(2) 40(2) -21(1) -7(1) -2(1) 
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C(8) 27(1) 29(1) 37(1) -13(1) -2(1) -11(1) 
C(9) 26(1) 21(1) 27(1) -7(1) -3(1) -5(1) 
C(10) 28(1) 22(1) 30(1) -8(1) -3(1) -6(1) 
C(11) 22(1) 23(1) 30(1) -12(1) -2(1) -4(1) 
C(12) 27(1) 21(1) 31(1) -10(1) -2(1) -2(1) 
C(13) 22(1) 22(1) 29(1) -10(1) -4(1) -4(1) 
C(14) 23(1) 23(1) 32(1) -12(1) -3(1) -4(1) 
C(15) 31(1) 21(1) 30(1) -10(1) -6(1) -5(1) 
C(16) 33(1) 26(1) 27(1) -11(1) -3(1) -10(1) 
C(17) 31(1) 26(1) 29(1) -14(1) 0(1) -5(1) 
C(18) 28(1) 22(1) 31(1) -13(1) -3(1) -4(1) 
C(19) 34(1) 23(1) 48(2) -16(1) -1(1) 0(1) 
C(20) 52(2) 26(1) 31(1) -7(1) -3(1) -7(1) 
C(21) 54(2) 34(2) 43(2) -17(1) 13(1) 2(1) 
C(22) 27(1) 25(1) 25(1) -12(1) -1(1) -4(1) 
C(23) 29(1) 23(1) 28(1) -9(1) -5(1) -2(1) 
C(24) 34(1) 23(1) 27(1) -9(1) -3(1) -6(1) 
C(25) 26(1) 34(1) 27(1) -14(1) 0(1) -9(1) 
C(26) 25(1) 29(1) 27(1) -9(1) -1(1) -5(1) 
C(27) 29(1) 23(1) 27(1) -9(1) -1(1) -4(1) 
Cl(3) 42(1) 41(1) 34(1) -18(1) 10(1) -8(1) 
Cl(4) 27(1) 41(1) 48(1) -26(1) 0(1) -10(1) 
S(2) 32(1) 24(1) 35(1) -10(1) -2(1) -6(1) 
F(4) 112(3) 73(2) 215(5) -98(3) -81(3) 20(2) 
F(5) 38(1) 120(2) 162(3) -111(2) 0(2) -19(1) 
F(6) 165(4) 227(5) 92(2) -103(3) 43(2) -150(4) 
O(5) 40(1) 24(1) 38(1) -16(1) -11(1) 2(1) 
O(6) 48(1) 27(1) 34(1) -13(1) -14(1) 0(1) 
O(7) 34(1) 23(1) 29(1) -12(1) -3(1) 0(1) 
O(8) 27(1) 39(1) 47(1) -21(1) 9(1) -13(1) 
N(4) 25(1) 27(1) 38(1) -9(1) -3(1) -8(1) 
N(5) 24(1) 27(1) 34(1) -13(1) -3(1) -6(1) 
N(6) 25(1) 24(1) 27(1) -11(1) -1(1) -5(1) 
C(28) 29(1) 41(2) 59(2) -28(2) -1(1) -8(1) 
C(29) 39(2) 58(2) 72(2) -38(2) 16(2) -30(2) 
C(30) 39(2) 54(2) 52(2) -29(2) 12(1) -23(2) 
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C(31) 25(1) 26(1) 41(1) -13(1) -3(1) -6(1) 
C(32) 31(1) 37(2) 39(2) -13(1) 0(1) -13(1) 
C(33) 34(2) 42(2) 45(2) -21(1) -1(1) -8(1) 
C(34) 39(2) 53(2) 72(2) -41(2) 2(2) -13(2) 
C(35) 26(1) 35(1) 39(1) -16(1) -1(1) -9(1) 
C(36) 24(1) 27(1) 30(1) -14(1) -4(1) -7(1) 
C(37) 25(1) 28(1) 27(1) -13(1) -4(1) -4(1) 
C(38) 24(1) 26(1) 32(1) -14(1) 0(1) -7(1) 
C(39) 36(1) 31(1) 34(1) -18(1) -4(1) -7(1) 
C(40) 23(1) 24(1) 29(1) -11(1) 2(1) -8(1) 
C(41) 26(1) 24(1) 32(1) -15(1) 2(1) -8(1) 
C(42) 26(1) 22(1) 36(1) -13(1) -3(1) -5(1) 
C(43) 30(1) 24(1) 29(1) -9(1) -4(1) -6(1) 
C(44) 33(1) 23(1) 30(1) -12(1) -2(1) -5(1) 
C(45) 26(1) 21(1) 30(1) -11(1) -1(1) -6(1) 
C(46) 44(2) 25(1) 42(2) -17(1) -5(1) -4(1) 
C(47) 61(2) 34(2) 42(2) -20(1) -20(2) 2(1) 
C(48) 34(1) 25(1) 34(1) -15(1) 3(1) -5(1) 
C(49) 23(1) 23(1) 29(1) -11(1) -1(1) -3(1) 
C(50) 33(1) 27(1) 29(1) -12(1) -1(1) -7(1) 
C(51) 31(1) 25(1) 31(1) -10(1) 4(1) -3(1) 
C(52) 27(1) 21(1) 40(1) -11(1) 4(1) -4(1) 
C(53) 25(1) 22(1) 37(1) -14(1) -1(1) -5(1) 
C(54) 24(1) 21(1) 29(1) -11(1) 0(1) -3(1) 
 
Table 5. Hydrogen coordinates (x 104) and isotropic displacement parameters 
(Å2 x 103) for 5.45. 
 x y z U(eq) 
     
H(1N) 2080(30) 4390(30) 2810(30) 35 
H(2) 7168 2892 3610 45 
H(3) 5765 4200 2802 42 
H(4) -4001 2849 1193 44 
H(5) 3643 2604 2940 49 
H(6) 5046 1299 3751 50 
H(8A) 3751 4901 2317 37 
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H(8B) 3891 4537 1604 37 
H(12A) -49 5362 1314 34 
H(12B) 28 5243 2274 34 
H(12C) -1049 4963 2071 34 
H(15) 951 1154 4550 33 
H(18) -1072 4219 3452 32 
H(19A) 1898 857 3436 44 
H(19B) 2827 1109 3814 44 
H(19C) 3050 1208 2839 44 
H(20A) 571 481 6044 47 
H(20B) -294 289 5563 47 
H(20C) -663 189 6533 47 
H(21A) -2921 4291 4189 58 
H(21B) -1988 4485 4618 58 
H(21C) -3172 4155 5176 58 
H(23) 158 2040 2202 33 
H(27) -1617 4671 870 33 
H(4N) 2050(30) -1390(30) 1450(30) 39 
H(8) -4817 -3998 3657 45 
H(29) 6325 -722 1719 62 
H(30) 5430 -1328 1092 54 
H(32) 3164 -2171 3246 44 
H(33) 4032 -1538 3860 48 
H(35A) 3962 -2018 1079 40 
H(35B) 3897 -2893 2013 40 
H(39A) 474 -1075 2498 38 
H(39B) 365 -1976 3400 38 
H(39C) -805 -1339 2871 38 
H(41) -1233 -490 1555 32 
H(44) -494 -1856 -315 35 
H(46A) -1759 1126 606 43 
H(46B) -2842 653 1184 43 
H(46C) -3104 1601 310 43 
H(47A) -2387 -1150 -1120 54 
H(47B) -1158 -868 -1633 54 
H(47C) -2415 -195 -1988 54 
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H(48A) 1733 -2760 111 37 
H(48B) 619 -3186 192 37 
H(48C) 1713 -3798 813 37 
H(50) -1477 -3013 4243 35 
H(54) -1415 -3349 2077 31 
H(9) -5460 2703 1057 64 
H(55A) -5891 3742 -537 390 
H(55B) -5499 2648 -59 390 
H(55C) -4502 3253 -413 390 
H(10O) -6510(20) -4240(20) 3180(20) 45 
H(10P) -5900(30) -4920(20) 3996(13) 45 
 
Table 6. Torsion angles [deg.] for 5.45. 
C(19)-O(1)-C(14)-C(13) 178.0(3) C(11)-C(13)-C(18)-C(17) 174.9(2) 
C(19)-O(1)-C(14)-C(15) -3.0(4) O(1)-C(14)-C(15)-C(16) -178.3(2) 
C(20)-O(2)-C(16)-C(15) 3.2(4) C(13)-C(14)-C(15)-C(16) 0.7(4) 
C(20)-O(2)-C(16)-C(17) -177.8(3) C(14)-C(15)-C(16)-C(17) -3.1(4) 
C(21)-O(3)-C(17)-C(16) -178.7(3) C(14)-C(15)-C(16)-O(2) 175.8(3) 
C(21)-O(3)-C(17)-C(18) -0.3(4) C(15)-C(16)-C(17)-C(18) 3.1(4) 
C(46)-O(5)-C(42)-C(43) -173.1(2) O(2)-C(16)-C(17)-O(3) 2.5(4) 
C(46)-O(5)-C(42)-C(41) 8.3(4) C(15)-C(16)-C(17)-O(3) -178.4(2) 
C(47)-O(6)-C(43)-C(42) -167.5(3) O(2)-C(16)-C(17)-C(18) -176.0(2) 
C(47)-O(6)-C(43)-C(44) 13.4(4) O(3)-C(17)-C(18)-C(13) -178.9(3) 
C(48)-O(7)-C(45)-C(40) -157.9(3) C(16)-C(17)-C(18)-C(13) -0.6(4) 
C(48)-O(7)-C(45)-C(44) 23.9(4) N(3)-C(22)-C(27)-C(26) 178.6(2) 
C(9)-N(1)-C(8)-C(4) -94.8(3) N(3)-C(22)-C(23)-C(24) -177.8(2) 
C(8)-N(1)-C(9)-C(11) -176.6(3) C(23)-C(22)-C(27)-C(26) -0.4(4) 
C(8)-N(1)-C(9)-N(2) 0.0(5) C(27)-C(22)-C(23)-C(24) 1.2(4) 
C(9)-N(2)-C(10)-S(1) -178.2(2) C(22)-C(23)-C(24)-Cl(1) 177.8(2) 
C(10)-N(2)-C(9)-N(1) 179.0(3) C(22)-C(23)-C(24)-C(25) -1.1(4) 
C(10)-N(2)-C(9)-C(11) -4.2(3) C(23)-C(24)-C(25)-O(4) 178.0(3) 
C(9)-N(2)-C(10)-N(3) 2.5(3) Cl(1)-C(24)-C(25)-C(26) -178.7(2) 
C(10)-N(3)-C(11)-C(9) -2.3(3) C(23)-C(24)-C(25)-C(26) 0.2(4) 
C(11)-N(3)-C(10)-N(2) 0.1(3) Cl(1)-C(24)-C(25)-O(4) -0.8(3) 
C(11)-N(3)-C(10)-S(1) -179.1(2) C(24)-C(25)-C(26)-C(27) 0.6(4) 
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C(11)-N(3)-C(22)-C(23) -99.7(3) C(24)-C(25)-C(26)-Cl(2) 179.5(2) 
C(22)-N(3)-C(11)-C(9) 170.4(2) O(4)-C(25)-C(26)-C(27) -177.0(3) 
C(22)-N(3)-C(11)-C(13) 50.3(3) O(4)-C(25)-C(26)-Cl(2) 2.0(4) 
C(11)-N(3)-C(22)-C(27) 81.3(3) Cl(2)-C(26)-C(27)-C(22) -179.5(2) 
C(10)-N(3)-C(11)-C(13) -122.4(2) C(25)-C(26)-C(27)-C(22) -0.5(4) 
C(22)-N(3)-C(10)-N(2) -172.5(2) C(34)-C(28)-C(33)-C(32) 177.5(4) 
C(10)-N(3)-C(22)-C(27) -107.1(3) C(29)-C(28)-C(33)-C(32) -0.5(6) 
C(10)-N(3)-C(22)-C(23) 71.9(3) C(33)-C(28)-C(34)-F(6) 17.4(6) 
C(22)-N(3)-C(10)-S(1) 8.3(4) C(33)-C(28)-C(34)-F(4) -102.8(4) 
C(10)-N(3)-C(11)-C(12) 111.0(2) C(34)-C(28)-C(29)-C(30) -176.8(4) 
C(22)-N(3)-C(11)-C(12) -76.3(3) C(33)-C(28)-C(34)-F(5) 141.5(4) 
C(35)-N(4)-C(36)-N(5) -1.6(5) C(29)-C(28)-C(34)-F(6) -164.6(5) 
C(36)-N(4)-C(35)-C(31) -110.6(3) C(29)-C(28)-C(34)-F(5) -40.6(6) 
C(35)-N(4)-C(36)-C(38) 173.8(3) C(33)-C(28)-C(29)-C(30) 1.2(6) 
C(36)-N(5)-C(37)-S(2) 177.4(2) C(29)-C(28)-C(34)-F(4) 75.1(5) 
C(37)-N(5)-C(36)-C(38) 6.4(3) C(28)-C(29)-C(30)-C(31) -0.8(6) 
C(36)-N(5)-C(37)-N(6) -3.3(3) C(29)-C(30)-C(31)-C(32) -0.3(5) 
C(37)-N(5)-C(36)-N(4) -177.9(3) C(29)-C(30)-C(31)-C(35) -178.7(4) 
C(37)-N(6)-C(49)-C(54) -86.6(3) C(30)-C(31)-C(35)-N(4) -131.7(3) 
C(49)-N(6)-C(37)-S(2) -4.3(4) C(30)-C(31)-C(32)-C(33) 1.0(5) 
C(49)-N(6)-C(37)-N(5) 176.4(2) C(35)-C(31)-C(32)-C(33) 179.4(3) 
C(49)-N(6)-C(38)-C(40) -52.6(3) C(32)-C(31)-C(35)-N(4) 49.9(4) 
C(38)-N(6)-C(49)-C(54) 90.5(3) C(31)-C(32)-C(33)-C(28) -0.6(5) 
C(37)-N(6)-C(49)-C(50) 89.7(4) N(5)-C(36)-C(38)-C(40) -126.7(3) 
C(38)-N(6)-C(37)-S(2) 178.3(2) N(4)-C(36)-C(38)-C(40) 57.4(4) 
C(49)-N(6)-C(38)-C(39) 75.6(3) N(4)-C(36)-C(38)-N(6) 177.5(3) 
C(38)-N(6)-C(37)-N(5) -1.1(3) N(5)-C(36)-C(38)-N(6) -6.6(3) 
C(37)-N(6)-C(38)-C(40) 124.9(2) N(4)-C(36)-C(38)-C(39) -69.7(3) 
C(37)-N(6)-C(38)-C(39) -107.0(3) N(5)-C(36)-C(38)-C(39) 106.2(3) 
C(49)-N(6)-C(38)-C(36) -173.2(2) C(36)-C(38)-C(40)-C(45) 50.6(3) 
C(38)-N(6)-C(49)-C(50) -93.2(3) C(39)-C(38)-C(40)-C(41) -6.3(4) 
C(37)-N(6)-C(38)-C(36) 4.3(3) C(36)-C(38)-C(40)-C(41) -130.0(3) 
C(6)-C(1)-C(7)-F(3) 23.1(4) N(6)-C(38)-C(40)-C(41) 119.4(3) 
C(2)-C(1)-C(7)-F(3) -157.3(3) C(39)-C(38)-C(40)-C(45) 174.3(2) 
C(6)-C(1)-C(7)-F(1) 144.2(3) N(6)-C(38)-C(40)-C(45) -60.1(3) 
C(6)-C(1)-C(2)-C(3) 1.2(5) C(41)-C(40)-C(45)-O(7) -178.6(2) 
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C(6)-C(1)-C(7)-F(2) -96.9(4) C(45)-C(40)-C(41)-C(42) -0.1(4) 
C(2)-C(1)-C(7)-F(2) 82.7(4) C(38)-C(40)-C(41)-C(42) -179.6(2) 
C(7)-C(1)-C(6)-C(5) 178.6(3) C(41)-C(40)-C(45)-C(44) -0.3(4) 
C(2)-C(1)-C(7)-F(1) -36.2(4) C(38)-C(40)-C(45)-C(44) 179.2(2) 
C(7)-C(1)-C(2)-C(3) -178.4(3) C(38)-C(40)-C(45)-O(7) 1.0(4) 
C(2)-C(1)-C(6)-C(5) -1.1(5) C(40)-C(41)-C(42)-O(5) 178.8(2) 
C(1)-C(2)-C(3)-C(4) -0.8(5) C(40)-C(41)-C(42)-C(43) 0.3(4) 
C(2)-C(3)-C(4)-C(8) -177.9(3) O(5)-C(42)-C(43)-C(44) -178.8(2) 
C(2)-C(3)-C(4)-C(5) 0.3(5) C(41)-C(42)-C(43)-O(6) -179.2(2) 
C(3)-C(4)-C(5)-C(6) -0.2(5) C(41)-C(42)-C(43)-C(44) -0.1(4) 
C(8)-C(4)-C(5)-C(6) 178.0(3) O(5)-C(42)-C(43)-O(6) 2.1(3) 
C(5)-C(4)-C(8)-N(1) 32.6(4) O(6)-C(43)-C(44)-C(45) 178.8(3) 
C(3)-C(4)-C(8)-N(1) -149.3(3) C(42)-C(43)-C(44)-C(45) -0.3(4) 
C(4)-C(5)-C(6)-C(1) 0.6(5) C(43)-C(44)-C(45)-C(40) 0.5(4) 
N(1)-C(9)-C(11)-C(13) -60.9(4) C(43)-C(44)-C(45)-O(7) 178.6(2) 
N(2)-C(9)-C(11)-C(12) -109.8(3) N(6)-C(49)-C(50)-C(51) -175.3(3) 
N(1)-C(9)-C(11)-C(12) 67.2(3) C(54)-C(49)-C(50)-C(51) 1.0(4) 
N(2)-C(9)-C(11)-C(13) 122.1(3) N(6)-C(49)-C(54)-C(53) 173.4(3) 
N(1)-C(9)-C(11)-N(3) -179.0(3) C(50)-C(49)-C(54)-C(53) -2.9(4) 
N(2)-C(9)-C(11)-N(3) 4.0(3) C(49)-C(50)-C(51)-Cl(3) -178.3(2) 
N(3)-C(11)-C(13)-C(18) -121.4(3) C(49)-C(50)-C(51)-C(52) 3.0(5) 
C(9)-C(11)-C(13)-C(18) 128.8(3) Cl(3)-C(51)-C(52)-O(8) -4.3(4) 
C(12)-C(11)-C(13)-C(18) 3.1(4) Cl(3)-C(51)-C(52)-C(53) 176.5(2) 
N(3)-C(11)-C(13)-C(14) 55.3(3) C(50)-C(51)-C(52)-O(8) 174.4(3) 
C(12)-C(11)-C(13)-C(14) 179.7(2) C(50)-C(51)-C(52)-C(53) -4.8(5) 
C(9)-C(11)-C(13)-C(14) -54.6(4) O(8)-C(52)-C(53)-Cl(4) 1.8(4) 
C(14)-C(13)-C(18)-C(17) -1.8(4) O(8)-C(52)-C(53)-C(54) -176.4(3) 
C(18)-C(13)-C(14)-C(15) 1.8(4) C(51)-C(52)-C(53)-Cl(4) -179.0(2) 
C(18)-C(13)-C(14)-O(1) -179.2(2) C(51)-C(52)-C(53)-C(54) 2.7(4) 
C(11)-C(13)-C(14)-C(15) -175.0(2) Cl(4)-C(53)-C(54)-C(49) -177.3(2) 
C(11)-C(13)-C(14)-O(1) 4.1(4) C(52)-C(53)-C(54)-C(49) 1.0(4) 
           Symmetry transformations used to generate equivalent atoms 
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Table 7. Hydrogen-bonds for 5.45 [Å and deg.]. 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
     
N(1)-H(1N)...S(2)#1 0.78(5) 2.65(5) 3.406(3) 165(5) 
O(4)-H(4)...Cl(2) 0.8400 2.5700 3.059(3) 118.00 
O(4)-H(4)...O(9) 0.8400 1.8400 2.588(3) 148.00 
N(4)-H(4N)...O(5)#2 0.83(5) 2.37(5) 2.925(3) 124(4) 
N(4)-H(4N)...O(6)#2 0.83(5) 2.40(5) 3.160(4) 153(4) 
O(8)-H(8)...Cl(4) 0.8400 2.5500 3.055(3) 119.00 
O(8)-H(8)...O(10) 0.8400 1.9200 2.670(4) 149.00 
O(10)-H(10O)...N(5)#3 0.87(3) 1.95(3) 2.801(4) 166(3) 
O(10)-H(10P)...Cl(3)#4 0.83(2) 2.77(3) 3.371(3) 132(3) 
C(5)-H(5)...O(1) 0.9500 2.4600 3.385(4) 166.00 
C(8)-H(8B)...N(2) 0.9900 2.5500 2.884(4) 100.00 
C(33)-H(33)...F(2)#5 0.9500 2.3700 3.251(4) 154.00 
C(35)-H(35B)...N(5) 0.9900 2.5100 2.906(4) 104.00 
C(39)-H(39B)...O(2)#6 0.9800 2.4800 3.161(4) 127.00 
C(39)-H(39C)...F(5)#3 0.9800 2.5400 3.516(5) 178.00 
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A.3.2 4-Chloro-3-ethyl-2-(4-hydroxyphenyl)benzo[b]thiophen-5-ol 
(10) 
 
 
 
 
 
 
 
 
Table 1. Crystal data and structure refinement for 10. 
Crystal Data    
Empirical formula  C16H13ClO2S 
Formula weight  304.78  
Crystal size  0.2548 x 0.1468 x 0.0543 mm  
Crystal description  plate  
Crystal colour  colourless  
Crystal system Triclinic  
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Space group  P -1  
Unit cell dimensions               a = 9.2721(4) Å alpha = 84.939(4) deg.  
                                         b = 9.4576(4) Å beta = 86.032(3) deg.  
                                         c = 16.7403(7) Å gamma = 69.579(4) deg.  
Volume  1369.21(11) Å
3
  
Z, Calculated density  4,  1.479 Mg/m
3
  
Absorption coefficient  3.875 mm
-1
  
F(000)  632  
    
Data Collection    
Measurement device type  SuperNova, Single source at offset), Atlas  
Measuremnet method  \w scans  
Temperature  123 K  
Wavelength  1.54184 Å  
Monochromator  graphite  
Theta range for data collection  5.00 to 76.76 deg.  
Index ranges  -11<=h<=11, -11<=k<=11, -20<=l<=21  
Reflections collected / unique  24243 / 5651 [R(int) = 0.0251]  
Reflections greater I>2\s(I) 5474  
Absorption correction  Analytical  
Max. and min. transmission  0.900 and 0.721  
    
Refinement   
Refinement method  Full-matrix least-squares on F
2
  
Hydrogen treatment  --- 
Data / restraints / parameters  5651 / 0 / 373  
Goodness-of-fit on F
2
  1.059  
Final R indices [I>2sigma(I)]      R1 = 0.0364, wR2 = 0.0979  
R indices (all data)               R1 = 0.0372, wR2 = 0.0986  
Absolute structure parameter  --- 
Largest diff. peak and hole  0.670 and -0.496 e. Å
-3
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Table 2. Atomic coordinates (x 104) and equivalent isotropic displacement 
parameters (Å2 x 103) for 10. U(eq) is defined as one third of the trace of the 
orthogonalized Uij tensor. 
 x y z U(eq) 
     
Cl(1) 4280(1) 1407(1) -2351(1) 28(1) 
S(1) 3528(1) 3044(1) 682(1) 22(1) 
O(1) 10472(2) 2045(2) 1927(1) 25(1) 
O(2) 886(2) 2499(1) -2295(1) 22(1) 
C(1) 9192(2) 2197(2) 1520(1) 20(1) 
C(2) 9126(2) 904(2) 1213(1) 22(1) 
C(3) 7879(2) 988(2) 774(1) 21(1) 
C(4) 6674(2) 2356(2) 641(1) 19(1) 
C(5) 6743(2) 3639(2) 964(1) 21(1) 
C(6) 7997(2) 3568(2) 1399(1) 21(1) 
C(7) 5325(2) 2427(2) 190(1) 19(1) 
C(8) 5288(2) 2068(2) -581(1) 18(1) 
C(9) 3726(2) 2321(2) -798(1) 17(1) 
C(10) 2644(2) 2862(2) -160(1) 19(1) 
C(11) 1064(2) 3215(2) -221(1) 21(1) 
C(12) 516(2) 3085(2) -943(1) 21(1) 
C(13) 1537(2) 2572(2) -1597(1) 19(1) 
C(14) 3118(2) 2161(2) -1521(1) 18(1) 
C(15) 6704(2) 1610(2) -1130(1) 23(1) 
C(16) 6796(2) 2900(2) -1727(1) 29(1) 
Cl(2) -10996(1) 7199(1) -4670(1) 29(1) 
S(2) -5897(1) 8584(1) -5387(1) 24(1) 
O(3) -1155(2) 5517(2) -2435(1) 24(1) 
O(4) -11994(2) 8800(2) -6224(1) 27(1) 
C(17) -2378(2) 5957(2) -2929(1) 19(1) 
C(18) -3448(2) 7404(2) -2870(1) 22(1) 
C(19) -4668(2) 7921(2) -3379(1) 23(1) 
C(20) -4840(2) 6999(2) -3945(1) 21(1) 
C(21) -3774(2) 5536(2) -3980(1) 24(1) 
C(22) -2544(2) 5013(2) -3478(1) 22(1) 
C(23) -6130(2) 7562(2) -4504(1) 21(1) 
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C(24) -7519(2) 7366(2) -4416(1) 20(1) 
C(25) -8456(2) 8028(2) -5107(1) 18(1) 
C(26) -7703(2) 8739(2) -5686(1) 21(1) 
C(27) -8393(2) 9510(2) -6404(1) 24(1) 
C(28) -9811(2) 9502(2) -6555(1) 24(1) 
C(29) -10585(2) 8783(2) -6007(1) 21(1) 
C(30) -9927(2) 8066(2) -5296(1) 21(1) 
C(31) -7973(2) 6545(2) -3679(1) 26(1) 
C(32) -7653(3) 4891(2) -3755(1) 38(1) 
 
Table 3. Bond lengths [Å] and angles [deg] for 10. 
Cl(1)-C(14) 1.7414(18) C(8)-C(9)-C(10) 111.95(15) 
Cl(2)-C(30) 1.7391(19) C(10)-C(9)-C(14) 116.16(17) 
S(1)-C(10) 1.7281(18) C(8)-C(9)-C(14) 131.87(16) 
S(1)-C(7) 1.7349(18) C(9)-C(10)-C(11) 123.18(16) 
S(2)-C(26) 1.735(2) S(1)-C(10)-C(9) 111.62(14) 
S(2)-C(23) 1.7371(18) S(1)-C(10)-C(11) 125.20(14) 
O(1)-C(1) 1.367(2) C(10)-C(11)-C(12) 118.75(17) 
O(2)-C(13) 1.371(2) C(11)-C(12)-C(13) 120.27(18) 
O(1)-H(1O) 0.73(3) O(2)-C(13)-C(14) 123.17(16) 
O(2)-H(2O) 0.73(3) O(2)-C(13)-C(12) 116.20(17) 
O(3)-C(17) 1.372(2) C(12)-C(13)-C(14) 120.63(16) 
O(4)-C(29) 1.374(2) Cl(1)-C(14)-C(9) 122.59(14) 
O(3)-H(3O) 0.71(3) C(9)-C(14)-C(13) 120.92(16) 
O(4)-H(4O) 0.91(3) Cl(1)-C(14)-C(13) 116.48(13) 
C(1)-C(6) 1.390(3) C(8)-C(15)-C(16) 112.80(15) 
C(1)-C(2) 1.390(3) C(1)-C(2)-H(2) 120.00 
C(2)-C(3) 1.387(3) C(3)-C(2)-H(2) 120.00 
C(3)-C(4) 1.396(2) C(4)-C(3)-H(3) 120.00 
C(4)-C(5) 1.394(2) C(2)-C(3)-H(3) 120.00 
C(4)-C(7) 1.484(3) C(4)-C(5)-H(5) 120.00 
C(5)-C(6) 1.393(3) C(6)-C(5)-H(5) 120.00 
C(7)-C(8) 1.368(2) C(1)-C(6)-H(6) 120.00 
C(8)-C(15) 1.505(3) C(5)-C(6)-H(6) 120.00 
C(8)-C(9) 1.450(3) C(12)-C(11)-H(11) 121.00 
C(9)-C(10) 1.414(2) C(10)-C(11)-H(11) 121.00 
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C(9)-C(14) 1.411(2) C(11)-C(12)-H(12) 120.00 
C(10)-C(11) 1.393(3) C(13)-C(12)-H(12) 120.00 
C(11)-C(12) 1.376(3) C(8)-C(15)-H(15A) 109.00 
C(12)-C(13) 1.399(3) C(8)-C(15)-H(15B) 109.00 
C(13)-C(14) 1.391(3) C(16)-C(15)-H(15A) 109.00 
C(15)-C(16) 1.529(3) C(16)-C(15)-H(15B) 109.00 
C(2)-H(2) 0.9500 H(15A)-C(15)-H(15B) 108.00 
C(3)-H(3) 0.9500 C(15)-C(16)-H(16C) 109.00 
C(5)-H(5) 0.9500 H(16A)-C(16)-H(16C) 109.00 
C(6)-H(6) 0.9500 H(16B)-C(16)-H(16C) 110.00 
C(11)-H(11) 0.9500 H(16A)-C(16)-H(16B) 109.00 
C(12)-H(12) 0.9500 C(15)-C(16)-H(16A) 109.00 
C(15)-H(15A) 0.9900 C(15)-C(16)-H(16B) 109.00 
C(15)-H(15B) 0.9900 C(18)-C(17)-C(22) 120.61(17) 
C(16)-H(16B) 0.9800 O(3)-C(17)-C(22) 121.88(16) 
C(16)-H(16C) 0.9800 O(3)-C(17)-C(18) 117.51(15) 
C(16)-H(16A) 0.9800 C(17)-C(18)-C(19) 119.58(16) 
C(17)-C(22) 1.388(2) C(18)-C(19)-C(20) 120.70(17) 
C(17)-C(18) 1.389(2) C(19)-C(20)-C(21) 118.71(17) 
C(18)-C(19) 1.385(3) C(19)-C(20)-C(23) 120.83(16) 
C(19)-C(20) 1.396(3) C(21)-C(20)-C(23) 120.46(16) 
C(20)-C(23) 1.487(3) C(20)-C(21)-C(22) 121.01(17) 
C(20)-C(21) 1.395(3) C(17)-C(22)-C(21) 119.36(16) 
C(21)-C(22) 1.384(3) S(2)-C(23)-C(24) 113.78(13) 
C(23)-C(24) 1.360(3) C(20)-C(23)-C(24) 127.69(16) 
C(24)-C(31) 1.513(3) S(2)-C(23)-C(20) 118.53(14) 
C(24)-C(25) 1.455(2) C(25)-C(24)-C(31) 126.12(17) 
C(25)-C(30) 1.410(3) C(23)-C(24)-C(25) 111.61(15) 
C(25)-C(26) 1.413(2) C(23)-C(24)-C(31) 122.27(16) 
C(26)-C(27) 1.419(2) C(26)-C(25)-C(30) 116.13(15) 
C(27)-C(28) 1.359(3) C(24)-C(25)-C(30) 132.03(16) 
C(28)-C(29) 1.399(3) C(24)-C(25)-C(26) 111.84(16) 
C(29)-C(30) 1.385(2) S(2)-C(26)-C(27) 125.64(14) 
C(31)-C(32) 1.502(3) S(2)-C(26)-C(25) 111.47(13) 
C(18)-H(18) 0.9500 C(25)-C(26)-C(27) 122.86(18) 
C(19)-H(19) 0.9500 C(26)-C(27)-C(28) 118.24(17) 
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C(21)-H(21) 0.9500 C(27)-C(28)-C(29) 120.81(17) 
C(22)-H(22) 0.9500 C(28)-C(29)-C(30) 120.82(18) 
C(27)-H(27) 0.9500 O(4)-C(29)-C(28) 116.48(16) 
C(28)-H(28) 0.9500 O(4)-C(29)-C(30) 122.67(17) 
C(31)-H(31A) 0.9900 Cl(2)-C(30)-C(25) 122.49(13) 
C(31)-H(31B) 0.9900 Cl(2)-C(30)-C(29) 116.43(15) 
C(32)-H(32A) 0.9800 C(25)-C(30)-C(29) 121.07(17) 
C(32)-H(32B) 0.9800 C(24)-C(31)-C(32) 114.69(16) 
C(32)-H(32C) 0.9800 C(17)-C(18)-H(18) 120.00 
  C(19)-C(18)-H(18) 120.00 
C(7)-S(1)-C(10) 91.34(9) C(18)-C(19)-H(19) 120.00 
C(23)-S(2)-C(26) 91.27(9) C(20)-C(19)-H(19) 120.00 
C(1)-O(1)-H(1O) 110(2) C(20)-C(21)-H(21) 119.00 
C(13)-O(2)-H(2O) 110(2) C(22)-C(21)-H(21) 119.00 
C(17)-O(3)-H(3O) 112(2) C(17)-C(22)-H(22) 120.00 
C(29)-O(4)-H(4O) 104.5(18) C(21)-C(22)-H(22) 120.00 
C(2)-C(1)-C(6) 120.00(17) C(26)-C(27)-H(27) 121.00 
O(1)-C(1)-C(2) 116.99(16) C(28)-C(27)-H(27) 121.00 
O(1)-C(1)-C(6) 123.01(16) C(27)-C(28)-H(28) 120.00 
C(1)-C(2)-C(3) 119.93(16) C(29)-C(28)-H(28) 120.00 
C(2)-C(3)-C(4) 120.89(16) C(24)-C(31)-H(31A) 109.00 
C(3)-C(4)-C(7) 120.51(15) C(24)-C(31)-H(31B) 109.00 
C(5)-C(4)-C(7) 120.90(16) C(32)-C(31)-H(31A) 109.00 
C(3)-C(4)-C(5) 118.56(17) C(32)-C(31)-H(31B) 109.00 
C(4)-C(5)-C(6) 120.93(16) H(31A)-C(31)-H(31B) 108.00 
C(1)-C(6)-C(5) 119.68(16) C(31)-C(32)-H(32A) 109.00 
S(1)-C(7)-C(4) 117.52(12) C(31)-C(32)-H(32B) 109.00 
S(1)-C(7)-C(8) 113.75(14) C(31)-C(32)-H(32C) 109.00 
C(4)-C(7)-C(8) 128.74(17) H(32A)-C(32)-H(32B) 109.00 
C(7)-C(8)-C(15) 122.30(17) H(32A)-C(32)-H(32C) 109.00 
C(9)-C(8)-C(15) 126.15(15) H(32B)-C(32)-H(32C) 110.00 
C(7)-C(8)-C(9) 111.34(16)   
           Symmetry transformations used to generate equivalent atoms:  
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Table 4. Anisotropic displacement parameters (Å2 x 103) for 10. The anisotropic 
displacement factor exponent takes the form:-2 pi2 [ h2 a*2 U11 +...+ 2 h k a* b* U12 ]. 
 U11 U22 U33 U23 U13 U12 
       
Cl(1) 23(1) 36(1) 23(1) -13(1) -3(1) -6(1) 
S(1) 21(1) 29(1) 16(1) -3(1) -2(1) -8(1) 
O(1) 23(1) 25(1) 30(1) -2(1) -11(1) -10(1) 
O(2) 20(1) 24(1) 21(1) -4(1) -7(1) -7(1) 
C(1) 20(1) 23(1) 17(1) 2(1) -4(1) -9(1) 
C(2) 21(1) 18(1) 24(1) 2(1) -6(1) -4(1) 
C(3) 25(1) 16(1) 23(1) 0(1) -7(1) -7(1) 
C(4) 20(1) 20(1) 16(1) 1(1) -5(1) -7(1) 
C(5) 22(1) 17(1) 21(1) -1(1) -6(1) -3(1) 
C(6) 26(1) 19(1) 21(1) -2(1) -5(1) -8(1) 
C(7) 19(1) 17(1) 19(1) 0(1) -5(1) -5(1) 
C(8) 19(1) 15(1) 20(1) 0(1) -5(1) -4(1) 
C(9) 18(1) 14(1) 19(1) 0(1) -4(1) -5(1) 
C(10) 21(1) 19(1) 17(1) 0(1) -3(1) -7(1) 
C(11) 22(1) 21(1) 21(1) 0(1) 0(1) -7(1) 
C(12) 18(1) 19(1) 26(1) 1(1) -4(1) -6(1) 
C(13) 22(1) 15(1) 20(1) 0(1) -8(1) -8(1) 
C(14) 20(1) 16(1) 18(1) -2(1) -3(1) -5(1) 
C(15) 17(1) 28(1) 21(1) -5(1) -4(1) -4(1) 
C(16) 27(1) 37(1) 26(1) -5(1) 2(1) -15(1) 
Cl(2) 27(1) 36(1) 26(1) 4(1) -4(1) -17(1) 
S(2) 25(1) 29(1) 22(1) 4(1) -6(1) -14(1) 
O(3) 22(1) 20(1) 28(1) -1(1) -11(1) -4(1) 
O(4) 22(1) 33(1) 27(1) -2(1) -8(1) -8(1) 
C(17) 19(1) 21(1) 17(1) 2(1) -6(1) -7(1) 
C(18) 27(1) 20(1) 20(1) -3(1) -7(1) -7(1) 
C(19) 25(1) 19(1) 23(1) -3(1) -8(1) -3(1) 
C(20) 22(1) 22(1) 20(1) -1(1) -6(1) -8(1) 
C(21) 27(1) 22(1) 22(1) -6(1) -7(1) -7(1) 
C(22) 23(1) 17(1) 24(1) -3(1) -5(1) -3(1) 
C(23) 24(1) 20(1) 18(1) -3(1) -5(1) -7(1) 
C(24) 24(1) 18(1) 18(1) -3(1) -3(1) -6(1) 
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C(25) 22(1) 15(1) 16(1) -4(1) -4(1) -5(1) 
C(26) 26(1) 19(1) 19(1) -2(1) -5(1) -9(1) 
C(27) 34(1) 29(1) 15(1) -1(1) -4(1) -18(1) 
C(28) 31(1) 21(1) 19(1) 0(1) -8(1) -7(1) 
C(29) 20(1) 19(1) 23(1) -6(1) -7(1) -4(1) 
C(30) 23(1) 20(1) 21(1) -3(1) -2(1) -8(1) 
C(31) 22(1) 34(1) 17(1) 8(1) -2(1) -6(1) 
C(32) 38(1) 29(1) 44(1) 9(1) 0(1) -11(1) 
 
Table 5. Hydrogen coordinates (x 10^4) and isotropic displacement parameters 
(Å2 x 103) for 10. 
 x y z U(eq) 
     
H(1O) 10480(30) 2790(30) 2012(15) 30 
H(2) 9935 -37 1303 26 
H(2O) 1490(30) 2130(30) -2591(15) 26 
H(3) 7844 101 562 25 
H(5) 5924 4575 886 25 
H(6) 8035 4451 1612 26 
H(11) 379 3540 229 26 
H(12) -560 3346 -999 25 
H(15A) 6707 754 -1431 27 
H(15B) 7629 1257 -803 27 
H(16A) 6815 3744 -1433 35 
H(16B) 5895 3239 -2062 35 
H(16C) 7736 2544 -2068 35 
H(3O) -680(30) 4750(30) -2480(15) 29 
H(4O) -12360(30) 8370(30) -5788(16) 33 
H(18) -3344 8035 -2483 26 
H(19) -5396 8913 -3342 28 
H(21) -3894 4889 -4353 28 
H(22) -1820 4018 -3510 27 
H(27) -7878 10019 -6769 29 
H(28) -10283 9990 -7039 29 
H(31A) -7413 6654 -3219 31 
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H(31B) -9087 7041 -3556 31 
H(32A) -6549 4382 -3867 45 
H(32B) -8234 4768 -4195 45 
H(32C) -7967 4445 -3252 45 
 
Table 6. Torsion angles [deg] for 10. 
  
C(10)-S(1)-C(7)-C(8) -0.89(14) 
C(7)-S(1)-C(10)-C(11) -178.55(16) 
C(7)-S(1)-C(10)-C(9) 0.61(13) 
C(10)-S(1)-C(7)-C(4) 179.06(13) 
C(23)-S(2)-C(26)-C(27) 178.90(16) 
C(26)-S(2)-C(23)-C(24) -1.55(14) 
C(26)-S(2)-C(23)-C(20) 177.93(14) 
C(23)-S(2)-C(26)-C(25) 0.66(13) 
C(2)-C(1)-C(6)-C(5) -0.6(3) 
C(6)-C(1)-C(2)-C(3) 1.1(3) 
O(1)-C(1)-C(6)-C(5) 178.74(16) 
O(1)-C(1)-C(2)-C(3) -178.24(16) 
C(1)-C(2)-C(3)-C(4) -0.6(3) 
C(2)-C(3)-C(4)-C(5) -0.5(3) 
C(2)-C(3)-C(4)-C(7) -178.37(17) 
C(5)-C(4)-C(7)-S(1) -57.7(2) 
C(3)-C(4)-C(7)-S(1) 120.17(16) 
C(3)-C(4)-C(5)-C(6) 1.0(3) 
C(5)-C(4)-C(7)-C(8) 122.3(2) 
C(3)-C(4)-C(7)-C(8) -59.9(3) 
C(7)-C(4)-C(5)-C(6) 178.91(16) 
C(4)-C(5)-C(6)-C(1) -0.5(3) 
C(4)-C(7)-C(8)-C(9) -179.04(16) 
S(1)-C(7)-C(8)-C(9) 0.91(18) 
C(4)-C(7)-C(8)-C(15) -4.2(3) 
S(1)-C(7)-C(8)-C(15) 175.80(13) 
C(15)-C(8)-C(9)-C(14) 3.2(3) 
C(7)-C(8)-C(15)-C(16) -100.6(2) 
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C(9)-C(8)-C(15)-C(16) 73.6(2) 
C(15)-C(8)-C(9)-C(10) -175.08(16) 
C(7)-C(8)-C(9)-C(10) -0.4(2) 
C(7)-C(8)-C(9)-C(14) 177.79(17) 
C(8)-C(9)-C(14)-C(13) -175.84(17) 
C(8)-C(9)-C(14)-Cl(1) 5.7(3) 
C(8)-C(9)-C(10)-C(11) 178.96(16) 
C(10)-C(9)-C(14)-Cl(1) -176.13(13) 
C(8)-C(9)-C(10)-S(1) -0.22(18) 
C(14)-C(9)-C(10)-S(1) -178.75(12) 
C(14)-C(9)-C(10)-C(11) 0.4(2) 
C(10)-C(9)-C(14)-C(13) 2.3(2) 
S(1)-C(10)-C(11)-C(12) 176.71(14) 
C(9)-C(10)-C(11)-C(12) -2.4(3) 
C(10)-C(11)-C(12)-C(13) 1.5(3) 
C(11)-C(12)-C(13)-C(14) 1.2(3) 
C(11)-C(12)-C(13)-O(2) -179.14(15) 
C(12)-C(13)-C(14)-Cl(1) 175.37(13) 
O(2)-C(13)-C(14)-C(9) 177.16(15) 
O(2)-C(13)-C(14)-Cl(1) -4.3(2) 
C(12)-C(13)-C(14)-C(9) -3.2(2) 
O(3)-C(17)-C(22)-C(21) -177.86(17) 
C(18)-C(17)-C(22)-C(21) 1.2(3) 
C(22)-C(17)-C(18)-C(19) -1.7(3) 
O(3)-C(17)-C(18)-C(19) 177.38(16) 
C(17)-C(18)-C(19)-C(20) 0.5(3) 
C(18)-C(19)-C(20)-C(23) -178.74(17) 
C(18)-C(19)-C(20)-C(21) 1.1(3) 
C(21)-C(20)-C(23)-S(2) -94.68(19) 
C(19)-C(20)-C(23)-S(2) 85.2(2) 
C(19)-C(20)-C(23)-C(24) -95.4(2) 
C(19)-C(20)-C(21)-C(22) -1.7(3) 
C(23)-C(20)-C(21)-C(22) 178.22(17) 
C(21)-C(20)-C(23)-C(24) 84.7(2) 
C(20)-C(21)-C(22)-C(17) 0.5(3) 
C(20)-C(23)-C(24)-C(25) -177.45(16) 
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S(2)-C(23)-C(24)-C(25) 1.96(19) 
S(2)-C(23)-C(24)-C(31) -178.27(13) 
C(20)-C(23)-C(24)-C(31) 2.3(3) 
C(31)-C(24)-C(25)-C(26) 178.81(16) 
C(31)-C(24)-C(25)-C(30) -2.0(3) 
C(23)-C(24)-C(25)-C(30) 177.75(18) 
C(25)-C(24)-C(31)-C(32) 85.6(2) 
C(23)-C(24)-C(31)-C(32) -94.1(2) 
C(23)-C(24)-C(25)-C(26) -1.4(2) 
C(24)-C(25)-C(26)-S(2) 0.29(18) 
C(30)-C(25)-C(26)-C(27) 2.7(2) 
C(24)-C(25)-C(30)-Cl(2) -1.2(3) 
C(24)-C(25)-C(30)-C(29) -180.00(17) 
C(26)-C(25)-C(30)-Cl(2) 177.95(13) 
C(26)-C(25)-C(30)-C(29) -0.8(2) 
C(24)-C(25)-C(26)-C(27) -178.00(16) 
C(30)-C(25)-C(26)-S(2) -179.04(12) 
S(2)-C(26)-C(27)-C(28) 178.90(14) 
C(25)-C(26)-C(27)-C(28) -3.1(3) 
C(26)-C(27)-C(28)-C(29) 1.5(3) 
C(27)-C(28)-C(29)-O(4) -178.25(16) 
C(27)-C(28)-C(29)-C(30) 0.2(3) 
O(4)-C(29)-C(30)-Cl(2) -1.1(2) 
O(4)-C(29)-C(30)-C(25) 177.79(16) 
C(28)-C(29)-C(30)-Cl(2) -179.42(14) 
C(28)-C(29)-C(30)-C(25) -0.6(3) 
         Symmetry transformations used to generate equivalent atoms:  
 
Table 7. Hydrogen-bonds for 10 [Å and deg.]. 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
     
O(1)-H(1O)...O(3)#1 0.73(3) 2.10(3) 2.808(2) 162(3) 
O(2)-H(2O)...Cl(1) 0.73(3) 2.49(3) 2.9475(15) 123(2) 
O(2)-H(2O)...O(4)#2 0.73(3) 2.20(3) 2.8308(19) 146(3) 
O(3)-H(3O)...O(2) 0.71(3) 2.13(3) 2.8212(19) 165(3) 
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O(4)-H(4O)...Cl(2) 0.91(3) 2.30(3) 2.9280(14) 126(2) 
C(15)-H(15A)...Cl(1) 0.9900 2.6800 3.205(2) 114.00 
C(16)-H(16B)...Cl(1) 0.9800 2.7500 3.380(2) 123.00 
C(31)-H(31B)...Cl(2) 0.9900 2.6200 3.201(2) 118.00 
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A.3.3 4-Chloro-2-(2,6-dichloro-4-hydroxyphenyl)-1-ethyl-1H-indol-
6-ol (104) 
 
 
 
 
 
 
Table 1. Crystal data and structure refinement for 104. 
Crystal Data    
Empirical formula  C16H12Cl3NO2, CH4O  
Formula weight  388.66  
Crystal size  0.1335 x 0.1171 x 0.1137 mm  
Crystal description  rod  
Crystal colour  colourless  
Crystal system Orthorhombic  
Space group  P b c a  
Unit cell dimensions a = 17.0072(6) Å alpha = 90 deg.  
 b = 9.0354(3) Å beta = 90 deg.  
 c = 23.0271(8) Å gamma = 90 deg.  
Volume  3538.5(2) Å
3
  
Z, Calculated density  8,  1.459 Mg/m
3
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Absorption coefficient  4.825 mm
-1
  
F(000)  1600  
  
Data Collection    
Measurement device type  SuperNova, Single source at offset), Atlas  
Measurement method  \w scans  
Temperature  123 K  
Wavelength  1.54184 Å  
Monochromator  graphite  
Theta range for data collection  3.84 to 76.71 deg.  
Index ranges  -20<=h<=21, -11<=k<=11, -28<=l<=26  
Reflections collected / unique  12713 / 3665 [R(int) = 0.0262]  
Reflections greater I>2\s(I) 3519  
Absorption correction  Analytical  
Max. and min. transmission  0.683 and 0.600  
    
Refinement  --- 
Refinement method  Full-matrix least-squares on F
2
  
Hydrogen treatment  --- 
Data / restraints / parameters  3665 / 0 / 227  
Goodness-of-fit on F
2
  1.054  
Final R indices [I>2sigma(I)]      R1 = 0.0655, wR2 = 0.1878  
R indices (all data)               R1 = 0.0667, wR2 = 0.1899  
Absolute structure parameter  --- 
Largest diff. peak and hole  2.071 and -0.287 e. Å
-3
  
 
Table 2. Atomic coordinates ( x 104) and equivalent isotropic displacement 
parameters (Å2 x 103) for 104. U(eq) is defined as one third of the trace of the 
orthogonalized Uij tensor. 
 x y z U(eq) 
     
Cl(1) 4979(1) 2279(1) 5564(1) 48(1) 
Cl(2) 1906(1) 3825(1) 5643(1) 32(1) 
Cl(3) 4877(1) 8389(1) 6507(1) 36(1) 
O(1) 3067(1) 620(3) 4040(1) 38(1) 
O(2) 3835(1) 6480(2) 8418(1) 35(1) 
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N(1) 3359(1) 3721(2) 6615(1) 27(1) 
C(1) 4035(2) 2286(3) 5270(1) 30(1) 
C(2) 3918(2) 1474(3) 4771(1) 31(1) 
C(3) 3165(2) 1409(3) 4537(1) 30(1) 
C(4) 2543(2) 2130(3) 4809(1) 30(1) 
C(5) 2693(2) 2939(3) 5308(1) 27(1) 
C(6) 3438(2) 3070(3) 5553(1) 27(1) 
C(7) 3602(2) 4040(3) 6054(1) 27(1) 
C(8) 4003(2) 5354(3) 6049(1) 28(1) 
C(9) 4030(2) 5869(3) 6631(1) 27(1) 
C(10) 3623(2) 4824(3) 6977(1) 26(1) 
C(11) 3535(2) 4978(3) 7579(1) 28(1) 
C(12) 3878(2) 6209(3) 7828(1) 28(1) 
C(13) 4289(2) 7268(3) 7505(1) 29(1) 
C(14) 4355(2) 7092(3) 6912(1) 28(1) 
C(15) 2969(2) 2365(3) 6809(1) 30(1) 
C(16) 3546(2) 1263(4) 7064(2) 48(1) 
O(3) 6711(2) 4266(3) 6414(1) 46(1) 
C(17) 6144(2) 5343(4) 6284(2) 55(1) 
 
Table 3. Bond lengths [Å] and angles [deg.] for 104. 
Cl(1)-C(1) 1.742(3) O(1)-C(3)-C(2) 117.5(3) 
Cl(2)-C(5) 1.739(3) C(3)-C(4)-C(5) 118.7(3) 
Cl(3)-C(14) 1.741(3) Cl(2)-C(5)-C(4) 117.9(2) 
O(1)-C(3) 1.359(4) Cl(2)-C(5)-C(6) 118.9(2) 
O(2)-C(12) 1.382(3) C(4)-C(5)-C(6) 123.3(3) 
O(1)-H(1O) 0.88(5) C(5)-C(6)-C(7) 122.6(2) 
O(2)-H(2O) 0.75(4) C(1)-C(6)-C(7) 121.8(2) 
O(3)-C(17) 1.402(4) C(1)-C(6)-C(5) 115.5(2) 
O(3)-H(3O) 0.89(5) N(1)-C(7)-C(6) 123.3(2) 
N(1)-C(10) 1.374(3) N(1)-C(7)-C(8) 109.6(2) 
N(1)-C(15) 1.463(3) C(6)-C(7)-C(8) 127.1(2) 
N(1)-C(7) 1.388(3) C(7)-C(8)-C(9) 107.0(2) 
C(1)-C(2) 1.378(4) C(10)-C(9)-C(14) 117.5(2) 
C(1)-C(6) 1.399(4) C(8)-C(9)-C(14) 135.3(3) 
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C(2)-C(3) 1.390(4) C(8)-C(9)-C(10) 107.2(2) 
C(3)-C(4) 1.392(4) N(1)-C(10)-C(9) 107.7(2) 
C(4)-C(5) 1.386(4) N(1)-C(10)-C(11) 129.5(2) 
C(5)-C(6) 1.391(4) C(9)-C(10)-C(11) 122.8(2) 
C(6)-C(7) 1.476(4) C(10)-C(11)-C(12) 116.4(2) 
C(7)-C(8) 1.370(4) C(11)-C(12)-C(13) 122.8(3) 
C(8)-C(9) 1.419(4) O(2)-C(12)-C(11) 121.9(2) 
C(9)-C(14) 1.395(4) O(2)-C(12)-C(13) 115.3(2) 
C(9)-C(10) 1.416(4) C(12)-C(13)-C(14) 119.2(3) 
C(10)-C(11) 1.403(4) Cl(3)-C(14)-C(9) 119.1(2) 
C(11)-C(12) 1.380(4) Cl(3)-C(14)-C(13) 119.6(2) 
C(12)-C(13) 1.399(4) C(9)-C(14)-C(13) 121.2(3) 
C(13)-C(14) 1.380(4) N(1)-C(15)-C(16) 112.0(2) 
C(15)-C(16) 1.517(5) C(3)-C(2)-H(2) 121.00 
C(2)-H(2) 0.9500 C(1)-C(2)-H(2) 121.00 
C(4)-H(4) 0.9500 C(3)-C(4)-H(4) 121.00 
C(8)-H(8) 0.9500 C(5)-C(4)-H(4) 121.00 
C(11)-H(11) 0.9500 C(7)-C(8)-H(8) 126.00 
C(13)-H(13) 0.9500 C(9)-C(8)-H(8) 126.00 
C(15)-H(15B) 0.9900 C(12)-C(11)-H(11) 122.00 
C(15)-H(15A) 0.9900 C(10)-C(11)-H(11) 122.00 
C(16)-H(16C) 0.9800 C(14)-C(13)-H(13) 120.00 
C(16)-H(16A) 0.9800 C(12)-C(13)-H(13) 120.00 
C(16)-H(16B) 0.9800 N(1)-C(15)-H(15A) 109.00 
C(17)-H(17A) 0.9800 C(16)-C(15)-H(15A) 109.00 
C(17)-H(17B) 0.9800 C(16)-C(15)-H(15B) 109.00 
C(17)-H(17C) 0.9800 N(1)-C(15)-H(15B) 109.00 
  H(15A)-C(15)-H(15B) 108.00 
C(3)-O(1)-H(1O) 109(3) C(15)-C(16)-H(16B) 109.00 
C(12)-O(2)-H(2O) 114(3) C(15)-C(16)-H(16C) 110.00 
C(17)-O(3)-H(3O) 94(4) C(15)-C(16)-H(16A) 109.00 
C(7)-N(1)-C(10) 108.4(2) H(16A)-C(16)-H(16C) 109.00 
C(7)-N(1)-C(15) 126.4(2) H(16B)-C(16)-H(16C) 110.00 
C(10)-N(1)-C(15) 124.8(2) H(16A)-C(16)-H(16B) 109.00 
Cl(1)-C(1)-C(2) 117.1(2) O(3)-C(17)-H(17A) 109.00 
Cl(1)-C(1)-C(6) 119.3(2) O(3)-C(17)-H(17B) 109.00 
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C(2)-C(1)-C(6) 123.6(3) O(3)-C(17)-H(17C) 109.00 
C(1)-C(2)-C(3) 118.6(3) H(17A)-C(17)-H(17B) 110.00 
C(2)-C(3)-C(4) 120.4(3) H(17A)-C(17)-H(17C) 110.00 
O(1)-C(3)-C(4) 122.1(3) H(17B)-C(17)-H(17C) 109.00 
           Symmetry transformations used to generate equivalent atoms 
 
Table 4. Anisotropic displacement parameters (Å2 x 103) for 104. The anisotropic 
displacement factor exponent takes the form: -2 pi2 [ h2 a*2 U11 +...+ 2 h k a* b* U12]. 
 U11 U22 U33 U23 U13 U12 
       
Cl(1) 32(1) 53(1) 60(1) -23(1) -10(1) 9(1) 
Cl(2) 33(1) 29(1) 34(1) 0(1) 3(1) 6(1) 
Cl(3) 40(1) 28(1) 39(1) -2(1) 9(1) -10(1) 
O(1) 43(1) 43(1) 29(1) -10(1) -2(1) 1(1) 
O(2) 50(1) 29(1) 25(1) -2(1) -1(1) -4(1) 
N(1) 34(1) 21(1) 26(1) 0(1) 1(1) -3(1) 
C(1) 31(1) 28(1) 31(1) -1(1) 0(1) 0(1) 
C(2) 33(1) 27(1) 31(1) -2(1) 4(1) 2(1) 
C(3) 39(2) 27(1) 23(1) -1(1) 1(1) -1(1) 
C(4) 34(1) 28(1) 27(1) 2(1) -4(1) 1(1) 
C(5) 33(1) 22(1) 26(1) 3(1) 2(1) 2(1) 
C(6) 34(1) 23(1) 25(1) 1(1) 1(1) -1(1) 
C(7) 31(1) 24(1) 25(1) -1(1) 1(1) 1(1) 
C(8) 33(1) 24(1) 27(1) 0(1) 5(1) -2(1) 
C(9) 30(1) 23(1) 29(1) 0(1) 2(1) 1(1) 
C(10) 28(1) 22(1) 27(1) 0(1) -1(1) 1(1) 
C(11) 34(1) 24(1) 25(1) 1(1) 0(1) 0(1) 
C(12) 33(1) 26(1) 26(1) -2(1) -3(1) 3(1) 
C(13) 32(1) 25(1) 32(1) -4(1) -1(1) 0(1) 
C(14) 29(1) 22(1) 34(1) -1(1) 3(1) -1(1) 
C(15) 37(1) 22(1) 31(1) 2(1) 0(1) -6(1) 
C(16) 47(2) 27(1) 68(2) 11(1) -9(2) 0(1) 
O(3) 48(1) 34(1) 57(1) 2(1) 18(1) 2(1) 
C(17) 49(2) 40(2) 76(3) 9(2) 4(2) 2(2) 
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Table 5. Hydrogen coordinates (x 104) and isotropic displacement parameters 
(Å2 x 103) for 104. 
 x y z U(eq) 
     
H(1O) 2560(30) 520(50) 3973(17) 46 
H(2) 4342 969 4590 37 
H(2O) 3680(30) 5840(50) 8590(18) 42 
H(4) 2025 2069 4655 35 
H(8) 4222 5830 5719 33 
H(11) 3255 4272 7804 33 
H(13) 4520 8098 7692 35 
H(15A) 2695 1904 6475 36 
H(15B) 2569 2616 7105 36 
H(16A) 3813 1711 7398 57 
H(16B) 3936 993 6769 57 
H(16C) 3263 375 7190 57 
H(3O) 6370(30) 3520(60) 6390(20) 55 
H(17A) 5696 5235 6548 66 
H(17B) 5966 5216 5882 66 
H(17C) 6375 6330 6330 66 
 
Table 6. Torsion angles [deg] for 104. 
C(7)-N(1)-C(10)-C(11) -179.0(3) 
C(15)-N(1)-C(10)-C(11) -5.5(4) 
C(7)-N(1)-C(15)-C(16) 96.3(3) 
C(10)-N(1)-C(15)-C(16) -76.0(3) 
C(15)-N(1)-C(7)-C(6) 5.1(4) 
C(7)-N(1)-C(10)-C(9) 1.0(3) 
C(15)-N(1)-C(10)-C(9) 174.4(2) 
C(10)-N(1)-C(7)-C(6) 178.5(2) 
C(10)-N(1)-C(7)-C(8) -1.4(3) 
C(15)-N(1)-C(7)-C(8) -174.8(2) 
C(2)-C(1)-C(6)-C(5) 2.3(4) 
Cl(1)-C(1)-C(6)-C(7) 7.5(4) 
C(6)-C(1)-C(2)-C(3) -0.9(4) 
Cl(1)-C(1)-C(6)-C(5) -176.1(2) 
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Cl(1)-C(1)-C(2)-C(3) 177.6(2) 
C(2)-C(1)-C(6)-C(7) -174.1(3) 
C(1)-C(2)-C(3)-C(4) -1.1(4) 
C(1)-C(2)-C(3)-O(1) 179.0(3) 
O(1)-C(3)-C(4)-C(5) -178.6(3) 
C(2)-C(3)-C(4)-C(5) 1.5(4) 
C(3)-C(4)-C(5)-C(6) 0.1(4) 
C(3)-C(4)-C(5)-Cl(2) -179.7(2) 
Cl(2)-C(5)-C(6)-C(1) 177.9(2) 
Cl(2)-C(5)-C(6)-C(7) -5.7(4) 
C(4)-C(5)-C(6)-C(1) -1.9(4) 
C(4)-C(5)-C(6)-C(7) 174.5(3) 
C(5)-C(6)-C(7)-C(8) -107.3(3) 
C(5)-C(6)-C(7)-N(1) 72.8(4) 
C(1)-C(6)-C(7)-C(8) 68.8(4) 
C(1)-C(6)-C(7)-N(1) -111.0(3) 
C(6)-C(7)-C(8)-C(9) -178.6(3) 
N(1)-C(7)-C(8)-C(9) 1.3(3) 
C(7)-C(8)-C(9)-C(14) 178.7(3) 
C(7)-C(8)-C(9)-C(10) -0.7(3) 
C(8)-C(9)-C(10)-N(1) -0.2(3) 
C(10)-C(9)-C(14)-C(13) 0.7(4) 
C(8)-C(9)-C(10)-C(11) 179.8(2) 
C(14)-C(9)-C(10)-N(1) -179.7(2) 
C(14)-C(9)-C(10)-C(11) 0.2(4) 
C(8)-C(9)-C(14)-Cl(3) -0.6(5) 
C(8)-C(9)-C(14)-C(13) -178.7(3) 
C(10)-C(9)-C(14)-Cl(3) 178.8(2) 
N(1)-C(10)-C(11)-C(12) 179.2(3) 
C(9)-C(10)-C(11)-C(12) -0.8(4) 
C(10)-C(11)-C(12)-C(13) 0.4(4) 
C(10)-C(11)-C(12)-O(2) -179.7(2) 
O(2)-C(12)-C(13)-C(14) -179.4(2) 
C(11)-C(12)-C(13)-C(14) 0.5(4) 
C(12)-C(13)-C(14)-C(9) -1.0(4) 
C(12)-C(13)-C(14)-Cl(3) -179.2(2) 
           Symmetry transformations used to generate equivalent atoms 
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Table 7. Hydrogen-bonds for 104 [Å and deg.]. 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
     
O(1)-H(1O)...O(3)#1 0.88(5) 1.71(5) 2.534(4) 155(4) 
O(2)-H(2O)...O(1)#2 0.75(4) 1.98(5) 2.712(3) 168(5) 
O(3)-H(3O)...O(2)#3 0.89(5) 1.93(5) 2.711(3) 146(5) 
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A.3.4 1-Ethyl-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol (128) 
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Table 1. Crystal data and structure refinement for 128. 
Crystal Data  
Empirical formula C17H17NO2 
Formula weight 267.32 
Crystal size 0.2090 x 0.1217 x 0.0337 mm 
Crystal description plate 
Crystal colour colourless to faint green 
Crystal system Triclinic 
Space group P -1 
Unit cell dimensions a = 8.7637(5) Å alpha = 100.284(5) deg. 
 b = 9.3986(5) Å beta = 100.946(5) deg. 
 c = 17.7622(10) Å gamma = 90.609(5) deg. 
Volume 1411.82(14) Å
3
 
Z, Calculated density 4,  1.258 Mg/m
3
 
Absorption coefficient 0.657 mm
-1
 
F(000) 568 
  
Data Collection  
Measurement device type SuperNova, Single source at offset), Atlas 
Measuremnet method \w scans 
Temperature 123 K 
Wavelength 1.54184 Å 
Monochromator graphite 
Theta range for data collection 4.79 to 76.99 deg. 
Index ranges -11<=h<=10, -11<=k<=10, -20<=l<=22 
Reflections collected / unique 8380 / 5315 [R(int) = 0.0229] 
Reflections greater I>2\s(I) 4684 
Absorption correction Analytical 
Max. and min. transmission 0.978 and 0.923 
  
Refinement  
Refinement method Full-matrix least-squares on F
2
 
Hydrogen treatment --- 
Data / restraints / parameters 5315 / 4 / 375 
Goodness-of-fit on F
2
 1.057 
Final R indices [I>2sigma(I)] R1 = 0.0576, wR2 = 0.1640 
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R indices (all data) R1 = 0.0638, wR2 = 0.1750 
Absolute structure parameter --- 
Largest diff. peak and hole 0.351 and -0.337 e. Å
-3
 
 
Table 2. Atomic coordinates (x 104) and equivalent isotropic displacement 
parameters (Å2 x 103) for 128. U(eq) is defined as one third of the trace of the 
orthogonalized Uij tensor. 
 x y z U(eq) 
     
O(1) 586(2) 8140(2) 1702(1) 44(1) 
O(2) -8978(2) -883(2) 380(1) 44(1) 
N(1) -3149(2) 1859(2) 1203(1) 28(1) 
C(1) -402(2) 6937(2) 1580(1) 29(1) 
C(2) -160(2) 5715(2) 1051(1) 30(1) 
C(3) -1163(2) 4499(2) 916(1) 27(1) 
C(4) -2408(2) 4487(2) 1303(1) 24(1) 
C(5) -2609(2) 5720(2) 1839(1) 29(1) 
C(6) -1615(2) 6941(2) 1976(1) 31(1) 
C(7) -3555(2) 3257(2) 1133(1) 24(1) 
C(8) -5140(2) 3291(2) 886(1) 26(1) 
C(9) -5752(2) 1851(2) 804(1) 27(1) 
C(10) -4500(2) 985(2) 1019(1) 28(1) 
C(11) -4732(2) -483(2) 1031(1) 33(1) 
C(12) -6248(2) -1071(2) 814(1) 34(1) 
C(13) -7481(2) -223(2) 590(1) 33(1) 
C(14) -7276(2) 1230(2) 582(1) 29(1) 
C(15) -1650(2) 1456(2) 1604(1) 37(1) 
C(16) -1434(3) 1985(4) 2474(2) 67(1) 
C(17) -6063(2) 4562(2) 719(1) 34(1) 
O(3) 1535(2) 9616(2) 3224(1) 43(1) 
O(4) 9507(3) 19911(2) 4227(1) 63(1) 
N(2) 4693(2) 15789(2) 3275(1) 34(1) 
C(18) 2532(2) 10806(2) 3320(1) 32(1) 
C(19) 3003(2) 11193(2) 2683(1) 35(1) 
C(20) 3967(2) 12415(2) 2781(1) 34(1) 
C(21) 4466(2) 13274(2) 3512(1) 30(1) 
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C(22) 4020(3) 12838(2) 4152(1) 37(1) 
C(23) 3067(3) 11608(2) 4058(1) 40(1) 
C(24) 5379(2) 14648(2) 3598(1) 30(1) 
C(25) 6884(2) 15035(2) 3966(1) 33(1) 
C(26) 7133(2) 16512(2) 3896(1) 33(1) 
C(27) 5754(2) 16953(2) 3477(1) 35(1) 
C(28) 5604(3) 18352(3) 3316(2) 48(1) 
C(29) 6874(4) 19315(3) 3590(2) 53(1) 
C(30) 8266(3) 18874(3) 3989(1) 46(1) 
C(31) 8429(3) 17506(2) 4147(1) 41(1) 
C(32) 3066(2) 15847(2) 2906(1) 40(1) 
C(33) 1999(3) 16117(3) 3484(2) 57(1) 
C(34) 8040(3) 14115(3) 4361(1) 45(1) 
 
Table 3. Bond lengths [Å] and angles [deg] for 128. 
O(1)-C(1) 1.377(3) C(8)-C(9)-C(10) 107.70(16) 
O(2)-C(13) 1.400(2) C(10)-C(9)-C(14) 119.78(17) 
O(1)-H(1O) 0.77(2) C(8)-C(9)-C(14) 132.50(17) 
O(2)-H(2O) 0.85(2) C(9)-C(10)-C(11) 121.57(17) 
O(3)-C(18) 1.378(2) N(1)-C(10)-C(11) 130.72(17) 
O(4)-C(30) 1.403(4) N(1)-C(10)-C(9) 107.71(16) 
O(3)-H(3O) 0.78(2) C(10)-C(11)-C(12) 117.65(17) 
O(4)-H(4O) 0.86(3) C(11)-C(12)-C(13) 120.82(18) 
N(1)-C(7) 1.385(2) O(2)-C(13)-C(12) 117.88(17) 
N(1)-C(10) 1.386(2) C(12)-C(13)-C(14) 122.33(17) 
N(1)-C(15) 1.459(2) O(2)-C(13)-C(14) 119.79(17) 
N(2)-C(32) 1.458(3) C(9)-C(14)-C(13) 117.84(17) 
N(2)-C(24) 1.393(3) N(1)-C(15)-C(16) 110.88(18) 
N(2)-C(27) 1.379(3) C(1)-C(2)-H(2) 120.00 
C(1)-C(6) 1.382(3) C(3)-C(2)-H(2) 120.00 
C(1)-C(2) 1.393(3) C(4)-C(3)-H(3) 120.00 
C(2)-C(3) 1.392(3) C(2)-C(3)-H(3) 120.00 
C(3)-C(4) 1.396(2) C(6)-C(5)-H(5) 119.00 
C(4)-C(5) 1.399(2) C(4)-C(5)-H(5) 119.00 
C(4)-C(7) 1.474(3) C(1)-C(6)-H(6) 120.00 
C(5)-C(6) 1.391(3) C(5)-C(6)-H(6) 120.00 
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C(7)-C(8) 1.378(3) C(10)-C(11)-H(11) 121.00 
C(8)-C(9) 1.423(3) C(12)-C(11)-H(11) 121.00 
C(8)-C(17) 1.492(3) C(11)-C(12)-H(12) 120.00 
C(9)-C(14) 1.408(3) C(13)-C(12)-H(12) 120.00 
C(9)-C(10) 1.408(3) C(9)-C(14)-H(14) 121.00 
C(10)-C(11) 1.397(3) C(13)-C(14)-H(14) 121.00 
C(11)-C(12) 1.390(3) N(1)-C(15)-H(15B) 110.00 
C(12)-C(13) 1.389(3) N(1)-C(15)-H(15A) 109.00 
C(13)-C(14) 1.379(3) C(16)-C(15)-H(15A) 109.00 
C(15)-C(16) 1.511(4) C(16)-C(15)-H(15B) 109.00 
C(2)-H(2) 0.9500 H(15A)-C(15)-H(15B) 108.00 
C(3)-H(3) 0.9500 C(15)-C(16)-H(16C) 109.00 
C(5)-H(5) 0.9500 H(16A)-C(16)-H(16B) 109.00 
C(6)-H(6) 0.9500 H(16A)-C(16)-H(16C) 109.00 
C(11)-H(11) 0.9500 C(15)-C(16)-H(16B) 110.00 
C(12)-H(12) 0.9500 H(16B)-C(16)-H(16C) 109.00 
C(14)-H(14) 0.9500 C(15)-C(16)-H(16A) 109.00 
C(15)-H(15A) 0.9900 H(17A)-C(17)-H(17C) 110.00 
C(15)-H(15B) 0.9900 H(17B)-C(17)-H(17C) 109.00 
C(16)-H(16B) 0.9800 C(8)-C(17)-H(17A) 110.00 
C(16)-H(16A) 0.9800 C(8)-C(17)-H(17B) 109.00 
C(16)-H(16C) 0.9800 H(17A)-C(17)-H(17B) 109.00 
C(17)-H(17B) 0.9800 C(8)-C(17)-H(17C) 109.00 
C(17)-H(17C) 0.9800 C(19)-C(18)-C(23) 120.04(18) 
C(17)-H(17A) 0.9800 O(3)-C(18)-C(23) 119.79(18) 
C(18)-C(23) 1.383(3) O(3)-C(18)-C(19) 120.17(17) 
C(18)-C(19) 1.380(3) C(18)-C(19)-C(20) 119.83(17) 
C(19)-C(20) 1.384(3) C(19)-C(20)-C(21) 121.23(17) 
C(20)-C(21) 1.389(3) C(20)-C(21)-C(24) 120.64(17) 
C(21)-C(24) 1.481(3) C(20)-C(21)-C(22) 118.07(17) 
C(21)-C(22) 1.396(3) C(22)-C(21)-C(24) 121.22(17) 
C(22)-C(23) 1.386(3) C(21)-C(22)-C(23) 120.89(18) 
C(24)-C(25) 1.370(3) C(18)-C(23)-C(22) 119.85(19) 
C(25)-C(34) 1.494(3) N(2)-C(24)-C(21) 119.70(16) 
C(25)-C(26) 1.434(3) N(2)-C(24)-C(25) 110.24(17) 
C(26)-C(31) 1.414(3) C(21)-C(24)-C(25) 130.07(17) 
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C(26)-C(27) 1.402(3) C(24)-C(25)-C(26) 106.00(16) 
C(27)-C(28) 1.397(3) C(26)-C(25)-C(34) 126.62(18) 
C(28)-C(29) 1.382(4) C(24)-C(25)-C(34) 127.39(19) 
C(29)-C(30) 1.396(4) C(25)-C(26)-C(31) 133.28(18) 
C(30)-C(31) 1.367(3) C(27)-C(26)-C(31) 118.84(18) 
C(32)-C(33) 1.507(3) C(25)-C(26)-C(27) 107.87(16) 
C(19)-H(19) 0.9500 C(26)-C(27)-C(28) 122.28(19) 
C(20)-H(20) 0.9500 N(2)-C(27)-C(26) 107.91(17) 
C(22)-H(22) 0.9500 N(2)-C(27)-C(28) 129.81(19) 
C(23)-H(23) 0.9500 C(27)-C(28)-C(29) 117.6(2) 
C(28)-H(28) 0.9500 C(28)-C(29)-C(30) 120.5(3) 
C(29)-H(29) 0.9500 O(4)-C(30)-C(31) 121.0(2) 
C(31)-H(31) 0.9500 O(4)-C(30)-C(29) 116.6(2) 
C(32)-H(32A) 0.9900 C(29)-C(30)-C(31) 122.4(3) 
C(32)-H(32B) 0.9900 C(26)-C(31)-C(30) 118.3(2) 
C(33)-H(33A) 0.9800 N(2)-C(32)-C(33) 113.04(19) 
C(33)-H(33B) 0.9800 C(18)-C(19)-H(19) 120.00 
C(33)-H(33C) 0.9800 C(20)-C(19)-H(19) 120.00 
C(34)-H(34A) 0.9800 C(19)-C(20)-H(20) 119.00 
C(34)-H(34B) 0.9800 C(21)-C(20)-H(20) 119.00 
C(34)-H(34C) 0.9800 C(21)-C(22)-H(22) 120.00 
  C(23)-C(22)-H(22) 119.00 
C(1)-O(1)-H(1O) 116(2) C(18)-C(23)-H(23) 120.00 
C(13)-O(2)-H(2O) 111.2(17) C(22)-C(23)-H(23) 120.00 
C(18)-O(3)-H(3O) 116(2) C(27)-C(28)-H(28) 121.00 
C(30)-O(4)-H(4O) 111(2) C(29)-C(28)-H(28) 121.00 
C(7)-N(1)-C(10) 108.07(15) C(28)-C(29)-H(29) 120.00 
C(10)-N(1)-C(15) 124.54(16) C(30)-C(29)-H(29) 120.00 
C(7)-N(1)-C(15) 125.36(16) C(26)-C(31)-H(31) 121.00 
C(24)-N(2)-C(27) 107.89(16) C(30)-C(31)-H(31) 121.00 
C(27)-N(2)-C(32) 124.80(16) N(2)-C(32)-H(32A) 109.00 
C(24)-N(2)-C(32) 126.54(16) N(2)-C(32)-H(32B) 109.00 
O(1)-C(1)-C(2) 119.06(16) C(33)-C(32)-H(32A) 109.00 
C(2)-C(1)-C(6) 120.48(17) C(33)-C(32)-H(32B) 109.00 
O(1)-C(1)-C(6) 120.46(17) H(32A)-C(32)-H(32B) 108.00 
C(1)-C(2)-C(3) 119.53(17) C(32)-C(33)-H(33A) 109.00 
 Appendix I 343 
C(2)-C(3)-C(4) 120.93(17) C(32)-C(33)-H(33B) 109.00 
C(3)-C(4)-C(7) 122.28(16) C(32)-C(33)-H(33C) 109.00 
C(5)-C(4)-C(7) 119.30(16) H(33A)-C(33)-H(33B) 110.00 
C(3)-C(4)-C(5) 118.34(17) H(33A)-C(33)-H(33C) 109.00 
C(4)-C(5)-C(6) 121.12(16) H(33B)-C(33)-H(33C) 109.00 
C(1)-C(6)-C(5) 119.59(17) C(25)-C(34)-H(34A) 109.00 
C(4)-C(7)-C(8) 127.01(17) C(25)-C(34)-H(34B) 109.00 
N(1)-C(7)-C(4) 123.02(16) C(25)-C(34)-H(34C) 110.00 
N(1)-C(7)-C(8) 109.98(16) H(34A)-C(34)-H(34B) 109.00 
C(9)-C(8)-C(17) 125.67(16) H(34A)-C(34)-H(34C) 109.00 
C(7)-C(8)-C(9) 106.51(16) H(34B)-C(34)-H(34C) 109.00 
C(7)-C(8)-C(17) 127.82(17)   
           Symmetry transformations used to generate equivalent atoms 
 
Table 4. Anisotropic displacement parameters (Å2 x 103) for 128. The anisotropic 
displacement factor exponent takes the form:-2 pi2 [ h2 a*2 U11 +...+ 2 h k a* b* U12]. 
 U11 U22 U33 U23 U13 U12 
       
O(1) 47(1) 44(1) 36(1) 7(1) -2(1) -24(1) 
O(2) 41(1) 51(1) 38(1) 1(1) 10(1) -23(1) 
N(1) 25(1) 27(1) 33(1) 6(1) 5(1) 0(1) 
C(1) 29(1) 31(1) 25(1) 6(1) 1(1) -9(1) 
C(2) 23(1) 41(1) 29(1) 8(1) 6(1) -3(1) 
C(3) 25(1) 30(1) 26(1) 4(1) 6(1) 0(1) 
C(4) 24(1) 26(1) 22(1) 6(1) 3(1) -1(1) 
C(5) 28(1) 33(1) 27(1) 3(1) 9(1) -3(1) 
C(6) 36(1) 29(1) 27(1) -1(1) 7(1) -5(1) 
C(7) 27(1) 25(1) 22(1) 4(1) 7(1) -1(1) 
C(8) 25(1) 31(1) 23(1) 6(1) 5(1) -2(1) 
C(9) 27(1) 32(1) 22(1) 5(1) 6(1) -4(1) 
C(10) 29(1) 27(1) 27(1) 4(1) 7(1) -5(1) 
C(11) 37(1) 29(1) 36(1) 6(1) 11(1) -1(1) 
C(12) 44(1) 28(1) 33(1) 2(1) 14(1) -9(1) 
C(13) 33(1) 39(1) 26(1) 2(1) 8(1) -13(1) 
C(14) 26(1) 38(1) 24(1) 6(1) 5(1) -4(1) 
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C(15) 27(1) 35(1) 50(1) 16(1) 5(1) 4(1) 
C(16) 54(2) 100(2) 50(2) 36(2) -5(1) 13(2) 
C(17) 28(1) 37(1) 40(1) 14(1) 8(1) 2(1) 
O(3) 47(1) 31(1) 51(1) -2(1) 18(1) -16(1) 
O(4) 79(1) 61(1) 45(1) -7(1) 21(1) -46(1) 
N(2) 31(1) 32(1) 41(1) 8(1) 10(1) -4(1) 
C(18) 33(1) 27(1) 35(1) 1(1) 11(1) -7(1) 
C(19) 42(1) 33(1) 27(1) -1(1) 6(1) -10(1) 
C(20) 42(1) 35(1) 27(1) 4(1) 10(1) -8(1) 
C(21) 30(1) 28(1) 30(1) 3(1) 7(1) -4(1) 
C(22) 48(1) 34(1) 27(1) -2(1) 9(1) -11(1) 
C(23) 55(1) 37(1) 30(1) 1(1) 17(1) -13(1) 
C(24) 33(1) 30(1) 27(1) 2(1) 9(1) -6(1) 
C(25) 33(1) 36(1) 27(1) 0(1) 6(1) -8(1) 
C(26) 36(1) 37(1) 25(1) -3(1) 13(1) -11(1) 
C(27) 38(1) 31(1) 39(1) 1(1) 18(1) -6(1) 
C(28) 55(1) 36(1) 56(1) 9(1) 21(1) -3(1) 
C(29) 72(2) 34(1) 60(1) 5(1) 31(1) -14(1) 
C(30) 57(1) 43(1) 37(1) -9(1) 25(1) -28(1) 
C(31) 41(1) 46(1) 32(1) -6(1) 14(1) -17(1) 
C(32) 35(1) 43(1) 45(1) 15(1) 6(1) -1(1) 
C(33) 41(1) 74(2) 70(2) 35(1) 23(1) 14(1) 
C(34) 43(1) 49(1) 38(1) 6(1) -3(1) -7(1) 
 
Table 5. Hydrogen coordinates ( x 104) and isotropic displacement parameters 
(A2 x 103) for 128. 
 x y z U(eq) 
     
H(1O) 880(30) 8500(30) 2133(11) 53 
H(2) 683 5712 785 37 
H(2O) -9290(30) -1080(30) 773(13) 53 
H(3) -998 3666 556 32 
H(5) -3439 5724 2114 35 
H(6) -1768 7772 2341 38 
H(11) -3884 -1060 1183 40 
H(12) -6443 -2065 820 41 
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H(14) -8136 1795 431 35 
H(15A) -803 1880 1404 44 
H(15B) -1589 390 1496 44 
H(16A) -2265 1556 2673 80 
H(16B) -1474 3042 2582 80 
H(16C) -423 1700 2731 80 
H(17A) -6649 4864 1134 41 
H(17B) -6788 4295 218 41 
H(17C) -5358 5362 695 41 
H(3O) 1210(30) 9240(30) 2791(11) 52 
H(4O) 10070(40) 19800(40) 4663(13) 76 
H(19) 2666 10622 2179 42 
H(20) 4294 12670 2341 41 
H(22) 4375 13391 4660 44 
H(23) 2781 11317 4500 49 
H(28) 4663 18631 3028 57 
H(29) 6798 20285 3506 64 
H(31) 9390 17231 4418 49 
H(32A) 2735 14919 2545 48 
H(32B) 2967 16626 2594 48 
H(33A) 2308 17043 3838 69 
H(33B) 2069 15335 3786 69 
H(33C) 926 16150 3205 69 
H(34A) 7542 13171 4352 54 
H(34B) 8423 14592 4903 54 
H(34C) 8914 13977 4088 54 
 
Table 6. Torsion angles [deg] for 128. 
  
C(15)-N(1)-C(7)-C(4) 14.2(3) 
C(7)-N(1)-C(10)-C(9) 2.21(19) 
C(15)-N(1)-C(10)-C(9) 166.69(17) 
C(7)-N(1)-C(10)-C(11) -176.96(19) 
C(15)-N(1)-C(10)-C(11) -12.5(3) 
C(7)-N(1)-C(15)-C(16) 68.6(3) 
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C(10)-N(1)-C(15)-C(16) -93.2(2) 
C(10)-N(1)-C(7)-C(4) 178.55(15) 
C(10)-N(1)-C(7)-C(8) -1.7(2) 
C(15)-N(1)-C(7)-C(8) -166.03(17) 
C(32)-N(2)-C(24)-C(25) -173.48(18) 
C(27)-N(2)-C(32)-C(33) -93.1(2) 
C(24)-N(2)-C(27)-C(28) -177.9(2) 
C(27)-N(2)-C(24)-C(25) -3.2(2) 
C(27)-N(2)-C(24)-C(21) 176.57(16) 
C(32)-N(2)-C(24)-C(21) 6.3(3) 
C(32)-N(2)-C(27)-C(26) 173.25(18) 
C(24)-N(2)-C(32)-C(33) 75.6(3) 
C(32)-N(2)-C(27)-C(28) -7.4(3) 
C(24)-N(2)-C(27)-C(26) 2.8(2) 
O(1)-C(1)-C(6)-C(5) 179.42(17) 
C(6)-C(1)-C(2)-C(3) 0.9(3) 
C(2)-C(1)-C(6)-C(5) -0.7(3) 
O(1)-C(1)-C(2)-C(3) -179.26(17) 
C(1)-C(2)-C(3)-C(4) 0.0(3) 
C(2)-C(3)-C(4)-C(7) 175.63(17) 
C(2)-C(3)-C(4)-C(5) -1.0(3) 
C(7)-C(4)-C(5)-C(6) -175.57(17) 
C(5)-C(4)-C(7)-N(1) -125.35(19) 
C(3)-C(4)-C(7)-N(1) 58.1(2) 
C(3)-C(4)-C(5)-C(6) 1.2(3) 
C(5)-C(4)-C(7)-C(8) 55.0(2) 
C(3)-C(4)-C(7)-C(8) -121.7(2) 
C(4)-C(5)-C(6)-C(1) -0.3(3) 
C(4)-C(7)-C(8)-C(17) 1.1(3) 
N(1)-C(7)-C(8)-C(17) -178.59(17) 
C(4)-C(7)-C(8)-C(9) -179.76(16) 
N(1)-C(7)-C(8)-C(9) 0.5(2) 
C(17)-C(8)-C(9)-C(10) 180.00(17) 
C(17)-C(8)-C(9)-C(14) -1.7(3) 
C(7)-C(8)-C(9)-C(14) 179.16(19) 
C(7)-C(8)-C(9)-C(10) 0.9(2) 
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C(14)-C(9)-C(10)-C(11) -1.2(3) 
C(8)-C(9)-C(10)-C(11) 177.36(16) 
C(8)-C(9)-C(10)-N(1) -1.90(19) 
C(14)-C(9)-C(10)-N(1) 179.54(16) 
C(8)-C(9)-C(14)-C(13) -177.62(18) 
C(10)-C(9)-C(14)-C(13) 0.5(3) 
N(1)-C(10)-C(11)-C(12) 179.83(18) 
C(9)-C(10)-C(11)-C(12) 0.8(3) 
C(10)-C(11)-C(12)-C(13) 0.3(3) 
C(11)-C(12)-C(13)-O(2) -179.90(17) 
C(11)-C(12)-C(13)-C(14) -1.0(3) 
C(12)-C(13)-C(14)-C(9) 0.6(3) 
O(2)-C(13)-C(14)-C(9) 179.43(16) 
O(3)-C(18)-C(19)-C(20) 178.05(17) 
O(3)-C(18)-C(23)-C(22) -177.4(2) 
C(19)-C(18)-C(23)-C(22) 2.9(3) 
C(23)-C(18)-C(19)-C(20) -2.3(3) 
C(18)-C(19)-C(20)-C(21) -0.5(3) 
C(19)-C(20)-C(21)-C(22) 2.6(3) 
C(19)-C(20)-C(21)-C(24) -174.45(17) 
C(20)-C(21)-C(22)-C(23) -2.0(3) 
C(24)-C(21)-C(22)-C(23) 175.1(2) 
C(20)-C(21)-C(24)-N(2) 65.5(2) 
C(20)-C(21)-C(24)-C(25) -114.7(2) 
C(22)-C(21)-C(24)-C(25) 68.3(3) 
C(22)-C(21)-C(24)-N(2) -111.4(2) 
C(21)-C(22)-C(23)-C(18) -0.8(4) 
N(2)-C(24)-C(25)-C(26) 2.3(2) 
N(2)-C(24)-C(25)-C(34) -177.67(19) 
C(21)-C(24)-C(25)-C(26) -177.46(18) 
C(21)-C(24)-C(25)-C(34) 2.6(3) 
C(34)-C(25)-C(26)-C(27) 179.42(19) 
C(24)-C(25)-C(26)-C(31) -179.5(2) 
C(24)-C(25)-C(26)-C(27) -0.6(2) 
C(34)-C(25)-C(26)-C(31) 0.5(4) 
C(25)-C(26)-C(31)-C(30) -179.2(2) 
348 Appendix I 
C(27)-C(26)-C(31)-C(30) 1.9(3) 
C(25)-C(26)-C(27)-N(2) -1.4(2) 
C(25)-C(26)-C(27)-C(28) 179.2(2) 
C(31)-C(26)-C(27)-N(2) 177.76(18) 
C(31)-C(26)-C(27)-C(28) -1.7(3) 
C(26)-C(27)-C(28)-C(29) -0.4(4) 
N(2)-C(27)-C(28)-C(29) -179.7(2) 
C(27)-C(28)-C(29)-C(30) 2.2(4) 
C(28)-C(29)-C(30)-O(4) 178.3(2) 
C(28)-C(29)-C(30)-C(31) -2.0(4) 
C(29)-C(30)-C(31)-C(26) -0.2(4) 
O(4)-C(30)-C(31)-C(26) 179.6(2) 
         Symmetry transformations used to generate equivalent atoms:  
 
Table 7. Hydrogen-bonds for 128 [A and deg.]. 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
     
O(1)-H(1O)...O(3) 0.77(2) 2.01(2) 2.776(2) 174(3) 
O(2)-H(2O)...O(1)#1 0.85(2) 1.94(2) 2.759(2) 162(3) 
O(3)-H(3O)...O(1) 0.78(2) 2.00(2) 2.776(2) 174(3) 
O(4)-H(4O)...O(4)#2 0.86(3) 1.91(2) 2.693(3) 152(3) 
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A.3.5 2-(4-Bromophenyl)-3-methylindolizine-8-carboxylic acid 
(9.3) 
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Table 1. Crystal data and structure refinement for 9.3. 
Crystal Data    
Empirical formula  C34H27Br2N3O4 
Formula weight  701.39  
Crystal size  0.2223 x 0.0487 x 0.0177 mm  
Crystal description  rod  
Crystal colour  yellow  
Crystal system Triclinic  
Space group  P -1  
Unit cell dimensions a = 9.9171(5) Å alpha = 71.961(5) deg.  
 b = 10.9238(6) Å beta = 87.812(4) deg.  
 c = 14.5789(8) Å gamma = 86.322(5) deg.  
Volume  1498.36(15) Å
3
  
Z, Calculated density  2,  1.555 Mg/m
3
  
Absorption coefficient  3.792 mm
-1
  
F(000)  708  
    
Data Collection    
Measurement device type  SuperNova, Single source at offset), Atlas  
Measuremnet method  \w scans  
Temperature  123 K  
Wavelength  1.54184 Å  
Monochromator   graphite  
Theta range for data collection  3.19 to 76.83 deg.  
Index ranges  -12<=h<=11, -13<=k<=13, -17<=l<=18  
Reflections collected / unique  10891 / 6112 [R(int) = 0.0195]  
Reflections greater I>2\s(I) 4978  
Absorption correction  Analytical  
Max. and min. transmission  0.937 and 0.679  
    
Refinement    
Refinement method  Full-matrix least-squares on F
2
  
Hydrogen treatment  --- 
Data / restraints / parameters  6112 / 0 / 423  
Goodness-of-fit on F
2
  1.090  
Final R indices [I>2sigma(I)]      R1 = 0.0506, wR2 = 0.1527  
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R indices (all data)               R1 = 0.0576, wR2 = 0.1627  
Absolute structure parameter  --- 
Largest diff. peak and hole  1.178 and -0.882 e. Å
-3
  
 
Table 2. Atomic coordinates (x 104) and equivalent isotropic displacement 
parameters (Å2 x 103) for 9.3. U(eq) is defined as one third of the trace of the 
orthogonalized Uij tensor. 
 x y z U(eq) 
     
Br(1) 5938(1) 9130(1) 4343(1) 26(1) 
O(1) 11191(1) 5089(1) 679(1) 21(1) 
O(2) 11974(1) 3355(1) 256(1) 25(1) 
N(1) 8276(1) 2782(1) 2511(1) 18(1) 
C(1) 6493(1) 7754(1) 3844(1) 21(1) 
C(2) 6598(1) 6497(1) 4458(1) 24(1) 
C(3) 7029(1) 5508(1) 4098(1) 24(1) 
C(4) 7346(1) 5739(1) 3127(1) 19(1) 
C(5) 7223(1) 7008(1) 2507(1) 25(1) 
C(6) 6806(1) 8018(1) 2854(1) 24(1) 
C(7) 7476(1) 3432(1) 3034(1) 19(1) 
C(8) 7863(1) 4695(1) 2748(1) 19(1) 
C(9) 8916(1) 4826(1) 2039(1) 19(1) 
C(10) 9172(1) 3645(1) 1895(1) 18(1) 
C(11) 10122(1) 3112(1) 1339(1) 20(1) 
C(12) 10116(1) 1832(1) 1396(1) 23(1) 
C(13) 9160(1) 1030(1) 2003(1) 26(1) 
C(14) 8268(1) 1515(1) 2553(1) 23(1) 
C(15) 6412(1) 2767(1) 3723(1) 22(1) 
C(16) 11138(1) 3949(1) 728(1) 19(1) 
C(106) 7790(7) 7725(6) 3636(5) 10(1) 
C(105) 8242(6) 6701(6) 3301(4) 3(1) 
C(102) 5519(7) 6901(7) 3818(5) 13(1) 
C(103) 6013(7) 5955(6) 3449(5) 9(1) 
Br(2) 873(1) 9118(1) 4371(1) 29(1) 
O(3) 6164(1) 5106(1) 690(1) 21(1) 
O(4) 6970(1) 3372(1) 282(1) 27(1) 
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N(2) 3245(1) 2791(1) 2519(1) 19(1) 
C(17) 1472(1) 7742(1) 3888(1) 22(1) 
C(18) 554(1) 6871(1) 3816(1) 27(1) 
C(19) 1019(1) 5879(1) 3467(1) 25(1) 
C(20) 2378(1) 5719(1) 3188(1) 20(1) 
C(21) 3261(1) 6636(1) 3296(1) 24(1) 
C(22) 2817(1) 7645(1) 3636(1) 25(1) 
C(23) 2460(1) 3434(1) 3054(1) 20(1) 
C(24) 2887(1) 4689(1) 2801(1) 21(1) 
C(25) 3957(1) 4815(1) 2104(1) 19(1) 
C(26) 4170(1) 3647(1) 1925(1) 19(1) 
C(27) 5102(1) 3126(1) 1352(1) 21(1) 
C(28) 5063(1) 1860(1) 1376(1) 25(1) 
C(29) 4087(1) 1063(1) 1964(1) 28(1) 
C(30) 3204(1) 1540(1) 2527(1) 24(1) 
C(31) 1437(1) 2744(1) 3769(1) 24(1) 
C(32) 6122(1) 3966(1) 746(1) 19(1) 
C(122) 1854(6) 7989(6) 2862(4) 4(1) 
C(121) 2261(6) 6970(6) 2524(5) 6(1) 
C(118) 1594(7) 6425(7) 4475(5) 10(1) 
C(119) 2038(8) 5453(8) 4087(6) 17(2) 
N(3) 7828(3) -228(2) 337(2) 119(1) 
C(33) 8206(3) 627(2) -249(1) 82(1) 
C(34) 8743(3) 1790(2) -1025(1) 90(1) 
 
Table 3. Bond lengths [Å] and angles [deg] for 9.3. 
Br(1)-C(1) 1.9063(10)  C(8)-C(9)-C(10) 107.78(8)  
Br(2)-C(17) 1.9015(10)  N(1)-C(10)-C(9) 107.24(7)  
O(1)-C(16) 1.2292(12)  C(9)-C(10)-C(11) 136.14(9)  
O(2)-C(16) 1.3221(12)  N(1)-C(10)-C(11) 116.54(9)  
O(2)-H(2A) 0.8400  C(12)-C(11)-C(16) 120.60(9)  
O(3)-C(32) 1.2253(12)  C(10)-C(11)-C(16) 118.94(9)  
O(4)-C(32) 1.3206(12)  C(10)-C(11)-C(12) 120.43(9)  
O(4)-H(4) 0.8400  C(11)-C(12)-C(13) 120.19(9)  
N(1)-C(10) 1.4163(11)  C(12)-C(13)-C(14) 120.15(10)  
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N(1)-C(7) 1.3892(12)  N(1)-C(14)-C(13) 120.12(9)  
N(1)-C(14) 1.3676(13)  O(1)-C(16)-C(11) 122.25(8)  
N(2)-C(26) 1.4183(12)  O(2)-C(16)-C(11) 113.87(9)  
N(2)-C(23) 1.3892(13)  O(1)-C(16)-O(2) 123.88(8)  
N(2)-C(30) 1.3671(13)  C(3)-C(2)-H(2) 120.00  
N(3)-C(33) 1.127(3)  C(1)-C(2)-H(2) 120.00  
C(1)-C(102) 1.394(7)  C(1)-C(102)-C(103) 112.6(6)  
C(1)-C(106) 1.311(7)  C(4)-C(3)-H(3) 119.00  
C(1)-C(2) 1.3871(16)  C(2)-C(3)-H(3) 119.00  
C(1)-C(6) 1.4081(15)  C(4)-C(103)-C(102) 128.6(6)  
C(2)-C(3) 1.3790(17)  C(4)-C(105)-C(106) 124.7(5)  
C(3)-C(4) 1.3863(15)  C(6)-C(5)-H(5) 120.00  
C(4)-C(103) 1.416(7)  C(4)-C(5)-H(5) 119.00  
C(4)-C(5) 1.4019(15)  C(1)-C(106)-C(105) 114.1(6)  
C(4)-C(105) 1.504(7)  C(1)-C(6)-H(6) 121.00  
C(4)-C(8) 1.4702(14)  C(5)-C(6)-H(6) 120.00  
C(5)-C(6) 1.3827(17)  C(10)-C(9)-H(9) 126.00  
C(7)-C(15) 1.4889(13)  C(8)-C(9)-H(9) 126.00  
C(7)-C(8) 1.3869(14)  C(13)-C(12)-H(12) 120.00  
C(8)-C(9) 1.4223(13)  C(11)-C(12)-H(12) 120.00  
C(9)-C(10) 1.3769(14)  C(14)-C(13)-H(13) 120.00  
C(10)-C(11) 1.4303(13)  C(12)-C(13)-H(13) 120.00  
C(11)-C(12) 1.3753(15)  N(1)-C(14)-H(14) 120.00  
C(11)-C(16) 1.4802(13)  C(13)-C(14)-H(14) 120.00  
C(12)-C(13) 1.4177(14)  C(7)-C(15)-H(15C) 109.00  
C(13)-C(14) 1.3624(14)  H(15B)-C(15)-H(15C) 109.00  
C(102)-C(103) 1.363(10)  C(7)-C(15)-H(15B) 109.00  
C(2)-H(2) 0.9500  H(15A)-C(15)-H(15C) 109.00  
C(3)-H(3) 0.9500  C(7)-C(15)-H(15A) 109.00  
C(5)-H(5) 0.9500  H(15A)-C(15)-H(15B) 109.00  
C(105)-C(106) 1.396(10)  C(1)-C(102)-H(102) 124.00  
C(6)-H(6) 0.9500  C(103)-C(102)-H(102) 124.00  
C(9)-H(9) 0.9500  C(4)-C(103)-H(103) 116.00  
C(12)-H(12) 0.9500  C(102)-C(103)-H(103) 116.00  
C(13)-H(13) 0.9500  C(106)-C(105)-H(105) 118.00  
C(14)-H(14) 0.9500  C(4)-C(105)-H(105) 118.00  
354 Appendix I 
C(15)-H(15A) 0.9800  C(105)-C(106)-H(106) 123.00  
C(15)-H(15C) 0.9800  C(1)-C(106)-H(106) 123.00  
C(15)-H(15B) 0.9800  Br(2)-C(17)-C(18) 119.39(8)  
C(102)-H(102) 0.9500  Br(2)-C(17)-C(118) 123.5(3)  
C(103)-H(103) 0.9500  Br(2)-C(17)-C(122) 120.9(3)  
C(105)-H(105) 0.9500  C(18)-C(17)-C(22) 122.64(10)  
C(106)-H(106) 0.9500  C(118)-C(17)-C(122) 115.6(4)  
C(17)-C(118) 1.429(8)  Br(2)-C(17)-C(22) 117.96(8)  
C(17)-C(122) 1.475(6)  C(17)-C(18)-C(19) 118.07(10)  
C(17)-C(18) 1.3871(16)  C(18)-C(19)-C(20) 122.70(11)  
C(17)-C(22) 1.3771(15)  C(19)-C(20)-C(24) 123.57(9)  
C(18)-C(19) 1.3805(18)  C(21)-C(20)-C(24) 120.44(9)  
C(19)-C(20) 1.4087(14)  C(24)-C(20)-C(119) 120.0(4)  
C(20)-C(21) 1.4198(15)  C(24)-C(20)-C(121) 116.3(3)  
C(20)-C(24) 1.4621(14)  C(119)-C(20)-C(121) 123.6(5)  
C(20)-C(119) 1.288(8)  C(19)-C(20)-C(21) 115.98(10)  
C(20)-C(121) 1.410(7)  C(20)-C(21)-C(22) 122.41(10)  
C(21)-C(22) 1.3830(17)  C(17)-C(22)-C(21) 118.18(11)  
C(23)-C(24) 1.3940(14)  N(2)-C(23)-C(24) 107.15(8)  
C(23)-C(31) 1.4882(13)  C(24)-C(23)-C(31) 132.33(9)  
C(24)-C(25) 1.4233(13)  N(2)-C(23)-C(31) 120.47(9)  
C(25)-C(26) 1.3818(14)  C(20)-C(24)-C(23) 127.27(9)  
C(26)-C(27) 1.4300(13)  C(20)-C(24)-C(25) 124.16(9)  
C(27)-C(32) 1.4812(13)  C(23)-C(24)-C(25) 108.54(9)  
C(27)-C(28) 1.3757(15)  C(24)-C(25)-C(26) 107.77(9)  
C(28)-C(29) 1.4181(15)  N(2)-C(26)-C(25) 107.36(8)  
C(29)-C(30) 1.3655(15)  C(25)-C(26)-C(27) 135.82(9)  
C(118)-C(119) 1.391(12)  N(2)-C(26)-C(27) 116.72(9)  
C(18)-H(18) 0.9500  C(26)-C(27)-C(32) 118.88(9)  
C(19)-H(19) 0.9500  C(28)-C(27)-C(32) 120.73(9)  
C(121)-C(122) 1.383(10)  C(26)-C(27)-C(28) 120.39(9)  
C(21)-H(21) 0.9500  C(27)-C(28)-C(29) 120.21(10)  
C(22)-H(22) 0.9500  C(28)-C(29)-C(30) 120.12(10)  
C(25)-H(25) 0.9500  N(2)-C(30)-C(29) 120.18(9)  
C(28)-H(28) 0.9500  O(3)-C(32)-C(27) 122.36(8)  
C(29)-H(29) 0.9500  O(4)-C(32)-C(27) 113.86(9)  
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C(30)-H(30) 0.9500  O(3)-C(32)-O(4) 123.78(8)  
C(31)-H(31B) 0.9800  C(17)-C(118)-C(119) 121.3(6)  
C(31)-H(31C) 0.9800  C(17)-C(18)-H(18) 121.00  
C(31)-H(31A) 0.9800  C(19)-C(18)-H(18) 121.00  
C(118)-H(118) 0.9500  C(20)-C(119)-C(118) 120.8(7)  
C(119)-H(119) 0.9500  C(20)-C(19)-H(19) 119.00  
C(121)-H(121) 0.9500  C(18)-C(19)-H(19) 119.00  
C(122)-H(122) 0.9500  C(22)-C(21)-H(21) 119.00  
C(33)-C(34) 1.526(3)  C(20)-C(121)-C(122) 118.7(5)  
C(34)-H(34A) 0.9800  C(20)-C(21)-H(21) 119.00  
C(34)-H(34B) 0.9800  C(17)-C(122)-C(121) 119.9(5)  
C(34)-H(34C) 0.9800  C(17)-C(22)-H(22) 121.00  
    C(21)-C(22)-H(22) 121.00  
C(16)-O(2)-H(2A) 109.00  C(24)-C(25)-H(25) 126.00  
C(32)-O(4)-H(4) 109.00  C(26)-C(25)-H(25) 126.00  
C(10)-N(1)-C(14) 122.52(8)  C(27)-C(28)-H(28) 120.00  
C(7)-N(1)-C(10) 109.29(8)  C(29)-C(28)-H(28) 120.00  
C(7)-N(1)-C(14) 128.19(8)  C(28)-C(29)-H(29) 120.00  
C(26)-N(2)-C(30) 122.35(8)  C(30)-C(29)-H(29) 120.00  
C(23)-N(2)-C(26) 109.18(8)  N(2)-C(30)-H(30) 120.00  
C(23)-N(2)-C(30) 128.47(8)  C(29)-C(30)-H(30) 120.00  
C(102)-C(1)-C(106) 130.2(4)  C(23)-C(31)-H(31A) 109.00  
Br(1)-C(1)-C(102) 117.1(3)  C(23)-C(31)-H(31B) 109.00  
C(2)-C(1)-C(6) 120.24(10)  C(23)-C(31)-H(31C) 109.00  
Br(1)-C(1)-C(6) 119.86(8)  H(31A)-C(31)-H(31B) 109.00  
Br(1)-C(1)-C(2) 119.90(8)  H(31A)-C(31)-H(31C) 110.00  
Br(1)-C(1)-C(106) 112.5(3)  H(31B)-C(31)-H(31C) 109.00  
C(1)-C(2)-C(3) 119.70(10)  C(17)-C(118)-H(118) 119.00  
C(2)-C(3)-C(4) 121.36(11)  C(119)-C(118)-H(118) 119.00  
C(8)-C(4)-C(105) 122.7(2)  C(20)-C(119)-H(119) 119.00  
C(103)-C(4)-C(105) 109.4(4)  C(118)-C(119)-H(119) 120.00  
C(8)-C(4)-C(103) 127.7(3)  C(20)-C(121)-H(121) 121.00  
C(3)-C(4)-C(8) 121.45(9)  C(122)-C(121)-H(121) 121.00  
C(3)-C(4)-C(5) 118.68(10)  C(17)-C(122)-H(122) 120.00  
C(5)-C(4)-C(8) 119.81(9)  C(121)-C(122)-H(122) 120.00  
C(4)-C(5)-C(6) 121.00(10)  N(3)-C(33)-C(34) 178.5(3)  
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C(1)-C(6)-C(5) 119.01(11)  C(33)-C(34)-H(34A) 109.00  
N(1)-C(7)-C(15) 121.00(9)  C(33)-C(34)-H(34B) 109.00  
N(1)-C(7)-C(8) 106.96(8)  C(33)-C(34)-H(34C) 109.00  
C(8)-C(7)-C(15) 132.01(9)  H(34A)-C(34)-H(34B) 109.00  
C(4)-C(8)-C(9) 123.98(9)  H(34A)-C(34)-H(34C) 109.00  
C(7)-C(8)-C(9) 108.73(9)  H(34B)-C(34)-H(34C) 110.00  
C(4)-C(8)-C(7) 127.24(9)    
           Symmetry transformations used to generate equivalent atoms:  
 
Table 4. Anisotropic displacement parameters (Å2 x 103) for 9.3. The anisotropic 
displacement factor exponent takes the form:-2 pi2 [ h2 a*2 U11 +...+ 2 h k a* b* U12]. 
 U11 U22 U33 U23 U13 U12 
       
Br(1) 26(1) 22(1) 33(1) -11(1) 8(1) -4(1) 
O(1) 16(1) 25(1) 23(1) -8(1) 7(1) -4(1) 
O(2) 20(1) 26(1) 29(1) -8(1) 12(1) -6(1) 
N(1) 13(1) 20(1) 19(1) -2(1) 4(1) -4(1) 
C(1) 15(1) 22(1) 26(1) -7(1) 5(1) -4(1) 
C(2) 20(1) 29(1) 22(1) -7(1) 3(1) -2(1) 
C(3) 21(1) 27(1) 22(1) -5(1) 3(1) -2(1) 
C(4) 13(1) 19(1) 25(1) -7(1) 4(1) -3(1) 
C(5) 22(1) 27(1) 22(1) -5(1) 6(1) -3(1) 
C(6) 22(1) 23(1) 26(1) -4(1) 5(1) -4(1) 
C(7) 13(1) 23(1) 21(1) -6(1) 4(1) -2(1) 
C(8) 13(1) 23(1) 20(1) -4(1) 3(1) 1(1) 
C(9) 14(1) 19(1) 22(1) -5(1) 5(1) -2(1) 
C(10) 14(1) 22(1) 17(1) -2(1) 4(1) -5(1) 
C(11) 13(1) 24(1) 22(1) -4(1) 3(1) -2(1) 
C(12) 18(1) 25(1) 25(1) -9(1) 6(1) -2(1) 
C(13) 25(1) 22(1) 32(1) -8(1) 8(1) -5(1) 
C(14) 17(1) 22(1) 27(1) -2(1) 7(1) -5(1) 
C(15) 17(1) 23(1) 23(1) -2(1) 7(1) -4(1) 
C(16) 13(1) 23(1) 20(1) -6(1) 3(1) -2(1) 
Br(2) 29(1) 23(1) 35(1) -10(1) 10(1) -3(1) 
O(3) 15(1) 25(1) 23(1) -7(1) 7(1) -4(1) 
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O(4) 21(1) 26(1) 31(1) -7(1) 12(1) -5(1) 
N(2) 14(1) 20(1) 19(1) -1(1) 3(1) -3(1) 
C(17) 22(1) 20(1) 22(1) -4(1) 6(1) -3(1) 
C(18) 16(1) 32(1) 30(1) -7(1) 4(1) -3(1) 
C(19) 17(1) 32(1) 26(1) -9(1) 3(1) -5(1) 
C(20) 16(1) 23(1) 21(1) -5(1) 3(1) -3(1) 
C(21) 16(1) 29(1) 25(1) -6(1) 5(1) -6(1) 
C(22) 19(1) 28(1) 27(1) -7(1) 3(1) -6(1) 
C(23) 12(1) 26(1) 21(1) -6(1) 4(1) -3(1) 
C(24) 14(1) 24(1) 22(1) -5(1) 2(1) 0(1) 
C(25) 14(1) 19(1) 22(1) -4(1) 5(1) -2(1) 
C(26) 13(1) 22(1) 19(1) -1(1) 4(1) -5(1) 
C(27) 14(1) 25(1) 23(1) -3(1) 5(1) -3(1) 
C(28) 19(1) 25(1) 30(1) -7(1) 8(1) -3(1) 
C(29) 26(1) 21(1) 34(1) -5(1) 9(1) -4(1) 
C(30) 18(1) 24(1) 27(1) -3(1) 6(1) -5(1) 
C(31) 17(1) 27(1) 23(1) -2(1) 7(1) -6(1) 
C(32) 12(1) 24(1) 20(1) -6(1) 3(1) -3(1) 
N(3) 219(3) 66(1) 67(1) -20(1) 26(1) 9(1) 
C(33) 125(2) 75(1) 45(1) -26(1) -9(1) 35(1) 
C(34) 136(2) 79(1) 47(1) -13(1) -6(1) 29(1) 
 
Table 5. Hydrogen coordinates (x 104) and isotropic displacement parameters 
(Å2 x 103) for 9.3. 
 x y z U(eq) 
     
H(2A) 12526 3875 -74 30 
H(3) 7111 4651 4524 29 
H(5) 7430 7178 1839 30 
H(6) 6732 8876 2430 29 
H(14) 7639 971 2967 28 
H(15A) 5524 3181 3508 26 
H(15B) 6580 2823 4366 26 
H(15C) 6430 1859 3748 26 
H(9) 9362 5592 1722 23 
H(12) 10754 1484 1029 28 
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H(13) 9142 153 2025 32 
H(2) 6373 6319 5124 29 
H(102) 4610 6972 4035 15 
H(103) 5379 5362 3401 11 
H(105) 9183 6605 3174 4 
H(106) 8371 8347 3707 12 
H(18) -367 6955 4002 32 
H(19) 397 5280 3413 30 
H(21) 4190 6554 3129 29 
H(22) 3424 8254 3694 30 
H(30) 2558 1000 2926 29 
H(31A) 547 3190 3612 29 
H(31B) 1683 2730 4417 29 
H(31C) 1409 1858 3748 29 
H(25) 4438 5568 1814 23 
H(28) 5691 1518 998 30 
H(29) 4047 195 1965 33 
H(4) 7493 3905 -72 32 
H(118) 1367 6208 5143 12 
H(119) 2092 4582 4489 21 
H(121) 2457 7110 1857 8 
H(122) 1821 8846 2435 5 
H(34A) 9478 2132 -763 108 
H(34B) 8013 2458 -1230 108 
H(34C) 9084 1527 -1579 108 
 
Table 6. Torsion angles [deg] for 9.3. 
  
C(14)-N(1)-C(7)-C(8) 179.41(8) 
C(10)-N(1)-C(7)-C(15) 178.39(8) 
C(14)-N(1)-C(7)-C(15) -2.33(13) 
C(7)-N(1)-C(10)-C(11) 176.83(7) 
C(7)-N(1)-C(14)-C(13) -178.01(9) 
C(10)-N(1)-C(14)-C(13) 1.18(13) 
C(7)-N(1)-C(10)-C(9) -0.25(9) 
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C(10)-N(1)-C(7)-C(8) 0.13(10) 
C(14)-N(1)-C(10)-C(11) -2.50(12) 
C(14)-N(1)-C(10)-C(9) -179.58(8) 
C(30)-N(2)-C(26)-C(27) -2.18(13) 
C(23)-N(2)-C(26)-C(25) 0.50(10) 
C(23)-N(2)-C(26)-C(27) 177.37(8) 
C(26)-N(2)-C(30)-C(29) 1.16(14) 
C(26)-N(2)-C(23)-C(31) -177.62(8) 
C(30)-N(2)-C(26)-C(25) -179.04(8) 
C(23)-N(2)-C(30)-C(29) -178.28(10) 
C(26)-N(2)-C(23)-C(24) -0.06(10) 
C(30)-N(2)-C(23)-C(31) 1.88(14) 
C(30)-N(2)-C(23)-C(24) 179.45(9) 
C(2)-C(1)-C(6)-C(5) -0.31(15) 
Br(1)-C(1)-C(2)-C(3) -178.56(8) 
Br(1)-C(1)-C(6)-C(5) 179.22(8) 
C(6)-C(1)-C(2)-C(3) 0.97(15) 
C(1)-C(2)-C(3)-C(4) -0.90(16) 
C(2)-C(3)-C(4)-C(8) 177.23(10) 
C(2)-C(3)-C(4)-C(5) 0.16(15) 
C(5)-C(4)-C(8)-C(9) 37.60(14) 
C(8)-C(4)-C(5)-C(6) -176.60(10) 
C(3)-C(4)-C(8)-C(9) -139.43(10) 
C(3)-C(4)-C(8)-C(7) 37.60(15) 
C(3)-C(4)-C(5)-C(6) 0.51(15) 
C(5)-C(4)-C(8)-C(7) -145.37(10) 
C(4)-C(5)-C(6)-C(1) -0.43(16) 
N(1)-C(7)-C(8)-C(9) 0.05(10) 
C(15)-C(7)-C(8)-C(4) 4.64(17) 
N(1)-C(7)-C(8)-C(4) -177.36(9) 
C(15)-C(7)-C(8)-C(9) -177.96(9) 
C(7)-C(8)-C(9)-C(10) -0.20(10) 
C(4)-C(8)-C(9)-C(10) 177.30(8) 
C(8)-C(9)-C(10)-N(1) 0.27(10) 
C(8)-C(9)-C(10)-C(11) -175.96(10) 
C(9)-C(10)-C(11)-C(16) -0.35(16) 
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C(9)-C(10)-C(11)-C(12) 177.60(10) 
N(1)-C(10)-C(11)-C(12) 1.63(13) 
N(1)-C(10)-C(11)-C(16) -176.33(7) 
C(10)-C(11)-C(16)-O(1) -0.31(13) 
C(12)-C(11)-C(16)-O(2) 1.25(13) 
C(10)-C(11)-C(12)-C(13) 0.47(14) 
C(16)-C(11)-C(12)-C(13) 178.39(9) 
C(10)-C(11)-C(16)-O(2) 179.19(8) 
C(12)-C(11)-C(16)-O(1) -178.26(9) 
C(11)-C(12)-C(13)-C(14) -1.89(15) 
C(12)-C(13)-C(14)-N(1) 1.06(15) 
C(18)-C(17)-C(22)-C(21) 0.15(17) 
C(22)-C(17)-C(18)-C(19) -0.69(17) 
Br(2)-C(17)-C(22)-C(21) 179.19(8) 
Br(2)-C(17)-C(18)-C(19) -179.72(8) 
C(17)-C(18)-C(19)-C(20) 0.25(17) 
C(18)-C(19)-C(20)-C(24) -178.87(10) 
C(18)-C(19)-C(20)-C(21) 0.67(16) 
C(19)-C(20)-C(21)-C(22) -1.24(16) 
C(21)-C(20)-C(24)-C(25) -32.06(15) 
C(19)-C(20)-C(24)-C(23) -34.53(16) 
C(19)-C(20)-C(24)-C(25) 147.46(10) 
C(24)-C(20)-C(21)-C(22) 178.32(10) 
C(21)-C(20)-C(24)-C(23) 145.96(10) 
C(20)-C(21)-C(22)-C(17) 0.86(17) 
N(2)-C(23)-C(24)-C(20) -178.67(9) 
C(31)-C(23)-C(24)-C(20) -1.51(17) 
N(2)-C(23)-C(24)-C(25) -0.41(11) 
C(31)-C(23)-C(24)-C(25) 176.76(10) 
C(20)-C(24)-C(25)-C(26) 179.06(9) 
C(23)-C(24)-C(25)-C(26) 0.73(11) 
C(24)-C(25)-C(26)-C(27) -176.72(10) 
C(24)-C(25)-C(26)-N(2) -0.74(10) 
N(2)-C(26)-C(27)-C(32) -177.84(8) 
N(2)-C(26)-C(27)-C(28) 1.28(13) 
C(25)-C(26)-C(27)-C(28) 176.98(10) 
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C(25)-C(26)-C(27)-C(32) -2.14(16) 
C(26)-C(27)-C(28)-C(29) 0.55(15) 
C(26)-C(27)-C(32)-O(4) 177.08(8) 
C(28)-C(27)-C(32)-O(3) 178.14(9) 
C(28)-C(27)-C(32)-O(4) -2.04(13) 
C(26)-C(27)-C(32)-O(3) -2.74(13) 
C(32)-C(27)-C(28)-C(29) 179.65(9) 
C(27)-C(28)-C(29)-C(30) -1.65(16) 
C(28)-C(29)-C(30)-N(2) 0.79(15) 
         Symmetry transformations used to generate equivalent atoms:  
 
Table 7. Hydrogen-bonds for 9.3 [Å and deg.]. 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
     
O(2)-H(2A)...O(3)#1 0.8400 1.7900 2.6288(10) 174.00 
O(4)-H(4)...O(1)#1 0.8400 1.7900 2.6181(10) 171.00 
C(9)-H(9)...O(1) 0.9500 2.4700 2.9151(11) 109.00 
C(12)-H(12)...O(2) 0.9500 2.3900 2.7155(12) 100.00 
C(15)-H(15C)...Br(1)#2 0.9800 2.9000 3.8480(10) 162.00 
C(25)-H(25)...O(3) 0.9500 2.4600 2.9122(11) 109.00 
C(28)-H(28)...O(4) 0.9500 2.3900 2.7188(13) 100.00 
C(31)-H(31C)...Br(2)#2 0.9800 2.9200 3.8553(11) 159.00 
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B.1 Compound library 
B.1.1 Compound library of hyaluronidase inhibitors (library 1) 
 
 
 
 
Compound library of hyaluronidase inhibitors (347 inhibitors, target molecule: SagHyal4755) 
tabulated according to the corresponding chemical classes. The substances served as templates 
for molecules synthesized on plates ori.hya.1-35. 
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Index Name ID IC50 (µM) 
SagHyal4755 
1 4-(Trifluoromethyl)-2-(4-sulfamoyloxyphenyl)-3-methyl-1-(perfluorobenzyl)-1H-indol-6-yl sulfamate UR-CT183 9 
2 4-(Trifluoromethyl)-2-(4-hydroxyphenyl)-3-methyl-1-(perfluorobenzyl)-1H-indol-6-yl sulfamate UR-CT184 5 
3 2-(4-Sulfamoyloxyphenyl)-3-methyl-1-(perfluorobenzyl)-1H-indol-5-yl sulfamate UR-CT185 27 
4 1-Ethyl-3-methyl-2-phenyl-1H-indol-6-yl sulfamate UR-CT186 550 
5 1-Ethyl-2-(4-sulfamoyloxyphenyl)-3-methyl-1H-indol-5-yl sulfamate UR-CT192 124 
6 1-Ethyl-2-(4-sulfamoyloxyphenyl)-3-methyl-1H-indol-6-yl sulfamate UR-CT193 109 
7 1-Ethyl-2-phenyl-1H-indol-5-yl sulfamate UR-CT194 62 
8 2-(4-Sulfamoyloxyphenyl)-3-methyl-1-(6-(pyrrolidin-1-yl)hexyl)-1H-indol-6-yl sulfamate UR-CT195 219 
9 1-Decyl-2-(4-hydroxyphenyl)-3-methyl-1H-indol-6-ol UR-CT201 17.8 
10 4-((E)-4-(4-Hydroxyphenyl)hex-3-en-3-yl)phenyl sulfamate UR-CT204 49 
11 2-(4-Hydroxyphenyl)-3-methyl-1-(perfluorobenzyl)-1H-indol-5-ol UR-CT205 15.8 
12 2-(4-Hydroxyphenyl)-3-methyl-1-(perfluorobenzyl)-1H-indol-6-ol UR-CT206 26 
13 4-(Trifluoromethyl)-2-(4-hydroxyphenyl)-3-methyl-1-(perfluorobenzyl)-1H-indol-6-ol UR-CT207 4.9 
14 1-Ethyl-3-methyl-2-phenyl-1H-indol-6-ol UR-CT208 66 
15 2-(4-Hydroxyphenyl)-3-methyl-1-(6-(pyrrolidin-1-yl)hexyl)-1H-indol-5-ol UR-CT216 300 
16 4-((E)-4-(4-Hydroxyphenyl)hex-3-en-3-yl)phenol UR-CT220 30 
17 1-Ethyl-2-(4-hydroxyphenyl)-1H-indol-6-ol UR-CT223 320 
18 1-Butyl-2-(4-hydroxyphenyl)-1H-indol-6-ol UR-CT224 66 
19 1-Heptyl-2-(4-hydroxyphenyl)-1H-indol-6-ol UR-CT225 8.9 
20 1-(4-Chlorobenzoyl)indol-3-acetic acid [8] 290 
21 1-(4-Methoxybenzoyl)indol-3-acetic acid [9] 640 
22 1-(4-Trifluormethylbenzoyl)indol-3-acetic acid [10] 300 
23 1-(Biphenyl-4-ylcarbonyl)indol-3-acetic acid [11] 59 
24 1-Decanoylindol-3-acetic acid [12] 250 
25 1-(4-Fluorbenzoyl)-2-methylindol-3-acetic acid [26] 210 
26 1-(4-Chlorbenzoyl)-2-methylindol-3-acetic acid [27] 120 
27 1-(4-Methoxybenzoyl)-2-methylindol-3-acetic acid [28] 290 
28 1-(4-Trifluormethylbenzoyl)-2-methylindol-3-acetic acid [29] 180 
29 1-(p-Biphenylcarbonyl)-2-methylindol-3-acetic acid [30] 44 ± 1.1 
30 1-Decanoyl-2-methylindol-3-acetic acid [31] inactive 
31 1-Hexadecanoyl-2-methylindol-3-acetic acid [32] 3.9 ± 0.1 
32 1-[6-(Biphenyl-4-yloxy)hexanoyl]-2-methylindol-3-acetic acid [33] 50 
33 4-[1-(p-Biphenylcarbonyl)indol-3-yl]butanoic acid-5-(biphenyl-4-oxy)pentylester [42] 320 
34 1-(4-Fluorobenzyl)indol-3-acetic acid [43] inactive 
35 2-[1-(Biphenyl-4-ylmethyl)indol-3-yl]acetic acid [44] 1200 
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36 1-(4-Fluorbenzyl)-2-methylindol-3-acetic acid [45] inactive 
37 2-[1-(Biphenyl-4-ylmethyl)-2-methylindol-3-yl]acetic acid [46] inactive 
38 1-(Biphenyl-4-ylmethyl)-3-(carboxymethyl)-5-hydroxyindol-2-carboxylic acid [52] 16 ± 0.3 
39 Lauryl gallate Chapter 5 13 ± 1 
40 1,3-Diacetylbenzimidazole-2-thione Chapter 5 160 
41 3-phenyl-1-(2-thioxobenzo[d]oxazol-3(2H)-yl)propan-1-one Chapter 5 15 ± 1 
42 tetradecane sulfonic acid Chapter 5 12 ± 1 
43 D-glucurono-6,3-lactone  > 20000 
44 1-O-Benzyl-beta-D-glucofuranosidurono-6,3-lactone 6.1 > 4000 
45 1-O-(3-Phenylpropyl)-beta-D-glucofuranosidurono-6,3-lactone 6.2 920 ± 103 
46 1-O-(Octan-1-yl)-beta-D-glucofuranosidurono-6,3-lactone 6.3 171 ± 10 
47 1-O-(8-Hydroxyoctan-1-yl)-beta-D-glucofuranosidurono-6,3-lactone 6.4 683 ± 62 
48 1-O-(Dodecan-1-yl)-beta-D-glucofuranosidurono-6,3-lactone 6.5 29 ± 2 
49 1-O-(Octan-1-yl)-beta-D-glucofuranosiduronic acid sodium salt 6.7 > 1200 
50 1-O-(8-Hydroxyoctan-1-yl)-beta-D-glucofuranosiduronic acid sodium salt 6.8 1170 ± 70 
51 1-O-(Dodecan-1-yl)-beta-D-glucofuranosiduronic acid sodium salt 6.9 36 ± 5 
52 1-O-(Hexadecan-1-yl)-beta-D-glucofuranosiduronic acid 6.10 4.7 ± 0.1 
53 1-O-(Dodecan-1-yl)-beta-D-glucofuranosiduronamide 6.11 82 ± 4 
54 1-O-(Hexadecan-1-yl)-beta-D-glucofuranosiduronamide 6.12 > 50 
55 1-O-(Hexadecan-1-yl)-N-benzyl-beta-D-glucofuranosiduronamide 6.13 > 50 
56 1-O-(Hexadecan-1-yl)-N-(2-phenylethyl)-beta-D-glucofuranosiduronamide 6.14 > 40 
57 1-O-(Hexadecan-1-yl)-N-butyl-beta-D-glucofuranosiduronamide 6.15 > 40 
58 1-O-(Hexadecan-1-yl)-N-(decan-1-yl)-beta-D-glucofuranosiduronamide 6.16 > 20 
59 1-O-(Hexadecan-1-yl)-N-(2-hydroxyethyl)-beta-D-glucofuranosiduronamide 6.17 > 50 
60 1-O-(Hexadecan-1-yl)-N-(4-aminobutyl)-beta-D-glucofuranosiduronamide 6.18 60 ± 5 
61 1-O-(Hexadecan-1-yl)-N-(12-aminododecan-1-yl)-beta-D-glucofuranosiduronamide 6.19 > 20 
62 1-O-(Hexadecan-1-yl)-N-(2-carboxyethyl)-beta-D-glucofuranosiduronamide 6.23 2.1 ± 0.1 
63 1-O-(Hexadecan-1-yl)-N-(3-carboxypropyl)-beta-D-glucofuranosiduronamide 6.24 4.2 ± 0.1 
64 1-O-(Hexadecan-1-yl)-5-O-(2,2-dimethylpropanoyl)-beta-D-glucofuranosidurono-6,3-lactone 6.27 > 30 
65 1-O-(Hexadecan-1-yl)-5-O-propanoyl-beta-D-glucofuranosidurono-6,3-lactone 6.28 > 30 
66 1-O-(Dodecan-1-yl)-2-O-(2-carboxyethanoyl)-beta-D-glucofuranosidurono-6,3-lactone 6.41 22 ± 2 
67 1-O-(Hexadecan-1-yl)-2-O-(2-carboxyethanoyl)-beta-D-glucofuranosidurono-6,3-lactone 6.42 2.9 ± 0.1 
68 1-O-(Hexadecan-1-yl)-2-O-(3-carboxypropanoyl)-beta-D-glucofuranosidurono-6,3-lactone 6.43 3.7 ± 0.1 
69 1-O-(Hexadecan-1-yl)-2-O-(2-dimethylaminoethanoyl)-beta-D-glucofuranosidurono-6,3-lactone 6.44 16 ± 2 
70 1-O-(Hexadecan-1-yl)-5-O-(2-carboxyethanoyl)-beta-D-glucofuranosidurono-6,3-lactone 6.47 3.9 ± 0.1 
71 1-O-(Hexadecan-1-yl)-5-O-(3-carboxypropanoyl)-beta-D-glucofuranosidurono-6,3-lactone 6.48 2.3 ± 0.2 
72 1-O-(Hexadecan-1-yl)-2,5-di-O-(2-carboxyethanoyl)-beta-D-glucofuranosidurono-6,3-lactone 6.51 2.3 ± 0.1 
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73 1-O-(Hexadecan-1-yl)-2,5-di-O-(3-carboxypropanoyl)-beta-D-glucofuranosidurono-6,3-lactone 6.52 2.6 ± 0.1 
74 1-O-(Hexadecan-1-yl)-beta-D-glucofuranosidurono-6,3-lactone-2-sulfate 6.54 3.5 ± 0.2 
75 1-O-(Hexadecan-1-yl)-beta-D-glucofuranosidurono-6,3-lactone-2,5-disulfate 6.55 3.1 ± 0.1 
76 6-O-Octanoyl-L-ascorbic acid 7.2a 772 ± 19 
77 6-O-Decanoyl-L-ascorbic acid 7.2b 102 ± 5 
78 6-O-Undecanoyl-L-ascorbic acid 7.2c 72 ± 2 
79 6-O-Dodecanoyl-L-ascorbic acid 7.2d 47 ± 2 
80 6-O-Tridecanoyl-L-ascorbic acid 7.2e 14 ± 1 
81 6-O-Tetradecanoyl-L-ascorbic acid 7.2f 8.4 ± 0.2 
82 6-O-(Biphenyl-4-ylacetyl)-L-ascorbic acid 7.2g 358 ± 15 
83 6-O-[6-(Phenylthio)hexanoyl]ascorbic acid 7.48 607 ± 58 
84 6-O-[6-(Benzylthio)hexanoyl]ascorbic acid 7.49 461 ± 19 
85 6-O-(6-Phenoxyhexanoyl)ascorbic acid 7.50 759 ± 45 
86 6-O-[6-(4-Ethylphenoxy)hexanoyl]ascorbic acid 7.51 280 ± 9 
87 6-O-[6-(4-Phenylphenoxy)hexanoyl]ascorbic acid 7.52 61 ± 1 
88 6-O-[6-(4-Benzyloxyphenoxy)hexanoyl]ascorbic acid 7.53 76 ± 1 
89 6-O-(6-Benzyloxyhexanoyl)ascorbic acid 7.54 437 ± 77 
90 6-O-[6-(4-Phenylphenoxy)hexanoyl]ascorbic acid 7.55 102 ± 2 
91 6-O-{6-[4-(Thiophen-3-yl)phenoxy]hexanoyl}ascorbic acid 7.56 54 ± 2 
92 6-O-{6-[4-(2-Methoxyphenyl)phenyloxy]hexanoyl}ascorbic acid 7.57 58 ± 6 
93 6-O-{6-[4-(4-Methylphenyl)phenyloxy]hexanoyl}ascorbic acid 7.58 24 ± 1 
94 6-O-{6-[4-(2-Methylphenyl)phenyloxy]hexanoyl}ascorbic acid 7.59 67 ± 2 
95 6-O-{6-[4-(4-Hydroxyphenyl)phenyloxy]hexanoyl}ascorbic acid 7.60 66 ± 1 
96 6-O-{6-[4-(3-Hydroxyphenyl)phenyloxy]hexanoyl}ascorbic acid 7.61 125 ± 3 
97 6-O-(11-Phenoxyundecanoyl)ascorbic acid 7.62 31 ± 1 
98 6-O-[11-(4-Phenylphenoxy)undecanoyl]ascorbic acid 7.63 7.5 ± 0.2 
99 6-O-[3-(Decan-1-yloxy)benzoyl]-L-ascorbic acid 7.88 5.4 ± 0.2 
100 6-O-[2-(Hexan-1-yl)dodecanoyl]-L-ascorbic acid 7.91 2.7 ± 0.1 
101 6-O-[2-(2-Phenylethyl)dodecanoyl]-L-ascorbic acid 7.93 6.8 ± 0.2 
102 6-O-[2-(4-Methoxybenzyl)dodecanoyl]-L-ascorbic acid 7.94 5.3 ± 0.3 
103 6-O-[2-(Hexan-1-yl)octadecanoyl]-L-ascorbic acid 7.95 2.2 ± 0.2 
104 6-O-{6-[4-(4-Methoxyphenyl)phenoxy]hexanoyl}-L-ascorbic acid 7.96 37 ± 1 
105 5-O-,6-O-Bis{6-[4-(4-methoxyphenyl)phenoxy]hexanoyl}-L-ascorbic acid 7.96a 8.0 ± 0.6 
106 6-O-{6-[4-(Naphthalen-1-yl)phenoxy]hexanoyl}-L-ascorbic acid 7.97 11 ± 1 
107 5,6-O-Bis{6-[4-(naphthalen-1-yl)phenoxy]hexanoyl}-L-ascorbic acid 7.97a 9.8 ± 1.0 
108 5,6-O-Bis[5-(heptan-1-yloxy)pentanoyl]-L-ascorbic acid 7.98a 17 ± 1 
109 5,6-O-Bis[4-(decan-1-yloxy)benzoyl]-L-ascorbic acid 7.100a 15 ± 1 
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110 6-O-(11-Carboxyundecanoyl)-L-ascorbic acid 7.101 124 ± 6 
111 6-O-{6-[4-(4-Carboxyphenyl)phenoxy]hexanoyl}-L-ascorbic acid 7.102 60 ± 2 
112 6-O-{6-[4-(3-Carboxyphenyl)phenoxy]hexanoyl}-L-ascorbic acid 7.103 94 ± 8 
113 5,6-O-Bis{6-[4-(3-carboxyphenyl)phenoxy]hexanoyl}-L-ascorbic acid 7.103a 4.7 ± 0.4 
114 3-{(1S)-1-[(5R)-3,4-Dihydroxy-2-oxo-2,5-dihydrofuran-5-yl]-2-(dodecanoyloxy)ethyloxy}-3-oxopropanoic acid 7.106 14 ± 1 
115 Bis{(2S)-2-[(5R)-3,4-dihydroxy-2-oxo-2,5-dihydrofuran-5-yl]-2-hydroxyethyl} dodecanedioate 7.110 22 ± 2 
116 Bis{(2S)-2-[(5R)-3,4-dihydroxy-2-oxo-2,5-dihydrofuran-5-yl]-2-hydroxyethyl} tetradecanedioate 7.111 22 ± 1 
117 Bis{(2S)-2-[(5R)-3,4-dihydroxy-2-oxo-2,5-dihydrofuran-5-yl]-2-hydroxyethyl} hexadecanedioate 7.112 7.4 ± 0.2 
118 Bis{(2S)-2-[(5R)-3,4-dihydroxy-2-oxo-2,5-dihydrofuran-5-yl]-2-hydroxyethyl} 13-oxo-12-azatricosanedioate 7.117 55 ± 2 
119 6-O-Hexadecanoyl-2-O-(3-phenylpropanoyl)-L-ascorbic acid 7.118 4.9 ± 0.3 
120 2-O-(3-Carboxypropanoyl)-6-O-hexadecanoyl-L-ascorbic acid 7.119 1.7 ± 0.1 
121 6-O-palmitoylascorbic acid  5000 
122 2-O-(4-Carboxybutanoyl)-6-O-hexadecanoyl-L-ascorbic acid 7.120 2.5 ± 0.2 
123 2-O-(5-Carboxypentanoyl)-6-O-hexadecanoyl-L-ascorbic acid 7.121 2.8 ± 0.1 
124 2,3-O-Bis(5-carboxypentanoyl)-6-O-hexadecanoyl-L-ascorbic acid 7.121a 4.9 ± 0.2 
125 2,3-O-Bis(carboxymethyl)-6-O-dodecanoyl-L-ascorbic acid 7.132 12 ± 1 
126 2-O-(Carboxymethyl)-6-O-dodecanoyl-L-ascorbic acid 7.146 15 ± 0.6 
127 2-O-(Carboxymethyl)-6-O-[11-(4-phenylphenoxy)undecanoyl]-L-ascorbic acid 7.147 2.4 ± 0.1 
128 3-O-(Carboxymethyl)-6-O-dodecanoyl-L-ascorbic acid 7.148 4.8 ± 0.3 
129 indole-3-butanoic acid  2200 
130 1-(3-Phenylpropanoyl)-1H-indole-3-butanoic acid 8.7 72 ± 4 
131 1-Decanoyl-1H-indole-3-butanoic acid 8.8 > 100 
132 N-[2-Deoxy-D-glucopyranose-2-yl]-1-decanoyl-1H-indole-3-butanoic acid amide 8.8a > 200 
133 1-(4-Chlorobenzoyl)-1H-indole-3-butanoic acid 8.9 125 ± 5 
134 1,1'-(p-Phenylendiacetyl)diindol-3,3'-dibutanoic acid 8.19 17 ± 3 
135 1,1'-Octanedioyldiindol-3,3'-dibutanoic acid 8.20 > 70 
136 1,1'-Dodecanedioyldiindol-3,3'-dibutanoic acid 8.21 18 ± 1 
137 1,1'-Hexadecanedioyldiindol-3,3'-dibutanoic acid 8.22 13 ± 1 
138 11-[3-(3-Carboxypropyl)-1H-indol-1-yl]undecanoic acid 8.32 12 ± 1 
139 16-[3-(3-Carboxypropyl)-1H-indol-1-yl]hexadecanoic acid 8.33 16.5 ± 0.4 
140 1-[11-Oxo-11-(thiazol-2-ylamino)undecan-1yl]-1H-indole-3-butanoic acid 8.42 > 100 
141 1-[11-(3-Hydroxyphenylamino)-11-oxoundecan-1yl]-1H-indole-3-butanoic acid 8.45 7.4 ± 3 
142 1-{11-[(S)-2-((R)-3,4-Dihydroxy-2-oxo-2,5-dihydrofuran-5-yl)-2-hydroxyethoxy]-11-oxoundecan-1-yl}-1H-indole-3-butanoic acid 8.46 7.7 ± 0.5 
143 1-[16-(3-Hydroxyphenylamino)-16-oxohexadecan-1-yl]-1H-indole-3-butanoic acid 8.48 > 30 
144 1-{16-[(S)-2-((R)-3,4-Dihydroxy-2-oxo-2,5-dihydrofuran-5-yl)-2-hydroxyethoxy]-16-oxohexadecan-1-yl}-1H-indole-3-butanoic acid 8.49 8.1 ± 0.3 
145 5-Benzyloxy-2-carboxy-1H-indole-3-butanoic acid 8.53 164 ± 1 
146 5-Benzyloxy-1H-indole-3-butanoic acid 8.54 318 ± 9 
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147 5-Hydroxy-1H-indole-3-butanoic acid 8.55 inactive 
148 2-Carboxy-5-(3-phenylpropoxy)-1H-indole-3-butanoic acid 8.62 53 ± 2 
149 2-Carboxy-5-(hexan-1-yloxy)-1H-indole-3-butanoic acid 8.63 44 ± 3 
150 2-Carboxy-5-(dodecan-1-yloxy)-1H-indole-3-butanoic acid 8.64 3.0 ± 0.1 
151 2-Carboxy-5-(hexadecan-1-yloxy)-1H-indole-3-butanoic acid 8.65 2.4 ± 0.1 
152 2-Carboxy-5-(octadecan-1-yloxy)-1H-indole-3-butanoic acid 8.66 6.3 ± 0.2 
153 2-Carboxy-5-(hexadecan-1-yloxy)-1-propyl-1H-indole-3-butanoic acid 8.70 > 50 
154 2-Carboxy-5-(hexadecan-1-yloxy)-1-(pyridin-3-ylmethyl)-1H-indole-3-butanoic acid hydrochloride 8.71 15 ± 1 
155 1-(4-Bromobenzyl)-2-carboxy-5-(hexadecan-1yloxy)-1H-indole-3-butanoic acid 8.72 108 ± 10 
156 5-Benzyloxy-1-(decan-1-yl)-2-ethoxycarbonyl-1H-indole-3-butanoic acid 8.74 > 40 
157 5-Benzyloxy-3-(3-carboxypropyl)-1-(decan-1-yl)-1H-indole-2-carboxylic acid 8.75 20 ± 2 
158 1-(Decan-1-yl)-2-ethoxycarbonyl-5-hydroxy-1H-indole-3-butanoic acid 8.76 7.5 ± 0.6 
159 2-Carboxy-1-(decan-1-yl)-5-hydroxy-1H-indole-3-butanoic acid 8.77 9.3 ± 0.3 
160 N-[2-Deoxy-D-glucopyranose-2-yl]-1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetamide 8.78 189 ± 33 
161 1,4-Phenylene-bis(beta-D-glucopyranoside) 9.8 1608 ± 60 
162 Sodium 2-[((3R,8aR)-1,4-dioxooctahydropyrrolo[1,2-a]pyrazin-3-yl)methylthio]acetate 9.5 > 3000 
163 1-O-(Hexadecan-1-yl)-beta-d-glucofuranosidurono-6,3-lactone 6.6 9.5 ± 0.7 
164 1-O-(Hexadecan-1-yl)-N-(trans-4-carboxycyclohexylmethy)-beta-d-glucofuranosiduronamide 6.25 > 50 
165 1-O-(Hexadecan-1-yl)-beta-D-glucuronic acid 6.26 > 60 
166 6-O-[2-(Decan-1-yloxy)benzoyl]-L-ascorbic acid 7.87 21 ± 1 
167 6-O-[2-(Hexan-1-yl)decanoyl]-L-ascorbic acid 7.89 9.3 ± 0.7 
168 6-O-[2-(Propan-1-yl)dodecanoyl]-L-ascorbic acid 7.90 13 ± 1 
169 6-O-[2-(Decan-1-yl)dodecanoyl]-L-ascorbic acid 7.92 6.4 ± 0.2 
170 6-O-[5-(Heptan-1-yloxy)pentanoyl]-L-ascorbic acid 7.98 257 ± 9 
171 6-O-[6-(Hexan-1-yloxy)hexanoyl]-L-ascorbic acid 7.99 221 ± 20 
172 5,6-O-Bis[6-(hexan-1-yloxy)hexanoyl]-L-ascorbic acid 7.99a 26 ± 3 
173 6-O-[4-(Decan-1-yloxy)benzoyl]-L-ascorbic acid 7.100 8.3 ± 0.3 
174 6-O-(Dodecan-1-yl)-L-ascorbic acid 7.127 26 ± 1 
175 6-O-(Octadecan-1-yl)-L-ascorbic acid 7.128 1.6 ± 0.1 
176 2-O-(Dodecan-1-yl)-L-ascorbic acid 7.139 40 ± 2 
177 2-O-(Hexadecan-1-yl)-L-ascorbic acid 7.140 4.1 ± 0.2 
178 3-O-(Dodecan-1-yl)-L-ascorbic acid 7.149 26 ± 1 
179 3-O-(Tetradecan-1-yl)-L-ascorbic acid 7.150 6.0 ± 0.2 
180 4-[1-(4-methoxybenzoyl)-1H-indol-3-yl]butanoic acid 8.10 > 400 
181 4-[1-(Biphenyl-4-ylcarbonyl)-1H-indol-3-yl]butanoic acid 8.11 > 60 
182 4-[1-(2-(4-methoxyphenyl)acetyl)-1H-indol-3-yl]butanoic acid 8.12 > 250 
183 4-[1-(2-(4-hydroxyphenyl)acetyl)-1H-indol-3-yl]butanoic acid 8.23 490 ± 30 
370 Appendix II 
184 1-[11-Oxo-11-(4-phenylpiperazin-1-yl)undecan-1yl]-1H-indole-3-butanoic acid ammonium salt 8.43 > 50 
185 1-[11-Oxo-11-(piperazin-1-yl)undecan-1yl]-1H-indole-3-butanoic ammonium salt 8.44 61 ± 1 
186 1-[16-Oxo-16-(4-phenylpiperazin-1-yl)hexadecan-1yl]-1H-indole-3-butanoic acid trifluoroacetic acid salt 8.47 > 30 
187 Hexadecyl 2-(trimethylammonio)ethyl phosphate 9.25 1.6 ± 0.3 
188 Octadecyl 2-(trimethylammonio)ethyl phosphate 9.26 1.9 ± 0.1 
189 2-(1-Methylpiperidinium-1-yl)ethyl octadecyl phosphate 9.27 0.88 ± 0.1 
190 1,1-Dimethylpiperidinium-4-yl octadecyl phosphate 9.28 1.5 ± 0.2 
191 (E)-3-(1-Hydroxyhexadecylidene)-1-methylpyrrolidine-2,4-dione Melophlin A 6.6 ± 3 
192 (5S,E)-3-(1-Hydroxy-4-methyldodecylidene)-1,5-dimethylpyrrolidine-2,4-dione Melophlin B 75 ± 7 
193 (E)-3-(1-Hydroxy-5-methyldodecylidene)-1,5-dimethylpyrrolidine-2,4-dione Melophlin C 33 ± 2 
194 (E)-3-(1-Hydroxytetradecylidene)-1-methylpyrrolidine-2,4-dione Melophlin G 14 ± 1 
195 (E)-3-(1-Hydroxyhexadecylidene)-1,5-dimethylpyrrolidine-2,4-dione Melophlin P 9.0 ±1.0 
196 (E)-3-(1-Hydroxy-13-methyltetradecylidene)-1,5-dimethylpyrrolidine-2,4-dione Melophlin Q > 250 
197 (E)-3-(1-Hydroxy-12-methyltetradecylidene)-1,5-dimethylpyrrolidine-2,4-dione Melophlin R 18 ± 1 
198 Calcium bis[(E)-3-(1-hydroxyhexadecylidene)-1-methylpyrrolidine-2,4-dione] Ca(Melophlin A)2 5.0 ± 0.2 
199 (E)-3-Dodec-5-enoyl-4-hydroxy-5-methylenefuran-2(5H)-one Agglomerin B > 100 
200 Dodecyl 3,4,5-trihydroxybenzoate Chapter 5 13 ± 1 
201 2-[1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-inden-3-yl]acetic acid 5-Indomethacin 350 
202 2-[2-(2,6-Dichlorophenylamino)phenyl]acetic acid 5-Diclofenac 161 ± 11 
203 sodium 5,5'-(2-hydroxypropane-1,3-diyl)bis(oxy)bis(4-oxo-4H-chromene-2-carboxylate) 5-DSCG 1208 ± 81 
204 3-(4-hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)propan-1-one 5-Phloretin 213 ± 8 
205 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one 5-Kaempferol 237 ± 15 
206 (2R,3R)-2-((2R,3R)-3-(3,4-Dimethoxyphenyl)-2-(hydroxymethyl)-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-3,5,7-trihydroxychroman-4-
one 5-Sylibinin 296 ± 18 
207 (3β,18α)-30-Hydroxy-11,30-dioxoolean-12-en-3-yl 2-O-β-D-glucopyranuronosyl-β-D-glucopyranosiduronic acid 5-Glycyrrhizic acid 46 ± 2 
208 3β-Hydroxy-11-oxoolean-12-en-30-oic acid 5-Glycyrrhetinic 
acid 54 ± 3 
209 (2S,4aS,6aS,6bR,8aR,10S,12aS,12bR,14bR)-10-(3-Carboxypropanoyloxy)-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-
1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carboxylic acid 5-Carbenoxolone 20 ± 1 
210 1-(Pyridin-3-ylmethyl)indoline 1 37% @ 3 mM 
211 1-(Pyridin-3-ylmethyl)-1H-indole 7 65% @ 2 mM 
212 (1H-Indol-1-yl)(pyridin-3-yl)methanone 8 60% @ 1.5 mM 
213 1-Nicotinoyl-1H-indole-2-carboxylic acid 19 45% @ 3.2 mM 
214 1-Nicotinoyl-1H-indole-3-carboxylic acid 20 80% @ 3.3 mM 
215 2-(1-Nicotinoyl-1H-indol-3-yl)acetic acid 21 50% @ 3.2 mM 
216 4-(1-Nicotinoyl-1H-indol-3-yl)butanoic acid 22 80% @ 3.2 mM 
217 1-Nicotinoyl-1H-indole-5-carboxylic acid 23 1850 ± 50 
218 1-(4-Chlorobenzoyl)-1H-indole-2-carboxylic acid 34 80% @3.2 mM 
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219 1-(3-Chlorobenzoyl)-1H-indole-2-carboxylic acid 35 950 ± 10 
220 1-(4-Chlorobenzoyl)-1H-indole-3-carboxylic acid 36 70% @ 3.2 mM 
221 1-(3-Chlorobenzoyl)-1H-indole-3-carboxylic acid 37 50% @ 3.2 mM 
222 2-[1-(4-Chlorobenzoyl)-1H-indol-3-yl]acetic acid 38 580 ± 40 
223 2-[1-(3-Chlorobenzoyl)-1H-indol-3-yl]acetic acid 39 480 ± 30 
224 4-[1-(4-Chlorobenzoyl)-1H-indol-3-yl]butanoic acid 40 125 ± 5 
225 4-[1-(3-Chlorobenzoyl)-1H-indol-3-yl]butanoic acid 41 330 ± 10 
226 1-(4-Chlorobenzoyl)-1H-indole-5-carboxylic acid 42 20% @ 600 µM 
227 1-(3-Chlorobenzoyl)-1H-indole-5-carboxylic acid 43 45% @ 700 µM 
228 4-[1-(4-Methoxybenzoyl)-1H-indol-3-yl]butanoic acid 45 70% @ 1.8 mM 
229 4-[1-(Biphenyl-4-ylcarbonyl)-1H-indol-3-yl]butanoic acid 51 60% @120 µM 
230 4-{1-[2-(Biphenyl-4-yl)acetyl]-1H-indol-3-yl}butanoic acid 52 30% @ 200 µM 
231 4-[1-(4-Benzoylbenzoyl)-1H-indol-3-yl]butanoic acid 53 20% @ 170 µM 
232 4-[1-(2-Naphthoyl)-1H-indol-3-yl]butanoic acid 54 80% @ 100 µM 
233 4-{1-[2-(4-Methoxyphenyl)acetyl]-1H-indol-3-yl}butanoic acid 55 30% @ 270 µM 
234 4-[1-(4-Hydroxybenzoyl)-1H-indol-3-yl]butanoic acid 58 490 ± 30 
235 5-Methoxy-2-(4-methoxyphenyl)-3-methylindole 9.4b 880 
236 5-Hydroxy-2-(4-hydroxyphenyl)indole 9.6a 75% @ 1000 µM 
237 6-Hydroxy-2-(4-hydroxyphenyl)-3-methylindole 9.6b 330 
238 5-Hydroxy-2-(4-hydroxyphenyl)-3-methylindole 9.6c 740 
239 5-Hydroxy-2-(4-hydroxyphenyl)-1-methyl-3-methylindole 9.6d 480 
240 5-Hydroxy-2-(4-hydroxyphenyl)-3-methyl-1-propylindole 9.6e 220 
241 5-Hydroxy-2-(4-hydroxyphenyl)-3-methyl-1-pentylindole 9.6f 23 
242 5-Hydroxy-2-(4-hydroxyphenyl)-1-heptyl-3-methylindole 9.6g 26 
243 1-Decyl-2-(4-hydroxyphenyl)-1H-indol-6-ol 9.23 13 
244 1-Decyl-2-(4-hydroxyphenyl)-1H-indol-6-yl sulfamate 9.24 8 
245 2-O-,3-O-Dimethyl-L-ascorbic acid 4.6 inactive 
246 2-O-,3-O-Dibenzyl-L-ascorbic acid 4.7 355 ± 59 
247 2-O-,3-O-Ethan-1,2-diyl-L-ascorbic acid 4.8 24% @ 2000 µM 
248 2-O-,3-O-Dimethyl-6-O-hexadecanoyl-L-ascorbic acid 4.9 5% @ 160 µM 
249 2-O-,3-O-Dibenzyl-6-O-hexadecanoyl-L-ascorbic acid 4.10 inactive 
250 2-O-,3-O-Ethan-1,2-diyl-6-O-hexadecanoyl-L-ascorbic acid 4.11 32% @ 190 µM 
251 6-O-(2,2-Dimethylpropanoyl)-L-ascorbic acid 4.18 43% @ 1100 µM 
252 6-O-Hexanoyl-L-ascorbic acid 4.19 475 ± 16 
253 6-O-Dodecanoyl-L-ascorbic acid 4.20 6.71 ± 0.28 
254 6-O-Hexadecanoyl-L-ascorbic acid 4.21 4.22 ± 0.13 
255 6-O-Octadecanoyl-L-ascorbic acid 4.22 0.93 ± 0.11 
372 Appendix II 
256 6-O-Benzoyl-L-ascorbic acid 4.23 131.6 ± 5.9 
257 1-(2-Thioxo-1H-benzo[d]imidazol-1-yl)ethanone 5.3 20% @ 460 µM 
258 1-(2-Thioxo-1H-benzo[d]imidazol-1-yl)propan-1one 5.4 4% @ 180 µM 
259 1-(2-Thioxo-1H-benzo[d]imidazol-1-yl)butan-1-one 5.5 7% @ 190 µM 
260 1-(2-Thioxo-1H-benzo[d]imidazol-1-yl)hexan-1-one 5.6 14% @ 170 µM 
261 1-(2-Thioxo-1H-benzo[d]imidazol-1-yl)-3-phenylpropan-1-one 5.7 5% @ 100 µM 
262 (3-Chlorophenyl)(2-thioxo-1H-benzo[d]imidazol-1-yl)methanone 5.8 16% @ 400 µM 
263 2-(Ethylsulfanyl)-1H-benzo[d]imidazole 5.9 18% @ 2000 µM 
264 1-[2-(Ethylsulfanyl)-1H-benzo[d]imidazol-1-yl]ethanone 5.12 4% @ 420 µM 
265 1-[2-(Heptylsulfanyl)-1H-benzo[d]imidazol-1-yl]ethanone 5.13 inactive 
266 1-(2-(Benzylsulfanyl)-1H-benzo[d]imidazol-1-yl)ethanone 5.14 4% @ 100 µM 
267 1-[2-(4-Methoxybenzylsulfanyl)-1H-benzo[d]imidazol-1-yl]ethanone 5.15 inactive 
268 1-(3-Acetyl-1,2-dihydro-2-thioxobenzo[d]imidazol-1-yl)hexan-1-one 5.16 50% @ 49 µM 
269 1,3-Diacetyl-1H-benzo[d]imidazol-2(3H)-one 5.18 10% @ 200 µM 
270 1,3-Diethyl-1H-benzo[d]imidazol-2(3H)-one 5.19 40% @ 4900 µM 
271 1,3-Diethyl-1H-benzo[d]imidazole-2(3H)-thione 5.20 inactive 
272 1-Ethyl-1H-benzo[d]imidazole-2(3H)-thione 5.24 19% @ 4200 µM 
273 1-(3-Ethyl-1,2-dihydro-2-thioxobenzo[d]imidazole-1-yl)ethanone 5.25 10% @ 380 µM 
274 Methyl 2-thioxo-3H-benzo[d]imidazole-5-carboxylate 5.27 25% @ 4500 µM 
275 1-(2-Methyl-1H-benzo[d]imidazol-1-yl)propan-1-one 5.29 12% @ 2000 µM 
276 1-(2-Thioxobenzo[d]oxazol-3(2H)-yl)ethanone 6.5 125 ± 5 
277 1-(2-Thioxobenzo[d]oxazol-3(2H)-yl)propan-1-one 6.6 128 ± 5 
278 1-(2-Thioxobenzo[d]oxazol-3(2H)-yl)hexan-1-one 6.7 51% @ 130 µM 
279 1-(2-Thioxobenzo[d]oxazol-3(2H)-yl)decan-1-one 6.8 41% @ 100 µM 
280 1-(2-Thioxobenzo[d]oxazol-3(2H)-yl)hexadecan-1-one 6.9 23% @ 63 µM 
281 2-Phenyl-1-(2-thioxobenzo[d]oxazol-3(2H)-yl)ethanone 6.10 260 ± 41 
282 3-Phenyl-1-(2-thioxobenzo[d]oxazol-3(2H)-yl)propan-1-one 6.11 15 ± 1 
283 4-Phenyl-1-(2-thioxobenzo[d]oxazol-3(2H)-yl)butan-1-one 6.12 47% @ 100 µM 
284 (E)-3-Phenyl-1-(2-thioxobenzo[d]oxazol-3(2H)-yl)prop-2-en-1-one 6.13 9% @ 80 µM 
285 3-Cyclohexyl-1-(2-thioxobenzo[d]oxazol-3(2H)-yl)propan-1-one 6.14 227 ± 122 
286 2-Phenoxy-1-(2-thioxobenzo[d]oxazol-3(2H)-yl)ethanone 6.15 213 ± 30 
287 Benzyl 2-thioxobenzo[d]oxazol-3(2H)-carboxylate 6.16 inactive 
288 3-Methanesulfonylbenzoxazole-2-thione 6.19 inactive 
289 3-Acetylbenzo[d]oxazol-2(3H)-one 6.21 inactive 
290 3-Hexanoylbenzo[d]oxazol-2(3H)-one 6.22 inactive 
291 3-Ethylbenzo[d]oxazole-2(3H)-thione 6.24 46% @ 400 µM 
292 Methyl 2-sulfanylbenzo[d]oxazole-5-carboxylate 6.28 1299 ± 223 
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293 Methyl 3-(3-phenylpropanoyl)-2,3-dihydro-2-thioxobenzo[d]oxazole-5-carboxylate 6.29 56% @ 200 µM 
294 2-Sulfanylbenzo[d]oxazole-5-sulfonic acid 6.30 781 ± 100 
295 N,N-Dimethylbenzo[d]oxazol-2-amine 6.33 20% @ 5700 µM 
296 1-(2-Methylbenzofuran-3-yl)ethanone 6.35 43% @ 2000 µM 
297 1-(2-Methylbenzofuran-3-yl)-3-phenylpropan-1-one 6.36 inactive 
298 1-(5-Amino-2-methyl-1H-indol-1-yl)propan-1-one 7.20 20% @ 2000 µM 
299 1-(5-Amino-2-methyl-1H-indol-1-yl)hexan-1-one 7.21 42% @ 600 µM 
300 1-(5-Amino-2-methyl-1H-indol-1-yl)decan-1-one 7.22 12% @ 100 µM 
301 1-(5-Amino-2-methyl-1H-indol-1-yl)-3-phenylpropan-1-one 7.23 3 % @ 200 µM 
302 1-(5-Amino-2-methyl-1H-indol-1-yl)-4-phenylbutan-1-one 7.24 10% @ 200 µM 
303 5-Amino-2-methyl-1H-indole 7.25 17% @ 5000 µM 
304 5-Amino-2-methyl-1-propyl-1H-indole 7.34 15% @ 2000 µM 
305 5-Amino-1-hexyl -2-methyl-1H-indole 7.35 334 ± 6 
306 5-Amino-2-methyl-1-octyl-1H-indole 7.36 285 ± 12 
307 5-Amino-1-decyl-2-methyl-1H-indole 7.37 47 ± 2 
308 5-Amino-2-methyl-1-(3-phenylpropyl)-1H-indole 7.38 31% @ 420 µM 
309 5-Amino-2-methyl-1-(4-phenylbenzyl)-1H-indole 7.39 13% @ 200 µM 
310 Ethyl 5-(5-amino-2-methyl-1H-indol-1-yl)pentanoate 7.40 25% @ 1600 µM 
311 N-(1-Decyl-2-methyl-1H-indol-5-yl)methanesulfonamide 7.47 16% @ 50 µM 
312 Ethyl 5-(5-amino-2-methyl-3-m-chlorobenzoyl-1H-indol-1-yl)pentanoate 7.54 20% @ 100 µM 
313 Ethyl 5-(5-amino-2-methyl-3-propanoyl-1H-indol-1-yl)pentanoate 7.55 52% @ 1600 µM 
314 1-(5-Amino-1-hexyl-2-methyl-1H-indol-3-yl)propan-1-one 7.56 60% @ 400 µM 
315 1-(1H-Indol-1-yl)-3-phenylpropan-1-one 7.60 inactive 
316 1-(3-Acetyl-1H-indol-yl)-3-phenylpropan-1-one 7.61 inactive 
317 1-(3-Phenylpropanoyl)-1H-indole-5-carboxylic acid 7.62 12% @ 200 µM 
318 2-Methyl-1H-indole-5-sulfonic acid 7.65 2310 ± 66 
319 1,3-Diacetylbenzimidazoline-2-thione 5.1 160 
320 1H-Benzo[d]imidazole-2(3H)-thione 5.2 1148 ± 50 
321 2-Methyl-1H-benzo[d]imidazole 5.28 inactive 
322 Benzo[d]oxazole-2(3H)-thione 6.1 42% @ 3800 µM 
323 Oxazolo[4,5-b]pyridine-2(3H)-thione 6.37 10% @ 2200 µM 
324 Benzo[d]thiazole-2(3H)-thione 6.38 45% @ 3700 µM 
325 (Z)-1-(3-Methylbenzo[d]thiazol-2(3H)-ylidene)hydrazine 6.39 12% @ 2000 µM 
326 2-(4-Hydroxyphenyl)-3-methyl-1H-indol-5-ol 6.40 740 
327 2-(4-hydroxyphenyl)-3-methyl-1-propyl-1H-indol-5-ol 6.41 220 
328 1-Heptyl-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol 6.42 26 
329 5,6-Di-O-dodecanoyl-L-ascorbic acid 7a no data 
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330 5,6-Di-O-hexadecanoyl-L-ascorbic acid 7b no data 
331 5,6-Di-O-{2-[2-(2-methoxyethoxy)ethoxy]acetyl}-L-ascorbic acid 7c > 120 
332 6-O-Dodecanoyl-L-ascorbic acid 8a 47 ± 2 
333 6-O-{2-[2-(2-Methoxyethoxy)ethoxy]acetyl}-L-ascorbic acid 8c no data 
334 6-O-Dodecanoyl-5-O-ethanoyl-L-ascorbic acid 10d 27 ± 1 
335 6-O-Dodecanoyl-5-O-propanoyl-L-ascorbic acid 10e 42 ± 2 
336 5-O-Butanoyl-6-O-dodecanoyl-L-ascorbic acid 10f 23 ± 1 
337 6-O-Dodecanoyl-5-O-pentanoyl-L-ascorbic acid 10g 22 ± 2 
338 6-O-Dodecanoyl-5-O-octanoyl-L-ascorbic acid 10h 13.3 ± 0.3 
339 5-O-Decanoyl-6-O-dodecanoyl-L-ascorbic acid 10i 9.2 ± 0.8 
340 6-O-Dodecanoyl-5-O-hexadecanoyl-L-ascorbic acid 10j 1.9 ± 0.7 
341 5-O-[5-(1,3-Dioxo-1,3-dihydroisoindol-2-yl)pentanoyl]-6-O-dodecanoyl-L-ascorbic acid 10k 7 ± 1 
342 6-O-Dodecanoyl-5-O-(3-phenylpropanoyl)-L-ascorbic acid 10l 7.9 ± 0.4 
343 5-O-(3-Carboxypropanoyl)-6-O-dodecanoyl-L-ascorbic acid 10m no data 
344 5-O-(4-Acetamidobutanoyl)-6-O-dodecanoyl-L-ascorbic acid 10n 24 ± 2 
345 6-O-Dodecanoyl-5-O-{2-[2-(2-methoxyethoxy)ethoxy]acetyl}-L-ascorbic acid 10o 11.6 ± 0.8 
346 2-O-[5-(1,3-Dioxo-1,3-dihydroisoindol-2-yl)pentanoyl]-6-O-hexadecanoyl-L-ascorbic acid 11 2.7 ± 0.2 
347 6-O-Hexadecanoyl-2,3-dihydro-L-ascorbic acid 12 90 ± 10 
 
The molecules of the present library (“library 1“) were selected from: compounds 1-19: cf. chapter 7; compounds 20-38: Textor, C., Hemmstoffe humaner und bakterieller 
Hyaluronidasen: Synthese und Struktur-Wirkungs-Beziehungen von N-Acylindolen, diploma thesis, University of Regensburg, Regensburg, 2008.; compounds 39-209: 
Spickenreither, M., Inhibitors of bacterial and mammalian hyaluronidases: design, synthesis and structure-activity relationships with focus on human enzymes, doctoral thesis, 
University of Regensburg, Regensburg, 2007.; compounds 210-234: Spickenreither, M. Hemmstoffe bakterieller Hyaluronat Lyasen: Synthese und Struktur-Wirkungs-Beziehungen 
von N-Acylindolen, diploma thesis, University of Regensburg, Regensburg, 2004.; compounds 235-244: Salmen, S. Inhibitors of bacterial and mammalian hyaluronidase, Synthesis 
and structure-activity relationships, doctoral thesis, University of Regensburg, Regensburg, 2003.; compounds 245-328: Braun, S., New inhibitors of bacterial hyaluronidase - 
synthesis and structure-activity relationships, doctoral thesis, University of Regensburg, Regensburg, 2005.; compounds 329-347: Binder, F., Hemmstoffe humaner 
Hyaluronidasen: Synthese und Untersuchung an rekombinanten Enzymen, diploma thesis, University of Regensburg, Regensburg, 2007. 
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B.1.2 Compound library of hyaluronidase inhibitors (library 2) 
 
Compound library of hyaluronidase inhibitors (32 inhibitors, target molecule: SagHyal4755). The substances served as templates for the exploration 
of bioisosteric molecules. 
Index Name ID IC50 (µM) 
SagHyal4755 
1 1-Decyl-2-(4-hydroxyphenyl)-3-methyl-1H-indol-6-ol UR-CT201 19 
2 2-(4-Hydroxyphenyl)-3-methyl-1-(perfluorobenzyl)-1H-indol-5-ol UR-CT205 19 
3 2-(4-Hydroxyphenyl)-3-methyl-1-(perfluorobenzyl)-1H-indol-6-ol UR-CT206 20 
4 2-(4-Hydroxyphenyl)-3-methyl-1-(perfluorobenzyl)-4-(trifluoromethyl)-1H-indol-6-ol UR-CT207 6 
5 2-(4-Hydroxyphenyl)-3-methyl-1-(6-(pyrrolidin-1-yl)hexyl)-1H-indol-5-ol UR-CT216 19 
6 2-(4-Hydroxyphenyl)-3-methyl-1-(4-(pyrrolidin-1-yl)butyl)-1H-indol-5-ol UR-CT218 330 
7 1-Butyl-2-(4-hydroxyphenyl)-1H-indol-6-ol UR-CT224 66 
8 1-Heptyl-2-(4-hydroxyphenyl)-1H-indol-6-ol UR-CT225 18 
9 1-(4-Aminobenzyl)-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol UR-CT316 49 
10 4-Chloro-2-(2,6-dichloro-4-hydroxyphenyl)-1-ethyl-1H-indol-6-ol UR-CT317 7 
11 1-Ethyl-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol UR-CT318 120 
12 2-(3-Hydroxyphenyl)-3-methyl-1-propyl-1H-indol-5-ol UR-CT319 105 
13 3-Ethyl-2-(4-hydroxyphenyl)-1-propyl-1H-indol-6-ol UR-CT321 67 
14 4-Chloro-2-(2,6-dichloro-4-hydroxyphenyl)-1-propyl-1H-indol-6-ol UR-CT323 10 
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15 2-(4-Hydroxyphenyl)-1,3-dimethyl-1H-indol-5-ol UR-CT324 370 
16 1-Benzyl-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol UR-CT340 31 
17 4-Chloro-2-(4-hydroxyphenyl)-3-methylbenzo[b]thiophen-5-ol UR-CT344 24 
18 4-Chloro-3-ethyl-2-(4-hydroxyphenyl)benzo[b]thiophen-5-ol UR-CT345 15 
19 1-(4-Azidobenzyl)-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol UR-CT348 22 
20 2-(4-Hydroxyphenyl)-3-propylbenzo[b]thiophen-5-ol UR-CT352 38 
21 1-(4-Bromobenzyl)-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol UR-CT355 19 
22 1-(Biphenyl-4-ylmethyl)-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol UR-CT356 21 
23 1-Ethyl-3-methyl-2-phenyl-1H-indol-6-ol UR-CT370 750 
24 3-(4-Hydroxybenzyl)benzo[b]thiophen-5-ol UR-CT372 150 
25 3-(4-Hydroxybenzyl)-2-methylbenzo[b]thiophen-6-ol UR-CT383 119 
26 2-(3-Hydroxyphenyl)-1-methyl-1H-indol-5-ol UR-CT385 460 
27 4-(5-Ethyl-7-methyl-5H-[1,3]dioxolo[4,5-f]indol-6-yl)phenol UR-CT397 95 
28 2-(4-Hydroxyphenyl)-3-methyl-1-[4-(piperidin-1-ylmethyl)benzyl]-1H-indol-5-ol UR-CT398 120 
29 1-(4-Fluorobenzyl)-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol UR-CT402 43 
30 2-(4-Hydroxyphenyl)-3-methyl-1-(4-methylbenzyl)-1H-indol-5-ol UR-CT403 46 
31 4-Chloro-2-(4-hydroxyphenyl)-3-propylbenzo[b]thiophen-5-ol UR-CT404 17 
32 1-(4-Chlorobenzyl)-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol UR-CT423 19 
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B.2 Screening plates ori.hya.1-9 
B.2.1 Starting materials of plates ori.hya.1-9 
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B.2.2 Mass spectal analysis of plates ori.hya.1-9 
ori.hya.1 
 
 
 
  
 
 
 
 
Well Peak width Expected mass Found mass Intensity 
A1         
B1         
C1         
D1         
E1         
F1         
G1         
H1         
A2 0 398.23 g/mol 0.00 g/mol 0 
B2 0 369.21 g/mol 0.00 g/mol 0 
C2 0 388.16 g/mol 0.00 g/mol 0 
D2 0 341.17 g/mol 0.00 g/mol 0 
E2 0,14 400.30 g/mol 400.24 g/mol 7995,78 
F2 0 383.22 g/mol 0.00 g/mol 0 
G2 0 372.19 g/mol 0.00 g/mol 0 
H2 0 387.19 g/mol 0.00 g/mol 0 
A3 0,02 392.22 g/mol 392.19 g/mol 520,23 
B3 0 369.21 g/mol 0.00 g/mol 0 
C3 0 399.23 g/mol 0.00 g/mol 0 
D3 0 339.19 g/mol 0.00 g/mol 0 
E3 0,08 392.22 g/mol 392.18 g/mol 1860,13 
F3 0 388.16 g/mol 388.14 g/mol 69,78 
G3 0 384.24 g/mol 0.00 g/mol 0 
H3 0 384.21 g/mol 0.00 g/mol 0 
A4 0,04 368.22 g/mol 368.18 g/mol 1043,63 
B4 0,04 347.27 g/mol 347.22 g/mol 5837,65 
C4 0 393.24 g/mol 0.00 g/mol 0 
D4 0,02 385.18 g/mol 385.15 g/mol 577,95 
E4 0 385.25 g/mol 0.00 g/mol 0 
F4 0 333.21 g/mol 0.00 g/mol 0 
G4 0,02 379.19 g/mol 379.18 g/mol 442,79 
H4 0 394.24 g/mol 394.20 g/mol 4391,94 
A5 0 383.18 g/mol 0.00 g/mol 0 
B5 0,04 371.16 g/mol 371.23 g/mol 928,86 
C5 0 340.18 g/mol 0.00 g/mol 0 
D5 0 332.22 g/mol 0.00 g/mol 0 
E5 0,04 398.20 g/mol 398.17 g/mol 989,05 
F5 0,02 369.21 g/mol 369.21 g/mol 435,95 
G5 0 374.19 g/mol 0.00 g/mol 0 
H5 0 397.24 g/mol 0.00 g/mol 0 
A6 0 371.16 g/mol 371.14 g/mol 71,27 
B6 0 388.30 g/mol 0.00 g/mol 0 
C6 0 369.20 g/mol 0.00 g/mol 0 
D6 0,04 396.19 g/mol 396.16 g/mol 918,62 
E6 0 399.16 g/mol 399.12 g/mol 173,78 
F6 0,08 371.16 g/mol 371.13 g/mol 1774,75 
G6 0,02 393.21 g/mol 393.16 g/mol 462,78 
H6 0 345.20 g/mol 0.00 g/mol 0 
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A7 0 375.27 g/mol 0.00 g/mol 0 
B7 0,02 368.22 g/mol 368.19 g/mol 452,38 
C7 0 361.25 g/mol 0.00 g/mol 0 
D7 0 341.16 g/mol 0.00 g/mol 0 
E7 0 398.23 g/mol 0.00 g/mol 0 
F7 0 397.09 g/mol 0.00 g/mol 0 
G7 0,02 348.26 g/mol 348.21 g/mol 516,15 
H7 0 393.21 g/mol 0.00 g/mol 0 
A8 0,1 354.20 g/mol 354.18 g/mol 2343,29 
B8 0 390.20 g/mol 390.19 g/mol 31,07 
C8 0 379.19 g/mol 0.00 g/mol 0 
D8 0 247.11 g/mol 247.07 g/mol 701,69 
E8 0 368.22 g/mol 368.19 g/mol 52,83 
F8 0 383.22 g/mol 0.00 g/mol 0 
G8 0 355.19 g/mol 355.18 g/mol 16,59 
H8 0 379.17 g/mol 379.14 g/mol 3442,3 
A9 0 375.13 g/mol 375.12 g/mol 13,81 
B9 0 369.21 g/mol 0.00 g/mol 0 
C9 0 376.25 g/mol 0.00 g/mol 0 
D9 0 379.23 g/mol 0.00 g/mol 0 
E9 0 385.21 g/mol 0.00 g/mol 0 
F9 0 369.05 g/mol 0.00 g/mol 0 
G9 0 371.16 g/mol 371.12 g/mol 16,46 
H9 0,02 391.10 g/mol 391.17 g/mol 452,89 
A10 0 392.16 g/mol 0.00 g/mol 0 
B10 0 371.22 g/mol 0.00 g/mol 0 
C10 0 399.23 g/mol 0.00 g/mol 0 
D10 0 388.19 g/mol 0.00 g/mol 0 
E10 0 370.24 g/mol 0.00 g/mol 0 
F10 0,02 382.24 g/mol 382.20 g/mol 499,37 
G10 0 347.27 g/mol 0.00 g/mol 0 
H10 0 362.23 g/mol 0.00 g/mol 0 
A11 0,04 323.16 g/mol 323.14 g/mol 1093,01 
B11 0 389.22 g/mol 0.00 g/mol 0 
C11 0 361.29 g/mol 0.00 g/mol 0 
D11 0 362.23 g/mol 0.00 g/mol 0 
E11 0 397.10 g/mol 0.00 g/mol 0 
F11 0 360.26 g/mol 0.00 g/mol 0 
G11 0 368.22 g/mol 368.19 g/mol 18,13 
H11 0,04 354.20 g/mol 354.17 g/mol 1025,36 
A12 0 387.27 g/mol 0.00 g/mol 0 
B12 0 398.07 g/mol 0.00 g/mol 0 
C12 0,04 384.21 g/mol 384.18 g/mol 918,28 
D12 0 391.27 g/mol 0.00 g/mol 0 
E12 0,04 397.24 g/mol 397.20 g/mol 1029,91 
F12 0,02 368.22 g/mol 368.20 g/mol 425,76 
G12 0,02 392.22 g/mol 392.19 g/mol 569,46 
H12 0,02 393.13 g/mol 393.11 g/mol 631,62 
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ori.hya.2 
 
 
 
  
 
 
 
 
Well Peak width Expected mass Found mass Intensity 
A1         
B1         
C1         
D1         
E1         
F1         
G1         
H1         
A2 0,02 306.16 g/mol 306.09 g/mol 404,1 
B2 0,02 379.19 g/mol 379.17 g/mol 549,56 
C2 0 397.24 g/mol 0.00 g/mol 0 
D2 0,08 389.24 g/mol 389.19 g/mol 4105,58 
E2 0 319.19 g/mol 0.00 g/mol 0 
F2 0 366.19 g/mol 0.00 g/mol 0 
G2 0 319.14 g/mol 319.13 g/mol 56,33 
H2 0 383.12 g/mol 0.00 g/mol 0 
A3 0 392.10 g/mol 0.00 g/mol 0 
B3 0 373.14 g/mol 373.12 g/mol 73,3 
C3 0 319.19 g/mol 319.20 g/mol 111,34 
D3 0 391.12 g/mol 391.10 g/mol 87,52 
E3 0 369.21 g/mol 369.19 g/mol 21,14 
F3 0 386.16 g/mol 386.14 g/mol 2962,63 
G3 0 379.23 g/mol 0.00 g/mol 0 
H3 0,02 381.18 g/mol 381.14 g/mol 496,75 
A4 0,02 343.23 g/mol 343.21 g/mol 427,46 
B4 0 380.22 g/mol 0.00 g/mol 0 
C4 0 315.15 g/mol 0.00 g/mol 0 
D4 0,04 355.19 g/mol 355.19 g/mol 861,15 
E4 0 369.10 g/mol 369.08 g/mol 16,07 
F4 0,1 389.24 g/mol 389.19 g/mol 13800,3 
G4 0 353.21 g/mol 0.00 g/mol 0 
H4 0 366.16 g/mol 0.00 g/mol 0 
A5 0 384.26 g/mol 0.00 g/mol 0 
B5 0 393.10 g/mol 0.00 g/mol 0 
C5 0 383.22 g/mol 0.00 g/mol 0 
D5 0,06 373.20 g/mol 373.17 g/mol 1453,1 
E5 0,12 394.22 g/mol 394.17 g/mol 10862,64 
F5 0 377.25 g/mol 0.00 g/mol 0 
G5 0,1 399.16 g/mol 399.13 g/mol 11790,12 
H5 0 372.15 g/mol 0.00 g/mol 0 
A6 0,1 354.20 g/mol 354.17 g/mol 2582,51 
B6 0,02 368.22 g/mol 368.20 g/mol 460,69 
C6 0 398.17 g/mol 398.13 g/mol 96,66 
D6 0,02 309.14 g/mol 309.14 g/mol 470,67 
E6 0 320.13 g/mol 320.12 g/mol 200,22 
F6 0,04 375.22 g/mol 375.18 g/mol 17601,96 
G6 0,08 379.23 g/mol 379.19 g/mol 10698,72 
H6 0 397.19 g/mol 0.00 g/mol 0 
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A7 0 343.18 g/mol 0.00 g/mol 0 
B7 0,02 383.22 g/mol 383.19 g/mol 489,74 
C7 0 355.19 g/mol 0.00 g/mol 0 
D7 0 314.16 g/mol 0.00 g/mol 0 
E7 0 369.21 g/mol 369.19 g/mol 68,88 
F7 0,1 347.27 g/mol 347.19 g/mol 7876,02 
G7 0,04 375.22 g/mol 375.17 g/mol 16147,8 
H7 0 397.10 g/mol 0.00 g/mol 0 
A8 0,02 375.12 g/mol 375.11 g/mol 533,72 
B8 0,06 378.20 g/mol 378.17 g/mol 8947,5 
C8 0 369.25 g/mol 0.00 g/mol 0 
D8 0 369.25 g/mol 0.00 g/mol 0 
E8 0,02 378.23 g/mol 378.20 g/mol 654,95 
F8 0,06 384.21 g/mol 384.18 g/mol 1702,71 
G8 0,02 348.21 g/mol 348.19 g/mol 423,43 
H8 0 348.21 g/mol 348.25 g/mol 42,33 
A9 0 397.09 g/mol 397.06 g/mol 155,87 
B9 0 386.24 g/mol 0.00 g/mol 0 
C9 0 337.21 g/mol 0.00 g/mol 0 
D9 0,06 370.27 g/mol 370.24 g/mol 8272,14 
E9 0 395.16 g/mol 0.00 g/mol 0 
F9 0 385.18 g/mol 0.00 g/mol 0 
G9 0,16 389.24 g/mol 389.19 g/mol 11152,44 
H9 0 305.17 g/mol 0.00 g/mol 0 
A10 0 375.13 g/mol 375.11 g/mol 102,84 
B10 0 380.18 g/mol 0.00 g/mol 0 
C10 0 387.16 g/mol 387.14 g/mol 105,77 
D10 0 358.24 g/mol 358.20 g/mol 260,49 
E10 0,04 354.20 g/mol 354.25 g/mol 832,31 
F10 0 398.07 g/mol 0.00 g/mol 0 
G10 0 358.14 g/mol 0.00 g/mol 0 
H10 0 374.14 g/mol 374.12 g/mol 166,16 
A11 0 393.08 g/mol 0.00 g/mol 0 
B11 0 293.17 g/mol 0.00 g/mol 0 
C11 0,04 391.19 g/mol 391.20 g/mol 1056,94 
D11 0 352.14 g/mol 352.11 g/mol 141,11 
E11 0 390.31 g/mol 390.25 g/mol 451,84 
F11 0,06 362.23 g/mol 362.20 g/mol 1434,29 
G11 0,02 384.21 g/mol 384.17 g/mol 484,09 
H11 0 383.22 g/mol 0.00 g/mol 0 
A12 0 384.05 g/mol 0.00 g/mol 0 
B12 0 371.22 g/mol 0.00 g/mol 0 
C12 0 277.14 g/mol 0.00 g/mol 0 
D12 0 325.11 g/mol 0.00 g/mol 0 
E12 0 387.20 g/mol 0.00 g/mol 0 
F12 0,04 343.23 g/mol 343.20 g/mol 910,9 
G12 0,02 331.18 g/mol 331.16 g/mol 461,11 
H12 0,08 368.22 g/mol 368.19 g/mol 2078,07 
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Well Peak width Expected mass Found mass Intensity 
A1         
B1         
C1         
D1         
E1         
F1         
G1         
H1         
A2 0,02 374.19 g/mol 374.19 g/mol 429,21 
B2 0 357.16 g/mol 0.00 g/mol 0 
C2 0 307.19 g/mol 0.00 g/mol 0 
D2 0 393.21 g/mol 393.18 g/mol 18 
E2 0,02 394.18 g/mol 394.14 g/mol 788,95 
F2 0 355.18 g/mol 355.15 g/mol 13,43 
G2 0,04 386.28 g/mol 386.24 g/mol 929,78 
H2 0,04 385.21 g/mol 385.20 g/mol 878,54 
A3 0 374.28 g/mol 0.00 g/mol 0 
B3 0 319.15 g/mol 0.00 g/mol 0 
C3 0 351.15 g/mol 351.13 g/mol 30,81 
D3 0,02 354.24 g/mol 354.20 g/mol 425,32 
E3 0 390.18 g/mol 0.00 g/mol 0 
F3 0,04 377.19 g/mol 377.15 g/mol 996,94 
G3 0 385.24 g/mol 0.00 g/mol 0 
H3 0 377.28 g/mol 0.00 g/mol 0 
A4 0 362.23 g/mol 0.00 g/mol 0 
B4 0 355.19 g/mol 0.00 g/mol 0 
C4 0 337.13 g/mol 0.00 g/mol 0 
D4 0 378.23 g/mol 0.00 g/mol 0 
E4 0 385.14 g/mol 385.09 g/mol 45,44 
F4 0 397.14 g/mol 397.16 g/mol 29,06 
G4 0,02 382.24 g/mol 382.21 g/mol 440,8 
H4 0 329.16 g/mol 0.00 g/mol 0 
A5 0 374.14 g/mol 0.00 g/mol 0 
B5 0 324.14 g/mol 0.00 g/mol 0 
C5 0 370.24 g/mol 0.00 g/mol 0 
D5 0 390.24 g/mol 0.00 g/mol 0 
E5 0 361.25 g/mol 0.00 g/mol 0 
F5 0,12 375.26 g/mol 375.30 g/mol 12756,3 
G5 0 355.18 g/mol 0.00 g/mol 0 
H5 0,02 369.21 g/mol 369.19 g/mol 433,69 
A6 0 400.17 g/mol 0.00 g/mol 0 
B6 0 329.16 g/mol 0.00 g/mol 0 
C6 0 358.17 g/mol 0.00 g/mol 0 
D6 0 384.21 g/mol 0.00 g/mol 0 
E6 0 368.18 g/mol 368.18 g/mol 53,05 
F6 0 379.24 g/mol 0.00 g/mol 0 
G6 0 382.18 g/mol 0.00 g/mol 0 
H6 0,06 354.20 g/mol 354.18 g/mol 1721,65 
384 Appendix II 
A7 0 386.24 g/mol 0.00 g/mol 0 
B7 0 385.05 g/mol 385.05 g/mol 57,3 
C7 0 385.20 g/mol 0.00 g/mol 0 
D7 0,02 372.19 g/mol 372.16 g/mol 5108,36 
E7 0 372.15 g/mol 0.00 g/mol 0 
F7 0 355.23 g/mol 0.00 g/mol 0 
G7 0 358.13 g/mol 358.13 g/mol 118,48 
H7 0 294.09 g/mol 0.00 g/mol 0 
A8 0 351.19 g/mol 0.00 g/mol 0 
B8 0 348.21 g/mol 0.00 g/mol 0 
C8 0 344.22 g/mol 0.00 g/mol 0 
D8 0,02 354.20 g/mol 354.18 g/mol 564,92 
E8 0 399.07 g/mol 0.00 g/mol 0 
F8 0 346.24 g/mol 346.22 g/mol 25,46 
G8 0,12 354.20 g/mol 354.18 g/mol 2901,61 
H8 0 359.22 g/mol 0.00 g/mol 0 
A9 0,06 383.27 g/mol 383.22 g/mol 9005,34 
B9 0 338.12 g/mol 0.00 g/mol 0 
C9 0 350.19 g/mol 0.00 g/mol 0 
D9 0 379.19 g/mol 0.00 g/mol 0 
E9 0 388.15 g/mol 388.11 g/mol 164,8 
F9 0,16 396.33 g/mol 396.28 g/mol 11961,66 
G9 0 373.14 g/mol 373.14 g/mol 28,44 
H9 0 345.16 g/mol 0.00 g/mol 0 
A10 0,12 367.21 g/mol 367.17 g/mol 8674,74 
B10 0 376.25 g/mol 0.00 g/mol 0 
C10 0 370.18 g/mol 370.16 g/mol 364,9 
D10 0,08 358.13 g/mol 358.10 g/mol 1676,42 
E10 0 366.14 g/mol 0.00 g/mol 0 
F10 0,02 383.07 g/mol 383.05 g/mol 565,56 
G10 0,04 400.25 g/mol 400.21 g/mol 6838,44 
H10 0,08 330.20 g/mol 330.24 g/mol 23109,78 
A11 0 320.22 g/mol 0.00 g/mol 0 
B11 0 324.13 g/mol 0.00 g/mol 0 
C11 0,06 366.25 g/mol 366.20 g/mol 5925,85 
D11 0,06 343.19 g/mol 343.18 g/mol 1357,06 
E11 0 392.29 g/mol 392.25 g/mol 1385,38 
F11 0 345.18 g/mol 0.00 g/mol 0 
G11 0 377.11 g/mol 377.10 g/mol 2042,68 
H11 0 384.21 g/mol 0.00 g/mol 0 
A12 0,14 382.16 g/mol 382.14 g/mol 12029,22 
B12 0,02 398.23 g/mol 398.21 g/mol 550,45 
C12 0 334.24 g/mol 0.00 g/mol 0 
D12 0 372.26 g/mol 0.00 g/mol 0 
E12 0 343.19 g/mol 343.18 g/mol 56,92 
F12 0 374.28 g/mol 0.00 g/mol 0 
G12 0,08 330.20 g/mol 330.16 g/mol 5951,54 
H12 0 393.28 g/mol 0.00 g/mol 0 
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Well Peak width Expected mass Found mass Intensity 
A1         
B1         
C1         
D1         
E1         
F1         
G1         
H1         
A2 0 391.12 g/mol 0.00 g/mol 0 
B2 0 389.15 g/mol 0.00 g/mol 0 
C2 0 343.18 g/mol 0.00 g/mol 0 
D2 0 385.24 g/mol 0.00 g/mol 0 
E2 0 339.17 g/mol 0.00 g/mol 0 
F2 0,06 380.22 g/mol 380.19 g/mol 9223,2 
G2 0 375.31 g/mol 0.00 g/mol 0 
H2 0 377.25 g/mol 0.00 g/mol 0 
A3 0 334.15 g/mol 0.00 g/mol 0 
B3 0 380.18 g/mol 0.00 g/mol 0 
C3 0 323.12 g/mol 0.00 g/mol 0 
D3 0 361.25 g/mol 0.00 g/mol 0 
E3 0 393.20 g/mol 0.00 g/mol 0 
F3 0,06 398.17 g/mol 398.14 g/mol 8703,72 
G3 0 398.13 g/mol 0.00 g/mol 0 
H3 0 368.20 g/mol 0.00 g/mol 0 
A4 0 383.16 g/mol 383.13 g/mol 106,56 
B4 0 347.20 g/mol 0.00 g/mol 0 
C4 0,1 389.21 g/mol 389.18 g/mol 13188,96 
D4 0 324.14 g/mol 0.00 g/mol 0 
E4 0 380.22 g/mol 380.20 g/mol 82,09 
F4 0 313.17 g/mol 0.00 g/mol 0 
G4 0 379.19 g/mol 379.19 g/mol 22,68 
H4 0 395.12 g/mol 0.00 g/mol 0 
A5 0 383.07 g/mol 0.00 g/mol 0 
B5 0 383.07 g/mol 0.00 g/mol 0 
C5 0 363.27 g/mol 0.00 g/mol 0 
D5 0 377.24 g/mol 0.00 g/mol 0 
E5 0 354.24 g/mol 0.00 g/mol 0 
F5 0 378.18 g/mol 378.15 g/mol 38,43 
G5 0 374.14 g/mol 0.00 g/mol 0 
H5 0 341.17 g/mol 0.00 g/mol 0 
A6 0 369.16 g/mol 0.00 g/mol 0 
B6 0 372.15 g/mol 0.00 g/mol 0 
C6 0 377.17 g/mol 0.00 g/mol 0 
D6 0 309.14 g/mol 0.00 g/mol 0 
E6 0 327.19 g/mol 0.00 g/mol 0 
F6 0,02 393.10 g/mol 393.08 g/mol 923,14 
G6 0,02 383.23 g/mol 383.21 g/mol 521,88 
H6 0 382.19 g/mol 382.18 g/mol 19,24 
386 Appendix II 
A7 0 379.23 g/mol 379.20 g/mol 19127,16 
B7 0 384.06 g/mol 384.05 g/mol 130,36 
C7 0 384.08 g/mol 0.00 g/mol 0 
D7 0 352.17 g/mol 0.00 g/mol 0 
E7 0 348.16 g/mol 0.00 g/mol 0 
F7 0 398.14 g/mol 0.00 g/mol 0 
G7 0,06 345.21 g/mol 345.19 g/mol 1408,82 
H7 0 373.14 g/mol 373.13 g/mol 151,63 
A8 0,1 398.17 g/mol 398.14 g/mol 9860,94 
B8 0,12 366.20 g/mol 366.17 g/mol 7363,26 
C8 0 371.12 g/mol 371.12 g/mol 134,76 
D8 0 387.20 g/mol 387.17 g/mol 359,84 
E8 0,02 319.19 g/mol 319.20 g/mol 482,29 
F8 0 305.17 g/mol 0.00 g/mol 0 
G8 0,04 393.10 g/mol 393.08 g/mol 1028,01 
H8 0 355.12 g/mol 0.00 g/mol 0 
A9 0,02 341.10 g/mol 341.09 g/mol 495,4 
B9 0 342.14 g/mol 342.13 g/mol 114,13 
C9 0,02 360.17 g/mol 360.16 g/mol 519,57 
D9 0 277.14 g/mol 0.00 g/mol 0 
E9 0 363.15 g/mol 0.00 g/mol 0 
F9 0 353.21 g/mol 0.00 g/mol 0 
G9 0 397.09 g/mol 0.00 g/mol 0 
H9 0 319.23 g/mol 319.21 g/mol 23,04 
A10 0,14 385.24 g/mol 385.21 g/mol 12127,2 
B10 0,02 363.13 g/mol 363.07 g/mol 471,75 
C10 0 341.16 g/mol 0.00 g/mol 0 
D10 0,12 392.22 g/mol 392.19 g/mol 12760,2 
E10 0 327.14 g/mol 0.00 g/mol 0 
F10 0 386.06 g/mol 386.04 g/mol 167,06 
G10 0 384.05 g/mol 0.00 g/mol 0 
H10 0 380.15 g/mol 0.00 g/mol 0 
A11 0,06 370.22 g/mol 370.18 g/mol 6602,22 
B11 0 369.20 g/mol 0.00 g/mol 0 
C11 0,02 374.14 g/mol 374.07 g/mol 440,83 
D11 0 372.19 g/mol 372.17 g/mol 13 
E11 0,02 355.19 g/mol 355.19 g/mol 408,59 
F11 0 383.19 g/mol 0.00 g/mol 0 
G11 0 233.09 g/mol 233.09 g/mol 322,66 
H11 0,08 397.14 g/mol 397.10 g/mol 2951,55 
A12 0,06 325.10 g/mol 325.09 g/mol 6790,32 
B12 0,02 348.21 g/mol 348.20 g/mol 526,73 
C12 0 354.21 g/mol 0.00 g/mol 0 
D12 0 371.27 g/mol 0.00 g/mol 0 
E12 0 395.12 g/mol 0.00 g/mol 0 
F12 0 348.26 g/mol 0.00 g/mol 0 
G12 0 399.23 g/mol 0.00 g/mol 0 
H12 0 398.08 g/mol 0.00 g/mol 0 
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Well Peak width Expected mass Found mass Intensity 
A1         
B1         
C1         
D1         
E1         
F1         
G1         
H1         
A2 0 299.07 g/mol 0.00 g/mol 0 
B2 0 385.18 g/mol 385.15 g/mol 148,51 
C2 0 364.18 g/mol 364.16 g/mol 298,84 
D2 0,02 368.22 g/mol 368.24 g/mol 444,15 
E2 0 384.21 g/mol 0.00 g/mol 0 
F2 0 395.12 g/mol 0.00 g/mol 0 
G2 0 397.14 g/mol 0.00 g/mol 0 
H2 0 394.09 g/mol 394.08 g/mol 182,05 
A3 0 368.20 g/mol 0.00 g/mol 0 
B3 0,08 350.14 g/mol 350.12 g/mol 24200,7 
C3 0,1 382.16 g/mol 382.14 g/mol 24800,52 
D3 0,02 380.16 g/mol 380.14 g/mol 517,01 
E3 0 319.12 g/mol 0.00 g/mol 0 
F3 0,1 343.19 g/mol 343.17 g/mol 2197,03 
G3 0,04 383.23 g/mol 383.21 g/mol 1142,89 
H3 0 344.22 g/mol 344.19 g/mol 3876,95 
A4 0 340.11 g/mol 340.17 g/mol 50,07 
B4 0 365.17 g/mol 365.15 g/mol 78,47 
C4 0 261.13 g/mol 0.00 g/mol 0 
D4 0 373.16 g/mol 0.00 g/mol 0 
E4 0,02 319.23 g/mol 319.21 g/mol 566,65 
F4 0 319.23 g/mol 319.22 g/mol 27,41 
G4 0,02 397.33 g/mol 397.29 g/mol 515,46 
H4 0,02 393.24 g/mol 393.22 g/mol 640,21 
A5 0,06 330.20 g/mol 330.19 g/mol 6257,76 
B5 0 379.19 g/mol 0.00 g/mol 0 
C5 0 318.20 g/mol 0.00 g/mol 0 
D5 0 342.14 g/mol 0.00 g/mol 0 
E5 0 343.23 g/mol 0.00 g/mol 0 
F5 0 383.18 g/mol 0.00 g/mol 0 
G5 0,02 370.27 g/mol 370.26 g/mol 475,11 
H5 0,02 355.18 g/mol 355.10 g/mol 453,52 
A6 0 329.16 g/mol 0.00 g/mol 0 
B6 0,02 360.12 g/mol 360.11 g/mol 560,13 
C6 0 313.17 g/mol 0.00 g/mol 0 
D6 0 390.20 g/mol 0.00 g/mol 0 
E6 0 396.10 g/mol 0.00 g/mol 0 
F6 0 385.14 g/mol 385.11 g/mol 320,19 
G6 0,12 330.20 g/mol 330.18 g/mol 11878,32 
H6 0 345.20 g/mol 0.00 g/mol 0 
388 Appendix II 
A7 0 388.30 g/mol 0.00 g/mol 0 
B7 0 360.26 g/mol 0.00 g/mol 0 
C7 0 354.13 g/mol 0.00 g/mol 0 
D7 0 382.17 g/mol 0.00 g/mol 0 
E7 0 364.23 g/mol 0.00 g/mol 0 
F7 0,02 377.21 g/mol 377.19 g/mol 696,65 
G7 0 291.15 g/mol 0.00 g/mol 0 
H7 0 383.26 g/mol 0.00 g/mol 0 
A8 0 355.18 g/mol 0.00 g/mol 0 
B8 0 377.21 g/mol 0.00 g/mol 0 
C8 0 355.08 g/mol 355.06 g/mol 104,23 
D8 0 383.23 g/mol 383.21 g/mol 114,35 
E8 0 383.22 g/mol 0.00 g/mol 0 
F8 0 388.18 g/mol 388.18 g/mol 17,27 
G8 0 365.25 g/mol 0.00 g/mol 0 
H8 0 332.18 g/mol 332.16 g/mol 136,45 
A9 0 376.25 g/mol 376.21 g/mol 4672,25 
B9 0 365.17 g/mol 0.00 g/mol 0 
C9 0 337.13 g/mol 0.00 g/mol 0 
D9 0 281.21 g/mol 0.00 g/mol 0 
E9 0 330.16 g/mol 0.00 g/mol 0 
F9 0 390.24 g/mol 0.00 g/mol 0 
G9 0,02 333.25 g/mol 333.16 g/mol 411,64 
H9 0,04 368.22 g/mol 368.20 g/mol 858,02 
A10 0,06 393.24 g/mol 393.21 g/mol 11696,16 
B10 0 374.28 g/mol 0.00 g/mol 0 
C10 0,1 330.20 g/mol 330.17 g/mol 10599,18 
D10 0 396.11 g/mol 396.07 g/mol 38,59 
E10 0 355.18 g/mol 0.00 g/mol 0 
F10 0 374.18 g/mol 374.15 g/mol 4030,68 
G10 0,02 347.20 g/mol 347.18 g/mol 482,2 
H10 0 358.17 g/mol 358.16 g/mol 20,39 
A11 0,02 394.24 g/mol 394.21 g/mol 628,91 
B11 0 365.22 g/mol 365.18 g/mol 734,28 
C11 0,04 338.12 g/mol 338.10 g/mol 964,26 
D11 0 352.14 g/mol 0.00 g/mol 0 
E11 0 327.19 g/mol 0.00 g/mol 0 
F11 0,02 383.22 g/mol 383.19 g/mol 464,26 
G11 0 313.17 g/mol 0.00 g/mol 0 
H11 0,08 372.26 g/mol 372.22 g/mol 6564,66 
A12 0 368.29 g/mol 368.25 g/mol 84,72 
B12 0,02 368.29 g/mol 368.26 g/mol 647,74 
C12 0 371.23 g/mol 0.00 g/mol 0 
D12 0,04 398.13 g/mol 398.09 g/mol 6243,24 
E12 0,06 339.17 g/mol 339.14 g/mol 1262,63 
F12 0 355.23 g/mol 0.00 g/mol 0 
G12 0 377.28 g/mol 0.00 g/mol 0 
H12 0 340.17 g/mol 0.00 g/mol 0 
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Well Peak width Expected mass Found mass Intensity 
A1         
B1         
C1         
D1         
E1         
F1         
G1         
H1         
A2 0,22 368.25 g/mol 368.21 g/mol 8607,48 
B2 0 345.18 g/mol 345.17 g/mol 43,56 
C2 0 370.04 g/mol 0.00 g/mol 0 
D2 0 368.20 g/mol 368.16 g/mol 3989 
E2 0 349.15 g/mol 349.13 g/mol 83,89 
F2 0 315.14 g/mol 0.00 g/mol 0 
G2 0 341.17 g/mol 0.00 g/mol 0 
H2 0 379.26 g/mol 0.00 g/mol 0 
A3 0 370.19 g/mol 0.00 g/mol 0 
B3 0,02 368.16 g/mol 368.13 g/mol 652,93 
C3 0 344.19 g/mol 0.00 g/mol 0 
D3 0,14 347.27 g/mol 347.23 g/mol 12027,9 
E3 0,02 319.23 g/mol 319.18 g/mol 368,4 
F3 0,08 330.20 g/mol 330.17 g/mol 8446,44 
G3 0 361.25 g/mol 0.00 g/mol 0 
H3 0 331.17 g/mol 331.14 g/mol 1445,24 
A4 0 329.16 g/mol 0.00 g/mol 0 
B4 0,2 365.19 g/mol 365.15 g/mol 9418,08 
C4 0 263.12 g/mol 0.00 g/mol 0 
D4 0 233.09 g/mol 0.00 g/mol 0 
E4 0 350.16 g/mol 0.00 g/mol 0 
F4 0,02 339.20 g/mol 339.15 g/mol 585,44 
G4 0,02 399.11 g/mol 399.08 g/mol 586,14 
H4 0 395.12 g/mol 395.08 g/mol 2895,94 
A5 0,04 335.22 g/mol 335.19 g/mol 1221,89 
B5 0 371.23 g/mol 0.00 g/mol 0 
C5 0 397.09 g/mol 0.00 g/mol 0 
D5 0 313.17 g/mol 0.00 g/mol 0 
E5 0,02 373.11 g/mol 373.12 g/mol 524,1 
F5 0 313.09 g/mol 0.00 g/mol 0 
G5 0 341.17 g/mol 0.00 g/mol 0 
H5 0,02 381.25 g/mol 381.20 g/mol 13255,26 
A6 0 348.26 g/mol 0.00 g/mol 0 
B6 0,02 372.15 g/mol 372.13 g/mol 574,9 
C6 0,14 397.14 g/mol 397.10 g/mol 11880,78 
D6 0,08 372.22 g/mol 372.19 g/mol 25773,78 
E6 0,02 359.15 g/mol 359.14 g/mol 483,22 
F6 0,16 374.31 g/mol 374.26 g/mol 8266,2 
G6 0 390.24 g/mol 390.21 g/mol 16,67 
H6 0 376.16 g/mol 0.00 g/mol 0 
390 Appendix II 
A7 0 370.27 g/mol 370.24 g/mol 98,47 
B7 0,02 332.22 g/mol 332.19 g/mol 526,06 
C7 0 387.22 g/mol 387.18 g/mol 110,46 
D7 0,06 393.24 g/mol 393.21 g/mol 21829,92 
E7 0 370.27 g/mol 0.00 g/mol 0 
F7 0,04 343.23 g/mol 343.20 g/mol 1062,83 
G7 0,02 394.20 g/mol 394.18 g/mol 550,02 
H7 0 398.06 g/mol 398.04 g/mol 95,42 
A8 0,06 396.19 g/mol 396.16 g/mol 9958,98 
B8 0 280.14 g/mol 0.00 g/mol 0 
C8 0 364.21 g/mol 0.00 g/mol 0 
D8 0 341.17 g/mol 341.15 g/mol 202,27 
E8 0,14 384.15 g/mol 384.13 g/mol 9423,9 
F8 0,02 355.19 g/mol 355.18 g/mol 484,56 
G8 0 291.15 g/mol 0.00 g/mol 0 
H8 0 247.11 g/mol 0.00 g/mol 0 
A9 0,02 309.14 g/mol 309.12 g/mol 4133,54 
B9 0,06 346.17 g/mol 346.14 g/mol 6684,42 
C9 0 360.11 g/mol 0.00 g/mol 0 
D9 0,04 362.28 g/mol 362.24 g/mol 6804,66 
E9 0 354.24 g/mol 354.22 g/mol 51,84 
F9 0 305.17 g/mol 0.00 g/mol 0 
G9 0,12 373.20 g/mol 373.17 g/mol 3014,77 
H9 0,04 369.10 g/mol 369.07 g/mol 4745,91 
A10 0,02 356.07 g/mol 356.05 g/mol 476,34 
B10 0 384.08 g/mol 0.00 g/mol 0 
C10 0,04 327.08 g/mol 327.08 g/mol 806,62 
D10 0 346.12 g/mol 0.00 g/mol 0 
E10 0 338.15 g/mol 0.00 g/mol 0 
F10 0 347.16 g/mol 347.13 g/mol 3968,69 
G10 0 395.26 g/mol 0.00 g/mol 0 
H10 0 357.20 g/mol 0.00 g/mol 0 
A11 0 376.21 g/mol 0.00 g/mol 0 
B11 0 341.17 g/mol 0.00 g/mol 0 
C11 0 396.10 g/mol 396.07 g/mol 9106,08 
D11 0 369.10 g/mol 369.07 g/mol 944,45 
E11 0,08 393.24 g/mol 393.21 g/mol 24539,22 
F11 0,08 359.27 g/mol 359.23 g/mol 8821,08 
G11 0,1 385.14 g/mol 385.11 g/mol 8261,46 
H11 0 398.13 g/mol 0.00 g/mol 0 
A12 0 380.15 g/mol 380.13 g/mol 81,05 
B12 0,04 386.27 g/mol 386.22 g/mol 8640,6 
C12 0 375.16 g/mol 0.00 g/mol 0 
D12 0 349.21 g/mol 0.00 g/mol 0 
E12 0 312.17 g/mol 0.00 g/mol 0 
F12 0,04 309.14 g/mol 309.05 g/mol 884,53 
G12 0 341.17 g/mol 0.00 g/mol 0 
H12 0,02 333.25 g/mol 333.23 g/mol 411,49 
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Well Peak width Expected mass Found mass Intensity 
A1         
B1         
C1         
D1         
E1         
F1         
G1         
H1         
A2 0,02 387.11 g/mol 387.09 g/mol 763,53 
B2 0 379.08 g/mol 0.00 g/mol 0 
C2 0 348.26 g/mol 0.00 g/mol 0 
D2 0,14 375.26 g/mol 375.25 g/mol 13359,06 
E2 0,08 357.25 g/mol 357.21 g/mol 7184,88 
F2 0,14 398.17 g/mol 398.15 g/mol 11983,92 
G2 0 348.26 g/mol 0.00 g/mol 0 
H2 0 380.19 g/mol 380.15 g/mol 5157,56 
A3 0 370.09 g/mol 0.00 g/mol 0 
B3 0,02 386.13 g/mol 386.07 g/mol 525,1 
C3 0 397.23 g/mol 0.00 g/mol 0 
D3 0 388.23 g/mol 388.19 g/mol 76,59 
E3 0 325.11 g/mol 325.13 g/mol 98,15 
F3 0,12 369.25 g/mol 369.21 g/mol 3679,13 
G3 0 360.23 g/mol 0.00 g/mol 0 
H3 0 400.25 g/mol 400.23 g/mol 127,35 
A4 0,02 356.17 g/mol 356.16 g/mol 545,58 
B4 0 390.23 g/mol 390.21 g/mol 19,23 
C4 0 396.15 g/mol 0.00 g/mol 0 
D4 0 320.13 g/mol 0.00 g/mol 0 
E4 0 344.22 g/mol 0.00 g/mol 0 
F4 0,04 358.12 g/mol 358.09 g/mol 2905,31 
G4 0 355.08 g/mol 0.00 g/mol 0 
H4 0,06 349.18 g/mol 349.15 g/mol 6241,86 
A5 0 357.20 g/mol 357.18 g/mol 115,27 
B5 0 363.23 g/mol 0.00 g/mol 0 
C5 0 358.21 g/mol 0.00 g/mol 0 
D5 0 326.19 g/mol 0.00 g/mol 0 
E5 0 372.21 g/mol 0.00 g/mol 0 
F5 0 332.25 g/mol 0.00 g/mol 0 
G5 0 386.22 g/mol 0.00 g/mol 0 
H5 0 362.28 g/mol 0.00 g/mol 0 
A6 0,14 343.23 g/mol 343.20 g/mol 4007,83 
B6 0 341.21 g/mol 0.00 g/mol 0 
C6 0 391.24 g/mol 0.00 g/mol 0 
D6 0 383.07 g/mol 0.00 g/mol 0 
E6 0,14 397.14 g/mol 397.11 g/mol 6614,7 
F6 0 395.12 g/mol 0.00 g/mol 0 
G6 0,02 350.14 g/mol 350.12 g/mol 753,85 
H6 0 247.11 g/mol 0.00 g/mol 0 
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A7 0,02 323.16 g/mol 323.14 g/mol 724,94 
B7 0 302.16 g/mol 0.00 g/mol 0 
C7 0,02 318.20 g/mol 318.17 g/mol 568,87 
D7 0,02 369.10 g/mol 369.08 g/mol 1756,58 
E7 0 345.18 g/mol 0.00 g/mol 0 
F7 0 391.24 g/mol 0.00 g/mol 0 
G7 0,06 369.10 g/mol 369.07 g/mol 6287,22 
H7 0 356.07 g/mol 356.05 g/mol 12,29 
A8 0,06 354.18 g/mol 354.15 g/mol 12314,1 
B8 0 352.16 g/mol 0.00 g/mol 0 
C8 0 394.27 g/mol 0.00 g/mol 0 
D8 0 333.16 g/mol 0.00 g/mol 0 
E8 0 341.16 g/mol 0.00 g/mol 0 
F8 0,02 366.20 g/mol 366.18 g/mol 642,55 
G8 0 369.10 g/mol 369.08 g/mol 58,17 
H8 0 372.04 g/mol 0.00 g/mol 0 
A9 0 394.18 g/mol 0.00 g/mol 0 
B9 0,04 360.21 g/mol 360.19 g/mol 1043,65 
C9 0 369.25 g/mol 0.00 g/mol 0 
D9 0 333.16 g/mol 0.00 g/mol 0 
E9 0 309.14 g/mol 0.00 g/mol 0 
F9 0,1 318.20 g/mol 318.19 g/mol 1882,3 
G9 0,04 388.04 g/mol 388.03 g/mol 1282,42 
H9 0,04 388.15 g/mol 388.12 g/mol 13353,18 
A10 0 352.16 g/mol 352.15 g/mol 112,85 
B10 0 294.16 g/mol 0.00 g/mol 0 
C10 0,12 369.25 g/mol 369.21 g/mol 5360,92 
D10 0 321.16 g/mol 0.00 g/mol 0 
E10 0 329.21 g/mol 0.00 g/mol 0 
F10 0 377.21 g/mol 0.00 g/mol 0 
G10 0,02 357.25 g/mol 357.21 g/mol 3981,85 
H10 0,02 379.08 g/mol 379.07 g/mol 481,52 
A11 0 342.18 g/mol 342.16 g/mol 490,57 
B11 0 318.19 g/mol 0.00 g/mol 0 
C11 0 329.21 g/mol 0.00 g/mol 0 
D11 0 315.19 g/mol 315.19 g/mol 51,45 
E11 0,1 397.14 g/mol 397.11 g/mol 3118,5 
F11 0,02 397.10 g/mol 397.07 g/mol 476,19 
G11 0 398.06 g/mol 0.00 g/mol 0 
H11 0 361.24 g/mol 0.00 g/mol 0 
A12 0 368.29 g/mol 368.26 g/mol 211,57 
B12 0,06 374.22 g/mol 374.19 g/mol 10251,24 
C12 0,04 331.18 g/mol 331.17 g/mol 1122,12 
D12 0,08 369.29 g/mol 369.26 g/mol 1889,83 
E12 0 355.08 g/mol 0.00 g/mol 0 
F12 0 383.07 g/mol 383.05 g/mol 20,82 
G12 0 380.07 g/mol 0.00 g/mol 0 
H12 0 355.10 g/mol 0.00 g/mol 0 
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Well Peak width Expected mass Found mass Intensity 
A1         
B1         
C1         
D1         
E1         
F1         
G1         
H1         
A2 0 337.17 g/mol 0.00 g/mol 0 
B2 0 337.18 g/mol 0.00 g/mol 0 
C2 0 384.05 g/mol 0.00 g/mol 0 
D2 0,04 397.25 g/mol 397.23 g/mol 1115,96 
E2 0,02 387.27 g/mol 387.24 g/mol 972,19 
F2 0,02 319.23 g/mol 319.28 g/mol 411,01 
G2 0 292.14 g/mol 0.00 g/mol 0 
H2 0 385.05 g/mol 0.00 g/mol 0 
A3 0,04 326.14 g/mol 326.04 g/mol 1234,6 
B3 0 326.08 g/mol 0.00 g/mol 0 
C3 0 325.18 g/mol 0.00 g/mol 0 
D3 0,02 332.22 g/mol 332.20 g/mol 476,13 
E3 0 346.09 g/mol 0.00 g/mol 0 
F3 0 362.28 g/mol 0.00 g/mol 0 
G3 0,02 359.26 g/mol 359.23 g/mol 587,54 
H3 0 312.12 g/mol 0.00 g/mol 0 
A4 0 326.10 g/mol 0.00 g/mol 0 
B4 0 308.21 g/mol 0.00 g/mol 0 
C4 0 395.20 g/mol 0.00 g/mol 0 
D4 0 313.17 g/mol 0.00 g/mol 0 
E4 0,04 332.22 g/mol 332.19 g/mol 14859,96 
F4 0 336.26 g/mol 0.00 g/mol 0 
G4 0 277.14 g/mol 0.00 g/mol 0 
H4 0 296.13 g/mol 0.00 g/mol 0 
A5 0 321.20 g/mol 0.00 g/mol 0 
B5 0 370.09 g/mol 370.07 g/mol 508,66 
C5 0 341.10 g/mol 0.00 g/mol 0 
D5 0 346.19 g/mol 0.00 g/mol 0 
E5 0 362.23 g/mol 0.00 g/mol 0 
F5 0 365.25 g/mol 0.00 g/mol 0 
G5 0 339.20 g/mol 0.00 g/mol 0 
H5 0 347.16 g/mol 0.00 g/mol 0 
A6 0,02 388.09 g/mol 388.06 g/mol 451,46 
B6 0 393.28 g/mol 0.00 g/mol 0 
C6 0,04 392.29 g/mol 392.26 g/mol 1055,01 
D6 0,02 397.10 g/mol 397.07 g/mol 470,53 
E6 0 355.08 g/mol 355.07 g/mol 146,83 
F6 0,02 398.13 g/mol 398.10 g/mol 5646,61 
G6 0,06 396.19 g/mol 396.16 g/mol 8970,24 
H6 0 369.14 g/mol 369.12 g/mol 100,17 
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A7 0 348.25 g/mol 0.00 g/mol 0 
B7 0 334.14 g/mol 0.00 g/mol 0 
C7 0 311.08 g/mol 0.00 g/mol 0 
D7 0 358.17 g/mol 358.15 g/mol 104,35 
E7 0 311.09 g/mol 0.00 g/mol 0 
F7 0 351.15 g/mol 0.00 g/mol 0 
G7 0 381.20 g/mol 0.00 g/mol 0 
H7 0 304.18 g/mol 0.00 g/mol 0 
A8 0 369.25 g/mol 0.00 g/mol 0 
B8 0,12 370.08 g/mol 370.06 g/mol 5849,79 
C8 0,02 372.04 g/mol 372.04 g/mol 531,43 
D8 0,1 347.22 g/mol 347.19 g/mol 9676,92 
E8 0 380.13 g/mol 0.00 g/mol 0 
F8 0,08 383.14 g/mol 383.11 g/mol 8261,88 
G8 0,06 399.13 g/mol 399.11 g/mol 9367,98 
H8 0,02 344.22 g/mol 344.20 g/mol 812,81 
A9 0 306.20 g/mol 306.19 g/mol 51,89 
B9 0,02 319.19 g/mol 319.14 g/mol 453,2 
C9 0 393.28 g/mol 0.00 g/mol 0 
D9 0 397.21 g/mol 0.00 g/mol 0 
E9 0 368.26 g/mol 368.23 g/mol 15,39 
F9 0 335.22 g/mol 0.00 g/mol 0 
G9 0,06 343.23 g/mol 343.20 g/mol 6096,12 
H9 0,14 393.24 g/mol 393.21 g/mol 13191,48 
A10 0 354.24 g/mol 354.21 g/mol 31,73 
B10 0 333.15 g/mol 333.13 g/mol 1154,08 
C10 0,06 397.18 g/mol 397.15 g/mol 9199,98 
D10 0 395.22 g/mol 0.00 g/mol 0 
E10 0 382.31 g/mol 382.27 g/mol 22,17 
F10 0,02 368.26 g/mol 368.22 g/mol 444,9 
G10 0,08 379.23 g/mol 379.19 g/mol 12279,9 
H10 0 374.26 g/mol 0.00 g/mol 0 
A11 0,02 382.28 g/mol 382.24 g/mol 946,6 
B11 0,12 330.20 g/mol 330.18 g/mol 9550,98 
C11 0 361.24 g/mol 0.00 g/mol 0 
D11 0 378.14 g/mol 0.00 g/mol 0 
E11 0,04 395.23 g/mol 395.21 g/mol 951,45 
F11 0,02 379.23 g/mol 379.20 g/mol 24139,14 
G11 0 384.29 g/mol 384.25 g/mol 217,1 
H11 0,12 364.24 g/mol 364.22 g/mol 18772,08 
A12 0 352.19 g/mol 0.00 g/mol 0 
B12 0 304.18 g/mol 0.00 g/mol 0 
C12 0 372.29 g/mol 372.25 g/mol 33,54 
D12 0 323.22 g/mol 0.00 g/mol 0 
E12 0 324.22 g/mol 0.00 g/mol 0 
F12 0,12 348.20 g/mol 348.18 g/mol 6946,8 
G12 0,02 341.21 g/mol 341.18 g/mol 1372,16 
H12 0 365.28 g/mol 0.00 g/mol 0 
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Well Peak width Expected mass Found mass Intensity 
A1         
B1         
C1         
D1         
E1         
F1         
G1         
H1         
A2 0 374.28 g/mol 0.00 g/mol 0 
B2 0,1 357.25 g/mol 357.20 g/mol 10336,74 
C2 0 380.13 g/mol 0.00 g/mol 0 
D2 0 318.20 g/mol 0.00 g/mol 0 
E2 0 382.23 g/mol 0.00 g/mol 0 
F2 0 384.21 g/mol 384.18 g/mol 84,18 
G2 0,12 359.27 g/mol 359.22 g/mol 9745,68 
H2 0,1 376.25 g/mol 376.20 g/mol 7211,04 
A3 0,02 348.21 g/mol 348.19 g/mol 475,13 
B3 0 387.11 g/mol 0.00 g/mol 0 
C3 0 375.31 g/mol 0.00 g/mol 0 
D3 0,02 370.27 g/mol 370.33 g/mol 3811,88 
E3 0 341.21 g/mol 0.00 g/mol 0 
F3 0,16 396.18 g/mol 396.15 g/mol 11425,14 
G3 0,02 348.20 g/mol 348.18 g/mol 619,45 
H3 0 368.26 g/mol 368.21 g/mol 98,8 
A4 0 365.29 g/mol 0.00 g/mol 0 
B4 0 381.18 g/mol 381.16 g/mol 63,94 
C4 0,06 366.20 g/mol 366.16 g/mol 5132,2 
D4 0 345.18 g/mol 0.00 g/mol 0 
E4 0,06 312.22 g/mol 312.18 g/mol 13229,7 
F4 0,16 333.25 g/mol 333.21 g/mol 6607,98 
G4 0 332.25 g/mol 0.00 g/mol 0 
H4 0,06 361.24 g/mol 361.20 g/mol 16786,8 
A5 0,04 375.26 g/mol 375.21 g/mol 8996,28 
B5 0 375.12 g/mol 375.10 g/mol 181,09 
C5 0 306.17 g/mol 0.00 g/mol 0 
D5 0 306.17 g/mol 0.00 g/mol 0 
E5 0,18 376.23 g/mol 376.19 g/mol 9520,44 
F5 0 362.23 g/mol 362.19 g/mol 5765,39 
G5 0,1 378.14 g/mol 378.13 g/mol 2414,66 
H5 0 398.28 g/mol 0.00 g/mol 0 
A6 0 356.15 g/mol 0.00 g/mol 0 
B6 0 381.18 g/mol 0.00 g/mol 0 
C6 0 345.25 g/mol 0.00 g/mol 0 
D6 0 309.20 g/mol 0.00 g/mol 0 
E6 0,14 357.25 g/mol 357.21 g/mol 9835,86 
F6 0,12 363.20 g/mol 363.16 g/mol 7259,04 
G6 0,04 331.17 g/mol 331.14 g/mol 8715,18 
H6 0,04 351.17 g/mol 351.15 g/mol 1038,32 
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A7 0 344.25 g/mol 0.00 g/mol 0 
B7 0,08 357.25 g/mol 357.20 g/mol 2588,68 
C7 0 343.19 g/mol 343.16 g/mol 70,64 
D7 0,16 361.21 g/mol 361.18 g/mol 11929,38 
E7 0 355.19 g/mol 0.00 g/mol 0 
F7 0 332.16 g/mol 0.00 g/mol 0 
G7 0,04 333.25 g/mol 333.21 g/mol 4794,53 
H7 0 391.24 g/mol 0.00 g/mol 0 
A8 0 368.15 g/mol 368.13 g/mol 31,75 
B8 0 362.20 g/mol 0.00 g/mol 0 
C8 0 305.17 g/mol 0.00 g/mol 0 
D8 0 393.24 g/mol 0.00 g/mol 0 
E8 0,04 381.25 g/mol 381.21 g/mol 15722,76 
F8 0 383.08 g/mol 0.00 g/mol 0 
G8 0 329.14 g/mol 0.00 g/mol 0 
H8 0 353.21 g/mol 353.18 g/mol 273,39 
A9 0 320.22 g/mol 0.00 g/mol 0 
B9 0 362.23 g/mol 362.20 g/mol 3587,63 
C9 0,04 336.19 g/mol 336.16 g/mol 16503,12 
D9 0 375.22 g/mol 375.19 g/mol 558,69 
E9 0,02 360.11 g/mol 360.08 g/mol 14597,46 
F9 0 333.06 g/mol 0.00 g/mol 0 
G9 0 370.16 g/mol 0.00 g/mol 0 
H9 0 320.22 g/mol 0.00 g/mol 0 
A10 0 332.22 g/mol 0.00 g/mol 0 
B10 0,06 329.17 g/mol 329.17 g/mol 1210,58 
C10 0 352.12 g/mol 0.00 g/mol 0 
D10 0 348.11 g/mol 0.00 g/mol 0 
E10 0 319.19 g/mol 0.00 g/mol 0 
F10 0 345.18 g/mol 0.00 g/mol 0 
G10 0 367.35 g/mol 0.00 g/mol 0 
H10 0,02 365.17 g/mol 365.15 g/mol 564,95 
A11 0 291.15 g/mol 0.00 g/mol 0 
B11 0 353.29 g/mol 0.00 g/mol 0 
C11 0 368.26 g/mol 0.00 g/mol 0 
D11 0,12 319.23 g/mol 319.30 g/mol 19916,1 
E11 0,12 319.23 g/mol 319.20 g/mol 7350,42 
F11 0,02 345.25 g/mol 345.21 g/mol 5792,11 
G11 0 305.17 g/mol 0.00 g/mol 0 
H11 0 347.08 g/mol 347.06 g/mol 68,11 
A12 0,06 332.25 g/mol 332.23 g/mol 1348,32 
B12 0,16 361.24 g/mol 361.21 g/mol 8633,4 
C12 0 379.19 g/mol 0.00 g/mol 0 
D12 0 337.15 g/mol 0.00 g/mol 0 
E12 0 385.21 g/mol 0.00 g/mol 0 
F12 0,16 331.23 g/mol 331.19 g/mol 10343,58 
G12 0,08 298.20 g/mol 298.17 g/mol 15521,58 
H12 0 332.22 g/mol 332.21 g/mol 60,37 
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B.3 Screening plates ori.hya.10-19 
B.3.1 Starting materials of plates ori.hya.10-19 
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B.3.2 Mass spectral analysis of plates ori.hya.10-19 
ori.hya.10 
 
 
 
  
 
 
 
Well Peak width Expected mass Found mass Intensity 
A1         
B1         
C1         
D1         
E1         
F1         
G1         
H1         
A2 0 326.33 g/mol 0.00 g/mol 0 
B2 0 240.24 g/mol 0.00 g/mol 0 
C2 0 198.18 g/mol 0.00 g/mol 0 
D2 0 254.26 g/mol 0.00 g/mol 0 
E2 0 254.26 g/mol 0.00 g/mol 0 
F2 0 360.18 g/mol 0.00 g/mol 0 
G2 0 224.20 g/mol 0.00 g/mol 0 
H2 0,04 250.19 g/mol 250.18 g/mol 595,68 
A3 0 356.30 g/mol 0.00 g/mol 0 
B3 0 270.21 g/mol 0.00 g/mol 0 
C3 0 228.15 g/mol 0.00 g/mol 0 
D3 0 284.23 g/mol 0.00 g/mol 0 
E3 0 284.23 g/mol 0.00 g/mol 0 
F3 0 390.15 g/mol 0.00 g/mol 0 
G3 0 254.17 g/mol 0.00 g/mol 0 
H3 0 280.16 g/mol 0.00 g/mol 0 
A4 0 338.33 g/mol 0.00 g/mol 0 
B4 0 252.24 g/mol 0.00 g/mol 0 
C4 0 210.18 g/mol 0.00 g/mol 0 
D4 0 266.26 g/mol 266.19 g/mol 72,97 
E4 0,02 266.26 g/mol 266.24 g/mol 616,27 
F4 0 372.18 g/mol 0.00 g/mol 0 
G4 0 236.20 g/mol 0.00 g/mol 0 
H4 0 262.19 g/mol 0.00 g/mol 0 
A5 0 299.24 g/mol 0.00 g/mol 0 
B5 0 213.15 g/mol 0.00 g/mol 0 
C5 0 171.09 g/mol 0.00 g/mol 0 
D5 0 227.17 g/mol 0.00 g/mol 0 
E5 0 227.17 g/mol 0.00 g/mol 0 
F5 0 333.09 g/mol 0.00 g/mol 0 
G5 0 197.11 g/mol 0.00 g/mol 0 
H5 0 223.10 g/mol 0.00 g/mol 0 
A6 0 316.26 g/mol 0.00 g/mol 0 
B6 0 230.17 g/mol 0.00 g/mol 0 
C6 0 188.11 g/mol 0.00 g/mol 0 
D6 0 244.19 g/mol 244.19 g/mol 833,15 
E6 0 244.19 g/mol 0.00 g/mol 0 
F6 0 350.11 g/mol 0.00 g/mol 0 
G6 0 214.13 g/mol 0.00 g/mol 0 
H6 0 240.12 g/mol 0.00 g/mol 0 
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A7 0 308.24 g/mol 0.00 g/mol 0 
B7 0 222.15 g/mol 0.00 g/mol 0 
C7 0 180.09 g/mol 0.00 g/mol 0 
D7 0 236.17 g/mol 0.00 g/mol 0 
E7 0 236.17 g/mol 0.00 g/mol 0 
F7 0 342.09 g/mol 0.00 g/mol 0 
G7 0 206.11 g/mol 0.00 g/mol 0 
H7 0 232.09 g/mol 0.00 g/mol 0 
A8 0 328.26 g/mol 0.00 g/mol 0 
B8 0 242.17 g/mol 0.00 g/mol 0 
C8 0,02 200.11 g/mol 200.05 g/mol 310,39 
D8 0 256.19 g/mol 0.00 g/mol 0 
E8 0 256.19 g/mol 0.00 g/mol 0 
F8 0 362.11 g/mol 0.00 g/mol 0 
G8 0 226.13 g/mol 0.00 g/mol 0 
H8 0 252.12 g/mol 0.00 g/mol 0 
A9 0 358.23 g/mol 0.00 g/mol 0 
B9 0 272.14 g/mol 0.00 g/mol 0 
C9 0 230.08 g/mol 0.00 g/mol 0 
D9 0 286.16 g/mol 0.00 g/mol 0 
E9 0 286.16 g/mol 286.19 g/mol 77,03 
F9 0 392.08 g/mol 0.00 g/mol 0 
G9 0 256.10 g/mol 0.00 g/mol 0 
H9 0 282.09 g/mol 0.00 g/mol 0 
A10 0 330.24 g/mol 0.00 g/mol 0 
B10 0 244.15 g/mol 0.00 g/mol 0 
C10 0 202.09 g/mol 0.00 g/mol 0 
D10 0 258.17 g/mol 0.00 g/mol 0 
E10 0 258.17 g/mol 0.00 g/mol 0 
F10 0 364.09 g/mol 0.00 g/mol 0 
G10 0 228.11 g/mol 0.00 g/mol 0 
H10 0 254.09 g/mol 0.00 g/mol 0 
A11 0 315.24 g/mol 0.00 g/mol 0 
B11 0 229.15 g/mol 0.00 g/mol 0 
C11 0 187.09 g/mol 0.00 g/mol 0 
D11 0 243.16 g/mol 0.00 g/mol 0 
E11 0 243.16 g/mol 0.00 g/mol 0 
F11 0 349.09 g/mol 0.00 g/mol 0 
G11 0 213.11 g/mol 0.00 g/mol 0 
H11 0 239.09 g/mol 0.00 g/mol 0 
A12 0 334.25 g/mol 0.00 g/mol 0 
B12 0 248.16 g/mol 0.00 g/mol 0 
C12 0 206.10 g/mol 0.00 g/mol 0 
D12 0 262.18 g/mol 0.00 g/mol 0 
E12 0 262.18 g/mol 0.00 g/mol 0 
F12 0 368.10 g/mol 0.00 g/mol 0 
G12 0 232.12 g/mol 0.00 g/mol 0 
H12 0 258.10 g/mol 0.00 g/mol 0 
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Well Peak width Expected mass Found mass Intensity 
A1         
B1         
C1         
D1         
E1         
F1         
G1         
H1         
A2 0 249.19 g/mol 0.00 g/mol 0 
B2 0 249.19 g/mol 0.00 g/mol 0 
C2 0 252.24 g/mol 0.00 g/mol 0 
D2 0 250.19 g/mol 0.00 g/mol 0 
E2 0 269.27 g/mol 0.00 g/mol 0 
F2 0 292.19 g/mol 292.12 g/mol 766,22 
G2 0,02 304.23 g/mol 304.25 g/mol 695 
H2 0 244.19 g/mol 0.00 g/mol 0 
A3 0 279.16 g/mol 0.00 g/mol 0 
B3 0 279.16 g/mol 0.00 g/mol 0 
C3 0 282.21 g/mol 0.00 g/mol 0 
D3 0 280.16 g/mol 0.00 g/mol 0 
E3 0 299.24 g/mol 0.00 g/mol 0 
F3 0 322.16 g/mol 322.19 g/mol 127,14 
G3 0 334.20 g/mol 0.00 g/mol 0 
H3 0 274.16 g/mol 0.00 g/mol 0 
A4 0 261.19 g/mol 0.00 g/mol 0 
B4 0 261.19 g/mol 0.00 g/mol 0 
C4 0 264.24 g/mol 0.00 g/mol 0 
D4 0 262.19 g/mol 0.00 g/mol 0 
E4 0,04 281.27 g/mol 281.29 g/mol 680,12 
F4 0 304.19 g/mol 304.22 g/mol 458,78 
G4 0,02 316.23 g/mol 316.26 g/mol 661,53 
H4 0 256.19 g/mol 0.00 g/mol 0 
A5 0 222.10 g/mol 0.00 g/mol 0 
B5 0 222.10 g/mol 0.00 g/mol 0 
C5 0 225.15 g/mol 0.00 g/mol 0 
D5 0 223.10 g/mol 0.00 g/mol 0 
E5 0 242.18 g/mol 0.00 g/mol 0 
F5 0 265.10 g/mol 0.00 g/mol 0 
G5 0 277.14 g/mol 0.00 g/mol 0 
H5 0 217.10 g/mol 0.00 g/mol 0 
A6 0 239.12 g/mol 0.00 g/mol 0 
B6 0 239.12 g/mol 0.00 g/mol 0 
C6 0,02 242.17 g/mol 242.19 g/mol 296,91 
D6 0 240.12 g/mol 240.16 g/mol 44,98 
E6 0 259.20 g/mol 0.00 g/mol 0 
F6 0 282.12 g/mol 0.00 g/mol 0 
G6 0,02 294.16 g/mol 294.20 g/mol 531,12 
H6 0 234.12 g/mol 0.00 g/mol 0 
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A7 0 231.10 g/mol 0.00 g/mol 0 
B7 0 231.10 g/mol 0.00 g/mol 0 
C7 0 234.15 g/mol 0.00 g/mol 0 
D7 0 232.09 g/mol 0.00 g/mol 0 
E7 0 251.18 g/mol 0.00 g/mol 0 
F7 0 274.10 g/mol 0.00 g/mol 0 
G7 0 286.14 g/mol 0.00 g/mol 0 
H7 0 226.10 g/mol 0.00 g/mol 0 
A8 0 251.12 g/mol 0.00 g/mol 0 
B8 0 251.12 g/mol 0.00 g/mol 0 
C8 0 254.17 g/mol 0.00 g/mol 0 
D8 0 252.12 g/mol 0.00 g/mol 0 
E8 0 271.20 g/mol 0.00 g/mol 0 
F8 0 294.12 g/mol 294.17 g/mol 144,91 
G8 0,02 306.16 g/mol 306.20 g/mol 474,73 
H8 0 246.12 g/mol 0.00 g/mol 0 
A9 0 281.09 g/mol 0.00 g/mol 0 
B9 0 281.09 g/mol 0.00 g/mol 0 
C9 0 284.14 g/mol 0.00 g/mol 0 
D9 0 282.09 g/mol 0.00 g/mol 0 
E9 0 301.17 g/mol 0.00 g/mol 0 
F9 0 324.09 g/mol 0.00 g/mol 0 
G9 0 336.13 g/mol 0.00 g/mol 0 
H9 0 276.09 g/mol 0.00 g/mol 0 
A10 0 253.10 g/mol 0.00 g/mol 0 
B10 0 253.10 g/mol 0.00 g/mol 0 
C10 0 256.15 g/mol 0.00 g/mol 0 
D10 0 254.09 g/mol 0.00 g/mol 0 
E10 0,06 273.18 g/mol 273.09 g/mol 992,71 
F10 0 296.09 g/mol 0.00 g/mol 0 
G10 0 308.14 g/mol 0.00 g/mol 0 
H10 0 248.10 g/mol 0.00 g/mol 0 
A11 0 238.10 g/mol 0.00 g/mol 0 
B11 0 238.10 g/mol 0.00 g/mol 0 
C11 0 241.14 g/mol 0.00 g/mol 0 
D11 0 239.09 g/mol 0.00 g/mol 0 
E11 0 258.18 g/mol 0.00 g/mol 0 
F11 0 281.09 g/mol 0.00 g/mol 0 
G11 0 293.14 g/mol 0.00 g/mol 0 
H11 0 233.10 g/mol 0.00 g/mol 0 
A12 0 257.11 g/mol 0.00 g/mol 0 
B12 0 257.11 g/mol 0.00 g/mol 0 
C12 0 260.16 g/mol 0.00 g/mol 0 
D12 0 258.10 g/mol 0.00 g/mol 0 
E12 0 277.19 g/mol 0.00 g/mol 0 
F12 0 300.10 g/mol 0.00 g/mol 0 
G12 0 312.15 g/mol 0.00 g/mol 0 
H12 0 252.11 g/mol 0.00 g/mol 0 
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Well Peak width Expected mass Found mass Intensity 
A1         
B1         
C1         
D1         
E1         
F1         
G1         
H1         
A2 0,02 424.43 g/mol 424.44 g/mol 685,28 
B2 0 338.33 g/mol 0.00 g/mol 0 
C2 0 296.28 g/mol 0.00 g/mol 0 
D2 0 352.35 g/mol 352.37 g/mol 15,57 
E2 0 352.35 g/mol 0.00 g/mol 0 
F2 0,04 458.27 g/mol 458.32 g/mol 1508,92 
G2 0 322.29 g/mol 0.00 g/mol 0 
H2 0 348.28 g/mol 348.31 g/mol 253,39 
A3 0 454.39 g/mol 0.00 g/mol 0 
B3 0 368.30 g/mol 0.00 g/mol 0 
C3 0 326.24 g/mol 326.27 g/mol 858,98 
D3 0 382.32 g/mol 382.35 g/mol 503,88 
E3 0 382.32 g/mol 0.00 g/mol 0 
F3 0,02 488.24 g/mol 488.30 g/mol 809,32 
G3 0 352.26 g/mol 352.30 g/mol 239,62 
H3 0,04 378.25 g/mol 378.29 g/mol 5187,38 
A4 0,02 436.43 g/mol 436.45 g/mol 712,84 
B4 0 350.33 g/mol 0.00 g/mol 0 
C4 0 308.27 g/mol 308.30 g/mol 258,85 
D4 0,02 364.35 g/mol 364.36 g/mol 1302,88 
E4 0 364.35 g/mol 0.00 g/mol 0 
F4 0,04 470.27 g/mol 470.32 g/mol 2114,48 
G4 0,02 334.29 g/mol 334.31 g/mol 4360,56 
H4 0,08 360.28 g/mol 360.31 g/mol 7503,66 
A5 0 397.33 g/mol 0.00 g/mol 0 
B5 0 311.24 g/mol 0.00 g/mol 0 
C5 0 269.18 g/mol 269.21 g/mol 756,2 
D5 0 325.26 g/mol 325.30 g/mol 362,23 
E5 0,02 325.26 g/mol 325.29 g/mol 598,47 
F5 0,06 431.18 g/mol 431.25 g/mol 2000,59 
G5 0,02 295.20 g/mol 295.25 g/mol 2595,72 
H5 0 321.19 g/mol 321.24 g/mol 271,83 
A6 0 414.36 g/mol 414.41 g/mol 170,41 
B6 0 328.26 g/mol 0.00 g/mol 0 
C6 0,08 286.21 g/mol 286.23 g/mol 4047,16 
D6 0 342.28 g/mol 342.31 g/mol 819,31 
E6 0 342.28 g/mol 342.31 g/mol 278,25 
F6 0,06 448.20 g/mol 448.28 g/mol 1934,16 
G6 0,04 312.22 g/mol 312.29 g/mol 1552,42 
H6 0,02 338.21 g/mol 338.25 g/mol 4248,56 
404 Appendix II 
A7 0 406.33 g/mol 0.00 g/mol 0 
B7 0 320.24 g/mol 0.00 g/mol 0 
C7 0 278.18 g/mol 0.00 g/mol 0 
D7 0 334.26 g/mol 0.00 g/mol 0 
E7 0 334.26 g/mol 0.00 g/mol 0 
F7 0 440.18 g/mol 0.00 g/mol 0 
G7 0 304.20 g/mol 0.00 g/mol 0 
H7 0 330.19 g/mol 0.00 g/mol 0 
A8 0 426.36 g/mol 0.00 g/mol 0 
B8 0 340.26 g/mol 0.00 g/mol 0 
C8 0,02 298.20 g/mol 298.25 g/mol 476,57 
D8 0,02 354.28 g/mol 354.32 g/mol 743,26 
E8 0 354.28 g/mol 0.00 g/mol 0 
F8 0,02 460.20 g/mol 460.28 g/mol 800,76 
G8 0,02 324.22 g/mol 324.26 g/mol 887,66 
H8 0,06 350.21 g/mol 350.25 g/mol 5803,76 
A9 0 456.32 g/mol 0.00 g/mol 0 
B9 0 370.23 g/mol 0.00 g/mol 0 
C9 0 328.17 g/mol 328.22 g/mol 331,89 
D9 0,02 384.25 g/mol 384.30 g/mol 565,79 
E9 0 384.25 g/mol 0.00 g/mol 0 
F9 0,02 490.17 g/mol 490.26 g/mol 674,71 
G9 0,02 354.19 g/mol 354.25 g/mol 890,53 
H9 0,02 380.18 g/mol 380.24 g/mol 1043,03 
A10 0 428.33 g/mol 0.00 g/mol 0 
B10 0 342.24 g/mol 0.00 g/mol 0 
C10 0,06 300.18 g/mol 300.22 g/mol 1344 
D10 0 356.26 g/mol 0.00 g/mol 0 
E10 0 356.26 g/mol 0.00 g/mol 0 
F10 0 462.18 g/mol 0.00 g/mol 0 
G10 0 326.20 g/mol 0.00 g/mol 0 
H10 0 352.18 g/mol 0.00 g/mol 0 
A11 0 413.33 g/mol 0.00 g/mol 0 
B11 0 327.24 g/mol 0.00 g/mol 0 
C11 0 285.18 g/mol 0.00 g/mol 0 
D11 0 341.26 g/mol 0.00 g/mol 0 
E11 0 341.26 g/mol 0.00 g/mol 0 
F11 0 447.18 g/mol 0.00 g/mol 0 
G11 0 311.20 g/mol 0.00 g/mol 0 
H11 0 337.18 g/mol 0.00 g/mol 0 
A12 0 432.34 g/mol 0.00 g/mol 0 
B12 0 346.25 g/mol 0.00 g/mol 0 
C12 0 304.19 g/mol 0.00 g/mol 0 
D12 0 360.27 g/mol 0.00 g/mol 0 
E12 0 360.27 g/mol 0.00 g/mol 0 
F12 0 466.19 g/mol 466.27 g/mol 86,47 
G12 0 330.21 g/mol 0.00 g/mol 0 
H12 0,02 356.19 g/mol 356.25 g/mol 658,3 
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Well Peak width Expected mass Found mass Intensity 
A1         
B1         
C1         
D1         
E1         
F1         
G1         
H1         
A2 0 347.29 g/mol 0.00 g/mol 0 
B2 0 347.29 g/mol 0.00 g/mol 0 
C2 0 350.33 g/mol 0.00 g/mol 0 
D2 0,04 348.28 g/mol 348.31 g/mol 1094,69 
E2 0 367.37 g/mol 0.00 g/mol 0 
F2 0 390.28 g/mol 0.00 g/mol 0 
G2 0 402.33 g/mol 0.00 g/mol 0 
H2 0 342.28 g/mol 0.00 g/mol 0 
A3 0 377.25 g/mol 377.31 g/mol 159,5 
B3 0 377.25 g/mol 0.00 g/mol 0 
C3 0,02 380.30 g/mol 380.34 g/mol 1186,01 
D3 0 378.25 g/mol 378.30 g/mol 2846,47 
E3 0 397.33 g/mol 0.00 g/mol 0 
F3 0,02 420.25 g/mol 420.31 g/mol 977,35 
G3 0 432.29 g/mol 432.34 g/mol 1503,2 
H3 0 372.25 g/mol 0.00 g/mol 0 
A4 0 359.29 g/mol 359.33 g/mol 404,9 
B4 0 359.29 g/mol 0.00 g/mol 0 
C4 0,02 362.33 g/mol 362.36 g/mol 1812,37 
D4 0,1 360.28 g/mol 360.32 g/mol 13390,62 
E4 0 379.37 g/mol 379.39 g/mol 152,65 
F4 0,04 402.28 g/mol 402.33 g/mol 1243,05 
G4 0 414.33 g/mol 414.37 g/mol 646,28 
H4 0,04 354.28 g/mol 354.33 g/mol 1137,45 
A5 0,1 320.20 g/mol 320.26 g/mol 2045,48 
B5 0 320.20 g/mol 0.00 g/mol 0 
C5 0,02 323.24 g/mol 323.31 g/mol 1068,37 
D5 0,14 321.19 g/mol 321.24 g/mol 7852,2 
E5 0 340.27 g/mol 0.00 g/mol 0 
F5 0,04 363.19 g/mol 363.25 g/mol 1286,92 
G5 0 375.23 g/mol 375.28 g/mol 5694,58 
H5 0 315.19 g/mol 0.00 g/mol 0 
A6 0 337.22 g/mol 337.27 g/mol 316,51 
B6 0 337.22 g/mol 0.00 g/mol 0 
C6 0,02 340.26 g/mol 340.30 g/mol 838,66 
D6 0,16 338.21 g/mol 338.26 g/mol 6119,1 
E6 0 357.30 g/mol 357.34 g/mol 115,8 
F6 0 380.21 g/mol 380.27 g/mol 793,06 
G6 0,04 392.26 g/mol 392.30 g/mol 7377,3 
H6 0,04 332.21 g/mol 332.24 g/mol 886,63 
406 Appendix II 
A7 0 329.19 g/mol 0.00 g/mol 0 
B7 0 329.19 g/mol 0.00 g/mol 0 
C7 0 332.24 g/mol 0.00 g/mol 0 
D7 0 330.19 g/mol 330.25 g/mol 132,13 
E7 0 349.27 g/mol 0.00 g/mol 0 
F7 0 372.19 g/mol 0.00 g/mol 0 
G7 0 384.23 g/mol 0.00 g/mol 0 
H7 0 324.19 g/mol 324.25 g/mol 189,89 
A8 0 349.22 g/mol 349.27 g/mol 605,29 
B8 0 349.22 g/mol 0.00 g/mol 0 
C8 0 352.26 g/mol 352.31 g/mol 261,8 
D8 0,12 350.21 g/mol 350.26 g/mol 6900,78 
E8 0,02 369.30 g/mol 369.26 g/mol 591,81 
F8 0 392.21 g/mol 392.27 g/mol 294,98 
G8 0,04 404.26 g/mol 404.31 g/mol 1244,5 
H8 0 344.21 g/mol 0.00 g/mol 0 
A9 0 379.18 g/mol 379.25 g/mol 126,95 
B9 0 379.18 g/mol 0.00 g/mol 0 
C9 0 382.23 g/mol 382.29 g/mol 50,84 
D9 0,02 380.18 g/mol 380.24 g/mol 5404,8 
E9 0,02 399.26 g/mol 399.32 g/mol 648,16 
F9 0,02 422.18 g/mol 422.25 g/mol 884,15 
G9 0,02 434.22 g/mol 434.30 g/mol 743,71 
H9 0 374.18 g/mol 0.00 g/mol 0 
A10 0 351.19 g/mol 0.00 g/mol 0 
B10 0 351.19 g/mol 0.00 g/mol 0 
C10 0 354.24 g/mol 0.00 g/mol 0 
D10 0 352.18 g/mol 0.00 g/mol 0 
E10 0 371.27 g/mol 0.00 g/mol 0 
F10 0 394.19 g/mol 394.25 g/mol 385,35 
G10 0 406.23 g/mol 406.29 g/mol 166,47 
H10 0 346.19 g/mol 0.00 g/mol 0 
A11 0 336.19 g/mol 0.00 g/mol 0 
B11 0 336.19 g/mol 0.00 g/mol 0 
C11 0 339.24 g/mol 0.00 g/mol 0 
D11 0 337.18 g/mol 0.00 g/mol 0 
E11 0 356.27 g/mol 0.00 g/mol 0 
F11 0 379.18 g/mol 0.00 g/mol 0 
G11 0 391.23 g/mol 0.00 g/mol 0 
H11 0 331.19 g/mol 0.00 g/mol 0 
A12 0 355.20 g/mol 0.00 g/mol 0 
B12 0 355.20 g/mol 0.00 g/mol 0 
C12 0 358.25 g/mol 0.00 g/mol 0 
D12 0 356.19 g/mol 356.21 g/mol 33,08 
E12 0 375.28 g/mol 0.00 g/mol 0 
F12 0 398.20 g/mol 0.00 g/mol 0 
G12 0 410.24 g/mol 0.00 g/mol 0 
H12 0 350.20 g/mol 350.26 g/mol 137,74 
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Well Peak width Expected mass Found mass Intensity 
A1         
B1         
C1         
D1         
E1         
F1         
G1         
H1         
A2 0 446.36 g/mol 446.42 g/mol 159,67 
B2 0 360.27 g/mol 0.00 g/mol 0 
C2 0 318.21 g/mol 0.00 g/mol 0 
D2 0 374.29 g/mol 0.00 g/mol 0 
E2 0 374.29 g/mol 0.00 g/mol 0 
F2 0,02 480.21 g/mol 480.29 g/mol 880,97 
G2 0,02 344.23 g/mol 344.28 g/mol 602,41 
H2 0 370.21 g/mol 370.27 g/mol 198,58 
A3 0 476.33 g/mol 0.00 g/mol 0 
B3 0 390.24 g/mol 0.00 g/mol 0 
C3 0,02 348.18 g/mol 348.24 g/mol 629,69 
D3 0 404.26 g/mol 0.00 g/mol 0 
E3 0 404.26 g/mol 0.00 g/mol 0 
F3 0 510.18 g/mol 510.27 g/mol 244,33 
G3 0,04 374.20 g/mol 374.26 g/mol 1015,55 
H3 0,02 400.18 g/mol 400.26 g/mol 517,01 
A4 0,02 458.36 g/mol 458.41 g/mol 849,14 
B4 0 372.27 g/mol 0.00 g/mol 0 
C4 0 330.21 g/mol 330.26 g/mol 267,67 
D4 0,02 386.29 g/mol 386.34 g/mol 606,11 
E4 0 386.29 g/mol 0.00 g/mol 0 
F4 0,02 492.21 g/mol 492.30 g/mol 680,27 
G4 0 356.23 g/mol 0.00 g/mol 0 
H4 0 382.21 g/mol 382.28 g/mol 187,96 
A5 0 419.27 g/mol 419.33 g/mol 78 
B5 0 333.18 g/mol 0.00 g/mol 0 
C5 0,04 291.12 g/mol 291.18 g/mol 756,54 
D5 0,04 347.20 g/mol 347.25 g/mol 1327,46 
E5 0 347.20 g/mol 347.25 g/mol 142,33 
F5 0 453.12 g/mol 453.22 g/mol 87,63 
G5 0 317.14 g/mol 317.12 g/mol 210,41 
H5 0 343.12 g/mol 343.14 g/mol 52,59 
A6 0 436.29 g/mol 436.35 g/mol 269,78 
B6 0 350.20 g/mol 0.00 g/mol 0 
C6 0,04 308.14 g/mol 308.19 g/mol 1122,01 
D6 0,02 364.22 g/mol 364.27 g/mol 820,15 
E6 0 364.22 g/mol 0.00 g/mol 0 
F6 0 470.14 g/mol 470.23 g/mol 78,66 
G6 0 334.16 g/mol 334.22 g/mol 398,65 
H6 0,02 360.14 g/mol 360.21 g/mol 493,26 
408 Appendix II 
A7 0 428.27 g/mol 0.00 g/mol 0 
B7 0 342.17 g/mol 0.00 g/mol 0 
C7 0 300.12 g/mol 0.00 g/mol 0 
D7 0 356.19 g/mol 0.00 g/mol 0 
E7 0 356.19 g/mol 0.00 g/mol 0 
F7 0 462.11 g/mol 0.00 g/mol 0 
G7 0 326.13 g/mol 0.00 g/mol 0 
H7 0 352.12 g/mol 0.00 g/mol 0 
A8 0 448.29 g/mol 0.00 g/mol 0 
B8 0 362.20 g/mol 0.00 g/mol 0 
C8 0,02 320.14 g/mol 320.19 g/mol 573,39 
D8 0 376.22 g/mol 376.28 g/mol 127,06 
E8 0 376.22 g/mol 0.00 g/mol 0 
F8 0 482.14 g/mol 482.23 g/mol 338,17 
G8 0,06 346.16 g/mol 346.22 g/mol 1557,32 
H8 0 372.14 g/mol 372.22 g/mol 211,52 
A9 0 478.26 g/mol 0.00 g/mol 0 
B9 0 392.17 g/mol 0.00 g/mol 0 
C9 0 350.11 g/mol 0.00 g/mol 0 
D9 0 406.19 g/mol 0.00 g/mol 0 
E9 0 406.19 g/mol 0.00 g/mol 0 
F9 0 512.11 g/mol 0.00 g/mol 0 
G9 0,02 376.13 g/mol 376.20 g/mol 660,02 
H9 0,04 402.11 g/mol 402.21 g/mol 982,41 
A10 0 450.26 g/mol 0.00 g/mol 0 
B10 0 364.17 g/mol 0.00 g/mol 0 
C10 0 322.11 g/mol 0.00 g/mol 0 
D10 0 378.19 g/mol 0.00 g/mol 0 
E10 0 378.19 g/mol 0.00 g/mol 0 
F10 0 484.11 g/mol 0.00 g/mol 0 
G10 0 348.13 g/mol 0.00 g/mol 0 
H10 0 374.12 g/mol 0.00 g/mol 0 
A11 0 435.26 g/mol 0.00 g/mol 0 
B11 0 349.17 g/mol 0.00 g/mol 0 
C11 0 307.11 g/mol 0.00 g/mol 0 
D11 0 363.19 g/mol 0.00 g/mol 0 
E11 0 363.19 g/mol 0.00 g/mol 0 
F11 0 469.11 g/mol 0.00 g/mol 0 
G11 0 333.13 g/mol 0.00 g/mol 0 
H11 0 359.12 g/mol 0.00 g/mol 0 
A12 0 454.27 g/mol 0.00 g/mol 0 
B12 0 368.18 g/mol 0.00 g/mol 0 
C12 0 326.12 g/mol 0.00 g/mol 0 
D12 0 382.20 g/mol 0.00 g/mol 0 
E12 0 382.20 g/mol 0.00 g/mol 0 
F12 0 488.12 g/mol 0.00 g/mol 0 
G12 0 352.14 g/mol 0.00 g/mol 0 
H12 0 378.13 g/mol 0.00 g/mol 0 
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Well Peak width Expected mass Found mass Intensity 
A1         
B1         
C1         
D1         
E1         
F1         
G1         
H1         
A2 0 369.22 g/mol 369.28 g/mol 47,88 
B2 0 369.22 g/mol 0.00 g/mol 0 
C2 0 372.27 g/mol 0.00 g/mol 0 
D2 0 370.21 g/mol 370.27 g/mol 416,83 
E2 0 389.30 g/mol 0.00 g/mol 0 
F2 0 412.22 g/mol 0.00 g/mol 0 
G2 0 424.26 g/mol 0.00 g/mol 0 
H2 0 364.22 g/mol 0.00 g/mol 0 
A3 0 399.19 g/mol 399.25 g/mol 288,21 
B3 0 399.19 g/mol 0.00 g/mol 0 
C3 0 402.24 g/mol 402.30 g/mol 116,53 
D3 0,04 400.18 g/mol 400.25 g/mol 1162,33 
E3 0 419.27 g/mol 0.00 g/mol 0 
F3 0 442.18 g/mol 442.26 g/mol 108,93 
G3 0,04 454.23 g/mol 454.29 g/mol 1394,39 
H3 0 394.19 g/mol 394.25 g/mol 97,33 
A4 0,02 381.22 g/mol 381.27 g/mol 621,63 
B4 0 381.22 g/mol 0.00 g/mol 0 
C4 0 384.27 g/mol 384.31 g/mol 272,4 
D4 0 382.21 g/mol 382.26 g/mol 4861,51 
E4 0 401.30 g/mol 401.35 g/mol 67,18 
F4 0,06 424.21 g/mol 424.28 g/mol 1788,38 
G4 0,04 436.26 g/mol 436.32 g/mol 1167,04 
H4 0,02 376.22 g/mol 376.27 g/mol 645,94 
A5 0 342.13 g/mol 0.00 g/mol 0 
B5 0 342.13 g/mol 0.00 g/mol 0 
C5 0,02 345.18 g/mol 345.23 g/mol 693,43 
D5 0,02 343.12 g/mol 343.19 g/mol 685,86 
E5 0 362.21 g/mol 0.00 g/mol 0 
F5 0 385.12 g/mol 385.20 g/mol 56,87 
G5 0 397.17 g/mol 0.00 g/mol 0 
H5 0 337.13 g/mol 0.00 g/mol 0 
A6 0 359.15 g/mol 0.00 g/mol 0 
B6 0 359.15 g/mol 0.00 g/mol 0 
C6 0 362.20 g/mol 362.25 g/mol 485,1 
D6 0 360.14 g/mol 360.20 g/mol 1080,24 
E6 0 379.23 g/mol 0.00 g/mol 0 
F6 0 402.15 g/mol 402.22 g/mol 108,91 
G6 0 414.19 g/mol 414.25 g/mol 1559,75 
H6 0 354.15 g/mol 354.21 g/mol 36,5 
410 Appendix II 
A7 0 351.13 g/mol 0.00 g/mol 0 
B7 0 351.13 g/mol 0.00 g/mol 0 
C7 0 354.17 g/mol 0.00 g/mol 0 
D7 0 352.12 g/mol 0.00 g/mol 0 
E7 0 371.21 g/mol 0.00 g/mol 0 
F7 0 394.12 g/mol 0.00 g/mol 0 
G7 0 406.17 g/mol 0.00 g/mol 0 
H7 0 346.12 g/mol 0.00 g/mol 0 
A8 0 371.15 g/mol 371.22 g/mol 128,18 
B8 0 371.15 g/mol 0.00 g/mol 0 
C8 0,02 374.20 g/mol 374.26 g/mol 628,49 
D8 0,02 372.14 g/mol 372.22 g/mol 640 
E8 0 391.23 g/mol 0.00 g/mol 0 
F8 0,04 414.15 g/mol 414.23 g/mol 1204,52 
G8 0 426.19 g/mol 426.26 g/mol 225,38 
H8 0 366.15 g/mol 0.00 g/mol 0 
A9 0 401.12 g/mol 401.21 g/mol 25,64 
B9 0 401.12 g/mol 0.00 g/mol 0 
C9 0 404.17 g/mol 0.00 g/mol 0 
D9 0,04 402.11 g/mol 402.20 g/mol 1040,92 
E9 0 421.20 g/mol 0.00 g/mol 0 
F9 0,02 444.11 g/mol 444.20 g/mol 624,82 
G9 0,04 456.16 g/mol 456.24 g/mol 1188,47 
H9 0 396.12 g/mol 0.00 g/mol 0 
A10 0 373.12 g/mol 0.00 g/mol 0 
B10 0 373.12 g/mol 0.00 g/mol 0 
C10 0 376.17 g/mol 0.00 g/mol 0 
D10 0 374.12 g/mol 0.00 g/mol 0 
E10 0 393.20 g/mol 0.00 g/mol 0 
F10 0 416.12 g/mol 0.00 g/mol 0 
G10 0 428.16 g/mol 0.00 g/mol 0 
H10 0 368.12 g/mol 0.00 g/mol 0 
A11 0 358.12 g/mol 0.00 g/mol 0 
B11 0 358.12 g/mol 0.00 g/mol 0 
C11 0 361.17 g/mol 0.00 g/mol 0 
D11 0 359.12 g/mol 0.00 g/mol 0 
E11 0 378.20 g/mol 0.00 g/mol 0 
F11 0 401.12 g/mol 0.00 g/mol 0 
G11 0 413.16 g/mol 0.00 g/mol 0 
H11 0 353.12 g/mol 0.00 g/mol 0 
A12 0 377.13 g/mol 0.00 g/mol 0 
B12 0 377.13 g/mol 0.00 g/mol 0 
C12 0 380.18 g/mol 0.00 g/mol 0 
D12 0 378.13 g/mol 0.00 g/mol 0 
E12 0 397.21 g/mol 0.00 g/mol 0 
F12 0 420.13 g/mol 0.00 g/mol 0 
G12 0 432.17 g/mol 0.00 g/mol 0 
H12 0 372.13 g/mol 0.00 g/mol 0 
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Well Peak width Expected mass Found mass Intensity 
A1         
B1         
C1         
D1         
E1         
F1         
G1         
H1         
A2 0 368.35 g/mol 0.00 g/mol 0 
B2 0 282.26 g/mol 0.00 g/mol 0 
C2 0 240.20 g/mol 0.00 g/mol 0 
D2 0 296.28 g/mol 0.00 g/mol 0 
E2 0 296.28 g/mol 0.00 g/mol 0 
F2 0 402.20 g/mol 0.00 g/mol 0 
G2 0 266.22 g/mol 0.00 g/mol 0 
H2 0 292.20 g/mol 0.00 g/mol 0 
A3 0 398.32 g/mol 0.00 g/mol 0 
B3 0 312.22 g/mol 0.00 g/mol 0 
C3 0 270.17 g/mol 0.00 g/mol 0 
D3 0 326.24 g/mol 0.00 g/mol 0 
E3 0 326.24 g/mol 0.00 g/mol 0 
F3 0 432.17 g/mol 0.00 g/mol 0 
G3 0 296.18 g/mol 0.00 g/mol 0 
H3 0 322.17 g/mol 0.00 g/mol 0 
A4 0 380.35 g/mol 0.00 g/mol 0 
B4 0 294.26 g/mol 0.00 g/mol 0 
C4 0 252.20 g/mol 0.00 g/mol 0 
D4 0 308.27 g/mol 0.00 g/mol 0 
E4 0 308.27 g/mol 0.00 g/mol 0 
F4 0 414.20 g/mol 0.00 g/mol 0 
G4 0 278.22 g/mol 0.00 g/mol 0 
H4 0,02 304.20 g/mol 304.28 g/mol 367,45 
A5 0 341.26 g/mol 0.00 g/mol 0 
B5 0 255.16 g/mol 0.00 g/mol 0 
C5 0 213.11 g/mol 0.00 g/mol 0 
D5 0 269.18 g/mol 0.00 g/mol 0 
E5 0 269.18 g/mol 0.00 g/mol 0 
F5 0 375.11 g/mol 0.00 g/mol 0 
G5 0 239.12 g/mol 0.00 g/mol 0 
H5 0 265.11 g/mol 0.00 g/mol 0 
A6 0 358.28 g/mol 0.00 g/mol 0 
B6 0 272.19 g/mol 0.00 g/mol 0 
C6 0 230.13 g/mol 0.00 g/mol 0 
D6 0 286.21 g/mol 0.00 g/mol 0 
E6 0 286.21 g/mol 0.00 g/mol 0 
F6 0 392.13 g/mol 0.00 g/mol 0 
G6 0 256.15 g/mol 0.00 g/mol 0 
H6 0 282.13 g/mol 282.22 g/mol 327,3 
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A7 0 350.25 g/mol 0.00 g/mol 0 
B7 0 264.16 g/mol 0.00 g/mol 0 
C7 0 222.10 g/mol 0.00 g/mol 0 
D7 0 278.18 g/mol 0.00 g/mol 0 
E7 0 278.18 g/mol 0.00 g/mol 0 
F7 0 384.10 g/mol 0.00 g/mol 0 
G7 0 248.12 g/mol 0.00 g/mol 0 
H7 0 274.11 g/mol 0.00 g/mol 0 
A8 0 370.28 g/mol 0.00 g/mol 0 
B8 0 284.19 g/mol 0.00 g/mol 0 
C8 0 242.13 g/mol 0.00 g/mol 0 
D8 0 298.20 g/mol 0.00 g/mol 0 
E8 0 298.20 g/mol 0.00 g/mol 0 
F8 0 404.13 g/mol 0.00 g/mol 0 
G8 0 268.15 g/mol 0.00 g/mol 0 
H8 0 294.13 g/mol 294.21 g/mol 617,65 
A9 0 400.25 g/mol 0.00 g/mol 0 
B9 0 314.15 g/mol 0.00 g/mol 0 
C9 0 272.10 g/mol 0.00 g/mol 0 
D9 0 328.17 g/mol 0.00 g/mol 0 
E9 0 328.17 g/mol 0.00 g/mol 0 
F9 0 434.10 g/mol 0.00 g/mol 0 
G9 0 298.11 g/mol 0.00 g/mol 0 
H9 0 324.10 g/mol 0.00 g/mol 0 
A10 0 372.25 g/mol 0.00 g/mol 0 
B10 0 286.16 g/mol 0.00 g/mol 0 
C10 0 244.10 g/mol 0.00 g/mol 0 
D10 0 300.18 g/mol 0.00 g/mol 0 
E10 0 300.18 g/mol 0.00 g/mol 0 
F10 0 406.10 g/mol 0.00 g/mol 0 
G10 0 270.12 g/mol 0.00 g/mol 0 
H10 0 296.11 g/mol 0.00 g/mol 0 
A11 0 357.25 g/mol 0.00 g/mol 0 
B11 0 271.16 g/mol 271.25 g/mol 857,77 
C11 0,18 229.10 g/mol 229.14 g/mol 28144,44 
D11 0 285.18 g/mol 0.00 g/mol 0 
E11 0 285.18 g/mol 0.00 g/mol 0 
F11 0 391.10 g/mol 0.00 g/mol 0 
G11 0 255.12 g/mol 0.00 g/mol 0 
H11 0 281.10 g/mol 0.00 g/mol 0 
A12 0 376.26 g/mol 0.00 g/mol 0 
B12 0 290.17 g/mol 0.00 g/mol 0 
C12 0 248.11 g/mol 0.00 g/mol 0 
D12 0 304.19 g/mol 0.00 g/mol 0 
E12 0 304.19 g/mol 0.00 g/mol 0 
F12 0 410.11 g/mol 0.00 g/mol 0 
G12 0 274.13 g/mol 0.00 g/mol 0 
H12 0 300.12 g/mol 0.00 g/mol 0 
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Well Peak width Expected mass Found mass Intensity 
A1         
B1         
C1         
D1         
E1         
F1         
G1         
H1         
A2 0 291.21 g/mol 0.00 g/mol 0 
B2 0 291.21 g/mol 0.00 g/mol 0 
C2 0 294.26 g/mol 0.00 g/mol 0 
D2 0 292.20 g/mol 0.00 g/mol 0 
E2 0 311.29 g/mol 0.00 g/mol 0 
F2 0 334.20 g/mol 0.00 g/mol 0 
G2 0 346.25 g/mol 0.00 g/mol 0 
H2 0 286.21 g/mol 0.00 g/mol 0 
A3 0 321.18 g/mol 0.00 g/mol 0 
B3 0 321.18 g/mol 0.00 g/mol 0 
C3 0 324.22 g/mol 0.00 g/mol 0 
D3 0 322.17 g/mol 0.00 g/mol 0 
E3 0 341.26 g/mol 0.00 g/mol 0 
F3 0 364.17 g/mol 0.00 g/mol 0 
G3 0 376.22 g/mol 0.00 g/mol 0 
H3 0 316.17 g/mol 0.00 g/mol 0 
A4 0 303.21 g/mol 0.00 g/mol 0 
B4 0 303.21 g/mol 0.00 g/mol 0 
C4 0 306.25 g/mol 0.00 g/mol 0 
D4 0,02 304.20 g/mol 304.28 g/mol 537,62 
E4 0 323.29 g/mol 0.00 g/mol 0 
F4 0 346.20 g/mol 0.00 g/mol 0 
G4 0 358.25 g/mol 0.00 g/mol 0 
H4 0 298.20 g/mol 0.00 g/mol 0 
A5 0 264.12 g/mol 0.00 g/mol 0 
B5 0 264.12 g/mol 0.00 g/mol 0 
C5 0 267.16 g/mol 0.00 g/mol 0 
D5 0 265.11 g/mol 0.00 g/mol 0 
E5 0 284.20 g/mol 0.00 g/mol 0 
F5 0 307.11 g/mol 0.00 g/mol 0 
G5 0 319.16 g/mol 0.00 g/mol 0 
H5 0 259.11 g/mol 0.00 g/mol 0 
A6 0 281.14 g/mol 0.00 g/mol 0 
B6 0 281.14 g/mol 0.00 g/mol 0 
C6 0 284.19 g/mol 0.00 g/mol 0 
D6 0,02 282.13 g/mol 282.20 g/mol 401,37 
E6 0 301.22 g/mol 0.00 g/mol 0 
F6 0 324.13 g/mol 0.00 g/mol 0 
G6 0 336.18 g/mol 0.00 g/mol 0 
H6 0 276.14 g/mol 0.00 g/mol 0 
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A7 0 273.11 g/mol 0.00 g/mol 0 
B7 0 273.11 g/mol 0.00 g/mol 0 
C7 0 276.16 g/mol 0.00 g/mol 0 
D7 0 274.11 g/mol 0.00 g/mol 0 
E7 0 293.19 g/mol 0.00 g/mol 0 
F7 0 316.11 g/mol 0.00 g/mol 0 
G7 0 328.15 g/mol 0.00 g/mol 0 
H7 0 268.11 g/mol 0.00 g/mol 0 
A8 0 293.14 g/mol 293.14 g/mol 33,45 
B8 0,04 293.14 g/mol 293.13 g/mol 678,44 
C8 0 296.18 g/mol 0.00 g/mol 0 
D8 0 294.13 g/mol 294.22 g/mol 72,88 
E8 0 313.22 g/mol 0.00 g/mol 0 
F8 0 336.13 g/mol 0.00 g/mol 0 
G8 0 348.18 g/mol 0.00 g/mol 0 
H8 0 288.14 g/mol 0.00 g/mol 0 
A9 0 323.11 g/mol 0.00 g/mol 0 
B9 0 323.11 g/mol 0.00 g/mol 0 
C9 0 326.15 g/mol 0.00 g/mol 0 
D9 0 324.10 g/mol 0.00 g/mol 0 
E9 0 343.19 g/mol 0.00 g/mol 0 
F9 0 366.10 g/mol 0.00 g/mol 0 
G9 0 378.15 g/mol 0.00 g/mol 0 
H9 0 318.10 g/mol 0.00 g/mol 0 
A10 0 295.11 g/mol 0.00 g/mol 0 
B10 0 295.11 g/mol 0.00 g/mol 0 
C10 0 298.16 g/mol 0.00 g/mol 0 
D10 0 296.11 g/mol 0.00 g/mol 0 
E10 0 315.19 g/mol 0.00 g/mol 0 
F10 0 338.11 g/mol 0.00 g/mol 0 
G10 0 350.15 g/mol 0.00 g/mol 0 
H10 0 290.11 g/mol 0.00 g/mol 0 
A11 0 280.11 g/mol 0.00 g/mol 0 
B11 0 280.11 g/mol 0.00 g/mol 0 
C11 0 283.16 g/mol 0.00 g/mol 0 
D11 0 281.10 g/mol 0.00 g/mol 0 
E11 0 300.19 g/mol 0.00 g/mol 0 
F11 0 323.11 g/mol 0.00 g/mol 0 
G11 0 335.15 g/mol 0.00 g/mol 0 
H11 0 275.11 g/mol 0.00 g/mol 0 
A12 0 299.12 g/mol 0.00 g/mol 0 
B12 0 299.12 g/mol 0.00 g/mol 0 
C12 0 302.17 g/mol 0.00 g/mol 0 
D12 0 300.12 g/mol 0.00 g/mol 0 
E12 0 319.20 g/mol 0.00 g/mol 0 
F12 0 342.12 g/mol 0.00 g/mol 0 
G12 0 354.16 g/mol 0.00 g/mol 0 
H12 0 294.12 g/mol 0.00 g/mol 0 
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Well Peak width Expected mass Found mass Intensity 
A1         
B1         
C1         
D1         
E1         
F1         
G1         
H1         
A2 0 351.33 g/mol 0.00 g/mol 0 
B2 0 265.23 g/mol 0.00 g/mol 0 
C2 0 223.18 g/mol 0.00 g/mol 0 
D2 0 279.25 g/mol 0.00 g/mol 0 
E2 0 279.25 g/mol 0.00 g/mol 0 
F2 0 385.17 g/mol 0.00 g/mol 0 
G2 0 249.19 g/mol 0.00 g/mol 0 
H2 0 275.18 g/mol 0.00 g/mol 0 
A3 0 381.29 g/mol 0.00 g/mol 0 
B3 0 295.20 g/mol 0.00 g/mol 0 
C3 0 253.14 g/mol 0.00 g/mol 0 
D3 0 309.22 g/mol 0.00 g/mol 0 
E3 0 309.22 g/mol 0.00 g/mol 0 
F3 0 415.14 g/mol 0.00 g/mol 0 
G3 0 279.16 g/mol 0.00 g/mol 0 
H3 0 305.15 g/mol 0.00 g/mol 0 
A4 0 363.33 g/mol 0.00 g/mol 0 
B4 0 277.23 g/mol 0.00 g/mol 0 
C4 0 235.18 g/mol 235.12 g/mol 2092,15 
D4 0,04 291.25 g/mol 291.27 g/mol 3520,17 
E4 0,02 291.25 g/mol 291.28 g/mol 618,88 
F4 0 397.17 g/mol 397.12 g/mol 1689,06 
G4 0 261.19 g/mol 261.22 g/mol 2079,64 
H4 0,08 287.18 g/mol 287.22 g/mol 4718,07 
A5 0 324.23 g/mol 0.00 g/mol 0 
B5 0 238.14 g/mol 0.00 g/mol 0 
C5 0 196.08 g/mol 0.00 g/mol 0 
D5 0 252.16 g/mol 0.00 g/mol 0 
E5 0 252.16 g/mol 0.00 g/mol 0 
F5 0,02 358.08 g/mol 358.16 g/mol 465,98 
G5 0 222.10 g/mol 0.00 g/mol 0 
H5 0 248.09 g/mol 248.15 g/mol 188,84 
A6 0 341.26 g/mol 0.00 g/mol 0 
B6 0 255.16 g/mol 0.00 g/mol 0 
C6 0 213.11 g/mol 0.00 g/mol 0 
D6 0 269.18 g/mol 269.22 g/mol 1435,49 
E6 0,02 269.18 g/mol 269.22 g/mol 655,95 
F6 0 375.11 g/mol 0.00 g/mol 0 
G6 0 239.12 g/mol 0.00 g/mol 0 
H6 0 265.11 g/mol 0.00 g/mol 0 
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A7 0 333.23 g/mol 0.00 g/mol 0 
B7 0 247.14 g/mol 0.00 g/mol 0 
C7 0 205.08 g/mol 205.13 g/mol 55,89 
D7 0 261.16 g/mol 261.20 g/mol 186,64 
E7 0 261.16 g/mol 0.00 g/mol 0 
F7 0,02 367.08 g/mol 367.16 g/mol 613,28 
G7 0 231.10 g/mol 0.00 g/mol 0 
H7 0 257.09 g/mol 0.00 g/mol 0 
A8 0 353.26 g/mol 0.00 g/mol 0 
B8 0 267.16 g/mol 0.00 g/mol 0 
C8 0 225.11 g/mol 225.16 g/mol 50,92 
D8 0 281.18 g/mol 0.00 g/mol 0 
E8 0 281.18 g/mol 0.00 g/mol 0 
F8 0 387.10 g/mol 387.19 g/mol 157,65 
G8 0,02 251.12 g/mol 251.16 g/mol 545,1 
H8 0 277.11 g/mol 277.17 g/mol 53,86 
A9 0 383.22 g/mol 0.00 g/mol 0 
B9 0 297.13 g/mol 0.00 g/mol 0 
C9 0 255.07 g/mol 0.00 g/mol 0 
D9 0 311.15 g/mol 0.00 g/mol 0 
E9 0 311.15 g/mol 0.00 g/mol 0 
F9 0 417.07 g/mol 0.00 g/mol 0 
G9 0 281.09 g/mol 0.00 g/mol 0 
H9 0 307.08 g/mol 0.00 g/mol 0 
A10 0 355.23 g/mol 0.00 g/mol 0 
B10 0 269.14 g/mol 0.00 g/mol 0 
C10 0 227.08 g/mol 0.00 g/mol 0 
D10 0 283.16 g/mol 0.00 g/mol 0 
E10 0 283.16 g/mol 0.00 g/mol 0 
F10 0 389.08 g/mol 0.00 g/mol 0 
G10 0 253.10 g/mol 0.00 g/mol 0 
H10 0 279.08 g/mol 0.00 g/mol 0 
A11 0 340.23 g/mol 0.00 g/mol 0 
B11 0 254.14 g/mol 0.00 g/mol 0 
C11 0 212.08 g/mol 0.00 g/mol 0 
D11 0 268.16 g/mol 0.00 g/mol 0 
E11 0 268.16 g/mol 0.00 g/mol 0 
F11 0 374.08 g/mol 0.00 g/mol 0 
G11 0 238.10 g/mol 0.00 g/mol 0 
H11 0 264.08 g/mol 0.00 g/mol 0 
A12 0 359.24 g/mol 0.00 g/mol 0 
B12 0 273.15 g/mol 0.00 g/mol 0 
C12 0 231.09 g/mol 0.00 g/mol 0 
D12 0 287.17 g/mol 0.00 g/mol 0 
E12 0 287.17 g/mol 0.00 g/mol 0 
F12 0 393.09 g/mol 0.00 g/mol 0 
G12 0 257.11 g/mol 0.00 g/mol 0 
H12 0,02 283.09 g/mol 283.15 g/mol 459,6 
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Well Peak width Expected mass Found mass Intensity 
A1         
B1         
C1         
D1         
E1         
F1         
G1         
H1         
A2 0 274.19 g/mol 0.00 g/mol 0 
B2 0 274.19 g/mol 0.00 g/mol 0 
C2 0 277.23 g/mol 0.00 g/mol 0 
D2 0 275.18 g/mol 0.00 g/mol 0 
E2 0 294.27 g/mol 0.00 g/mol 0 
F2 0 317.18 g/mol 0.00 g/mol 0 
G2 0 329.23 g/mol 0.00 g/mol 0 
H2 0 269.18 g/mol 0.00 g/mol 0 
A3 0 304.16 g/mol 0.00 g/mol 0 
B3 0 304.16 g/mol 0.00 g/mol 0 
C3 0 307.20 g/mol 0.00 g/mol 0 
D3 0 305.15 g/mol 0.00 g/mol 0 
E3 0 324.23 g/mol 0.00 g/mol 0 
F3 0 347.15 g/mol 0.00 g/mol 0 
G3 0 359.20 g/mol 0.00 g/mol 0 
H3 0 299.15 g/mol 0.00 g/mol 0 
A4 0 286.19 g/mol 286.24 g/mol 457,09 
B4 0 286.19 g/mol 0.00 g/mol 0 
C4 0 289.23 g/mol 289.29 g/mol 223,92 
D4 0 287.18 g/mol 287.23 g/mol 4371,62 
E4 0 306.27 g/mol 0.00 g/mol 0 
F4 0 329.18 g/mol 0.00 g/mol 0 
G4 0,08 341.23 g/mol 341.27 g/mol 5304,19 
H4 0 281.18 g/mol 0.00 g/mol 0 
A5 0 247.10 g/mol 0.00 g/mol 0 
B5 0 247.10 g/mol 0.00 g/mol 0 
C5 0 250.14 g/mol 0.00 g/mol 0 
D5 0 248.09 g/mol 0.00 g/mol 0 
E5 0 267.18 g/mol 0.00 g/mol 0 
F5 0 290.09 g/mol 0.00 g/mol 0 
G5 0 302.14 g/mol 302.19 g/mol 1872,48 
H5 0 242.09 g/mol 0.00 g/mol 0 
A6 0,02 264.12 g/mol 264.11 g/mol 375,81 
B6 0 264.12 g/mol 0.00 g/mol 0 
C6 0 267.16 g/mol 0.00 g/mol 0 
D6 0 265.11 g/mol 265.17 g/mol 429,03 
E6 0 284.20 g/mol 0.00 g/mol 0 
F6 0 307.11 g/mol 307.16 g/mol 26,76 
G6 0 319.16 g/mol 0.00 g/mol 0 
H6 0 259.11 g/mol 0.00 g/mol 0 
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A7 0 256.09 g/mol 256.16 g/mol 77,46 
B7 0 256.09 g/mol 0.00 g/mol 0 
C7 0 259.14 g/mol 259.18 g/mol 359,82 
D7 0 257.09 g/mol 0.00 g/mol 0 
E7 0 276.17 g/mol 0.00 g/mol 0 
F7 0 299.09 g/mol 0.00 g/mol 0 
G7 0,02 311.13 g/mol 311.20 g/mol 617,77 
H7 0 251.09 g/mol 0.00 g/mol 0 
A8 0 276.12 g/mol 0.00 g/mol 0 
B8 0 276.12 g/mol 0.00 g/mol 0 
C8 0,06 279.16 g/mol 279.21 g/mol 1165,51 
D8 0 277.11 g/mol 0.00 g/mol 0 
E8 0 296.20 g/mol 0.00 g/mol 0 
F8 0 319.11 g/mol 0.00 g/mol 0 
G8 0 331.16 g/mol 0.00 g/mol 0 
H8 0 271.11 g/mol 0.00 g/mol 0 
A9 0 306.09 g/mol 0.00 g/mol 0 
B9 0 306.09 g/mol 0.00 g/mol 0 
C9 0 309.13 g/mol 0.00 g/mol 0 
D9 0 307.08 g/mol 0.00 g/mol 0 
E9 0 326.16 g/mol 0.00 g/mol 0 
F9 0 349.08 g/mol 0.00 g/mol 0 
G9 0 361.13 g/mol 361.20 g/mol 198,37 
H9 0 301.08 g/mol 0.00 g/mol 0 
A10 0 278.09 g/mol 0.00 g/mol 0 
B10 0 278.09 g/mol 0.00 g/mol 0 
C10 0 281.14 g/mol 0.00 g/mol 0 
D10 0 279.08 g/mol 0.00 g/mol 0 
E10 0 298.17 g/mol 0.00 g/mol 0 
F10 0 321.09 g/mol 0.00 g/mol 0 
G10 0 333.13 g/mol 0.00 g/mol 0 
H10 0 273.09 g/mol 0.00 g/mol 0 
A11 0 263.09 g/mol 0.00 g/mol 0 
B11 0 263.09 g/mol 0.00 g/mol 0 
C11 0 266.14 g/mol 0.00 g/mol 0 
D11 0 264.08 g/mol 0.00 g/mol 0 
E11 0 283.17 g/mol 0.00 g/mol 0 
F11 0 306.09 g/mol 0.00 g/mol 0 
G11 0 318.13 g/mol 0.00 g/mol 0 
H11 0 258.09 g/mol 0.00 g/mol 0 
A12 0 282.10 g/mol 0.00 g/mol 0 
B12 0 282.10 g/mol 0.00 g/mol 0 
C12 0 285.15 g/mol 0.00 g/mol 0 
D12 0 283.09 g/mol 283.17 g/mol 18,56 
E12 0 302.18 g/mol 0.00 g/mol 0 
F12 0 325.10 g/mol 0.00 g/mol 0 
G12 0 337.14 g/mol 0.00 g/mol 0 
H12 0 277.10 g/mol 0.00 g/mol 0 
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B.4 Screening plates ori.hya.20-35 
B.4.1 Starting materials of plates ori.hya.20-35 
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B.4.2 Mass spectral analysis of plates ori.hya.20-35 
ori.hya.20 
 
 
 
  
 
 
 
Well Peak width Expected mass Found mass Intensity 
A1         
B1         
C1         
D1         
E1         
F1         
G1         
H1         
A2 0,1 382.42 g/mol 382.44 g/mol 11084,64 
B2 0 296.33 g/mol 0.00 g/mol 0 
C2 0,1 254.27 g/mol 254.29 g/mol 7765,74 
D2 0,12 310.35 g/mol 310.37 g/mol 7343,7 
E2 0 310.35 g/mol 310.37 g/mol 438,98 
F2 0 416.27 g/mol 0.00 g/mol 0 
G2 0 280.29 g/mol 280.32 g/mol 551,19 
H2 0 306.28 g/mol 0.00 g/mol 0 
A3 0 412.39 g/mol 412.43 g/mol 203,38 
B3 0 326.30 g/mol 0.00 g/mol 0 
C3 0 284.24 g/mol 0.00 g/mol 0 
D3 0 340.32 g/mol 340.35 g/mol 184,03 
E3 0 340.32 g/mol 340.35 g/mol 194,14 
F3 0 446.24 g/mol 0.00 g/mol 0 
G3 0,04 310.26 g/mol 310.22 g/mol 1581,98 
H3 0 336.25 g/mol 0.00 g/mol 0 
A4 0,12 394.42 g/mol 394.44 g/mol 16202,64 
B4 0 308.33 g/mol 0.00 g/mol 0 
C4 0,1 266.27 g/mol 266.19 g/mol 6322,5 
D4 0,12 322.35 g/mol 322.37 g/mol 6463,62 
E4 0 322.35 g/mol 0.00 g/mol 0 
F4 0 428.27 g/mol 0.00 g/mol 0 
G4 0,06 292.29 g/mol 292.32 g/mol 1402,27 
H4 0 318.28 g/mol 0.00 g/mol 0 
A5 0,12 355.33 g/mol 355.36 g/mol 6249,72 
B5 0 269.24 g/mol 0.00 g/mol 0 
C5 0,02 227.18 g/mol 227.22 g/mol 295,68 
D5 0,04 283.26 g/mol 283.29 g/mol 3091,91 
E5 0,02 283.26 g/mol 283.29 g/mol 2389,84 
F5 0 389.18 g/mol 0.00 g/mol 0 
G5 0 253.20 g/mol 253.24 g/mol 54,74 
H5 0 279.19 g/mol 0.00 g/mol 0 
A6 0,08 372.35 g/mol 372.38 g/mol 8201,52 
B6 0 286.26 g/mol 0.00 g/mol 0 
C6 0,04 244.20 g/mol 244.16 g/mol 990,71 
D6 0,08 300.28 g/mol 300.34 g/mol 9002,04 
E6 0 300.28 g/mol 0.00 g/mol 0 
F6 0 406.20 g/mol 0.00 g/mol 0 
G6 0,02 270.22 g/mol 270.26 g/mol 355,9 
H6 0 296.21 g/mol 0.00 g/mol 0 
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A7 0,02 364.33 g/mol 364.34 g/mol 625,38 
B7 0 278.24 g/mol 0.00 g/mol 0 
C7 0 236.18 g/mol 0.00 g/mol 0 
D7 0 292.26 g/mol 292.28 g/mol 232,54 
E7 0 292.26 g/mol 0.00 g/mol 0 
F7 0 398.18 g/mol 0.00 g/mol 0 
G7 0 262.20 g/mol 262.29 g/mol 12,51 
H7 0 288.18 g/mol 0.00 g/mol 0 
A8 0 384.35 g/mol 384.38 g/mol 53,6 
B8 0 298.26 g/mol 0.00 g/mol 0 
C8 0 256.20 g/mol 256.24 g/mol 12,32 
D8 0,02 312.28 g/mol 312.31 g/mol 685,68 
E8 0 312.28 g/mol 0.00 g/mol 0 
F8 0 418.20 g/mol 0.00 g/mol 0 
G8 0 282.22 g/mol 282.26 g/mol 310,11 
H8 0 308.21 g/mol 0.00 g/mol 0 
A9 0 414.32 g/mol 0.00 g/mol 0 
B9 0 328.23 g/mol 0.00 g/mol 0 
C9 0 286.17 g/mol 0.00 g/mol 0 
D9 0 342.25 g/mol 0.00 g/mol 0 
E9 0 342.25 g/mol 0.00 g/mol 0 
F9 0 448.17 g/mol 0.00 g/mol 0 
G9 0 312.19 g/mol 0.00 g/mol 0 
H9 0 338.18 g/mol 0.00 g/mol 0 
A10 0 386.33 g/mol 0.00 g/mol 0 
B10 0 300.24 g/mol 0.00 g/mol 0 
C10 0,02 258.18 g/mol 258.22 g/mol 347,63 
D10 0 314.26 g/mol 0.00 g/mol 0 
E10 0 314.26 g/mol 0.00 g/mol 0 
F10 0 420.18 g/mol 0.00 g/mol 0 
G10 0 284.20 g/mol 0.00 g/mol 0 
H10 0 310.18 g/mol 0.00 g/mol 0 
A11 0 371.33 g/mol 0.00 g/mol 0 
B11 0 285.23 g/mol 0.00 g/mol 0 
C11 0 243.18 g/mol 0.00 g/mol 0 
D11 0 299.25 g/mol 0.00 g/mol 0 
E11 0 299.25 g/mol 0.00 g/mol 0 
F11 0 405.18 g/mol 0.00 g/mol 0 
G11 0 269.20 g/mol 0.00 g/mol 0 
H11 0 295.18 g/mol 0.00 g/mol 0 
A12 0 390.34 g/mol 390.38 g/mol 212,13 
B12 0 304.25 g/mol 0.00 g/mol 0 
C12 0,02 262.19 g/mol 262.23 g/mol 2266,35 
D12 0,1 318.27 g/mol 318.30 g/mol 8497,68 
E12 0 318.27 g/mol 0.00 g/mol 0 
F12 0 424.19 g/mol 424.26 g/mol 5447,18 
G12 0,02 288.21 g/mol 288.25 g/mol 26593,02 
H12 0 314.19 g/mol 314.24 g/mol 2666,64 
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Well Peak width Expected mass Found mass Intensity 
A1         
B1         
C1         
D1         
E1         
F1         
G1         
H1         
A2 0 305.28 g/mol 0.00 g/mol 0 
B2 0 305.28 g/mol 0.00 g/mol 0 
C2 0,21 308.33 g/mol 308.34 g/mol 6444,96 
D2 0 306.28 g/mol 0.00 g/mol 0 
E2 0 325.36 g/mol 0.00 g/mol 0 
F2 0,04 348.28 g/mol 348.30 g/mol 2870,14 
G2 0,16 360.32 g/mol 360.34 g/mol 8271,12 
H2 0,1 300.28 g/mol 300.29 g/mol 11570,82 
A3 0 335.25 g/mol 0.00 g/mol 0 
B3 0 335.25 g/mol 0.00 g/mol 0 
C3 0 338.30 g/mol 338.32 g/mol 356,43 
D3 0,08 336.25 g/mol 336.27 g/mol 5556,1 
E3 0 355.33 g/mol 0.00 g/mol 0 
F3 0 378.25 g/mol 0.00 g/mol 0 
G3 0 390.29 g/mol 390.32 g/mol 442,03 
H3 0 330.25 g/mol 0.00 g/mol 0 
A4 0 317.28 g/mol 0.00 g/mol 0 
B4 0 317.28 g/mol 0.00 g/mol 0 
C4 0,1 320.33 g/mol 320.34 g/mol 22660,74 
D4 0 318.28 g/mol 318.31 g/mol 186,99 
E4 0 337.36 g/mol 0.00 g/mol 0 
F4 0,06 360.28 g/mol 360.31 g/mol 4412,08 
G4 0,12 372.32 g/mol 372.35 g/mol 13107,84 
H4 0,04 312.28 g/mol 312.30 g/mol 3566,95 
A5 0 278.19 g/mol 0.00 g/mol 0 
B5 0 278.19 g/mol 0.00 g/mol 0 
C5 0,1 281.24 g/mol 281.25 g/mol 6343,86 
D5 0 279.19 g/mol 279.22 g/mol 33,72 
E5 0 298.27 g/mol 0.00 g/mol 0 
F5 0 321.19 g/mol 0.00 g/mol 0 
G5 0 333.23 g/mol 333.27 g/mol 4363,86 
H5 0 273.19 g/mol 0.00 g/mol 0 
A6 0 295.21 g/mol 0.00 g/mol 0 
B6 0 295.21 g/mol 0.00 g/mol 0 
C6 0,12 298.26 g/mol 298.28 g/mol 5646,16 
D6 0 296.21 g/mol 0.00 g/mol 0 
E6 0 315.29 g/mol 0.00 g/mol 0 
F6 0 338.21 g/mol 338.26 g/mol 56,11 
G6 0,08 350.25 g/mol 350.29 g/mol 17088,96 
H6 0 290.21 g/mol 290.24 g/mol 49,03 
424 Appendix II 
A7 0 287.19 g/mol 0.00 g/mol 0 
B7 0 287.19 g/mol 0.00 g/mol 0 
C7 0,02 290.24 g/mol 290.27 g/mol 442,31 
D7 0 288.18 g/mol 0.00 g/mol 0 
E7 0 307.27 g/mol 0.00 g/mol 0 
F7 0 330.19 g/mol 0.00 g/mol 0 
G7 0 342.23 g/mol 0.00 g/mol 0 
H7 0 282.19 g/mol 0.00 g/mol 0 
A8 0 307.21 g/mol 0.00 g/mol 0 
B8 0 307.21 g/mol 0.00 g/mol 0 
C8 0,02 310.26 g/mol 310.29 g/mol 527,6 
D8 0 308.21 g/mol 0.00 g/mol 0 
E8 0 327.29 g/mol 0.00 g/mol 0 
F8 0 350.21 g/mol 0.00 g/mol 0 
G8 0,02 362.25 g/mol 362.29 g/mol 4408,94 
H8 0 302.21 g/mol 0.00 g/mol 0 
A9 0 337.18 g/mol 0.00 g/mol 0 
B9 0 337.18 g/mol 0.00 g/mol 0 
C9 0 340.23 g/mol 0.00 g/mol 0 
D9 0 338.18 g/mol 0.00 g/mol 0 
E9 0 357.26 g/mol 0.00 g/mol 0 
F9 0 380.18 g/mol 0.00 g/mol 0 
G9 0 392.22 g/mol 0.00 g/mol 0 
H9 0 332.18 g/mol 0.00 g/mol 0 
A10 0 309.19 g/mol 0.00 g/mol 0 
B10 0 309.19 g/mol 0.00 g/mol 0 
C10 0 312.24 g/mol 0.00 g/mol 0 
D10 0,02 310.18 g/mol 310.25 g/mol 369,57 
E10 0 329.27 g/mol 0.00 g/mol 0 
F10 0 352.18 g/mol 0.00 g/mol 0 
G10 0 364.23 g/mol 0.00 g/mol 0 
H10 0 304.19 g/mol 0.00 g/mol 0 
A11 0 294.19 g/mol 0.00 g/mol 0 
B11 0 294.19 g/mol 0.00 g/mol 0 
C11 0 297.23 g/mol 0.00 g/mol 0 
D11 0 295.18 g/mol 0.00 g/mol 0 
E11 0 314.27 g/mol 0.00 g/mol 0 
F11 0 337.18 g/mol 0.00 g/mol 0 
G11 0 349.23 g/mol 0.00 g/mol 0 
H11 0 289.18 g/mol 0.00 g/mol 0 
A12 0 313.20 g/mol 0.00 g/mol 0 
B12 0 313.20 g/mol 313.25 g/mol 207,65 
C12 0 316.25 g/mol 0.00 g/mol 0 
D12 0 314.19 g/mol 314.25 g/mol 14,35 
E12 0 333.28 g/mol 0.00 g/mol 0 
F12 0,08 356.19 g/mol 356.25 g/mol 5108,36 
G12 0,16 368.24 g/mol 368.29 g/mol 16250,04 
H12 0,02 308.20 g/mol 308.23 g/mol 389,73 
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Well Peak width Expected mass Found mass Intensity 
A1         
B1         
C1         
D1         
E1         
F1         
G1         
H1         
A2 0,08 450.36 g/mol 450.39 g/mol 5300,26 
B2 0 364.27 g/mol 0.00 g/mol 0 
C2 0,02 322.21 g/mol 322.25 g/mol 3691,85 
D2 0,08 378.29 g/mol 378.32 g/mol 6337,5 
E2 0,02 378.29 g/mol 378.36 g/mol 636,86 
F2 0 484.21 g/mol 0.00 g/mol 0 
G2 0 348.23 g/mol 348.28 g/mol 123,36 
H2 0 374.21 g/mol 0.00 g/mol 0 
A3 0 480.33 g/mol 480.39 g/mol 73,9 
B3 0 394.24 g/mol 0.00 g/mol 0 
C3 0,02 352.18 g/mol 352.23 g/mol 626,03 
D3 0 408.26 g/mol 0.00 g/mol 0 
E3 0 408.26 g/mol 0.00 g/mol 0 
F3 0 514.18 g/mol 0.00 g/mol 0 
G3 0 378.20 g/mol 0.00 g/mol 0 
H3 0 404.18 g/mol 0.00 g/mol 0 
A4 0,04 462.36 g/mol 462.40 g/mol 8047,62 
B4 0 376.27 g/mol 0.00 g/mol 0 
C4 0 334.21 g/mol 334.26 g/mol 347,01 
D4 0,02 390.29 g/mol 390.32 g/mol 7740,06 
E4 0 390.29 g/mol 0.00 g/mol 0 
F4 0 496.21 g/mol 0.00 g/mol 0 
G4 0,06 360.23 g/mol 360.27 g/mol 1489,34 
H4 0 386.21 g/mol 0.00 g/mol 0 
A5 0 423.27 g/mol 0.00 g/mol 0 
B5 0 337.18 g/mol 0.00 g/mol 0 
C5 0 295.12 g/mol 0.00 g/mol 0 
D5 0 351.20 g/mol 0.00 g/mol 0 
E5 0 351.20 g/mol 0.00 g/mol 0 
F5 0 457.12 g/mol 0.00 g/mol 0 
G5 0,02 321.14 g/mol 321.21 g/mol 541,35 
H5 0 347.12 g/mol 0.00 g/mol 0 
A6 0 440.29 g/mol 440.34 g/mol 234,31 
B6 0 354.20 g/mol 0.00 g/mol 0 
C6 0 312.14 g/mol 312.19 g/mol 362,97 
D6 0 368.22 g/mol 368.26 g/mol 3896,12 
E6 0 368.22 g/mol 368.27 g/mol 213,02 
F6 0 474.14 g/mol 0.00 g/mol 0 
G6 0,02 338.16 g/mol 338.21 g/mol 853,99 
H6 0 364.14 g/mol 0.00 g/mol 0 
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A7 0 432.27 g/mol 0.00 g/mol 0 
B7 0 346.17 g/mol 0.00 g/mol 0 
C7 0 304.12 g/mol 0.00 g/mol 0 
D7 0 360.19 g/mol 0.00 g/mol 0 
E7 0 360.19 g/mol 0.00 g/mol 0 
F7 0 466.12 g/mol 0.00 g/mol 0 
G7 0 330.14 g/mol 0.00 g/mol 0 
H7 0 356.12 g/mol 0.00 g/mol 0 
A8 0 452.29 g/mol 0.00 g/mol 0 
B8 0 366.20 g/mol 0.00 g/mol 0 
C8 0 324.14 g/mol 0.00 g/mol 0 
D8 0 380.22 g/mol 0.00 g/mol 0 
E8 0 380.22 g/mol 0.00 g/mol 0 
F8 0 486.14 g/mol 0.00 g/mol 0 
G8 0 350.16 g/mol 0.00 g/mol 0 
H8 0 376.14 g/mol 0.00 g/mol 0 
A9 0 482.26 g/mol 0.00 g/mol 0 
B9 0 396.17 g/mol 0.00 g/mol 0 
C9 0 354.11 g/mol 0.00 g/mol 0 
D9 0 410.19 g/mol 0.00 g/mol 0 
E9 0 410.19 g/mol 0.00 g/mol 0 
F9 0 516.11 g/mol 0.00 g/mol 0 
G9 0 380.13 g/mol 0.00 g/mol 0 
H9 0 406.11 g/mol 0.00 g/mol 0 
A10 0 454.26 g/mol 0.00 g/mol 0 
B10 0 368.17 g/mol 0.00 g/mol 0 
C10 0 326.11 g/mol 0.00 g/mol 0 
D10 0 382.19 g/mol 0.00 g/mol 0 
E10 0 382.19 g/mol 0.00 g/mol 0 
F10 0 488.11 g/mol 0.00 g/mol 0 
G10 0 352.13 g/mol 0.00 g/mol 0 
H10 0 378.12 g/mol 0.00 g/mol 0 
A11 0 439.26 g/mol 0.00 g/mol 0 
B11 0 353.17 g/mol 0.00 g/mol 0 
C11 0 311.11 g/mol 0.00 g/mol 0 
D11 0 367.19 g/mol 0.00 g/mol 0 
E11 0 367.19 g/mol 0.00 g/mol 0 
F11 0 473.11 g/mol 0.00 g/mol 0 
G11 0 337.13 g/mol 0.00 g/mol 0 
H11 0 363.12 g/mol 0.00 g/mol 0 
A12 0,04 458.27 g/mol 458.34 g/mol 1460,27 
B12 0 372.18 g/mol 0.00 g/mol 0 
C12 0,02 330.12 g/mol 330.19 g/mol 671,69 
D12 0,02 386.20 g/mol 386.27 g/mol 726,51 
E12 0,02 386.20 g/mol 386.27 g/mol 564,88 
F12 0 492.12 g/mol 492.22 g/mol 375,7 
G12 0,02 356.14 g/mol 356.20 g/mol 12720,12 
H12 0,02 382.13 g/mol 382.21 g/mol 695,15 
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Well Peak width Expected mass Found mass Intensity 
A1         
B1         
C1         
D1         
E1         
F1         
G1         
H1         
A2 0 373.22 g/mol 0.00 g/mol 0 
B2 0 373.22 g/mol 0.00 g/mol 0 
C2 0,16 376.27 g/mol 376.31 g/mol 4122,18 
D2 0,02 374.21 g/mol 374.27 g/mol 575,96 
E2 0 393.30 g/mol 0.00 g/mol 0 
F2 0,02 416.22 g/mol 416.28 g/mol 825,06 
G2 0 428.26 g/mol 428.31 g/mol 1776,89 
H2 0,1 368.22 g/mol 368.27 g/mol 11345,64 
A3 0 403.19 g/mol 0.00 g/mol 0 
B3 0 403.19 g/mol 0.00 g/mol 0 
C3 0 406.24 g/mol 0.00 g/mol 0 
D3 0 404.18 g/mol 0.00 g/mol 0 
E3 0 423.27 g/mol 0.00 g/mol 0 
F3 0 446.18 g/mol 0.00 g/mol 0 
G3 0 458.23 g/mol 0.00 g/mol 0 
H3 0 398.19 g/mol 0.00 g/mol 0 
A4 0 385.22 g/mol 0.00 g/mol 0 
B4 0 385.22 g/mol 0.00 g/mol 0 
C4 0,1 388.27 g/mol 388.31 g/mol 7059,42 
D4 0 386.21 g/mol 0.00 g/mol 0 
E4 0 405.30 g/mol 0.00 g/mol 0 
F4 0 428.22 g/mol 428.29 g/mol 732,49 
G4 0 440.26 g/mol 440.32 g/mol 511,25 
H4 0,02 380.22 g/mol 380.27 g/mol 921,13 
A5 0 346.13 g/mol 0.00 g/mol 0 
B5 0 346.13 g/mol 0.00 g/mol 0 
C5 0 349.18 g/mol 0.00 g/mol 0 
D5 0 347.12 g/mol 0.00 g/mol 0 
E5 0 366.21 g/mol 0.00 g/mol 0 
F5 0 389.12 g/mol 0.00 g/mol 0 
G5 0 401.17 g/mol 401.25 g/mol 62,47 
H5 0 341.13 g/mol 0.00 g/mol 0 
A6 0 363.15 g/mol 0.00 g/mol 0 
B6 0 363.15 g/mol 0.00 g/mol 0 
C6 0,02 366.20 g/mol 366.25 g/mol 4441,91 
D6 0 364.14 g/mol 0.00 g/mol 0 
E6 0 383.23 g/mol 0.00 g/mol 0 
F6 0,04 406.15 g/mol 406.20 g/mol 1054,93 
G6 0,02 418.19 g/mol 418.26 g/mol 753,58 
H6 0 358.15 g/mol 358.21 g/mol 154,74 
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A7 0 355.13 g/mol 0.00 g/mol 0 
B7 0 355.13 g/mol 0.00 g/mol 0 
C7 0 358.17 g/mol 0.00 g/mol 0 
D7 0 356.12 g/mol 0.00 g/mol 0 
E7 0 375.21 g/mol 0.00 g/mol 0 
F7 0 398.12 g/mol 0.00 g/mol 0 
G7 0 410.17 g/mol 0.00 g/mol 0 
H7 0 350.12 g/mol 0.00 g/mol 0 
A8 0 375.15 g/mol 0.00 g/mol 0 
B8 0 375.15 g/mol 0.00 g/mol 0 
C8 0,02 378.20 g/mol 378.26 g/mol 616,67 
D8 0 376.14 g/mol 0.00 g/mol 0 
E8 0 395.23 g/mol 0.00 g/mol 0 
F8 0 418.15 g/mol 0.00 g/mol 0 
G8 0,02 430.19 g/mol 430.27 g/mol 667,03 
H8 0 370.15 g/mol 0.00 g/mol 0 
A9 0 405.12 g/mol 0.00 g/mol 0 
B9 0 405.12 g/mol 0.00 g/mol 0 
C9 0 408.17 g/mol 0.00 g/mol 0 
D9 0 406.11 g/mol 0.00 g/mol 0 
E9 0 425.20 g/mol 0.00 g/mol 0 
F9 0 448.11 g/mol 0.00 g/mol 0 
G9 0 460.16 g/mol 0.00 g/mol 0 
H9 0 400.12 g/mol 0.00 g/mol 0 
A10 0 377.13 g/mol 0.00 g/mol 0 
B10 0 377.13 g/mol 0.00 g/mol 0 
C10 0 380.17 g/mol 0.00 g/mol 0 
D10 0 378.12 g/mol 0.00 g/mol 0 
E10 0 397.20 g/mol 0.00 g/mol 0 
F10 0 420.12 g/mol 0.00 g/mol 0 
G10 0 432.17 g/mol 0.00 g/mol 0 
H10 0 372.12 g/mol 0.00 g/mol 0 
A11 0 362.12 g/mol 0.00 g/mol 0 
B11 0 362.12 g/mol 0.00 g/mol 0 
C11 0 365.17 g/mol 0.00 g/mol 0 
D11 0 363.12 g/mol 0.00 g/mol 0 
E11 0 382.20 g/mol 0.00 g/mol 0 
F11 0 405.12 g/mol 0.00 g/mol 0 
G11 0 417.16 g/mol 0.00 g/mol 0 
H11 0 357.12 g/mol 0.00 g/mol 0 
A12 0 381.14 g/mol 0.00 g/mol 0 
B12 0 381.14 g/mol 0.00 g/mol 0 
C12 0 384.18 g/mol 0.00 g/mol 0 
D12 0,02 382.13 g/mol 382.21 g/mol 752,86 
E12 0 401.21 g/mol 0.00 g/mol 0 
F12 0 424.13 g/mol 424.23 g/mol 183,51 
G12 0,06 436.17 g/mol 436.25 g/mol 9209,34 
H12 0 376.13 g/mol 376.21 g/mol 134,95 
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Well Peak width Expected mass Found mass Intensity 
A1         
B1         
C1         
D1         
E1         
F1         
G1         
H1         
A2 0,12 382.42 g/mol 382.43 g/mol 8462,28 
B2 0 296.33 g/mol 0.00 g/mol 0 
C2 0,06 254.27 g/mol 254.28 g/mol 8992,44 
D2 0,08 310.35 g/mol 310.36 g/mol 6986,1 
E2 0,06 310.35 g/mol 310.36 g/mol 1303,33 
F2 0 416.27 g/mol 0.00 g/mol 0 
G2 0 280.29 g/mol 280.32 g/mol 109,06 
H2 0 306.28 g/mol 0.00 g/mol 0 
A3 0,02 412.39 g/mol 412.42 g/mol 746,15 
B3 0 326.30 g/mol 0.00 g/mol 0 
C3 0 284.24 g/mol 284.27 g/mol 496,71 
D3 0 340.32 g/mol 0.00 g/mol 0 
E3 0 340.32 g/mol 0.00 g/mol 0 
F3 0 446.24 g/mol 0.00 g/mol 0 
G3 0,02 310.26 g/mol 310.29 g/mol 823,96 
H3 0 336.25 g/mol 0.00 g/mol 0 
A4 0,08 394.42 g/mol 394.44 g/mol 12839,28 
B4 0 308.33 g/mol 0.00 g/mol 0 
C4 0,1 266.27 g/mol 266.29 g/mol 2163 
D4 0,1 322.35 g/mol 322.37 g/mol 2220,32 
E4 0 322.35 g/mol 0.00 g/mol 0 
F4 0 428.27 g/mol 0.00 g/mol 0 
G4 0 292.29 g/mol 0.00 g/mol 0 
H4 0 318.28 g/mol 0.00 g/mol 0 
A5 0,04 355.33 g/mol 355.37 g/mol 1176,63 
B5 0 269.24 g/mol 0.00 g/mol 0 
C5 0,04 227.18 g/mol 227.23 g/mol 771,11 
D5 0,04 283.26 g/mol 283.29 g/mol 1168,93 
E5 0 283.26 g/mol 283.29 g/mol 353,15 
F5 0,06 389.18 g/mol 389.25 g/mol 1572,05 
G5 0 253.20 g/mol 253.25 g/mol 284,68 
H5 0 279.19 g/mol 279.24 g/mol 23,77 
A6 0,1 372.35 g/mol 372.38 g/mol 8002,26 
B6 0 286.26 g/mol 0.00 g/mol 0 
C6 0 244.20 g/mol 244.24 g/mol 135,22 
D6 0,1 300.28 g/mol 300.31 g/mol 5835,16 
E6 0 300.28 g/mol 0.00 g/mol 0 
F6 0 406.20 g/mol 0.00 g/mol 0 
G6 0,02 270.22 g/mol 270.27 g/mol 497,46 
H6 0 296.21 g/mol 0.00 g/mol 0 
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A7 0 364.33 g/mol 0.00 g/mol 0 
B7 0 278.24 g/mol 0.00 g/mol 0 
C7 0 236.18 g/mol 0.00 g/mol 0 
D7 0 292.26 g/mol 292.27 g/mol 154,57 
E7 0 292.26 g/mol 0.00 g/mol 0 
F7 0 398.18 g/mol 0.00 g/mol 0 
G7 0 262.20 g/mol 0.00 g/mol 0 
H7 0 288.18 g/mol 0.00 g/mol 0 
A8 0 384.35 g/mol 0.00 g/mol 0 
B8 0 298.26 g/mol 0.00 g/mol 0 
C8 0,02 256.20 g/mol 256.24 g/mol 346,62 
D8 0 312.28 g/mol 312.31 g/mol 420,43 
E8 0 312.28 g/mol 0.00 g/mol 0 
F8 0 418.20 g/mol 0.00 g/mol 0 
G8 0 282.22 g/mol 282.26 g/mol 206,61 
H8 0 308.21 g/mol 0.00 g/mol 0 
A9 0 414.32 g/mol 0.00 g/mol 0 
B9 0 328.23 g/mol 0.00 g/mol 0 
C9 0 286.17 g/mol 0.00 g/mol 0 
D9 0 342.25 g/mol 0.00 g/mol 0 
E9 0 342.25 g/mol 0.00 g/mol 0 
F9 0 448.17 g/mol 0.00 g/mol 0 
G9 0 312.19 g/mol 0.00 g/mol 0 
H9 0 338.18 g/mol 0.00 g/mol 0 
A10 0 386.33 g/mol 0.00 g/mol 0 
B10 0 300.24 g/mol 0.00 g/mol 0 
C10 0 258.18 g/mol 0.00 g/mol 0 
D10 0 314.26 g/mol 0.00 g/mol 0 
E10 0 314.26 g/mol 0.00 g/mol 0 
F10 0 420.18 g/mol 0.00 g/mol 0 
G10 0 284.20 g/mol 0.00 g/mol 0 
H10 0 310.18 g/mol 0.00 g/mol 0 
A11 0 371.33 g/mol 0.00 g/mol 0 
B11 0 285.23 g/mol 0.00 g/mol 0 
C11 0 243.18 g/mol 0.00 g/mol 0 
D11 0 299.25 g/mol 0.00 g/mol 0 
E11 0 299.25 g/mol 0.00 g/mol 0 
F11 0 405.18 g/mol 0.00 g/mol 0 
G11 0 269.20 g/mol 0.00 g/mol 0 
H11 0 295.18 g/mol 0.00 g/mol 0 
A12 0,02 390.34 g/mol 390.30 g/mol 4383,26 
B12 0 304.25 g/mol 0.00 g/mol 0 
C12 0 262.19 g/mol 262.25 g/mol 8839,14 
D12 0,02 318.27 g/mol 318.31 g/mol 813,52 
E12 0 318.27 g/mol 318.30 g/mol 66,95 
F12 0,02 424.19 g/mol 424.27 g/mol 4230,76 
G12 0,16 288.21 g/mol 288.25 g/mol 6028,74 
H12 0 314.19 g/mol 314.17 g/mol 178,47 
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Well Peak width Expected mass Found mass Intensity 
A1         
B1         
C1         
D1         
E1         
F1         
G1         
H1         
A2 0 305.28 g/mol 0.00 g/mol 0 
B2 0 305.28 g/mol 0.00 g/mol 0 
C2 0,06 308.33 g/mol 308.35 g/mol 13529,52 
D2 0,02 306.28 g/mol 306.32 g/mol 395,66 
E2 0 325.36 g/mol 0.00 g/mol 0 
F2 0 348.28 g/mol 348.32 g/mol 389,16 
G2 0,1 360.32 g/mol 360.36 g/mol 7058,82 
H2 0,16 300.28 g/mol 300.31 g/mol 6746,76 
A3 0 335.25 g/mol 0.00 g/mol 0 
B3 0 335.25 g/mol 0.00 g/mol 0 
C3 0,02 338.30 g/mol 338.34 g/mol 708,49 
D3 0,04 336.25 g/mol 336.29 g/mol 5113,58 
E3 0 355.33 g/mol 0.00 g/mol 0 
F3 0 378.25 g/mol 0.00 g/mol 0 
G3 0 390.29 g/mol 0.00 g/mol 0 
H3 0 330.25 g/mol 330.30 g/mol 453,17 
A4 0 317.28 g/mol 0.00 g/mol 0 
B4 0 317.28 g/mol 0.00 g/mol 0 
C4 0,16 320.33 g/mol 320.43 g/mol 3676,97 
D4 0,02 318.28 g/mol 318.32 g/mol 507,99 
E4 0 337.36 g/mol 0.00 g/mol 0 
F4 0 360.28 g/mol 360.33 g/mol 117,39 
G4 0,08 372.32 g/mol 372.36 g/mol 7244,16 
H4 0 312.28 g/mol 312.31 g/mol 2679,1 
A5 0 278.19 g/mol 0.00 g/mol 0 
B5 0 278.19 g/mol 0.00 g/mol 0 
C5 0 281.24 g/mol 0.00 g/mol 0 
D5 0 279.19 g/mol 0.00 g/mol 0 
E5 0 298.27 g/mol 0.00 g/mol 0 
F5 0 321.19 g/mol 321.28 g/mol 32,33 
G5 0 333.23 g/mol 0.00 g/mol 0 
H5 0 273.19 g/mol 0.00 g/mol 0 
A6 0 295.21 g/mol 0.00 g/mol 0 
B6 0 295.21 g/mol 0.00 g/mol 0 
C6 0 298.26 g/mol 0.00 g/mol 0 
D6 0 296.21 g/mol 0.00 g/mol 0 
E6 0 315.29 g/mol 0.00 g/mol 0 
F6 0 338.21 g/mol 0.00 g/mol 0 
G6 0 350.25 g/mol 0.00 g/mol 0 
H6 0 290.21 g/mol 0.00 g/mol 0 
432 Appendix II 
A7 0 287.19 g/mol 287.27 g/mol 13,96 
B7 0 287.19 g/mol 0.00 g/mol 0 
C7 0,02 290.24 g/mol 290.30 g/mol 512,51 
D7 0 288.18 g/mol 0.00 g/mol 0 
E7 0 307.27 g/mol 0.00 g/mol 0 
F7 0 330.19 g/mol 0.00 g/mol 0 
G7 0 342.23 g/mol 0.00 g/mol 0 
H7 0 282.19 g/mol 0.00 g/mol 0 
A8 0 307.21 g/mol 0.00 g/mol 0 
B8 0 307.21 g/mol 0.00 g/mol 0 
C8 0,02 310.26 g/mol 310.30 g/mol 528,78 
D8 0 308.21 g/mol 0.00 g/mol 0 
E8 0 327.29 g/mol 0.00 g/mol 0 
F8 0 350.21 g/mol 0.00 g/mol 0 
G8 0 362.25 g/mol 362.31 g/mol 1827,91 
H8 0 302.21 g/mol 0.00 g/mol 0 
A9 0 337.18 g/mol 0.00 g/mol 0 
B9 0 337.18 g/mol 0.00 g/mol 0 
C9 0 340.23 g/mol 0.00 g/mol 0 
D9 0 338.18 g/mol 0.00 g/mol 0 
E9 0 357.26 g/mol 0.00 g/mol 0 
F9 0 380.18 g/mol 0.00 g/mol 0 
G9 0 392.22 g/mol 0.00 g/mol 0 
H9 0 332.18 g/mol 0.00 g/mol 0 
A10 0 309.19 g/mol 0.00 g/mol 0 
B10 0 309.19 g/mol 0.00 g/mol 0 
C10 0 312.24 g/mol 0.00 g/mol 0 
D10 0 310.18 g/mol 0.00 g/mol 0 
E10 0 329.27 g/mol 0.00 g/mol 0 
F10 0 352.18 g/mol 0.00 g/mol 0 
G10 0 364.23 g/mol 0.00 g/mol 0 
H10 0 304.19 g/mol 0.00 g/mol 0 
A11 0 294.19 g/mol 0.00 g/mol 0 
B11 0 294.19 g/mol 0.00 g/mol 0 
C11 0 297.23 g/mol 0.00 g/mol 0 
D11 0 295.18 g/mol 0.00 g/mol 0 
E11 0 314.27 g/mol 0.00 g/mol 0 
F11 0 337.18 g/mol 0.00 g/mol 0 
G11 0 349.23 g/mol 0.00 g/mol 0 
H11 0 289.18 g/mol 0.00 g/mol 0 
A12 0 313.20 g/mol 0.00 g/mol 0 
B12 0 313.20 g/mol 313.25 g/mol 62,88 
C12 0,02 316.25 g/mol 316.29 g/mol 906,68 
D12 0 314.19 g/mol 314.25 g/mol 1576,97 
E12 0 333.28 g/mol 0.00 g/mol 0 
F12 0,12 356.19 g/mol 356.25 g/mol 5585,7 
G12 0,08 368.24 g/mol 368.30 g/mol 22000,14 
H12 0 308.20 g/mol 308.25 g/mol 70,75 
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Well Peak width Expected mass Found mass Intensity 
A1         
B1         
C1         
D1         
E1         
F1         
G1         
H1         
A2 0,1 396.44 g/mol 396.47 g/mol 14312,88 
B2 0 310.35 g/mol 0.00 g/mol 0 
C2 0,04 268.29 g/mol 268.31 g/mol 11044,98 
D2 0,14 324.37 g/mol 324.39 g/mol 5554,61 
E2 0 324.37 g/mol 324.39 g/mol 4998,91 
F2 0 430.29 g/mol 430.36 g/mol 125,66 
G2 0 294.31 g/mol 294.33 g/mol 2120,55 
H2 0 320.30 g/mol 0.00 g/mol 0 
A3 0 426.41 g/mol 426.44 g/mol 1109,15 
B3 0 340.32 g/mol 0.00 g/mol 0 
C3 0 298.26 g/mol 298.29 g/mol 420,03 
D3 0 354.34 g/mol 354.37 g/mol 117,31 
E3 0 354.34 g/mol 354.37 g/mol 405,49 
F3 0,02 460.26 g/mol 460.34 g/mol 735,34 
G3 0 324.28 g/mol 324.31 g/mol 1498,82 
H3 0 350.27 g/mol 0.00 g/mol 0 
A4 0,12 408.44 g/mol 408.47 g/mol 9370,5 
B4 0 322.35 g/mol 0.00 g/mol 0 
C4 0,14 280.29 g/mol 280.32 g/mol 2775,21 
D4 0,14 336.37 g/mol 336.40 g/mol 3312,02 
E4 0,12 336.37 g/mol 336.39 g/mol 5498,54 
F4 0 442.29 g/mol 442.35 g/mol 3009,38 
G4 0,12 306.31 g/mol 306.34 g/mol 6811,86 
H4 0 332.30 g/mol 0.00 g/mol 0 
A5 0,06 369.35 g/mol 369.38 g/mol 1991,94 
B5 0 283.26 g/mol 0.00 g/mol 0 
C5 0,02 241.20 g/mol 241.23 g/mol 582,54 
D5 0,1 297.28 g/mol 297.31 g/mol 2308,29 
E5 0 297.28 g/mol 297.32 g/mol 1249,71 
F5 0,04 403.20 g/mol 403.27 g/mol 1051,1 
G5 0 267.22 g/mol 267.26 g/mol 465,6 
H5 0,02 293.21 g/mol 293.24 g/mol 437,34 
A6 0,16 386.37 g/mol 386.40 g/mol 7192,44 
B6 0 300.28 g/mol 0.00 g/mol 0 
C6 0 258.22 g/mol 258.25 g/mol 937,21 
D6 0,17 314.30 g/mol 314.33 g/mol 5510,68 
E6 0,04 314.30 g/mol 314.33 g/mol 2576,78 
F6 0 420.22 g/mol 420.29 g/mol 330,59 
G6 0 284.24 g/mol 284.27 g/mol 961,34 
H6 0 310.23 g/mol 0.00 g/mol 0 
434 Appendix II 
A7 0 378.35 g/mol 0.00 g/mol 0 
B7 0 292.26 g/mol 0.00 g/mol 0 
C7 0 250.20 g/mol 0.00 g/mol 0 
D7 0 306.28 g/mol 0.00 g/mol 0 
E7 0 306.28 g/mol 0.00 g/mol 0 
F7 0 412.20 g/mol 0.00 g/mol 0 
G7 0 276.22 g/mol 0.00 g/mol 0 
H7 0 302.20 g/mol 0.00 g/mol 0 
A8 0 398.37 g/mol 398.40 g/mol 504,08 
B8 0 312.28 g/mol 0.00 g/mol 0 
C8 0 270.22 g/mol 270.26 g/mol 95,45 
D8 0,02 326.30 g/mol 326.26 g/mol 664,08 
E8 0,02 326.30 g/mol 326.33 g/mol 485,59 
F8 0 432.22 g/mol 0.00 g/mol 0 
G8 0 296.24 g/mol 296.28 g/mol 23,71 
H8 0 322.23 g/mol 0.00 g/mol 0 
A9 0 428.34 g/mol 0.00 g/mol 0 
B9 0 342.25 g/mol 0.00 g/mol 0 
C9 0 300.19 g/mol 0.00 g/mol 0 
D9 0 356.27 g/mol 0.00 g/mol 0 
E9 0 356.27 g/mol 0.00 g/mol 0 
F9 0 462.19 g/mol 0.00 g/mol 0 
G9 0 326.21 g/mol 0.00 g/mol 0 
H9 0 352.19 g/mol 0.00 g/mol 0 
A10 0 400.35 g/mol 0.00 g/mol 0 
B10 0 314.26 g/mol 0.00 g/mol 0 
C10 0 272.20 g/mol 0.00 g/mol 0 
D10 0 328.27 g/mol 0.00 g/mol 0 
E10 0 328.27 g/mol 0.00 g/mol 0 
F10 0 434.20 g/mol 0.00 g/mol 0 
G10 0 298.22 g/mol 0.00 g/mol 0 
H10 0 324.20 g/mol 0.00 g/mol 0 
A11 0 385.35 g/mol 0.00 g/mol 0 
B11 0 299.25 g/mol 0.00 g/mol 0 
C11 0 257.20 g/mol 0.00 g/mol 0 
D11 0 313.27 g/mol 0.00 g/mol 0 
E11 0 313.27 g/mol 0.00 g/mol 0 
F11 0 419.19 g/mol 0.00 g/mol 0 
G11 0 283.21 g/mol 0.00 g/mol 0 
H11 0 309.20 g/mol 0.00 g/mol 0 
A12 0 404.36 g/mol 404.40 g/mol 154,81 
B12 0 318.27 g/mol 0.00 g/mol 0 
C12 0,14 276.21 g/mol 276.24 g/mol 5485,86 
D12 0 332.28 g/mol 332.32 g/mol 3304,46 
E12 0 332.28 g/mol 0.00 g/mol 0 
F12 0,06 438.21 g/mol 438.28 g/mol 10231,74 
G12 0,04 302.23 g/mol 302.26 g/mol 9700,8 
H12 0 328.21 g/mol 328.26 g/mol 2015,84 
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Well Peak width Expected mass Found mass Intensity 
A1         
B1         
C1         
D1         
E1         
F1         
G1         
H1         
A2 0 319.30 g/mol 0.00 g/mol 0 
B2 0 319.30 g/mol 0.00 g/mol 0 
C2 0,17 322.35 g/mol 322.36 g/mol 7113,54 
D2 0,04 320.30 g/mol 320.30 g/mol 838,15 
E2 0 339.38 g/mol 0.00 g/mol 0 
F2 0 362.30 g/mol 362.33 g/mol 478,14 
G2 0,14 374.34 g/mol 374.37 g/mol 4027,25 
H2 0,21 314.30 g/mol 314.31 g/mol 7022,04 
A3 0 349.27 g/mol 0.00 g/mol 0 
B3 0 349.27 g/mol 0.00 g/mol 0 
C3 0,02 352.32 g/mol 352.35 g/mol 690,24 
D3 0 350.27 g/mol 350.17 g/mol 4826,46 
E3 0 369.35 g/mol 0.00 g/mol 0 
F3 0 392.27 g/mol 0.00 g/mol 0 
G3 0 404.31 g/mol 0.00 g/mol 0 
H3 0,02 344.27 g/mol 344.30 g/mol 562,61 
A4 0 331.30 g/mol 0.00 g/mol 0 
B4 0 331.30 g/mol 0.00 g/mol 0 
C4 0,12 334.35 g/mol 334.37 g/mol 23682,6 
D4 0,04 332.30 g/mol 332.32 g/mol 998,11 
E4 0 351.38 g/mol 0.00 g/mol 0 
F4 0,02 374.30 g/mol 374.33 g/mol 3095,36 
G4 0,12 386.34 g/mol 386.37 g/mol 8536,14 
H4 0 326.30 g/mol 326.33 g/mol 321,84 
A5 0 292.21 g/mol 0.00 g/mol 0 
B5 0 292.21 g/mol 0.00 g/mol 0 
C5 0 295.26 g/mol 295.31 g/mol 281,79 
D5 0 293.21 g/mol 0.00 g/mol 0 
E5 0 312.29 g/mol 0.00 g/mol 0 
F5 0,02 335.21 g/mol 335.25 g/mol 521,96 
G5 0,02 347.25 g/mol 347.29 g/mol 587,78 
H5 0 287.21 g/mol 0.00 g/mol 0 
A6 0 309.23 g/mol 0.00 g/mol 0 
B6 0 309.23 g/mol 0.00 g/mol 0 
C6 0,12 312.28 g/mol 312.31 g/mol 5503,82 
D6 0 310.23 g/mol 0.00 g/mol 0 
E6 0 329.31 g/mol 329.34 g/mol 33,84 
F6 0 352.23 g/mol 352.28 g/mol 56,85 
G6 0,16 364.27 g/mol 364.29 g/mol 7383,18 
H6 0 304.23 g/mol 304.26 g/mol 251,55 
436 Appendix II 
A7 0 301.21 g/mol 0.00 g/mol 0 
B7 0 301.21 g/mol 0.00 g/mol 0 
C7 0 304.26 g/mol 0.00 g/mol 0 
D7 0 302.20 g/mol 0.00 g/mol 0 
E7 0,04 321.29 g/mol 321.34 g/mol 829,73 
F7 0 344.21 g/mol 0.00 g/mol 0 
G7 0 356.25 g/mol 0.00 g/mol 0 
H7 0 296.21 g/mol 0.00 g/mol 0 
A8 0 321.23 g/mol 0.00 g/mol 0 
B8 0 321.23 g/mol 0.00 g/mol 0 
C8 0,02 324.28 g/mol 324.31 g/mol 398,63 
D8 0 322.23 g/mol 0.00 g/mol 0 
E8 0 341.31 g/mol 0.00 g/mol 0 
F8 0 364.23 g/mol 0.00 g/mol 0 
G8 0,06 376.27 g/mol 376.31 g/mol 3717,88 
H8 0 316.23 g/mol 0.00 g/mol 0 
A9 0 351.20 g/mol 0.00 g/mol 0 
B9 0 351.20 g/mol 0.00 g/mol 0 
C9 0 354.25 g/mol 0.00 g/mol 0 
D9 0 352.19 g/mol 0.00 g/mol 0 
E9 0 371.28 g/mol 0.00 g/mol 0 
F9 0 394.20 g/mol 0.00 g/mol 0 
G9 0 406.24 g/mol 0.00 g/mol 0 
H9 0 346.20 g/mol 0.00 g/mol 0 
A10 0 323.21 g/mol 0.00 g/mol 0 
B10 0 323.21 g/mol 0.00 g/mol 0 
C10 0 326.25 g/mol 0.00 g/mol 0 
D10 0,02 324.20 g/mol 324.24 g/mol 389,65 
E10 0 343.29 g/mol 0.00 g/mol 0 
F10 0 366.20 g/mol 0.00 g/mol 0 
G10 0 378.25 g/mol 0.00 g/mol 0 
H10 0 318.21 g/mol 0.00 g/mol 0 
A11 0 308.21 g/mol 0.00 g/mol 0 
B11 0 308.21 g/mol 0.00 g/mol 0 
C11 0 311.25 g/mol 311.20 g/mol 347,92 
D11 0 309.20 g/mol 0.00 g/mol 0 
E11 0 328.29 g/mol 0.00 g/mol 0 
F11 0 351.20 g/mol 0.00 g/mol 0 
G11 0 363.25 g/mol 0.00 g/mol 0 
H11 0 303.20 g/mol 0.00 g/mol 0 
A12 0 327.22 g/mol 0.00 g/mol 0 
B12 0 327.22 g/mol 327.27 g/mol 143,19 
C12 0 330.26 g/mol 330.30 g/mol 268,7 
D12 0 328.21 g/mol 0.00 g/mol 0 
E12 0 347.30 g/mol 0.00 g/mol 0 
F12 0 370.21 g/mol 370.27 g/mol 487,87 
G12 0,04 382.26 g/mol 382.31 g/mol 16097,64 
H12 0 322.21 g/mol 322.27 g/mol 62,04 
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Well Peak width Expected mass Found mass Intensity 
A1         
B1         
C1         
D1         
E1         
F1         
G1         
H1         
A2 0,08 398.40 g/mol 398.42 g/mol 6675,6 
B2 0 312.31 g/mol 0.00 g/mol 0 
C2 0,14 270.25 g/mol 270.27 g/mol 4350,84 
D2 0,06 326.33 g/mol 326.35 g/mol 14933,04 
E2 0 326.33 g/mol 0.00 g/mol 0 
F2 0,06 432.25 g/mol 432.31 g/mol 4821,4 
G2 0,08 296.27 g/mol 296.30 g/mol 5253,32 
H2 0 322.25 g/mol 0.00 g/mol 0 
A3 0 428.37 g/mol 0.00 g/mol 0 
B3 0 342.28 g/mol 0.00 g/mol 0 
C3 0,04 300.22 g/mol 300.25 g/mol 752,42 
D3 0 356.30 g/mol 0.00 g/mol 0 
E3 0 356.30 g/mol 0.00 g/mol 0 
F3 0 462.22 g/mol 0.00 g/mol 0 
G3 0 326.24 g/mol 0.00 g/mol 0 
H3 0 352.22 g/mol 0.00 g/mol 0 
A4 0 410.40 g/mol 0.00 g/mol 0 
B4 0 324.31 g/mol 0.00 g/mol 0 
C4 0 282.25 g/mol 282.25 g/mol 262,57 
D4 0 338.33 g/mol 0.00 g/mol 0 
E4 0 338.33 g/mol 338.38 g/mol 93,52 
F4 0 444.25 g/mol 444.31 g/mol 1602,21 
G4 0 308.27 g/mol 0.00 g/mol 0 
H4 0,02 334.25 g/mol 334.31 g/mol 768,26 
A5 0 371.31 g/mol 0.00 g/mol 0 
B5 0 285.22 g/mol 0.00 g/mol 0 
C5 0 243.16 g/mol 0.00 g/mol 0 
D5 0 299.24 g/mol 0.00 g/mol 0 
E5 0 299.24 g/mol 0.00 g/mol 0 
F5 0 405.16 g/mol 405.24 g/mol 77,25 
G5 0 269.18 g/mol 0.00 g/mol 0 
H5 0 295.16 g/mol 0.00 g/mol 0 
A6 0 388.33 g/mol 0.00 g/mol 0 
B6 0 302.24 g/mol 0.00 g/mol 0 
C6 0 260.18 g/mol 0.00 g/mol 0 
D6 0 316.26 g/mol 0.00 g/mol 0 
E6 0 316.26 g/mol 0.00 g/mol 0 
F6 0,02 422.18 g/mol 422.25 g/mol 764,17 
G6 0 286.20 g/mol 0.00 g/mol 0 
H6 0,02 312.18 g/mol 312.25 g/mol 359,15 
438 Appendix II 
A7 0 380.31 g/mol 0.00 g/mol 0 
B7 0 294.21 g/mol 0.00 g/mol 0 
C7 0 252.16 g/mol 0.00 g/mol 0 
D7 0 308.23 g/mol 0.00 g/mol 0 
E7 0 308.23 g/mol 0.00 g/mol 0 
F7 0 414.16 g/mol 0.00 g/mol 0 
G7 0 278.18 g/mol 0.00 g/mol 0 
H7 0 304.16 g/mol 0.00 g/mol 0 
A8 0 400.33 g/mol 0.00 g/mol 0 
B8 0 314.24 g/mol 0.00 g/mol 0 
C8 0 272.18 g/mol 0.00 g/mol 0 
D8 0 328.26 g/mol 0.00 g/mol 0 
E8 0 328.26 g/mol 0.00 g/mol 0 
F8 0,04 434.18 g/mol 434.26 g/mol 1234,76 
G8 0 298.20 g/mol 0.00 g/mol 0 
H8 0 324.18 g/mol 0.00 g/mol 0 
A9 0 430.30 g/mol 0.00 g/mol 0 
B9 0 344.21 g/mol 0.00 g/mol 0 
C9 0 302.15 g/mol 0.00 g/mol 0 
D9 0 358.23 g/mol 0.00 g/mol 0 
E9 0 358.23 g/mol 0.00 g/mol 0 
F9 0 464.15 g/mol 0.00 g/mol 0 
G9 0 328.17 g/mol 0.00 g/mol 0 
H9 0 354.15 g/mol 0.00 g/mol 0 
A10 0 402.30 g/mol 0.00 g/mol 0 
B10 0 316.21 g/mol 0.00 g/mol 0 
C10 0 274.15 g/mol 0.00 g/mol 0 
D10 0 330.23 g/mol 0.00 g/mol 0 
E10 0 330.23 g/mol 0.00 g/mol 0 
F10 0 436.15 g/mol 0.00 g/mol 0 
G10 0 300.17 g/mol 0.00 g/mol 0 
H10 0 326.16 g/mol 0.00 g/mol 0 
A11 0 387.30 g/mol 0.00 g/mol 0 
B11 0 301.21 g/mol 0.00 g/mol 0 
C11 0 259.15 g/mol 0.00 g/mol 0 
D11 0 315.23 g/mol 0.00 g/mol 0 
E11 0 315.23 g/mol 0.00 g/mol 0 
F11 0 421.15 g/mol 0.00 g/mol 0 
G11 0 285.17 g/mol 0.00 g/mol 0 
H11 0 311.16 g/mol 0.00 g/mol 0 
A12 0 406.31 g/mol 0.00 g/mol 0 
B12 0 320.22 g/mol 0.00 g/mol 0 
C12 0,02 278.16 g/mol 278.23 g/mol 1311,05 
D12 0 334.24 g/mol 0.00 g/mol 0 
E12 0 334.24 g/mol 0.00 g/mol 0 
F12 0 440.16 g/mol 0.00 g/mol 0 
G12 0,14 304.18 g/mol 304.23 g/mol 2622,53 
H12 0 330.17 g/mol 0.00 g/mol 0 
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Well Peak width Expected mass Found mass Intensity 
A1         
B1         
C1         
D1         
E1         
F1         
G1         
H1         
A2 0 321.26 g/mol 0.00 g/mol 0 
B2 0 321.26 g/mol 0.00 g/mol 0 
C2 0,2 324.31 g/mol 324.33 g/mol 7922,64 
D2 0 322.25 g/mol 0.00 g/mol 0 
E2 0 341.34 g/mol 0.00 g/mol 0 
F2 0 364.26 g/mol 364.30 g/mol 5591,75 
G2 0 376.30 g/mol 0.00 g/mol 0 
H2 0 316.26 g/mol 316.29 g/mol 3543,11 
A3 0 351.23 g/mol 0.00 g/mol 0 
B3 0 351.23 g/mol 0.00 g/mol 0 
C3 0,1 354.28 g/mol 354.32 g/mol 2265,93 
D3 0 352.22 g/mol 0.00 g/mol 0 
E3 0 371.31 g/mol 0.00 g/mol 0 
F3 0 394.22 g/mol 0.00 g/mol 0 
G3 0,02 406.27 g/mol 406.32 g/mol 1540,16 
H3 0 346.23 g/mol 0.00 g/mol 0 
A4 0 333.26 g/mol 0.00 g/mol 0 
B4 0 333.26 g/mol 0.00 g/mol 0 
C4 0 336.31 g/mol 336.36 g/mol 151,89 
D4 0 334.25 g/mol 0.00 g/mol 0 
E4 0 353.34 g/mol 0.00 g/mol 0 
F4 0 376.26 g/mol 376.32 g/mol 554,4 
G4 0 388.30 g/mol 0.00 g/mol 0 
H4 0 328.26 g/mol 0.00 g/mol 0 
A5 0 294.17 g/mol 0.00 g/mol 0 
B5 0 294.17 g/mol 0.00 g/mol 0 
C5 0,08 297.22 g/mol 297.25 g/mol 3614,03 
D5 0 295.16 g/mol 0.00 g/mol 0 
E5 0 314.25 g/mol 0.00 g/mol 0 
F5 0 337.17 g/mol 0.00 g/mol 0 
G5 0 349.21 g/mol 0.00 g/mol 0 
H5 0 289.17 g/mol 289.23 g/mol 24,6 
A6 0 311.19 g/mol 0.00 g/mol 0 
B6 0 311.19 g/mol 0.00 g/mol 0 
C6 0 314.24 g/mol 0.00 g/mol 0 
D6 0 312.18 g/mol 0.00 g/mol 0 
E6 0 331.27 g/mol 0.00 g/mol 0 
F6 0 354.19 g/mol 0.00 g/mol 0 
G6 0 366.23 g/mol 0.00 g/mol 0 
H6 0 306.19 g/mol 306.25 g/mol 85,64 
440 Appendix II 
A7 0 303.17 g/mol 0.00 g/mol 0 
B7 0 303.17 g/mol 0.00 g/mol 0 
C7 0 306.21 g/mol 0.00 g/mol 0 
D7 0 304.16 g/mol 0.00 g/mol 0 
E7 0 323.25 g/mol 0.00 g/mol 0 
F7 0 346.16 g/mol 0.00 g/mol 0 
G7 0 358.21 g/mol 0.00 g/mol 0 
H7 0 298.16 g/mol 298.22 g/mol 270,74 
A8 0 323.19 g/mol 0.00 g/mol 0 
B8 0 323.19 g/mol 0.00 g/mol 0 
C8 0 326.24 g/mol 0.00 g/mol 0 
D8 0 324.18 g/mol 0.00 g/mol 0 
E8 0 343.27 g/mol 0.00 g/mol 0 
F8 0 366.19 g/mol 366.25 g/mol 73,06 
G8 0 378.23 g/mol 0.00 g/mol 0 
H8 0 318.19 g/mol 318.24 g/mol 29,42 
A9 0 353.16 g/mol 0.00 g/mol 0 
B9 0 353.16 g/mol 0.00 g/mol 0 
C9 0 356.21 g/mol 0.00 g/mol 0 
D9 0 354.15 g/mol 0.00 g/mol 0 
E9 0 373.24 g/mol 0.00 g/mol 0 
F9 0 396.15 g/mol 0.00 g/mol 0 
G9 0 408.20 g/mol 0.00 g/mol 0 
H9 0 348.16 g/mol 0.00 g/mol 0 
A10 0 325.17 g/mol 0.00 g/mol 0 
B10 0 325.17 g/mol 0.00 g/mol 0 
C10 0 328.21 g/mol 0.00 g/mol 0 
D10 0 326.16 g/mol 0.00 g/mol 0 
E10 0 345.25 g/mol 0.00 g/mol 0 
F10 0 368.16 g/mol 0.00 g/mol 0 
G10 0,14 380.21 g/mol 380.30 g/mol 3240,79 
H10 0 320.16 g/mol 0.00 g/mol 0 
A11 0 310.16 g/mol 0.00 g/mol 0 
B11 0 310.16 g/mol 0.00 g/mol 0 
C11 0 313.21 g/mol 0.00 g/mol 0 
D11 0 311.16 g/mol 0.00 g/mol 0 
E11 0 330.24 g/mol 0.00 g/mol 0 
F11 0 353.16 g/mol 0.00 g/mol 0 
G11 0 365.20 g/mol 0.00 g/mol 0 
H11 0 305.16 g/mol 0.00 g/mol 0 
A12 0 329.18 g/mol 0.00 g/mol 0 
B12 0 329.18 g/mol 0.00 g/mol 0 
C12 0 332.22 g/mol 0.00 g/mol 0 
D12 0,02 330.17 g/mol 330.23 g/mol 935,06 
E12 0 349.25 g/mol 0.00 g/mol 0 
F12 0 372.17 g/mol 372.26 g/mol 84,09 
G12 0,04 384.22 g/mol 384.29 g/mol 1537,56 
H12 0,06 324.17 g/mol 324.14 g/mol 1393,9 
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Well Peak width Expected mass Found mass Intensity 
A1         
B1         
C1         
D1         
E1         
F1         
G1         
H1         
A2 0,16 466.34 g/mol 466.37 g/mol 8102,64 
B2 0 380.25 g/mol 0.00 g/mol 0 
C2 0,08 338.19 g/mol 338.22 g/mol 4184,05 
D2 0,1 394.26 g/mol 394.30 g/mol 6140,34 
E2 0,06 394.26 g/mol 394.30 g/mol 1766,76 
F2 0,04 500.19 g/mol 500.26 g/mol 1267,05 
G2 0,06 364.21 g/mol 364.24 g/mol 4133,19 
H2 0,06 390.19 g/mol 390.24 g/mol 1511,39 
A3 0 496.31 g/mol 0.00 g/mol 0 
B3 0 410.21 g/mol 0.00 g/mol 0 
C3 0 368.16 g/mol 0.00 g/mol 0 
D3 0 424.23 g/mol 0.00 g/mol 0 
E3 0 424.23 g/mol 0.00 g/mol 0 
F3 0 530.15 g/mol 0.00 g/mol 0 
G3 0 394.17 g/mol 0.00 g/mol 0 
H3 0 420.16 g/mol 0.00 g/mol 0 
A4 0,02 478.34 g/mol 478.38 g/mol 790,63 
B4 0 392.24 g/mol 0.00 g/mol 0 
C4 0 350.19 g/mol 0.00 g/mol 0 
D4 0 406.26 g/mol 0.00 g/mol 0 
E4 0,02 406.26 g/mol 406.32 g/mol 553,11 
F4 0,04 512.19 g/mol 512.26 g/mol 1936,72 
G4 0 376.21 g/mol 376.25 g/mol 2288,96 
H4 0,04 402.19 g/mol 402.25 g/mol 3544,96 
A5 0 439.25 g/mol 0.00 g/mol 0 
B5 0 353.15 g/mol 0.00 g/mol 0 
C5 0 311.10 g/mol 0.00 g/mol 0 
D5 0 367.17 g/mol 0.00 g/mol 0 
E5 0 367.17 g/mol 0.00 g/mol 0 
F5 0 473.09 g/mol 0.00 g/mol 0 
G5 0 337.11 g/mol 0.00 g/mol 0 
H5 0 363.10 g/mol 0.00 g/mol 0 
A6 0,02 456.27 g/mol 456.33 g/mol 766,64 
B6 0 370.18 g/mol 0.00 g/mol 0 
C6 0,04 328.12 g/mol 328.17 g/mol 1097,09 
D6 0 384.20 g/mol 0.00 g/mol 0 
E6 0 384.20 g/mol 0.00 g/mol 0 
F6 0 490.12 g/mol 490.20 g/mol 722,83 
G6 0 354.14 g/mol 354.19 g/mol 388,68 
H6 0 380.12 g/mol 380.19 g/mol 278,62 
442 Appendix II 
A7 0 448.24 g/mol 0.00 g/mol 0 
B7 0 362.15 g/mol 0.00 g/mol 0 
C7 0 320.09 g/mol 0.00 g/mol 0 
D7 0 376.17 g/mol 0.00 g/mol 0 
E7 0 376.17 g/mol 0.00 g/mol 0 
F7 0 482.09 g/mol 0.00 g/mol 0 
G7 0 346.11 g/mol 0.00 g/mol 0 
H7 0 372.10 g/mol 0.00 g/mol 0 
A8 0,02 468.27 g/mol 468.34 g/mol 745,53 
B8 0 382.18 g/mol 0.00 g/mol 0 
C8 0 340.12 g/mol 0.00 g/mol 0 
D8 0 396.19 g/mol 0.00 g/mol 0 
E8 0 396.19 g/mol 0.00 g/mol 0 
F8 0 502.12 g/mol 0.00 g/mol 0 
G8 0 366.14 g/mol 0.00 g/mol 0 
H8 0 392.12 g/mol 0.00 g/mol 0 
A9 0 498.24 g/mol 0.00 g/mol 0 
B9 0 412.14 g/mol 0.00 g/mol 0 
C9 0 370.09 g/mol 0.00 g/mol 0 
D9 0 426.16 g/mol 0.00 g/mol 0 
E9 0 426.16 g/mol 0.00 g/mol 0 
F9 0 532.08 g/mol 0.00 g/mol 0 
G9 0 396.10 g/mol 0.00 g/mol 0 
H9 0 422.09 g/mol 0.00 g/mol 0 
A10 0 470.24 g/mol 0.00 g/mol 0 
B10 0 384.15 g/mol 0.00 g/mol 0 
C10 0 342.09 g/mol 0.00 g/mol 0 
D10 0 398.17 g/mol 0.00 g/mol 0 
E10 0 398.17 g/mol 0.00 g/mol 0 
F10 0 504.09 g/mol 0.00 g/mol 0 
G10 0 368.11 g/mol 0.00 g/mol 0 
H10 0 394.10 g/mol 0.00 g/mol 0 
A11 0 455.24 g/mol 0.00 g/mol 0 
B11 0 369.15 g/mol 0.00 g/mol 0 
C11 0 327.09 g/mol 0.00 g/mol 0 
D11 0 383.17 g/mol 0.00 g/mol 0 
E11 0 383.17 g/mol 0.00 g/mol 0 
F11 0 489.09 g/mol 0.00 g/mol 0 
G11 0 353.11 g/mol 0.00 g/mol 0 
H11 0 379.09 g/mol 0.00 g/mol 0 
A12 0 474.25 g/mol 0.00 g/mol 0 
B12 0 388.16 g/mol 0.00 g/mol 0 
C12 0 346.10 g/mol 0.00 g/mol 0 
D12 0 402.18 g/mol 0.00 g/mol 0 
E12 0 402.18 g/mol 0.00 g/mol 0 
F12 0 508.10 g/mol 0.00 g/mol 0 
G12 0 372.12 g/mol 0.00 g/mol 0 
H12 0 398.11 g/mol 0.00 g/mol 0 
 
 
 
 
 
 
 
 Appendix II 443 
ori.hya.31 
 
 
 
  
 
 
 
 
Well Peak width Expected mass Found mass Intensity 
A1         
B1         
C1         
D1         
E1         
F1         
G1         
H1         
A2 0 389.20 g/mol 0.00 g/mol 0 
B2 0 389.20 g/mol 0.00 g/mol 0 
C2 0,08 392.24 g/mol 392.29 g/mol 7376,88 
D2 0 390.19 g/mol 390.25 g/mol 335,58 
E2 0 409.28 g/mol 0.00 g/mol 0 
F2 0,04 432.19 g/mol 432.26 g/mol 4004,96 
G2 0 444.24 g/mol 0.00 g/mol 0 
H2 0 384.19 g/mol 0.00 g/mol 0 
A3 0 419.17 g/mol 0.00 g/mol 0 
B3 0 419.17 g/mol 0.00 g/mol 0 
C3 0 422.21 g/mol 0.00 g/mol 0 
D3 0 420.16 g/mol 0.00 g/mol 0 
E3 0 439.25 g/mol 0.00 g/mol 0 
F3 0 462.16 g/mol 0.00 g/mol 0 
G3 0 474.21 g/mol 0.00 g/mol 0 
H3 0 414.16 g/mol 0.00 g/mol 0 
A4 0 401.20 g/mol 401.26 g/mol 157,46 
B4 0,02 401.20 g/mol 401.26 g/mol 651,61 
C4 0,02 404.24 g/mol 404.31 g/mol 924,31 
D4 0,06 402.19 g/mol 402.25 g/mol 4699,29 
E4 0 421.28 g/mol 0.00 g/mol 0 
F4 0 444.19 g/mol 444.26 g/mol 2232,7 
G4 0 456.24 g/mol 0.00 g/mol 0 
H4 0 396.19 g/mol 0.00 g/mol 0 
A5 0 362.11 g/mol 0.00 g/mol 0 
B5 0 362.11 g/mol 0.00 g/mol 0 
C5 0 365.15 g/mol 0.00 g/mol 0 
D5 0 363.10 g/mol 0.00 g/mol 0 
E5 0 382.19 g/mol 0.00 g/mol 0 
F5 0 405.10 g/mol 0.00 g/mol 0 
G5 0 417.15 g/mol 0.00 g/mol 0 
H5 0 357.10 g/mol 0.00 g/mol 0 
A6 0 379.13 g/mol 379.20 g/mol 130,79 
B6 0 379.13 g/mol 379.16 g/mol 105,58 
C6 0,02 382.17 g/mol 382.24 g/mol 651,01 
D6 0 380.12 g/mol 380.21 g/mol 113,23 
E6 0 399.21 g/mol 0.00 g/mol 0 
F6 0 422.12 g/mol 422.21 g/mol 237,14 
G6 0 434.17 g/mol 0.00 g/mol 0 
H6 0 374.13 g/mol 0.00 g/mol 0 
444 Appendix II 
A7 0 371.10 g/mol 0.00 g/mol 0 
B7 0 371.10 g/mol 0.00 g/mol 0 
C7 0 374.15 g/mol 0.00 g/mol 0 
D7 0 372.10 g/mol 0.00 g/mol 0 
E7 0 391.18 g/mol 0.00 g/mol 0 
F7 0 414.10 g/mol 0.00 g/mol 0 
G7 0 426.14 g/mol 0.00 g/mol 0 
H7 0 366.10 g/mol 0.00 g/mol 0 
A8 0 391.13 g/mol 0.00 g/mol 0 
B8 0 391.13 g/mol 0.00 g/mol 0 
C8 0 394.17 g/mol 0.00 g/mol 0 
D8 0 392.12 g/mol 0.00 g/mol 0 
E8 0 411.21 g/mol 0.00 g/mol 0 
F8 0 434.12 g/mol 0.00 g/mol 0 
G8 0 446.17 g/mol 0.00 g/mol 0 
H8 0 386.12 g/mol 0.00 g/mol 0 
A9 0 421.10 g/mol 0.00 g/mol 0 
B9 0 421.10 g/mol 0.00 g/mol 0 
C9 0 424.14 g/mol 0.00 g/mol 0 
D9 0 422.09 g/mol 0.00 g/mol 0 
E9 0 441.18 g/mol 0.00 g/mol 0 
F9 0 464.09 g/mol 0.00 g/mol 0 
G9 0 476.14 g/mol 0.00 g/mol 0 
H9 0 416.09 g/mol 0.00 g/mol 0 
A10 0 393.10 g/mol 0.00 g/mol 0 
B10 0 393.10 g/mol 0.00 g/mol 0 
C10 0 396.15 g/mol 0.00 g/mol 0 
D10 0 394.10 g/mol 0.00 g/mol 0 
E10 0 413.18 g/mol 0.00 g/mol 0 
F10 0 436.10 g/mol 0.00 g/mol 0 
G10 0 448.14 g/mol 0.00 g/mol 0 
H10 0 388.10 g/mol 0.00 g/mol 0 
A11 0 378.10 g/mol 0.00 g/mol 0 
B11 0 378.10 g/mol 0.00 g/mol 0 
C11 0 381.15 g/mol 0.00 g/mol 0 
D11 0 379.09 g/mol 0.00 g/mol 0 
E11 0 398.18 g/mol 0.00 g/mol 0 
F11 0 421.10 g/mol 0.00 g/mol 0 
G11 0 433.14 g/mol 0.00 g/mol 0 
H11 0 373.10 g/mol 0.00 g/mol 0 
A12 0 397.11 g/mol 0.00 g/mol 0 
B12 0 397.11 g/mol 0.00 g/mol 0 
C12 0 400.16 g/mol 0.00 g/mol 0 
D12 0 398.11 g/mol 0.00 g/mol 0 
E12 0 417.19 g/mol 0.00 g/mol 0 
F12 0 440.11 g/mol 440.20 g/mol 163,76 
G12 0 452.15 g/mol 0.00 g/mol 0 
H12 0 392.11 g/mol 0.00 g/mol 0 
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Well Peak width Expected mass Found mass Intensity 
A1         
B1         
C1         
D1         
E1         
F1         
G1         
H1         
A2 0,08 398.40 g/mol 398.42 g/mol 25868,04 
B2 0 312.31 g/mol 0.00 g/mol 0 
C2 0,02 270.25 g/mol 270.27 g/mol 3223,4 
D2 0,1 326.33 g/mol 326.35 g/mol 5853,22 
E2 0 326.33 g/mol 0.00 g/mol 0 
F2 0,02 432.25 g/mol 432.31 g/mol 936,19 
G2 0,06 296.27 g/mol 296.29 g/mol 1652,24 
H2 0 322.25 g/mol 0.00 g/mol 0 
A3 0,04 428.37 g/mol 428.40 g/mol 1133,98 
B3 0 342.28 g/mol 0.00 g/mol 0 
C3 0 300.22 g/mol 0.00 g/mol 0 
D3 0 356.30 g/mol 0.00 g/mol 0 
E3 0 356.30 g/mol 0.00 g/mol 0 
F3 0 462.22 g/mol 0.00 g/mol 0 
G3 0 326.24 g/mol 0.00 g/mol 0 
H3 0 352.22 g/mol 0.00 g/mol 0 
A4 0 410.40 g/mol 0.00 g/mol 0 
B4 0 324.31 g/mol 0.00 g/mol 0 
C4 0 282.25 g/mol 0.00 g/mol 0 
D4 0 338.33 g/mol 0.00 g/mol 0 
E4 0 338.33 g/mol 0.00 g/mol 0 
F4 0 444.25 g/mol 0.00 g/mol 0 
G4 0,04 308.27 g/mol 308.32 g/mol 743,41 
H4 0 334.25 g/mol 0.00 g/mol 0 
A5 0 371.31 g/mol 0.00 g/mol 0 
B5 0 285.22 g/mol 0.00 g/mol 0 
C5 0 243.16 g/mol 0.00 g/mol 0 
D5 0 299.24 g/mol 0.00 g/mol 0 
E5 0 299.24 g/mol 0.00 g/mol 0 
F5 0 405.16 g/mol 0.00 g/mol 0 
G5 0 269.18 g/mol 0.00 g/mol 0 
H5 0 295.16 g/mol 0.00 g/mol 0 
A6 0 388.33 g/mol 0.00 g/mol 0 
B6 0 302.24 g/mol 0.00 g/mol 0 
C6 0 260.18 g/mol 0.00 g/mol 0 
D6 0 316.26 g/mol 0.00 g/mol 0 
E6 0 316.26 g/mol 0.00 g/mol 0 
F6 0 422.18 g/mol 0.00 g/mol 0 
G6 0 286.20 g/mol 0.00 g/mol 0 
H6 0 312.18 g/mol 0.00 g/mol 0 
446 Appendix II 
A7 0 380.31 g/mol 0.00 g/mol 0 
B7 0 294.21 g/mol 0.00 g/mol 0 
C7 0 252.16 g/mol 0.00 g/mol 0 
D7 0 308.23 g/mol 0.00 g/mol 0 
E7 0 308.23 g/mol 0.00 g/mol 0 
F7 0 414.16 g/mol 0.00 g/mol 0 
G7 0 278.18 g/mol 0.00 g/mol 0 
H7 0 304.16 g/mol 0.00 g/mol 0 
A8 0 400.33 g/mol 0.00 g/mol 0 
B8 0 314.24 g/mol 0.00 g/mol 0 
C8 0 272.18 g/mol 0.00 g/mol 0 
D8 0 328.26 g/mol 0.00 g/mol 0 
E8 0 328.26 g/mol 0.00 g/mol 0 
F8 0 434.18 g/mol 0.00 g/mol 0 
G8 0 298.20 g/mol 0.00 g/mol 0 
H8 0 324.18 g/mol 0.00 g/mol 0 
A9 0 430.30 g/mol 0.00 g/mol 0 
B9 0 344.21 g/mol 0.00 g/mol 0 
C9 0 302.15 g/mol 0.00 g/mol 0 
D9 0 358.23 g/mol 0.00 g/mol 0 
E9 0 358.23 g/mol 0.00 g/mol 0 
F9 0 464.15 g/mol 0.00 g/mol 0 
G9 0 328.17 g/mol 0.00 g/mol 0 
H9 0 354.15 g/mol 0.00 g/mol 0 
A10 0 402.30 g/mol 402.32 g/mol 13,7 
B10 0 316.21 g/mol 0.00 g/mol 0 
C10 0 274.15 g/mol 0.00 g/mol 0 
D10 0 330.23 g/mol 0.00 g/mol 0 
E10 0 330.23 g/mol 0.00 g/mol 0 
F10 0 436.15 g/mol 0.00 g/mol 0 
G10 0 300.17 g/mol 0.00 g/mol 0 
H10 0 326.16 g/mol 0.00 g/mol 0 
A11 0 387.30 g/mol 0.00 g/mol 0 
B11 0 301.21 g/mol 0.00 g/mol 0 
C11 0 259.15 g/mol 0.00 g/mol 0 
D11 0 315.23 g/mol 0.00 g/mol 0 
E11 0 315.23 g/mol 0.00 g/mol 0 
F11 0 421.15 g/mol 0.00 g/mol 0 
G11 0 285.17 g/mol 0.00 g/mol 0 
H11 0 311.16 g/mol 0.00 g/mol 0 
A12 0 406.31 g/mol 0.00 g/mol 0 
B12 0 320.22 g/mol 0.00 g/mol 0 
C12 0 278.16 g/mol 0.00 g/mol 0 
D12 0 334.24 g/mol 0.00 g/mol 0 
E12 0 334.24 g/mol 0.00 g/mol 0 
F12 0 440.16 g/mol 0.00 g/mol 0 
G12 0 304.18 g/mol 0.00 g/mol 0 
H12 0 330.17 g/mol 0.00 g/mol 0 
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Well Peak width Expected mass Found mass Intensity 
A1         
B1         
C1         
D1         
E1         
F1         
G1         
H1         
A2 0 321.26 g/mol 0.00 g/mol 0 
B2 0 321.26 g/mol 0.00 g/mol 0 
C2 0,14 324.31 g/mol 324.32 g/mol 22138,86 
D2 0 322.25 g/mol 0.00 g/mol 0 
E2 0 341.34 g/mol 0.00 g/mol 0 
F2 0 364.26 g/mol 0.00 g/mol 0 
G2 0 376.30 g/mol 0.00 g/mol 0 
H2 0,1 316.26 g/mol 316.28 g/mol 4309,88 
A3 0 351.23 g/mol 0.00 g/mol 0 
B3 0 351.23 g/mol 0.00 g/mol 0 
C3 0 354.28 g/mol 0.00 g/mol 0 
D3 0 352.22 g/mol 0.00 g/mol 0 
E3 0 371.31 g/mol 0.00 g/mol 0 
F3 0 394.23 g/mol 0.00 g/mol 0 
G3 0 406.27 g/mol 0.00 g/mol 0 
H3 0,02 346.23 g/mol 346.26 g/mol 1249,46 
A4 0 333.26 g/mol 0.00 g/mol 0 
B4 0 333.26 g/mol 0.00 g/mol 0 
C4 0 336.31 g/mol 0.00 g/mol 0 
D4 0 334.25 g/mol 0.00 g/mol 0 
E4 0 353.34 g/mol 0.00 g/mol 0 
F4 0 376.26 g/mol 0.00 g/mol 0 
G4 0 388.30 g/mol 0.00 g/mol 0 
H4 0 328.26 g/mol 0.00 g/mol 0 
A5 0 294.17 g/mol 0.00 g/mol 0 
B5 0 294.17 g/mol 0.00 g/mol 0 
C5 0 297.22 g/mol 0.00 g/mol 0 
D5 0 295.16 g/mol 0.00 g/mol 0 
E5 0 314.25 g/mol 0.00 g/mol 0 
F5 0 337.17 g/mol 0.00 g/mol 0 
G5 0 349.21 g/mol 0.00 g/mol 0 
H5 0 289.17 g/mol 289.19 g/mol 45,92 
A6 0 311.19 g/mol 0.00 g/mol 0 
B6 0 311.19 g/mol 0.00 g/mol 0 
C6 0 314.24 g/mol 314.29 g/mol 31,93 
D6 0 312.18 g/mol 0.00 g/mol 0 
E6 0 331.27 g/mol 0.00 g/mol 0 
F6 0 354.19 g/mol 0.00 g/mol 0 
G6 0 366.23 g/mol 0.00 g/mol 0 
H6 0 306.19 g/mol 306.24 g/mol 128,02 
448 Appendix II 
A7 0 303.17 g/mol 0.00 g/mol 0 
B7 0 303.17 g/mol 0.00 g/mol 0 
C7 0 306.21 g/mol 0.00 g/mol 0 
D7 0 304.16 g/mol 0.00 g/mol 0 
E7 0 323.25 g/mol 0.00 g/mol 0 
F7 0 346.16 g/mol 0.00 g/mol 0 
G7 0 358.21 g/mol 0.00 g/mol 0 
H7 0 298.16 g/mol 0.00 g/mol 0 
A8 0 323.19 g/mol 0.00 g/mol 0 
B8 0 323.19 g/mol 0.00 g/mol 0 
C8 0 326.24 g/mol 0.00 g/mol 0 
D8 0 324.18 g/mol 0.00 g/mol 0 
E8 0 343.27 g/mol 0.00 g/mol 0 
F8 0 366.19 g/mol 0.00 g/mol 0 
G8 0 378.23 g/mol 0.00 g/mol 0 
H8 0 318.19 g/mol 0.00 g/mol 0 
A9 0 353.16 g/mol 0.00 g/mol 0 
B9 0 353.16 g/mol 0.00 g/mol 0 
C9 0 356.21 g/mol 0.00 g/mol 0 
D9 0 354.15 g/mol 0.00 g/mol 0 
E9 0 373.24 g/mol 0.00 g/mol 0 
F9 0 396.15 g/mol 0.00 g/mol 0 
G9 0 408.20 g/mol 0.00 g/mol 0 
H9 0 348.16 g/mol 0.00 g/mol 0 
A10 0 325.17 g/mol 0.00 g/mol 0 
B10 0 325.17 g/mol 0.00 g/mol 0 
C10 0 328.21 g/mol 0.00 g/mol 0 
D10 0 326.16 g/mol 0.00 g/mol 0 
E10 0 345.25 g/mol 0.00 g/mol 0 
F10 0 368.16 g/mol 0.00 g/mol 0 
G10 0,02 380.21 g/mol 380.26 g/mol 654,41 
H10 0 320.16 g/mol 0.00 g/mol 0 
A11 0 310.16 g/mol 0.00 g/mol 0 
B11 0 310.16 g/mol 0.00 g/mol 0 
C11 0,02 313.21 g/mol 313.11 g/mol 1376,53 
D11 0 311.16 g/mol 0.00 g/mol 0 
E11 0 330.24 g/mol 0.00 g/mol 0 
F11 0 353.16 g/mol 0.00 g/mol 0 
G11 0 365.20 g/mol 0.00 g/mol 0 
H11 0 305.16 g/mol 0.00 g/mol 0 
A12 0 329.18 g/mol 329.24 g/mol 213,49 
B12 0 329.18 g/mol 0.00 g/mol 0 
C12 0 332.22 g/mol 0.00 g/mol 0 
D12 0 330.17 g/mol 0.00 g/mol 0 
E12 0 349.25 g/mol 0.00 g/mol 0 
F12 0 372.17 g/mol 0.00 g/mol 0 
G12 0 384.22 g/mol 0.00 g/mol 0 
H12 0 324.17 g/mol 0.00 g/mol 0 
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Well Peak width Expected mass Found mass Intensity 
A1         
B1         
C1         
D1         
E1         
F1         
G1         
H1         
A2 0,1 412.42 g/mol 412.44 g/mol 26194,74 
B2 0 326.33 g/mol 0.00 g/mol 0 
C2 0,22 284.27 g/mol 284.30 g/mol 4309,21 
D2 0,04 340.35 g/mol 340.36 g/mol 10253,4 
E2 0 340.35 g/mol 0.00 g/mol 0 
F2 0 446.27 g/mol 0.00 g/mol 0 
G2 0,14 310.29 g/mol 310.31 g/mol 7787,22 
H2 0 336.27 g/mol 0.00 g/mol 0 
A3 0 442.39 g/mol 442.42 g/mol 189,67 
B3 0 356.30 g/mol 0.00 g/mol 0 
C3 0,02 314.24 g/mol 314.28 g/mol 457,59 
D3 0 370.32 g/mol 0.00 g/mol 0 
E3 0 370.32 g/mol 0.00 g/mol 0 
F3 0 476.24 g/mol 0.00 g/mol 0 
G3 0 340.26 g/mol 0.00 g/mol 0 
H3 0 366.24 g/mol 0.00 g/mol 0 
A4 0 424.42 g/mol 0.00 g/mol 0 
B4 0 338.33 g/mol 0.00 g/mol 0 
C4 0 296.27 g/mol 0.00 g/mol 0 
D4 0 352.35 g/mol 0.00 g/mol 0 
E4 0 352.35 g/mol 0.00 g/mol 0 
F4 0 458.27 g/mol 0.00 g/mol 0 
G4 0 322.29 g/mol 0.00 g/mol 0 
H4 0 348.27 g/mol 0.00 g/mol 0 
A5 0 385.33 g/mol 0.00 g/mol 0 
B5 0 299.24 g/mol 0.00 g/mol 0 
C5 0 257.18 g/mol 0.00 g/mol 0 
D5 0 313.26 g/mol 0.00 g/mol 0 
E5 0 313.26 g/mol 0.00 g/mol 0 
F5 0 419.18 g/mol 0.00 g/mol 0 
G5 0 283.20 g/mol 0.00 g/mol 0 
H5 0 309.18 g/mol 0.00 g/mol 0 
A6 0 402.35 g/mol 0.00 g/mol 0 
B6 0 316.26 g/mol 0.00 g/mol 0 
C6 0 274.20 g/mol 0.00 g/mol 0 
D6 0 330.28 g/mol 0.00 g/mol 0 
E6 0 330.28 g/mol 0.00 g/mol 0 
F6 0 436.20 g/mol 0.00 g/mol 0 
G6 0 300.22 g/mol 0.00 g/mol 0 
H6 0 326.20 g/mol 0.00 g/mol 0 
450 Appendix II 
A7 0 394.33 g/mol 0.00 g/mol 0 
B7 0 308.23 g/mol 0.00 g/mol 0 
C7 0 266.18 g/mol 0.00 g/mol 0 
D7 0 322.25 g/mol 0.00 g/mol 0 
E7 0 322.25 g/mol 0.00 g/mol 0 
F7 0 428.18 g/mol 0.00 g/mol 0 
G7 0 292.19 g/mol 0.00 g/mol 0 
H7 0 318.18 g/mol 0.00 g/mol 0 
A8 0 414.35 g/mol 414.43 g/mol 244,1 
B8 0 328.26 g/mol 0.00 g/mol 0 
C8 0 286.20 g/mol 0.00 g/mol 0 
D8 0,02 342.28 g/mol 342.35 g/mol 475,75 
E8 0 342.28 g/mol 0.00 g/mol 0 
F8 0 448.20 g/mol 0.00 g/mol 0 
G8 0 312.22 g/mol 0.00 g/mol 0 
H8 0 338.20 g/mol 0.00 g/mol 0 
A9 0 444.32 g/mol 0.00 g/mol 0 
B9 0 358.23 g/mol 0.00 g/mol 0 
C9 0 316.17 g/mol 0.00 g/mol 0 
D9 0 372.25 g/mol 0.00 g/mol 0 
E9 0 372.25 g/mol 0.00 g/mol 0 
F9 0 478.17 g/mol 0.00 g/mol 0 
G9 0 342.19 g/mol 0.00 g/mol 0 
H9 0 368.17 g/mol 0.00 g/mol 0 
A10 0 416.32 g/mol 0.00 g/mol 0 
B10 0 330.23 g/mol 0.00 g/mol 0 
C10 0,06 288.17 g/mol 288.22 g/mol 1046,54 
D10 0 344.25 g/mol 0.00 g/mol 0 
E10 0 344.25 g/mol 0.00 g/mol 0 
F10 0 450.17 g/mol 0.00 g/mol 0 
G10 0 314.19 g/mol 0.00 g/mol 0 
H10 0 340.18 g/mol 0.00 g/mol 0 
A11 0 401.32 g/mol 0.00 g/mol 0 
B11 0 315.23 g/mol 0.00 g/mol 0 
C11 0 273.17 g/mol 0.00 g/mol 0 
D11 0 329.25 g/mol 0.00 g/mol 0 
E11 0 329.25 g/mol 0.00 g/mol 0 
F11 0 435.17 g/mol 0.00 g/mol 0 
G11 0 299.19 g/mol 0.00 g/mol 0 
H11 0 325.18 g/mol 0.00 g/mol 0 
A12 0 420.33 g/mol 0.00 g/mol 0 
B12 0 334.24 g/mol 0.00 g/mol 0 
C12 0 292.18 g/mol 0.00 g/mol 0 
D12 0 348.26 g/mol 0.00 g/mol 0 
E12 0 348.26 g/mol 0.00 g/mol 0 
F12 0 454.18 g/mol 0.00 g/mol 0 
G12 0 318.20 g/mol 0.00 g/mol 0 
H12 0 344.19 g/mol 0.00 g/mol 0 
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ori.hya.35 
 
 
 
  
 
 
 
 
Well Peak width Expected mass Found mass Intensity 
A1         
B1         
C1         
D1         
E1         
F1         
G1         
H1         
A2 0 335.28 g/mol 0.00 g/mol 0 
B2 0 335.28 g/mol 0.00 g/mol 0 
C2 0 338.33 g/mol 0.00 g/mol 0 
D2 0 336.27 g/mol 0.00 g/mol 0 
E2 0 355.36 g/mol 0.00 g/mol 0 
F2 0 378.28 g/mol 0.00 g/mol 0 
G2 0 390.32 g/mol 0.00 g/mol 0 
H2 0 330.28 g/mol 0.00 g/mol 0 
A3 0 365.25 g/mol 0.00 g/mol 0 
B3 0 365.25 g/mol 0.00 g/mol 0 
C3 0 368.30 g/mol 368.33 g/mol 276,72 
D3 0 366.24 g/mol 0.00 g/mol 0 
E3 0 385.33 g/mol 0.00 g/mol 0 
F3 0 408.24 g/mol 0.00 g/mol 0 
G3 0 420.29 g/mol 420.36 g/mol 125,5 
H3 0 360.25 g/mol 360.20 g/mol 290,42 
A4 0 347.28 g/mol 0.00 g/mol 0 
B4 0 347.28 g/mol 0.00 g/mol 0 
C4 0 350.33 g/mol 0.00 g/mol 0 
D4 0 348.27 g/mol 0.00 g/mol 0 
E4 0 367.36 g/mol 0.00 g/mol 0 
F4 0 390.28 g/mol 390.35 g/mol 71,37 
G4 0 402.32 g/mol 0.00 g/mol 0 
H4 0 342.28 g/mol 0.00 g/mol 0 
A5 0 308.19 g/mol 0.00 g/mol 0 
B5 0 308.19 g/mol 0.00 g/mol 0 
C5 0 311.24 g/mol 0.00 g/mol 0 
D5 0 309.18 g/mol 0.00 g/mol 0 
E5 0 328.27 g/mol 0.00 g/mol 0 
F5 0 351.18 g/mol 0.00 g/mol 0 
G5 0 363.23 g/mol 0.00 g/mol 0 
H5 0 303.19 g/mol 0.00 g/mol 0 
A6 0 325.21 g/mol 0.00 g/mol 0 
B6 0 325.21 g/mol 0.00 g/mol 0 
C6 0 328.26 g/mol 0.00 g/mol 0 
D6 0 326.20 g/mol 0.00 g/mol 0 
E6 0 345.29 g/mol 0.00 g/mol 0 
F6 0 368.21 g/mol 0.00 g/mol 0 
G6 0 380.25 g/mol 0.00 g/mol 0 
H6 0 320.21 g/mol 320.25 g/mol 131,77 
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A7 0 317.19 g/mol 0.00 g/mol 0 
B7 0 317.19 g/mol 0.00 g/mol 0 
C7 0 320.23 g/mol 0.00 g/mol 0 
D7 0 318.18 g/mol 0.00 g/mol 0 
E7 0 337.27 g/mol 0.00 g/mol 0 
F7 0 360.18 g/mol 0.00 g/mol 0 
G7 0 372.23 g/mol 0.00 g/mol 0 
H7 0 312.18 g/mol 0.00 g/mol 0 
A8 0 337.21 g/mol 0.00 g/mol 0 
B8 0 337.21 g/mol 0.00 g/mol 0 
C8 0 340.26 g/mol 0.00 g/mol 0 
D8 0 338.20 g/mol 0.00 g/mol 0 
E8 0 357.29 g/mol 0.00 g/mol 0 
F8 0 380.21 g/mol 0.00 g/mol 0 
G8 0 392.25 g/mol 0.00 g/mol 0 
H8 0 332.21 g/mol 0.00 g/mol 0 
A9 0 367.18 g/mol 0.00 g/mol 0 
B9 0 367.18 g/mol 0.00 g/mol 0 
C9 0 370.23 g/mol 0.00 g/mol 0 
D9 0 368.17 g/mol 0.00 g/mol 0 
E9 0 387.26 g/mol 0.00 g/mol 0 
F9 0 410.17 g/mol 0.00 g/mol 0 
G9 0 422.22 g/mol 0.00 g/mol 0 
H9 0 362.18 g/mol 0.00 g/mol 0 
A10 0 339.19 g/mol 0.00 g/mol 0 
B10 0 339.19 g/mol 0.00 g/mol 0 
C10 0,06 342.23 g/mol 342.29 g/mol 1220,74 
D10 0 340.18 g/mol 0.00 g/mol 0 
E10 0 359.26 g/mol 0.00 g/mol 0 
F10 0 382.18 g/mol 0.00 g/mol 0 
G10 0,04 394.23 g/mol 394.29 g/mol 1068,83 
H10 0 334.18 g/mol 0.00 g/mol 0 
A11 0 324.18 g/mol 0.00 g/mol 0 
B11 0 324.18 g/mol 0.00 g/mol 0 
C11 0 327.23 g/mol 0.00 g/mol 0 
D11 0 325.18 g/mol 0.00 g/mol 0 
E11 0 344.26 g/mol 0.00 g/mol 0 
F11 0 367.18 g/mol 0.00 g/mol 0 
G11 0 379.22 g/mol 0.00 g/mol 0 
H11 0 319.18 g/mol 0.00 g/mol 0 
A12 0 343.19 g/mol 0.00 g/mol 0 
B12 0 343.19 g/mol 0.00 g/mol 0 
C12 0,02 346.24 g/mol 346.29 g/mol 449,15 
D12 0 344.19 g/mol 0.00 g/mol 0 
E12 0 363.27 g/mol 0.00 g/mol 0 
F12 0 386.19 g/mol 0.00 g/mol 0 
G12 0 398.23 g/mol 0.00 g/mol 0 
H12 0 338.19 g/mol 0.00 g/mol 0 
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B.5 Screening plates ori.hya.scr.1-7 
Generated compounds from plates ori.hya.10-35 were combined to plates ori.hya.scr.1-7. 
ori.hya.scr.1 
 
 
 
 
 
 
 
Well Exact molecular weight ID 
A1 
  
B1 
  
C1 
  
D1 
  
E1 
  
F1 
  
G1 
  
H1 
  
A2 249.1797 g/mol ori.hya.10_H2 
B2 265.2533 g/mol ori.hya.10_D4 
C2 265.2533 g/mol ori.hya.10_E4 
D2 243.1841 g/mol ori.hya.10_D6 
E2 199.1056 g/mol ori.hya.10_C8 
F2 285.1524 g/mol ori.hya.10_E9 
G2 291.1821 g/mol ori.hya.11_F2 
H2 303.2267 g/mol ori.hya.11_G2 
A3 321.1508 g/mol ori.hya.11_F3 
B3 280.2658 g/mol ori.hya.11_E4 
C3 303.1816 g/mol ori.hya.11_F4 
D3 315.2262 g/mol ori.hya.11_G4 
E3 241.1641 g/mol ori.hya.11_C6 
F3 239.1101 g/mol ori.hya.11_D6 
G3 293.1569 g/mol ori.hya.11_G6 
H3 293.1119 g/mol ori.hya.11_F8 
A4 305.1564 g/mol ori.hya.11_G8 
B4 272.1710 g/mol ori.hya.11_E10 
C4 423.4176 g/mol ori.hya.12_A2 
D4 351.3452 g/mol ori.hya.12_D2 
E4 457.2666 g/mol ori.hya.12_F2 
F4 347.2712 g/mol ori.hya.12_H2 
G4 325.2360 g/mol ori.hya.12_C3 
H4 381.3140 g/mol ori.hya.12_D3 
A5 487.2354 g/mol ori.hya.12_F3 
B5 351.2550 g/mol ori.hya.12_G3 
C5 377.2401 g/mol ori.hya.12_H3 
D5 435.4172 g/mol ori.hya.12_A4 
E5 307.2667 g/mol ori.hya.12_C4 
F5 363.3447 g/mol ori.hya.12_D4 
G5 469.2662 g/mol ori.hya.12_F4 
H5 333.2857 g/mol ori.hya.12_G4 
A6 359.2708 g/mol ori.hya.12_H4 
B6 268.1761 g/mol ori.hya.12_C5 
C6 324.2541 g/mol ori.hya.12_D5 
D6 324.2541 g/mol ori.hya.12_E5 
E6 430.1755 g/mol ori.hya.12_F5 
F6 294.1951 g/mol ori.hya.12_G5 
G6 320.1801 g/mol ori.hya.12_H5 
H6 413.3479 g/mol ori.hya.12_A6 
454 Appendix II 
A7 285.1975 g/mol ori.hya.12_C6 
B7 341.2755 g/mol ori.hya.12_D6 
C7 341.2755 g/mol ori.hya.12_E6 
D7 447.1969 g/mol ori.hya.12_F6 
E7 311.2165 g/mol ori.hya.12_G6 
F7 337.2015 g/mol ori.hya.12_H6 
G7 297.1970 g/mol ori.hya.12_C8 
H7 353.2750 g/mol ori.hya.12_D8 
A8 459.1964 g/mol ori.hya.12_F8 
B8 323.2160 g/mol ori.hya.12_G8 
C8 349.2010 g/mol ori.hya.12_H8 
D8 327.1658 g/mol ori.hya.12_C9 
E8 383.2438 g/mol ori.hya.12_D9 
F8 489.1652 g/mol ori.hya.12_F9 
G8 353.1848 g/mol ori.hya.12_G9 
H8 379.1698 g/mol ori.hya.12_H9 
A9 299.1719 g/mol ori.hya.12_C10 
B9 465.1811 g/mol ori.hya.12_F12 
C9 355.1857 g/mol ori.hya.12_H12 
D9 347.2712 g/mol ori.hya.13_D2 
E9 376.2471 g/mol ori.hya.13_A3 
F9 379.2940 g/mol ori.hya.13_C3 
G9 377.2401 g/mol ori.hya.13_D3 
H9 419.2424 g/mol ori.hya.13_F3 
A10 431.2870 g/mol ori.hya.13_G3 
B10 358.2778 g/mol ori.hya.13_A4 
C10 361.3247 g/mol ori.hya.13_C4 
D10 359.2708 g/mol ori.hya.13_D4 
E10 378.3572 g/mol ori.hya.13_E4 
F10 401.2731 g/mol ori.hya.13_F4 
G10 413.3177 g/mol ori.hya.13_G4 
H10 353.2750 g/mol ori.hya.13_H4 
A11 319.1872 g/mol ori.hya.13_A5 
B11 322.2341 g/mol ori.hya.13_C5 
C11 320.1801 g/mol ori.hya.13_D5 
D11 362.1825 g/mol ori.hya.13_F5 
E11 374.2271 g/mol ori.hya.13_G5 
F11 336.2086 g/mol ori.hya.13_A6 
G11 339.2555 g/mol ori.hya.13_C6 
H11 337.2015 g/mol ori.hya.13_D6 
A12   
B12   
C12   
D12   
E12   
F12   
G12   
H12   
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ori.hya.scr.2 
 
 
 
 
 
 
 
Well 
Exact molecular 
weight 
ID 
A1 
  
B1 
  
C1 
  
D1 
  
E1 
  
F1 
  
G1 
  
H1 
  
A2 356.2880 g/mol ori.hya.13_E6 
B2 379.2039 g/mol ori.hya.13_F6 
C2 391.2485 g/mol ori.hya.13_G6 
D2 331.2058 g/mol ori.hya.13_H6 
E2 329.1777 g/mol ori.hya.13_D7 
F2 323.1820 g/mol ori.hya.13_H7 
G2 348.2081 g/mol ori.hya.13_A8 
H2 351.2550 g/mol ori.hya.13_C8 
A3 349.2010 g/mol ori.hya.13_D8 
B3 368.2875 g/mol ori.hya.13_E8 
C3 391.2034 g/mol ori.hya.13_F8 
D3 403.2480 g/mol ori.hya.13_G8 
E3 378.1768 g/mol ori.hya.13_A9 
F3 381.2238 g/mol ori.hya.13_C9 
G3 379.1698 g/mol ori.hya.13_D9 
H3 398.2563 g/mol ori.hya.13_E9 
A4 421.1721 g/mol ori.hya.13_F9 
B4 433.2168 g/mol ori.hya.13_G9 
C4 393.1783 g/mol ori.hya.13_F10 
D4 405.2229 g/mol ori.hya.13_G10 
E4 355.1856 g/mol ori.hya.13_D12 
F4 349.1899 g/mol ori.hya.13_H12 
G4 445.3516 g/mol ori.hya.14_A2 
H4 479.2005 g/mol ori.hya.14_F2 
A5 343.2201 g/mol ori.hya.14_G2 
B5 369.2051 g/mol ori.hya.14_H2 
C5 347.1699 g/mol ori.hya.14_C3 
D5 509.1693 g/mol ori.hya.14_F3 
E5 373.1889 g/mol ori.hya.14_G3 
F5 399.1740 g/mol ori.hya.14_H3 
G5 457.3511 g/mol ori.hya.14_A4 
H5 329.2006 g/mol ori.hya.14_C4 
A6 385.2787 g/mol ori.hya.14_D4 
B6 491.2001 g/mol ori.hya.14_F4 
C6 381.2047 g/mol ori.hya.14_H4 
D6 418.2605 g/mol ori.hya.14_A5 
E6 290.1100 g/mol ori.hya.14_C5 
F6 346.1880 g/mol ori.hya.14_D5 
G6 346.1880 g/mol ori.hya.14_E5 
H6 452.1094 g/mol ori.hya.14_F5 
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A7 316.1290 g/mol ori.hya.14_G5 
B7 342.1140 g/mol ori.hya.14_H5 
C7 435.2819 g/mol ori.hya.14_A6 
D7 307.1314 g/mol ori.hya.14_C6 
E7 363.2095 g/mol ori.hya.14_D6 
F7 469.1309 g/mol ori.hya.14_F6 
G7 333.1505 g/mol ori.hya.14_G6 
H7 359.1355 g/mol ori.hya.14_H6 
A8 319.1309 g/mol ori.hya.14_C8 
B8 375.2090 g/mol ori.hya.14_D8 
C8 481.1304 g/mol ori.hya.14_F8 
D8 345.1500 g/mol ori.hya.14_G8 
E8 371.1350 g/mol ori.hya.14_H8 
F8 375.1187 g/mol ori.hya.14_G9 
G8 401.1038 g/mol ori.hya.14_H9 
H8 368.2122 g/mol ori.hya.15_A2 
A9 369.2051 g/mol ori.hya.15_D2 
B9 398.1810 g/mol ori.hya.15_A3 
C9 401.2280 g/mol ori.hya.15_C3 
D9 399.1740 g/mol ori.hya.15_D3 
E9 441.1763 g/mol ori.hya.15_F3 
F9 453.2208 g/mol ori.hya.15_G3 
G9 393.1783 g/mol ori.hya.15_H3 
H9 380.2116 g/mol ori.hya.15_A4 
A10 383.2586 g/mol ori.hya.15_C4 
B10 381.2047 g/mol ori.hya.15_D4 
C10 400.2912 g/mol ori.hya.15_E4 
D10 423.2070 g/mol ori.hya.15_F4 
E10 435.2516 g/mol ori.hya.15_G4 
F10 375.2090 g/mol ori.hya.15_H4 
G10 344.1681 g/mol ori.hya.15_C5 
H10 342.1140 g/mol ori.hya.15_D5 
A11 384.1164 g/mol ori.hya.15_F5 
B11 361.1895 g/mol ori.hya.15_C6 
C11 359.1355 g/mol ori.hya.15_D6 
D11 401.1378 g/mol ori.hya.15_F6 
E11 413.1823 g/mol ori.hya.15_G6 
F11 353.1398 g/mol ori.hya.15_H6 
G11 370.1420 g/mol ori.hya.15_A8 
H11 373.1890 g/mol ori.hya.15_C8 
A12   
B12   
C12   
D12   
E12   
F12   
G12   
H12   
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ori.hya.scr.3 
 
 
 
 
 
 
 
Well Exact molecular weight ID 
A1 
  
B1 
  
C1 
  
D1 
  
E1 
  
F1 
  
G1 
  
H1 
  
A2 371.1350 g/mol ori.hya.15_D8 
B2 413.1373 g/mol ori.hya.15_F8 
C2 425.1819 g/mol ori.hya.15_G8 
D2 400.1108 g/mol ori.hya.15_A9 
E2 401.1038 g/mol ori.hya.15_D9 
F2 443.1061 g/mol ori.hya.15_F9 
G2 455.1506 g/mol ori.hya.15_G9 
H2 303.1927 g/mol ori.hya.16_H4 
A3 281.1235 g/mol ori.hya.16_H6 
B3 293.1230 g/mol ori.hya.16_H8 
C3 270.1509 g/mol ori.hya.16_B11 
D3 228.0925 g/mol ori.hya.16_C11 
E3 303.1927 g/mol ori.hya.17_D4 
F3 281.1234 g/mol ori.hya.17_D6 
G3 292.1300 g/mol ori.hya.17_A8 
H3 292.1300 g/mol ori.hya.17_B8 
A4 293.1230 g/mol ori.hya.17_D8 
B4 234.1673 g/mol ori.hya.18_C4 
C4 290.2453 g/mol ori.hya.18_D4 
D4 290.2453 g/mol ori.hya.18_E4 
E4 396.1667 g/mol ori.hya.18_F4 
F4 260.1863 g/mol ori.hya.18_G4 
G4 286.1713 g/mol ori.hya.18_H4 
H4 357.0761 g/mol ori.hya.18_F5 
A5 247.0807 g/mol ori.hya.18_H5 
B5 268.1761 g/mol ori.hya.18_D6 
C5 268.1761 g/mol ori.hya.18_E6 
D5 204.0743 g/mol ori.hya.18_C7 
E5 260.1523 g/mol ori.hya.18_D7 
F5 366.0737 g/mol ori.hya.18_F7 
G5 224.0976 g/mol ori.hya.18_C8 
H5 386.0970 g/mol ori.hya.18_F8 
A6 250.1166 g/mol ori.hya.18_G8 
B6 276.1016 g/mol ori.hya.18_H8 
C6 282.0862 g/mol ori.hya.18_H12 
D6 285.1783 g/mol ori.hya.19_A4 
E6 288.2253 g/mol ori.hya.19_C4 
F6 286.1713 g/mol ori.hya.19_D4 
G6 340.2181 g/mol ori.hya.19_G4 
H6 301.1275 g/mol ori.hya.19_G5 
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A7 263.1091 g/mol ori.hya.19_A6 
B7 264.1021 g/mol ori.hya.19_D6 
C7 306.1044 g/mol ori.hya.19_F6 
D7 255.0853 g/mol ori.hya.19_A7 
E7 258.1323 g/mol ori.hya.19_C7 
F7 310.1252 g/mol ori.hya.19_G7 
G7 278.1556 g/mol ori.hya.19_C8 
H7 360.1172 g/mol ori.hya.19_G9 
A8 282.0862 g/mol ori.hya.19_D12 
B8 381.4153 g/mol ori.hya.20_A2 
C8 253.2649 g/mol ori.hya.20_C2 
D8 309.3429 g/mol ori.hya.20_D2 
E8 309.3429 g/mol ori.hya.20_E2 
F8 279.2839 g/mol ori.hya.20_G2 
G8 411.3841 g/mol ori.hya.20_A3 
H8 339.3117 g/mol ori.hya.20_D3 
A9 339.3116 g/mol ori.hya.20_E3 
B9 309.2527 g/mol ori.hya.20_G3 
C9 393.4149 g/mol ori.hya.20_A4 
D9 265.2643 g/mol ori.hya.20_C4 
E9 321.3424 g/mol ori.hya.20_D4 
F9 291.2834 g/mol ori.hya.20_G4 
G9 354.3242 g/mol ori.hya.20_A5 
H9 226.1738 g/mol ori.hya.20_C5 
A10 282.2518 g/mol ori.hya.20_D5 
B10 282.2518 g/mol ori.hya.20_E5 
C10 252.1928 g/mol ori.hya.20_G5 
D10 371.3456 g/mol ori.hya.20_A6 
E10 243.1952 g/mol ori.hya.20_C6 
F10 299.2732 g/mol ori.hya.20_D6 
G10 269.2142 g/mol ori.hya.20_G6 
H10 363.3219 g/mol ori.hya.20_A7 
A11 291.2494 g/mol ori.hya.20_D7 
B11 261.1903 g/mol ori.hya.20_G7 
C11 383.3451 g/mol ori.hya.20_A8 
D11 255.1947 g/mol ori.hya.20_C8 
E11 311.2727 g/mol ori.hya.20_D8 
F11 281.2137 g/mol ori.hya.20_G8 
G11 257.1696 g/mol ori.hya.20_C10 
H11 389.3298 g/mol ori.hya.20_A12 
A12   
B12   
C12   
D12   
E12   
F12   
G12   
H12   
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ori.hya.scr.4 
 
 
 
 
 
 
 
Well Exact molecular weight ID 
A1 
  
B1 
  
C1 
  
D1 
  
E1 
  
F1 
  
G1 
  
H1 
  
A2 261.1793 g/mol ori.hya.20_C12 
B2 317.2573 g/mol ori.hya.20_D12 
C2 423.1787 g/mol ori.hya.20_F12 
D2 287.1983 g/mol ori.hya.20_G12 
E2 313.1833 g/mol ori.hya.20_H12 
F2 307.3229 g/mol ori.hya.21_C2 
G2 347.2712 g/mol ori.hya.21_F2 
H2 359.3158 g/mol ori.hya.21_G2 
A3 299.2732 g/mol ori.hya.21_H2 
B3 337.2917 g/mol ori.hya.21_C3 
C3 335.2377 g/mol ori.hya.21_D3 
D3 389.2846 g/mol ori.hya.21_G3 
E3 319.3224 g/mol ori.hya.21_C4 
F3 317.2684 g/mol ori.hya.21_D4 
G3 359.2708 g/mol ori.hya.21_F4 
H3 371.3154 g/mol ori.hya.21_G4 
A4 311.2727 g/mol ori.hya.21_H4 
B4 280.2318 g/mol ori.hya.21_C5 
C4 278.1778 g/mol ori.hya.21_D5 
D4 332.2248 g/mol ori.hya.21_G5 
E4 297.2532 g/mol ori.hya.21_C6 
F4 337.2015 g/mol ori.hya.21_F6 
G4 349.2462 g/mol ori.hya.21_G6 
H4 289.2034 g/mol ori.hya.21_H6 
A5 289.2294 g/mol ori.hya.21_C7 
B5 309.2527 g/mol ori.hya.21_C8 
C5 361.2456 g/mol ori.hya.21_G8 
D5 309.1736 g/mol ori.hya.21_D10 
E5 312.1903 g/mol ori.hya.21_B12 
F5 313.1833 g/mol ori.hya.21_D12 
G5 355.1856 g/mol ori.hya.21_F12 
H5 367.2303 g/mol ori.hya.21_G12 
A6 307.1876 g/mol ori.hya.21_H12 
B6 449.3522 g/mol ori.hya.22_A2 
C6 321.2017 g/mol ori.hya.22_C2 
D6 377.2798 g/mol ori.hya.22_D2 
E6 377.2797 g/mol ori.hya.22_E2 
F6 347.2207 g/mol ori.hya.22_G2 
G6 479.3210 g/mol ori.hya.22_A3 
H6 351.1705 g/mol ori.hya.22_C3 
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A7 461.3517 g/mol ori.hya.22_A4 
B7 333.2012 g/mol ori.hya.22_C4 
C7 389.2793 g/mol ori.hya.22_D4 
D7 359.2203 g/mol ori.hya.22_G4 
E7 320.1296 g/mol ori.hya.22_G5 
F7 439.2825 g/mol ori.hya.22_A6 
G7 311.1320 g/mol ori.hya.22_C6 
H7 367.2101 g/mol ori.hya.22_D6 
A8 367.2101 g/mol ori.hya.22_E6 
B8 337.1510 g/mol ori.hya.22_G6 
C8 457.2667 g/mol ori.hya.22_A12 
D8 329.1161 g/mol ori.hya.22_C12 
E8 385.1942 g/mol ori.hya.22_D12 
F8 385.1942 g/mol ori.hya.22_E12 
G8 491.1156 g/mol ori.hya.22_F12 
H8 355.1351 g/mol ori.hya.22_G12 
A9 381.1202 g/mol ori.hya.22_H12 
B9 375.2597 g/mol ori.hya.23_C2 
C9 373.2058 g/mol ori.hya.23_D2 
D9 415.2081 g/mol ori.hya.23_F2 
E9 427.2526 g/mol ori.hya.23_G2 
F9 367.2100 g/mol ori.hya.23_H2 
G9 387.2593 g/mol ori.hya.23_C4 
H9 427.2076 g/mol ori.hya.23_F4 
A10 439.2523 g/mol ori.hya.23_G4 
B10 379.2096 g/mol ori.hya.23_H4 
C10 400.1615 g/mol ori.hya.23_G5 
D10 365.1900 g/mol ori.hya.23_C6 
E10 405.1383 g/mol ori.hya.23_F6 
F10 417.1830 g/mol ori.hya.23_G6 
G10 357.1403 g/mol ori.hya.23_H6 
H10 377.1895 g/mol ori.hya.23_C8 
A11 429.1825 g/mol ori.hya.23_G8 
B11 381.1202 g/mol ori.hya.23_D12 
C11 423.1225 g/mol ori.hya.23_F12 
D11 435.1671 g/mol ori.hya.23_G12 
E11 375.1245 g/mol ori.hya.23_H12 
F11 381.4153 g/mol ori.hya.24_A2 
G11 253.2648 g/mol ori.hya.24_C2 
H11 309.3429 g/mol ori.hya.24_D2 
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ori.hya.scr.5 
 
 
 
 
 
 
 
Well Exact molecular weight ID 
A1 
  
B1 
  
C1 
  
D1 
  
E1 
  
F1 
  
G1 
  
H1 
  
A2 309.3429 g/mol ori.hya.24_E2 
B2 279.2838 g/mol ori.hya.24_G2 
C2 411.3842 g/mol ori.hya.24_A3 
D2 283.2337 g/mol ori.hya.24_C3 
E2 309.2527 g/mol ori.hya.24_G3 
F2 393.4149 g/mol ori.hya.24_A4 
G2 265.2644 g/mol ori.hya.24_C4 
H2 321.3424 g/mol ori.hya.24_D4 
A3 354.3242 g/mol ori.hya.24_A5 
B3 226.1738 g/mol ori.hya.24_C5 
C3 282.2518 g/mol ori.hya.24_D5 
D3 282.2518 g/mol ori.hya.24_E5 
E3 388.1732 g/mol ori.hya.24_F5 
F3 252.1928 g/mol ori.hya.24_G5 
G3 278.1778 g/mol ori.hya.24_H5 
H3 371.3456 g/mol ori.hya.24_A6 
A4 243.1952 g/mol ori.hya.24_C6 
B4 299.2732 g/mol ori.hya.24_D6 
C4 269.2142 g/mol ori.hya.24_G6 
D4 291.2494 g/mol ori.hya.24_D7 
E4 255.1947 g/mol ori.hya.24_C8 
F4 311.2727 g/mol ori.hya.24_D8 
G4 281.2137 g/mol ori.hya.24_G8 
H4 389.3298 g/mol ori.hya.24_A12 
A5 261.1792 g/mol ori.hya.24_C12 
B5 317.2573 g/mol ori.hya.24_D12 
C5 317.2573 g/mol ori.hya.24_E12 
D5 423.1787 g/mol ori.hya.24_F12 
E5 287.1983 g/mol ori.hya.24_G12 
F5 313.1833 g/mol ori.hya.24_H12 
G5 307.3228 g/mol ori.hya.25_C2 
H5 305.2689 g/mol ori.hya.25_D2 
A6 347.2712 g/mol ori.hya.25_F2 
B6 359.3159 g/mol ori.hya.25_G2 
C6 299.2731 g/mol ori.hya.25_H2 
D6 337.2917 g/mol ori.hya.25_C3 
E6 335.2378 g/mol ori.hya.25_D3 
F6 329.2420 g/mol ori.hya.25_H3 
G6 319.3224 g/mol ori.hya.25_C4 
H6 317.2684 g/mol ori.hya.25_D4 
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A7 359.2708 g/mol ori.hya.25_F4 
B7 371.3154 g/mol ori.hya.25_G4 
C7 311.2727 g/mol ori.hya.25_H4 
D7 320.1801 g/mol ori.hya.25_F5 
E7 286.1823 g/mol ori.hya.25_A7 
F7 289.2294 g/mol ori.hya.25_C7 
G7 309.2527 g/mol ori.hya.25_C8 
H7 361.2457 g/mol ori.hya.25_G8 
A8 312.1903 g/mol ori.hya.25_B12 
B8 315.2373 g/mol ori.hya.25_C12 
C8 313.1833 g/mol ori.hya.25_D12 
D8 355.1856 g/mol ori.hya.25_F12 
E8 367.2303 g/mol ori.hya.25_G12 
F8 307.1876 g/mol ori.hya.25_H12 
G8 395.4348 g/mol ori.hya.26_A2 
H8 267.2844 g/mol ori.hya.26_C2 
A9 323.3624 g/mol ori.hya.26_D2 
B9 323.3624 g/mol ori.hya.26_E2 
C9 429.2838 g/mol ori.hya.26_F2 
D9 293.3033 g/mol ori.hya.26_G2 
E9 425.4036 g/mol ori.hya.26_A3 
F9 297.2531 g/mol ori.hya.26_C3 
G9 353.3312 g/mol ori.hya.26_D3 
H9 353.3312 g/mol ori.hya.26_E3 
A10 459.2526 g/mol ori.hya.26_F3 
B10 323.2722 g/mol ori.hya.26_G3 
C10 407.4344 g/mol ori.hya.26_A4 
D10 279.2839 g/mol ori.hya.26_C4 
E10 335.3619 g/mol ori.hya.26_D4 
F10 335.3619 g/mol ori.hya.26_E4 
G10 441.2834 g/mol ori.hya.26_F4 
H10 305.3029 g/mol ori.hya.26_G4 
A11 368.3437 g/mol ori.hya.26_A5 
B11 240.1933 g/mol ori.hya.26_C5 
C11 296.2713 g/mol ori.hya.26_D5 
D11 296.2713 g/mol ori.hya.26_E5 
E11 402.1927 g/mol ori.hya.26_F5 
F11 266.2123 g/mol ori.hya.26_G5 
G11 292.1973 g/mol ori.hya.26_H5 
H11 385.3651 g/mol ori.hya.26_A6 
A12   
B12   
C12   
D12   
E12   
F12   
G12   
H12   
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ori.hya.scr.6 
 
 
 
 
 
 
 
Well Exact molecular weight ID 
A1 
  
B1 
  
C1 
  
D1 
  
E1 
  
F1 
  
G1 
  
H1 
  
A2 257.2147 g/mol ori.hya.26_C6 
B2 313.2927 g/mol ori.hya.26_D6 
C2 313.2927 g/mol ori.hya.26_E6 
D2 419.2141 g/mol ori.hya.26_F6 
E2 283.2337 g/mol ori.hya.26_G6 
F2 397.3646 g/mol ori.hya.26_A8 
G2 269.2142 g/mol ori.hya.26_C8 
H2 325.2922 g/mol ori.hya.26_D8 
A3 325.2922 g/mol ori.hya.26_E8 
B3 295.2332 g/mol ori.hya.26_G8 
C3 403.3493 g/mol ori.hya.26_A12 
D3 275.1988 g/mol ori.hya.26_C12 
E3 331.2769 g/mol ori.hya.26_D12 
F3 437.1982 g/mol ori.hya.26_F12 
G3 301.2178 g/mol ori.hya.26_G12 
H3 327.2028 g/mol ori.hya.26_H12 
A4 321.3423 g/mol ori.hya.27_C2 
B4 319.2884 g/mol ori.hya.27_D2 
C4 361.2907 g/mol ori.hya.27_F2 
D4 373.3354 g/mol ori.hya.27_G2 
E4 313.2926 g/mol ori.hya.27_H2 
F4 351.3112 g/mol ori.hya.27_C3 
G4 349.2572 g/mol ori.hya.27_D3 
H4 343.2615 g/mol ori.hya.27_H3 
A5 333.3419 g/mol ori.hya.27_C4 
B5 331.2880 g/mol ori.hya.27_D4 
C5 373.2903 g/mol ori.hya.27_F4 
D5 385.3349 g/mol ori.hya.27_G4 
E5 325.2922 g/mol ori.hya.27_H4 
F5 294.2513 g/mol ori.hya.27_C5 
G5 334.1996 g/mol ori.hya.27_F5 
H5 346.2443 g/mol ori.hya.27_G5 
A6 311.2727 g/mol ori.hya.27_C6 
B6 328.3052 g/mol ori.hya.27_E6 
C6 351.2210 g/mol ori.hya.27_F6 
D6 363.2657 g/mol ori.hya.27_G6 
E6 303.2229 g/mol ori.hya.27_H6 
F6 320.2814 g/mol ori.hya.27_E7 
G6 323.2722 g/mol ori.hya.27_C8 
H6 375.2652 g/mol ori.hya.27_G8 
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A7 323.1931 g/mol ori.hya.27_D10 
B7 310.2457 g/mol ori.hya.27_C11 
C7 326.2098 g/mol ori.hya.27_B12 
D7 329.2568 g/mol ori.hya.27_C12 
E7 369.2052 g/mol ori.hya.27_F12 
F7 381.2498 g/mol ori.hya.27_G12 
G7 321.2071 g/mol ori.hya.27_H12 
H7 397.3924 g/mol ori.hya.28_A2 
A8 269.2420 g/mol ori.hya.28_C2 
B8 325.3200 g/mol ori.hya.28_D2 
C8 431.2414 g/mol ori.hya.28_F2 
D8 295.2610 g/mol ori.hya.28_G2 
E8 299.2108 g/mol ori.hya.28_C3 
F8 281.2415 g/mol ori.hya.28_C4 
G8 337.3195 g/mol ori.hya.28_E4 
H8 443.2410 g/mol ori.hya.28_F4 
A9 333.2456 g/mol ori.hya.28_H4 
B9 404.1503 g/mol ori.hya.28_F5 
C9 421.1717 g/mol ori.hya.28_F6 
D9 311.1763 g/mol ori.hya.28_H6 
E9 433.1712 g/mol ori.hya.28_F8 
F9 277.1564 g/mol ori.hya.28_C12 
G9 303.1754 g/mol ori.hya.28_G12 
H9 323.3000 g/mol ori.hya.29_C2 
A10 363.2483 g/mol ori.hya.29_F2 
B10 315.2503 g/mol ori.hya.29_H2 
C10 353.2688 g/mol ori.hya.29_C3 
D10 405.2617 g/mol ori.hya.29_G3 
E10 335.2995 g/mol ori.hya.29_C4 
F10 375.2479 g/mol ori.hya.29_F4 
G10 296.2089 g/mol ori.hya.29_C5 
H10 288.1592 g/mol ori.hya.29_H5 
A11 305.1806 g/mol ori.hya.29_H6 
B11 297.1568 g/mol ori.hya.29_H7 
C11 365.1782 g/mol ori.hya.29_F8 
D11 317.1801 g/mol ori.hya.29_H8 
E11 379.1977 g/mol ori.hya.29_G10 
F11 329.1604 g/mol ori.hya.29_D12 
G11 371.1628 g/mol ori.hya.29_F12 
H11 383.2074 g/mol ori.hya.29_G12 
A12   
B12   
C12   
D12   
E12   
F12   
G12   
H12   
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ori.hya.scr.7 
 
 
 
 
 
 
 
Well Exact molecular weight ID 
A1 
  
B1 
  
C1 
  
D1 
  
E1 
  
F1 
  
G1 
  
H1 
  
A2 323.1647 g/mol ori.hya.29_H12 
B2 465.3293 g/mol ori.hya.30_A2 
C2 337.1788 g/mol ori.hya.30_C2 
D2 393.2569 g/mol ori.hya.30_D2 
E2 393.2568 g/mol ori.hya.30_E2 
F2 499.1783 g/mol ori.hya.30_F2 
G2 363.1978 g/mol ori.hya.30_G2 
H2 389.1829 g/mol ori.hya.30_H2 
A3 477.3288 g/mol ori.hya.30_A4 
B3 405.2564 g/mol ori.hya.30_E4 
C3 511.1778 g/mol ori.hya.30_F4 
D3 375.1974 g/mol ori.hya.30_G4 
E3 401.1824 g/mol ori.hya.30_H4 
F3 455.2596 g/mol ori.hya.30_A6 
G3 327.1091 g/mol ori.hya.30_C6 
H3 489.1085 g/mol ori.hya.30_F6 
A4 353.1281 g/mol ori.hya.30_G6 
B4 379.1131 g/mol ori.hya.30_H6 
C4 467.2591 g/mol ori.hya.30_A8 
D4 391.2368 g/mol ori.hya.31_C2 
E4 389.1829 g/mol ori.hya.31_D2 
F4 431.1852 g/mol ori.hya.31_F2 
G4 400.1894 g/mol ori.hya.31_A4 
H4 400.1894 g/mol ori.hya.31_B4 
A5 403.2364 g/mol ori.hya.31_C4 
B5 401.1824 g/mol ori.hya.31_D4 
C5 443.1847 g/mol ori.hya.31_F4 
D5 378.1201 g/mol ori.hya.31_A6 
E5 378.1201 g/mol ori.hya.31_B6 
F5 381.1671 g/mol ori.hya.31_C6 
G5 379.1131 g/mol ori.hya.31_D6 
H5 421.1154 g/mol ori.hya.31_F6 
A6 439.0996 g/mol ori.hya.31_F12 
B6 397.3924 g/mol ori.hya.32_A2 
C6 269.2420 g/mol ori.hya.32_C2 
D6 325.3200 g/mol ori.hya.32_D2 
E6 431.2414 g/mol ori.hya.32_F2 
F6 295.2610 g/mol ori.hya.32_G2 
G6 427.3613 g/mol ori.hya.32_A3 
H6 307.2605 g/mol ori.hya.32_G4 
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A7 401.2971 g/mol ori.hya.32_A10 
B7 323.3000 g/mol ori.hya.33_C2 
C7 315.2502 g/mol ori.hya.33_H2 
D7 345.2191 g/mol ori.hya.33_H3 
E7 288.1592 g/mol ori.hya.33_H5 
F7 313.2303 g/mol ori.hya.33_C6 
G7 305.1806 g/mol ori.hya.33_H6 
H7 379.1977 g/mol ori.hya.33_G10 
A8 312.2033 g/mol ori.hya.33_C11 
B8 328.1674 g/mol ori.hya.33_A12 
C8 411.4120 g/mol ori.hya.34_A2 
D8 283.2615 g/mol ori.hya.34_C2 
E8 339.3395 g/mol ori.hya.34_D2 
F8 309.2805 g/mol ori.hya.34_G2 
G8 441.3807 g/mol ori.hya.34_A3 
H8 313.2303 g/mol ori.hya.34_C3 
A9 413.3418 g/mol ori.hya.34_A8 
B9 341.2693 g/mol ori.hya.34_D8 
C9 287.1662 g/mol ori.hya.34_C10 
D9 367.2883 g/mol ori.hya.35_C3 
E9 419.2812 g/mol ori.hya.35_G3 
F9 359.2386 g/mol ori.hya.35_H3 
G9 389.2674 g/mol ori.hya.35_F4 
H9 319.2001 g/mol ori.hya.35_H6 
A10 341.2242 g/mol ori.hya.35_C10 
B10 393.2172 g/mol ori.hya.35_G10 
C10 345.2340 g/mol ori.hya.35_C12 
D10   
E10   
F10   
G10   
H10   
A11   
B11   
C11   
D11   
E11   
F11   
G11   
H11   
A12   
B12   
C12   
D12   
E12   
F12   
G12   
H12   
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B.6 Screening plates ori.hya.44-47 
B.6.1 Starting materials of plates ori.hya.44-47 
Cf. section 5.4.1; chemsets (see Figure 5.12) are indicated for each well 
B.6.2 Mass spectral analysis of plates ori.hya.44-47 
ori.hya.44 
 
 
 
  
 
 
Well Chemset Peak width Expected mass Found mass Intensity 
A1 empty         
B1 empty         
C1 empty         
D1 empty         
E1 empty         
F1 empty         
G1 empty         
H1 empty         
A2 9 {1,1,1} 0,04 490.13 g/mol 490.13 g/mol 1269,61 
B2 9 {2,1,1} 0 506.13 g/mol 506.06 g/mol 29,69 
C2 9 {3,1,1} 0,02 490.13 g/mol 490.12 g/mol 2134,32 
D2 9 {4,1,1} 0 490.13 g/mol 490.13 g/mol 111,63 
E2 9 {5,1,1} 0,02 558.05 g/mol 558.05 g/mol 687,43 
F2 9 {6,1,1} 0 526.11 g/mol 526.11 g/mol 230,33 
G2 9 {7,1,1} 0 520.15 g/mol 520.13 g/mol 301,08 
H2 9 {8,1,1} 0,02 474.14 g/mol 474.13 g/mol 596,6 
A3 9 {1,2,1} 0 474.14 g/mol 0.00 g/mol 0 
B3 9 {2,2,1} 0 490.13 g/mol 0.00 g/mol 0 
C3 9 {3,2,1} 0 474.14 g/mol 474.13 g/mol 1228,17 
D3 9 {4,2,1} 0,02 474.14 g/mol 474.13 g/mol 2725,56 
E3 9 {5,2,1} 0 542.05 g/mol 542.09 g/mol 268,73 
F3 9 {6,2,1} 0,02 510.11 g/mol 510.11 g/mol 761,93 
G3 9 {7,2,1} 0 504.15 g/mol 504.14 g/mol 261,5 
H3 9 {8,2,1} 0,02 458.14 g/mol 458.15 g/mol 587,98 
A4 9 {1,3,1} 0 474.14 g/mol 0.00 g/mol 0 
B4 9 {2,3,1} 0 490.13 g/mol 0.00 g/mol 0 
C4 9 {3,3,1} 0 474.14 g/mol 474.14 g/mol 67,84 
D4 9 {4,3,1} 0,04 474.14 g/mol 474.13 g/mol 4088,77 
E4 9 {5,3,1} 0,02 542.05 g/mol 542.06 g/mol 706,63 
F4 9 {6,3,1} 0,02 510.11 g/mol 510.11 g/mol 2104,57 
G4 9 {7,3,1} 0 504.15 g/mol 504.14 g/mol 526,36 
H4 9 {8,3,1} 0,02 458.14 g/mol 458.14 g/mol 714,5 
A5 9 {1,4,1} 0 490.13 g/mol 0.00 g/mol 0 
B5 9 {2,4,1} 0 506.13 g/mol 0.00 g/mol 0 
C5 9 {3,4,1} 0 490.13 g/mol 490.13 g/mol 864,02 
D5 9 {4,4,1} 0 490.13 g/mol 490.13 g/mol 271,59 
E5 9 {5,4,1} 0 558.05 g/mol 558.05 g/mol 80,96 
F5 9 {6,4,1} 0,04 526.11 g/mol 526.12 g/mol 1407,7 
G5 9 {7,4,1} 0 520.15 g/mol 0.00 g/mol 0 
H5 9 {8,4,1} 0,02 474.14 g/mol 474.14 g/mol 689,74 
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A6 9 {1,5,1} 0 490.13 g/mol 490.13 g/mol 331,48 
B6 9 {2,5,1} 0 506.13 g/mol 0.00 g/mol 0 
C6 9 {3,5,1} 0 490.13 g/mol 490.13 g/mol 1469,48 
D6 9 {4,5,1} 0 490.13 g/mol 490.12 g/mol 2527,78 
E6 9 {5,5,1} 0 558.05 g/mol 558.07 g/mol 100,13 
F6 9 {6,5,1} 0 526.11 g/mol 526.11 g/mol 1252,35 
G6 9 {7,5,1} 0 520.15 g/mol 520.14 g/mol 395,82 
H6 9 {8,5,1} 0,04 474.14 g/mol 474.14 g/mol 1208,87 
A7 9 {1,6,1} 0 490.13 g/mol 490.13 g/mol 743,6 
B7 9 {2,6,1} 0 506.13 g/mol 506.13 g/mol 115,56 
C7 9 {3,6,1} 0 490.13 g/mol 490.13 g/mol 544,75 
D7 9 {4,6,1} 0 490.13 g/mol 490.13 g/mol 1198,17 
E7 9 {5,6,1} 0 558.05 g/mol 0.00 g/mol 0 
F7 9 {6,6,1} 0 526.11 g/mol 526.12 g/mol 71,66 
G7 9 {7,6,1} 0 520.15 g/mol 520.14 g/mol 368,34 
H7 9 {8,6,1} 0,02 474.14 g/mol 474.14 g/mol 715,47 
A8 9 {1,7,1} 0 506.13 g/mol 0.00 g/mol 0 
B8 9 {2,7,1} 0 522.12 g/mol 0.00 g/mol 0 
C8 9 {3,7,1} 0,04 506.13 g/mol 506.13 g/mol 1337,1 
D8 9 {4,7,1} 0 506.13 g/mol 0.00 g/mol 0 
E8 9 {5,7,1} 0 574.04 g/mol 0.00 g/mol 0 
F8 9 {6,7,1} 0 542.10 g/mol 542.12 g/mol 20,07 
G8 9 {7,7,1} 0 536.14 g/mol 0.00 g/mol 0 
H8 9 {8,7,1} 0 490.13 g/mol 0.00 g/mol 0 
A9 9 {1,8,1} 0,02 490.13 g/mol 490.14 g/mol 861,34 
B9 9 {2,8,1} 0 506.13 g/mol 0.00 g/mol 0 
C9 9 {3,8,1} 0 490.13 g/mol 490.13 g/mol 97,14 
D9 9 {4,8,1} 0 490.13 g/mol 490.13 g/mol 2535,46 
E9 9 {5,8,1} 0 558.05 g/mol 0.00 g/mol 0 
F9 9 {6,8,1} 0 526.11 g/mol 526.11 g/mol 1207,41 
G9 9 {7,8,1} 0,06 520.15 g/mol 520.14 g/mol 2109,19 
H9 9 {8,8,1} 0,02 474.14 g/mol 474.14 g/mol 723,85 
A10 9 {1,9,1} 0 506.13 g/mol 0.00 g/mol 0 
B10 9 {2,9,1} 0 522.12 g/mol 0.00 g/mol 0 
C10 9 {3,9,1} 0 506.13 g/mol 506.14 g/mol 124,36 
D10 9 {4,9,1} 0 506.13 g/mol 0.00 g/mol 0 
E10 9 {5,9,1} 0 574.04 g/mol 0.00 g/mol 0 
F10 9 {6,9,1} 0 542.10 g/mol 0.00 g/mol 0 
G10 9 {7,9,1} 0 536.14 g/mol 0.00 g/mol 0 
H10 9 {8,9,1} 0 490.13 g/mol 0.00 g/mol 0 
A11 9 {1,10,1} 0 506.13 g/mol 0.00 g/mol 0 
B11 9 {2,10,1} 0 522.12 g/mol 0.00 g/mol 0 
C11 9 {3,10,1} 0 506.13 g/mol 0.00 g/mol 0 
D11 9 {4,10,1} 0 506.13 g/mol 0.00 g/mol 0 
E11 9 {5,10,1} 0 574.04 g/mol 0.00 g/mol 0 
F11 9 {6,10,1} 0 542.10 g/mol 0.00 g/mol 0 
G11 9 {7,10,1} 0 536.14 g/mol 0.00 g/mol 0 
H11 9 {8,10,1} 0 490.13 g/mol 0.00 g/mol 0 
A12 9 {1,11,1} 0,02 506.13 g/mol 506.13 g/mol 992,11 
B12 9 {2,11,1} 0 522.12 g/mol 0.00 g/mol 0 
C12 9 {3,11,1} 0 506.13 g/mol 506.13 g/mol 181,16 
D12 9 {4,11,1} 0 506.13 g/mol 506.13 g/mol 784,38 
E12 9 {5,11,1} 0,04 574.04 g/mol 574.05 g/mol 1548,62 
F12 9 {6,11,1} 0 542.10 g/mol 0.00 g/mol 0 
G12 9 {7,11,1} 0 536.14 g/mol 536.14 g/mol 219,51 
H12 9 {8,11,1} 0,04 490.13 g/mol 490.13 g/mol 1284,58 
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Well Chemset Peak width Expected mass Found mass Intensity 
A1 empty         
B1 empty         
C1 empty         
D1 empty         
E1 empty         
F1 empty         
G1 empty         
H1 empty         
A2 9 {1,1,2} 0 478.23 g/mol 478.21 g/mol 688,61 
B2 9 {2,1,2} 0,04 494.22 g/mol 494.21 g/mol 1429,33 
C2 9 {3,1,2} 0,08 478.23 g/mol 478.20 g/mol 6519,36 
D2 9 {4,1,2} 0 478.23 g/mol 478.21 g/mol 347,4 
E2 9 {5,1,2} 0 546.14 g/mol 546.13 g/mol 1060,2 
F2 9 {6,1,2} 0 514.20 g/mol 514.19 g/mol 785,32 
G2 9 {7,1,2} 0 508.24 g/mol 508.22 g/mol 628,4 
H2 9 {8,1,2} 0,06 462.23 g/mol 462.22 g/mol 1745,75 
A3 9 {1,2,2} 0 462.23 g/mol 462.22 g/mol 520,23 
B3 9 {2,2,2} 0 478.23 g/mol 0.00 g/mol 0 
C3 9 {3,2,2} 0,06 462.23 g/mol 462.21 g/mol 5856,08 
D3 9 {4,2,2} 0,06 462.23 g/mol 462.21 g/mol 6174,66 
E3 9 {5,2,2} 0 530.15 g/mol 530.15 g/mol 75,63 
F3 9 {6,2,2} 0,06 498.21 g/mol 498.19 g/mol 5900,78 
G3 9 {7,2,2} 0 492.25 g/mol 492.23 g/mol 456,83 
H3 9 {8,2,2} 0,02 446.24 g/mol 446.22 g/mol 663,45 
A4 9 {1,3,2} 0 462.23 g/mol 462.20 g/mol 2891,31 
B4 9 {2,3,2} 0 478.23 g/mol 0.00 g/mol 0 
C4 9 {3,3,2} 0 462.23 g/mol 462.21 g/mol 2074,49 
D4 9 {4,3,2} 0,12 462.23 g/mol 462.21 g/mol 7535,1 
E4 9 {5,3,2} 0 530.15 g/mol 530.14 g/mol 121,38 
F4 9 {6,3,2} 0,02 498.21 g/mol 498.19 g/mol 6180,84 
G4 9 {7,3,2} 0 492.25 g/mol 492.22 g/mol 97,64 
H4 9 {8,3,2} 0,1 446.24 g/mol 446.23 g/mol 2774,07 
A5 9 {1,4,2} 0 478.23 g/mol 0.00 g/mol 0 
B5 9 {2,4,2} 0 494.22 g/mol 0.00 g/mol 0 
C5 9 {3,4,2} 0 478.23 g/mol 478.21 g/mol 1550,28 
D5 9 {4,4,2} 0,02 478.23 g/mol 478.21 g/mol 960,07 
E5 9 {5,4,2} 0 546.14 g/mol 546.13 g/mol 370,69 
F5 9 {6,4,2} 0,04 514.20 g/mol 514.19 g/mol 1745,02 
G5 9 {7,4,2} 0 508.24 g/mol 0.00 g/mol 0 
H5 9 {8,4,2} 0,02 462.23 g/mol 462.21 g/mol 2225,79 
A6 9 {1,5,2} 0 478.23 g/mol 478.21 g/mol 1128,28 
B6 9 {2,5,2} 0 494.22 g/mol 0.00 g/mol 0 
C6 9 {3,5,2} 0 478.23 g/mol 478.21 g/mol 3193,98 
D6 9 {4,5,2} 0,04 478.23 g/mol 478.21 g/mol 4675,63 
E6 9 {5,5,2} 0,04 546.14 g/mol 546.14 g/mol 1433,71 
F6 9 {6,5,2} 0,04 514.20 g/mol 514.19 g/mol 4367,79 
G6 9 {7,5,2} 0,02 508.24 g/mol 508.23 g/mol 750,82 
H6 9 {8,5,2} 0 462.23 g/mol 0.00 g/mol 0 
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A7 9 {1,6,2} 0,06 478.23 g/mol 478.21 g/mol 2492,31 
B7 9 {2,6,2} 0,02 494.22 g/mol 494.21 g/mol 1020,77 
C7 9 {3,6,2} 0 478.23 g/mol 478.21 g/mol 3111,04 
D7 9 {4,6,2} 0 478.23 g/mol 478.21 g/mol 726,02 
E7 9 {5,6,2} 0 546.14 g/mol 546.13 g/mol 1423,57 
F7 9 {6,6,2} 0 514.20 g/mol 514.19 g/mol 1314,5 
G7 9 {7,6,2} 0,06 508.24 g/mol 508.22 g/mol 2630,82 
H7 9 {8,6,2} 0,02 462.23 g/mol 462.21 g/mol 972,34 
A8 9 {1,7,2} 0 494.22 g/mol 0.00 g/mol 0 
B8 9 {2,7,2} 0 510.22 g/mol 0.00 g/mol 0 
C8 9 {3,7,2} 0,02 494.22 g/mol 494.22 g/mol 650,54 
D8 9 {4,7,2} 0 494.22 g/mol 0.00 g/mol 0 
E8 9 {5,7,2} 0,08 562.14 g/mol 562.13 g/mol 2739,47 
F8 9 {6,7,2} 0,04 530.20 g/mol 530.19 g/mol 1358,93 
G8 9 {7,7,2} 0 524.24 g/mol 0.00 g/mol 0 
H8 9 {8,7,2} 0 478.23 g/mol 478.22 g/mol 200,89 
A9 9 {1,8,2} 0,02 478.23 g/mol 478.21 g/mol 1233,26 
B9 9 {2,8,2} 0 494.22 g/mol 0.00 g/mol 0 
C9 9 {3,8,2} 0 478.23 g/mol 478.21 g/mol 3295,52 
D9 9 {4,8,2} 0,06 478.23 g/mol 478.18 g/mol 7372,38 
E9 9 {5,8,2} 0 546.14 g/mol 0.00 g/mol 0 
F9 9 {6,8,2} 0,04 514.20 g/mol 514.19 g/mol 4990,58 
G9 9 {7,8,2} 0 508.24 g/mol 508.22 g/mol 862,87 
H9 9 {8,8,2} 0 462.23 g/mol 462.22 g/mol 500,94 
A10 9 {1,9,2} 0 494.22 g/mol 0.00 g/mol 0 
B10 9 {2,9,2} 0 510.22 g/mol 0.00 g/mol 0 
C10 9 {3,9,2} 0 494.22 g/mol 0.00 g/mol 0 
D10 9 {4,9,2} 0 494.22 g/mol 0.00 g/mol 0 
E10 9 {5,9,2} 0,02 562.14 g/mol 562.14 g/mol 742,74 
F10 9 {6,9,2} 0 530.20 g/mol 0.00 g/mol 0 
G10 9 {7,9,2} 0 524.24 g/mol 0.00 g/mol 0 
H10 9 {8,9,2} 0 478.23 g/mol 0.00 g/mol 0 
A11 9 {1,10,2} 0 494.22 g/mol 0.00 g/mol 0 
B11 9 {2,10,2} 0 510.22 g/mol 0.00 g/mol 0 
C11 9 {3,10,2} 0 494.22 g/mol 0.00 g/mol 0 
D11 9 {4,10,2} 0 494.22 g/mol 0.00 g/mol 0 
E11 9 {5,10,2} 0 562.14 g/mol 0.00 g/mol 0 
F11 9 {6,10,2} 0 530.20 g/mol 0.00 g/mol 0 
G11 9 {7,10,2} 0 524.24 g/mol 0.00 g/mol 0 
H11 9 {8,10,2} 0 478.23 g/mol 0.00 g/mol 0 
A12 9 {1,11,2} 0,02 494.22 g/mol 494.21 g/mol 1065,45 
B12 9 {2,11,2} 0 510.22 g/mol 0.00 g/mol 0 
C12 9 {3,11,2} 0,02 494.22 g/mol 494.22 g/mol 663,12 
D12 9 {4,11,2} 0 494.22 g/mol 494.20 g/mol 2585,34 
E12 9 {5,11,2} 0 562.14 g/mol 562.13 g/mol 133,31 
F12 9 {6,11,2} 0,06 530.20 g/mol 530.19 g/mol 2039,68 
G12 9 {7,11,2} 0 524.24 g/mol 0.00 g/mol 0 
H12 9 {8,11,2} 0,14 478.23 g/mol 478.21 g/mol 4455,74 
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Well Chemset Peak width Expected mass Found mass Intensity 
A1 empty         
B1 empty         
C1 empty         
D1 empty         
E1 empty         
F1 empty         
G1 empty         
H1 empty         
A2 9 {1,1,3} 0 436.17 g/mol 436.14 g/mol 363,92 
B2 9 {2,1,3} 0 452.16 g/mol 0.00 g/mol 0 
C2 9 {3,1,3} 0,1 436.17 g/mol 436.13 g/mol 3705,87 
D2 9 {4,1,3} 0 436.17 g/mol 436.15 g/mol 353,43 
E2 9 {5,1,3} 0 504.08 g/mol 504.08 g/mol 418,88 
F2 9 {6,1,3} 0,08 472.14 g/mol 472.13 g/mol 2477,72 
G2 9 {7,1,3} 0 466.18 g/mol 0.00 g/mol 0 
H2 9 {8,1,3} 0,02 420.17 g/mol 420.16 g/mol 739,36 
A3 9 {1,2,3} 0,04 420.17 g/mol 420.15 g/mol 1561,49 
B3 9 {2,2,3} 0 436.17 g/mol 0.00 g/mol 0 
C3 9 {3,2,3} 0,04 420.17 g/mol 420.15 g/mol 1981,07 
D3 9 {4,2,3} 0,04 420.17 g/mol 420.15 g/mol 4241,53 
E3 9 {5,2,3} 0,02 488.09 g/mol 488.08 g/mol 735,95 
F3 9 {6,2,3} 0 456.15 g/mol 456.13 g/mol 854,77 
G3 9 {7,2,3} 0,04 450.19 g/mol 450.17 g/mol 1941,79 
H3 9 {8,2,3} 0 404.18 g/mol 0.00 g/mol 0 
A4 9 {1,3,3} 0,02 420.17 g/mol 420.15 g/mol 940,92 
B4 9 {2,3,3} 0 436.17 g/mol 0.00 g/mol 0 
C4 9 {3,3,3} 0 420.17 g/mol 420.15 g/mol 884,69 
D4 9 {4,3,3} 0,1 420.17 g/mol 420.15 g/mol 3419,79 
E4 9 {5,3,3} 0 488.09 g/mol 488.07 g/mol 1886,36 
F4 9 {6,3,3} 0 456.15 g/mol 456.12 g/mol 4482,14 
G4 9 {7,3,3} 0 450.19 g/mol 450.16 g/mol 1854,41 
H4 9 {8,3,3} 0 404.18 g/mol 404.17 g/mol 119,29 
A5 9 {1,4,3} 0 436.17 g/mol 0.00 g/mol 0 
B5 9 {2,4,3} 0 452.16 g/mol 0.00 g/mol 0 
C5 9 {3,4,3} 0,02 436.17 g/mol 436.15 g/mol 943,77 
D5 9 {4,4,3} 0 436.17 g/mol 436.15 g/mol 191,47 
E5 9 {5,4,3} 0 504.08 g/mol 504.09 g/mol 215,84 
F5 9 {6,4,3} 0 472.14 g/mol 0.00 g/mol 0 
G5 9 {7,4,3} 0 466.18 g/mol 0.00 g/mol 0 
H5 9 {8,4,3} 0 420.17 g/mol 420.27 g/mol 83,6 
A6 9 {1,5,3} 0 436.17 g/mol 436.16 g/mol 414,08 
B6 9 {2,5,3} 0 452.16 g/mol 0.00 g/mol 0 
C6 9 {3,5,3} 0 436.17 g/mol 436.15 g/mol 942,19 
D6 9 {4,5,3} 0,06 436.17 g/mol 436.15 g/mol 3935,73 
E6 9 {5,5,3} 0,02 504.08 g/mol 504.08 g/mol 1187,17 
F6 9 {6,5,3} 0 472.14 g/mol 472.13 g/mol 1185,1 
G6 9 {7,5,3} 0 466.18 g/mol 466.17 g/mol 452,27 
H6 9 {8,5,3} 0 420.17 g/mol 420.27 g/mol 128,98 
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A7 9 {1,6,3} 0 436.17 g/mol 436.16 g/mol 422,96 
B7 9 {2,6,3} 0 452.16 g/mol 452.09 g/mol 104,81 
C7 9 {3,6,3} 0 436.17 g/mol 436.17 g/mol 61,82 
D7 9 {4,6,3} 0 436.17 g/mol 436.17 g/mol 110,85 
E7 9 {5,6,3} 0 504.08 g/mol 504.08 g/mol 251,89 
F7 9 {6,6,3} 0,04 472.14 g/mol 472.14 g/mol 1120,08 
G7 9 {7,6,3} 0 466.18 g/mol 0.00 g/mol 0 
H7 9 {8,6,3} 0,02 420.17 g/mol 420.16 g/mol 692,05 
A8 9 {1,7,3} 0 452.16 g/mol 0.00 g/mol 0 
B8 9 {2,7,3} 0 468.16 g/mol 0.00 g/mol 0 
C8 9 {3,7,3} 0 452.16 g/mol 0.00 g/mol 0 
D8 9 {4,7,3} 0 452.16 g/mol 0.00 g/mol 0 
E8 9 {5,7,3} 0 520.08 g/mol 0.00 g/mol 0 
F8 9 {6,7,3} 0 488.14 g/mol 0.00 g/mol 0 
G8 9 {7,7,3} 0 482.18 g/mol 0.00 g/mol 0 
H8 9 {8,7,3} 0 436.17 g/mol 0.00 g/mol 0 
A9 9 {1,8,3} 0 436.17 g/mol 436.16 g/mol 363,48 
B9 9 {2,8,3} 0 452.16 g/mol 0.00 g/mol 0 
C9 9 {3,8,3} 0,02 436.17 g/mol 436.19 g/mol 2389,5 
D9 9 {4,8,3} 0,02 436.17 g/mol 436.16 g/mol 4119,15 
E9 9 {5,8,3} 0,02 504.08 g/mol 504.08 g/mol 1349,29 
F9 9 {6,8,3} 0,12 472.14 g/mol 472.13 g/mol 5094,17 
G9 9 {7,8,3} 0 466.18 g/mol 466.17 g/mol 307,94 
H9 9 {8,8,3} 0,04 420.17 g/mol 420.26 g/mol 5228,38 
A10 9 {1,9,3} 0 452.16 g/mol 0.00 g/mol 0 
B10 9 {2,9,3} 0 468.16 g/mol 0.00 g/mol 0 
C10 9 {3,9,3} 0 452.16 g/mol 0.00 g/mol 0 
D10 9 {4,9,3} 0 452.16 g/mol 452.13 g/mol 36,23 
E10 9 {5,9,3} 0 520.08 g/mol 0.00 g/mol 0 
F10 9 {6,9,3} 0 488.14 g/mol 0.00 g/mol 0 
G10 9 {7,9,3} 0 482.18 g/mol 0.00 g/mol 0 
H10 9 {8,9,3} 0 436.17 g/mol 0.00 g/mol 0 
A11 9 {1,10,3} 0 452.16 g/mol 0.00 g/mol 0 
B11 9 {2,10,3} 0 468.16 g/mol 0.00 g/mol 0 
C11 9 {3,10,3} 0 452.16 g/mol 0.00 g/mol 0 
D11 9 {4,10,3} 0 452.16 g/mol 0.00 g/mol 0 
E11 9 {5,10,3} 0 520.08 g/mol 0.00 g/mol 0 
F11 9 {6,10,3} 0 488.14 g/mol 0.00 g/mol 0 
G11 9 {7,10,3} 0 482.18 g/mol 0.00 g/mol 0 
H11 9 {8,10,3} 0 436.17 g/mol 0.00 g/mol 0 
A12 9 {1,11,3} 0,02 452.16 g/mol 452.16 g/mol 735,5 
B12 9 {2,11,3} 0 468.16 g/mol 0.00 g/mol 0 
C12 9 {3,11,3} 0 452.16 g/mol 452.15 g/mol 688,1 
D12 9 {4,11,3} 0 452.16 g/mol 452.16 g/mol 261,02 
E12 9 {5,11,3} 0,02 520.08 g/mol 520.08 g/mol 1340,93 
F12 9 {6,11,3} 0 488.14 g/mol 488.14 g/mol 212,36 
G12 9 {7,11,3} 0 482.18 g/mol 0.00 g/mol 0 
H12 9 {8,11,3} 0 436.17 g/mol 436.16 g/mol 146,93 
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Well Chemset Peak width Expected mass Found mass Intensity 
A1 empty         
B1 empty         
C1 empty         
D1 empty         
E1 empty         
F1 empty         
G1 empty         
H1 empty         
A2 9 {1,1,4} 0 456.11 g/mol 456.11 g/mol 83,59 
B2 9 {2,1,4} 0,02 472.10 g/mol 472.11 g/mol 878,76 
C2 9 {3,1,4} 0,06 456.11 g/mol 456.11 g/mol 5477,36 
D2 9 {4,1,4} 0 456.11 g/mol 0.00 g/mol 0 
E2 9 {5,1,4} 0 524.02 g/mol 524.03 g/mol 271,76 
F2 9 {6,1,4} 0 492.08 g/mol 492.09 g/mol 754,01 
G2 9 {7,1,4} 0 486.12 g/mol 0.00 g/mol 0 
H2 9 {8,1,4} 0,02 440.11 g/mol 440.12 g/mol 804,62 
A3 9 {1,2,4} 0 440.11 g/mol 440.12 g/mol 160,23 
B3 9 {2,2,4} 0 456.11 g/mol 0.00 g/mol 0 
C3 9 {3,2,4} 0 440.11 g/mol 440.13 g/mol 153,95 
D3 9 {4,2,4} 0 440.11 g/mol 440.12 g/mol 348,75 
E3 9 {5,2,4} 0 508.03 g/mol 508.04 g/mol 169,05 
F3 9 {6,2,4} 0,02 476.09 g/mol 476.11 g/mol 758,61 
G3 9 {7,2,4} 0 470.13 g/mol 470.15 g/mol 71,23 
H3 9 {8,2,4} 0 424.12 g/mol 424.13 g/mol 59,59 
A4 9 {1,3,4} 0 440.11 g/mol 440.12 g/mol 185,9 
B4 9 {2,3,4} 0 456.11 g/mol 0.00 g/mol 0 
C4 9 {3,3,4} 0 440.11 g/mol 440.13 g/mol 75,12 
D4 9 {4,3,4} 0,04 440.11 g/mol 440.11 g/mol 5114,24 
E4 9 {5,3,4} 0 508.03 g/mol 508.04 g/mol 927,35 
F4 9 {6,3,4} 0 476.09 g/mol 476.09 g/mol 2376,22 
G4 9 {7,3,4} 0,02 470.13 g/mol 470.13 g/mol 800,88 
H4 9 {8,3,4} 0,02 424.12 g/mol 424.12 g/mol 635,15 
A5 9 {1,4,4} 0 456.11 g/mol 0.00 g/mol 0 
B5 9 {2,4,4} 0 472.10 g/mol 0.00 g/mol 0 
C5 9 {3,4,4} 0,02 456.11 g/mol 456.11 g/mol 955,58 
D5 9 {4,4,4} 0 456.11 g/mol 456.12 g/mol 244,93 
E5 9 {5,4,4} 0 524.02 g/mol 524.04 g/mol 246,4 
F5 9 {6,4,4} 0 492.08 g/mol 492.10 g/mol 85,49 
G5 9 {7,4,4} 0 486.12 g/mol 0.00 g/mol 0 
H5 9 {8,4,4} 0 440.11 g/mol 440.11 g/mol 3081,56 
A6 9 {1,5,4} 0 456.11 g/mol 456.12 g/mol 226,77 
B6 9 {2,5,4} 0 472.10 g/mol 0.00 g/mol 0 
C6 9 {3,5,4} 0 456.11 g/mol 0.00 g/mol 0 
D6 9 {4,5,4} 0 456.11 g/mol 456.11 g/mol 961,06 
E6 9 {5,5,4} 0,02 524.02 g/mol 524.05 g/mol 719,17 
F6 9 {6,5,4} 0,02 492.08 g/mol 492.10 g/mol 971,9 
G6 9 {7,5,4} 0,02 486.12 g/mol 486.15 g/mol 653,63 
H6 9 {8,5,4} 0 440.11 g/mol 440.12 g/mol 199,93 
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A7 9 {1,6,4} 0,02 456.11 g/mol 456.11 g/mol 1359,14 
B7 9 {2,6,4} 0 472.10 g/mol 0.00 g/mol 0 
C7 9 {3,6,4} 0,02 456.11 g/mol 456.11 g/mol 1858,84 
D7 9 {4,6,4} 0 456.11 g/mol 456.11 g/mol 728,16 
E7 9 {5,6,4} 0 524.02 g/mol 524.04 g/mol 330,5 
F7 9 {6,6,4} 0 492.08 g/mol 492.10 g/mol 250,93 
G7 9 {7,6,4} 0,02 486.12 g/mol 486.12 g/mol 947,54 
H7 9 {8,6,4} 0,04 440.11 g/mol 440.12 g/mol 1289,39 
A8 9 {1,7,4} 0 472.10 g/mol 0.00 g/mol 0 
B8 9 {2,7,4} 0 488.10 g/mol 0.00 g/mol 0 
C8 9 {3,7,4} 0,02 472.10 g/mol 472.09 g/mol 610,53 
D8 9 {4,7,4} 0 472.10 g/mol 0.00 g/mol 0 
E8 9 {5,7,4} 0 540.02 g/mol 0.00 g/mol 0 
F8 9 {6,7,4} 0 508.08 g/mol 0.00 g/mol 0 
G8 9 {7,7,4} 0 502.12 g/mol 0.00 g/mol 0 
H8 9 {8,7,4} 0 456.11 g/mol 456.11 g/mol 547,28 
A9 9 {1,8,4} 0 456.11 g/mol 456.11 g/mol 1209,43 
B9 9 {2,8,4} 0 472.10 g/mol 0.00 g/mol 0 
C9 9 {3,8,4} 0,02 456.11 g/mol 456.11 g/mol 602,53 
D9 9 {4,8,4} 0 456.11 g/mol 456.11 g/mol 1296,05 
E9 9 {5,8,4} 0 524.02 g/mol 524.04 g/mol 397,14 
F9 9 {6,8,4} 0,02 492.08 g/mol 492.10 g/mol 1170,86 
G9 9 {7,8,4} 0 486.12 g/mol 486.12 g/mol 83,29 
H9 9 {8,8,4} 0 440.11 g/mol 440.12 g/mol 191,85 
A10 9 {1,9,4} 0 472.10 g/mol 0.00 g/mol 0 
B10 9 {2,9,4} 0 488.10 g/mol 0.00 g/mol 0 
C10 9 {3,9,4} 0 472.10 g/mol 472.11 g/mol 27,54 
D10 9 {4,9,4} 0 472.10 g/mol 0.00 g/mol 0 
E10 9 {5,9,4} 0 540.02 g/mol 540.04 g/mol 102,46 
F10 9 {6,9,4} 0 508.08 g/mol 0.00 g/mol 0 
G10 9 {7,9,4} 0 502.12 g/mol 0.00 g/mol 0 
H10 9 {8,9,4} 0 456.11 g/mol 0.00 g/mol 0 
A11 9 {1,10,4} 0 472.10 g/mol 0.00 g/mol 0 
B11 9 {2,10,4} 0 488.10 g/mol 0.00 g/mol 0 
C11 9 {3,10,4} 0 472.10 g/mol 0.00 g/mol 0 
D11 9 {4,10,4} 0 472.10 g/mol 0.00 g/mol 0 
E11 9 {5,10,4} 0 540.02 g/mol 0.00 g/mol 0 
F11 9 {6,10,4} 0 508.08 g/mol 0.00 g/mol 0 
G11 9 {7,10,4} 0 502.12 g/mol 0.00 g/mol 0 
H11 9 {8,10,4} 0 456.11 g/mol 0.00 g/mol 0 
A12 9 {1,11,4} 0 472.10 g/mol 0.00 g/mol 0 
B12 9 {2,11,4} 0 488.10 g/mol 0.00 g/mol 0 
C12 9 {3,11,4} 0 472.10 g/mol 472.11 g/mol 59,66 
D12 9 {4,11,4} 0,04 472.10 g/mol 472.11 g/mol 1403,23 
E12 9 {5,11,4} 0 540.02 g/mol 0.00 g/mol 0 
F12 9 {6,11,4} 0 508.08 g/mol 508.09 g/mol 105,65 
G12 9 {7,11,4} 0 502.12 g/mol 0.00 g/mol 0 
H12 9 {8,11,4} 0 456.11 g/mol 456.11 g/mol 959,16 
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B.7 Screening plates ori.hya.48-54 
B.7.1 Starting materials ori.hya.48-54 
Cf. section 6.2; chemsets (see Figure 6.5) are indicated for each well. 
B.7.2 Mass spectral analysis of plates ori.hya.48-54 
ori.hya.48 
 
 
 
  
 
 
Well Chemset Peak Width Expected mass Found mass Intensity 
A1 empty         
B1 empty         
C1 empty         
D1 empty         
E1 empty         
F1 empty         
G1 empty         
H1 empty         
A2 13 {1,1,1} 0.0 298.19 g/mol 0.00 g/mol 0.00 
B2 13 {2,1,1} 0.0 298.19 g/mol 0.00 g/mol 0.00 
C2 13 {3,1,1} 0.10 298.19 g/mol 298.17 g/mol 26972.10 
D2 13 {4,1,1} 0.00 298.19 g/mol 298.15 g/mol 159.58 
E2 13 {1,2,1} 0.04 366.10 g/mol 366.08 g/mol 2210.30 
F2 13 {2,2,1} 0.0 366.10 g/mol 0.00 g/mol 0.00 
G2 13 {3,2,1} 0.18 366.10 g/mol 366.09 g/mol 9772.74 
H2 13 {4,2,1} 0.0 366.10 g/mol 0.00 g/mol 0.00 
A3 13 {1,1,2} 0.00 314.13 g/mol 314.13 g/mol 83.20 
B3 13 {2,1,2} 0.0 314.13 g/mol 0.00 g/mol 0.00 
C3 13 {3,1,2} 0.00 314.13 g/mol 314.12 g/mol 819.40 
D3 13 {4,1,2} 0.0 314.13 g/mol 0.00 g/mol 0.00 
E3 13 {1,2,2} 0.02 382.05 g/mol 382.05 g/mol 550.24 
F3 13 {2,2,2} 0.0 382.05 g/mol 0.00 g/mol 0.00 
G3 13 {3,2,2} 0.10 382.05 g/mol 382.03 g/mol 3067.49 
H3 13 {4,2,2} 0.0 382.05 g/mol 0.00 g/mol 0.00 
A4 13 {1,1,3} 0.00 282.15 g/mol 282.13 g/mol 332.72 
B4 13 {2,1,3} 0.0 282.15 g/mol 0.00 g/mol 0.00 
C4 13 {3,1,3} 0.10 282.15 g/mol 282.14 g/mol 25097.64 
D4 13 {4,1,3} 0.0 282.15 g/mol 0.00 g/mol 0.00 
E4 13 {1,2,3} 0.00 350.06 g/mol 350.06 g/mol 184.10 
F4 13 {2,2,3} 0.0 350.06 g/mol 0.00 g/mol 0.00 
G4 13 {3,2,3} 0.18 350.06 g/mol 350.06 g/mol 11722.50 
H4 13 {4,2,3} 0.0 350.06 g/mol 0.00 g/mol 0.00 
A5 13 {1,1,4} 0.02 300.16 g/mol 300.15 g/mol 372.41 
B5 13 {2,1,4} 0.0 300.16 g/mol 0.00 g/mol 0.00 
C5 13 {3,1,4} 0.22 300.16 g/mol 300.15 g/mol 5625.84 
D5 13 {4,1,4} 0.0 300.16 g/mol 0.00 g/mol 0.00 
E5 13 {1,2,4} 0.0 368.08 g/mol 0.00 g/mol 0.00 
F5 13 {2,2,4} 0.0 368.08 g/mol 0.00 g/mol 0.00 
G5 13 {3,2,4} 0.18 368.08 g/mol 368.07 g/mol 5040.71 
H5 13 {4,2,4} 0.0 368.08 g/mol 0.00 g/mol 0.00 
476 Appendix II 
A6 13 {1,1,5} 0.0 256.13 g/mol 0.00 g/mol 0.00 
B6 13 {2,1,5} 0.0 256.13 g/mol 0.00 g/mol 0.00 
C6 13 {3,1,5} 0.20 256.13 g/mol 256.12 g/mol 4821.45 
D6 13 {4,1,5} 0.0 256.13 g/mol 0.00 g/mol 0.00 
E6 13 {1,2,5} 0.0 324.04 g/mol 0.00 g/mol 0.00 
F6 13 {2,2,5} 0.0 324.04 g/mol 0.00 g/mol 0.00 
G6 13 {3,2,5} 0.0 324.04 g/mol 0.00 g/mol 0.00 
H6 13 {4,2,5} 0.0 324.04 g/mol 0.00 g/mol 0.00 
A7 13 {1,1,6} 0.02 298.19 g/mol 298.28 g/mol 613.06 
B7 13 {2,1,6} 0.0 298.19 g/mol 0.00 g/mol 0.00 
C7 13 {3,1,6} 0.08 298.19 g/mol 298.17 g/mol 25264.44 
D7 13 {4,1,6} 0.0 298.19 g/mol 0.00 g/mol 0.00 
E7 13 {1,2,6} 0.0 366.10 g/mol 0.00 g/mol 0.00 
F7 13 {2,2,6} 0.0 366.10 g/mol 0.00 g/mol 0.00 
G7 13 {3,2,6} 0.08 366.10 g/mol 366.07 g/mol 23434.20 
H7 13 {4,2,6} 0.0 366.10 g/mol 0.00 g/mol 0.00 
A8 13 {1,1,7} 0.0 318.14 g/mol 0.00 g/mol 0.00 
B8 13 {2,1,7} 0.0 318.14 g/mol 0.00 g/mol 0.00 
C8 13 {3,1,7} 0.02 318.14 g/mol 318.13 g/mol 4433.03 
D8 13 {4,1,7} 0.0 318.14 g/mol 0.00 g/mol 0.00 
E8 13 {1,2,7} 0.0 386.06 g/mol 0.00 g/mol 0.00 
F8 13 {2,2,7} 0.0 386.06 g/mol 0.00 g/mol 0.00 
G8 13 {3,2,7} 0.04 386.06 g/mol 386.06 g/mol 8377.62 
H8 13 {4,2,7} 0.0 386.06 g/mol 0.00 g/mol 0.00 
A9 13 {1,1,8} 0.0 282.15 g/mol 0.00 g/mol 0.00 
B9 13 {2,1,8} 0.0 282.15 g/mol 0.00 g/mol 0.00 
C9 13 {3,1,8} 0.06 282.15 g/mol 282.16 g/mol 1038.32 
D9 13 {4,1,8} 0.0 282.15 g/mol 0.00 g/mol 0.00 
E9 13 {1,2,8} 0.0 350.06 g/mol 0.00 g/mol 0.00 
F9 13 {2,2,8} 0.0 350.06 g/mol 0.00 g/mol 0.00 
G9 13 {3,2,8} 0.02 350.06 g/mol 350.06 g/mol 563.57 
H9 13 {4,2,8} 0.0 350.06 g/mol 0.00 g/mol 0.00 
A10 13 {1,1,9} 0.0 333.16 g/mol 0.00 g/mol 0.00 
B10 13 {2,1,9} 0.0 333.16 g/mol 0.00 g/mol 0.00 
C10 13 {3,1,9} 0.0 333.16 g/mol 0.00 g/mol 0.00 
D10 13 {4,1,9} 0.0 333.16 g/mol 0.00 g/mol 0.00 
E10 13 {1,2,9} 0.0 401.07 g/mol 0.00 g/mol 0.00 
F10 13 {2,2,9} 0.0 401.07 g/mol 0.00 g/mol 0.00 
G10 13 {3,2,9} 0.0 401.07 g/mol 0.00 g/mol 0.00 
H10 13 {4,2,9} 0.0 401.07 g/mol 0.00 g/mol 0.00 
A11 13 {1,1,10} 0.00 312.21 g/mol 312.20 g/mol 213.52 
B11 13 {2,1,10} 0.0 312.21 g/mol 0.00 g/mol 0.00 
C11 13 {3,1,10} 0.06 312.21 g/mol 312.21 g/mol 24369.72 
D11 13 {4,1,10} 0.02 312.21 g/mol 312.17 g/mol 545.57 
E11 13 {1,2,10} 0.00 380.12 g/mol 380.11 g/mol 1856.81 
F11 13 {2,2,10} 0.0 380.12 g/mol 0.00 g/mol 0.00 
G11 13 {3,2,10} 0.22 380.12 g/mol 380.11 g/mol 5362.93 
H11 13 {4,2,10} 0.0 380.12 g/mol 0.00 g/mol 0.00 
A12 empty         
B12 empty         
C12 empty         
D12 empty         
E12 empty         
F12 empty         
G12 empty         
H12 empty         
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ori.hya.49 
 
 
 
  
 
 
 
 
Well Chemset Peak Width Expected mass Found mass Intensity 
A1 empty         
B1 empty         
C1 empty         
D1 empty         
E1 empty         
F1 empty         
G1 empty         
H1 empty         
A2 13 {1,1,11} 0.0 313.20 g/mol 0.00 g/mol 0.00 
B2 13 {2,1,11} 0.0 313.20 g/mol 0.00 g/mol 0.00 
C2 13 {3,1,11} 0.0 313.20 g/mol 0.00 g/mol 0.00 
D2 13 {4,1,11} 0.0 313.20 g/mol 0.00 g/mol 0.00 
E2 13 {1,2,11} 0.0 381.11 g/mol 0.00 g/mol 0.00 
F2 13 {2,2,11} 0.0 381.11 g/mol 0.00 g/mol 0.00 
G2 13 {3,2,11} 0.0 381.11 g/mol 0.00 g/mol 0.00 
H2 13 {4,2,11} 0.0 381.11 g/mol 0.00 g/mol 0.00 
A3 13 {1,1,12} 0.0 314.18 g/mol 0.00 g/mol 0.00 
B3 13 {2,1,12} 0.0 314.18 g/mol 0.00 g/mol 0.00 
C3 13 {3,1,12} 0.14 314.18 g/mol 314.17 g/mol 26663.64 
D3 13 {4,1,12} 0.0 314.18 g/mol 0.00 g/mol 0.00 
E3 13 {1,2,12} 0.0 382.10 g/mol 0.00 g/mol 0.00 
F3 13 {2,2,12} 0.0 382.10 g/mol 0.00 g/mol 0.00 
G3 13 {3,2,12} 0.18 382.10 g/mol 382.09 g/mol 6680.52 
H3 13 {4,2,12} 0.0 382.10 g/mol 0.00 g/mol 0.00 
A4 13 {1,1,13} 0.02 312.21 g/mol 312.19 g/mol 679.95 
B4 13 {2,1,13} 0.0 312.21 g/mol 0.00 g/mol 0.00 
C4 13 {3,1,13} 0.06 312.21 g/mol 312.19 g/mol 23847.12 
D4 13 {4,1,13} 0.0 312.21 g/mol 0.00 g/mol 0.00 
E4 13 {1,2,13} 0.0 380.12 g/mol 0.00 g/mol 0.00 
F4 13 {2,2,13} 0.0 380.12 g/mol 0.00 g/mol 0.00 
G4 13 {3,2,13} 0.06 380.12 g/mol 380.11 g/mol 18585.48 
H4 13 {4,2,13} 0.0 380.12 g/mol 0.00 g/mol 0.00 
A5 13 {1,1,14} 0.02 310.19 g/mol 310.19 g/mol 693.83 
B5 13 {2,1,14} 0.0 310.19 g/mol 0.00 g/mol 0.00 
C5 13 {3,1,14} 0.12 310.19 g/mol 310.18 g/mol 28338.90 
D5 13 {4,1,14} 0.0 310.19 g/mol 0.00 g/mol 0.00 
E5 13 {1,2,14} 0.00 378.10 g/mol 378.04 g/mol 159.03 
F5 13 {2,2,14} 0.0 378.10 g/mol 0.00 g/mol 0.00 
G5 13 {3,2,14} 0.18 378.10 g/mol 378.10 g/mol 10638.06 
H5 13 {4,2,14} 0.0 378.10 g/mol 0.00 g/mol 0.00 
A6 13 {1,1,15} 0.0 284.17 g/mol 0.00 g/mol 0.00 
B6 13 {2,1,15} 0.0 284.17 g/mol 0.00 g/mol 0.00 
C6 13 {3,1,15} 0.10 284.17 g/mol 284.16 g/mol 26545.56 
D6 13 {4,1,15} 0.0 284.17 g/mol 0.00 g/mol 0.00 
E6 13 {1,2,15} 0.00 352.08 g/mol 352.08 g/mol 606.72 
F6 13 {2,2,15} 0.0 352.08 g/mol 0.00 g/mol 0.00 
G6 13 {3,2,15} 0.20 352.08 g/mol 352.08 g/mol 8563.62 
H6 13 {4,2,15} 0.0 352.08 g/mol 0.00 g/mol 0.00 
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A7 13 {1,1,16} 0.0 298.19 g/mol 0.00 g/mol 0.00 
B7 13 {2,1,16} 0.0 298.19 g/mol 0.00 g/mol 0.00 
C7 13 {3,1,16} 0.00 298.19 g/mol 298.18 g/mol 22064.82 
D7 13 {4,1,16} 0.0 298.19 g/mol 0.00 g/mol 0.00 
E7 13 {1,2,16} 0.00 366.10 g/mol 366.11 g/mol 153.76 
F7 13 {2,2,16} 0.0 366.10 g/mol 0.00 g/mol 0.00 
G7 13 {3,2,16} 0.00 366.10 g/mol 366.10 g/mol 14803.98 
H7 13 {4,2,16} 0.0 366.10 g/mol 0.00 g/mol 0.00 
A8 13 {1,1,17} 0.00 270.15 g/mol 270.15 g/mol 62.38 
B8 13 {2,1,17} 0.0 270.15 g/mol 0.00 g/mol 0.00 
C8 13 {3,1,17} 0.20 270.15 g/mol 270.15 g/mol 7492.92 
D8 13 {4,1,17} 0.0 270.15 g/mol 0.00 g/mol 0.00 
E8 13 {1,2,17} 0.0 338.06 g/mol 0.00 g/mol 0.00 
F8 13 {2,2,17} 0.0 338.06 g/mol 0.00 g/mol 0.00 
G8 13 {3,2,17} 0.16 338.06 g/mol 338.07 g/mol 6367.62 
H8 13 {4,2,17} 0.0 338.06 g/mol 0.00 g/mol 0.00 
A9 13 {1,1,18} 0.02 312.21 g/mol 312.19 g/mol 2271.17 
B9 13 {2,1,18} 0.0 312.21 g/mol 0.00 g/mol 0.00 
C9 13 {3,1,18} 0.02 312.21 g/mol 312.19 g/mol 23679.48 
D9 13 {4,1,18} 0.00 312.21 g/mol 312.20 g/mol 54.58 
E9 13 {1,2,18} 0.00 380.12 g/mol 380.12 g/mol 158.57 
F9 13 {2,2,18} 0.0 380.12 g/mol 0.00 g/mol 0.00 
G9 13 {3,2,18} 0.20 380.12 g/mol 380.15 g/mol 9630.60 
H9 13 {4,2,18} 0.0 380.12 g/mol 0.00 g/mol 0.00 
A10 13 {1,1,19} 0.00 312.21 g/mol 312.20 g/mol 265.49 
B10 13 {2,1,19} 0.0 312.21 g/mol 0.00 g/mol 0.00 
C10 13 {3,1,19} 0.08 312.21 g/mol 312.19 g/mol 23360.94 
D10 13 {4,1,19} 0.02 312.21 g/mol 312.20 g/mol 448.60 
E10 13 {1,2,19} 0.0 380.12 g/mol 0.00 g/mol 0.00 
F10 13 {2,2,19} 0.0 380.12 g/mol 0.00 g/mol 0.00 
G10 13 {3,2,19} 0.20 380.12 g/mol 380.12 g/mol 8438.94 
H10 13 {4,2,19} 0.0 380.12 g/mol 0.00 g/mol 0.00 
A11 13 {1,1,20} 0.0 314.18 g/mol 0.00 g/mol 0.00 
B11 13 {2,1,20} 0.0 314.18 g/mol 0.00 g/mol 0.00 
C11 13 {3,1,20} 0.0 314.18 g/mol 0.00 g/mol 0.00 
D11 13 {4,1,20} 0.0 314.18 g/mol 0.00 g/mol 0.00 
E11 13 {1,2,20} 0.0 382.10 g/mol 0.00 g/mol 0.00 
F11 13 {2,2,20} 0.0 382.10 g/mol 0.00 g/mol 0.00 
G11 13 {3,2,20} 0.00 382.10 g/mol 382.10 g/mol 12850.44 
H11 13 {4,2,20} 0.0 382.10 g/mol 0.00 g/mol 0.00 
A12 empty         
B12 empty         
C12 empty         
D12 empty         
E12 empty         
F12 empty         
G12 empty         
H12 empty         
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ori.hya.50 
 
 
 
  
 
 
 
 
Well Chemset Peak Width Expected mass Found mass Intensity 
A1 empty         
B1 empty         
C1 empty         
D1 empty         
E1 empty         
F1 empty         
G1 empty         
H1 empty         
A2 13 {5,3,1} 0.02 328.20 g/mol 328.20 g/mol 3842.65 
B2 13 {6,3,1} 0.0 400.13 g/mol 0.00 g/mol 0.00 
C2 13 {7,3,1} 0.20 312.21 g/mol 312.19 g/mol 6345.72 
D2 13 {8,3,1} 0.06 316.17 g/mol 316.17 g/mol 21843.42 
E2 13 {9,3,1} 0.00 366.10 g/mol 366.10 g/mol 1586.96 
F2 13 {10,3,1} 0.0 313.20 g/mol 0.00 g/mol 0.00 
G2 13 {5,4,1} 0.08 328.20 g/mol 328.19 g/mol 22225.02 
H2 13 {6,4,1} 0.0 400.13 g/mol 0.00 g/mol 0.00 
A3 13 {7,4,1} 0.12 312.21 g/mol 312.23 g/mol 26459.58 
B3 13 {8,4,1} 0.10 316.17 g/mol 316.17 g/mol 24504.24 
C3 13 {9,4,1} 0.04 366.10 g/mol 366.10 g/mol 2808.07 
D3 13 {10,4,1} 0.0 313.20 g/mol 0.00 g/mol 0.00 
E3 13 {5,5,1} 0.08 344.19 g/mol 344.18 g/mol 17040.30 
F3 13 {6,5,1} 0.0 416.12 g/mol 0.00 g/mol 0.00 
G3 13 {7,5,1} 0.04 328.20 g/mol 328.19 g/mol 26148.78 
H3 13 {8,5,1} 0.08 332.17 g/mol 332.17 g/mol 25184.76 
A4 13 {9,5,1} 0.00 382.10 g/mol 382.09 g/mol 1090.46 
B4 13 {10,5,1} 0.0 329.19 g/mol 0.00 g/mol 0.00 
C4 13 {5,6,1} 0.0 344.19 g/mol 0.00 g/mol 0.00 
D4 13 {6,6,1} 0.0 416.12 g/mol 0.00 g/mol 0.00 
E4 13 {7,6,1} 0.00 328.20 g/mol 328.16 g/mol 91.62 
F4 13 {8,6,1} 0.10 332.17 g/mol 332.16 g/mol 4200.37 
G4 13 {9,6,1} 0.0 382.10 g/mol 0.00 g/mol 0.00 
H4 13 {10,6,1} 0.0 329.19 g/mol 0.00 g/mol 0.00 
A5 13 {5,7,1} 0.0 344.19 g/mol 0.00 g/mol 0.00 
B5 13 {6,7,1} 0.0 416.12 g/mol 0.00 g/mol 0.00 
C5 13 {7,7,1} 0.02 328.20 g/mol 328.17 g/mol 518.39 
D5 13 {8,7,1} 0.00 332.17 g/mol 332.16 g/mol 1526.43 
E5 13 {9,7,1} 0.0 382.10 g/mol 0.00 g/mol 0.00 
F5 13 {10,7,1} 0.0 329.19 g/mol 0.00 g/mol 0.00 
G5 13 {5,8,1} 0.10 340.24 g/mol 340.23 g/mol 25278.54 
H5 13 {6,8,1} 0.02 412.17 g/mol 412.17 g/mol 492.25 
A6 13 {7,8,1} 0.10 324.25 g/mol 324.23 g/mol 24151.14 
B6 13 {8,8,1} 0.16 328.22 g/mol 328.21 g/mol 28207.20 
C6 13 {9,8,1} 0.16 378.15 g/mol 378.13 g/mol 6088.38 
D6 13 {10,8,1} 0.0 325.24 g/mol 0.00 g/mol 0.00 
E6 13 {5,9,1} 0.00 468.02 g/mol 468.01 g/mol 671.45 
F6 13 {6,9,1} 0.0 539.95 g/mol 0.00 g/mol 0.00 
G6 13 {7,9,1} 0.02 452.03 g/mol 452.01 g/mol 4426.16 
H6 13 {8,9,1} 0.24 455.99 g/mol 455.99 g/mol 6698.22 
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A7 13 {9,9,1} 0.0 505.92 g/mol 0.00 g/mol 0.00 
B7 13 {10,9,1} 0.0 453.02 g/mol 0.00 g/mol 0.00 
C7 13 {5,10,1} 0.06 390.11 g/mol 390.09 g/mol 8152.38 
D7 13 {6,10,1} 0.0 462.04 g/mol 0.00 g/mol 0.00 
E7 13 {7,10,1} 0.20 374.12 g/mol 374.11 g/mol 7445.94 
F7 13 {8,10,1} 0.04 378.09 g/mol 378.08 g/mol 23924.64 
G7 13 {9,10,1} 0.0 428.02 g/mol 0.00 g/mol 0.00 
H7 13 {10,10,1} 0.0 375.11 g/mol 0.00 g/mol 0.00 
A8 13 {5,3,2} 0.06 344.15 g/mol 344.14 g/mol 4620.31 
B8 13 {6,3,2} 0.06 416.08 g/mol 416.09 g/mol 1592.38 
C8 13 {7,3,2} 0.18 328.15 g/mol 328.16 g/mol 7508.88 
D8 13 {8,3,2} 0.14 332.12 g/mol 332.13 g/mol 7381.56 
E8 13 {9,3,2} 0.18 382.05 g/mol 382.06 g/mol 5231.92 
F8 13 {10,3,2} 0.0 329.15 g/mol 0.00 g/mol 0.00 
G8 13 {5,4,2} 0.12 344.15 g/mol 344.15 g/mol 5099.78 
H8 13 {6,4,2} 0.00 416.08 g/mol 416.09 g/mol 238.72 
A9 13 {7,4,2} 0.06 328.15 g/mol 328.15 g/mol 9207.12 
B9 13 {8,4,2} 0.21 332.12 g/mol 332.13 g/mol 6052.44 
C9 13 {9,4,2} 0.02 382.05 g/mol 381.95 g/mol 1975.44 
D9 13 {10,4,2} 0.0 329.15 g/mol 0.00 g/mol 0.00 
E9 13 {5,5,2} 0.06 360.14 g/mol 360.14 g/mol 3280.38 
F9 13 {6,5,2} 0.00 432.07 g/mol 432.08 g/mol 1548.80 
G9 13 {7,5,2} 0.16 344.15 g/mol 344.15 g/mol 7523.10 
H9 13 {8,5,2} 0.19 348.12 g/mol 348.12 g/mol 6739.26 
A10 13 {9,5,2} 0.00 398.05 g/mol 398.05 g/mol 967.57 
B10 13 {10,5,2} 0.0 345.14 g/mol 0.00 g/mol 0.00 
C10 13 {5,6,2} 0.0 360.14 g/mol 0.00 g/mol 0.00 
D10 13 {6,6,2} 0.0 432.07 g/mol 0.00 g/mol 0.00 
E10 13 {7,6,2} 0.0 344.15 g/mol 0.00 g/mol 0.00 
F10 13 {8,6,2} 0.02 348.12 g/mol 348.13 g/mol 400.91 
G10 13 {9,6,2} 0.0 398.05 g/mol 0.00 g/mol 0.00 
H10 13 {10,6,2} 0.0 345.14 g/mol 0.00 g/mol 0.00 
A11 13 {5,7,2} 0.00 360.14 g/mol 360.14 g/mol 40812 
B11 13 {6,7,2} 0.0 432.07 g/mol 0.00 g/mol 0.00 
C11 13 {7,7,2} 0.00 344.15 g/mol 344.11 g/mol 134.28 
D11 13 {8,7,2} 0.00 348.12 g/mol 348.13 g/mol 113.56 
E11 13 {9,7,2} 0.00 398.05 g/mol 398.06 g/mol 29.52 
F11 13 {10,7,2} 0.0 345.14 g/mol 0.00 g/mol 0.00 
G11 13 {5,8,2} 0.10 356.19 g/mol 356.19 g/mol 20636.76 
H11 13 {6,8,2} 0.06 428.12 g/mol 428.13 g/mol 1778.29 
A12 empty         
B12 empty         
C12 empty         
D12 empty         
E12 empty         
F12 empty         
G12 empty         
H12 empty         
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Well Chemset Peak Width Expected mass Found mass Intensity 
A1 empty         
B1 empty         
C1 empty         
D1 empty         
E1 empty         
F1 empty         
G1 empty         
H1 empty         
A2 13 {7,8,2} 0.02 340.20 g/mol 340.19 g/mol 24634.50 
B2 13 {8,8,2} 0.14 344.17 g/mol 344.17 g/mol 28045.86 
C2 13 {9,8,2} 0.10 394.10 g/mol 394.10 g/mol 5116.44 
D2 13 {10,8,2} 0.0 341.19 g/mol 0.00 g/mol 0.00 
E2 13 {5,9,2} 0.00 483.97 g/mol 483.97 g/mol 832.48 
F2 13 {6,9,2} 0.0 555.90 g/mol 0.00 g/mol 0.00 
G2 13 {7,9,2} 0.14 467.98 g/mol 467.98 g/mol 4849.32 
H2 13 {8,9,2} 0.06 471.94 g/mol 471.95 g/mol 5451.04 
A3 13 {9,9,2} 0.0 521.87 g/mol 0.00 g/mol 0.00 
B3 13 {10,9,2} 0.0 468.97 g/mol 0.00 g/mol 0.00 
C3 13 {5,10,2} 0.00 406.06 g/mol 406.06 g/mol 5196.89 
D3 13 {6,10,2} 0.00 477.99 g/mol 478.01 g/mol 231.51 
E3 13 {7,10,2} 0.14 390.07 g/mol 390.15 g/mol 6660.18 
F3 13 {8,10,2} 0.22 394.04 g/mol 394.05 g/mol 9598.98 
G3 13 {9,10,2} 0.06 443.97 g/mol 443.98 g/mol 1576.43 
H3 13 {10,10,2} 0.0 391.06 g/mol 0.00 g/mol 0.00 
A4 13 {5,3,4} 0.12 330.17 g/mol 330.17 g/mol 6977.70 
B4 13 {6,3,4} 0.04 402.10 g/mol 402.11 g/mol 1160.13 
C4 13 {7,3,4} 0.02 314.18 g/mol 314.17 g/mol 7932.42 
D4 13 {8,3,4} 0.08 318.15 g/mol 318.15 g/mol 15462.84 
E4 13 {9,3,4} 0.14 368.08 g/mol 368.09 g/mol 5596.55 
F4 13 {10,3,4} 0.0 315.17 g/mol 0.00 g/mol 0.00 
G4 13 {5,4,4} 0.12 330.17 g/mol 330.17 g/mol 6536.64 
H4 13 {6,4,4} 0.0 402.10 g/mol 0.00 g/mol 0.00 
A5 13 {7,4,4} 0.22 314.18 g/mol 314.18 g/mol 8740.32 
B5 13 {8,4,4} 0.20 318.15 g/mol 318.15 g/mol 14865.42 
C5 13 {9,4,4} 0.00 368.08 g/mol 368.08 g/mol 330.60 
D5 13 {10,4,4} 0.0 315.17 g/mol 0.00 g/mol 0.00 
E5 13 {5,5,4} 0.10 346.17 g/mol 346.16 g/mol 5736.05 
F5 13 {6,5,4} 0.0 418.10 g/mol 0.00 g/mol 0.00 
G5 13 {7,5,4} 0.18 330.17 g/mol 330.17 g/mol 9775.68 
H5 13 {8,5,4} 0.08 334.14 g/mol 334.15 g/mol 23892.00 
A6 13 {9,5,4} 0.00 384.07 g/mol 384.08 g/mol 220.85 
B6 13 {10,5,4} 0.0 331.17 g/mol 0.00 g/mol 0.00 
C6 13 {5,6,4} 0.0 346.17 g/mol 0.00 g/mol 0.00 
D6 13 {6,6,4} 0.0 418.10 g/mol 0.00 g/mol 0.00 
E6 13 {7,6,4} 0.0 330.17 g/mol 0.00 g/mol 0.00 
F6 13 {8,6,4} 0.0 334.14 g/mol 0.00 g/mol 0.00 
G6 13 {9,6,4} 0.0 384.07 g/mol 0.00 g/mol 0.00 
H6 13 {10,6,4} 0.0 331.17 g/mol 0.00 g/mol 0.00 
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A7 13 {5,7,4} 0.02 346.17 g/mol 346.17 g/mol 412.90 
B7 13 {6,7,4} 0.0 418.10 g/mol 0.00 g/mol 0.00 
C7 13 {7,7,4} 0.00 330.17 g/mol 330.17 g/mol 4658.54 
D7 13 {8,7,4} 0.00 334.14 g/mol 334.16 g/mol 41.34 
E7 13 {9,7,4} 0.00 384.07 g/mol 384.09 g/mol 109.85 
F7 13 {10,7,4} 0.0 331.17 g/mol 0.00 g/mol 0.00 
G7 13 {5,8,4} 0.20 342.22 g/mol 342.21 g/mol 6006.78 
H7 13 {6,8,4} 0.00 414.15 g/mol 414.15 g/mol 120.40 
A8 13 {7,8,4} 0.04 326.22 g/mol 326.22 g/mol 15583.74 
B8 13 {8,8,4} 0.04 330.19 g/mol 330.20 g/mol 25294.14 
C8 13 {9,8,4} 0.00 380.12 g/mol 380.12 g/mol 1794.32 
D8 13 {10,8,4} 0.0 327.22 g/mol 0.00 g/mol 0.00 
E8 13 {5,9,4} 0.00 470.00 g/mol 469.99 g/mol 210.34 
F8 13 {6,9,4} 0.0 541.92 g/mol 0.00 g/mol 0.00 
G8 13 {7,9,4} 0.10 454.00 g/mol 454.00 g/mol 4324.68 
H8 13 {8,9,4} 0.02 457.97 g/mol 457.97 g/mol 7048.50 
A9 13 {9,9,4} 0.0 507.90 g/mol 0.00 g/mol 0.00 
B9 13 {10,9,4} 0.0 454.99 g/mol 0.00 g/mol 0.00 
C9 13 {5,10,4} 0.06 392.09 g/mol 392.08 g/mol 4181.36 
D9 13 {6,10,4} 0.0 464.02 g/mol 0.00 g/mol 0.00 
E9 13 {7,10,4} 0.00 376.09 g/mol 376.11 g/mol 9016.26 
F9 13 {8,10,4} 0.12 380.06 g/mol 380.07 g/mol 15810.72 
G9 13 {9,10,4} 0.0 429.99 g/mol 0.00 g/mol 0.00 
H9 13 {10,10,4} 0.0 377.09 g/mol 0.00 g/mol 0.00 
A10 13 {5,3,6} 0.20 328.20 g/mol 328.19 g/mol 9458.64 
B10 13 {6,3,6} 0.04 400.13 g/mol 400.13 g/mol 958.55 
C10 13 {7,3,6} 0.02 312.21 g/mol 312.20 g/mol 23969.22 
D10 13 {8,3,6} 0.08 316.17 g/mol 316.17 g/mol 27283.32 
E10 13 {9,3,6} 0.22 366.10 g/mol 366.10 g/mol 8975.28 
F10 13 {10,3,6} 0.0 313.20 g/mol 0.00 g/mol 0.00 
G10 13 {5,4,6} 0.06 328.20 g/mol 328.19 g/mol 15959.82 
H10 13 {6,4,6} 0.0 400.13 g/mol 0.00 g/mol 0.00 
A11 13 {7,4,6} 0.14 312.21 g/mol 312.20 g/mol 24103.86 
B11 13 {8,4,6} 0.12 316.17 g/mol 316.19 g/mol 25838.04 
C11 13 {9,4,6} 0.02 366.10 g/mol 366.10 g/mol 631.75 
D11 13 {10,4,6} 0.0 313.20 g/mol 0.00 g/mol 0.00 
E11 13 {5,5,6} 0.16 344.19 g/mol 344.29 g/mol 6593.76 
F11 13 {6,5,6} 0.0 416.12 g/mol 0.00 g/mol 0.00 
G11 13 {7,5,6} 0.14 328.20 g/mol 328.19 g/mol 26705.94 
H11 13 {8,5,6} 0.02 332.17 g/mol 332.17 g/mol 19495.92 
A12 empty         
B12 empty         
C12 empty         
D12 empty         
E12 empty         
F12 empty         
G12 empty         
H12 empty         
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Well Chemset Peak Width  Expected mass Found mass Intensity 
A1 empty         
B1 empty         
C1 empty         
D1 empty         
E1 empty         
F1 empty         
G1 empty         
H1 empty         
A2 13 {9,5,6} 0.0 382.10 g/mol 0.00 g/mol 0.00 
B2 13 {10,5,6} 0.0 329.19 g/mol 0.00 g/mol 0.00 
C2 13 {5,6,6} 0.0 344.19 g/mol 0.00 g/mol 0.00 
D2 13 {6,6,6} 0.0 416.12 g/mol 0.00 g/mol 0.00 
E2 13 {7,6,6} 0.0 328.20 g/mol 0.00 g/mol 0.00 
F2 13 {8,6,6} 0.00 332.17 g/mol 332.15 g/mol 645.72 
G2 13 {9,6,6} 0.0 382.10 g/mol 0.00 g/mol 0.00 
H2 13 {10,6,6} 0.0 329.19 g/mol 0.00 g/mol 0.00 
A3 13 {5,7,6} 0.04 344.19 g/mol 344.18 g/mol 3918.92 
B3 13 {6,7,6} 0.0 416.12 g/mol 0.00 g/mol 0.00 
C3 13 {7,7,6} 0.14 328.20 g/mol 328.18 g/mol 15947.04 
D3 13 {8,7,6} 0.10 332.17 g/mol 332.15 g/mol 6187.44 
E3 13 {9,7,6} 0.0 382.10 g/mol 0.00 g/mol 0.00 
F3 13 {10,7,6} 0.0 329.19 g/mol 0.00 g/mol 0.00 
G3 13 {5,8,6} 0.22 340.24 g/mol 340.21 g/mol 8771.64 
H3 13 {6,8,6} 0.0 412.17 g/mol 0.00 g/mol 0.00 
A4 13 {7,8,6} 0.22 324.25 g/mol 324.23 g/mol 30334.80 
B4 13 {8,8,6} 0.00 328.22 g/mol 328.21 g/mol 25420.50 
C4 13 {9,8,6} 0.00 378.15 g/mol 378.13 g/mol 1150.53 
D4 13 {10,8,6} 0.0 325.24 g/mol 0.00 g/mol 0.00 
E4 13 {5,9,6} 0.00 468.02 g/mol 468.00 g/mol 915.17 
F4 13 {6,9,6} 0.0 539.95 g/mol 0.00 g/mol 0.00 
G4 13 {7,9,6} 0.20 452.03 g/mol 452.01 g/mol 7009.20 
H4 13 {8,9,6} 0.02 455.99 g/mol 455.98 g/mol 7870.14 
A5 13 {9,9,6} 0.0 505.92 g/mol 0.00 g/mol 0.00 
B5 13 {10,9,6} 0.0 453.02 g/mol 0.00 g/mol 0.00 
C5 13 {5,10,6} 0.22 390.11 g/mol 390.10 g/mol 6585.30 
D5 13 {6,10,6} 0.0 462.04 g/mol 0.00 g/mol 0.00 
E5 13 {7,10,6} 0.22 374.12 g/mol 374.10 g/mol 7452.54 
F5 13 {8,10,6} 0.16 378.09 g/mol 378.08 g/mol 19545.24 
G5 13 {9,10,6} 0.0 428.02 g/mol 0.00 g/mol 0.00 
H5 13 {10,10,6} 0.0 375.11 g/mol 0.00 g/mol 0.00 
A6 13 {5,3,15} 0.22 314.18 g/mol 314.21 g/mol 6712.38 
B6 13 {6,3,15} 0.02 386.11 g/mol 386.11 g/mol 746.02 
C6 13 {7,3,15} 0.10 298.19 g/mol 298.18 g/mol 25164.00 
D6 13 {8,3,15} 0.14 302.15 g/mol 302.15 g/mol 27569.22 
E6 13 {9,3,15} 0.26 352.08 g/mol 352.08 g/mol 7914.12 
F6 13 {10,3,15} 0.0 299.18 g/mol 0.00 g/mol 0.00 
G6 13 {5,4,15} 0.16 314.18 g/mol 314.17 g/mol 21033.66 
H6 13 {6,4,15} 0.0 386.11 g/mol 0.00 g/mol 0.00 
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A7 13 {7,4,15} 0.04 298.19 g/mol 298.18 g/mol 23566.62 
B7 13 {8,4,15} 0.06 302.15 g/mol 302.15 g/mol 6177.96 
C7 13 {9,4,15} 0.06 352.08 g/mol 352.08 g/mol 1820.34 
D7 13 {10,4,15} 0.0 299.18 g/mol 0.00 g/mol 0.00 
E7 13 {5,5,15} 0.14 330.17 g/mol 330.17 g/mol 7222.68 
F7 13 {6,5,15} 0.0 402.10 g/mol 0.00 g/mol 0.00 
G7 13 {7,5,15} 0.25 314.18 g/mol 314.18 g/mol 11725.86 
H7 13 {8,5,15} 0.26 318.15 g/mol 318.15 g/mol 7365.42 
A8 13 {9,5,15} 0.00 368.08 g/mol 368.08 g/mol 428.58 
B8 13 {10,5,15} 0.0 315.17 g/mol 0.00 g/mol 0.00 
C8 13 {5,6,15} 0.0 330.17 g/mol 0.00 g/mol 0.00 
D8 13 {6,6,15} 0.0 402.10 g/mol 0.00 g/mol 0.00 
E8 13 {7,6,15} 0.0 314.18 g/mol 0.00 g/mol 0.00 
F8 13 {8,6,15} 0.08 318.15 g/mol 318.14 g/mol 14245.56 
G8 13 {9,6,15} 0.0 368.08 g/mol 0.00 g/mol 0.00 
H8 13 {10,6,15} 0.0 315.17 g/mol 0.00 g/mol 0.00 
A9 13 {5,7,15} 0.02 330.17 g/mol 330.16 g/mol 2475.16 
B9 13 {6,7,15} 0.0 402.10 g/mol 0.00 g/mol 0.00 
C9 13 {7,7,15} 0.12 314.18 g/mol 314.17 g/mol 16917.60 
D9 13 {8,7,15} 0.12 318.15 g/mol 318.14 g/mol 4981.39 
E9 13 {9,7,15} 0.00 368.08 g/mol 368.09 g/mol 98.59 
F9 13 {10,7,15} 0.0 315.17 g/mol 0.00 g/mol 0.00 
G9 13 {5,8,15} 0.10 326.22 g/mol 326.21 g/mol 26247.48 
H9 13 {6,8,15} 0.0 398.15 g/mol 0.00 g/mol 0.00 
A10 13 {7,8,15} 0.14 310.23 g/mol 310.22 g/mol 27512.88 
B10 13 {8,8,15} 0.18 314.20 g/mol 314.19 g/mol 28619.88 
C10 13 {9,8,15} 0.06 364.13 g/mol 364.12 g/mol 3583.39 
D10 13 {10,8,15} 0.0 311.22 g/mol 0.00 g/mol 0.00 
E10 13 {5,9,15} 0.00 454.00 g/mol 454.00 g/mol 636.38 
F10 13 {6,9,15} 0.0 525.93 g/mol 0.00 g/mol 0.00 
G10 13 {7,9,15} 0.00 438.01 g/mol 438.00 g/mol 3621.29 
H10 13 {8,9,15} 0.02 441.98 g/mol 441.98 g/mol 9285.96 
A11 13 {9,9,15} 0.0 491.90 g/mol 0.00 g/mol 0.00 
B11 13 {10,9,15} 0.0 439.00 g/mol 0.00 g/mol 0.00 
C11 13 {5,10,15} 0.16 376.09 g/mol 376.09 g/mol 13129.98 
D11 13 {6,10,15} 0.0 448.02 g/mol 0.00 g/mol 0.00 
E11 13 {7,10,15} 0.24 360.10 g/mol 360.10 g/mol 7244.16 
F11 13 {8,10,15} 0.14 364.07 g/mol 364.07 g/mol 24588.48 
G11 13 {9,10,15} 0.0 414.00 g/mol 0.00 g/mol 0.00 
H11 13 {10,10,15} 0.0 361.09 g/mol 0.00 g/mol 0.00 
A12 empty         
B12 empty         
C12 empty         
D12 empty         
E12 empty         
F12 empty         
G12 empty         
H12 empty         
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Well Chemset Peak Width  Expected mass Found mass Intensity 
A1 empty         
B1 empty         
C1 empty         
D1 empty         
E1 empty         
F1 empty         
G1 empty         
H1 empty         
A2 13 {11,11,21} 0.00 437.07 g/mol 437.06 g/mol 153.73 
B2 13 {3,11,21} 0.00 385.15 g/mol 385.15 g/mol 1206.33 
C2 13 {11,12,21} 0.00 401.07 g/mol 401.08 g/mol 343.62 
D2 13 {3,12,21} 0.00 349.15 g/mol 349.16 g/mol 33.44 
E2 13 {11,13,21} 0.00 437.00 g/mol 437.02 g/mol 57.67 
F2 13 {3,13,21} 0.00 385.08 g/mol 385.17 g/mol 61.42 
G2 13 {11,2,21} 0.04 453.00 g/mol 453.01 g/mol 1093.16 
H2 13 {3,2,21} 0.00 401.07 g/mol 401.07 g/mol 37.82 
A3 13 {11,11,22} 0.04 440.07 g/mol 440.07 g/mol 7904.28 
B3 13 {3,11,22} 0.40 388.15 g/mol 388.15 g/mol 13486.68 
C3 13 {11,12,22} 0.08 404.08 g/mol 404.08 g/mol 15225.24 
D3 13 {3,12,22} 0.12 352.15 g/mol 352.15 g/mol 23614.38 
E3 13 {11,13,22} 0.0 440.00 g/mol 0.00 g/mol 0.00 
F3 13 {3,13,22} 0.44 388.08 g/mol 388.08 g/mol 10662.96 
G3 13 {11,2,22} 0.0 456.00 g/mol 0.00 g/mol 0.00 
H3 13 {3,2,22} 0.12 404.08 g/mol 404.07 g/mol 7670.22 
A4 13 {11,11,23} 0.06 467.04 g/mol 467.05 g/mol 4233.99 
B4 13 {3,11,23} 0.00 415.11 g/mol 415.14 g/mol 186.11 
C4 13 {11,12,23} 0.04 431.04 g/mol 431.05 g/mol 3706.48 
D4 13 {3,12,23} 0.00 379.12 g/mol 379.12 g/mol 1652.11 
E4 13 {11,13,23} 0.0 466.97 g/mol 0.00 g/mol 0.00 
F4 13 {3,13,23} 0.04 415.05 g/mol 415.06 g/mol 1178.56 
G4 13 {11,2,23} 0.00 482.96 g/mol 482.98 g/mol 350.58 
H4 13 {3,2,23} 0.06 431.04 g/mol 431.05 g/mol 4378.65 
A5 13 {11,11,21} 0.06 426.05 g/mol 426.06 g/mol 7564.74 
B5 13 {3,11,24} 0.18 374.13 g/mol 374.22 g/mol 27886.56 
C5 13 {11,12,24} 0.00 390.06 g/mol 390.06 g/mol 12667.20 
D5 13 {3,12,24} 0.20 338.13 g/mol 338.14 g/mol 10149.54 
E5 13 {11,13,24} 0.00 425.98 g/mol 426.00 g/mol 423.74 
F5 13 {3,13,24} 0.36 374.06 g/mol 374.07 g/mol 13504.02 
G5 13 {11,2,24} 0.00 441.98 g/mol 441.99 g/mol 7867.74 
H5 13 {3,2,24} 0.22 390.06 g/mol 390.13 g/mol 6788.16 
A6 13 {11,11,25} 0.00 458.03 g/mol 458.05 g/mol 280.48 
B6 13 {3,11,25} 0.22 406.11 g/mol 406.12 g/mol 8632.56 
C6 13 {11,12,25} 0.02 422.04 g/mol 422.06 g/mol 551.97 
D6 13 {3,12,25} 0.06 370.11 g/mol 370.12 g/mol 4785.12 
E6 13 {11,13,25} 0.0 457.96 g/mol 0.00 g/mol 0.00 
F6 13 {3,13,25} 0.00 406.04 g/mol 406.06 g/mol 1487.02 
G6 13 {11,2,25} 0.02 473.96 g/mol 473.99 g/mol 1161.52 
H6 13 {3,2,25} 0.12 422.04 g/mol 422.05 g/mol 5508.88 
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A7 13 {11,11,26} 0.12 440.04 g/mol 440.07 g/mol 3225.98 
B7 13 {3,11,26} 0.04 388.12 g/mol 388.14 g/mol 1095.31 
C7 13 {11,12,26} 0.06 404.05 g/mol 404.07 g/mol 1544.66 
D7 13 {3,12,26} 0.00 352.13 g/mol 352.13 g/mol 317.52 
E7 13 {11,13,26} 0.00 439.98 g/mol 439.99 g/mol 27.28 
F7 13 {3,13,26} 0.0 388.05 g/mol 0.00 g/mol 0.00 
G7 13 {11,2,26} 0.02 455.97 g/mol 455.99 g/mol 715.12 
H7 13 {3,2,26} 0.02 404.05 g/mol 404.07 g/mol 601.31 
A8 13 {11,11,27} 0.0 489.97 g/mol 0.00 g/mol 0.00 
B8 13 {3,11,27} 0.02 438.05 g/mol 438.06 g/mol 2140.33 
C8 13 {11,12,27} 0.0 453.98 g/mol 0.00 g/mol 0.00 
D8 13 {3,12,27} 0.00 402.06 g/mol 402.07 g/mol 233.75 
E8 13 {11,13,27} 0.00 489.91 g/mol 489.94 g/mol 129.30 
F8 13 {3,13,27} 0.02 437.98 g/mol 438.01 g/mol 645.86 
G8 13 {11,2,27} 0.00 505.90 g/mol 505.92 g/mol 1557.76 
H8 13 {3,2,27} 0.00 453.98 g/mol 454.00 g/mol 2384.53 
A9 13 {11,11,28} 0.0 496.10 g/mol 0.00 g/mol 0.00 
B9 13 {3,11,28} 0.0 444.18 g/mol 0.00 g/mol 0.00 
C9 13 {11,12,28} 0.0 460.11 g/mol 0.00 g/mol 0.00 
D9 13 {3,12,28} 0.0 408.19 g/mol 0.00 g/mol 0.00 
E9 13 {11,13,28} 0.0 496.04 g/mol 0.00 g/mol 0.00 
F9 13 {3,13,28} 0.0 444.11 g/mol 0.00 g/mol 0.00 
G9 13 {11,2,28} 0.0 512.03 g/mol 0.00 g/mol 0.00 
H9 13 {3,2,28} 0.0 460.11 g/mol 0.00 g/mol 0.00 
A10 13 {11,11,29} 0.0 443.13 g/mol 0.00 g/mol 0.00 
B10 13 {3,11,29} 0.0 391.21 g/mol 0.00 g/mol 0.00 
C10 13 {11,12,29} 0.0 407.13 g/mol 0.00 g/mol 0.00 
D10 13 {3,12,29} 0.0 355.21 g/mol 0.00 g/mol 0.00 
E10 13 {11,13,29} 0.0 443.06 g/mol 0.00 g/mol 0.00 
F10 13 {3,13,29} 0.0 391.14 g/mol 0.00 g/mol 0.00 
G10 13 {11,2,29} 0.0 459.06 g/mol 0.00 g/mol 0.00 
H10 13 {3,2,29} 0.0 407.13 g/mol 0.00 g/mol 0.00 
A11 13 {11,11,30} 0.00 423.05 g/mol 423.07 g/mol 620.09 
B11 13 {3,11,30} 0.18 371.13 g/mol 371.16 g/mol 21238.74 
C11 13 {11,12,30} 0.14 387.05 g/mol 387.06 g/mol 5620.52 
D11 13 {3,12,30} 0.10 335.13 g/mol 335.14 g/mol 4406.42 
E11 13 {11,13,30} 0.0 422.98 g/mol 0.00 g/mol 0.00 
F11 13 {3,13,30} 0.00 371.06 g/mol 371.07 g/mol 1472.39 
G11 13 {11,2,30} 0.00 438.98 g/mol 439.00 g/mol 933.28 
H11 13 {3,2,30} 0.04 387.05 g/mol 387.07 g/mol 3431.95 
A12 empty         
B12 empty         
C12 empty         
D12 empty         
E12 empty         
F12 empty         
G12 empty         
H12 empty         
 
 
 
 
 
 
 
 
 Appendix II 487 
ori.hya.54 
 
 
 
  
 
 
 
 
Well Chemset Peak Width  Expected mass Found mass Intensity 
A1 empty         
B1 empty         
C1 empty         
D1 empty         
E1 empty         
F1 empty         
G1 empty         
H1 empty         
A2 13 {11,11,31} 0.12 442.03 g/mol 442.05 g/mol 6292.44 
B2 13 {3,11,31} 0.24 390.11 g/mol 390.12 g/mol 29295.36 
C2 13 {11,12,31} 0.26 406.03 g/mol 406.04 g/mol 8643.72 
D2 13 {3,12,31} 0.20 354.11 g/mol 354.12 g/mol 10792.68 
E2 13 {11,13,31} 0.00 441.96 g/mol 441.99 g/mol 62.12 
F2 13 {3,13,31} 0.42 390.04 g/mol 390.05 g/mol 17343.42 
G2 13 {11,2,31} 0.0 457.96 g/mol 0.00 g/mol 0.00 
H2 13 {3,2,31} 0.22 406.03 g/mol 406.05 g/mol 9592.44 
A3 13 {11,11,32} 0.0 442.03 g/mol 0.00 g/mol 0.00 
B3 13 {3,11,32} 0.0 390.11 g/mol 0.00 g/mol 0.00 
C3 13 {11,12,32} 0.0 406.03 g/mol 0.00 g/mol 0.00 
D3 13 {3,12,32} 0.0 354.11 g/mol 0.00 g/mol 0.00 
E3 13 {11,13,32} 0.0 441.96 g/mol 0.00 g/mol 0.00 
F3 13 {3,13,32} 0.0 390.04 g/mol 0.00 g/mol 0.00 
G3 13 {11,2,32} 0.0 457.96 g/mol 0.00 g/mol 0.00 
H3 13 {3,2,32} 0.0 406.03 g/mol 0.00 g/mol 0.00 
A4 13 {11,11,33} 0.0 443.02 g/mol 0.00 g/mol 0.00 
B4 13 {3,11,33} 0.0 391.10 g/mol 0.00 g/mol 0.00 
C4 13 {11,12,33} 0.0 407.03 g/mol 0.00 g/mol 0.00 
D4 13 {3,12,33} 0.0 355.10 g/mol 0.00 g/mol 0.00 
E4 13 {11,13,33} 0.0 442.95 g/mol 0.00 g/mol 0.00 
F4 13 {3,13,33} 0.0 391.03 g/mol 0.00 g/mol 0.00 
G4 13 {11,2,33} 0.0 458.95 g/mol 0.00 g/mol 0.00 
H4 13 {3,2,33} 0.0 407.03 g/mol 0.00 g/mol 0.00 
A5 13 {11,11,34} 0.02 441.06 g/mol 441.06 g/mol 722.38 
B5 13 {3,11,34} 0.04 389.14 g/mol 389.15 g/mol 1020.68 
C5 13 {11,12,34} 0.0 405.07 g/mol 0.00 g/mol 0.00 
D5 13 {3,12,34} 0.0 353.15 g/mol 0.00 g/mol 0.00 
E5 13 {11,13,34} 0.0 441.00 g/mol 0.00 g/mol 0.00 
F5 13 {3,13,34} 0.00 389.07 g/mol 389.09 g/mol 297.69 
G5 13 {11,2,34} 0.0 456.99 g/mol 0.00 g/mol 0.00 
H5 13 {3,2,34} 0.0 405.07 g/mol 0.00 g/mol 0.00 
A6 13 {11,11,35} 0.14 440.08 g/mol 440.09 g/mol 8140.98 
B6 13 {3,11,35} 0.04 388.16 g/mol 388.23 g/mol 23523.66 
C6 13 {11,12,35} 0.16 404.09 g/mol 404.09 g/mol 6563.94 
D6 13 {3,12,35} 0.14 352.16 g/mol 352.17 g/mol 6735.72 
E6 13 {11,13,35} 0.04 440.01 g/mol 440.03 g/mol 1064.31 
F6 13 {3,13,35} 0.14 388.09 g/mol 388.10 g/mol 6375.42 
G6 13 {11,2,35} 0.00 456.01 g/mol 456.02 g/mol 237.79 
H6 13 {3,2,35} 0.00 404.09 g/mol 404.10 g/mol 199.78 
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A7 13 {11,11,1} 0.12 402.10 g/mol 402.10 g/mol 7500.54 
B7 13 {3,11,1} 0.14 350.17 g/mol 350.17 g/mol 28180.98 
C7 13 {11,12,1} 0.22 366.10 g/mol 366.11 g/mol 9801.18 
D7 13 {3,12,1} 0.24 314.18 g/mol 314.18 g/mol 6114.78 
E7 13 {11,13,1} 0.00 402.03 g/mol 402.04 g/mol 1077.64 
F7 13 {3,13,1} 0.38 350.11 g/mol 350.11 g/mol 30374.22 
G7 13 {11,2,1} 0.16 418.02 g/mol 418.03 g/mol 13757.88 
H7 13 {3,2,1} 0.02 366.10 g/mol 366.11 g/mol 16382.34 
A8 13 {11,11,2} 0.18 418.05 g/mol 418.06 g/mol 19420.86 
B8 13 {3,11,2} 0.12 366.12 g/mol 366.14 g/mol 29501.52 
C8 13 {11,12,2} 0.20 382.05 g/mol 382.06 g/mol 7621.26 
D8 13 {3,12,2} 0.06 330.13 g/mol 330.14 g/mol 18568.44 
E8 13 {11,13,2} 0.02 417.98 g/mol 417.99 g/mol 3077.47 
F8 13 {3,13,2} 0.04 366.06 g/mol 366.07 g/mol 22446.54 
G8 13 {11,2,2} 0.02 433.97 g/mol 433.99 g/mol 6375.48 
H8 13 {3,2,2} 0.20 382.05 g/mol 382.06 g/mol 8296.98 
A9 13 {11,11,4} 0.36 404.07 g/mol 404.08 g/mol 14172.84 
B9 13 {3,11,4} 0.04 352.15 g/mol 352.16 g/mol 26174.82 
C9 13 {11,12,4} 0.18 368.08 g/mol 368.08 g/mol 12153.66 
D9 13 {3,12,4} 0.14 316.15 g/mol 316.16 g/mol 5829.50 
E9 13 {11,13,4} 0.00 404.01 g/mol 404.02 g/mol 570.38 
F9 13 {3,13,4} 0.20 352.08 g/mol 352.09 g/mol 24047.04 
G9 13 {11,2,4} 0.00 420.00 g/mol 420.01 g/mol 10388.70 
H9 13 {3,2,4} 0.16 368.08 g/mol 368.08 g/mol 6181.26 
A10 13 {11,11,6} 0.00 402.10 g/mol 402.10 g/mol 8936.82 
B10 13 {3,11,6} 0.20 350.17 g/mol 350.18 g/mol 28771.80 
C10 13 {11,12,6} 0.30 366.10 g/mol 366.11 g/mol 16596.60 
D10 13 {3,12,6} 0.18 314.18 g/mol 314.28 g/mol 15523.38 
E10 13 {11,13,6} 0.0 402.03 g/mol 0.00 g/mol 0.00 
F10 13 {3,13,6} 0.44 350.11 g/mol 350.11 g/mol 12862.56 
G10 13 {11,2,6} 0.12 418.02 g/mol 418.03 g/mol 10086.72 
H10 13 {3,2,6} 0.00 366.10 g/mol 366.10 g/mol 89.46 
A11 13 {11,11,15} 0.42 388.08 g/mol 388.08 g/mol 11918.94 
B11 13 {3,11,15} 0.10 336.15 g/mol 336.25 g/mol 26462.88 
C11 13 {11,12,15} 0.18 352.08 g/mol 352.09 g/mol 22371.12 
D11 13 {3,12,15} 0.10 300.16 g/mol 300.16 g/mol 19999.26 
E11 13 {11,13,15} 0.00 388.01 g/mol 388.02 g/mol 1039.55 
F11 13 {3,13,15} 0.10 336.09 g/mol 336.09 g/mol 9274.20 
G11 13 {11,2,15} 0.00 404.00 g/mol 404.01 g/mol 10842.30 
H11 13 {3,2,15} 0.18 352.08 g/mol 352.09 g/mol 7010.28 
A12 empty         
B12 empty         
C12 empty         
D12 empty         
E12 empty         
F12 empty         
G12 empty         
H12 empty         
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B.8 On-screen assay validation 
B.8.1 On-screen assay validation for plates ori.hya.1-9 
 
Run (measurement)   
No. Description SW Z‘ 
1 ori.hya.1; plate 1 48.1 0.9220 
2 ori.hya.1; plate 2 68.5 0.9140 
3 ori.hya.2; plate 1 26.3 0.8940 
4 ori.hya.2; plate 2 35.8 0.9050 
5 ori.hya.3; plate 1 29.4 0.8960 
6 ori.hya.3; plate 2 38.1 0.9160 
7 ori.hya.4; plate 1 23.4 0.8680 
8 ori.hya.4; plate 2 29.5 0.8850 
9 ori.hya.5; plate 1 22.1 0.8630 
10 ori.hya.5; plate 2 37.6 0.9070 
11 ori.hya.6; plate 1 27.4 0.8790 
12 ori.hya.6; plate 2 34.7 0.8900 
13 ori.hya.7; plate 1 28.2 0.8480 
14 ori.hya.7; plate 2 24.9 0.8430 
15 ori.hya.8; plate 1 5.8 0.6100 
16 ori.hya.8; plate 2 7.6 0.6500 
17 ori.hya.9; plate 1 31.7 0.8920 
18 ori.hya.9; plate 2 27.9 0.8730 
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B.8.2 On-screen assay validation for plates ori.hya.scr.1-7 
 
Run (measurement)   
No. Description SW Z‘ 
1 ori.hya.scr.1; plate 1 144.4 0.9590 
2 ori.hya.scr.1; plate 2 68.4 0.8660 
3 ori.hya.scr.2; plate 1 62.9 0.8980 
4 ori.hya.scr.2; plate 2 63.5 0.8620 
5 ori.hya.scr.3; plate 1 64.9 0.8580 
6 ori.hya.scr.3; plate 2 71.3 0.9300 
7 ori.hya.scr.4; plate 1 53.5 0.8110 
8 ori.hya.scr.4; plate 2 61.4 0.5530 
9 ori.hya.scr.5; plate 1 29.9 0.8220 
10 ori.hya.scr.5; plate 2 98.1 0.9460 
11 ori.hya.scr.6; plate 1 62.8 0.8630 
12 ori.hya.scr.6; plate 2 46.1 0.8520 
13 ori.hya.scr.7; plate 1 38.3 0.8330 
14 ori.hya.scr.7; plate 2 67.4 0.9090 
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B.8.3 On-screen assay validation for plates ori.hya.44-47 
 
Run (measurement)   
No. Description SW Z‘ 
1 ori.hya.44; plate 1 46.5 0.8880 
2 ori.hya.44; plate 2 50.3 0.9640 
3 ori.hya.45; plate 1 23.1 0.9220 
4 ori.hya.45; plate 2 20.7 0.8680 
5 ori.hya.46; plate 1 74.0 0.8010 
6 ori.hya.46; plate 2 30.3 0.7700 
7 ori.hya.47; plate 1 44.3 0.8010 
8 ori.hya.47; plate 2 51.0 0.8630 
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B.8.4 On-screen assay validation for plates ori.hya.48-54 
 
Run (measurement)   
No. Description SW Z‘ 
1 ori.hya.48; plate 1 11.7 0.6830 
2 ori.hya.48; plate 2 28.7 0.7400 
3 ori.hya.49; plate 1 24.5 0.7580 
4 ori.hya.49; plate 2 26.4 0.7300 
5 ori.hya.50; plate 1 13.9 0.8100 
6 ori.hya.50; plate 2 14.4 0.6180 
7 ori.hya.51; plate 1 8.2 0.6470 
8 ori.hya.51; plate 2 13.7 0.6400 
9 ori.hya.52; plate 1 22.4 0.7750 
10 ori.hya.52; plate 2 14.8 0.7580 
11 ori.hya.53; plate 1 9.3 0.5790 
12 ori.hya.53; plate 2 11.3 0.5930 
13 ori.hya.54; plate 1 14.1 0.5650 
14 ori.hya.54; plate 2 56.6 0.7520 
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B.9 Pharmacological results 
B.9.1 Tabulation of screening hits 
Plate Well Compound Comment 
ori.hya.2 B2 6.5 missed hit criteria 
ori.hya.scr.3 H3 5.1 hit 
ori.hya.scr.6 E7 5.2 hit 
ori.hya.scr.7 A6 5.3 hit 
ori.hya.scr.1 G2 5.4 missed hit criteria 
ori.hya.scr.1 A3 5.5 missed hit criteria 
ori.hya.scr.1 C3 5.6 missed hit criteria 
ori.hya.scr.1 A5 5.7 missed hit criteria 
ori.hya.scr.1 B5 5.8 missed hit criteria 
ori.hya.scr.1 F9 5.9 missed hit criteria 
ori.hya.scr.3 C7 5.10 missed hit criteria 
ori.hya.scr.6 C7 5.11 missed hit criteria 
ori.hya.44 A2  hit 
ori.hya.44 D2 5.17 hit 
ori.hya.44 E2  hit 
ori.hya.44 D3  hit 
ori.hya.44 D5  hit 
ori.hya.44 D6  hit 
ori.hya.44 A7 5.16 hit 
ori.hya.44 D7  hit 
ori.hya.44 A9  hit 
ori.hya.44 D9  hit 
ori.hya.44 D12  hit 
ori.hya.45 D2 5.18 hit 
ori.hya.45 D5  hit 
ori.hya.45 D6  hit 
ori.hya.45 D7  hit 
ori.hya.45 D9  hit 
ori.hya.45 D10 5.21 hit 
ori.hya.45 E10  hit 
ori.hya.46 D2  hit 
ori.hya.46 D3  hit 
ori.hya.46 D7  hit 
ori.hya.46 D9  hit 
ori.hya.47 D5  hit 
ori.hya.47 D7  hit 
ori.hya.47 E7  hit 
ori.hya.50 F4 6.1 hit 
ori.hya.50 C5 6.2 hit 
ori.hya.50 D5 6.3 hit 
ori.hya.50 G11 6.6 missed hit criteria 
ori.hya.50 H11 6.4 hit 
ori.hya.52 A7 6.7 missed hit criteria 
ori.hya.52 B7 6.8 missed hit criteria 
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B.9.2 Pharmacological results for plates ori.hya.1-9 
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plate ori.hya.4
well number (by column, then row)
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plate ori.hya.5
well number (by column, then row)
8 16 32 40 56 64 80 880 24 48 72 96
m
e
a
n
 e
n
z
y
m
a
ti
c
 a
c
ti
v
it
y
 (
%
)
0
20
40
60
80
100
weighted effect
1e-1 1e+0 1e+1 1e+2 1e+3 1e+4 1e+5
m
e
a
n
 e
n
z
y
m
a
ti
c
 a
c
ti
v
it
y
 (
%
)
0
20
40
60
80
100
 
plate ori.hya.6
well number (by column, then row)
8 16 32 40 56 64 80 880 24 48 72 96
m
e
a
n
 e
n
z
y
m
a
ti
c
 a
c
ti
v
it
y
 (
%
)
0
20
40
60
80
100
weighted effect
1e-1 1e+0 1e+1 1e+2 1e+3 1e+4 1e+5
m
e
a
n
 e
n
z
y
m
a
ti
c
 a
c
ti
v
it
y
 (
%
)
0
20
40
60
80
100
 
 
 
496 Appendix II 
 
plate ori.hya.7
well number (by column, then row)
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B.9.3 Pharmacological results for plates ori.hya.scr.1-7 
plate ori.hya.scr.1
well number (by column, then row)
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well number (by column, then row)
8 16 32 40 56 64 80 880 24 48 72 96
m
e
a
n
 e
n
z
y
m
a
ti
c
 a
c
ti
v
it
y
 (
%
)
0
20
40
60
80
100
weighted effect
1e-1 1e+0 1e+1 1e+2 1e+3 1e+4 1e+5
m
e
a
n
 e
n
z
y
m
a
ti
c
 a
c
ti
v
it
y
 (
%
)
0
20
40
60
80
100
 
 
 
498 Appendix II 
 
plate ori.hya.scr.4
well number (by column, then row)
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plate ori.hya.scr.5
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plate ori.hya.scr.6
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plate ori.hya.scr.7
well number (by column, then row)
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B.9.4 Pharmacological results for plates ori.hya.44-47 
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B.9.5 Pharmacological results for plates ori.hya.48-54 
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plate ori.hya.54
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B.10 Preparation of the compounds 5.71-5.74 
B.10.1 General procedure 
A solution of the pertinent aldehyde (1 eq) and amine (1 eq) in dry MeOH (1 mL per mmol) 
was stirred for 1 h at room temperature and was subsequently cooled to 0 °C. After the 
addition of KOCN (4 eq), pyridinium chloride (4 eq) and the corresponding isocyanide 
(1 eq), the mixture was stirred overnight below 20 °C. Insoluble material was removed by 
filtration and the solvent (MeOH) was removed under reduced pressure. After addition of 
ethyl acetate as solvent, precipitated material was removed by filtration and the crude 
product was obtained as residue after evaporation. The crude substance was submitted to 
RP-HPLC (method indicated) yielding the corresponding {[M + H]+ + 16} product. 
 
B.10.2 1-(3,5-Dichloro-4-hydroxyphenyl)-5-hydroxy-4-[4-
(trifluoromethyl)benzylamino]-5-(2,4,5-trihydroxyphenyl)-1H-
imidazol-2(5H)-one (5.71) 
The title compound was prepared from 2,4,5-trihydroxybenzaldehyde (0.3 mmol, 46 mg), 
4-amino-2,6-dichlorophenol (0.3 mmol, 53 mg) and 1-(isocyanomethyl)-4-
(trifluoromethyl)benzene (0.3 mmol, 56 mg) according to the general procedure. The 
crude product was obtained as residue after evaporation from ethyl acetate, and gave 
orange oil, which was stored at +7 °C for 7 days. A partial conversion to the 
corresponding {[M + H]+ + 16} derivative was observed under the specified conditions. MS 
(CI-MS)b m/z (rel. int. in %) = 628.0 (10), 585.0 (90), 542.0 ([M + H]+, 100), 385.1 (95), 
361.1 (15), 218.1 (5). MS (CI-MS)d m/z (rel. int. in %) = 628.0 (10), 585.0 (90), 558.0 
([M + H]+ + 16, 10), 542.0 ([M + H]+, 100), 385.1 (95), 361.1 (15), 218.1 (5). 
C23H16Cl2F3N3O6 (Mr* = 558.29 g/mol). 
Note: mass spectral data refer to [M + H]
+
 (Mr  = 542.29 g/mol) and {[M + H]
+
 + 16} (Mr* = 558.29 g/mol). 
b
 17 h 
after completion of the experiment; relative abundance (TIC): Mr (542.29 g/mol) = 15 %; relative abundance 
(TIC): Mr* (558.29 g/mol) = 0 %; 
d
 168 h after completion of the experiment; relative abundance (TIC): 
Mr (542.29 g/mol) = 15 %; relative abundance (TIC): Mr* (558.29 g/mol) = 5 %.  
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B.10.3 1-(3,5-Dichloro-4-hydroxyphenyl)-5-hydroxy-5-phenyl-
4-[4-(trifluoromethyl) benzylamino]-1H-imidazol-2(5H)-one (5.72) 
The title compound was prepared from benzaldehyde (0.3 mmol, 32 mg), 4-amino-2,6-
dichlorophenol (0.3 mmol, 53 mg) and 1-(isocyanomethyl)-4-(trifluoromethyl)benzene 
(0.3 mmol, 56 mg) according to the general procedure. The crude product was obtained 
as residue after evaporation from ethyl acetate, and gave dark yellow oil which was stored 
at +7 °C for 20 days. A partial conversion to the corresponding {[M + H]+ + 16} derivative 
was observed under the specified conditions. MS (CI-MS)b m/z (rel. int. in %) = 539.0 (50), 
494.0 ([M + H]+, 100). MS (CI-MS)d m/z (rel. int. in %) = 528.1 (5), 524.1 (90), 510.0 
([M + H]+ + 16, 80), 494.0 ([M + H]+, 100), 492.0 (10). C23H16Cl2F3N3O3 (Mr* = 510.29 
g/mol). 
Note: mass spectral data refer to [M + H]
+
 (Mr  = 494.29 g/mol) and {[M + H]
+
 + 16} (Mr* = 510.29 g/mol). 
b
 20 h 
after completion of the experiment; relative abundance (TIC): Mr (494.29 g/mol) = 50 %; relative abundance 
(TIC): Mr* (510.29 g/mol) = 0 %; 
d
 20 d after completion of the experiment; relative abundance (TIC): 
Mr (494.29 g/mol) = 40 %; relative abundance (TIC): Mr* (510.29 g/mol) = 4 0%. 
 
B.10.4 1-(3,5-Dichloro-4-hydroxyphenyl)-5-hydroxy-4-[4-
(trifluoromethyl)benzylamino]-5-(2,4,5-trimethoxyphenyl)-1H-
imidazol-2(5H)-one (5.73) 
The title compound was prepared from 2,4,5-trimethoxybenzaldehyde (0.3 mmol, 59 mg), 
4-amino-2,6-dichlorophenol (0.3 mmol, 53 mg) and 1-(isocyanomethyl)-4-
(trifluoromethyl)benzene (0.3 mmol, 56 mg) according to the general procedure. The 
crude product was obtained as residue after evaporation from ethyl acetate, and gave 
yellow oil which was stored at +7 °C for 20 days. A partial conversion to the corresponding 
{[M + H]+ + 16} derivative was observed under the specified conditions. MS (CI-MS)b m/z 
(rel. int. in %) = 584.0 ([M + H]+, 100), 405.2 (5), 345.1 (5), 275.1 (5). MS (CI-MS)d m/z 
(rel. int. in %) = 600.1 ([M + H]+ + 16, 100), 584.0 ([M + H]+, 5), 531.0 (5), 354.1 (5). 
C26H22Cl2F3N3O6 (Mr* = 600.37 g/mol). 
Note: mass spectral data refer to [M + H]
+
 (Mr  = 584.37 g/mol) and {[M + H]
+
 + 16} (Mr* = 600.37 g/mol).
b
 20 h 
after completion of the experiment; relative abundance (TIC): Mr (584.37 g/mol) = 20 %; relative abundance 
(TIC): Mr* (600.37 g/mol) = 5 %; 
d
 20 d after completion of the experiment; relative abundance (TIC): 
Mr (584.37 g/mol) = 3 %; relative abundance (TIC): Mr* (600.37 g/mol) = 20 %. 
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B.10.5 1-(3,5-Dichloro-4-hydroxyphenyl)-5-hydroxy-5-(1H-
indazol-5-yl)-4-[4-(trifluoromethyl) benzylamino]-1H-imidazol-
2(5H)-one (5.74) 
The title compound was prepared from 2,4,5-trimethoxybenzaldehyde (0.3 mmol, 59 mg), 
4-amino-2,6-dichlorophenol (0.3 mmol, 53 mg) and 1-(isocyanomethyl)-4-
(trifluoromethyl)benzene (0.3 mmol, 56 mg) according to the general procedure. The 
crude product was obtained as residue after evaporation from ethyl acetate, and gave 
yellow oil which was stored at +7 °C for 20 days. A partial conversion to the corresponding 
{[M + H]+ + 16} derivative was observed under the specified conditions. MS (CI-MS)b m/z 
(rel. int. in %) = 558.1 (10), 534.1 ([M + H]+, 100), 434.2 (5), 376.0 (5), 304.4 (5), 218.1 
(15). MS (CI-MS)d m/z (rel. int. in %) = 550.1 ([M + H]+ + 16, 5), 385.1 (70), 218.1 (100). 
C24H16Cl2F3N5O6 (Mr* = 550.32 g/mol). 
Note: mass spectral data refer to [M + H]
+
 (Mr  = 534.32 g/mol) and {[M + H]
+
 + 16} (Mr* = 550.32 g/mol). 
b
 20 h 
after completion of the experiment; relative abundance (TIC): Mr (534.32 g/mol) = 5 %; relative abundance 
(TIC): Mr* (550.32 g/mol) = 0 %; 
d
 20 d after completion of the experiment; relative abundance (TIC): 
Mr (534.32 g/mol) = 0 %; relative abundance (TIC): Mr* (550.32 g/mol) = 5 %.  
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B.11 Mass spectral analysis of the oxidation of 5.22 
B.11.1 Molecular properties of 5.22 and 5.62 
   
B.11.2 Documentation of LC-MS data 
  
  
MS data after completion of the experiment; above: 
TIC (total ion count) and ion counts of compounds 1-3, 
below: peak counts of compounds 1-3 
MS data after 24 h; above: TIC (total ion count) and 
ion counts of compounds 1-3, below: peak counts of 
compounds 1-3 
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MS data after 48 h; above: TIC (total ion count) and ion 
counts of compounds 1-3, below: peak counts of 
compounds 1-3 
MS data after 72 h; above: TIC (total ion count) 
and ion counts of compounds 1-3, below: peak 
counts of compounds 1-3 
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MS data after 96 h; above: TIC (total ion count) and ion 
counts of compounds 1-3, below: peak counts of 
compounds 1-3 
MS data after 184 h; above: TIC (total ion count) 
and ion counts of compounds 1-3, below: peak 
counts of compounds 1-3 
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MS data after 226 h; above: TIC (total ion count) and 
ion counts of compounds 1-3, below: peak counts of 
compounds 1-3 
MS data after 302 h; above: TIC (total ion count) and 
ion counts of compounds 1-3, below: peak counts of 
compounds 1-3 
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C.1 Small scale expression of S. pneumoniae 
hyaluronate lyase 
In collaboration with Dr. Janina Hamberger from our workgroup, SpnHyl-6-His was 
expressed in E. coli BL21(DE3) cells as described by Jedrzejas.1, 2 A transformed E. coli 
cell colony was selected on LB medium with 100 µg/mL ampicillin. Multiple colonies were 
inoculated into 200 mL of LB medium with the same antibiotic and incubated at 37 °C on 
an incubator shaker overnight. Protein expression was induced by addition of isopropyl--
D-1-thiogalactopyranoside (IPTG, Sigma-Aldrich, Munich, Germany) to the final 
concentration of 1 mM and growth was continued for another 3 hours. The cells were 
harvested by centrifugation at 6000 rpm for 10 minutes at 4 °C. All additional procedures 
were performed on ice. The resulting cell pellet was resuspended in McIlvaine’s buffer 
(pH = 5.0), supplemented with 20 % of glycerol and frozen at -80 °C. After thawing on ice, 
the suspension was again centrifuged and the pellet resuspended in McIlvaine’s buffer pH 
6.0. The sample was sonicated for 5 x 20 s with 1 min intervals on ice and the resulting 
cell lysate was centrifuged at 15000 rpm at 4 °C for 30 min. the supernatant was used for 
activity measurements, SDS-PAGE and Western Blot analysis were performed as 
described in the doctoral thesis of Dr. Janina Hamberger.2 
 
C.2 Large scale expression of S. pneumoniae 
hyaluronate lyase 
Large scale expression was performed in a bioreactor (BIOSTAT C-Laborfermenter, 
B. Braun, Melsungen, Germany) in collaboration with the Institute of Biotechnology (Prof. 
Dr. R. Rudolph) at the Martin-Luther University Halle-Wittenberg Germany. 6 L of sterile 
complete medium (50 g/L LB medium, 2.5 g/L (NH4)2SO4, 0.5 g/L NH4Cl, 14.6 g/L 
K2HPO4, 4 g/L NaH2PO4 x H2O, 4 g Na2SO4, 20 g/L glucose, 0.1 g/L thiamine, 2.5 g/L 
MgSO4 x 7H2O) containing 100 µg/mL of ampicillin were initiated by addition of 100 mL of 
E. coli BL21(DE3) overnight culture grown for 17 h in LB-medium with 100 µg/mL 
ampicillin. Fermentation was monitored by measuring pH, temperature, pressure, and 
glucose concentration. The pH value was controlled by automated addition of 10% (v/v) 
H3PO4 and 25% (v/v) NH3, respectively. For the fermentation process the pH was adjusted 
to 7.0. As illustrated in Figure 1, the culture was continuously fed by addition of 20 g/h 
sterile feeding solution (550 g/L glucose, 22 g/L Na2SO4, 24,92 g/L (NH4)2SO4, 5 g/L 
NH4Cl, 146 g/L, K2HPO4, 36 g/L NaH2PO4 x H2O, 2,2 mL 1 M MgSO4 solution) for 5 h. 
Subsequently, the addition of feeding solution was increased. After fermentation for 18 h, 
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1 mM IPTG (from a 1 M stock solution in water) was added to induce expression of 
SpnHyl-6-His. The bacteria were cultured for additional 4 h before the suspension was 
centrifuged (20 min, 4 °C) and the pellets were stored at -80 °C. 
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Figure 1 Illustration of glucose feed in 
g/h during culture fermentation (22 h); 
after 18 h, IPTG (1 M) was added to 
induce expression of SpnHyl-6-His. 
 
 
 
C.3 Purification of S. pneumoniae hyaluronate lyase 
A bacterial pellet of 10 g (wet weight) was thawed on ice and resuspended in 50 mL of 
binding buffer (500 mM NaCl, 20 mM NaH2PO4, 20 mM imidazole, pH 7.4), supplemented 
with an EDTA-free protease inhibitor cocktail (Sigma-Aldrich, Munich, Germany) following 
sonication as described above. The cell lysate was centrifuged at 15000 rpm at 4 °C for 
30 min and the supernatant was used for purification with ion metal affinity 
chromatography (IMAC). 
Two Ni-IMAC columns (HisTrap FFTM, CV = 5 mL, GE Healthcare, Munich, Germany) 
were equilibrated with wash buffer (500 mM NaCl, 20 mM NaH2PO4, 15 mM imidazole, 
pH = 7.4) at 4 °C. After loading sample (10 mL supernatant of SpnHyl-6-His), the column 
was washed with 30 column volumes (CV) of wash buffer. Subsequently, SpnHyl-6-His 
was eluted by washing with elution buffer (500 mM NaCl, 20 mM NaH2PO4, 500 mM 
imidazole, pH = 7.4). Elution fractions of 6.5 mL (cf. Figure 2) were collected and analyzed 
with respect to protein content, purity and enzymatic activity. 
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As shown in Figure 3, elution fractions 25 and 26 were of satisfying purity. After desalting 
by dialysis (MWCO 14000, 4 °C, buffer: citrate-phosphate buffer, pH = 6, 0.1 M NaCl), the 
protein content of the elution fractions was determined using the method of Bradford in the 
microtiter plate format.3  
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Figure 2: Purification of SpnHyl-
6-His by Ni-IMAC (CV 5 mL). 
Elution profile plotted as 
absorbance signal (254 nm) 
versus elution volume (mL). After 
150 mL, the wash buffer (20 mM 
imidazole) was replaced by 
elution buffer (500 mM imidazole) 
as indicated (red line). A total of 
34 fractions was collected 
(fraction volume 6.5 mL). 
 
 
Figure 3: SDS-page of SpnHyl-
6His after large-scale purification 
.
a
 (ref) total cell lysate prior to 
purification (target protein 
highlighted); (3)-(6) elution 
fractions 3-6; (m) peqlab marker, 
a: 116 kDa, b: 60.2 kDa, c: 
45 kDa, d: 35 kDa, e: 25 kDa, f: 
18.4 kDa, g: 14.4 kDa; (24)-(28) 
elution fractions 24-28 (purified 
target protein (84 kDa) high-
lighted in fractions 25, 26). 
a 
20 µL were applied to the SDS-
gel and staining was accom-
plished with Coomassie brilliant 
blue; SDS-gel electrophoresis 
was performed by Dr. Janina 
Hamberger. 
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C.4 Colorimetric hyaluronidase activity assay and 
protein characterization 
Enzymatic activity was measured using the colorimetric hyaluronidase assay. Specific 
activity in U/mg was calculated by dividing enzymatic activity by protein content (Table 1). 
Table 1: Enzymatic activity and specific activity of SpnHyl in the elution fractions as determined with the 
colorimetric assay.
a
 Fractions 25 and 26 contained 13.5 and 5.5 µg/mL protein, respectively. Results are 
presented as mean ± SEM from two independent experiments.  
elution fraction enzymatic activity (mU/mL) specific activity (U/mg) 
25 63.5 ± 3.9 4.7 ± 0.3 
26 21.3 ± 1.7 3.9 ± 0.3 
a
 data were kindly provided by Dr. Janina Hamberger  
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